|
article-title
|
COVID‐19 under spotlight: A close look at the origin, transmission, diagnosis, and treatment of the 2019‐nCoV disease
|
|
alt-title
|
SHEERVALILOU et al.
|
|
abstract
|
Abstract
Months after the outbreak of a new flu‐like disease in China, the entire world is now in a state of caution. The subsequent less‐anticipated propagation of the novel coronavirus disease, formally known as COVID‐19, not only made it to headlines by an overwhelmingly high transmission rate and fatality reports, but also raised an alarm for the medical community all around the globe. Since the causative agent, SARS‐CoV‐2, is a recently discovered species, there is no specific medicine for downright treatment of the infection. This has led to an unprecedented societal fear of the newly born disease, adding a psychological aspect to the physical manifestation of the virus. Herein, the COVID‐19 structure, epidemiology, pathogenesis, etiology, diagnosis, and therapy have been reviewed.
|
|
title
|
Abstract
|
|
p
|
Months after the outbreak of a new flu‐like disease in China, the entire world is now in a state of caution. The subsequent less‐anticipated propagation of the novel coronavirus disease, formally known as COVID‐19, not only made it to headlines by an overwhelmingly high transmission rate and fatality reports, but also raised an alarm for the medical community all around the globe. Since the causative agent, SARS‐CoV‐2, is a recently discovered species, there is no specific medicine for downright treatment of the infection. This has led to an unprecedented societal fear of the newly born disease, adding a psychological aspect to the physical manifestation of the virus. Herein, the COVID‐19 structure, epidemiology, pathogenesis, etiology, diagnosis, and therapy have been reviewed.
|
|
abstract
|
Since the causative agent, SARS‐CoV‐2, is a recently discovered species, there is no specific medicine for downright treatment of the infection. This has led to an unprecedented societal fear of the newly born disease, adding a psychological aspect to the physical manifestation of the virus. Herein, the COVID‐19 structure, epidemiology, pathogenesis, etiology, diagnosis, and therapy have been reviewed.
|
|
p
|
Since the causative agent, SARS‐CoV‐2, is a recently discovered species, there is no specific medicine for downright treatment of the infection. This has led to an unprecedented societal fear of the newly born disease, adding a psychological aspect to the physical manifestation of the virus. Herein, the COVID‐19 structure, epidemiology, pathogenesis, etiology, diagnosis, and therapy have been reviewed.
|
|
body
|
1 INTRODUCTION
CoVs were recognized as “novel respiratory tract viruses” over half a century ago. The title was conferred in 1962, following the examination of samples collected from individuals who had manifested symptoms of respiratory tract infection (Hamre & Procknow, 1966). Initially, CoVs were not considered as highly pathogenic for humans. That was until 2002, however, that CoVs emerged in the form of Severe Acute Respiratory Syndrome (SARS) in the Guangdong state of China (Sahin et al., 2020). Almost a decade later, another highly pathogenic CoV appeared in the Middle East countries, which similarly led to severe respiratory symptoms of acute onset. The then‐novel species was named Middle East Respiratory Syndrome Coronavirus (MERS‐CoV; Zaki, Van Boheemen, Bestebroer, Osterhaus, & Fouchier, 2012).
In December 2019, a cluster of insidious Coronavirus infections was reported in the Huanan Seafood Market, located in Wuhan State of Hubei Province in China. Unlike the name, livestock animals were also traded in the market alongside their marine relatives. Days later, the cluster turned into a local network and set off the alarm for the Chinese government. It was then that a pneumonia epidemic of unknown cause became the focus of global attention (Sahin et al., 2020). Chinese authorities announced on January 7, 2020 that a new type of CoV (novel CoV, nCoV) was isolated (Imperial College London, 2020; World Health Organization, 2020). On December 12, 2019, a pneumonia case of unknown origin was reported in Wuhan, China. Initial laboratory tests ruled out Influenza and infection with recognized CoVs. Following the incident, 27 new cases of pneumonia of viral origin were officially reported on December 31, 2019. A week later on January 7, 2020, the Chinese authorities announced that a new species of CoV was isolated in the country (Zumla, Hui, Azhar, Memish, & Maeurer, 2020).
Given the whereabouts of the first case ever reported, the infection was speculated to have been contracted from a zoonotic agent. Etiologic investigations on patients who had been hospitalized with a similar medical history supported the likelihood of a viral infection transmitted from animals to humans (Sahin et al., 2020; World Health Organization, 2020; Yin & Wunderink, 2018). nCoV was duly reported to have been originated from wild bats. Falling in the category of group 2 β‐CoVs, the novel Coronavirus only shares a 70% similarity in genetic sequence with its predecessor, SARS‐CoV, which also belongs to the exact same family (Gralinski & Menachery, 2020).
The tantalizing surge in the number of cases infected with SARS‐CoV‐2 in China, despite the closure of markets and evacuation of the vicinity, fulfilled the burden of proof that the virus can also be transmitted from human to human. Soon thereafter, peculiar cases of acute respiratory syndrome started appearing in other Asian countries, ultimately spreading to North America and Europe. (Sahin et al., 2020; World Health Organization, 2020; Yin & Wunderink, 2018). Following an emergent briefing on January 30, 2020, The World Health Organization (WHO) declared the outbreak of COVID‐19 as a Public Health Emergency of International Concern (Organization, 2020).
The epidemic began to emerge with the advent of the Chinese New Year, a traditionally important festival that is heavily celebrated across the country. The coincidence paved the way for SARS‐CoV‐2 to turn into an unprecedented massive Coronavirus outbreak, which required extensive measurements to be contained. With a population of 10 million, Wuhan City also served as an important pathway for millions of people traveling in celebration of the Spring Festival. Accordingly, the number of cases to be diagnosed with COVID‐19 showed an overwhelming increase between January 10–22, 2020 (Chen, Zhang et al., 2020).
Despite the arbitrary speculations, not only did the recent outbreak of COVID‐19 egress the country of origin, it also proceeded to become a global concern in the form of a pandemic (Yang et al., 2020). COVID‐19 is an acute self‐resolving respiratory disease in most of the cases, however, it can also be fatal in some cases. The disease was initially reported to have a mortality rate of 2%. If severe, COVID‐19 might result in death as a result of the preceding extensive alveolar damage, and failure of the lungs (Xu et al., 2020). As of February 15, 2020, a total of 66,580 cases had been confirmed, with over 1,524 deaths. However, there have no specific reports on pathology, as performing an autopsy or biopsy was not possible in most of the cases (Chan et al., 2020; Huang et al., 2020). Table 1. Represents the WHO situation reports on March 24, 2020 (www.WHO.int).
Table 1 The number of cases and death of Covid‐19 outbreak according to World Health Organization statistics (April 13, 2020)
Region Total (new) cases in last 24 hr Total (new) death in last 24 hr
Globally 1,773,084 confirmed (76,498) 111,652 deaths (5,702)
Western Pacific Region 121,426 confirmed (1,310) 4,125 deaths (67)
European Region 913,349 confirmed (33,243) 77,419 deaths (3,183)
South‐East Asia Region 16,883 confirmed (842) 766 deaths (38)
Eastern Mediterranean Region 99,713 confirmed (3,768) 5,107 deaths (164)
American Region 610,742 confirmed (36,804) 23,759 deaths (2,228)
African Region 10,259 confirmed (531) 464 deaths (21)
John Wiley & Sons, Ltd. This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency. A total of 8,096 SARS cases and 774 deaths across 29 countries were reported for an overall case‐fatality rate (CFR) of 9.6%. MERS is still not contained and is thus far responsible for 2,494 confirmed cases and 858 deaths across 27 countries for a CFR of 34.4%. Despite the much higher CFR of 9.6% and 34.4% for SARS and MERS, the novel Coronavirus epidemic has led to a larger death toll. The Chinese government had reported 72,528 confirmed cases, with 1,870 deaths, as of February 18, 2020. These statistics yield a crude CFR of 2.6%. However, one should not haste to generalize this number, as most possibly the total number of patients with COVID‐19 is much higher. That is, because the cases are not readily identifiable, as many asymptomatic patients are missed during the process (Wu et al., 2020; Yan et al., 2020). Despite the higher transmissibility than SARS and MERS, COVID‐19 is still a relatively unknown disease and requires further investigations to be fully understood (Yan et al., 2020).
2 PATHOGENESIS
Initially, the virus interacts with sensitive human cells that exhibit distinct receptors for the viral Spike protein. After making a successful entry, the RNA‐based genome starts replicating itself, and expressing specific sequences that results in production of useful accessory proteins; facilitating the adaptation of CoV to its human host (ViralZone., 2019). Alterations in genetic make‐up that result from recombination, exchange, insertion, or deletion of genes, are frequently reported among CoVs; a phenomenon that might have played a part in the past epidemics (Sahin et al., 2020). Therefore, the classification of CoVs is continuously being changed. Based on the most recent classification provided by The International Committee on Taxonomy of Viruses, there are four genera of CoVs, that comprise a total of 38 unique species (Subissi et al., 2014). Thus, variable mechanisms could be involved in the process of pathogenesis. For instance, SARS‐CoV binds to angiotensin I converting enzyme 2 (ACE2). On the other hand, MERS‐CoV is more inclined to attach the cellular receptor of dipeptidyl peptidase 4 (Lambeir, Durinx, Scharpé, & De Meester, 2003). Following a cascade of signals after binding, the viral genome is successfully injected into the target cell. The genomic RNA that regulates the expression of structural and nonstructural polyproteins, is polyadenylated and encapsulated. These proteins are then cleaved by certain proteases that exhibit chymotrypsin‐like activity (Lambeir et al., 2003; ViralZone, 2019). Through replication and transcription, the resulting protein complex drives the production of negative‐sense RNA or (−) RNA. Full‐length (−)RNAs produced by replication are ultimately used as templates for generation of positive‐sense RNA or (+) RNA (Luk, Li, Fung, Lau, & Woo, 2019; ViralZone, 2019). All of the structural proteins are then translated from a subset of 7–9 subgenomic RNAs, which are products of discontinuous transcription. The resulting protein complex is the assembled together to envelope the viral genome, making a nucleocapsid in the process, that will bud into the lumen of the endoplasmic reticulum to finally complete the intracellular cycle. Newly formed virions are then expelled from the infected cell through exocytosis. The CoVs released thereafter are now capable to infect a wide spectrum of human cells, including lung, renal, hepatic, intestinal, and lower respiratory tract cells, as well as T lymphocytes (Chhikara, Rathi, Singh, & Poonam, 2020; Lambeir et al., 2003). Figure 1 presents a schematic of viral structure and the entry mechanism of SARS‐CoV‐2.
Figure 1 Presents a schematic of viral structure and the entry mechanism of SARS‐CoV‐2
2.1 Respiratory system
SARS‐CoV‐2 tends to infect the respiratory tract, thus, pneumonia is a primary clinical finding in patients with COVID‐19 (Huang et al., 2020; Li, Guan, et al., 2020; Zhu et al., 2020). However, pneumonia is only a component of the SARS that might develop in some cases. The resulting SARS may then be aggravated and lead to serious conditions that are extremely difficult to control, for example, septic shock, metabolic acidosis, and coagulation dysfunction (Kofi Ayittey, Dzuvor, Kormla Ayittey, Bennita Chiwero, & Habib, 2020).
Investigation on the radiological findings of COVID‐19‐associated pneumonia have yielded little, if any, information that are mostly unspecific. Progressive lung lesions are usually detected in patients with COVID‐19, about 1 week after the onset of signs and symptoms (Ooi et al., 2004). The lesions then become aggravated during the 2nd week, and lead to formation of irregular reticular opacities mixed with ground glass opacities (GGOs), which can be detected by CT at the fourth week. In a recent cohort study, 85.7% (54/63) of subjects with COVID‐19‐associated pneumonia showed disease progression, defined by an increased extent of GGO, on early follow‐up CT (Pan et al., 2020). Pulmonary fibrous cords was reported in one particular patient that displayed signs of improvement, as the inflammatory secretions had been absorbed (Pan & Guan, 2020). Long‐term complications of COVID‐19 in patients with severe pneumonia might include an array of fibrotic changes often observed in the late stages of lung injury, for example, reticulation, interlobular septal thickening, and traction bronchiectasis (Kim, 2020).
2.2 Immune system
There have been several reports that indicated meager Cytolethal Distending Toxin‐induced lymphocytes, with a density as low as 200 cells/mm3 in three patients with SARS‐CoV infection (Chu et al., 2014; Zhou et al., 2014). As in the case of SARS‐CoV‐2, it has been suspected that infection with this type of CoV might lead to inflammatory cytokine storm (Chen, Liu, et al., 2020; Zumla et al., 2020); a life‐threatening condition characterized by elevated levels of interleukin 6 (IL‐6) in plasma. A number of investigations recently conducted on COVID‐19 have reported that IL‐6 levels was actually higher in the patients with severe disease (Cai, 2020; Chen, Liu, et al., 2020; Xiang et al., 2020). This could highlight the importance of IL‐6 as a biomarker for evaluation of disease severity (Chen, Zhao, et al., 2020).
2.3 Liver damage
Impaired liver function tests have been reported for a number of patients with SARS‐CoV‐2 infection, suggesting hepatic damage as an extrapulmonary complication of COVID‐19 in almost one half of the patients (Chen, Zhou, et al., 2020; Wang, Hu, et al., 2020). A recent study has concluded that liver function abnormality might stem from infection of bile duct cells with SARS‐CoV‐2. Nonetheless, the alkaline phosphatase value, which is an index of bile duct damage, were not specific in patients with COVID‐19 (Chen, Zhou, et al., 2020; Wang, Hu, et al., 2020). Investigation of liver biopsy specimens was accompanied by new pathological findings. Scientists have reported moderate microvascular steatosis, and mild lobular and portal activity in these patients, that suggests liver damage may have arisen from either SARS‐CoV‐2 infection or drug‐induced liver (Xu et al., 2020).
2.4 Myocardial, gastrointestinal, and renal symptoms: homeostasis of electrolytes
An essential player in maintenance of electrolyte balance and blood pressure, ACE2 is regarded by many as the principal counter‐regulatory arm in the axis of renin–angiotensin‐aldosterone system (RAAS; Santos, Ferreira, & Simões e Silva, 2008). Upon infection, SARS‐CoV‐2 binds ACE2. This results in degradation of ACE2, which subsequently dampens the counter‐effect of ACE2 on RAAS. The final effect of ACE2 in an otherwise healthy adult is to increase reabsorption of sodium and the reciprocal excretion of potassium ions (K+). The concomitant re‐uptake of water with sodium reabsorption prompts an increase in blood pressure (Weir & Rolfe, 2010). Potassium is the predominant intracellular ion, that is majorly involved in regulation of cell membrane polarity. Too low levels of K+ in blood, known as hypokalemia, can result in cellular hyper‐polarity. A hyper‐polarized cell membrane tends to be depolarized faster than normal, causing aberrancy in the function of cardiac cells (Bielecka‐Dabrowa et al., 2012).
In a recent cohort study, patients diagnosed with COVID‐19 were categorized into three groups: severe hypokalemia, hypokalemia, and normokalemia. The study reported that 93% of patients with a severe clinical condition had hypokalemia. Scientists did not find a direct link between gastrointestinal symptoms and hypokalemia among 108 patients with both severe or moderate hypokalemia. Further investigations established an association between parameters such as body temperature, creatine kinase (CK), creatine kinase myocardial band (CK‐MB), lactate dehydrogenase (LDH), and C‐reactive protein (CRP) with the severity of hypokalemia. Reportedly, hypokalemia was most often observed with patients who had elevated levels of serum CK, CK‐MB, LDH, and CRP. Potassium (K+) loss in the urine was determined to be the primary cause of hypokalemia.
Hypokalemia requires strenuous efforts to be corrected. This is chiefly due to the incessant loss of K+ in the urine, as a result of ACE2 degradation. In the case of COVID‐19‐associated hypokalemia, however, the patients seemed to respond well to potassium supplements when the critical phase had passed [49]. Therefore, one should consider the impact of hypokalemia in COVID‐19 morbidity, and its effect on the outcomes of treatment. This is a condition that must be carefully addressed for, as patients with COVID‐19 are more inclined to develop dysfunctions in heart, lungs, and other vital organs (Li, Hu, Su, & Dai, 2020).
3 POSSIBLE FACTORS CORRELATED WITH COVID‐19
3.1 Sex
Several studies have sought to compare the sex differences in the clinical findings of severe COVID‐19. In one study, scientists investigated 47 patients with COVID‐19, 28 (59.6%) of whom were men. Procalcitonin (PCT) level was reported to be higher in men than in women. The results also showed higher amounts of serum N‐terminal‐pro brain natriuretic peptide, as increased levels of the molecule were detected in men 57.1% than women 26.3%. Furthermore, 17.9% of male patients were reported test‐positive for influenza A antibody, whereas no such records were registered for female patients. During a 2‐week stay at the hospital, 17.9% of male, and 5.3% of female patients deteriorated, and hence were reassigned to the critical‐type group. There was no mortality reports among women, whereas 3.6% of male patients had deceased due to COVID‐19 complications. A total of 21.1% and 3.6% of female and male patients successfully recovered, and were discharged from the hospital. Based on the current evidence, men are more likely to develop complications, and experience worse in‐hospital outcomes compared with women (Li, Zhang, et al., 2020).
3.2 Pregnancy
A group of researchers led by Chen investigated the clinical characteristics of SARS‐CoV‐2 infection in nine pregnant women. Their aim was to evaluate the likelihood of intrauterine/vertical transmission of SARS‐CoV‐2 from mother to baby. All of the women who were being investigated had cesarean section in the third trimester of their previous pregnancies. Seven patients were febrile, and variably presented other symptoms such as cough, sore throat, myalgia, and malaise. Fetal distress was reported in two cases. Lymphopenia and increased aminotransferase activity were observed in five and three patients, respectively. There was no mortality cases, as none of the patients in the study developed severe COVID‐19‐associated pneumonia. Nine livebirths were recorded. The newborns displayed no signs of asphyxia. A 1‐min Apgar score of 8–9, and a 5‐min Apgar score of 9–10 were calculated for all nine newborns. Samples collected from six patients, including amniotic fluid, cord blood, neonatal throat swab, and breastmilk proved test‐negative for SARS‐CoV‐2. The clinical features of COVID‐19‐associated pneumonia observed in these pregnant women shared a great similarity to characteristics reported for COVID‐19‐associated pneumonia in nonpregnant adult patients (Chen, Guo, et al., 2020).
3.3 Blood type
In a recent investigation, scientists in China looked into the pattern of blood type distribution in 2,173 patients in three hospitals, who had been confirmed to have SARS‐CoV‐2 infection. Accordingly, they compared their findings regarding the blood type of patients with that of the healthy population who lived in the same area as the patients in the study. Apparently, there was a higher prevalence of blood type A among the patients with COVID‐19 than in the normal population. On the contrary, it seemed that individuals with O blood type were spared somehow, as there were fewer patients with this blood type in this study (both p < .001). A series of meta‐analyses on the available data indicated a significantly higher risk for COVID‐19 in people with blood type A, relative to individuals with non‐A blood types. However, an opposite scenario seemed to be true for the blood type O community, since, according to the literature, are less susceptible for contracting infectious diseases such as COVID‐19 (Zhao et al., 2020).
4 ETIOLOGY: SOURCES AND MODES OF TRANSMISSION
According to the literature, the pathogen and area of origin were similar in both SARS and COVID‐19 outbreaks. However, despite this similarity, the raised public awareness and extensive interventional procedures that might have once proved effective for SARS containment, have been rendered ineffective against the 2019 novel Coronavirus; as the disease is already more widespread than SARS (Liu, Gayle, Wilder‐Smith, & Rocklöv, 2020). A large family of viruses, CoVs are common among many different animal species, including cattle, civets, camels, and bats. However, these CoVs are not solely restricted to animal populations, as they can occasionally infect humans, bringing epidemics such as SARS, MERS, and in recent memory, COVID‐19 (Sahin et al., 2020). Recent investigations conducted on the origins of CoVs responsible for the past epidemics have reported bats as the primary reservoir for both SARS‐CoV and MERS‐CoV; suggesting that other animal species were involved in the process merely as intermediate hosts. Accordingly, the majority of bat‐associated CoVs belong to α‐CoV and β‐CoV genera, while almost all of the avian CoVs fall in the other two genera; γ‐CoVs and δ‐CoVs (Yin & Wunderink, 2018). It has been suggested that species responsible for the recent epidemic is reminiscent of the CoV isolated in bats. Trafficking of wild animals in Huanan Seafood Market, located in Wuhan State of Hubei Province in China, where the first cases were reported, further supports this finding. Only 10 days following the first outbreak, secondary cases started emerging. Although the new cases had no contact with the marketplace, they did have a history of social contact with the salesmen and people who had previously been there. The growing pile of confirmed cases from healthcare workers in Wuhan City is an strong indicator of human‐to‐human transmission in the case of SARS‐CoV‐2 (Sahin et al., 2020).
Transmission of the virus from human to human occurs mostly with close contact. The short distance between individuals in close social contacts makes it possible for respiratory droplets of the infected person, released by coughing and sneezing, to reach other people in the proximity. This is similar to the transmission of Influenza and other respiratory infection. It still remains unclear if the virus can be contracted by touching surfaces, and then touching mouth, nose, or even eyes (WHO, 2020). Apparently, COVID‐19 is considered most contagious when individuals infected with the virus is symptomatic. However, there have been cases who reportedly had contracted the disease from asymptomatic patients in the prodrome period of COVID‐19. Transmission of the novel Coronavirus has yet to be clarified by more investigations. (Rothe et al., 2020).
4.1 Presumed asymptomatic carrier‐based transmission of COVID‐19
Investigation on a familial cluster of five patients concluded that SARS‐CoV‐2 might have actually been transmitted by an asymptomatic carrier in the family (Bai et al., 2020). Surprisingly, the first reverse transcription polymerase chain reaction (RT‐PCR) test of the asymptomatic family member was reported negative; a noteworthy example of a false‐negative result. Unwanted false‐negative results are inevitably reported due to a number of factors, for example, quality of the test kit, sufficiency of the collected sample, or performance of the test by clinicians. To this date, RT‐PCR has widely been used as a reliable diagnostic method (Corman et al., 2020). Thus, her second RT‐PCR result, reported positive, was unlikely to have been a false‐positive result; hence, it was accepted as the definite evidence that the suspected person had indeed been infected with SARS‐CoV‐2 (Bai et al., 2020).
There was also another study that reported an asymptomatic young boy with COVID‐19 infection. However, CT scans obtained from the subject exhibited abnormalities, indicative of an on‐going pulmonary pathology (Chan et al., 2020). If we presume that the findings regarding asymptomatic carrier‐based transmission of COVID‐19 can be replicated, this would prove COVID‐19 an overwhelmingly challenging issue to be controlled (Bai et al., 2020). The incubation period for the asymptomatic patient in the case of familial cluster was 19 days. Despite being a long period, it still perfectly falls in the suggested incubation period of 0–24 days (Bai et al., 2020; Guan et al., 2020).
5 DIAGNOSIS
A proper diagnosis of COVID‐19 is made based on the following criteria, which have been recently suggested based on the initial investigations: (a) clinical signs and symptoms, (b) history of traveling or close contact with people suspected to be infected, (c) positive test result for the pathogen, and (d) pathologic findings on CT images. The key clinical features of COVID‐19, though nonspecific, include fever, dry cough, dyspnea, and pneumonia (Chen, Zhou, et al., 2020; Huang et al., 2020; Li, Guan, et al., 2020; Wang, Hu, et al., 2020). Rapid screening of patients with acute respiratory symptoms, initiation of an appropriate quarantine program, and development of therapeutic measures have been suggested as a top‐priority strategy to control the spread of COVID‐19 (Tian et al., 2020; Wang, Kang, et al., 2020). According to the data gathered by individual‐level surveillance, it is strongly recommended that the elderly and male patients should be diagnosed in a timely manner, as progression of the respiratory pathology to pneumonia might result in catastrophic outcomes (Jian‐ya, 2020).
5.1 Clinical symptom spectrum
Understanding the otherwise nonspecific clinical signs and symptoms of COVID‐19 is a crucial step toward appropriate management of the disease. Patients mostly complain of fever, non‐productive cough, and body ache or extreme tiredness. In some cases, diarrhea and nausea precede fever by a few days, suggesting that fever might not be the initial manifestation of infection. A small number of patients reportedly had headache, or even developed hemoptysis (Guan et al., 2020; Wang, Hu, et al., 2020). Some patients remained asymptomatic, despite being tested positive for the disease (Chan et al., 2020). According to several studies, infection with SARS‐CoV‐2 in the elderly, especially the male community, is more likely to result in severe alveolar damage and respiratory failure (Chen, Zhou, et al., 2020). Occasionally, the disease may be demonstrated with a fulminant natural history, rapidly progressing to organ dysfunction, and even death in critical cases. Organ dysfunction includes conditions such as shock, ARDS, acute cardiac injury, and acute kidney injury (Huang et al., 2020; Wang, Hu, et al., 2020). From a laboratory point of view, lymphopenia, thrombocytopenia, impaired prothrombin time (PT), and elevated serum levels of CRP stand among the findings that can be reported for patients with COVID‐19 (Chen, Zhou, et al., 2020; Guan et al., 2020; Huang et al., 2020; Wang, Hu, et al., 2020). Overall, any patient with fever and acute respiratory symptoms, who is reported to have lymphopenia or leukopenia on lab examination, should be suspected. A history of travel to Wuhan or having close contact with local residents is a strong indicator for careful management of the patient (Zu et al., 2020). Table 2 represents the criteria for diagnosis of COVID‐19 infected patients (Committee, 2020b; Zu et al., 2020; WWW.ClinicalTrials.gov).
Table 2 Criteria for clinical severity of confirmed COVID‐19 pneumonia
Patient Clinical findings CT (imaging findings of pneumonia) Organ damage
Mild Negative None None
No dyspnea, with or without cough, fever <38°C (quelled without treatment)
No history of chronic respiratory disease
Moderate dyspnea, with or without cough Multifocal patchy GGOs with subpleural distribution None
SpO2 >93% without oxygen inhalation
Severe Fever Diffuse heterogeneous consolidation with GGO, None
Muscle ache Rapid progression (>50%) on CT imaging within 24–48 hr
Headache
Confusion
Respiratory distress:
RR ≥ 30 times/min
SpO2 < 93% at rest
PaO2/FiO2 ≤ 300 mmHg
Critical Shock “Extra pulmonary” organ failure or MODS
Respiratory failure
need mechanical assistance
Intensive care unit is needed
Abbreviations: FiO2, fraction of inspired oxygen; GGO, ground‐glass opacity; MODS, multiple organ dysfunction syndrome; PaO2, partial pressure of oxygen; RR, respiratory rate, SpO2, oxygen saturation.
John Wiley & Sons, Ltd. This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.
5.2 Epidemiological history
Shortly after the onset of the epidemic, The National Health Commission of China (Committee, 2020a; Organization, 2020a) initiated the Diagnosis and Treatment Program of COVID‐19‐associated pneumonia, following the guidelines provided by WHO on SARS and MERS (Azhar & EI‐Kafrawy, 2014; Organization, 2017, 2020b).
According to the newly formulated criteria, a “suspected case” is defined as a patient with epidemiological history, that is traveling and contact, and two clinical findings pertinent to the disease. If, however, an epidemiological history is not confirmed, then the patient must present at least three clinical findings to be considered as a suspected case. Based on the Trial, Fifth Edition (Committee, 2020b), pathologic findings indicative of viral pneumonia on chest CT scans provide enough evidence for clinical diagnosis of COVID‐19. Nonetheless, as of February 17, 2020, WHO does not approve of any diagnosis based solely on radiologic findings, without obtaining an RT‐PCR test from the patient (Organization, 2020c). In the more recent revision of the Chinese Diagnosis and Treatment Program, 6th Edition, the term “clinical diagnosis” was removed and replaced with “etiological diagnosis” (Organization, 2020a). According to the recent revision, it is imperative that an etiological diagnosis of COVID‐19 is made at first, which can then be complemented by a positive real‐time RT‐PCR assay for SARS‐CoV‐2, which is duly performed on the sputum or blood sample of the patient. After the final diagnosis is made, confirmed patients are categorized into mild, moderate, severe, and critical types, based on the severity of disease (Zu et al., 2020).
5.3 COVID‐19 detection tests: Pathogenic laboratory testing, real‐time RT‐PCR, and sequencing of nucleic acid
Table 3 (Ai et al., 2020; Bai et al., 2020; Chen, Zhao, et al., 2020; Shi et al., 2020; Tian et al., 2020; Wang, Kang, et al., 2020; Wu & McGoogan, 2020; Yan et al., 2020; Yang et al., 2020) and Table 4 represent 2020 studies on diagnosis of COVID‐19 infected patients and related clinical trials, respectively.
Table 3 Studies for diagnosis, prognosis and therapy of COVID‐19 patients
Study/region Study type/medical team Patient/median age/sex Diagnostic test Sample Inclusion criteria/residency Test results Most common symptoms/chronic disease Incubation period (day) Case fatality rate Diagnosis/prognosis/therapy
Wu et al. (2020), China Retrospective study/Chinese Center for Disease Control and Prevention 72,314; subjects: confirmed cases 44,672 (62%), suspected cases 16,186 (22%), diagnosed cases 10,567 (15%), asymptomatic cases 889 (1%)/age N = 44,672: 80: 3% (1,408), 30–79: 87% (38,680), 20–29: 8% (3,619), 10–19: 1% (549), <10: 1% (416) PCR Throat swab samples Confirmed cases based on positive PCR, suspected cases based on symptoms and exposures only, clinically cases based on symptoms, exposures, and CT, asymptomatic cases diagnosis by positive PCR Spectrum of disease: (N = 44,415); mild: 81% (36,160), severe: 14% (6,168), critical: 5% (2,087) Cardiovascular disease: 10.5%, diabetes: 7.3%, chronic respiratory disease: 6.3%, hypertension: 6.0%, cancer: 5.6% About a week 2.3% (1,023 of 44,672 confirmed cases), 14.8% aged >80 years (208 of 1,408), 8.0% aged 70–79 years (312 of 3,918) 49.0% in critical cases (1,023 of 2,087) Next step: to help “buy time” for more diagnostic and therapeutic research before COVID‐19 becomes too widespread
Tian et al. (2020), China Retrospective study/Beijing Emergency Medical Service 262/47.5/48.5% male Real‐time RT‐PCR Respiratory specimens COVID‐19 infected patients/residents of Beijing: 92 (73.3%), patients had been to Wuhan: 50 (26.0%), close contact with confirmed cases: 116 (60.4%), no contact history: 21 (10.9%) Spectrum of disease: sever: 46 (17.6%); common: 216; (82.4%); mild: 192 (73.3%); nonpneumonia: 11 (4.2%); asymptomatic:13 (5.0%) Fever (82.1%), cough (45.8%), fatigue (26.3%), dyspnea (6.9%), headache (6.5%)/pulmonary infection, chronic cardiovascular disease and heart failure: 1, pulmonary infection and multiple chronic diseases: 1 Incubation: 6.7 days, illness onset to visit hospital: 4.5 days 3 (0.9%) Results: As of February 10, 45 (17.2%) patients have discharged
For COVID‐19 control: first step is prevent transmission at early stage, next steps is early isolation and quarantine of suspected subjects
Wang et al. (2020), China Retrospective cohort/Xi'an Jiaotong University First Affiliated Hospital, Nanchang University First Hospital and Xi'an No.8 Hospital of Xi'an Medical College 99 CT, artificial intelligence, inception migration‐learning model – Pathogen‐confirmed COVID‐19 patients Spectrum of disease: typical viral pneumonia or negative group: 55, confirmed nucleic acid testing or positive group: 44. CT (453 CT images): negative: 258, positive: 195 Viral pneumonia symptoms – – Screening:
The internal validation; accuracy: 82·9%, specificity: 80·5%, sensitivity: 84%
The external testing; accuracy: 73·1%, specificity: 67%, sensitivity: 74%
Algorithm prediction: a rate of 2 s per case on the graphic processing unit
Interpretation: the early diagnosis through fast, accurate, safe and noninvasive methods is crucial for control of virus
Yan et al. (2020), China Retrospective study/Tongji Hospital 375, 58.83, 58.7% males CT, machine learning model (a supervised XGBoost classifier) – Validated or suspected COVID‐19 patient/Wuhan residents (37.9%), familial cluster (6.4%), health workers (1.9%) Spectrum of disease: critical patients: 46.1%, severe cases: RR ≥ 30bpm or SPO2 ≤93% on rest Fever: 49.9%, cough: 13.9%, fatigue 3.7%, dyspnea 2.1%, shock: 2 174
16 + 1 Interpretation: the three indices‐based prognostic prediction model might predict themortality risk, recognition of critical cases, help to early identification, on time intervention, reducing mortality rate
Shi et al. (2020), China Retrospective/hospitals in Wuhan 81, 49–5, 42 (52%) men and 39 (48%) women Next‐generation sequencing or RT‐PCR, serial chest CT Throat swab specimens Confirmed COVID‐19 pneumonia patients/direct exposure to Huanan seafood market: 31 (38%), health‐care workers: 15 (19%), familial clusters: 7 (9%), any obvious history of exposure: 28 (35%) Spectrum of disease: mean number of involved lung segments: 10.5 (SD 6.4): group 1: subclinical patients (CT before symptom onset): 2.8 (3.3), group 2: ≤1 week after symptom onset/11.1 (5.4), group 3: >1–2 weeks/13.0 (5.7), group 4: >2–3 weeks/12.1 (5.9).
CT:
ALL:
bilateral abnormality: 64 [79%], peripheral 44 [54%], Ill‐defined 66 [81%], GGO: 53 [65%], mainly involving the right lower lobes: 225 [27%] of 849.
Group 1 (n=15): unilateral: 9 [60%]/multifocal 8 [53%]/GGO: 14 [93%]; Group 2 (n = 21): bilateral 19 [90%]/diffuse 11 [52%]/GGO predominance 17 [81%]; Group 3 (n = 30): GGO 17 [57%], consolidation/mixed patterns: 12 [40%]; Group 4 (n=15): consolidation/mixed patterns: 8 [53%].
Blood:
Group1: Lower CRP and AST Fever: 59 [73%], dry cough: 48 [59%] nonspecific symptoms:
dizziness:
2 [2%], diarrhea:
3 [4%], vomiting:
4 [5%], headache:
5 [6%], generalised weakness:
7 [9%]/chronic pulmonary disease (tuberculosis): 1, T2D: 1, hypertension/cardiovascular/erebrovascular disease: 1 Symptom onset and discharge of 23–2 days 3 (4%) By February 8, 2020, 62 (77%) patients discharged
Interpretation: COVID‐19 pneumonia include CT abnormalities that rapidly progress from focal unilateral to diffuse bilateral GGO coexisted with consolidations within 1–3 weeks (even in asymptomatic patients).
Early diagnosis through combined CT with clinical and laboratory findings
Bai et al. (2020), China Case study/The Fifth People's Hospital of Anyang 6, Patient 1: 20‐year‐old woman, patients 2–6: four women 42–57 years old CT, RT‐PCR Nasopharyngeal swabs Patient 1: met with Patients 2 and 3, and accompanied five relatives (Patients 2–6), Patients 2–6: no visited Wuhan or been in contact with any other people traveled to Wuhan Spectrum of disease: severe pneumonia: 2, moderate: others. A familial cluster of five patients with respiratory symptoms, 1 asymptomatic family member.
Blood:
all symptomatic patients: increased CRP, reduced lymphocyte.
CT: multifocal GGO: in all symptomatic patients, subsegmental consolidation/fibrosis: 1.
Patient 1: normal CT, CRP and lymphocyte count, RT‐PCR: negative, positive, negative.
Patients 2–6:
COVID‐19 confirmed.
PCR: positive for patients 2–6 within 1 day Fever: patients 2–6 19 days for patient 1 – Transmission: COVID‐19 transmission could transmit by an asymptomatic carrier S
Ai et al. (2020), China Cohort/Tangji hospital of Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei 1,014/51 ± 15/46% man Laboratory test, chest CT (7 day interval), RT‐PCR (Taq man one step): multiple assays (3 day interval) Throat swab Suspected of nCoV/China Positive CT: 88% (888/1,014), positive RT‐PCR: 59% (601/1,014).
Sensitivity of CT based on positive RT‐PCR: 97% (95%CI, 95–98%, 580/601).
Negative RT‐PCR/positive CT: 75% (308/413).
Initial positive CT consistent with COVID‐19 before the initial positive RT‐PCR: 60–93%.
Improvement in follow‐up CT before the RT‐PCR turning negative: 42% (24/57), CT: GGO: 46% [409/888], consolidations: 50% [447/888], bilateral findings: 90% [801/888] Fever, dry cough Initial + to − PCR: 5.1 ± 1.5 days,
Initial − to + PCR: 6.9 ± 2.3 days – Diagnosis: chest CT, as a highly sensitive method, could be considered as a primary tool for infection diagnosis in epidemic areas
Chen et al. (2020), China General Hospital of Central Theater Command, PLA 48/age; critically ill: 79.6 ± 12, sever: 63.9 ± 15, mild: 45.8 ± 14/31 males (77.1%) and 17 females (22.9%) Real‐time RT‐PCR, CT, GLMs analysis Serum, throat‐swab specimens Laboratory confirmed cases Spectrum of disease: mild: 21 (43.7%), severe 10 (20.8%), critically ill 17 (35.4%).
Blood: low/lower lymphocytes: severe and critically ill, higher neutrophils: critically ill, higher PCT: critically ill.
Parameters stand for the organ dysfunction; TnT, AST, ALT, CRE, and BUN: higher in critically ill patients.
PCR:
positive RNAaemia: (a) serum: 5 (10.4%) of critically ill, (b) throat‐swab: 48 positive.
IL‐6: value ≥100: 35.3% in critically ill, 10‐folds higher IL‐6 (cytokine storm): critically ill, RNAaemia positive: IL‐6 ≥100 (R = 0.902) Mild: fever, respiratory symptoms
Severe: shortness of breath, RR ≥ 30 times/min, oxygen saturation (resting state) ≤93%, PaO2/FiO2 ≤300 mmHg
Critically ill: respiratory failure, shock, multiple organ failure/diabetes: 12 [25%], hypertension: 23 [49.7%], heart disease: 8 [16.7%], mixed fungal infection: 27.1%, bacterial infection: (2.1%) – 3 Diagnosis; RNAaemia positive test confirmed critically ill patients
Prognosis: strong association between RNAaemia with cytokine storm can be applied to predict the poor prognosis
Therapeutic approach: in critically patients, IL‐6 should be considered as a therapeutic target
Fan et al. (2020), China Retrospective cohort study/three tertiary hospitals of Wenzhou 149/45.11 ± 13.35/81 (54.4%) males Laboratory test, PCR, CT Blood RT‐PCR confirmed patients: Hubei travel/residence history: N=85,
contact with people of Hubei: N=49, no traceable exposure history: N=15 Blood:
decreased oxygen saturation: 14(9.4%), leukopenia: 33 (24.2%), lymphopenia: 53 (35.6%), low platelets: 20 (13.4%), elevated CRP: 82 (55.0%), ALT/AST/CK and D‐dimer: less common.
CT: most involved lung segments: 6 and, GGO: 287 segments, mixed opacity: 637 segments, consolidation: 170 segments, lesions: more in the peripheral lung with a patchy form, normal CT on admission: N=17, negative CT: N=12, no significant difference between patients with or without exposure history Fever:
114/149, 76.5%,
Cough: 87/149, 58.4%,
Expectoration:
4 8/149, 32.2%, mild infection/cerebrovascular or digestive diseases:
52 (34.9%) Negative CT: 10 days, 6.8 (5.0) days 0 (0.0%) Diagnosis: a normal CT cannot exclude the diagnosis of COVID‐19
Fan et al. (2020), China Retrospective, case series/Chongqing University Three Gorges Hospital 51/45/32 (62.7%) men Laboratory test, CT Blood Confirmed COVID‐19: patients had been to Wuhan:
43 (84.3%), contact history of COVID‐19 patients: 4 (7.7%), no clear contact history:4 (7.7%) Spectrum of disease:
nonsevere patients: n = 44, severe patients: 7 (13.7%)
Blood: lymphopenia: 26 (51.0%), elevated CRP: 32 (62.7%).
CT:
GGO: 41 [80.4%], local consolidation of pneumonia:
17 [33.3%], pleural thickening: 20 (39.2%), small amount of pleural effusion:
7 (13.7%), streak shadow of lung: 8 (15.7%), multiple solid nodular shadow: 4 (7.8%), air bronchogram: 2 (3.9%), single lobe lesions: 2 (3.9%), multiple lobe lesions: 49 (96.1%) Fever:
43 [84.3%], cough:
38 [74.5%], dry cough with expectoration:
16 (31.4%), fatigue: 22 [43.1%], asthenia: 22 (43.1%), dyspnea: 11/DM: 4 [57.1%] 2–5 days 1 Therapy:
TCM decoction: 28 [54.9%], aerosol inhalation of recombinant human
Interferon a‐1b: 51 (100%), Lopinavir/Ritonavir: 51 [100%], Bacillus licheniformis capsules: 44 [86.3%], glucocorticoid treatment: 10 (19.6%)
Older patients with server COVID‐19 (N = 7)
Antibiotic treatment: 7 [100%], nutritional diet: 6 [85.7%), human albumin infusion: 4 (57.1%), immunoglobulin treatment: 4 (57.1%), mechanical ventilation: 6 [85.7%]
Results and interpretation: discharged 50 patients after 12 days, without the common clinical symptoms, with the significant increased lymphocyte (p = .008) and significant decreased CRP significantly (p < .001)
Fan et al. (2020), China Retrospective/Shanghai Public Health Clinical Center 148/50.5/49.3% females and 50.7% males Laboratory test, RT‐PCR and CT scanning Sera Confirmed SARS‐CoV‐2‐infected patients/a history of related epidemiology Blood:
elevated LDH, AST, ALT, GGT, TB, ALP:
35.1%, 21.6%, 18.2%, 17.6%, 6.1%, 4.1% in all patients; lower CD4+ and CD8+ T cells: (62.67%)/(56.1%) patients with abnormal liver function received more treatment compared with normal liver function (25%) (p = .009) Fever: (70.1%), cough: (45.3%), expectoration at admission:
(26.7%),
Abnormal liver functions at admission: 75 patients (50.7%) with moderate‐high degree fever (44%) in males,/chronic hepatitis B or C: N = 8 5 days (3–7) 1 Therapy:
Antibiotics (Levofloxacin, Meropenem, Moxifloxacin, Cephalosporin), interferon, antiviral drugs (Arbidol, Lopinavir/ritonavir, Dnrunavir)
Results and interpretation:
all patients discharged from the hospital.
Lopinavir/Ritonavir treatment can significantly alleviate the SARS‐CoV‐2‐induced liver function damage
Chen et al. (2020) China Retrospective/Zhongnan Hospital of Wuhan University, Wuhan 9/26–34/female Clinical records, laboratory results, CT scans Amniotic fluid, cord blood, and neonatal throat swab, breastmilk samples Pregnant women with laboratory‐confirmed COVID‐19 pneumonia and caesarean section in their third trimester/a history of epidemiological exposure to COVID‐19 Blood:
lymphopenia: N = 5, elevated CRP: N = 6, increased ALT and AST: N = 3, normal WBC count: N = 7, lower WBC: N = 1.
Nine mothers: none developed severe COVID‐19 pneumonia or dying as of Feb4.
Six mothers:
amniotic fluid, cord blood, neonatal throat swab, and breastmilk: negative for COVID‐19.
Nine livebirths:
with 1‐min Apgar score of 8–9 and a 5‐min Apgar score of 9–10, No neonatal asphyxia.
CT:
multiple patchy ground‐glass shadows: N=8 Fever: N = 7, cough N = 4, myalgia N = 3, sore throat: N = 2, malaise: N = 2, fetal distress:
N = 2/gestational hypertension:
N = 1, pre‐eclampsia: N = 1, influenza virus infection: N = 1 Short None Therapy: oxygen support (nasal cannula) and empirical antibiotic treatment: N = 9, antiviral therapy: N = 6
Interpretation: no evidence for intrauterine infection caused by vertical transmission in late pregnancy
Lim et al. (2020), Korea Public health center, Myongji Hospital 1/54/male PCR, CT Throat swab, sputum A Korean man living in Wuhan China/Virus transmission;
from index patient Patient A to Patients B, C, D@@ Spectrum of disease: mild respiratory symptoms.
CT:
small consolidation in right upper lobe, GGO in both lower lobes Chills, muscle pain 5–7 days – Therapy:
Lopinavir/Ritonavir
Results and interpretation:
significant decrease in β‐coronavirus viral loads due to the natural course of the healing process rather than administration of Lopinavir/Ritonavir, or both
Wu et al. (2020), China Retrospective/three Grade IIIA hospitals of Jiangsu 80/46.1/41 female (51.25%) Laboratory testing, real time RT‐PCR, CT Throat swab and/or nose swab, blood Confirmed COVID‐19 patients/with a history of epidemic in Wuhan and without contact with the seafood market Spectrum of disease:
mild: 28 (35.00%), moderate: 49 (61.25%), severe: 3 (3.75%), critically ill: none
Laboratory:
lower WBC: 36 (45.00%), lymphocytopenia: 26 (32.50%), lower platelets: 11 (13.75%), high CRP: 62 (77.50%), high ESR: 59 (73.75%), elevated PCT: 1 (1.25%).
Liver function:
increased ALT/AST: 3 (3.75%), lower albumin: 2 (2.50%).
Abnormal myocardial enzyme spectrum and increase of CK: 18 (22.50%).
Increased LDH: 17 (21.25%).
Renal function damage: 2 (2.50%).
Serious renal function damage: 1.
Hyperglycemia: 19 (23.17%).
Increased D‐dimer: 3 (3.75%).
9 kinds of respiratory pathogens and influenza A/B nucleic acids: all patients.
CT: abnormal: 55 (68.75%), bilateral pneumonia: 36 (45.00%), unilateral pneumonia: 19 (23.75%), normal: 25 (31.25%).
Organ damage: acute respiratory injury: 10 (12.50%), renal injury: 2 (2.50%) Fever:
63 (78.75%), cough: 51 (63.75%), shortness of breath: 30 (37.50%), muscle ache: 18 (22.50%), headache: 13 (16.25%) liver dysfunction: 3 (3.75%)/cardiovascular/cerebrovascular, endocrine, digestive, respiratory, malignancies and nervous system diseases: 38 (47.50%) 8.0 Not now Therapy:
all patients:
single antibiotic mainly Moxifloxacin and Ribavirin antiviral therapy, 12 (14.63%) patients:
methylprednisolone sodium succinate or methylprednisolone, 35 (43.75%) patients:
noninvasive ventilator, 1 patient: hemodialysis, 3 patients: TCM
Interpretation: 21 cases discharged from the hospital: With no obvious gender susceptivity, lower proportion of liver dysfunction, abnormal CT and higher frequency nucleic acid detection
Li et al. (2020), China Retrospective study/hospital in Wenzhou 175/46/92 women, 83/men Real‐time PCR, CT Respiratory tract samples or blood samples Confirmed COVID‐19/a history of exposure to the epidemic area: 57 (33%) patients Spectrum of disease:
COVID‐19:
mild: mild clinical manifestations, no pneumonia; moderate: respiratory symptoms, mild pneumonia, severe (37): pneumonia, ARDS with RR >30 times/min, oxygen saturation <93%; critical (3): pneumonia, shock, respiratory failure, and failures in other organs, nearly all patients: GGO
K+:
severe hypokalemia: 39 (higher body temperature, higher heart rate and RR, higher prevalence of dyspnea or tachypnea (p < .05)), hypokalemia 69, normokalemia patients 67.
Correlations: severity of hypokalemia with body temperature, CK, CK‐MB, LDH, and CRP (p < .01), 93% of severe/critically ill patients showed hypokalemia Cough, fever, pneumonia/hypertension: 28, diabetes: 12, other conditions:31 6 – Therapy:
1 severe hypokalemia patients;
3 g/day K+, 34 (SD = 4) g potassium during hospital stay
Good response of patients to K+ supplements when they inclined to recovery
Interpretation: hypokalemia is prevailing in COVID‐19 patients
Lan et al. (2020), China Case study/Zhongnan Hospital of Wuhan University, Wuhan 4, 30–36 years, 2 male RT‐PCR, thin‐section CT Throat swabs Medical personnel quarantined at home with COVID‐19 Spectrum of disease: mild to moderate
Results: (at admission); PCR positive: for all CT positive: for all GGO, or mixed GGO/consolidation
(after therapy); 2 consecutive negative RT‐PCR: all (after discharge); repeated RT‐PCR 5–13 days later: all positive Fever:3, cough: 3, both: 3 Symptom onset to recovery: 12–32 days – Therapy: antiviral treatment (75 mg of oseltamivir every 12 hr)
Resolved clinical symptoms and CT abnormalities: 3
Delicate patches of GGO: 1
Interpretation: possibility of at least a proportion of recovered patients act as virus carriers
Li et al. (2020), China Retrospective study/Sino‐French New Town area Tongji Hospital 47, 62, 28 (59.6%) men Real‐time RT‐PCR Throat‐swab specimens, sputum or endotracheal aspirates Patients with severe COVID‐19 Spectrum of disease: severe: 41 critical: 5(17.9%) men and 1 (5.3%) women
Common: oxygen saturation <93% after routine
Nasal oxygen supply: 3 men/1 woman
Blood: PCT: higher in men, N‐terminal‐pro brain natriuretic peptide: Higher in 16(57.1%) men/5 (26.3%) women,
Positive influenza A antibody: 5 men (17.9%) Fever: 34 [72.3%], cough: 36 [76.6%], myalgia: 5 [10.6%], fatigue: 7 [14.9%]/comorbidities: 30 (63.8%):
COPD, hypertension/CVD lower in men – 3.6% in men and 0 in women Therapy:
antibiotics applied more in the men than the women
Results and interpretation: 4 (21.1%) women/1 man (3.6%) discharged.
Possibility of sex differences in severe COVID‐19 patients, Men with more complicated clinical condition and worse outcomes
Han et al. (2020) Case study/People's Hospital in Wuwei A 47‐year‐old man/smoking for 20 years/no alcohol abuse RT‐PCR, CT Nasopharyngeal swab specimens Confirmed SARS‐CoV‐2/returned to Wuwei city on January 18 from Wuhan city by car Blood:
decreased lymphocytes, increased CRP, slightly elevated fibrinogen, neutrophil, LDH, and fibrinogen
PCR: positive for expression of RdRPN, N and E genes
CT: multiple patchy high‐density shadows scattered mainly in the border regions of lungs, solid changes, GGO changes, slightly thickened pleura Fever, cough productive of white phlegm, bosom frowsty, stuffy/runny noses, vertigo, fatigue, chest tightness, nausea, expiratory dyspnea, poor diet, lethargy/hypertension grade 2 and T2D – – Therapy:
combination therapy including:
Lopinavir/Ritonavir (800/200 mg daily), methylprednisolone (40 mg daily), recombinant human interferon α‐2b (10 million IU daily), ambroxol hydrochloride (60 mg daily) moxifloxacin hydrochloride (0.4 g daily), high flow humidification oxygen inhalation therapy, treatment of blood glucose, blood pressure, and rehydration therapy
Results interpretation: the persistent negative results of SARS‐CoV‐2 on days 6 and 7, normal TLC, lung lesions partially absorbed, The patient discharged. Laboratory tests like TLC are necessary, CT combined with RT‐PCR is helpful, Lopinavir/Ritonavir are effective after failure of methylprednisolone/interferon alfa‐2b
Liu et al. (2020), China Retrospective cohort and case study/Zhongnan Hospital of Wuhan University Dawu County People's Hospital 124 patients, 22 patients:
12 therapy (mean age 53), 10 control (mean age 58) CT, PCR Serum 124 confirmed COVID‐19 cases, 12 HCOV infected patients Blood: (Study 1) decreased platelet: 25 (20.2%), prolonged PT: 77 (62.1%), increased FIB: 27 (21.8%), and increased D‐dimer: 26 (21.0%)
Spectrum of disease: (study 2) severe cases: 6 mild cases: 4 critically ill: 2
CT: (study 2) Bilateral pneumonia: all Study 1: hypercoagulability
Study 2: cough: all shortness of breath: most of them, nausea and vomiting: 60.0%/DM, cardiovascular and cerebrovascular diseases: 4 patients from the DIP, 5 patients control group – 1 Therapy: Dipyridamole (150 mg in three separate doses for 7 consecutive days), antiviral (ribavirin, 0.5 g, Q12hr), corticoid (methylprednisolone sodium succinate, 40 mg, qd), oxygen therapy, nutritional support
Results and interpretation: significant increase in platelet/lymphocyte, significant decrease in D‐dimer levels
Discharged patients: 50% of severe cases and all 4 mild cases.
Dipyridamole adjunctive therapy could significantly reduce viral replication, inhibits hypercoagulability and improves immune recovery
Abbreviations: ALP, alkaline phosphatase; ALT, alanine aminotransferase; ARDS, acute respiratory distress syndrome; AST, aspartate aminotransferase; BUN, blood urea nitrogen; CK, creatine kinase; CK‐MB, creatine kinase myocardial band; COPD, chronic obstructive pulmonary disease; CRE, serum creatinine; CRP, C‐reactive protein; CT, computed tomography; CVD, cardiovascular disease; DM, diabetes mellitus; DM, diabetes mellitus; ESR, erythrocyte sedimentation rate; FIB, fibrinogen; FiO2, fraction of inspired oxygen; GGO, ground‐glass opacity; GGT, γ‐glutamyltransferase; GLM, Generalized Linear Model; LDH, lactate dehydrogenase; nCoV, novel coronavirus; PaO2, partial pressure of oxygen; PCT, procalcitonin; PT, prothrombin time; RNAaemia, SARS‐CoV‐2 nucleic acid; RR, respiratory rate; RT‐PCR, reverse transcriptase polymerase chain reaction; SpO2, oxygen saturation; T2D, type 2 diabetes; TB, total bilirubin; TCM, traditional Chinese medicine; TCM, traditional Chinese medicine; TLC, total lymphocyte count; TnT, troponin T; WBC, white blood cell.
John Wiley & Sons, Ltd. This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.
Table 4 Clinical trials for COVID‐19 or SARS‐nCoV2
Study title Interventions Location/condition Subjects, sex, age Primary purpose Arms Phase Measure outcome/time frame Code/status/date
The efficacy and safety of huaier in the adjuvant treatment of COVID‐19 Drug: Huaier Granule COVID‐19 550, all, 18–75 Treatment Experimental group: standard therapy + Huaier granule 20 g, po, tid for 2 weeks (or until discharge)
Control group: standard therapy II, III Primary (up to 28 days): all cause mortality
Secondary (up to 28 days): clinical status, differences in oxygen intake methods, supplemental oxygenation, mechanical ventilation, mean PaO2/FiO2, length of hospital stay, Length of ICU stay (days), pulmonary function (up to 3 months after discharge) NCT04291053/Not yet recruiting, Apr1‐Sep1 2020
Clinical trial on regularity of TCM syndrome and differentiation treatment of COVID‐19 Drug: TCM prescriptions China/COVID‐19 340, all, 18–75 Treatment Exposure group: integrated TCM and western medicine cohort (routine treatment + one or two of the following antiviral drugs + the following TCM regimens: take decocted or granule, one dose a day)
Control group: western medicine cohort (routine treatment + one or both of the following antiviral drugs) Not applicable Primary (9 days): The relief/disappearance rate of main symptoms, chest CT absorption
Secondary (9 days): virus antigen negative conversion rate, Clinical effective time: the average effective time. The number of severe and critical conversion cases, Incidence of complications, Traditional Chinese Medicine Syndrome Score
Other outcome measures (9 days): CRP changes, ESR changes, PCTchanges, The index of T cell subsets changed NCT04306497/Recruiting, Mar2‐May 2020
Recombinant human angiotensin‐converting enzyme 2 (rhACE2) as a treatment for patients with COVID‐19 Drug: Recombinant human angiotensin‐converting enzyme 2 (rhACE2) China/COVID‐19 24, all, 18–80 Treatment Experimental group: 0.4 mg/kg rhACE2 IV BID for 7 days and standard of care
Control group: standard of care Not applicable Primary (14 days): time course of body temperature, viral load over time
Secondary (14 days): P/F ratio over time, sequential organ failure assessment score over time, Pulmonary Severity Index, image examination of chest over time, proportion of subjects who progressed to critical illness or death, Time from first dose to conversion to normal or mild pneumonia, T‐lymphocyte counts over time, C‐reactive protein levels over time, angiotensin II (Ang II) changes over time, angiotensin 1–7 (Ang 1–7) changes over time, angiotensin 1–5 (Ang 1–5) changes over time, renin changes over time, aldosterone changes over time, angiotensin‐converting enzyme changes over time, angiotensin‐converting enzyme 2 (ACE2) changes over time, IL‐6 changes over time, IL‐8 changes over time, soluble tumor necrosis factor receptor type II (sTNFrII) changes over time, Plasminogen activator inhibitor type‐1 changes over time, Von willebrand factor changes over time, tumor necrosis factor‐α changes over time, soluble receptor for advanced glycation end products (sRAGE) changes over time, surfactant protein‐D changes over time, angiopoietin‐2 changes over time, frequency of adverse events and severe adverse events NCT04287686/Withdraw, Feb‐Apr 2020
The COVID‐19 mobile health study (CMHS) nCapp, a cell phone‐based autodiagnosis system China/COVID‐19 450, all, 18–90 Diagnosis Training: nCapp, a cell phone‐based autodiagnosis system, combined with 15 questions online, and a predicated formula to autodiagnosis of the risk of COVID‐19
Validation: nCapp, a cell phone‐based autodiagnosis system, combined with 15 questions online, and a predicated formula to auto‐diagnosis of the risk of COVID‐19 – Primary (1 day): accuracy of nCapp COVID‐19 risk diagnostic model NCT04275947/Recruiting, Feb 14‐May 31 2020
A Pilot Study of Sildenafil in COVID‐19 Drug: Sildenafil citrate tablets (G1) China/COVID‐19 10, all, 18 years and older Treatment Experimental group: sildenafil citrate tablet 0.1 g/day for 14 days Not applicable Primary (14 days): rate of disease remission, rate of entering the critical stage, time of entering the critical stage
Secondary (14 days): rate of no fever, rate of respiratory symptom remission, rate of lung imaging recovery, rate of C‐reactive protein (CRP) recovery, rate of Biochemical criterion (CK, ALT, Mb) recovery, rate of undetectable viral RNA (continuous twice), time for hospitalization, rate of adverse event NCT04304313/Recruiting, Feb 9‐Nov 9 2020
Critically Ill patients with COVID‐19 in Hong Kong: a multicentre observational cohort study – Hong Kong/COVID‐19 8 descriptive A case series of 41 hospitalized patients with confirmed infection
30% required critical care admission: developed severe respiratory failure, 10% required mechanical ventilation, 5% needed extracorporeal membrane oxygenation support mortality rate: 15% − Primary (28 days): 28 day mortality
Secondary (28 days): vasopressor days, days on mechanical ventilation, sequential organ function assessment score, ECMO use, percentage nitric oxide use, percentage free from oxygen supplement NCT04285801/Completed, Feb 14‐Feb 25 2020
Treatment of mild cases and chemoprophylaxis of contacts as prevention of the COVID‐19 epidemic Drug: antiviral treatment and prophylaxis, Standard Public Health measures COVID‐19 3,040, All, 18 Years and older Treatment Experimental: antiviral treatment and prophylaxis: darunavir 800 mg/cobicistat 150 mg tablets (oral, 1 tablet q24h, taking for 7 days) and hydroxychloroquine (200 mg tablets) 800 mg on Day 1, and 400 mg on days 2, 3, 4. Contacts: a prophylactic regimen of hydroxychloroquine (200 mg tablets) 800 mg on Day 1, and 400 mg on days 2,3,4. Other: standard public health measures
Active comparator: standard public health measures III Primary (up to 14 days after start of treatment): effectiveness of chemoprophylaxis assessed by incidence of secondary COVID‐19 cases
Secondary: the virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at days 3, the mortality rate of subjects at weeks 2, proportion of participants that drop out of study (up to 14 days after start of treatment), proportion of participants that show noncompliance with study drug (up to 14 days after start of treatment) NCT04304053/Not yet recruiting, Mar15‐Jul15 2020
Comparison of lopinavir/ritonavir or hydroxychloroquine in patients with mild coronavirus disease (COVID‐19) Drug: lopinavir/ritonavir, Drug: hydroxychloroquine sulfate Korea/COVID‐19 150, all, 16 years to 99 years Treatment Experimental: lopinavir/ritonavir 200 mg/100 mg 2 tablets by mouth, every 12 hr for 7–10 days
Active comparator: hydroxychloroquine 200 mg 2 tablets by mouth, every 12 hr for 7–10 days
No intervention: control, no lopinavir/ritonavir and hydroxychloroquine II Primary: viral load (hospital Day 3, 5, 7, 10, 14, 18)
Secondary viral load change (hospital Day 3, 5, 7, 10, 14, 18), time to clinical improvement (time frame: up to 28 days), percentage of progression to supplemental oxygen requirement by Day 7, Time to NEWS2 (National Early Warning Score 2) of 3 or more maintained for 24 hr by Day 7, time to clinical failure, defined as the time to death, mechanical ventilation, or ICU admission (up to 28 days), rate of switch to lopinavir/ritonavir or hydroxychloroquine by Day 7, adverse effects (up to 28 days), concentration of lopinavir/ritonavir and hydroxychloroquine (1, 2, 4, 5, 12 hr after taking intervention medicine) NCT04307693/Recruiting, Mar11‐May 2020
Study to evaluate the safety and antiviral activity of remdesivir (GS‐5734™) in participants with severe coronavirus disease (COVID‐19) Drug: remdesivir, standard of care United States, Hong Kong/COVID‐19 400, all, 18 years and older Treatment Experimental: demdesivir (RDV), 5 days participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, and 5
Experimental: remdesivir, 10 days participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, 5, 6, 7, 8, 9, and 10 III Primary: proportion of participants with normalization of fever and oxygen saturation through day 14
Secondary: proportion of participants with treatment emergent adverse events leading to study drug discontinuation (first dose date up to 10 days) NCT04292899/Recruiting, Mar6‐May 2020
Study to evaluate the safety and antiviral activity of remdesivir (GS‐5734™) in participants with moderate coronavirus disease (COVID‐19) compared to standard of care treatment Drug: remdesivir, standard of care United States, Hong Kong, 600, all, 18 years and older Treatment Experimental: remdesivir, 5 days participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, and 5.
Experimental: remdesivir, 10 days participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, 5, 6, 7, 8, 9, and 10.
Active comparator: continued standard of care therapy III Primary (up to 14 days): proportion of participants discharged by day 14‐secondary (up to 10 days): proportion of participants with treatment emergent adverse events leading to study drug discontinuation NCT04292730/Recruiting, Mar‐May 2020
Bevacizumab in severe or critical patients with COVID‐19 pneumonia‐RCT Drug: bevacizumab China/COVID‐19 Pneumonia 118, all, 18–80 Treatment Experimental; bevacizumab, group:
bevacizumab 500 mg + 0.9% NaCl 100 ml, intravenous drip
No intervention: control group Not applicable Primary: proportion of patients whose oxygenation index increased by 100 mmHg on the 7th day after admission NCT04305106/Not yet recruiting, Mar12‐May31 2020
The efficacy and safety of thalidomide in the adjuvant treatment of moderate new coronavirus (COVID‐19) pneumonia Drug: thalidomide, placebo COVID‐19 thalidomide 100, all, 18 years and older Treatment Placebo comparator: control group: placebo 100 mg, po, qn, for 14 days
Experimental: thalidomide group 100 mg, po, qn, for 14 days. Other name: fanyingting II Primary (up to 28 days): time to clinical recovery time to clinical recovery (up to 28 days)
Secondary (up to 28 days): all cause mortality (up to 28 days), frequency of respiratory progression, Time to defervescence
Others(up to 28 days): time to cough reported as mild or absent, respiratory improvement time, frequency of requirement for supplemental oxygen or noninvasive ventilation, Time to 2019‐nCoV RT‐PCR negative in upper respiratory tract specimen, change (reduction) in 2019‐nCoV viral load in upper respiratory tract specimen as assessed by area under viral load curve, frequency of requirement for mechanical ventilation, frequency of serious adverse events, Serum TNF‐α, IL‐1β, IL‐2, IL‐6, IL‐7, IL‐10, GSCF, IP10, MCP1, MIP1α and other cytokine expression levels before and after treatment NCT04273529/Not yet recruiting, Feb20‐Jun30 2020
The efficacy and safety of thalidomide combined with low‐dose hormones in the treatment of Severe COVID‐19 Placebo, drug: thalidomide COVID‐19 thalidomide 40, all, 18 years and older Treatment Placebo comparator: control group α‐interferon: nebulized inhalation, 5 million U or equivalent dose added 2 ml of sterile water for injection, 2 times a day, for 7 days; abidol, 200 mg/time, 3 times a day, for 7 days; methylprednisolone: 40 mg, q12h, for 5 days. placebo: 100 mg/d, qn, for 14 days
Experimental: thalidomide group α‐interferon: nebulized inhalation, 5 million U or equivalent dose added 2 ml of sterile water for injection, 2 times a day, for 7 days; abidol, 200 mg/time, 3 times a day, for 7 days; methylprednisolone: 40 mg, q12h, for 5 days. thalidomide: 100 mg/d qn for 14 days II Primary (up to 28 days): time to clinical improvement
Secondary (up to 28 days): clinical status (days 7, 14, 21, and 28), time to hospital discharge or NEWS2 (National Early Warning Score 2) of ≤2 maintained for 24 hr, all cause mortality, duration (days) of mechanical ventilation, duration (days) of extracorporeal membrane oxygenation, duration (days) of supplemental oxygenation, length of hospital stay (days), time to 2019‐nCoV RT‐PCR, change (reduction) in 2019‐nCoV viral load in upper and lower respiratory tract specimens as assessed by area under viral load curve, frequency of serious adverse drug events, Serum TNF‐α, IL‐1β, IL‐2, IL‐6, IL‐7, IL‐10, GSCF, IP10#MCP1, MIP1α, and other cytokine expression levels before and after treatment NCT04273581/Not yet recruiting, Feb18‐May30 2020
Tetrandrine tablets used in the treatment of COVID‐19 Drug: tetrandrine China/COVID‐19 60, all, 18–75 Treatment Experimental: tetrandrine cohort after the subjects were enrolled, they were given “Tetrandrine 60 mg QD” for a course of 1 week (take 6 days, stop using for 1 day)
No intervention: control cohort treatment according to standard protocols without intervention IV Primary (12 weeks): survival rate secondary (2 weeks): body temperature NCT04308317/Enrolling by invitation, Mar5‐May1 2020
Fingolimod in COVID‐19 Biological: UC‐MSCs, other: placebo China/COVID‐19 30, all, 18–80 Treatment Experimental: treatment group: each patient in the fingolimod treatment group was given 0.5 mg of fingolimod orally once daily, for three consecutive days
No Intervention: control group II Primary (5 day after treatment): the change of pneumonia severity on X‐ray images NCT04280588/Recruiting, Feb22‐Jul1 2020
Therapy for pneumonia patients infected by 2019 novel coronavirus Biological: UC‐MSCs, other: placebo China/COVID‐19 48, all, 18–75 Treatment Experimental: UC‐MSCs treatment group, participants will receive conventional treatment plus four times of 0.5*10E6 UC‐MSCs/kg body weight intravenously at Day1, Day3, Day5, Day7)
Placebo comparator: control group, participants will receive conventional treatment plus 4 times of placebo intravenously at Day1, Day3, Day5, Day7 Not applicable Primary (at baseline, Day 1, Weeks 1, 2, 4, 8): size of lesion area by chest imaging, blood oxygen saturation
Secondary (at baseline, Day 1, Weeks 1, 2, 4, 8): rate of mortality within 28‐days, sequential organ failure assessment, side effects in the UC‐MSCs treatment group, Electrocardiogram, the changes of ST‐T interval mostly, Concentration of C‐reactive protein C‐reactive protein, immunoglobulin, CD4 + and CD8 + T cells count, Concentration of the blood cytokine (IL‐1β, IL‐6, IL‐8,IL‐10,TNF‐α), Concentration of the myocardial enzymes NCT04293692/Recruiting, Feb24‐Feb1 2020–2021
The Use PUL‐042 inhalation solution to prevent COVID‐19 in adults exposed to SARS‐CoV‐2 Drug: PUL‐042 inhalation solution, drug: placebo COVID‐19 200, all, 18 years and older Treatment Experimental: PUL‐042 inhalation solution, PUL‐042 inhalation solution (20.3 µg Pam2: 29.8 µg ODN/mL) given by nebulization on study days 1,3, 6, and 10
Placebo comparator: sterile normal saline for inhalation, sterile normal saline for inhalation given by nebulization on study days 1, 3, 6, and 10 II Primary (14 days): Prevention of COVID‐19 NCT04313023/Not yet recruiting, Apr‐Oct 2020
Treatment of COVID‐19 patients using Wharton's jelly‐mesenchymal stem cells Biological: WJ‐MSCs Arabia Amman, Jordan/use of stem cells for COVID‐19 treatment 5, all, 18 years and older Treatment Experimental: WJ‐MSCs WJ‐MSCs will be derived from cord tissue of newborns, screened for HIV1/2, HBV, HCV, CMV, mycoplasma, and cultured to enrich for MSCs.
WJ‐MSCs will be counted and suspended in 25 ml of saline solution containing 0.5% human serum albumin, and will be given to patient intravenously I Primary (3 weeks): Clinical outcome, CT Scan, RT‐PCR results
Secondary (8 weeks): RT‐PCR results NCT04313322/Recruiting, Mar16‐Sep30 2020
Myocardial damage in COVID‐19 Non China/COVID‐19 cardiovascular diseases 500, all, 18 years and older Prognostic Discharged group (no intervention) the individual which is defined as patient discharged from hospital
Dead group (no intervention) The individual which is defined as patient with all‐cause death – Primary (75 days): the myocardial injury incidence, the risk factors analysis for the death
Secondary (75 days): clinical characteristics, clinical course, cardiovascular comorbidity, Analysis of causes of death NCT04312464/Enrolling by invitation, Jun1‐Mar18 2020
Treatment with mesenchymal stem cells for severe corona virus disease 2019(COVID‐19) Biological: MSCs, biological: saline containing 1%, human serum albumin (solution of MSC China/COVID‐19 60, all, 18–70 Treatment Experimental: mesenchymal stem cells (MSCs), conventional treatment plus MSCs participants will receive conventional treatment plus 3 times of MSCs ((4.0*10E7 cells per time) intravenously at Day 0, Day 3, Day 6)
Placebo comparator: placebo conventional treatment plus placebo participants will receive conventional treatment plus 3 times of placebo (saline containing 1% human serum albumin (solution of MSC) 3 times of placebo (intravenously at Day 0, Day 3, Day 6) I, II Primary (28 days): improvement time of clinical critical treatment index, side effects in the MSCs treatment group
Secondary: proportion of patients in each classification of clinical critical treatment index (baseline, Days 7, 14, 28), all cause mortality on Day 28, invasive mechanical ventilation rate (Day 28), duration of oxygen therapy (Day 28), duration of hospitalization (Day 28), incidence of nosocomial infection (Day 28), CD4+ T cell count by flow cytometry in two groups (baseline, Day, 3, 6, 10, 14, 21, 28) NCT04288102/Recruiting, May5‐Dec31 2020–2021
The clinical study of carrimycin on treatment patients with COVID‐19 Drug: carrimycin, drug: lopinavir/ritonavir tablets or arbidol or chloroquine phosphate, Drug: basic treatment – 520, all, 18–75 Treatment Experimental: carrimycin basic treatment + carrimycin
Active comparator: lopinavir/ritonavir or arbidol or chloroquine phosphate any of basic treatment + lopinavir/ritonavir tablets or arbidol or chloroquine phosphate IV Primary (30 days): fever to normal time (day), pulmonary inflammation resolution time (HRCT) (day), negative conversion (%) of 2019‐nCOVRNA in gargle (throat swabs) at the end of treatment NCT04286503/Not yet recruiting, Feb23‐Feb28 2020–2021
Efficacy and safety of corticosteroids in COVID‐19 Drug: methylprednisolone China/COVID‐19 400, all, 18 years and older Treatment Experimental; Pred group: methylprednisolone 1 mg/kg/day ivgtt for 7 days
No intervention: con group Not applicable Primary (14 days): the incidence of treatment failure in 14 days
Secondary: clinical cure incidence (14 days), the duration of virus change to negative (14 days), mortality at Day 30, ICU admission rate in 30 days NCT04273321/Recruiting, Feb14‐May30 2020
Evaluation of the efficacy and safety of sarilumab in hospitalized patients with COVID‐19 Drug: sarilumab, drug: placebo United States/COVID‐19 400, all, 18 years and older Treatment Experimental: sarilumab high dose: single intravenous (IV) dose of sarilumab, other names: Kevzara®, REGN88, SAR153191
Experimental: sarilumab low dose: single intravenous (IV) dose of sarilumab Other Names: Kevzara®, REGN88, SAR153191
Placebo comparator: single intravenous (IV) dose of placebo to match sarilumab administration II, III Primary: time to resolution of fever for at least 48 hr without antipyretics for 48 hr (Up to Day 29), percentage of patients reporting each severity rating on a 6‐point ordinal scale (Day 15)
Secondary (up to Day 29): time to improvement in oxygenation for at least 48 hr, mean change in the 6‐point ordinal scale, clinical status using the 6‐point ordinal scale, time to improvement in one category from admission using the 6‐point ordinal scale, time to resolution of fever for at least 48 hr without antipyretics by clinical severity, time to resolution of fever for at least 48 hr without antipyretics by baseline IL‐6 levels, time to improvement in oxygenation for at least 48 hr by clinical severity, time to improvement in oxygenation for at least 48 hr by baseline IL‐6 levels, time to resolution of fever and improvement in oxygenation for at least 48 hr, time to change in National Early Warning Score 2 (NEWS2) scoring system, time to score of <2 maintained for 24 hr in NEWS2 scoring system, mean change in NEWS2 scoring system, number of days with fever, number of patients alive off oxygen, number of days of resting respiratory rate >24 breaths/min, number of days with hypoxemia, number of days of supplemental oxygen use, time to saturation ≥94% on room air, number of ventilator free days in the first 28 days, number of patients requiring initiation of mechanical ventilation, number of patients requiring noninvasive ventilation, number of patients requiring the use of high flow nasal cannula, number of patients admitted into an intensive care unit, number of days of hospitalization among survivors, number of deaths due to any cause (up to Day 60), incidence of serious adverse events (Up to Day 60), incidence of severe or life‐threatening bacterial, invasive fungal, or opportunistic infection, Incidence of severe or life‐threatening bacterial, invasive fungal, or opportunistic infection in patients with grade 4 neutropenia, Incidence of hypersensitivity reactions, incidence of infusion reactions, incidence of gastrointestinal perforation, white blood cell count, hemoglobin levels, platelet count, creatinine levels, total bilirubin level, alanine aminotransferase level, aspartate aminotransferase level NCT04315298/Recruiting, Mar16‐Mar16 2020–2021
Washed microbiota transplantation for patients with 2019‐nCoV infection Other: washed microbiota transplantation, other: placebo China/COVID‐19 complicated with refractory intestinal infections 0, all, 14–70 complicated with refractory intestinal infections Treatment Experimental: observational group 5 u washed microbiota suspension administered via nasogastric tube, nasojejunal tube or oral, combining with standard therapy
Placebo comparator: control group 5 u placebo (edible suspension of the same color as the washed microbiota suspension) administered via nasogastric tube, nasojejunal tube or oral, combining with standard therapy Not applicable Primary (2 weeks): number of participants with improvement from severe type to common type NCT04251767/Withdrawn, Feb5‐Apr30 2020
Safety and immunity of Covid‐19 aAPC vaccine Biological: pathogen‐specific aAPC China/Covid‐19 infection 100, all, 6 months to 80 years Treat and Prevent Covid‐19 Infection Experimental: the subjects will receive three injections of 5×10^6 each Covid‐19/aAPC vaccine via subcutaneous injections I Primary (0–28 day): frequency of vaccine events, frequency of serious vaccine events, proportion of subjects with positive T cell response
Secondary (0–28 day): mortality, duration of mechanical ventilation if applicable, proportion of patients in each category of the 7‐point scale (7, 14, and 28 days after randomization), proportion of patients with normalized inflammation factors (7 and 14 days after randomization), clinical improvement based on the 7‐point scale if applicable, lower Murray lung injury score if applicable (7 days after randomization) NCT04299724/Recruiting, Feb15‐Dec31 2020–2024
Safety related factors of endotracheal intubation in patients with severe Covid‐19 pneumonia Severe covid‐19 pneumonia with ET COVID‐19 endotracheal intubation 120, all, 18–90 Observational Intervention details: other: severe covid‐19 pneumonia with ET, severe covid‐19 pneumonia undergoing endotracheal intubation – Primary:
Success rate of intubation (the time span between 1 hr before intubation and 24 hr after intubation), infection rate of anesthesiologist (the time span between 1 hr before intubation and 14 days after intubation)
Secondary:
Extubation time (the time span between 1 hr before intubation and 30 days after intubation) NCT04298814/Not yet recruiting, Mar7‐Jul30 2020
Immunity and safety of Covid‐19 synthetic minigene vaccine Biological: injection and infusion of LV‐SMENP‐DC vaccine and antigen‐specific CTLs China/COVID‐19 100, all, 6 months to 80 years Treatment Experimental: pathogen‐specific DC and CTLs patients will receive approximately 5 × 106 LV‐DC vaccine and 1 × 108 CTLs via subcutaneous injections and iv infusions, respectively I
II Primary:
Clinical improvement based on the 7‐point scale (28 days after randomization), lower Murray lung injury score (7 days after randomization)
Secondary (0–28 day): 28‐day mortality, duration of mechanical ventilation, duration of hospitalization, proportion of patients with negative RT‐PCR results (7 and 14 days after randomization), proportion of patients in each category of the 7‐point scale (7, 14, and 28 days after randomization), proportion of patients with normalized inflammation factors (7 and 14 days after randomization), frequency of vaccine/CTL events, frequency of serious vaccine/CTL events NCT04276896/Recruiting, Mar24‐Dec31 2020–2024
Phase I clinical trial in healthy adult Biological: recombinant novel coronavirus vaccine (adenovirus type 5 vector) – 108, all, 18–60 Prevention Experimental: low‐dose group subjects received one dose of 5E10 vp Ad5‐nCoV at 18–60 years old
Experimental: middle‐dose group
Subjects received one dose of 1E11 vp Ad5‐nCoV at 18–60 years old
Experimental: high‐dose group
Subjects received one dose of 1.5E11vp Ad5‐nCoV at 18–60 years old I Primary (0–7 days postvaccination): safety indexes of adverse reactions
Secondary (Day 14, 28, Month 3, 6 postvaccination):
Safety indexes of adverse events (0–28 days postvaccination), safety indexes of SAE (0–28 days, within 6 mouths postvaccination), safety indexes of lab measures (pre‐vaccination, Day 7 postvaccination), immunogencity indexes of GMT(ELISA) (Day 14, 28, Month 3, 6 postvaccination), immunogencity indexes of GMT (pseudoviral neutralization test method), immunogencity indexes of seropositivity rates, immunogencity indexes of seropositivity rates (pseudoviral neutralization test method, immunogencity indexes of GMI (ELISA), immunogencity indexes of GMI (pseudoviral neutralization test method), immunogencity indexes of GMC (Ad5 vector), immunogencity indexes of GMI (Ad5 vector), immunogencity indexes of cellular immune
Other (day、14,28, Month3,6 postvaccination):
Consistency analysis(ELISA and pseudoviral neutralization test method), Dose‐response relationship (Humoral immunity), Persistence analysis of anti‐S protein antibodies, Time‐dose‐response relationship (Humoral immunity), Dose‐response relationship (cellular immunity), Persistence analysis of cellular immuse, Time‐dose‐response relationship (cellular immunity) NCT04313127/Not yet recruiting, Mar1Dec20 2020–2022
Development and verification of a new coronavirus multiplex nucleic acid detection system Diagnostic test: new QIAstat‐Dx fully automatic multiple PCR detection platform China/COVID‐19 100, all, 16 years to 100 years Diagnostic Diagnostic test: new QIAstat‐Dx fully automatic multiple PCR detection platform
We use the new QIAstat‐Dx fully automatic multiple PCR detection platform to test the enrolled patients – Primary:
Sensitivity, spectivity turnaround time of the New QIAstat‐Dx fully automatic multiple PCR detection platform (3 months) NCT04311398/Not yet recruiting, Mar14‐Dec1, 2020
Hydroxychloroquine treatment for severe COVID‐19 pulmonary infection (HYDRA Trial) Drug: hydroxychloroquine, drug: placebo oral tablet COVID‐19 severe acute respiratory syndrome 500, all, 18–0 Treatment Active comparator: treatment
Hydroxychloroquine tablet 200 mg every 12 hr for 10 days
Placebo comparator: placebo
identical placebo, one tablet every 12 hr for 10 days III Primary (up to120 days):
All‐cause hospital mortality
Secondary (up to120 days):
Length of hospital stay, Need of mechanical ventilation, ventilator free days, Grade 3–4 adverse reaction NCT04315896/Not yet recruiting, Mar23‐Mar22 2020–2012
Tocilizumab in COVID‐19 pneumonia (TOCIVID‐19) Drug: tocilizumab Injection Italy/COVID‐19 pneumonia 330, child, adult, older adult, child, adult, older adult Treatment Experimental: Tocilizumab Injection
Tocilizumab 8 mg/kg (up to a maximum of 800 mg per dose), with an interval of 12 hr II Primary (up to 1 month):
One‐month mortality rate
Secondary (up to 1 month):
interleukin‐6 level, lymphocyte count, C‐reactive protein level (cycle 1 and 2 every 12 hr), PaO2 (partial pressure of oxygen)/FiO2 (fraction of inspired oxygen, FiO2) ratio (or P/F ratio) (baseline, during treatment (cycle 1 and 2 every 12 hr), change of the SOFA (sequential organ failure assessment) (baseline, during treatment (cycle 1 and 2 every 12 hr), number of participants with treatment‐related side effects as assessed by Common Terminology Criteria for Adverse Event version 5.0, Radiological response, Time Frame: at baseline (optional), after 7 days and if clinically indicated, duration of hospitalization. Time Frame: from baseline up to patient's discharge, Remission of respiratory symptoms NCT04317092/Recruiting, Mar19‐Dec19 2020–2022
Mesenchymal stem cell NestCell® to treat patients with severe COVID‐19 pneumonia Biological: NestCell® COVID‐19 pneumonia 6, all, 18 years and older Treatment Experimental: NestCell®:
All patients will receive conventional treatment plus 3 times of 1 × 106 cells/kg body weight intravenously on Day1, Day3, and Day7 I Primary (28 days):
Disappear time of ground‐glass shadow in the lungs
Secondary:
Rate of mortality within 28‐days, Improvement of clinical symptoms including duration of fever and respiratory (At Baseline, Day 3, 7, 10, 14, 21, 28), Time of nucleic acid turning negative (28 days), CD4+ and CD8+ T cell count (At Baseline, Day 3, 6, 10, 14, 21, and 28), changes of blood oxygen (At Baseline, Day 3, 6, 10, 14, 21, and Day 28), side effects in the treatment group (28 days) NCT04315987/Not yet recruiting, Apr‐Jun 2020
CD24Fc as a non‐antiviral immunomodulator in COVID‐19 treatment Drug: CD24Fc, drug: placebo United States/severe coronavirus disease (COVID‐19) 230, all, 18 years and older Treatment Experimental: CD24Fc treatment
Single dose at Day 1, CD24Fc, 480 mg, diluted to 100 ml with normal saline, IV infusion in 60 min
Placebo comparator: placebo
Single dose at Day 1, normal saline solution 100 ml, IV infusion in 60 min III Primary (14 days):
Improvement of COVID‐19 disease status secondary (14 days):
Conversion rate of clinical status at Day 8 (7 days), conversion rate of clinical status at Day 15, hospital discharge time, all cause of death, duration of mechanical ventilation, duration of pressors, duration of ECMO, duration of oxygen therapy, length of hospital stay, absolute lymphocyte count NCT04317040/Not yet recruiting,May‐May 2020–2022
Acute kidney injury in patients hospitalized with COVID‐19 – China/COVID‐19 acute kidney injury‐kidney function 287, all, 18 years and older Observational Acute kidney injury:
COVID‐19 patients with acute kidney injury
nonacute kidney injury:
COVID‐19 patients without acute kidney injury –
Rate of death, the length of hospital stay Primary (up to 60 days):
Rate of acute kidney injury
Secondary (up to 60 days): NCT04316299/Completed, Feb 26‐Mar8 2020
Phase I clinical trial in healthy adult Logical: recombinant novel coronavirus vaccine (adenovirus type 5 vector) COVID‐19 108, all, 18–60 Treatment (Adenovirus Type 5 Vector)
Experimental: low‐dose group
Subjects received one dose of 5E10 vp Ad5‐nCoV at 18–60 years old
Experimental: middle‐dose group
Subjects received one dose of 1E11 vp Ad5‐nCoV at 18–60 years old
Experimental: high‐dose group subjects received one dose of 1.5E11vp Ad5‐nCoV at 18–60 years old I Primary (0–7 days postvaccination):
Safety indexes of adverse reactions
Secondary (0–28 days postvaccination, within 6 mouths postvaccination):
Safety indexes of adverse events, Safety indexes of SAE, Safety indexes of lab measures, Immunogencity indexes of GMT (ELISA), Immunogencity indexes of GMT (pseudoviral neutralization test method) (Day 14, 28, Month 6 postvaccination), Immunogencity indexes of seropositivity rates (ELISA) (Day 14, 28, Month 3, 6 postvaccination), Immunogencity indexes of seropositivity rates(pseudoviral neutralization test method) (Day 14, 28, Month 6 postvaccination), Immunogencity indexes of GMI (ELISA) (Day 14, 28, Month 3, 6 postvaccination), Immunogencity indexes of GMI (pseudoviral neutralization test method) (Day 14, 28, Month 6 postvaccination), Immunogencity indexes of GMC (Ad5 vector) (Day 14, 28, Month 3, 6 postvaccination), Immunogencity indexes of GMI(Ad5 vector) (Day 14, 28, Month 3, 6 postvaccination), Immunogencity indexes of cellular immune (Day 14, 28, Month 6 postvaccination)
Other (Day 14,28, Month 6 postvaccination):
Consistency analysis (ELISA and pseudoviral neutralization test method), dose‐response relationship (humoral immunity) (Day 14, 28, Month 3, 6 postvaccination), Persistence analysis of anti‐S protein antibodies (Day 14, 28, Month 3, 6 postvaccination), Time‐dose‐response relationship (Humoral immunity) (Day 14, 28, Month 3, 6 postvaccination), Dose‐response relationship (cellular immunity) (Day 14, 28, Month 6 postvaccination), Persistence analysis of cellular immuse (Day 14, 28, Month 6 postvaccination), Time‐dose‐response relationship (cellular immunity) (Day 14, 28, Month 6 postvaccination) NCT04313127/Not yet recruiting, Mar19‐Dec20 2020–2021
Favipiravir combined with tocilizumab in the treatment of corona virus disease 2019 Drug: favipiravir combined with tocilizumab, drug: favipiravir, drug: tocilizumab China, COVID‐19 150, all, 18–65 Treatment Experimental: favipiravir combined with tocilizumab group
Favipiravir: On the 1st day, 1,600 mg each time, twice a day; from the 2nd to the 7th day, 600 mg each time, twice a day. Oral administration, the maximum number of days taken is not more than 7 days.
Tocilizumab: the first dose is 4–8 mg/kg and the recommended dose is 400 mg. For fever patients, an additional application (the same dose as before) is given if there is still fever within 24 hr after the first dose and the interval between two medications ≥12 hr. Intravenous infusion. The maximum of cumulative number is two, and the maximum single dose does not exceed 800 mg
Active comparator: favipiravir group
On the 1st day, 1,600 mg each time, twice a day; from the 2nd to the 7th day, 600 mg each time, twice a day. Oral administration, the maximum number of days taken is not more than 7 days
Active comparator: tocilizumab group
The first dose is 4–8 mg/kg and the recommended dose is 400 mg. For fever patients, an additional application (the same dose as before) is given if there is still fever within 24 hr after the first dose and the interval between two medications ≥12 hr. Intravenous infusion, The maximum of cumulative number is two, and the maximum single dose does not exceed 800 mg Not applicable Primary (3 months):
Clinical cure rate
Secondary (14 days after taking medicine):
Viral nucleic acid test negative conversion rate and days from positive to negative, duration of fever, lung imaging improvement time, mortality rate because of corona virus disease 2019 (3 months), rate of noninvasive or invasive mechanical ventilation when respiratory failure occurs (3 months), mean in‐hospital time (3 months) NCT04310228/Recruiting, Mar8‐May 2020
Novel coronavirus induced severe pneumonia treated by dental pulp mesenchymal stem cells Biological: dental pulp mesenchymal stem cells ‐COVID‐19 24, all, 18–75 Treatment Experimental: pulp mesenchymal stem cells 1. 3, 7 days to increase the injection of mesenchymal stem cells Early Phase I Primary (14 days):
Disppear time of ground‐glass shadow in the lungs
Secondary:
Absorption of lung shadow absorption by CT Scan‐Chest (7, 14, 28, and 360 days), Changes of blood oxygen (3, 7, and 14 days) NCT04302519/Not yet Recruiting, Mar5‐Jul30 2020–2021
Multicenter clinical study on the efficacy and safety of Xiyanping injection in the treatment of new coronavirus infection pneumonia (general and severe) Drug: lopinavir/ritonavir tablets combined with Xiyanping injection drug: lopinavir/ritonavir treatment COVID‐19 80, all, 18–100 Treatment Experimental: experimental group of ordinary COVID‐19:
Xiyanping injection, 10–20 ml daily, Qd, the maximum daily does not exceed 500 mg (20 ml) + lopinavir tablet or ritonavir tablet + alpha‐interferon nebulization, for 7–14 days,
Active comparator: control group of ordinary COVID‐19:
Lopinavir/ritonavir tablets, two times a day, two tablets at a time; alpha‐interferon nebulization
Experimental: experimental group of severe COVID‐19:
Xiyanping injection, 10–20 ml daily, Qd, the maximum daily does not exceed 500 mg (20 ml) + lopinavir tablet or ritonavir tablet + alpha‐interferon nebulization, for 7–14 days Not applicable Primary:
Clinical recovery time (up to Day 28) NCT04295551/Not yet Recruiting, Mar14‐Apr14 2020–2021
Prognostic factors of patients with COVID‐19 – China/SARS‐CoV‐2 outcome, fatal 201, all, 18 years and older Prognostic SARS‐CoV‐2Outcome, fatal – Primary (30 days):
all‐cause mortality
Secondary (15 days):
all‐cause mortality,
Severe state NCT04292964/Completed Mar1‐Mar13 2020
Chloroquine prevention of coronavirus disease (COVID‐19) in the healthcare setting Drug: chloroquine, drug: placebo COVID19 coronavirus acute respiratory illnesses 10,000, all, 16 years and older Prevention Experimental: chloroquine:
a loading dose of 10 mg base/kg followed by 150 mg daily (250 mg chloroquine phosphate salt) will be taken for 3 months
Placebo comparator: placebo Not applicable Primary (approximately 100 days):
Number of symptomatic COVID‐19 infections
Secondary (approximately 100 days):
Symptoms severity of COVID‐19, duration of COVID‐19, number of asymptomatic cases of COVID‐19, number of symptomatic acute respiratory illnesses, genetic loci and levels of biochemical components will be correlated with frequency of COVID‐19, ARI, and disease severity
Other (approximately 100 days):
Drug exposure‐protection relationship NCT04303507/Not yet recruiting, May‐May 2020–2022
Yinhu Qingwen decoction for the treatment of mild/common CoVID‐19 Drug: YinHu QingWen decoction, drug: YinHu QingWen decoction(low dose), other: Chinese medicine treatment, other: standard western medicine treatment China/CoVID‐19 Chinese medicine 300, all, 18 years and older Treatment Experimental: Yin Hu Qing Wen decoction group
Based on the standard western medicine treatment, the patients will be given Yinhu Qingwen decoction (granula) for 10 days.
Drug: YinHu QingWen decoction YinHu QingWen decoction (granula) consits of 11 Chinese herbal medicine as honeysuckle, Polygonum cuspidatum, Schizonepeta, Longspur epimedium, and so forth. The decoction granula will be dissolved into 600 ml decoction and divided to three times (once with 200 ml). It will be given a 200 ml per time, three times a day, for 10 days
Other: standard western medicine treatment treatment is according to the protocol of treatment of CoVID‐19 infection according to guideline appoved by National Health Commission of China
Placebo comparator: Yinhu Qingwen decoction low‐dose group
Based on the standard western medicine treatment, the patients will be given 10% dose of Yinhu Qingwen decoction (granula) for 10 days
Drug: YinHu QingWen decoction (low dose) this intervention is given as 10% dose of YinHu QingWen decoction (granula). The granula will be dissolved into 600 ml decoction and divided to three times (once with 200 ml). It will be given a 200 ml per time, three times a day, for 10 days
Other: standard western medicine treatment standard western medicine treatment is according to the protocol of treatment of CoVID‐19 infection according to guideline appoved by National Health Commission of China
Active comparator: integrated Chinese and western medicine group
Based on the standard western medicine treatment, the patients will be given Chinese medicine decotion granula according to their symptoms. The daily dose of Chinese medicine decoction granula will also be dissolved to 600 ml decoction and divided into three times (once with 200 ml). The Chinese medicine decoction will be given 200 ml per time, three times a day for 10 days
Other: Chinese medicine treatment
This intervention will be given with Chinese medicine decoction granula based on the symptoms differentiation of the patients for 10 days
Other: standard western medicine treatment
Standard western medicine treatment is according to the protocol of treatment of CoVID‐19 infection according to guideline appoved by National Health Commission of China II
III Primary (up to 28 days):
Mean clinical recovery time
Secondary (up to 28 days):
Time to CoVID‐19 RT‐PCR negative in upper respiratory tract specimen, change (reduction) in CoVID‐19 viral load in upper respiratory tract specimen as assessed by area under viral load curve, time to defervescence (in those with fever at enrollment), time to cough reported as mild or absent (in those with cough at enrollment rated severe or moderate), time to dyspnea reported as mild or absent (on a scale of severe, moderate, mild absent, in those with dyspnea at enrollment rated as severe or moderate)
Frequency of requirement for supplemental oxygen or noninvasive ventilation, frequency of respiratory progression, severe case incidence, proportion of rehospitalization or admission to ICU, all‐cause mortality, frequency of serious adverse events NCT04278963/Active, Not Recruiting, Feb27‐Jan 2020
Prognositc factors in COVID‐19 patients complicated with hypertension – China, COVID‐19 0, all, 18–100 Prognostic ACEI treatment
hypertension patients with ACEI treatment when suffered with novel coronavirus infection in China
Control
hypertension patients without ACEI treatment when suffered with novel coronavirus infection in China – Primary (up to 28 days):
Occupancy rate in the intensive care unit, mechanical ventilation, death
Secondary (up to 28 days):
All cause mortality, time from onset of symptoms to main outcome and its components, time to clinical recovery NCT04272710/Withdrawn, Jan25‐Apr30 2020
Evaluating the efficacy and safety of bromhexine hydrochloride tablets combined with standard treatment/standard treatment in patients with suspected and mild novel coronavirus pneumonia (COVID‐19) Drug: bromhexine hydrochloride tablets, drug: arbidol hydrochloride granules, drug: recombinant human interferon α2b spray, drug: favipiravir tablets China, novel coronavirus pneumonia 2019‐nCoV 60, all, 18–80 Treatment Experimental: group A treatment group:
Bromhexine hydrochloride tablets, arbidol hydrochloride granules:
Standard treatment refers to the latest edition of pneumonia diagnosis and treatment scheme for novel coronavirus infection. Arbidol hydrochloride granules is recommended but not enforced to use
Recombinant human interferon α2b spray:
Standard treatment refers to the latest edition of pneumonia diagnosis and treatment scheme for novel coronavirus infection
Favipiravir tablets
Active comparator; group B control group:
Drug: arbidol hydrochloride granules
Standard treatment refers to the latest edition of pneumonia diagnosis and treatment scheme for novel coronavirus infection. arbidol hydrochloride granules is recommended but not enforced to use
Drug: recombinant human interferon α2b spray
Standard treatment refers to the latest edition of pneumonia diagnosis and treatment scheme for novel coronavirus infection Not applicable Primary (within 14 days from the start of medication):
Time to clinical recovery after treatment
Secondary (within 14 days from the start of medication):
Rate of aggravation, clinical remission rate, dynamic changes of oxygenation index, time to cure, rate to cure, time to defervescence, time to cough remission,days of supplemental oxygenation, rate of patients with requring supplemental oxygen, rate of patients with mechanical ventilation, time of negative COVID‐19 nucleic acid results, rate of negative COVID‐19 nucleic acid results, rate of ICU admission, 28‐day mortality (From the first day of screening to the day of follow‐up (28 days)) NCT04273763/Enrolling by invitation, Feb16‐Apr30 2020
Various combination of protease inhibitors, oseltamivir, favipiravir, and chloroquin for treatment of covid19: a randomized control trial Drug: oral Thailand, coronavirus infections COVID19 80, all, 16–100 Treatment Experimental: oseltamivir plus chloroquin in mild COVID19
Oseltamivir 300 mg per day plus chloroquin 1,000 mg per Day In mild COVID19
Experimental: lopinavir and ritonavir plus favipiravir
Lopinavir 10 mg/kg and ritonavir 2.5 mg/kg plus favipiravir 2,400 mg, 2,400 mg, and 1,200 mg every 8 hr on Day 1, and a maintenance dose of 1,200 mg twice a day in Mild COVID19
Experimental: lopinavir and ritonavir plus oseltamivir in mild COVID19
Lopipinavir 10 mg/kg and ritonavir 2.5 mg/kg plus oseltamivir 4–6 mg/kg In mild COVID19
Experimental: lopinavir and ritonavir oseltamivir moderate to severe COVID19
Lopipinavir 10 mg/kg and ritonavir 2.5 mg/kg plus oseltamivir 4–6 mg/kg in moderate to critically ill COVID19
Experimental: favipiravir lopinavir/ritonavir for mod. To severe
favipiravir 2,400 mg, 2,400 mg, and 1,200 mg every 8 hr on Day 1, and a maintenance dose of 1,200 mg twice a day plus lopipinavir 10 mg/kg and ritonavir 2.5 mg/kg in moderate to critically ill COVID19
Experimental: darunavir/ritonavir oseltamivir chloroquine mod‐severe
Combination of Darunavir 400 mg every 8 hr ritonavir Ritonavir 2.5 mg/kg plus Oseltamivir 4–6 mg/kg plus Chloroquine 500 mg per Day In moderate to critically ill COVID19
Experimental: darunavir/ritonavir favipiravir chloroquine mod‐severe
Favipiravir 2,400 mg, 2,400 mg, and 1,200 mg every 8 hr on Day 1, and a maintenance dose of 1,200 mg twice a day plus darunavir 400 mg every 8 hr ritonavir ritonavir 2.5 mg/kg plus chloroquine 500 mg per Day In moderate to critically ill COVID19
No intervention: conventional qurantine
Patient who unwilling to treatment and willing to quarantine in mild COVID19 III Primary (Up to 24 weeks):
SARS‐CoV‐2 eradication time
Secondary (up to 24 weeks):
Number of patient with death, number of patient with recovery adjusted by initial severity in each arm, number of day with ventilator dependent adjusted by initial severity in each arm,number of patient developed acute respiratory distress syndrome after treatment
Other (up to 24 weeks):
Number of patient with acute respiratory distress syndrome recovery NCT04303299/Not yet recruiting, Mar15‐Nov30 2020
Yinhu Qingwen Granula for the treatment of severe CoVID‐19 Drug: Yinhu Qingwen granula, drug: Yin Hu Qing Wen granula (low does), other: standard medical treatment China, COVID‐19 severe pneumonia Chinese medicine 116, all, 18 years and older Treatment Experimental:
Yinhu Qingwen granula group:
Drug: Yinhu Qingwen Granula
Yinhu Qingwen granula is a kind of herbal granula made from “Yinhu Qingwen Decoction,” which consits of 11 Chinese herbal medicine as honeysuckle, Polygonum cuspidatum, schizonepeta, Longspur epimedium, etc. The granula will be dissolved into 600 ml decoction and divided to three times (once with 200 ml). It will be given a 200 ml per time, three times a day, for 10 days.
Other: standard medical treatment Standard medical treatment is adhered to the protocol of the treatment for the severe CoVID‐19 according to the guideline approved by National Health Commission of China.
Placebo comparator: Yinhu Qingwen granula low‐dose group:
Drug: Yin Hu Qing Wen granula (low does). This intervention is given as 10% dose of YinHu QingWen Granula.The granula will be dissolved into 600 ml decoction and divided to three times (once with 200 ml).
Other: standard medical treatment Standard medical treatment is adhered to the protocol of the treatment for the severe CoVID‐19 according to the guideline approved by National Health Commission of China. II Primary (Day 10):
changes in the ratio of PaO2 to FiO2 from baseline
Secondary (up to 30 days):
PaO2, blood oxygen saturation (SpO2), clinical status rating on the 7‐point ordinal scale, time to clinical improvement, duration (hours) of noninvasive mechanical ventilation or high‐flow nasal catheter oxygen inhalation use, duration (hours) of invasive mechanical ventilation use, duration (hours) of extracorporeal membrane oxygenation (ECMO) use, duration (days) of oxygen use, The proportion of the patients reporting 2019‐nCoV RT‐PCR negativity at Day 10 after treatment, the counts/percentage of lymphocyte, time to hospital discharge with clinical recovery from the randomization, the incidence of critical status conversion in 30 days, all‐cause mortality within 30 days, frequency of severe adverse drug events NCT04310865/Not yet recruiting, Mar20‐Jun30 2020–2021
Clinical characteristics and long‐term prognosis of 2019‐nCoV infection in children – China, 2019‐nCoV 500, all, up to 18 years Prognosis 2019‐nCoV infection group
Children hospitalized with direct laboratory confirmed of novel coronavirus with or without pneumonia are classified as the 2019‐nCoV infection group
Control group Children hospitalized with pneumonia other than the novel coronavirus pneumonia during the same hospitalization period as 2019‐nCoV infection group are classified as the control group – Primary (6 months):
The cure rate of 2019‐nCoV, the improvement rate of 2019‐nCoV, the incidence of long‐term adverse outcomes
Secondary (2 weeks):
Duration of fever, duration of respiratory symptoms, duration of hospitalization, number of participant(s) need intensive care, number of participant(s) with acute respiratory distress syndrome, number of participant(s) with extra‐pulmonary complications, including shock, renal failure, multiple organ failure, hemophagocytosis syndrome, et al., number of participant(s) who died during the trial (10 months) NCT04270383/Not yet recruiting, Feb15‐Dec30 2020
The effect of T89 on improving oxygen saturation and clinical symptoms in patients with COVID‐19 Drug: T89 Coronavirus disease 2019 novel coronavirus pneumonia 120, all, 18–85 Treatment Experimental: The T89 treatment group Besides a standard background treatment (antiviral drug + antibacterial + oxygen therapy + Traditional Chinese Medicine decoction), all subjects in the T89 treatment group will receive 30 pills of T89 each time, orally, BID (every morning and evening), for 10 days (depending on clinical need and practicability, the use can be extended for up to 14 days)
No intervention: the blank control group
All subjects in the blank control group will only receive a standard background treatment (antiviral drug + antibacterial + oxygen therapy + Traditional Chinese Medicine decoction), for 10 days. Not applicable Primary (Day −1 to 10): the time to oxygen saturation recovery to normal level (≥97%), the proportion of patients with normal level of oxygen saturation(≥97%)
Secondary (Day −1 to 10):
The degree of remission of symptoms of patients, including: fatigue, nausea, vomiting, chest tightness, shortness of breath, and so forth, the time to the myocardial enzyme spectrum recovery to normal after treatment, the proportion of the patients with normal myocardial enzyme spectrum after treatment, the time to the electrocardiogram recovery to normal level after treatment, the proportion of the patients with normal electrocardiogram after treatment, the time to the hemodynamics recovery to normal after treatment, the proportion of the patients with normal hemodynamics after treatment, the time to exacerbation or remission of the disease after treatment, the proportion of the patients with exacerbation or remission of disease after treatment, the proportion of patients who need other treatment (e.g., heparin, anticoagulants) due to microcirculation disorders, the all‐cause mortality rate, the proportion of patients with acidosis, the total duration of the patients in‐hospital, the total duration of oxygen inhalation during treatment, the oxygen flow rate during treatment, the oxygen concentration during treatment NCT04285190/Not yet recruiting, Feb26‐Sep15 2020
Immunoregulatory therapy for 2019‐nCoV Drug: PD‐1 blocking antibody + standard treatment, drug: Thymosin + standard treatment, other: standard treatment ‐2019 nCoV, PD‐1 120, all, 18 years and older Treatment Experimental: PD‐1 group
Anti‐PD‐1 antibody, 200 mg, IV, one time
Experimental: thymosin group
Thymosin, 1.6 mg sc qd, last for 5 days
Placebo comparator: control group stand treatment II Primary (7 days):
lung injury score
Secondary:
Absolute lymphocyte counts (7, 14 and 28 days), serum level of CRP, PCT and IL‐6 (3, 7 and 14 days), SOFA score (7 days), all cause mortality rate (28 days), ventilation free days (28 days), ICU free days (up to 28 days) NCT04268537/Not yet recruiting, Feb10‐Oct31 2020
Tocilizumab vs CRRT in management of cytokine release syndrome (CRS) in COVID‐19 Drug: tocilizumab, other: standard of care, procedure: continuous renal replacement therapy China, Covid‐19 SARS cytokine storm (and 2 more…) 120, all, 18–80 Observational Tocilizumab
Subjects received 8 mg/kg (body weight) Tocilizumab once in 100 ml 0.9% saline solution and administered intravenously within no <60 min. Tocilizumab was administered according—continuous renal replacement therapy
Femoral vein catheterization was performed to complete continuous renal replacement therapy for consecutive three times or more. to the local label
Standard care
Standard of care therapy per local written policies or guidelines – Primary (up to 14 days):
Proportion of participants with normalization of fever and oxygen saturation
Secondary:
Duration of hospitalization (Up to 28 days), proportion of participants with normalization of fever (up to 14 days), change from baseline in white blood cell and differential count (up to 28 days), time to first negative in 2019 novel corona virus RT‐PCR test (Up to 28 days), all‐cause mortality (up to 12 weeks), change from baseline in hsCRP (Up to 28 days), change from baseline in cytokines IL‐1β, IL‐10, sIL‐2R, IL‐6, IL‐8 and TNF‐α (Up to 28 days), change from baseline in proportion of CD4 + CD3/CD8 + CD3 T cells (Up to 28 days) NCT04306705/Recruiting, Feb20‐Jun20 2020
Sars‐CoV2 seroconversion among front line medical and paramedical staff in emergency, intensive care units and infectious disease departments during the 2020 Epidemic Other: blood sample France, Sars‐CoV2 1,000, all, child, adult, older adult Other Caregiver
caregivers from emergency, ICU, virology and infectious disease services:
Two blood samples at T0 and 3 months Not applicable Primary (3 months):
Quantify the proportion of patients with documented Sars‐CoV2 infection among medical and paramedical staff
Secondary (3 months):
Identification of risk factors for seroconversion, quantify the proportion of asymptomatic infections among staff who have seroconverted, describe symptomatic infections for personnel developing acute clinical (respiratory or digestive) viral syndrome NCT04304690/Recruiting, Mar16‐Oct16 2020
John Wiley & Sons, Ltd. This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.
5.3.1 Reverse transcriptase polymerase chain reaction
Despite being the diagnostic gold standard, pathogenic lab testing is a rather time‐consuming procedure, with unavoidable false‐positive results (Wang, Kang, et al., 2020). It is recommended that lab testing should be performed, as soon as the patient is identified as a “person under investigation” (PUI). Viral nucleic acid required for an RT‐PCR test is usually extracted from secretions of the lower respiratory tract, for example, bronchoalveolar lavage; however, tracheal aspirate or sputum can also be used (Chu et al., 2020; Corman et al., 2020). Since the onset of the epidemic, several factors have been found to affect the final efficiency of nucleic acid testing, that is, availability, quality, stability, and reproducibility of detection kits. In most of the cases, the tests need to be repeated for several times (Wang, Kang, et al., 2020), as the estimated detection rate of the test falls in an underwhelming range of 30–50% (Chu et al., 2020; Corman et al., 2020; Zhang et al., 2020). In spite of being a valuable asset, the undesirable false‐negative results of RT‐PCR have prompted careful clinical and etiological evaluation of COVID‐19 in suspected cases as the first‐line diagnostic method (Zu et al., 2020).
5.3.2 Computed tomography (CT)
CT has proved to be of great value in diagnosis of the COVID‐19‐associated pneumonia, as it provides major evidence, that cannot readily be obtained with alternative methods. It is true that CT is a reliable imaging modality in subtle detection of viral pneumonia and screening of suspected cases; however, it should be noted that many pulmonary diseases of inflammatory nature share similar radiographic findings (Wang, Kang, et al., 2020). The majority of patients with COVID‐19 present with GGO in their chest CT, which later progress into multilobar consolidations. There have been several reports of rounded opacities, which are sometimes peripherally distributed in the lung (Chung et al., 2020; Huang et al., 2020). In contrast to CT, plain chest radiography (CXR) has not been recommended as a first‐line imaging method, because this modality does not provide the clarity viewed on CT scans, especially in the early stages of pulmonary infection (Ng et al., 2020). Nevertheless, CXR is capable of recording pathologic changes in patients with severely progressed COVID‐19, as the bilateral multifocal consolidations present in these patients are too dense to be missed. The notorious “white lung” appearance can be optimally viewed on CXRs of critically ill patients (Zu et al., 2020). CT resulted in diagnosis of 14,840 new cases as of February 13, 2020 (Zu et al., 2020). Therefore, slice chest CT is an adequately sensitive and reliable method in early detection of pneumonia in patients with COVID‐19 (Chan et al., 2020; Ng et al., 2020).
5.3.3 Novel approaches: Artificial intelligence‐based technologies
Depp learning, as a novel AI‐based modality might be able to analyze radiographic features of COVID‐19, and help clinicians provide an accurate clinical diagnosis based on a precedented pattern (Wang, Kang, et al., 2020). As part of recent advancements, Convolutional Neural Network (CNN), a class of deep neural networks, has been shown to be capable of medical image analysis. To this date, CNN has been successfully employed in investigations on the nature of pulmonary nodules reported in CT images, diagnosis of pneumonia in children based on CXR, and image recognition in cystoscopy videos (Choe et al., 2019; Kermany et al., 2018; Negassi, Suarez‐Ibarrola, Hein, Miernik, & Reiterer, 2020; Wang et al., 2018).
The 21st century has seen many AI‐based models to be incorporated in several scientific fields, particularly imaging studies. Diagnostic AI‐based models might actually be a forward leap in tasks that simply cannot be handled by manpower, especially risk prioritization, that can greatly help improve patient turnaround time. Given the shortage of human resources and inadequate number of hospital beds in a country like China, AI‐based models for analysis of CXR and CT scans can be useful in ruling out irrelevant cases, and resource‐wise admission of patients to the hospitals (Kim, 2020).
6 PREDICTION
Recent studies focused on prognosis of COVID‐19 concluded that the load of SARS‐CoV‐2 RNA in blood (RNAemia) is correlated with Cytokine Release Storm (CRS) and poor prognosis of the disease. In one particular study, scientists used Generalized Linear Models to generate a prediction model for natural history of disease based on the C t value of real‐time RT‐PCR results. They reported that traceable amounts of SARS‐CoV‐2 RNA was detected in blood plasma of 15% of COVID‐19 positive patients enrolled at the study. Their findings drew a direct link between serum markers and disease severity, as RNAemia and high levels of IL‐6 (nearly 10‐fold) were exclusively reported in critically ill patients. Interestingly, there was also an association between the extremely high levels of IL‐6 with the incidence of RNAemia (R = 0.902) in patients. Findings also suggested that vital signs of patients were also affected by high levels of both serum markers (R = 0.682). According to this study, IL‐6 might be of clinical value in identification and treatment of patients with an excessive inflammatory response (Chen, Zhao, et al., 2020). Table 3 (Chen, Zhao, et al., 2020; Yan et al., 2020) and Table 4 represent 2020 studies on prognosis of COVID‐19 infected patients and related clinical trials, respectively.
7 THERAPY
Scientists have made strenuous efforts to come up with an effective regimen for successful treatment of COVID‐19 (Gao, Tian, & Yang, 2020). Table 3 (Chen, Guo, et al., 2020; Fan et al., 2020; Han et al., 2020; Lan et al., 2020; Li, Zhang, et al., 2020; Li, Hu, et al., 2020; Lim et al., 2020; Liu et al., 2020; Liu et al., 2020; Wu et al., 2020; Wu & McGoogan, 2020), Tables 4 and 5 (Zhang & Liu, 2020) represent 2020 studies on treatment of COVID‐19 infected patients, related clinical trials and available therapeutic options, respectively.
Table 5 Therapeutic options that are available for the treatment of novel coronaviruses (cell line, animal, and human studies)
General treatment Nutritional interventions, targets or function Vit A Measles virus, measles‐related pneumonia, HIV, avian CoV, IBV Upregulating the elements of the innate immune, Making the cells refractory to infection
B vit MERS‐CoV Enhancing immune system, Inhibiting the of neutrophil infiltration into the lungs, Anti‐inflammatory effects during ventilator‐induced lung injury
Vit C Avian CoV Supporting immune functions, protecting against CoV infection, preventing of the lower respiratory tract infections
Vit D Bovine CoV Triggering the maturation of immune cells
Vit E Coxsackievirus, bovine CoV Antioxidant function
Omega‐3 PUFA Influenza virus, HIV Attenuating the replication of influenza virus
Selenium Influenza virus, avian CoV Antioxidant function, inducing immune response
Zinc Influenza virus, avian CoV, SARS‐CoV Maintenance/development of innate and adaptive immune systems simultaneously
Iron Viral mutations Enhancing the immune system
Immunoenhancers IFNs SARS‐CoV, MERS‐CoV Acting as apart of the innate immune response, Inhibiting the replication of CoVs in animal and human
IVIg SARS‐CoV Increasing the viscosity in hypercoagulable states
Ta1 SARS‐CoV Restoring the homeostasis of the immune system, Increasint the resistance glucocorticoid‐induced death of thymocyte
TP5, munox Restore antibody production Restoring antibody production, Enhancing the antibody response, As adjuvant treatment
Levamisole Immunostimulant/immunosuppressive agent Increasing the functions of cellular immunity, Act as immunostimulant agent or immunosuppressive agent through dose‐ and time‐dependent manner, reversing the depressed helper/inducer lymphocytes
Cyclosporine A SARS‐CoV, avian infectious bronchitis virus Both facilitating or inhibiting virus replication, blocking the all genera replication of CoV
CTM Glycyrrhizin, Baicalin, Ginseng SARS‐CoV, avian infectious bronchitis virus Enhancing host immunity, Inhibiting the replication of SARS‐associated virus and SARS‐CoV, Enhancing the specific‐antibody responses
Specific treatments Protease inhibitors 3C‐like inhibitors Cinanserin, SARS‐CoV Act as serotonin receptor antagonist, Inhibiting the replication
Flavonoids MERS‐CoV Act as antioxidant and antiviral compound, blocking the enzymatic activity of MERS‐CoV/3CLpro
PLP inhibitors SARS‐CoV Inhibit PLP of SARS‐CoV
S protein‐ACE2 blockers Human mAb SARS‐CoV Neutralizing SARS‐CoV, inhibiting syncytia formation between cells expressing the S protein and the SARS‐CoV receptor ACE2
Chloroquine SARS‐CoV Possess antiviral effect, inhibiting of SARS‐CoV infection via interfering with ACE2
Emodin SARS‐CoV Blocking the interaction between the S protein of virus and ACE2
Promazine SARS‐CoV Inhibiting the replication of virus, inhibiting the binding of S protein to ACE2
Nicotianamine Inhibiting the ACE2
Antiviral treatments Ribavirin SARS‐CoV Inhibiting the the replication of SARS‐associated CoV
LPV/RTV (Kaletra) HIV, SARS‐CoV, MERS‐CoV protease inhibitor
RDV SARS‐CoV, MERS‐CoV Improving the pulmonary function, reducing the lung viral loads and severe lung pathology
Nelfinavir HIV, SARS‐CoV Act as selective inhibitor of HIV protease, Inhibiting the replication virus
ARB influenza A/B, hepatitis C virus Blocking viral fusion, entry and replication
Nitric oxide SARS Antiviral effects
Other compounds ALA human CoV‐229E, HIV Act as antioxidant, inhibiting the replication of HIV‐1
Estradiol and phytoestrogen SARS‐CoV, MERS, influenza A Reducing virus replication in primary human nasal epithelial cells
Mucroporin‐M1 influenza H5N1 viruses, and SARS‐CoV Virucidal activity against viruses
Abbreviations: 3 CLpro, 3C‐like protease; Ab, antibody; ACE2, angiotensin converting enzyme 2; ALA, α‐lipoic acid; ARB, arbidol; CoV, coronavirus; CTM, Chinese traditional medicine; HIV, human immunodeficiency virus; IBV, bronchitis virus; IFN, interferons; IVIg, intravenous gammaglobulin; LPV/RTV, lopinavir/ritonavir; mAb, monoclonal antibody; PLpro, papain‐like protease; PUFA, polyunsaturated fatty acids; RDV, remdesivir; S, spike; Ta1, thymosin α‐1; TP5, thymopentin; Vit, vitamin.
John Wiley & Sons, Ltd. This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.
7.1 Chloroquine phosphate
Chloroquine phosphate is an old medicine, that has been widely used for treatment of malaria in endemic regions. It is also a salutary treatment of choice for certain progressive anti‐inflammatory diseases, for example, rheumatoid arthritis, and systemic lupus erythematosus. Recently, an investigation in China reported that remdesivir and chloroquine phosphate were effective experimental agents for controlling SARS‐CoV‐2 infection in the lab (Chen et al., 2013). Initial findings reported by a recent study on effectiveness of therapeutic agents in management of SARS‐CoV‐2 infection, and suggested successful application of chloroquine phosphate in treatment of patients with COVID‐19‐associated pneumonia. Following the promising results, scientists recommended chloroquine phosphate to be included in treatment regimen of COVID‐19 patients with severe involvement of the lungs (Yu et al., 2013). On February 15, 2020, participants from different organizations, including medical experts and authorities, made an agreement on potency of Chloroquine phosphate against SARS‐CoV‐2 infection (https://www.clinicaltrialsarena.com/analysis/coronavirus-mers-cov-drugs/).
So far, close monitoring of over 100 patients, who were under treatment of chloroquine phosphate, has provided further evidence regarding the effectiveness of this long‐known medicine. Investigations indicated that chloroquine phosphate prevented exacerbation of pneumonia in these patients, improved their chest CT findings, and shortened the otherwise long natural course of the disease. Importantly, there have been no records of severe reaction or hypersensitivity to this therapeutic agent. It has been suggested that the broad‐spectrum antiviral activity of chloroquine phosphate lies within the complicated pharmacodynamics of the drug that results in a basic shift in the endosomal pH required for successful fusion of virus onto the host cell. chloroquine phosphate also seems to have disruptive effects on glycosylation of cellular receptors of SARS‐CoV (Yin & Wunderink, 2018; Zumla et al., 2020), rendering them nonfunctional. It also interferes with activation of p38 mitogen‐activated protein kinase, a signaling event involved in replication of HCoV‐229E (Kono et al., 2008).
7.2 Lopinavir/ritonavir, leronlimab, galidesivir
Lopinavir/Ritonavir, commonly used for treatment of HIV infection, has been indicated for treatment of COVID‐19 in a number of reports (Kim et al., 2020). Previous studies suggested that when combined together, Lopinavir and Ritonavir act in concert to hinder further replication of SARS‐CoV, and improve the clinical status of patients with SARS (Chu et al., 2004). This might also mean that the well‐known antiretroviral duo can also prove beneficial in treatment of COVID‐19.
Other candidates for possible management of SARS‐CoV‐2 include Leronlimab and Galidesivir, both of which have been of clinical value in treatment of several fatal viral infections, and were shown to improve the survival of patients. Leronlimab is a humanized monoclonal antibody (CCR5 antagonist). Galidesivir, on the other hand, belongs to the family of nucleoside RNA polymerase inhibitors (https://www.clinicaltrialsarena.com/analysis/coronavirus-mers-cov-drugs/). In the absence of any specific therapeutic agents to quell SARs‐CoV‐2, it might be a salutary strategy to repurpose the already available medicine, and include them in treatment of COVID‐19 (Tian et al., 2020).
Several clinical trials can be viewed at ClinicalTrials.gov, that are currently in progress. These trials have specially focused on potency of Remdesivir, immunoglobulins, and combinational therapies, for example, Arbidol hydrochloride with interferon atomization, ASC09F and oseltamivir, ritonavir and oseltamivir, and lopinavir combined with ritonavir (https://clinicaltrials.gov/ct2/results?cond=&2019nCoV&term=&cntry=&state=&city=&dist=).
7.3 RAAS inhibitors
ACE2 is a prominent regulatory arm in the RAAS axis, thus, a disruption in ACE‐Angiotensin II‐Angiotensin Type 1 Receptor (AT1R), and ACE2/Angiotensin‐(1‐7)/Mas Receptor axes can result in multisystem inflammation. Increased levels of ACE and Angiotensin II in plasma are considered poor prognostic factors in severe pneumonia. Several studies on animal models have reported effectiveness of RAAS inhibitors in alleviation of severe pneumonia and acute respiratory failure. In the aftermath of SARS‐CoV‐2 and ACE2 binding, the enzyme is eventually degraded, hence, the inhibition of ACE2/Angiotensin‐(1‐7)/Mas Receptor pathway. Accordingly, it is assumed that ACE and AT1R inhibitors might be game‐changing agents that can especially be administered for COVID‐19 patients who have serious impairments in their homeostasis. Maintenance of homeostasis may ultimately result in suppression of the inflammatory response, mostly in the pulmonary tissue (Sun, Yang, Sun, & Su, 2020).
7.4 Combination therapy
Combination therapy is a more extensive and rigorous approach mainly aimed at correction of life‐threatening events such as shock, hypoxemia, secondary or super infection, and maintenance of homeostasis, that is, electrolyte, acid and base balance. As a palliative practice, antiviral treatment in the early stages of COVID‐19 might lessen the severity and prevent further progression of the disease. Trials on combination therapy with lopinavir/ritonavir and arbidol (umifenovir) have reported satisfactory results in treatment of COVID‐19. Alongside a proper antiviral treatment, patients may also benefit from an artificial liver blood purification system, which is capable of rapidly removing the inflammatory factors from blood, thus, halting the disastrous cytokine release syndrome. This system can also facilitate the sustenance of critically ill patients by preserving the balance of bodily fluid. Administration of glucocorticoids in moderate doses is another intervention that has recently been indicated for patients with severe COVID‐19‐associated pneumonia. However, secondary fungal infection should be considered. Patients with an oxygenation index of less than 200 mmHg might benefit more from oxygen therapy than noninvasive ventilation. A rational prescription of antimicrobial medicines has been cautioned only for patients with remittent fever and elevated antimicrobial prophylaxis should be prescribed rationally and was not recommended except for patients with long course of disease, repeated fever, and elevated PCT levels. Ultimately, to maintain the balance of intestinal microbiota, oral intake of prebiotics or probiotics has been suggested. This can reduce the risk of secondary infections as a result of microbial translocation; however, effectiveness of such interventions on postinfection clearance pattern of SARS‐CoV‐2 has not been studied (Xu et al., 2020).
7.5 Other future possible options
7.5.1 Convalescent blood therapy
A conspicuously conventional method, transfusion of human convalescent plasma, might be viewed as a beneficial strategy for prevention and even treatment of COVID‐19. The method is as facile as its age since it only requires an adequate number of recovered patients who are willing to donate their immunoglobulin‐containing serum. Although one still might argue the possibility of SARS‐CoV‐2 infection via convalescent blood transfusion, no such incident with SARS‐CoV was reported by WHO amidst the outbreak of the disease in 2003. The heft of past experience should come to mind once it is noted that the majority of approaches and therapeutic strategies that are currently being tested for COVID‐19 are derived from clinical experience in treatment of SARS, MERS, and other correspondents viral epidemics (Casadevall & Pirofski, 2020; Cunningham, Goh, & Koh, 2020).
7.5.2 Mesenchymal stem cell (MSC) therapy
A new therapeutic for treating immune‐mediated diseases, MSC therapy might have the capability to terminate the inappropriate release of cytokines in COVID‐19. Through its anti‐inflammatory effects, MSC therapy has been reported to improve respiratory function in murine models with acute lung injury. Evidence suggests that MSCs might be doing so by repressing the aberrant release of inflammatory factors (Hu & Li, 2018; Wang, Yao, Lv, Ling, & Li, 2017; Xiang et al., 2017). In particular, a study by Chinese scientists concluded that transplantation of MSCs could be considered as a novel approach in treatment of viral pneumonia, noting promissory implications of this method in management of H7N9‐induced ARDS. Since H7N9 and SARS‐CoV‐2 can result in similar complications, for example, ARDS and respiratory failure, MSC‐based therapy might lead to a new path in treatment of COVID‐19‐associated pneumonia (Chen, Hu, et al., 2020).
7.5.3 Nano drug delivery systems
It has long been known that the traditional circulation‐based delivery of therapeutic agents is not as effect, prompting pharmaceutical industries to develop novel platforms for delivery of molecules to hard‐to‐reach tissues in human body. Conjugation of antiviral agents, particularly nucleoside analogs, with specific nanoparticles has proved to be effectual in treatment of resistant HIV infection (Agarwal, Chhikara, Doncel, & Parang, 2017; Agarwal, Chhikara, Quiterio, Doncel, & Parang, 2012). Today, an appreciable number of drug delivery platforms based on nanotechnology are available that can be experimentally used with custom therapeutic formulations for treatment of COVID‐19 (Chhikara & Varma, 2019) in hopes of shortening the course of the disease (Chhikara et al., 2020).
7.5.4 Psychological interventions
Progression of COVID‐19, similar to any other disease, can result in suffering of the patients, prompting psychological symptoms, which will require special interventions. It has been well‐established today that individuals who fall victim to public health emergencies, for example, disease outbreaks, develop variable degrees of stress disorders. The problem persists even after the individual has recovered and discharged from the hospital (Cheng, Wong, Tsang, & Wong, 2004; Fan, Long, Zhou, Zheng, & Liu, 2015). With that in mind, one should consider several factors for classification of patients who will most probably benefit from psychological interventions; that is overall course of the disease, severity, and quality of hospitalization (e.g., home, ordinary wards, ICU, etc.) (Duan & Zhu, 2020).
In large‐scale outbreaks such as COVID‐19 epidemic, healthcare workers become the frontline at providing psychological cares for patients who battle against the disease. Primary medical and mental care should be provided for those individuals who are recognized as “suspected case” and duly quarantined at home. (Duan & Zhu, 2020).
Interventions should be discreetly formulated following a thorough evaluation of risk factors involved in emerging of these psychological issues, including a history of impaired mental health, bereavement after a deceased family member, panic, separation from loved ones, and a low income (Kun, Han, Chen, Yao, & Anxiety, 2009).
8 PATIENTS RECOVERED FROM COVID‐19
The following criteria must be met in order for a patient to be discharged from hospital or released from quarantine: (a) having been afebrile for at least 3 consecutive days, (b) remission of respiratory distress, (c) regression of infiltrations/consolidations on chest CT images, and two consecutive negative reports of RT‐PCR test performed at least 1 day apart (d). Despite these thoroughly formulated criteria, one study reported positive RT‐PCR test results 5–13 days after hospital discharge for four patients with COVID‐19, who met all of the criteria above before they were discharged. These findings are important in that they imply the slight possibility that even a fully recovered patient might still be a silent carrier of the virus. In this scenario, however, no family members were reported to be infected, since all of the four patients with bizarrely late positive tests were medical professional, and followed all of the guidelines while they were at home quarantine. With due attention to this incident, the current criteria for hospital discharge may need to be reconsidered (Lan et al., 2020).
9 CONCLUSIONS AND FUTURE PERSPECTIVES
Deemed a global health emergency, COVID‐19 outbreak has continued to be the headline of the news. The number of confirmed cases is on the rise, and the seamless spread of the virus has become a plight for general population, and the entire medical community. In spite of the extreme preventive measures while near a patient, clinicians are still at great risk for contracting the disease from the visitors. Else, it is vividly known that quarantine alone is not the optimal choice for containing of the virus. On the other hand, the devastating potential impact of the outbreak is a much feared topic around the world. Science has always been the ultimate arsenal of weaponry when it comes to battling obstinate pathogens; however, time is needed for conduction of proper investigations on human‐to‐human and animal‐to‐human transmission of SARS‐CoV‐2.
With no access to requisite information on the structure and life cycle of the novel Coronavirus, research and development programs on therapeutic agents become a far‐fetched milestone, rendering the tried‐and‐true primary prevention measures the only proper means to confront SARS‐CoV‐2. As of today, few existing drugs have been considered for treatment of COVID‐19, with scant reports on benevolence of the results. As our meager knowledge of SARS‐CoV‐2 is advancing, one may speculate the advent of an effectual vaccine, alongside treatment options that might include antiviral agents, and even monoclonal antibodies. At the time of writing this manuscript, no definitive treatment option has been known for COVID‐19; however, the unabating flow of investigations and clinical trials may soon lead us to the optimal therapy for COVID‐19‐associated pneumonia.
Needless to say, the fascinatingly high transmissibility of COVID‐19 demands meticulous monitoring of the transmission routes and patterns to a reach a firm theory on adaptive mechanisms wielded by SARs‐CoV‐2, thus, making an accurate prediction about the future outcomes regarding pathogenicity, transmissibility, and evolution of the virus. These efforts will hopefully result in better prognosis and fewer mortalities.
CONFLICT OF INTERESTS
The authors declare that they have no conflict of interest.
AUTHOR CONTRIBUTIONS
All authors contributed to different parts of the study.
|
|
sec
|
1 INTRODUCTION
CoVs were recognized as “novel respiratory tract viruses” over half a century ago. The title was conferred in 1962, following the examination of samples collected from individuals who had manifested symptoms of respiratory tract infection (Hamre & Procknow, 1966). Initially, CoVs were not considered as highly pathogenic for humans. That was until 2002, however, that CoVs emerged in the form of Severe Acute Respiratory Syndrome (SARS) in the Guangdong state of China (Sahin et al., 2020). Almost a decade later, another highly pathogenic CoV appeared in the Middle East countries, which similarly led to severe respiratory symptoms of acute onset. The then‐novel species was named Middle East Respiratory Syndrome Coronavirus (MERS‐CoV; Zaki, Van Boheemen, Bestebroer, Osterhaus, & Fouchier, 2012).
In December 2019, a cluster of insidious Coronavirus infections was reported in the Huanan Seafood Market, located in Wuhan State of Hubei Province in China. Unlike the name, livestock animals were also traded in the market alongside their marine relatives. Days later, the cluster turned into a local network and set off the alarm for the Chinese government. It was then that a pneumonia epidemic of unknown cause became the focus of global attention (Sahin et al., 2020). Chinese authorities announced on January 7, 2020 that a new type of CoV (novel CoV, nCoV) was isolated (Imperial College London, 2020; World Health Organization, 2020). On December 12, 2019, a pneumonia case of unknown origin was reported in Wuhan, China. Initial laboratory tests ruled out Influenza and infection with recognized CoVs. Following the incident, 27 new cases of pneumonia of viral origin were officially reported on December 31, 2019. A week later on January 7, 2020, the Chinese authorities announced that a new species of CoV was isolated in the country (Zumla, Hui, Azhar, Memish, & Maeurer, 2020).
Given the whereabouts of the first case ever reported, the infection was speculated to have been contracted from a zoonotic agent. Etiologic investigations on patients who had been hospitalized with a similar medical history supported the likelihood of a viral infection transmitted from animals to humans (Sahin et al., 2020; World Health Organization, 2020; Yin & Wunderink, 2018). nCoV was duly reported to have been originated from wild bats. Falling in the category of group 2 β‐CoVs, the novel Coronavirus only shares a 70% similarity in genetic sequence with its predecessor, SARS‐CoV, which also belongs to the exact same family (Gralinski & Menachery, 2020).
The tantalizing surge in the number of cases infected with SARS‐CoV‐2 in China, despite the closure of markets and evacuation of the vicinity, fulfilled the burden of proof that the virus can also be transmitted from human to human. Soon thereafter, peculiar cases of acute respiratory syndrome started appearing in other Asian countries, ultimately spreading to North America and Europe. (Sahin et al., 2020; World Health Organization, 2020; Yin & Wunderink, 2018). Following an emergent briefing on January 30, 2020, The World Health Organization (WHO) declared the outbreak of COVID‐19 as a Public Health Emergency of International Concern (Organization, 2020).
The epidemic began to emerge with the advent of the Chinese New Year, a traditionally important festival that is heavily celebrated across the country. The coincidence paved the way for SARS‐CoV‐2 to turn into an unprecedented massive Coronavirus outbreak, which required extensive measurements to be contained. With a population of 10 million, Wuhan City also served as an important pathway for millions of people traveling in celebration of the Spring Festival. Accordingly, the number of cases to be diagnosed with COVID‐19 showed an overwhelming increase between January 10–22, 2020 (Chen, Zhang et al., 2020).
Despite the arbitrary speculations, not only did the recent outbreak of COVID‐19 egress the country of origin, it also proceeded to become a global concern in the form of a pandemic (Yang et al., 2020). COVID‐19 is an acute self‐resolving respiratory disease in most of the cases, however, it can also be fatal in some cases. The disease was initially reported to have a mortality rate of 2%. If severe, COVID‐19 might result in death as a result of the preceding extensive alveolar damage, and failure of the lungs (Xu et al., 2020). As of February 15, 2020, a total of 66,580 cases had been confirmed, with over 1,524 deaths. However, there have no specific reports on pathology, as performing an autopsy or biopsy was not possible in most of the cases (Chan et al., 2020; Huang et al., 2020). Table 1. Represents the WHO situation reports on March 24, 2020 (www.WHO.int).
Table 1 The number of cases and death of Covid‐19 outbreak according to World Health Organization statistics (April 13, 2020)
Region Total (new) cases in last 24 hr Total (new) death in last 24 hr
Globally 1,773,084 confirmed (76,498) 111,652 deaths (5,702)
Western Pacific Region 121,426 confirmed (1,310) 4,125 deaths (67)
European Region 913,349 confirmed (33,243) 77,419 deaths (3,183)
South‐East Asia Region 16,883 confirmed (842) 766 deaths (38)
Eastern Mediterranean Region 99,713 confirmed (3,768) 5,107 deaths (164)
American Region 610,742 confirmed (36,804) 23,759 deaths (2,228)
African Region 10,259 confirmed (531) 464 deaths (21)
John Wiley & Sons, Ltd. This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency. A total of 8,096 SARS cases and 774 deaths across 29 countries were reported for an overall case‐fatality rate (CFR) of 9.6%. MERS is still not contained and is thus far responsible for 2,494 confirmed cases and 858 deaths across 27 countries for a CFR of 34.4%. Despite the much higher CFR of 9.6% and 34.4% for SARS and MERS, the novel Coronavirus epidemic has led to a larger death toll. The Chinese government had reported 72,528 confirmed cases, with 1,870 deaths, as of February 18, 2020. These statistics yield a crude CFR of 2.6%. However, one should not haste to generalize this number, as most possibly the total number of patients with COVID‐19 is much higher. That is, because the cases are not readily identifiable, as many asymptomatic patients are missed during the process (Wu et al., 2020; Yan et al., 2020). Despite the higher transmissibility than SARS and MERS, COVID‐19 is still a relatively unknown disease and requires further investigations to be fully understood (Yan et al., 2020).
|
|
label
|
1
|
|
title
|
INTRODUCTION
|
|
p
|
CoVs were recognized as “novel respiratory tract viruses” over half a century ago. The title was conferred in 1962, following the examination of samples collected from individuals who had manifested symptoms of respiratory tract infection (Hamre & Procknow, 1966). Initially, CoVs were not considered as highly pathogenic for humans. That was until 2002, however, that CoVs emerged in the form of Severe Acute Respiratory Syndrome (SARS) in the Guangdong state of China (Sahin et al., 2020). Almost a decade later, another highly pathogenic CoV appeared in the Middle East countries, which similarly led to severe respiratory symptoms of acute onset. The then‐novel species was named Middle East Respiratory Syndrome Coronavirus (MERS‐CoV; Zaki, Van Boheemen, Bestebroer, Osterhaus, & Fouchier, 2012).
|
|
p
|
In December 2019, a cluster of insidious Coronavirus infections was reported in the Huanan Seafood Market, located in Wuhan State of Hubei Province in China. Unlike the name, livestock animals were also traded in the market alongside their marine relatives. Days later, the cluster turned into a local network and set off the alarm for the Chinese government. It was then that a pneumonia epidemic of unknown cause became the focus of global attention (Sahin et al., 2020). Chinese authorities announced on January 7, 2020 that a new type of CoV (novel CoV, nCoV) was isolated (Imperial College London, 2020; World Health Organization, 2020). On December 12, 2019, a pneumonia case of unknown origin was reported in Wuhan, China. Initial laboratory tests ruled out Influenza and infection with recognized CoVs. Following the incident, 27 new cases of pneumonia of viral origin were officially reported on December 31, 2019. A week later on January 7, 2020, the Chinese authorities announced that a new species of CoV was isolated in the country (Zumla, Hui, Azhar, Memish, & Maeurer, 2020).
|
|
p
|
Given the whereabouts of the first case ever reported, the infection was speculated to have been contracted from a zoonotic agent. Etiologic investigations on patients who had been hospitalized with a similar medical history supported the likelihood of a viral infection transmitted from animals to humans (Sahin et al., 2020; World Health Organization, 2020; Yin & Wunderink, 2018). nCoV was duly reported to have been originated from wild bats. Falling in the category of group 2 β‐CoVs, the novel Coronavirus only shares a 70% similarity in genetic sequence with its predecessor, SARS‐CoV, which also belongs to the exact same family (Gralinski & Menachery, 2020).
|
|
p
|
The tantalizing surge in the number of cases infected with SARS‐CoV‐2 in China, despite the closure of markets and evacuation of the vicinity, fulfilled the burden of proof that the virus can also be transmitted from human to human. Soon thereafter, peculiar cases of acute respiratory syndrome started appearing in other Asian countries, ultimately spreading to North America and Europe. (Sahin et al., 2020; World Health Organization, 2020; Yin & Wunderink, 2018). Following an emergent briefing on January 30, 2020, The World Health Organization (WHO) declared the outbreak of COVID‐19 as a Public Health Emergency of International Concern (Organization, 2020).
|
|
p
|
The epidemic began to emerge with the advent of the Chinese New Year, a traditionally important festival that is heavily celebrated across the country. The coincidence paved the way for SARS‐CoV‐2 to turn into an unprecedented massive Coronavirus outbreak, which required extensive measurements to be contained. With a population of 10 million, Wuhan City also served as an important pathway for millions of people traveling in celebration of the Spring Festival. Accordingly, the number of cases to be diagnosed with COVID‐19 showed an overwhelming increase between January 10–22, 2020 (Chen, Zhang et al., 2020).
|
|
p
|
Despite the arbitrary speculations, not only did the recent outbreak of COVID‐19 egress the country of origin, it also proceeded to become a global concern in the form of a pandemic (Yang et al., 2020). COVID‐19 is an acute self‐resolving respiratory disease in most of the cases, however, it can also be fatal in some cases. The disease was initially reported to have a mortality rate of 2%. If severe, COVID‐19 might result in death as a result of the preceding extensive alveolar damage, and failure of the lungs (Xu et al., 2020). As of February 15, 2020, a total of 66,580 cases had been confirmed, with over 1,524 deaths. However, there have no specific reports on pathology, as performing an autopsy or biopsy was not possible in most of the cases (Chan et al., 2020; Huang et al., 2020). Table 1. Represents the WHO situation reports on March 24, 2020 (www.WHO.int).
|
|
table-wrap
|
Table 1 The number of cases and death of Covid‐19 outbreak according to World Health Organization statistics (April 13, 2020)
Region Total (new) cases in last 24 hr Total (new) death in last 24 hr
Globally 1,773,084 confirmed (76,498) 111,652 deaths (5,702)
Western Pacific Region 121,426 confirmed (1,310) 4,125 deaths (67)
European Region 913,349 confirmed (33,243) 77,419 deaths (3,183)
South‐East Asia Region 16,883 confirmed (842) 766 deaths (38)
Eastern Mediterranean Region 99,713 confirmed (3,768) 5,107 deaths (164)
American Region 610,742 confirmed (36,804) 23,759 deaths (2,228)
African Region 10,259 confirmed (531) 464 deaths (21)
John Wiley & Sons, Ltd. This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.
|
|
label
|
Table 1
|
|
caption
|
The number of cases and death of Covid‐19 outbreak according to World Health Organization statistics (April 13, 2020)
|
|
p
|
The number of cases and death of Covid‐19 outbreak according to World Health Organization statistics (April 13, 2020)
|
|
table
|
Region Total (new) cases in last 24 hr Total (new) death in last 24 hr
Globally 1,773,084 confirmed (76,498) 111,652 deaths (5,702)
Western Pacific Region 121,426 confirmed (1,310) 4,125 deaths (67)
European Region 913,349 confirmed (33,243) 77,419 deaths (3,183)
South‐East Asia Region 16,883 confirmed (842) 766 deaths (38)
Eastern Mediterranean Region 99,713 confirmed (3,768) 5,107 deaths (164)
American Region 610,742 confirmed (36,804) 23,759 deaths (2,228)
African Region 10,259 confirmed (531) 464 deaths (21)
|
|
tr
|
Region Total (new) cases in last 24 hr Total (new) death in last 24 hr
|
|
th
|
Region
|
|
th
|
Total (new) cases in last 24 hr
|
|
th
|
Total (new) death in last 24 hr
|
|
tr
|
Globally 1,773,084 confirmed (76,498) 111,652 deaths (5,702)
|
|
td
|
Globally
|
|
td
|
1,773,084 confirmed (76,498)
|
|
td
|
111,652 deaths (5,702)
|
|
tr
|
Western Pacific Region 121,426 confirmed (1,310) 4,125 deaths (67)
|
|
td
|
Western Pacific Region
|
|
td
|
121,426 confirmed (1,310)
|
|
td
|
4,125 deaths (67)
|
|
tr
|
European Region 913,349 confirmed (33,243) 77,419 deaths (3,183)
|
|
td
|
European Region
|
|
td
|
913,349 confirmed (33,243)
|
|
td
|
77,419 deaths (3,183)
|
|
tr
|
South‐East Asia Region 16,883 confirmed (842) 766 deaths (38)
|
|
td
|
South‐East Asia Region
|
|
td
|
16,883 confirmed (842)
|
|
td
|
766 deaths (38)
|
|
tr
|
Eastern Mediterranean Region 99,713 confirmed (3,768) 5,107 deaths (164)
|
|
td
|
Eastern Mediterranean Region
|
|
td
|
99,713 confirmed (3,768)
|
|
td
|
5,107 deaths (164)
|
|
tr
|
American Region 610,742 confirmed (36,804) 23,759 deaths (2,228)
|
|
td
|
American Region
|
|
td
|
610,742 confirmed (36,804)
|
|
td
|
23,759 deaths (2,228)
|
|
tr
|
African Region 10,259 confirmed (531) 464 deaths (21)
|
|
td
|
African Region
|
|
td
|
10,259 confirmed (531)
|
|
td
|
464 deaths (21)
|
|
p
|
A total of 8,096 SARS cases and 774 deaths across 29 countries were reported for an overall case‐fatality rate (CFR) of 9.6%. MERS is still not contained and is thus far responsible for 2,494 confirmed cases and 858 deaths across 27 countries for a CFR of 34.4%. Despite the much higher CFR of 9.6% and 34.4% for SARS and MERS, the novel Coronavirus epidemic has led to a larger death toll. The Chinese government had reported 72,528 confirmed cases, with 1,870 deaths, as of February 18, 2020. These statistics yield a crude CFR of 2.6%. However, one should not haste to generalize this number, as most possibly the total number of patients with COVID‐19 is much higher. That is, because the cases are not readily identifiable, as many asymptomatic patients are missed during the process (Wu et al., 2020; Yan et al., 2020). Despite the higher transmissibility than SARS and MERS, COVID‐19 is still a relatively unknown disease and requires further investigations to be fully understood (Yan et al., 2020).
|
|
sec
|
2 PATHOGENESIS
Initially, the virus interacts with sensitive human cells that exhibit distinct receptors for the viral Spike protein. After making a successful entry, the RNA‐based genome starts replicating itself, and expressing specific sequences that results in production of useful accessory proteins; facilitating the adaptation of CoV to its human host (ViralZone., 2019). Alterations in genetic make‐up that result from recombination, exchange, insertion, or deletion of genes, are frequently reported among CoVs; a phenomenon that might have played a part in the past epidemics (Sahin et al., 2020). Therefore, the classification of CoVs is continuously being changed. Based on the most recent classification provided by The International Committee on Taxonomy of Viruses, there are four genera of CoVs, that comprise a total of 38 unique species (Subissi et al., 2014). Thus, variable mechanisms could be involved in the process of pathogenesis. For instance, SARS‐CoV binds to angiotensin I converting enzyme 2 (ACE2). On the other hand, MERS‐CoV is more inclined to attach the cellular receptor of dipeptidyl peptidase 4 (Lambeir, Durinx, Scharpé, & De Meester, 2003). Following a cascade of signals after binding, the viral genome is successfully injected into the target cell. The genomic RNA that regulates the expression of structural and nonstructural polyproteins, is polyadenylated and encapsulated. These proteins are then cleaved by certain proteases that exhibit chymotrypsin‐like activity (Lambeir et al., 2003; ViralZone, 2019). Through replication and transcription, the resulting protein complex drives the production of negative‐sense RNA or (−) RNA. Full‐length (−)RNAs produced by replication are ultimately used as templates for generation of positive‐sense RNA or (+) RNA (Luk, Li, Fung, Lau, & Woo, 2019; ViralZone, 2019). All of the structural proteins are then translated from a subset of 7–9 subgenomic RNAs, which are products of discontinuous transcription. The resulting protein complex is the assembled together to envelope the viral genome, making a nucleocapsid in the process, that will bud into the lumen of the endoplasmic reticulum to finally complete the intracellular cycle. Newly formed virions are then expelled from the infected cell through exocytosis. The CoVs released thereafter are now capable to infect a wide spectrum of human cells, including lung, renal, hepatic, intestinal, and lower respiratory tract cells, as well as T lymphocytes (Chhikara, Rathi, Singh, & Poonam, 2020; Lambeir et al., 2003). Figure 1 presents a schematic of viral structure and the entry mechanism of SARS‐CoV‐2.
Figure 1 Presents a schematic of viral structure and the entry mechanism of SARS‐CoV‐2
2.1 Respiratory system
SARS‐CoV‐2 tends to infect the respiratory tract, thus, pneumonia is a primary clinical finding in patients with COVID‐19 (Huang et al., 2020; Li, Guan, et al., 2020; Zhu et al., 2020). However, pneumonia is only a component of the SARS that might develop in some cases. The resulting SARS may then be aggravated and lead to serious conditions that are extremely difficult to control, for example, septic shock, metabolic acidosis, and coagulation dysfunction (Kofi Ayittey, Dzuvor, Kormla Ayittey, Bennita Chiwero, & Habib, 2020).
Investigation on the radiological findings of COVID‐19‐associated pneumonia have yielded little, if any, information that are mostly unspecific. Progressive lung lesions are usually detected in patients with COVID‐19, about 1 week after the onset of signs and symptoms (Ooi et al., 2004). The lesions then become aggravated during the 2nd week, and lead to formation of irregular reticular opacities mixed with ground glass opacities (GGOs), which can be detected by CT at the fourth week. In a recent cohort study, 85.7% (54/63) of subjects with COVID‐19‐associated pneumonia showed disease progression, defined by an increased extent of GGO, on early follow‐up CT (Pan et al., 2020). Pulmonary fibrous cords was reported in one particular patient that displayed signs of improvement, as the inflammatory secretions had been absorbed (Pan & Guan, 2020). Long‐term complications of COVID‐19 in patients with severe pneumonia might include an array of fibrotic changes often observed in the late stages of lung injury, for example, reticulation, interlobular septal thickening, and traction bronchiectasis (Kim, 2020).
2.2 Immune system
There have been several reports that indicated meager Cytolethal Distending Toxin‐induced lymphocytes, with a density as low as 200 cells/mm3 in three patients with SARS‐CoV infection (Chu et al., 2014; Zhou et al., 2014). As in the case of SARS‐CoV‐2, it has been suspected that infection with this type of CoV might lead to inflammatory cytokine storm (Chen, Liu, et al., 2020; Zumla et al., 2020); a life‐threatening condition characterized by elevated levels of interleukin 6 (IL‐6) in plasma. A number of investigations recently conducted on COVID‐19 have reported that IL‐6 levels was actually higher in the patients with severe disease (Cai, 2020; Chen, Liu, et al., 2020; Xiang et al., 2020). This could highlight the importance of IL‐6 as a biomarker for evaluation of disease severity (Chen, Zhao, et al., 2020).
2.3 Liver damage
Impaired liver function tests have been reported for a number of patients with SARS‐CoV‐2 infection, suggesting hepatic damage as an extrapulmonary complication of COVID‐19 in almost one half of the patients (Chen, Zhou, et al., 2020; Wang, Hu, et al., 2020). A recent study has concluded that liver function abnormality might stem from infection of bile duct cells with SARS‐CoV‐2. Nonetheless, the alkaline phosphatase value, which is an index of bile duct damage, were not specific in patients with COVID‐19 (Chen, Zhou, et al., 2020; Wang, Hu, et al., 2020). Investigation of liver biopsy specimens was accompanied by new pathological findings. Scientists have reported moderate microvascular steatosis, and mild lobular and portal activity in these patients, that suggests liver damage may have arisen from either SARS‐CoV‐2 infection or drug‐induced liver (Xu et al., 2020).
2.4 Myocardial, gastrointestinal, and renal symptoms: homeostasis of electrolytes
An essential player in maintenance of electrolyte balance and blood pressure, ACE2 is regarded by many as the principal counter‐regulatory arm in the axis of renin–angiotensin‐aldosterone system (RAAS; Santos, Ferreira, & Simões e Silva, 2008). Upon infection, SARS‐CoV‐2 binds ACE2. This results in degradation of ACE2, which subsequently dampens the counter‐effect of ACE2 on RAAS. The final effect of ACE2 in an otherwise healthy adult is to increase reabsorption of sodium and the reciprocal excretion of potassium ions (K+). The concomitant re‐uptake of water with sodium reabsorption prompts an increase in blood pressure (Weir & Rolfe, 2010). Potassium is the predominant intracellular ion, that is majorly involved in regulation of cell membrane polarity. Too low levels of K+ in blood, known as hypokalemia, can result in cellular hyper‐polarity. A hyper‐polarized cell membrane tends to be depolarized faster than normal, causing aberrancy in the function of cardiac cells (Bielecka‐Dabrowa et al., 2012).
In a recent cohort study, patients diagnosed with COVID‐19 were categorized into three groups: severe hypokalemia, hypokalemia, and normokalemia. The study reported that 93% of patients with a severe clinical condition had hypokalemia. Scientists did not find a direct link between gastrointestinal symptoms and hypokalemia among 108 patients with both severe or moderate hypokalemia. Further investigations established an association between parameters such as body temperature, creatine kinase (CK), creatine kinase myocardial band (CK‐MB), lactate dehydrogenase (LDH), and C‐reactive protein (CRP) with the severity of hypokalemia. Reportedly, hypokalemia was most often observed with patients who had elevated levels of serum CK, CK‐MB, LDH, and CRP. Potassium (K+) loss in the urine was determined to be the primary cause of hypokalemia.
Hypokalemia requires strenuous efforts to be corrected. This is chiefly due to the incessant loss of K+ in the urine, as a result of ACE2 degradation. In the case of COVID‐19‐associated hypokalemia, however, the patients seemed to respond well to potassium supplements when the critical phase had passed [49]. Therefore, one should consider the impact of hypokalemia in COVID‐19 morbidity, and its effect on the outcomes of treatment. This is a condition that must be carefully addressed for, as patients with COVID‐19 are more inclined to develop dysfunctions in heart, lungs, and other vital organs (Li, Hu, Su, & Dai, 2020).
|
|
label
|
2
|
|
title
|
PATHOGENESIS
|
|
p
|
Initially, the virus interacts with sensitive human cells that exhibit distinct receptors for the viral Spike protein. After making a successful entry, the RNA‐based genome starts replicating itself, and expressing specific sequences that results in production of useful accessory proteins; facilitating the adaptation of CoV to its human host (ViralZone., 2019). Alterations in genetic make‐up that result from recombination, exchange, insertion, or deletion of genes, are frequently reported among CoVs; a phenomenon that might have played a part in the past epidemics (Sahin et al., 2020). Therefore, the classification of CoVs is continuously being changed. Based on the most recent classification provided by The International Committee on Taxonomy of Viruses, there are four genera of CoVs, that comprise a total of 38 unique species (Subissi et al., 2014). Thus, variable mechanisms could be involved in the process of pathogenesis. For instance, SARS‐CoV binds to angiotensin I converting enzyme 2 (ACE2). On the other hand, MERS‐CoV is more inclined to attach the cellular receptor of dipeptidyl peptidase 4 (Lambeir, Durinx, Scharpé, & De Meester, 2003). Following a cascade of signals after binding, the viral genome is successfully injected into the target cell. The genomic RNA that regulates the expression of structural and nonstructural polyproteins, is polyadenylated and encapsulated. These proteins are then cleaved by certain proteases that exhibit chymotrypsin‐like activity (Lambeir et al., 2003; ViralZone, 2019). Through replication and transcription, the resulting protein complex drives the production of negative‐sense RNA or (−) RNA. Full‐length (−)RNAs produced by replication are ultimately used as templates for generation of positive‐sense RNA or (+) RNA (Luk, Li, Fung, Lau, & Woo, 2019; ViralZone, 2019). All of the structural proteins are then translated from a subset of 7–9 subgenomic RNAs, which are products of discontinuous transcription. The resulting protein complex is the assembled together to envelope the viral genome, making a nucleocapsid in the process, that will bud into the lumen of the endoplasmic reticulum to finally complete the intracellular cycle. Newly formed virions are then expelled from the infected cell through exocytosis. The CoVs released thereafter are now capable to infect a wide spectrum of human cells, including lung, renal, hepatic, intestinal, and lower respiratory tract cells, as well as T lymphocytes (Chhikara, Rathi, Singh, & Poonam, 2020; Lambeir et al., 2003). Figure 1 presents a schematic of viral structure and the entry mechanism of SARS‐CoV‐2.
|
|
figure
|
Figure 1 Presents a schematic of viral structure and the entry mechanism of SARS‐CoV‐2
|
|
label
|
Figure 1
|
|
caption
|
Presents a schematic of viral structure and the entry mechanism of SARS‐CoV‐2
|
|
p
|
Presents a schematic of viral structure and the entry mechanism of SARS‐CoV‐2
|
|
sec
|
2.1 Respiratory system
SARS‐CoV‐2 tends to infect the respiratory tract, thus, pneumonia is a primary clinical finding in patients with COVID‐19 (Huang et al., 2020; Li, Guan, et al., 2020; Zhu et al., 2020). However, pneumonia is only a component of the SARS that might develop in some cases. The resulting SARS may then be aggravated and lead to serious conditions that are extremely difficult to control, for example, septic shock, metabolic acidosis, and coagulation dysfunction (Kofi Ayittey, Dzuvor, Kormla Ayittey, Bennita Chiwero, & Habib, 2020).
Investigation on the radiological findings of COVID‐19‐associated pneumonia have yielded little, if any, information that are mostly unspecific. Progressive lung lesions are usually detected in patients with COVID‐19, about 1 week after the onset of signs and symptoms (Ooi et al., 2004). The lesions then become aggravated during the 2nd week, and lead to formation of irregular reticular opacities mixed with ground glass opacities (GGOs), which can be detected by CT at the fourth week. In a recent cohort study, 85.7% (54/63) of subjects with COVID‐19‐associated pneumonia showed disease progression, defined by an increased extent of GGO, on early follow‐up CT (Pan et al., 2020). Pulmonary fibrous cords was reported in one particular patient that displayed signs of improvement, as the inflammatory secretions had been absorbed (Pan & Guan, 2020). Long‐term complications of COVID‐19 in patients with severe pneumonia might include an array of fibrotic changes often observed in the late stages of lung injury, for example, reticulation, interlobular septal thickening, and traction bronchiectasis (Kim, 2020).
|
|
label
|
2.1
|
|
title
|
Respiratory system
|
|
p
|
SARS‐CoV‐2 tends to infect the respiratory tract, thus, pneumonia is a primary clinical finding in patients with COVID‐19 (Huang et al., 2020; Li, Guan, et al., 2020; Zhu et al., 2020). However, pneumonia is only a component of the SARS that might develop in some cases. The resulting SARS may then be aggravated and lead to serious conditions that are extremely difficult to control, for example, septic shock, metabolic acidosis, and coagulation dysfunction (Kofi Ayittey, Dzuvor, Kormla Ayittey, Bennita Chiwero, & Habib, 2020).
|
|
p
|
Investigation on the radiological findings of COVID‐19‐associated pneumonia have yielded little, if any, information that are mostly unspecific. Progressive lung lesions are usually detected in patients with COVID‐19, about 1 week after the onset of signs and symptoms (Ooi et al., 2004). The lesions then become aggravated during the 2nd week, and lead to formation of irregular reticular opacities mixed with ground glass opacities (GGOs), which can be detected by CT at the fourth week. In a recent cohort study, 85.7% (54/63) of subjects with COVID‐19‐associated pneumonia showed disease progression, defined by an increased extent of GGO, on early follow‐up CT (Pan et al., 2020). Pulmonary fibrous cords was reported in one particular patient that displayed signs of improvement, as the inflammatory secretions had been absorbed (Pan & Guan, 2020). Long‐term complications of COVID‐19 in patients with severe pneumonia might include an array of fibrotic changes often observed in the late stages of lung injury, for example, reticulation, interlobular septal thickening, and traction bronchiectasis (Kim, 2020).
|
|
sec
|
2.2 Immune system
There have been several reports that indicated meager Cytolethal Distending Toxin‐induced lymphocytes, with a density as low as 200 cells/mm3 in three patients with SARS‐CoV infection (Chu et al., 2014; Zhou et al., 2014). As in the case of SARS‐CoV‐2, it has been suspected that infection with this type of CoV might lead to inflammatory cytokine storm (Chen, Liu, et al., 2020; Zumla et al., 2020); a life‐threatening condition characterized by elevated levels of interleukin 6 (IL‐6) in plasma. A number of investigations recently conducted on COVID‐19 have reported that IL‐6 levels was actually higher in the patients with severe disease (Cai, 2020; Chen, Liu, et al., 2020; Xiang et al., 2020). This could highlight the importance of IL‐6 as a biomarker for evaluation of disease severity (Chen, Zhao, et al., 2020).
|
|
label
|
2.2
|
|
title
|
Immune system
|
|
p
|
There have been several reports that indicated meager Cytolethal Distending Toxin‐induced lymphocytes, with a density as low as 200 cells/mm3 in three patients with SARS‐CoV infection (Chu et al., 2014; Zhou et al., 2014). As in the case of SARS‐CoV‐2, it has been suspected that infection with this type of CoV might lead to inflammatory cytokine storm (Chen, Liu, et al., 2020; Zumla et al., 2020); a life‐threatening condition characterized by elevated levels of interleukin 6 (IL‐6) in plasma. A number of investigations recently conducted on COVID‐19 have reported that IL‐6 levels was actually higher in the patients with severe disease (Cai, 2020; Chen, Liu, et al., 2020; Xiang et al., 2020). This could highlight the importance of IL‐6 as a biomarker for evaluation of disease severity (Chen, Zhao, et al., 2020).
|
|
sec
|
2.3 Liver damage
Impaired liver function tests have been reported for a number of patients with SARS‐CoV‐2 infection, suggesting hepatic damage as an extrapulmonary complication of COVID‐19 in almost one half of the patients (Chen, Zhou, et al., 2020; Wang, Hu, et al., 2020). A recent study has concluded that liver function abnormality might stem from infection of bile duct cells with SARS‐CoV‐2. Nonetheless, the alkaline phosphatase value, which is an index of bile duct damage, were not specific in patients with COVID‐19 (Chen, Zhou, et al., 2020; Wang, Hu, et al., 2020). Investigation of liver biopsy specimens was accompanied by new pathological findings. Scientists have reported moderate microvascular steatosis, and mild lobular and portal activity in these patients, that suggests liver damage may have arisen from either SARS‐CoV‐2 infection or drug‐induced liver (Xu et al., 2020).
|
|
label
|
2.3
|
|
title
|
Liver damage
|
|
p
|
Impaired liver function tests have been reported for a number of patients with SARS‐CoV‐2 infection, suggesting hepatic damage as an extrapulmonary complication of COVID‐19 in almost one half of the patients (Chen, Zhou, et al., 2020; Wang, Hu, et al., 2020). A recent study has concluded that liver function abnormality might stem from infection of bile duct cells with SARS‐CoV‐2. Nonetheless, the alkaline phosphatase value, which is an index of bile duct damage, were not specific in patients with COVID‐19 (Chen, Zhou, et al., 2020; Wang, Hu, et al., 2020). Investigation of liver biopsy specimens was accompanied by new pathological findings. Scientists have reported moderate microvascular steatosis, and mild lobular and portal activity in these patients, that suggests liver damage may have arisen from either SARS‐CoV‐2 infection or drug‐induced liver (Xu et al., 2020).
|
|
sec
|
2.4 Myocardial, gastrointestinal, and renal symptoms: homeostasis of electrolytes
An essential player in maintenance of electrolyte balance and blood pressure, ACE2 is regarded by many as the principal counter‐regulatory arm in the axis of renin–angiotensin‐aldosterone system (RAAS; Santos, Ferreira, & Simões e Silva, 2008). Upon infection, SARS‐CoV‐2 binds ACE2. This results in degradation of ACE2, which subsequently dampens the counter‐effect of ACE2 on RAAS. The final effect of ACE2 in an otherwise healthy adult is to increase reabsorption of sodium and the reciprocal excretion of potassium ions (K+). The concomitant re‐uptake of water with sodium reabsorption prompts an increase in blood pressure (Weir & Rolfe, 2010). Potassium is the predominant intracellular ion, that is majorly involved in regulation of cell membrane polarity. Too low levels of K+ in blood, known as hypokalemia, can result in cellular hyper‐polarity. A hyper‐polarized cell membrane tends to be depolarized faster than normal, causing aberrancy in the function of cardiac cells (Bielecka‐Dabrowa et al., 2012).
In a recent cohort study, patients diagnosed with COVID‐19 were categorized into three groups: severe hypokalemia, hypokalemia, and normokalemia. The study reported that 93% of patients with a severe clinical condition had hypokalemia. Scientists did not find a direct link between gastrointestinal symptoms and hypokalemia among 108 patients with both severe or moderate hypokalemia. Further investigations established an association between parameters such as body temperature, creatine kinase (CK), creatine kinase myocardial band (CK‐MB), lactate dehydrogenase (LDH), and C‐reactive protein (CRP) with the severity of hypokalemia. Reportedly, hypokalemia was most often observed with patients who had elevated levels of serum CK, CK‐MB, LDH, and CRP. Potassium (K+) loss in the urine was determined to be the primary cause of hypokalemia.
Hypokalemia requires strenuous efforts to be corrected. This is chiefly due to the incessant loss of K+ in the urine, as a result of ACE2 degradation. In the case of COVID‐19‐associated hypokalemia, however, the patients seemed to respond well to potassium supplements when the critical phase had passed [49]. Therefore, one should consider the impact of hypokalemia in COVID‐19 morbidity, and its effect on the outcomes of treatment. This is a condition that must be carefully addressed for, as patients with COVID‐19 are more inclined to develop dysfunctions in heart, lungs, and other vital organs (Li, Hu, Su, & Dai, 2020).
|
|
label
|
2.4
|
|
title
|
Myocardial, gastrointestinal, and renal symptoms: homeostasis of electrolytes
|
|
p
|
An essential player in maintenance of electrolyte balance and blood pressure, ACE2 is regarded by many as the principal counter‐regulatory arm in the axis of renin–angiotensin‐aldosterone system (RAAS; Santos, Ferreira, & Simões e Silva, 2008). Upon infection, SARS‐CoV‐2 binds ACE2. This results in degradation of ACE2, which subsequently dampens the counter‐effect of ACE2 on RAAS. The final effect of ACE2 in an otherwise healthy adult is to increase reabsorption of sodium and the reciprocal excretion of potassium ions (K+). The concomitant re‐uptake of water with sodium reabsorption prompts an increase in blood pressure (Weir & Rolfe, 2010). Potassium is the predominant intracellular ion, that is majorly involved in regulation of cell membrane polarity. Too low levels of K+ in blood, known as hypokalemia, can result in cellular hyper‐polarity. A hyper‐polarized cell membrane tends to be depolarized faster than normal, causing aberrancy in the function of cardiac cells (Bielecka‐Dabrowa et al., 2012).
|
|
p
|
In a recent cohort study, patients diagnosed with COVID‐19 were categorized into three groups: severe hypokalemia, hypokalemia, and normokalemia. The study reported that 93% of patients with a severe clinical condition had hypokalemia. Scientists did not find a direct link between gastrointestinal symptoms and hypokalemia among 108 patients with both severe or moderate hypokalemia. Further investigations established an association between parameters such as body temperature, creatine kinase (CK), creatine kinase myocardial band (CK‐MB), lactate dehydrogenase (LDH), and C‐reactive protein (CRP) with the severity of hypokalemia. Reportedly, hypokalemia was most often observed with patients who had elevated levels of serum CK, CK‐MB, LDH, and CRP. Potassium (K+) loss in the urine was determined to be the primary cause of hypokalemia.
|
|
p
|
Hypokalemia requires strenuous efforts to be corrected. This is chiefly due to the incessant loss of K+ in the urine, as a result of ACE2 degradation. In the case of COVID‐19‐associated hypokalemia, however, the patients seemed to respond well to potassium supplements when the critical phase had passed [49]. Therefore, one should consider the impact of hypokalemia in COVID‐19 morbidity, and its effect on the outcomes of treatment. This is a condition that must be carefully addressed for, as patients with COVID‐19 are more inclined to develop dysfunctions in heart, lungs, and other vital organs (Li, Hu, Su, & Dai, 2020).
|
|
sec
|
3 POSSIBLE FACTORS CORRELATED WITH COVID‐19
3.1 Sex
Several studies have sought to compare the sex differences in the clinical findings of severe COVID‐19. In one study, scientists investigated 47 patients with COVID‐19, 28 (59.6%) of whom were men. Procalcitonin (PCT) level was reported to be higher in men than in women. The results also showed higher amounts of serum N‐terminal‐pro brain natriuretic peptide, as increased levels of the molecule were detected in men 57.1% than women 26.3%. Furthermore, 17.9% of male patients were reported test‐positive for influenza A antibody, whereas no such records were registered for female patients. During a 2‐week stay at the hospital, 17.9% of male, and 5.3% of female patients deteriorated, and hence were reassigned to the critical‐type group. There was no mortality reports among women, whereas 3.6% of male patients had deceased due to COVID‐19 complications. A total of 21.1% and 3.6% of female and male patients successfully recovered, and were discharged from the hospital. Based on the current evidence, men are more likely to develop complications, and experience worse in‐hospital outcomes compared with women (Li, Zhang, et al., 2020).
3.2 Pregnancy
A group of researchers led by Chen investigated the clinical characteristics of SARS‐CoV‐2 infection in nine pregnant women. Their aim was to evaluate the likelihood of intrauterine/vertical transmission of SARS‐CoV‐2 from mother to baby. All of the women who were being investigated had cesarean section in the third trimester of their previous pregnancies. Seven patients were febrile, and variably presented other symptoms such as cough, sore throat, myalgia, and malaise. Fetal distress was reported in two cases. Lymphopenia and increased aminotransferase activity were observed in five and three patients, respectively. There was no mortality cases, as none of the patients in the study developed severe COVID‐19‐associated pneumonia. Nine livebirths were recorded. The newborns displayed no signs of asphyxia. A 1‐min Apgar score of 8–9, and a 5‐min Apgar score of 9–10 were calculated for all nine newborns. Samples collected from six patients, including amniotic fluid, cord blood, neonatal throat swab, and breastmilk proved test‐negative for SARS‐CoV‐2. The clinical features of COVID‐19‐associated pneumonia observed in these pregnant women shared a great similarity to characteristics reported for COVID‐19‐associated pneumonia in nonpregnant adult patients (Chen, Guo, et al., 2020).
3.3 Blood type
In a recent investigation, scientists in China looked into the pattern of blood type distribution in 2,173 patients in three hospitals, who had been confirmed to have SARS‐CoV‐2 infection. Accordingly, they compared their findings regarding the blood type of patients with that of the healthy population who lived in the same area as the patients in the study. Apparently, there was a higher prevalence of blood type A among the patients with COVID‐19 than in the normal population. On the contrary, it seemed that individuals with O blood type were spared somehow, as there were fewer patients with this blood type in this study (both p < .001). A series of meta‐analyses on the available data indicated a significantly higher risk for COVID‐19 in people with blood type A, relative to individuals with non‐A blood types. However, an opposite scenario seemed to be true for the blood type O community, since, according to the literature, are less susceptible for contracting infectious diseases such as COVID‐19 (Zhao et al., 2020).
|
|
label
|
3
|
|
title
|
POSSIBLE FACTORS CORRELATED WITH COVID‐19
|
|
sec
|
3.1 Sex
Several studies have sought to compare the sex differences in the clinical findings of severe COVID‐19. In one study, scientists investigated 47 patients with COVID‐19, 28 (59.6%) of whom were men. Procalcitonin (PCT) level was reported to be higher in men than in women. The results also showed higher amounts of serum N‐terminal‐pro brain natriuretic peptide, as increased levels of the molecule were detected in men 57.1% than women 26.3%. Furthermore, 17.9% of male patients were reported test‐positive for influenza A antibody, whereas no such records were registered for female patients. During a 2‐week stay at the hospital, 17.9% of male, and 5.3% of female patients deteriorated, and hence were reassigned to the critical‐type group. There was no mortality reports among women, whereas 3.6% of male patients had deceased due to COVID‐19 complications. A total of 21.1% and 3.6% of female and male patients successfully recovered, and were discharged from the hospital. Based on the current evidence, men are more likely to develop complications, and experience worse in‐hospital outcomes compared with women (Li, Zhang, et al., 2020).
|
|
label
|
3.1
|
|
title
|
Sex
|
|
p
|
Several studies have sought to compare the sex differences in the clinical findings of severe COVID‐19. In one study, scientists investigated 47 patients with COVID‐19, 28 (59.6%) of whom were men. Procalcitonin (PCT) level was reported to be higher in men than in women. The results also showed higher amounts of serum N‐terminal‐pro brain natriuretic peptide, as increased levels of the molecule were detected in men 57.1% than women 26.3%. Furthermore, 17.9% of male patients were reported test‐positive for influenza A antibody, whereas no such records were registered for female patients. During a 2‐week stay at the hospital, 17.9% of male, and 5.3% of female patients deteriorated, and hence were reassigned to the critical‐type group. There was no mortality reports among women, whereas 3.6% of male patients had deceased due to COVID‐19 complications. A total of 21.1% and 3.6% of female and male patients successfully recovered, and were discharged from the hospital. Based on the current evidence, men are more likely to develop complications, and experience worse in‐hospital outcomes compared with women (Li, Zhang, et al., 2020).
|
|
sec
|
3.2 Pregnancy
A group of researchers led by Chen investigated the clinical characteristics of SARS‐CoV‐2 infection in nine pregnant women. Their aim was to evaluate the likelihood of intrauterine/vertical transmission of SARS‐CoV‐2 from mother to baby. All of the women who were being investigated had cesarean section in the third trimester of their previous pregnancies. Seven patients were febrile, and variably presented other symptoms such as cough, sore throat, myalgia, and malaise. Fetal distress was reported in two cases. Lymphopenia and increased aminotransferase activity were observed in five and three patients, respectively. There was no mortality cases, as none of the patients in the study developed severe COVID‐19‐associated pneumonia. Nine livebirths were recorded. The newborns displayed no signs of asphyxia. A 1‐min Apgar score of 8–9, and a 5‐min Apgar score of 9–10 were calculated for all nine newborns. Samples collected from six patients, including amniotic fluid, cord blood, neonatal throat swab, and breastmilk proved test‐negative for SARS‐CoV‐2. The clinical features of COVID‐19‐associated pneumonia observed in these pregnant women shared a great similarity to characteristics reported for COVID‐19‐associated pneumonia in nonpregnant adult patients (Chen, Guo, et al., 2020).
|
|
label
|
3.2
|
|
title
|
Pregnancy
|
|
p
|
A group of researchers led by Chen investigated the clinical characteristics of SARS‐CoV‐2 infection in nine pregnant women. Their aim was to evaluate the likelihood of intrauterine/vertical transmission of SARS‐CoV‐2 from mother to baby. All of the women who were being investigated had cesarean section in the third trimester of their previous pregnancies. Seven patients were febrile, and variably presented other symptoms such as cough, sore throat, myalgia, and malaise. Fetal distress was reported in two cases. Lymphopenia and increased aminotransferase activity were observed in five and three patients, respectively. There was no mortality cases, as none of the patients in the study developed severe COVID‐19‐associated pneumonia. Nine livebirths were recorded. The newborns displayed no signs of asphyxia. A 1‐min Apgar score of 8–9, and a 5‐min Apgar score of 9–10 were calculated for all nine newborns. Samples collected from six patients, including amniotic fluid, cord blood, neonatal throat swab, and breastmilk proved test‐negative for SARS‐CoV‐2. The clinical features of COVID‐19‐associated pneumonia observed in these pregnant women shared a great similarity to characteristics reported for COVID‐19‐associated pneumonia in nonpregnant adult patients (Chen, Guo, et al., 2020).
|
|
sec
|
3.3 Blood type
In a recent investigation, scientists in China looked into the pattern of blood type distribution in 2,173 patients in three hospitals, who had been confirmed to have SARS‐CoV‐2 infection. Accordingly, they compared their findings regarding the blood type of patients with that of the healthy population who lived in the same area as the patients in the study. Apparently, there was a higher prevalence of blood type A among the patients with COVID‐19 than in the normal population. On the contrary, it seemed that individuals with O blood type were spared somehow, as there were fewer patients with this blood type in this study (both p < .001). A series of meta‐analyses on the available data indicated a significantly higher risk for COVID‐19 in people with blood type A, relative to individuals with non‐A blood types. However, an opposite scenario seemed to be true for the blood type O community, since, according to the literature, are less susceptible for contracting infectious diseases such as COVID‐19 (Zhao et al., 2020).
|
|
label
|
3.3
|
|
title
|
Blood type
|
|
p
|
In a recent investigation, scientists in China looked into the pattern of blood type distribution in 2,173 patients in three hospitals, who had been confirmed to have SARS‐CoV‐2 infection. Accordingly, they compared their findings regarding the blood type of patients with that of the healthy population who lived in the same area as the patients in the study. Apparently, there was a higher prevalence of blood type A among the patients with COVID‐19 than in the normal population. On the contrary, it seemed that individuals with O blood type were spared somehow, as there were fewer patients with this blood type in this study (both p < .001). A series of meta‐analyses on the available data indicated a significantly higher risk for COVID‐19 in people with blood type A, relative to individuals with non‐A blood types. However, an opposite scenario seemed to be true for the blood type O community, since, according to the literature, are less susceptible for contracting infectious diseases such as COVID‐19 (Zhao et al., 2020).
|
|
sec
|
4 ETIOLOGY: SOURCES AND MODES OF TRANSMISSION
According to the literature, the pathogen and area of origin were similar in both SARS and COVID‐19 outbreaks. However, despite this similarity, the raised public awareness and extensive interventional procedures that might have once proved effective for SARS containment, have been rendered ineffective against the 2019 novel Coronavirus; as the disease is already more widespread than SARS (Liu, Gayle, Wilder‐Smith, & Rocklöv, 2020). A large family of viruses, CoVs are common among many different animal species, including cattle, civets, camels, and bats. However, these CoVs are not solely restricted to animal populations, as they can occasionally infect humans, bringing epidemics such as SARS, MERS, and in recent memory, COVID‐19 (Sahin et al., 2020). Recent investigations conducted on the origins of CoVs responsible for the past epidemics have reported bats as the primary reservoir for both SARS‐CoV and MERS‐CoV; suggesting that other animal species were involved in the process merely as intermediate hosts. Accordingly, the majority of bat‐associated CoVs belong to α‐CoV and β‐CoV genera, while almost all of the avian CoVs fall in the other two genera; γ‐CoVs and δ‐CoVs (Yin & Wunderink, 2018). It has been suggested that species responsible for the recent epidemic is reminiscent of the CoV isolated in bats. Trafficking of wild animals in Huanan Seafood Market, located in Wuhan State of Hubei Province in China, where the first cases were reported, further supports this finding. Only 10 days following the first outbreak, secondary cases started emerging. Although the new cases had no contact with the marketplace, they did have a history of social contact with the salesmen and people who had previously been there. The growing pile of confirmed cases from healthcare workers in Wuhan City is an strong indicator of human‐to‐human transmission in the case of SARS‐CoV‐2 (Sahin et al., 2020).
Transmission of the virus from human to human occurs mostly with close contact. The short distance between individuals in close social contacts makes it possible for respiratory droplets of the infected person, released by coughing and sneezing, to reach other people in the proximity. This is similar to the transmission of Influenza and other respiratory infection. It still remains unclear if the virus can be contracted by touching surfaces, and then touching mouth, nose, or even eyes (WHO, 2020). Apparently, COVID‐19 is considered most contagious when individuals infected with the virus is symptomatic. However, there have been cases who reportedly had contracted the disease from asymptomatic patients in the prodrome period of COVID‐19. Transmission of the novel Coronavirus has yet to be clarified by more investigations. (Rothe et al., 2020).
4.1 Presumed asymptomatic carrier‐based transmission of COVID‐19
Investigation on a familial cluster of five patients concluded that SARS‐CoV‐2 might have actually been transmitted by an asymptomatic carrier in the family (Bai et al., 2020). Surprisingly, the first reverse transcription polymerase chain reaction (RT‐PCR) test of the asymptomatic family member was reported negative; a noteworthy example of a false‐negative result. Unwanted false‐negative results are inevitably reported due to a number of factors, for example, quality of the test kit, sufficiency of the collected sample, or performance of the test by clinicians. To this date, RT‐PCR has widely been used as a reliable diagnostic method (Corman et al., 2020). Thus, her second RT‐PCR result, reported positive, was unlikely to have been a false‐positive result; hence, it was accepted as the definite evidence that the suspected person had indeed been infected with SARS‐CoV‐2 (Bai et al., 2020).
There was also another study that reported an asymptomatic young boy with COVID‐19 infection. However, CT scans obtained from the subject exhibited abnormalities, indicative of an on‐going pulmonary pathology (Chan et al., 2020). If we presume that the findings regarding asymptomatic carrier‐based transmission of COVID‐19 can be replicated, this would prove COVID‐19 an overwhelmingly challenging issue to be controlled (Bai et al., 2020). The incubation period for the asymptomatic patient in the case of familial cluster was 19 days. Despite being a long period, it still perfectly falls in the suggested incubation period of 0–24 days (Bai et al., 2020; Guan et al., 2020).
|
|
label
|
4
|
|
title
|
ETIOLOGY: SOURCES AND MODES OF TRANSMISSION
|
|
p
|
According to the literature, the pathogen and area of origin were similar in both SARS and COVID‐19 outbreaks. However, despite this similarity, the raised public awareness and extensive interventional procedures that might have once proved effective for SARS containment, have been rendered ineffective against the 2019 novel Coronavirus; as the disease is already more widespread than SARS (Liu, Gayle, Wilder‐Smith, & Rocklöv, 2020). A large family of viruses, CoVs are common among many different animal species, including cattle, civets, camels, and bats. However, these CoVs are not solely restricted to animal populations, as they can occasionally infect humans, bringing epidemics such as SARS, MERS, and in recent memory, COVID‐19 (Sahin et al., 2020). Recent investigations conducted on the origins of CoVs responsible for the past epidemics have reported bats as the primary reservoir for both SARS‐CoV and MERS‐CoV; suggesting that other animal species were involved in the process merely as intermediate hosts. Accordingly, the majority of bat‐associated CoVs belong to α‐CoV and β‐CoV genera, while almost all of the avian CoVs fall in the other two genera; γ‐CoVs and δ‐CoVs (Yin & Wunderink, 2018). It has been suggested that species responsible for the recent epidemic is reminiscent of the CoV isolated in bats. Trafficking of wild animals in Huanan Seafood Market, located in Wuhan State of Hubei Province in China, where the first cases were reported, further supports this finding. Only 10 days following the first outbreak, secondary cases started emerging. Although the new cases had no contact with the marketplace, they did have a history of social contact with the salesmen and people who had previously been there. The growing pile of confirmed cases from healthcare workers in Wuhan City is an strong indicator of human‐to‐human transmission in the case of SARS‐CoV‐2 (Sahin et al., 2020).
|
|
p
|
Transmission of the virus from human to human occurs mostly with close contact. The short distance between individuals in close social contacts makes it possible for respiratory droplets of the infected person, released by coughing and sneezing, to reach other people in the proximity. This is similar to the transmission of Influenza and other respiratory infection. It still remains unclear if the virus can be contracted by touching surfaces, and then touching mouth, nose, or even eyes (WHO, 2020). Apparently, COVID‐19 is considered most contagious when individuals infected with the virus is symptomatic. However, there have been cases who reportedly had contracted the disease from asymptomatic patients in the prodrome period of COVID‐19. Transmission of the novel Coronavirus has yet to be clarified by more investigations. (Rothe et al., 2020).
|
|
sec
|
4.1 Presumed asymptomatic carrier‐based transmission of COVID‐19
Investigation on a familial cluster of five patients concluded that SARS‐CoV‐2 might have actually been transmitted by an asymptomatic carrier in the family (Bai et al., 2020). Surprisingly, the first reverse transcription polymerase chain reaction (RT‐PCR) test of the asymptomatic family member was reported negative; a noteworthy example of a false‐negative result. Unwanted false‐negative results are inevitably reported due to a number of factors, for example, quality of the test kit, sufficiency of the collected sample, or performance of the test by clinicians. To this date, RT‐PCR has widely been used as a reliable diagnostic method (Corman et al., 2020). Thus, her second RT‐PCR result, reported positive, was unlikely to have been a false‐positive result; hence, it was accepted as the definite evidence that the suspected person had indeed been infected with SARS‐CoV‐2 (Bai et al., 2020).
There was also another study that reported an asymptomatic young boy with COVID‐19 infection. However, CT scans obtained from the subject exhibited abnormalities, indicative of an on‐going pulmonary pathology (Chan et al., 2020). If we presume that the findings regarding asymptomatic carrier‐based transmission of COVID‐19 can be replicated, this would prove COVID‐19 an overwhelmingly challenging issue to be controlled (Bai et al., 2020). The incubation period for the asymptomatic patient in the case of familial cluster was 19 days. Despite being a long period, it still perfectly falls in the suggested incubation period of 0–24 days (Bai et al., 2020; Guan et al., 2020).
|
|
label
|
4.1
|
|
title
|
Presumed asymptomatic carrier‐based transmission of COVID‐19
|
|
p
|
Investigation on a familial cluster of five patients concluded that SARS‐CoV‐2 might have actually been transmitted by an asymptomatic carrier in the family (Bai et al., 2020). Surprisingly, the first reverse transcription polymerase chain reaction (RT‐PCR) test of the asymptomatic family member was reported negative; a noteworthy example of a false‐negative result. Unwanted false‐negative results are inevitably reported due to a number of factors, for example, quality of the test kit, sufficiency of the collected sample, or performance of the test by clinicians. To this date, RT‐PCR has widely been used as a reliable diagnostic method (Corman et al., 2020). Thus, her second RT‐PCR result, reported positive, was unlikely to have been a false‐positive result; hence, it was accepted as the definite evidence that the suspected person had indeed been infected with SARS‐CoV‐2 (Bai et al., 2020).
|
|
p
|
There was also another study that reported an asymptomatic young boy with COVID‐19 infection. However, CT scans obtained from the subject exhibited abnormalities, indicative of an on‐going pulmonary pathology (Chan et al., 2020). If we presume that the findings regarding asymptomatic carrier‐based transmission of COVID‐19 can be replicated, this would prove COVID‐19 an overwhelmingly challenging issue to be controlled (Bai et al., 2020). The incubation period for the asymptomatic patient in the case of familial cluster was 19 days. Despite being a long period, it still perfectly falls in the suggested incubation period of 0–24 days (Bai et al., 2020; Guan et al., 2020).
|
|
sec
|
5 DIAGNOSIS
A proper diagnosis of COVID‐19 is made based on the following criteria, which have been recently suggested based on the initial investigations: (a) clinical signs and symptoms, (b) history of traveling or close contact with people suspected to be infected, (c) positive test result for the pathogen, and (d) pathologic findings on CT images. The key clinical features of COVID‐19, though nonspecific, include fever, dry cough, dyspnea, and pneumonia (Chen, Zhou, et al., 2020; Huang et al., 2020; Li, Guan, et al., 2020; Wang, Hu, et al., 2020). Rapid screening of patients with acute respiratory symptoms, initiation of an appropriate quarantine program, and development of therapeutic measures have been suggested as a top‐priority strategy to control the spread of COVID‐19 (Tian et al., 2020; Wang, Kang, et al., 2020). According to the data gathered by individual‐level surveillance, it is strongly recommended that the elderly and male patients should be diagnosed in a timely manner, as progression of the respiratory pathology to pneumonia might result in catastrophic outcomes (Jian‐ya, 2020).
5.1 Clinical symptom spectrum
Understanding the otherwise nonspecific clinical signs and symptoms of COVID‐19 is a crucial step toward appropriate management of the disease. Patients mostly complain of fever, non‐productive cough, and body ache or extreme tiredness. In some cases, diarrhea and nausea precede fever by a few days, suggesting that fever might not be the initial manifestation of infection. A small number of patients reportedly had headache, or even developed hemoptysis (Guan et al., 2020; Wang, Hu, et al., 2020). Some patients remained asymptomatic, despite being tested positive for the disease (Chan et al., 2020). According to several studies, infection with SARS‐CoV‐2 in the elderly, especially the male community, is more likely to result in severe alveolar damage and respiratory failure (Chen, Zhou, et al., 2020). Occasionally, the disease may be demonstrated with a fulminant natural history, rapidly progressing to organ dysfunction, and even death in critical cases. Organ dysfunction includes conditions such as shock, ARDS, acute cardiac injury, and acute kidney injury (Huang et al., 2020; Wang, Hu, et al., 2020). From a laboratory point of view, lymphopenia, thrombocytopenia, impaired prothrombin time (PT), and elevated serum levels of CRP stand among the findings that can be reported for patients with COVID‐19 (Chen, Zhou, et al., 2020; Guan et al., 2020; Huang et al., 2020; Wang, Hu, et al., 2020). Overall, any patient with fever and acute respiratory symptoms, who is reported to have lymphopenia or leukopenia on lab examination, should be suspected. A history of travel to Wuhan or having close contact with local residents is a strong indicator for careful management of the patient (Zu et al., 2020). Table 2 represents the criteria for diagnosis of COVID‐19 infected patients (Committee, 2020b; Zu et al., 2020; WWW.ClinicalTrials.gov).
Table 2 Criteria for clinical severity of confirmed COVID‐19 pneumonia
Patient Clinical findings CT (imaging findings of pneumonia) Organ damage
Mild Negative None None
No dyspnea, with or without cough, fever <38°C (quelled without treatment)
No history of chronic respiratory disease
Moderate dyspnea, with or without cough Multifocal patchy GGOs with subpleural distribution None
SpO2 >93% without oxygen inhalation
Severe Fever Diffuse heterogeneous consolidation with GGO, None
Muscle ache Rapid progression (>50%) on CT imaging within 24–48 hr
Headache
Confusion
Respiratory distress:
RR ≥ 30 times/min
SpO2 < 93% at rest
PaO2/FiO2 ≤ 300 mmHg
Critical Shock “Extra pulmonary” organ failure or MODS
Respiratory failure
need mechanical assistance
Intensive care unit is needed
Abbreviations: FiO2, fraction of inspired oxygen; GGO, ground‐glass opacity; MODS, multiple organ dysfunction syndrome; PaO2, partial pressure of oxygen; RR, respiratory rate, SpO2, oxygen saturation.
John Wiley & Sons, Ltd. This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.
5.2 Epidemiological history
Shortly after the onset of the epidemic, The National Health Commission of China (Committee, 2020a; Organization, 2020a) initiated the Diagnosis and Treatment Program of COVID‐19‐associated pneumonia, following the guidelines provided by WHO on SARS and MERS (Azhar & EI‐Kafrawy, 2014; Organization, 2017, 2020b).
According to the newly formulated criteria, a “suspected case” is defined as a patient with epidemiological history, that is traveling and contact, and two clinical findings pertinent to the disease. If, however, an epidemiological history is not confirmed, then the patient must present at least three clinical findings to be considered as a suspected case. Based on the Trial, Fifth Edition (Committee, 2020b), pathologic findings indicative of viral pneumonia on chest CT scans provide enough evidence for clinical diagnosis of COVID‐19. Nonetheless, as of February 17, 2020, WHO does not approve of any diagnosis based solely on radiologic findings, without obtaining an RT‐PCR test from the patient (Organization, 2020c). In the more recent revision of the Chinese Diagnosis and Treatment Program, 6th Edition, the term “clinical diagnosis” was removed and replaced with “etiological diagnosis” (Organization, 2020a). According to the recent revision, it is imperative that an etiological diagnosis of COVID‐19 is made at first, which can then be complemented by a positive real‐time RT‐PCR assay for SARS‐CoV‐2, which is duly performed on the sputum or blood sample of the patient. After the final diagnosis is made, confirmed patients are categorized into mild, moderate, severe, and critical types, based on the severity of disease (Zu et al., 2020).
5.3 COVID‐19 detection tests: Pathogenic laboratory testing, real‐time RT‐PCR, and sequencing of nucleic acid
Table 3 (Ai et al., 2020; Bai et al., 2020; Chen, Zhao, et al., 2020; Shi et al., 2020; Tian et al., 2020; Wang, Kang, et al., 2020; Wu & McGoogan, 2020; Yan et al., 2020; Yang et al., 2020) and Table 4 represent 2020 studies on diagnosis of COVID‐19 infected patients and related clinical trials, respectively.
Table 3 Studies for diagnosis, prognosis and therapy of COVID‐19 patients
Study/region Study type/medical team Patient/median age/sex Diagnostic test Sample Inclusion criteria/residency Test results Most common symptoms/chronic disease Incubation period (day) Case fatality rate Diagnosis/prognosis/therapy
Wu et al. (2020), China Retrospective study/Chinese Center for Disease Control and Prevention 72,314; subjects: confirmed cases 44,672 (62%), suspected cases 16,186 (22%), diagnosed cases 10,567 (15%), asymptomatic cases 889 (1%)/age N = 44,672: 80: 3% (1,408), 30–79: 87% (38,680), 20–29: 8% (3,619), 10–19: 1% (549), <10: 1% (416) PCR Throat swab samples Confirmed cases based on positive PCR, suspected cases based on symptoms and exposures only, clinically cases based on symptoms, exposures, and CT, asymptomatic cases diagnosis by positive PCR Spectrum of disease: (N = 44,415); mild: 81% (36,160), severe: 14% (6,168), critical: 5% (2,087) Cardiovascular disease: 10.5%, diabetes: 7.3%, chronic respiratory disease: 6.3%, hypertension: 6.0%, cancer: 5.6% About a week 2.3% (1,023 of 44,672 confirmed cases), 14.8% aged >80 years (208 of 1,408), 8.0% aged 70–79 years (312 of 3,918) 49.0% in critical cases (1,023 of 2,087) Next step: to help “buy time” for more diagnostic and therapeutic research before COVID‐19 becomes too widespread
Tian et al. (2020), China Retrospective study/Beijing Emergency Medical Service 262/47.5/48.5% male Real‐time RT‐PCR Respiratory specimens COVID‐19 infected patients/residents of Beijing: 92 (73.3%), patients had been to Wuhan: 50 (26.0%), close contact with confirmed cases: 116 (60.4%), no contact history: 21 (10.9%) Spectrum of disease: sever: 46 (17.6%); common: 216; (82.4%); mild: 192 (73.3%); nonpneumonia: 11 (4.2%); asymptomatic:13 (5.0%) Fever (82.1%), cough (45.8%), fatigue (26.3%), dyspnea (6.9%), headache (6.5%)/pulmonary infection, chronic cardiovascular disease and heart failure: 1, pulmonary infection and multiple chronic diseases: 1 Incubation: 6.7 days, illness onset to visit hospital: 4.5 days 3 (0.9%) Results: As of February 10, 45 (17.2%) patients have discharged
For COVID‐19 control: first step is prevent transmission at early stage, next steps is early isolation and quarantine of suspected subjects
Wang et al. (2020), China Retrospective cohort/Xi'an Jiaotong University First Affiliated Hospital, Nanchang University First Hospital and Xi'an No.8 Hospital of Xi'an Medical College 99 CT, artificial intelligence, inception migration‐learning model – Pathogen‐confirmed COVID‐19 patients Spectrum of disease: typical viral pneumonia or negative group: 55, confirmed nucleic acid testing or positive group: 44. CT (453 CT images): negative: 258, positive: 195 Viral pneumonia symptoms – – Screening:
The internal validation; accuracy: 82·9%, specificity: 80·5%, sensitivity: 84%
The external testing; accuracy: 73·1%, specificity: 67%, sensitivity: 74%
Algorithm prediction: a rate of 2 s per case on the graphic processing unit
Interpretation: the early diagnosis through fast, accurate, safe and noninvasive methods is crucial for control of virus
Yan et al. (2020), China Retrospective study/Tongji Hospital 375, 58.83, 58.7% males CT, machine learning model (a supervised XGBoost classifier) – Validated or suspected COVID‐19 patient/Wuhan residents (37.9%), familial cluster (6.4%), health workers (1.9%) Spectrum of disease: critical patients: 46.1%, severe cases: RR ≥ 30bpm or SPO2 ≤93% on rest Fever: 49.9%, cough: 13.9%, fatigue 3.7%, dyspnea 2.1%, shock: 2 174
16 + 1 Interpretation: the three indices‐based prognostic prediction model might predict themortality risk, recognition of critical cases, help to early identification, on time intervention, reducing mortality rate
Shi et al. (2020), China Retrospective/hospitals in Wuhan 81, 49–5, 42 (52%) men and 39 (48%) women Next‐generation sequencing or RT‐PCR, serial chest CT Throat swab specimens Confirmed COVID‐19 pneumonia patients/direct exposure to Huanan seafood market: 31 (38%), health‐care workers: 15 (19%), familial clusters: 7 (9%), any obvious history of exposure: 28 (35%) Spectrum of disease: mean number of involved lung segments: 10.5 (SD 6.4): group 1: subclinical patients (CT before symptom onset): 2.8 (3.3), group 2: ≤1 week after symptom onset/11.1 (5.4), group 3: >1–2 weeks/13.0 (5.7), group 4: >2–3 weeks/12.1 (5.9).
CT:
ALL:
bilateral abnormality: 64 [79%], peripheral 44 [54%], Ill‐defined 66 [81%], GGO: 53 [65%], mainly involving the right lower lobes: 225 [27%] of 849.
Group 1 (n=15): unilateral: 9 [60%]/multifocal 8 [53%]/GGO: 14 [93%]; Group 2 (n = 21): bilateral 19 [90%]/diffuse 11 [52%]/GGO predominance 17 [81%]; Group 3 (n = 30): GGO 17 [57%], consolidation/mixed patterns: 12 [40%]; Group 4 (n=15): consolidation/mixed patterns: 8 [53%].
Blood:
Group1: Lower CRP and AST Fever: 59 [73%], dry cough: 48 [59%] nonspecific symptoms:
dizziness:
2 [2%], diarrhea:
3 [4%], vomiting:
4 [5%], headache:
5 [6%], generalised weakness:
7 [9%]/chronic pulmonary disease (tuberculosis): 1, T2D: 1, hypertension/cardiovascular/erebrovascular disease: 1 Symptom onset and discharge of 23–2 days 3 (4%) By February 8, 2020, 62 (77%) patients discharged
Interpretation: COVID‐19 pneumonia include CT abnormalities that rapidly progress from focal unilateral to diffuse bilateral GGO coexisted with consolidations within 1–3 weeks (even in asymptomatic patients).
Early diagnosis through combined CT with clinical and laboratory findings
Bai et al. (2020), China Case study/The Fifth People's Hospital of Anyang 6, Patient 1: 20‐year‐old woman, patients 2–6: four women 42–57 years old CT, RT‐PCR Nasopharyngeal swabs Patient 1: met with Patients 2 and 3, and accompanied five relatives (Patients 2–6), Patients 2–6: no visited Wuhan or been in contact with any other people traveled to Wuhan Spectrum of disease: severe pneumonia: 2, moderate: others. A familial cluster of five patients with respiratory symptoms, 1 asymptomatic family member.
Blood:
all symptomatic patients: increased CRP, reduced lymphocyte.
CT: multifocal GGO: in all symptomatic patients, subsegmental consolidation/fibrosis: 1.
Patient 1: normal CT, CRP and lymphocyte count, RT‐PCR: negative, positive, negative.
Patients 2–6:
COVID‐19 confirmed.
PCR: positive for patients 2–6 within 1 day Fever: patients 2–6 19 days for patient 1 – Transmission: COVID‐19 transmission could transmit by an asymptomatic carrier S
Ai et al. (2020), China Cohort/Tangji hospital of Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei 1,014/51 ± 15/46% man Laboratory test, chest CT (7 day interval), RT‐PCR (Taq man one step): multiple assays (3 day interval) Throat swab Suspected of nCoV/China Positive CT: 88% (888/1,014), positive RT‐PCR: 59% (601/1,014).
Sensitivity of CT based on positive RT‐PCR: 97% (95%CI, 95–98%, 580/601).
Negative RT‐PCR/positive CT: 75% (308/413).
Initial positive CT consistent with COVID‐19 before the initial positive RT‐PCR: 60–93%.
Improvement in follow‐up CT before the RT‐PCR turning negative: 42% (24/57), CT: GGO: 46% [409/888], consolidations: 50% [447/888], bilateral findings: 90% [801/888] Fever, dry cough Initial + to − PCR: 5.1 ± 1.5 days,
Initial − to + PCR: 6.9 ± 2.3 days – Diagnosis: chest CT, as a highly sensitive method, could be considered as a primary tool for infection diagnosis in epidemic areas
Chen et al. (2020), China General Hospital of Central Theater Command, PLA 48/age; critically ill: 79.6 ± 12, sever: 63.9 ± 15, mild: 45.8 ± 14/31 males (77.1%) and 17 females (22.9%) Real‐time RT‐PCR, CT, GLMs analysis Serum, throat‐swab specimens Laboratory confirmed cases Spectrum of disease: mild: 21 (43.7%), severe 10 (20.8%), critically ill 17 (35.4%).
Blood: low/lower lymphocytes: severe and critically ill, higher neutrophils: critically ill, higher PCT: critically ill.
Parameters stand for the organ dysfunction; TnT, AST, ALT, CRE, and BUN: higher in critically ill patients.
PCR:
positive RNAaemia: (a) serum: 5 (10.4%) of critically ill, (b) throat‐swab: 48 positive.
IL‐6: value ≥100: 35.3% in critically ill, 10‐folds higher IL‐6 (cytokine storm): critically ill, RNAaemia positive: IL‐6 ≥100 (R = 0.902) Mild: fever, respiratory symptoms
Severe: shortness of breath, RR ≥ 30 times/min, oxygen saturation (resting state) ≤93%, PaO2/FiO2 ≤300 mmHg
Critically ill: respiratory failure, shock, multiple organ failure/diabetes: 12 [25%], hypertension: 23 [49.7%], heart disease: 8 [16.7%], mixed fungal infection: 27.1%, bacterial infection: (2.1%) – 3 Diagnosis; RNAaemia positive test confirmed critically ill patients
Prognosis: strong association between RNAaemia with cytokine storm can be applied to predict the poor prognosis
Therapeutic approach: in critically patients, IL‐6 should be considered as a therapeutic target
Fan et al. (2020), China Retrospective cohort study/three tertiary hospitals of Wenzhou 149/45.11 ± 13.35/81 (54.4%) males Laboratory test, PCR, CT Blood RT‐PCR confirmed patients: Hubei travel/residence history: N=85,
contact with people of Hubei: N=49, no traceable exposure history: N=15 Blood:
decreased oxygen saturation: 14(9.4%), leukopenia: 33 (24.2%), lymphopenia: 53 (35.6%), low platelets: 20 (13.4%), elevated CRP: 82 (55.0%), ALT/AST/CK and D‐dimer: less common.
CT: most involved lung segments: 6 and, GGO: 287 segments, mixed opacity: 637 segments, consolidation: 170 segments, lesions: more in the peripheral lung with a patchy form, normal CT on admission: N=17, negative CT: N=12, no significant difference between patients with or without exposure history Fever:
114/149, 76.5%,
Cough: 87/149, 58.4%,
Expectoration:
4 8/149, 32.2%, mild infection/cerebrovascular or digestive diseases:
52 (34.9%) Negative CT: 10 days, 6.8 (5.0) days 0 (0.0%) Diagnosis: a normal CT cannot exclude the diagnosis of COVID‐19
Fan et al. (2020), China Retrospective, case series/Chongqing University Three Gorges Hospital 51/45/32 (62.7%) men Laboratory test, CT Blood Confirmed COVID‐19: patients had been to Wuhan:
43 (84.3%), contact history of COVID‐19 patients: 4 (7.7%), no clear contact history:4 (7.7%) Spectrum of disease:
nonsevere patients: n = 44, severe patients: 7 (13.7%)
Blood: lymphopenia: 26 (51.0%), elevated CRP: 32 (62.7%).
CT:
GGO: 41 [80.4%], local consolidation of pneumonia:
17 [33.3%], pleural thickening: 20 (39.2%), small amount of pleural effusion:
7 (13.7%), streak shadow of lung: 8 (15.7%), multiple solid nodular shadow: 4 (7.8%), air bronchogram: 2 (3.9%), single lobe lesions: 2 (3.9%), multiple lobe lesions: 49 (96.1%) Fever:
43 [84.3%], cough:
38 [74.5%], dry cough with expectoration:
16 (31.4%), fatigue: 22 [43.1%], asthenia: 22 (43.1%), dyspnea: 11/DM: 4 [57.1%] 2–5 days 1 Therapy:
TCM decoction: 28 [54.9%], aerosol inhalation of recombinant human
Interferon a‐1b: 51 (100%), Lopinavir/Ritonavir: 51 [100%], Bacillus licheniformis capsules: 44 [86.3%], glucocorticoid treatment: 10 (19.6%)
Older patients with server COVID‐19 (N = 7)
Antibiotic treatment: 7 [100%], nutritional diet: 6 [85.7%), human albumin infusion: 4 (57.1%), immunoglobulin treatment: 4 (57.1%), mechanical ventilation: 6 [85.7%]
Results and interpretation: discharged 50 patients after 12 days, without the common clinical symptoms, with the significant increased lymphocyte (p = .008) and significant decreased CRP significantly (p < .001)
Fan et al. (2020), China Retrospective/Shanghai Public Health Clinical Center 148/50.5/49.3% females and 50.7% males Laboratory test, RT‐PCR and CT scanning Sera Confirmed SARS‐CoV‐2‐infected patients/a history of related epidemiology Blood:
elevated LDH, AST, ALT, GGT, TB, ALP:
35.1%, 21.6%, 18.2%, 17.6%, 6.1%, 4.1% in all patients; lower CD4+ and CD8+ T cells: (62.67%)/(56.1%) patients with abnormal liver function received more treatment compared with normal liver function (25%) (p = .009) Fever: (70.1%), cough: (45.3%), expectoration at admission:
(26.7%),
Abnormal liver functions at admission: 75 patients (50.7%) with moderate‐high degree fever (44%) in males,/chronic hepatitis B or C: N = 8 5 days (3–7) 1 Therapy:
Antibiotics (Levofloxacin, Meropenem, Moxifloxacin, Cephalosporin), interferon, antiviral drugs (Arbidol, Lopinavir/ritonavir, Dnrunavir)
Results and interpretation:
all patients discharged from the hospital.
Lopinavir/Ritonavir treatment can significantly alleviate the SARS‐CoV‐2‐induced liver function damage
Chen et al. (2020) China Retrospective/Zhongnan Hospital of Wuhan University, Wuhan 9/26–34/female Clinical records, laboratory results, CT scans Amniotic fluid, cord blood, and neonatal throat swab, breastmilk samples Pregnant women with laboratory‐confirmed COVID‐19 pneumonia and caesarean section in their third trimester/a history of epidemiological exposure to COVID‐19 Blood:
lymphopenia: N = 5, elevated CRP: N = 6, increased ALT and AST: N = 3, normal WBC count: N = 7, lower WBC: N = 1.
Nine mothers: none developed severe COVID‐19 pneumonia or dying as of Feb4.
Six mothers:
amniotic fluid, cord blood, neonatal throat swab, and breastmilk: negative for COVID‐19.
Nine livebirths:
with 1‐min Apgar score of 8–9 and a 5‐min Apgar score of 9–10, No neonatal asphyxia.
CT:
multiple patchy ground‐glass shadows: N=8 Fever: N = 7, cough N = 4, myalgia N = 3, sore throat: N = 2, malaise: N = 2, fetal distress:
N = 2/gestational hypertension:
N = 1, pre‐eclampsia: N = 1, influenza virus infection: N = 1 Short None Therapy: oxygen support (nasal cannula) and empirical antibiotic treatment: N = 9, antiviral therapy: N = 6
Interpretation: no evidence for intrauterine infection caused by vertical transmission in late pregnancy
Lim et al. (2020), Korea Public health center, Myongji Hospital 1/54/male PCR, CT Throat swab, sputum A Korean man living in Wuhan China/Virus transmission;
from index patient Patient A to Patients B, C, D@@ Spectrum of disease: mild respiratory symptoms.
CT:
small consolidation in right upper lobe, GGO in both lower lobes Chills, muscle pain 5–7 days – Therapy:
Lopinavir/Ritonavir
Results and interpretation:
significant decrease in β‐coronavirus viral loads due to the natural course of the healing process rather than administration of Lopinavir/Ritonavir, or both
Wu et al. (2020), China Retrospective/three Grade IIIA hospitals of Jiangsu 80/46.1/41 female (51.25%) Laboratory testing, real time RT‐PCR, CT Throat swab and/or nose swab, blood Confirmed COVID‐19 patients/with a history of epidemic in Wuhan and without contact with the seafood market Spectrum of disease:
mild: 28 (35.00%), moderate: 49 (61.25%), severe: 3 (3.75%), critically ill: none
Laboratory:
lower WBC: 36 (45.00%), lymphocytopenia: 26 (32.50%), lower platelets: 11 (13.75%), high CRP: 62 (77.50%), high ESR: 59 (73.75%), elevated PCT: 1 (1.25%).
Liver function:
increased ALT/AST: 3 (3.75%), lower albumin: 2 (2.50%).
Abnormal myocardial enzyme spectrum and increase of CK: 18 (22.50%).
Increased LDH: 17 (21.25%).
Renal function damage: 2 (2.50%).
Serious renal function damage: 1.
Hyperglycemia: 19 (23.17%).
Increased D‐dimer: 3 (3.75%).
9 kinds of respiratory pathogens and influenza A/B nucleic acids: all patients.
CT: abnormal: 55 (68.75%), bilateral pneumonia: 36 (45.00%), unilateral pneumonia: 19 (23.75%), normal: 25 (31.25%).
Organ damage: acute respiratory injury: 10 (12.50%), renal injury: 2 (2.50%) Fever:
63 (78.75%), cough: 51 (63.75%), shortness of breath: 30 (37.50%), muscle ache: 18 (22.50%), headache: 13 (16.25%) liver dysfunction: 3 (3.75%)/cardiovascular/cerebrovascular, endocrine, digestive, respiratory, malignancies and nervous system diseases: 38 (47.50%) 8.0 Not now Therapy:
all patients:
single antibiotic mainly Moxifloxacin and Ribavirin antiviral therapy, 12 (14.63%) patients:
methylprednisolone sodium succinate or methylprednisolone, 35 (43.75%) patients:
noninvasive ventilator, 1 patient: hemodialysis, 3 patients: TCM
Interpretation: 21 cases discharged from the hospital: With no obvious gender susceptivity, lower proportion of liver dysfunction, abnormal CT and higher frequency nucleic acid detection
Li et al. (2020), China Retrospective study/hospital in Wenzhou 175/46/92 women, 83/men Real‐time PCR, CT Respiratory tract samples or blood samples Confirmed COVID‐19/a history of exposure to the epidemic area: 57 (33%) patients Spectrum of disease:
COVID‐19:
mild: mild clinical manifestations, no pneumonia; moderate: respiratory symptoms, mild pneumonia, severe (37): pneumonia, ARDS with RR >30 times/min, oxygen saturation <93%; critical (3): pneumonia, shock, respiratory failure, and failures in other organs, nearly all patients: GGO
K+:
severe hypokalemia: 39 (higher body temperature, higher heart rate and RR, higher prevalence of dyspnea or tachypnea (p < .05)), hypokalemia 69, normokalemia patients 67.
Correlations: severity of hypokalemia with body temperature, CK, CK‐MB, LDH, and CRP (p < .01), 93% of severe/critically ill patients showed hypokalemia Cough, fever, pneumonia/hypertension: 28, diabetes: 12, other conditions:31 6 – Therapy:
1 severe hypokalemia patients;
3 g/day K+, 34 (SD = 4) g potassium during hospital stay
Good response of patients to K+ supplements when they inclined to recovery
Interpretation: hypokalemia is prevailing in COVID‐19 patients
Lan et al. (2020), China Case study/Zhongnan Hospital of Wuhan University, Wuhan 4, 30–36 years, 2 male RT‐PCR, thin‐section CT Throat swabs Medical personnel quarantined at home with COVID‐19 Spectrum of disease: mild to moderate
Results: (at admission); PCR positive: for all CT positive: for all GGO, or mixed GGO/consolidation
(after therapy); 2 consecutive negative RT‐PCR: all (after discharge); repeated RT‐PCR 5–13 days later: all positive Fever:3, cough: 3, both: 3 Symptom onset to recovery: 12–32 days – Therapy: antiviral treatment (75 mg of oseltamivir every 12 hr)
Resolved clinical symptoms and CT abnormalities: 3
Delicate patches of GGO: 1
Interpretation: possibility of at least a proportion of recovered patients act as virus carriers
Li et al. (2020), China Retrospective study/Sino‐French New Town area Tongji Hospital 47, 62, 28 (59.6%) men Real‐time RT‐PCR Throat‐swab specimens, sputum or endotracheal aspirates Patients with severe COVID‐19 Spectrum of disease: severe: 41 critical: 5(17.9%) men and 1 (5.3%) women
Common: oxygen saturation <93% after routine
Nasal oxygen supply: 3 men/1 woman
Blood: PCT: higher in men, N‐terminal‐pro brain natriuretic peptide: Higher in 16(57.1%) men/5 (26.3%) women,
Positive influenza A antibody: 5 men (17.9%) Fever: 34 [72.3%], cough: 36 [76.6%], myalgia: 5 [10.6%], fatigue: 7 [14.9%]/comorbidities: 30 (63.8%):
COPD, hypertension/CVD lower in men – 3.6% in men and 0 in women Therapy:
antibiotics applied more in the men than the women
Results and interpretation: 4 (21.1%) women/1 man (3.6%) discharged.
Possibility of sex differences in severe COVID‐19 patients, Men with more complicated clinical condition and worse outcomes
Han et al. (2020) Case study/People's Hospital in Wuwei A 47‐year‐old man/smoking for 20 years/no alcohol abuse RT‐PCR, CT Nasopharyngeal swab specimens Confirmed SARS‐CoV‐2/returned to Wuwei city on January 18 from Wuhan city by car Blood:
decreased lymphocytes, increased CRP, slightly elevated fibrinogen, neutrophil, LDH, and fibrinogen
PCR: positive for expression of RdRPN, N and E genes
CT: multiple patchy high‐density shadows scattered mainly in the border regions of lungs, solid changes, GGO changes, slightly thickened pleura Fever, cough productive of white phlegm, bosom frowsty, stuffy/runny noses, vertigo, fatigue, chest tightness, nausea, expiratory dyspnea, poor diet, lethargy/hypertension grade 2 and T2D – – Therapy:
combination therapy including:
Lopinavir/Ritonavir (800/200 mg daily), methylprednisolone (40 mg daily), recombinant human interferon α‐2b (10 million IU daily), ambroxol hydrochloride (60 mg daily) moxifloxacin hydrochloride (0.4 g daily), high flow humidification oxygen inhalation therapy, treatment of blood glucose, blood pressure, and rehydration therapy
Results interpretation: the persistent negative results of SARS‐CoV‐2 on days 6 and 7, normal TLC, lung lesions partially absorbed, The patient discharged. Laboratory tests like TLC are necessary, CT combined with RT‐PCR is helpful, Lopinavir/Ritonavir are effective after failure of methylprednisolone/interferon alfa‐2b
Liu et al. (2020), China Retrospective cohort and case study/Zhongnan Hospital of Wuhan University Dawu County People's Hospital 124 patients, 22 patients:
12 therapy (mean age 53), 10 control (mean age 58) CT, PCR Serum 124 confirmed COVID‐19 cases, 12 HCOV infected patients Blood: (Study 1) decreased platelet: 25 (20.2%), prolonged PT: 77 (62.1%), increased FIB: 27 (21.8%), and increased D‐dimer: 26 (21.0%)
Spectrum of disease: (study 2) severe cases: 6 mild cases: 4 critically ill: 2
CT: (study 2) Bilateral pneumonia: all Study 1: hypercoagulability
Study 2: cough: all shortness of breath: most of them, nausea and vomiting: 60.0%/DM, cardiovascular and cerebrovascular diseases: 4 patients from the DIP, 5 patients control group – 1 Therapy: Dipyridamole (150 mg in three separate doses for 7 consecutive days), antiviral (ribavirin, 0.5 g, Q12hr), corticoid (methylprednisolone sodium succinate, 40 mg, qd), oxygen therapy, nutritional support
Results and interpretation: significant increase in platelet/lymphocyte, significant decrease in D‐dimer levels
Discharged patients: 50% of severe cases and all 4 mild cases.
Dipyridamole adjunctive therapy could significantly reduce viral replication, inhibits hypercoagulability and improves immune recovery
Abbreviations: ALP, alkaline phosphatase; ALT, alanine aminotransferase; ARDS, acute respiratory distress syndrome; AST, aspartate aminotransferase; BUN, blood urea nitrogen; CK, creatine kinase; CK‐MB, creatine kinase myocardial band; COPD, chronic obstructive pulmonary disease; CRE, serum creatinine; CRP, C‐reactive protein; CT, computed tomography; CVD, cardiovascular disease; DM, diabetes mellitus; DM, diabetes mellitus; ESR, erythrocyte sedimentation rate; FIB, fibrinogen; FiO2, fraction of inspired oxygen; GGO, ground‐glass opacity; GGT, γ‐glutamyltransferase; GLM, Generalized Linear Model; LDH, lactate dehydrogenase; nCoV, novel coronavirus; PaO2, partial pressure of oxygen; PCT, procalcitonin; PT, prothrombin time; RNAaemia, SARS‐CoV‐2 nucleic acid; RR, respiratory rate; RT‐PCR, reverse transcriptase polymerase chain reaction; SpO2, oxygen saturation; T2D, type 2 diabetes; TB, total bilirubin; TCM, traditional Chinese medicine; TCM, traditional Chinese medicine; TLC, total lymphocyte count; TnT, troponin T; WBC, white blood cell.
John Wiley & Sons, Ltd. This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.
Table 4 Clinical trials for COVID‐19 or SARS‐nCoV2
Study title Interventions Location/condition Subjects, sex, age Primary purpose Arms Phase Measure outcome/time frame Code/status/date
The efficacy and safety of huaier in the adjuvant treatment of COVID‐19 Drug: Huaier Granule COVID‐19 550, all, 18–75 Treatment Experimental group: standard therapy + Huaier granule 20 g, po, tid for 2 weeks (or until discharge)
Control group: standard therapy II, III Primary (up to 28 days): all cause mortality
Secondary (up to 28 days): clinical status, differences in oxygen intake methods, supplemental oxygenation, mechanical ventilation, mean PaO2/FiO2, length of hospital stay, Length of ICU stay (days), pulmonary function (up to 3 months after discharge) NCT04291053/Not yet recruiting, Apr1‐Sep1 2020
Clinical trial on regularity of TCM syndrome and differentiation treatment of COVID‐19 Drug: TCM prescriptions China/COVID‐19 340, all, 18–75 Treatment Exposure group: integrated TCM and western medicine cohort (routine treatment + one or two of the following antiviral drugs + the following TCM regimens: take decocted or granule, one dose a day)
Control group: western medicine cohort (routine treatment + one or both of the following antiviral drugs) Not applicable Primary (9 days): The relief/disappearance rate of main symptoms, chest CT absorption
Secondary (9 days): virus antigen negative conversion rate, Clinical effective time: the average effective time. The number of severe and critical conversion cases, Incidence of complications, Traditional Chinese Medicine Syndrome Score
Other outcome measures (9 days): CRP changes, ESR changes, PCTchanges, The index of T cell subsets changed NCT04306497/Recruiting, Mar2‐May 2020
Recombinant human angiotensin‐converting enzyme 2 (rhACE2) as a treatment for patients with COVID‐19 Drug: Recombinant human angiotensin‐converting enzyme 2 (rhACE2) China/COVID‐19 24, all, 18–80 Treatment Experimental group: 0.4 mg/kg rhACE2 IV BID for 7 days and standard of care
Control group: standard of care Not applicable Primary (14 days): time course of body temperature, viral load over time
Secondary (14 days): P/F ratio over time, sequential organ failure assessment score over time, Pulmonary Severity Index, image examination of chest over time, proportion of subjects who progressed to critical illness or death, Time from first dose to conversion to normal or mild pneumonia, T‐lymphocyte counts over time, C‐reactive protein levels over time, angiotensin II (Ang II) changes over time, angiotensin 1–7 (Ang 1–7) changes over time, angiotensin 1–5 (Ang 1–5) changes over time, renin changes over time, aldosterone changes over time, angiotensin‐converting enzyme changes over time, angiotensin‐converting enzyme 2 (ACE2) changes over time, IL‐6 changes over time, IL‐8 changes over time, soluble tumor necrosis factor receptor type II (sTNFrII) changes over time, Plasminogen activator inhibitor type‐1 changes over time, Von willebrand factor changes over time, tumor necrosis factor‐α changes over time, soluble receptor for advanced glycation end products (sRAGE) changes over time, surfactant protein‐D changes over time, angiopoietin‐2 changes over time, frequency of adverse events and severe adverse events NCT04287686/Withdraw, Feb‐Apr 2020
The COVID‐19 mobile health study (CMHS) nCapp, a cell phone‐based autodiagnosis system China/COVID‐19 450, all, 18–90 Diagnosis Training: nCapp, a cell phone‐based autodiagnosis system, combined with 15 questions online, and a predicated formula to autodiagnosis of the risk of COVID‐19
Validation: nCapp, a cell phone‐based autodiagnosis system, combined with 15 questions online, and a predicated formula to auto‐diagnosis of the risk of COVID‐19 – Primary (1 day): accuracy of nCapp COVID‐19 risk diagnostic model NCT04275947/Recruiting, Feb 14‐May 31 2020
A Pilot Study of Sildenafil in COVID‐19 Drug: Sildenafil citrate tablets (G1) China/COVID‐19 10, all, 18 years and older Treatment Experimental group: sildenafil citrate tablet 0.1 g/day for 14 days Not applicable Primary (14 days): rate of disease remission, rate of entering the critical stage, time of entering the critical stage
Secondary (14 days): rate of no fever, rate of respiratory symptom remission, rate of lung imaging recovery, rate of C‐reactive protein (CRP) recovery, rate of Biochemical criterion (CK, ALT, Mb) recovery, rate of undetectable viral RNA (continuous twice), time for hospitalization, rate of adverse event NCT04304313/Recruiting, Feb 9‐Nov 9 2020
Critically Ill patients with COVID‐19 in Hong Kong: a multicentre observational cohort study – Hong Kong/COVID‐19 8 descriptive A case series of 41 hospitalized patients with confirmed infection
30% required critical care admission: developed severe respiratory failure, 10% required mechanical ventilation, 5% needed extracorporeal membrane oxygenation support mortality rate: 15% − Primary (28 days): 28 day mortality
Secondary (28 days): vasopressor days, days on mechanical ventilation, sequential organ function assessment score, ECMO use, percentage nitric oxide use, percentage free from oxygen supplement NCT04285801/Completed, Feb 14‐Feb 25 2020
Treatment of mild cases and chemoprophylaxis of contacts as prevention of the COVID‐19 epidemic Drug: antiviral treatment and prophylaxis, Standard Public Health measures COVID‐19 3,040, All, 18 Years and older Treatment Experimental: antiviral treatment and prophylaxis: darunavir 800 mg/cobicistat 150 mg tablets (oral, 1 tablet q24h, taking for 7 days) and hydroxychloroquine (200 mg tablets) 800 mg on Day 1, and 400 mg on days 2, 3, 4. Contacts: a prophylactic regimen of hydroxychloroquine (200 mg tablets) 800 mg on Day 1, and 400 mg on days 2,3,4. Other: standard public health measures
Active comparator: standard public health measures III Primary (up to 14 days after start of treatment): effectiveness of chemoprophylaxis assessed by incidence of secondary COVID‐19 cases
Secondary: the virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at days 3, the mortality rate of subjects at weeks 2, proportion of participants that drop out of study (up to 14 days after start of treatment), proportion of participants that show noncompliance with study drug (up to 14 days after start of treatment) NCT04304053/Not yet recruiting, Mar15‐Jul15 2020
Comparison of lopinavir/ritonavir or hydroxychloroquine in patients with mild coronavirus disease (COVID‐19) Drug: lopinavir/ritonavir, Drug: hydroxychloroquine sulfate Korea/COVID‐19 150, all, 16 years to 99 years Treatment Experimental: lopinavir/ritonavir 200 mg/100 mg 2 tablets by mouth, every 12 hr for 7–10 days
Active comparator: hydroxychloroquine 200 mg 2 tablets by mouth, every 12 hr for 7–10 days
No intervention: control, no lopinavir/ritonavir and hydroxychloroquine II Primary: viral load (hospital Day 3, 5, 7, 10, 14, 18)
Secondary viral load change (hospital Day 3, 5, 7, 10, 14, 18), time to clinical improvement (time frame: up to 28 days), percentage of progression to supplemental oxygen requirement by Day 7, Time to NEWS2 (National Early Warning Score 2) of 3 or more maintained for 24 hr by Day 7, time to clinical failure, defined as the time to death, mechanical ventilation, or ICU admission (up to 28 days), rate of switch to lopinavir/ritonavir or hydroxychloroquine by Day 7, adverse effects (up to 28 days), concentration of lopinavir/ritonavir and hydroxychloroquine (1, 2, 4, 5, 12 hr after taking intervention medicine) NCT04307693/Recruiting, Mar11‐May 2020
Study to evaluate the safety and antiviral activity of remdesivir (GS‐5734™) in participants with severe coronavirus disease (COVID‐19) Drug: remdesivir, standard of care United States, Hong Kong/COVID‐19 400, all, 18 years and older Treatment Experimental: demdesivir (RDV), 5 days participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, and 5
Experimental: remdesivir, 10 days participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, 5, 6, 7, 8, 9, and 10 III Primary: proportion of participants with normalization of fever and oxygen saturation through day 14
Secondary: proportion of participants with treatment emergent adverse events leading to study drug discontinuation (first dose date up to 10 days) NCT04292899/Recruiting, Mar6‐May 2020
Study to evaluate the safety and antiviral activity of remdesivir (GS‐5734™) in participants with moderate coronavirus disease (COVID‐19) compared to standard of care treatment Drug: remdesivir, standard of care United States, Hong Kong, 600, all, 18 years and older Treatment Experimental: remdesivir, 5 days participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, and 5.
Experimental: remdesivir, 10 days participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, 5, 6, 7, 8, 9, and 10.
Active comparator: continued standard of care therapy III Primary (up to 14 days): proportion of participants discharged by day 14‐secondary (up to 10 days): proportion of participants with treatment emergent adverse events leading to study drug discontinuation NCT04292730/Recruiting, Mar‐May 2020
Bevacizumab in severe or critical patients with COVID‐19 pneumonia‐RCT Drug: bevacizumab China/COVID‐19 Pneumonia 118, all, 18–80 Treatment Experimental; bevacizumab, group:
bevacizumab 500 mg + 0.9% NaCl 100 ml, intravenous drip
No intervention: control group Not applicable Primary: proportion of patients whose oxygenation index increased by 100 mmHg on the 7th day after admission NCT04305106/Not yet recruiting, Mar12‐May31 2020
The efficacy and safety of thalidomide in the adjuvant treatment of moderate new coronavirus (COVID‐19) pneumonia Drug: thalidomide, placebo COVID‐19 thalidomide 100, all, 18 years and older Treatment Placebo comparator: control group: placebo 100 mg, po, qn, for 14 days
Experimental: thalidomide group 100 mg, po, qn, for 14 days. Other name: fanyingting II Primary (up to 28 days): time to clinical recovery time to clinical recovery (up to 28 days)
Secondary (up to 28 days): all cause mortality (up to 28 days), frequency of respiratory progression, Time to defervescence
Others(up to 28 days): time to cough reported as mild or absent, respiratory improvement time, frequency of requirement for supplemental oxygen or noninvasive ventilation, Time to 2019‐nCoV RT‐PCR negative in upper respiratory tract specimen, change (reduction) in 2019‐nCoV viral load in upper respiratory tract specimen as assessed by area under viral load curve, frequency of requirement for mechanical ventilation, frequency of serious adverse events, Serum TNF‐α, IL‐1β, IL‐2, IL‐6, IL‐7, IL‐10, GSCF, IP10, MCP1, MIP1α and other cytokine expression levels before and after treatment NCT04273529/Not yet recruiting, Feb20‐Jun30 2020
The efficacy and safety of thalidomide combined with low‐dose hormones in the treatment of Severe COVID‐19 Placebo, drug: thalidomide COVID‐19 thalidomide 40, all, 18 years and older Treatment Placebo comparator: control group α‐interferon: nebulized inhalation, 5 million U or equivalent dose added 2 ml of sterile water for injection, 2 times a day, for 7 days; abidol, 200 mg/time, 3 times a day, for 7 days; methylprednisolone: 40 mg, q12h, for 5 days. placebo: 100 mg/d, qn, for 14 days
Experimental: thalidomide group α‐interferon: nebulized inhalation, 5 million U or equivalent dose added 2 ml of sterile water for injection, 2 times a day, for 7 days; abidol, 200 mg/time, 3 times a day, for 7 days; methylprednisolone: 40 mg, q12h, for 5 days. thalidomide: 100 mg/d qn for 14 days II Primary (up to 28 days): time to clinical improvement
Secondary (up to 28 days): clinical status (days 7, 14, 21, and 28), time to hospital discharge or NEWS2 (National Early Warning Score 2) of ≤2 maintained for 24 hr, all cause mortality, duration (days) of mechanical ventilation, duration (days) of extracorporeal membrane oxygenation, duration (days) of supplemental oxygenation, length of hospital stay (days), time to 2019‐nCoV RT‐PCR, change (reduction) in 2019‐nCoV viral load in upper and lower respiratory tract specimens as assessed by area under viral load curve, frequency of serious adverse drug events, Serum TNF‐α, IL‐1β, IL‐2, IL‐6, IL‐7, IL‐10, GSCF, IP10#MCP1, MIP1α, and other cytokine expression levels before and after treatment NCT04273581/Not yet recruiting, Feb18‐May30 2020
Tetrandrine tablets used in the treatment of COVID‐19 Drug: tetrandrine China/COVID‐19 60, all, 18–75 Treatment Experimental: tetrandrine cohort after the subjects were enrolled, they were given “Tetrandrine 60 mg QD” for a course of 1 week (take 6 days, stop using for 1 day)
No intervention: control cohort treatment according to standard protocols without intervention IV Primary (12 weeks): survival rate secondary (2 weeks): body temperature NCT04308317/Enrolling by invitation, Mar5‐May1 2020
Fingolimod in COVID‐19 Biological: UC‐MSCs, other: placebo China/COVID‐19 30, all, 18–80 Treatment Experimental: treatment group: each patient in the fingolimod treatment group was given 0.5 mg of fingolimod orally once daily, for three consecutive days
No Intervention: control group II Primary (5 day after treatment): the change of pneumonia severity on X‐ray images NCT04280588/Recruiting, Feb22‐Jul1 2020
Therapy for pneumonia patients infected by 2019 novel coronavirus Biological: UC‐MSCs, other: placebo China/COVID‐19 48, all, 18–75 Treatment Experimental: UC‐MSCs treatment group, participants will receive conventional treatment plus four times of 0.5*10E6 UC‐MSCs/kg body weight intravenously at Day1, Day3, Day5, Day7)
Placebo comparator: control group, participants will receive conventional treatment plus 4 times of placebo intravenously at Day1, Day3, Day5, Day7 Not applicable Primary (at baseline, Day 1, Weeks 1, 2, 4, 8): size of lesion area by chest imaging, blood oxygen saturation
Secondary (at baseline, Day 1, Weeks 1, 2, 4, 8): rate of mortality within 28‐days, sequential organ failure assessment, side effects in the UC‐MSCs treatment group, Electrocardiogram, the changes of ST‐T interval mostly, Concentration of C‐reactive protein C‐reactive protein, immunoglobulin, CD4 + and CD8 + T cells count, Concentration of the blood cytokine (IL‐1β, IL‐6, IL‐8,IL‐10,TNF‐α), Concentration of the myocardial enzymes NCT04293692/Recruiting, Feb24‐Feb1 2020–2021
The Use PUL‐042 inhalation solution to prevent COVID‐19 in adults exposed to SARS‐CoV‐2 Drug: PUL‐042 inhalation solution, drug: placebo COVID‐19 200, all, 18 years and older Treatment Experimental: PUL‐042 inhalation solution, PUL‐042 inhalation solution (20.3 µg Pam2: 29.8 µg ODN/mL) given by nebulization on study days 1,3, 6, and 10
Placebo comparator: sterile normal saline for inhalation, sterile normal saline for inhalation given by nebulization on study days 1, 3, 6, and 10 II Primary (14 days): Prevention of COVID‐19 NCT04313023/Not yet recruiting, Apr‐Oct 2020
Treatment of COVID‐19 patients using Wharton's jelly‐mesenchymal stem cells Biological: WJ‐MSCs Arabia Amman, Jordan/use of stem cells for COVID‐19 treatment 5, all, 18 years and older Treatment Experimental: WJ‐MSCs WJ‐MSCs will be derived from cord tissue of newborns, screened for HIV1/2, HBV, HCV, CMV, mycoplasma, and cultured to enrich for MSCs.
WJ‐MSCs will be counted and suspended in 25 ml of saline solution containing 0.5% human serum albumin, and will be given to patient intravenously I Primary (3 weeks): Clinical outcome, CT Scan, RT‐PCR results
Secondary (8 weeks): RT‐PCR results NCT04313322/Recruiting, Mar16‐Sep30 2020
Myocardial damage in COVID‐19 Non China/COVID‐19 cardiovascular diseases 500, all, 18 years and older Prognostic Discharged group (no intervention) the individual which is defined as patient discharged from hospital
Dead group (no intervention) The individual which is defined as patient with all‐cause death – Primary (75 days): the myocardial injury incidence, the risk factors analysis for the death
Secondary (75 days): clinical characteristics, clinical course, cardiovascular comorbidity, Analysis of causes of death NCT04312464/Enrolling by invitation, Jun1‐Mar18 2020
Treatment with mesenchymal stem cells for severe corona virus disease 2019(COVID‐19) Biological: MSCs, biological: saline containing 1%, human serum albumin (solution of MSC China/COVID‐19 60, all, 18–70 Treatment Experimental: mesenchymal stem cells (MSCs), conventional treatment plus MSCs participants will receive conventional treatment plus 3 times of MSCs ((4.0*10E7 cells per time) intravenously at Day 0, Day 3, Day 6)
Placebo comparator: placebo conventional treatment plus placebo participants will receive conventional treatment plus 3 times of placebo (saline containing 1% human serum albumin (solution of MSC) 3 times of placebo (intravenously at Day 0, Day 3, Day 6) I, II Primary (28 days): improvement time of clinical critical treatment index, side effects in the MSCs treatment group
Secondary: proportion of patients in each classification of clinical critical treatment index (baseline, Days 7, 14, 28), all cause mortality on Day 28, invasive mechanical ventilation rate (Day 28), duration of oxygen therapy (Day 28), duration of hospitalization (Day 28), incidence of nosocomial infection (Day 28), CD4+ T cell count by flow cytometry in two groups (baseline, Day, 3, 6, 10, 14, 21, 28) NCT04288102/Recruiting, May5‐Dec31 2020–2021
The clinical study of carrimycin on treatment patients with COVID‐19 Drug: carrimycin, drug: lopinavir/ritonavir tablets or arbidol or chloroquine phosphate, Drug: basic treatment – 520, all, 18–75 Treatment Experimental: carrimycin basic treatment + carrimycin
Active comparator: lopinavir/ritonavir or arbidol or chloroquine phosphate any of basic treatment + lopinavir/ritonavir tablets or arbidol or chloroquine phosphate IV Primary (30 days): fever to normal time (day), pulmonary inflammation resolution time (HRCT) (day), negative conversion (%) of 2019‐nCOVRNA in gargle (throat swabs) at the end of treatment NCT04286503/Not yet recruiting, Feb23‐Feb28 2020–2021
Efficacy and safety of corticosteroids in COVID‐19 Drug: methylprednisolone China/COVID‐19 400, all, 18 years and older Treatment Experimental; Pred group: methylprednisolone 1 mg/kg/day ivgtt for 7 days
No intervention: con group Not applicable Primary (14 days): the incidence of treatment failure in 14 days
Secondary: clinical cure incidence (14 days), the duration of virus change to negative (14 days), mortality at Day 30, ICU admission rate in 30 days NCT04273321/Recruiting, Feb14‐May30 2020
Evaluation of the efficacy and safety of sarilumab in hospitalized patients with COVID‐19 Drug: sarilumab, drug: placebo United States/COVID‐19 400, all, 18 years and older Treatment Experimental: sarilumab high dose: single intravenous (IV) dose of sarilumab, other names: Kevzara®, REGN88, SAR153191
Experimental: sarilumab low dose: single intravenous (IV) dose of sarilumab Other Names: Kevzara®, REGN88, SAR153191
Placebo comparator: single intravenous (IV) dose of placebo to match sarilumab administration II, III Primary: time to resolution of fever for at least 48 hr without antipyretics for 48 hr (Up to Day 29), percentage of patients reporting each severity rating on a 6‐point ordinal scale (Day 15)
Secondary (up to Day 29): time to improvement in oxygenation for at least 48 hr, mean change in the 6‐point ordinal scale, clinical status using the 6‐point ordinal scale, time to improvement in one category from admission using the 6‐point ordinal scale, time to resolution of fever for at least 48 hr without antipyretics by clinical severity, time to resolution of fever for at least 48 hr without antipyretics by baseline IL‐6 levels, time to improvement in oxygenation for at least 48 hr by clinical severity, time to improvement in oxygenation for at least 48 hr by baseline IL‐6 levels, time to resolution of fever and improvement in oxygenation for at least 48 hr, time to change in National Early Warning Score 2 (NEWS2) scoring system, time to score of <2 maintained for 24 hr in NEWS2 scoring system, mean change in NEWS2 scoring system, number of days with fever, number of patients alive off oxygen, number of days of resting respiratory rate >24 breaths/min, number of days with hypoxemia, number of days of supplemental oxygen use, time to saturation ≥94% on room air, number of ventilator free days in the first 28 days, number of patients requiring initiation of mechanical ventilation, number of patients requiring noninvasive ventilation, number of patients requiring the use of high flow nasal cannula, number of patients admitted into an intensive care unit, number of days of hospitalization among survivors, number of deaths due to any cause (up to Day 60), incidence of serious adverse events (Up to Day 60), incidence of severe or life‐threatening bacterial, invasive fungal, or opportunistic infection, Incidence of severe or life‐threatening bacterial, invasive fungal, or opportunistic infection in patients with grade 4 neutropenia, Incidence of hypersensitivity reactions, incidence of infusion reactions, incidence of gastrointestinal perforation, white blood cell count, hemoglobin levels, platelet count, creatinine levels, total bilirubin level, alanine aminotransferase level, aspartate aminotransferase level NCT04315298/Recruiting, Mar16‐Mar16 2020–2021
Washed microbiota transplantation for patients with 2019‐nCoV infection Other: washed microbiota transplantation, other: placebo China/COVID‐19 complicated with refractory intestinal infections 0, all, 14–70 complicated with refractory intestinal infections Treatment Experimental: observational group 5 u washed microbiota suspension administered via nasogastric tube, nasojejunal tube or oral, combining with standard therapy
Placebo comparator: control group 5 u placebo (edible suspension of the same color as the washed microbiota suspension) administered via nasogastric tube, nasojejunal tube or oral, combining with standard therapy Not applicable Primary (2 weeks): number of participants with improvement from severe type to common type NCT04251767/Withdrawn, Feb5‐Apr30 2020
Safety and immunity of Covid‐19 aAPC vaccine Biological: pathogen‐specific aAPC China/Covid‐19 infection 100, all, 6 months to 80 years Treat and Prevent Covid‐19 Infection Experimental: the subjects will receive three injections of 5×10^6 each Covid‐19/aAPC vaccine via subcutaneous injections I Primary (0–28 day): frequency of vaccine events, frequency of serious vaccine events, proportion of subjects with positive T cell response
Secondary (0–28 day): mortality, duration of mechanical ventilation if applicable, proportion of patients in each category of the 7‐point scale (7, 14, and 28 days after randomization), proportion of patients with normalized inflammation factors (7 and 14 days after randomization), clinical improvement based on the 7‐point scale if applicable, lower Murray lung injury score if applicable (7 days after randomization) NCT04299724/Recruiting, Feb15‐Dec31 2020–2024
Safety related factors of endotracheal intubation in patients with severe Covid‐19 pneumonia Severe covid‐19 pneumonia with ET COVID‐19 endotracheal intubation 120, all, 18–90 Observational Intervention details: other: severe covid‐19 pneumonia with ET, severe covid‐19 pneumonia undergoing endotracheal intubation – Primary:
Success rate of intubation (the time span between 1 hr before intubation and 24 hr after intubation), infection rate of anesthesiologist (the time span between 1 hr before intubation and 14 days after intubation)
Secondary:
Extubation time (the time span between 1 hr before intubation and 30 days after intubation) NCT04298814/Not yet recruiting, Mar7‐Jul30 2020
Immunity and safety of Covid‐19 synthetic minigene vaccine Biological: injection and infusion of LV‐SMENP‐DC vaccine and antigen‐specific CTLs China/COVID‐19 100, all, 6 months to 80 years Treatment Experimental: pathogen‐specific DC and CTLs patients will receive approximately 5 × 106 LV‐DC vaccine and 1 × 108 CTLs via subcutaneous injections and iv infusions, respectively I
II Primary:
Clinical improvement based on the 7‐point scale (28 days after randomization), lower Murray lung injury score (7 days after randomization)
Secondary (0–28 day): 28‐day mortality, duration of mechanical ventilation, duration of hospitalization, proportion of patients with negative RT‐PCR results (7 and 14 days after randomization), proportion of patients in each category of the 7‐point scale (7, 14, and 28 days after randomization), proportion of patients with normalized inflammation factors (7 and 14 days after randomization), frequency of vaccine/CTL events, frequency of serious vaccine/CTL events NCT04276896/Recruiting, Mar24‐Dec31 2020–2024
Phase I clinical trial in healthy adult Biological: recombinant novel coronavirus vaccine (adenovirus type 5 vector) – 108, all, 18–60 Prevention Experimental: low‐dose group subjects received one dose of 5E10 vp Ad5‐nCoV at 18–60 years old
Experimental: middle‐dose group
Subjects received one dose of 1E11 vp Ad5‐nCoV at 18–60 years old
Experimental: high‐dose group
Subjects received one dose of 1.5E11vp Ad5‐nCoV at 18–60 years old I Primary (0–7 days postvaccination): safety indexes of adverse reactions
Secondary (Day 14, 28, Month 3, 6 postvaccination):
Safety indexes of adverse events (0–28 days postvaccination), safety indexes of SAE (0–28 days, within 6 mouths postvaccination), safety indexes of lab measures (pre‐vaccination, Day 7 postvaccination), immunogencity indexes of GMT(ELISA) (Day 14, 28, Month 3, 6 postvaccination), immunogencity indexes of GMT (pseudoviral neutralization test method), immunogencity indexes of seropositivity rates, immunogencity indexes of seropositivity rates (pseudoviral neutralization test method, immunogencity indexes of GMI (ELISA), immunogencity indexes of GMI (pseudoviral neutralization test method), immunogencity indexes of GMC (Ad5 vector), immunogencity indexes of GMI (Ad5 vector), immunogencity indexes of cellular immune
Other (day、14,28, Month3,6 postvaccination):
Consistency analysis(ELISA and pseudoviral neutralization test method), Dose‐response relationship (Humoral immunity), Persistence analysis of anti‐S protein antibodies, Time‐dose‐response relationship (Humoral immunity), Dose‐response relationship (cellular immunity), Persistence analysis of cellular immuse, Time‐dose‐response relationship (cellular immunity) NCT04313127/Not yet recruiting, Mar1Dec20 2020–2022
Development and verification of a new coronavirus multiplex nucleic acid detection system Diagnostic test: new QIAstat‐Dx fully automatic multiple PCR detection platform China/COVID‐19 100, all, 16 years to 100 years Diagnostic Diagnostic test: new QIAstat‐Dx fully automatic multiple PCR detection platform
We use the new QIAstat‐Dx fully automatic multiple PCR detection platform to test the enrolled patients – Primary:
Sensitivity, spectivity turnaround time of the New QIAstat‐Dx fully automatic multiple PCR detection platform (3 months) NCT04311398/Not yet recruiting, Mar14‐Dec1, 2020
Hydroxychloroquine treatment for severe COVID‐19 pulmonary infection (HYDRA Trial) Drug: hydroxychloroquine, drug: placebo oral tablet COVID‐19 severe acute respiratory syndrome 500, all, 18–0 Treatment Active comparator: treatment
Hydroxychloroquine tablet 200 mg every 12 hr for 10 days
Placebo comparator: placebo
identical placebo, one tablet every 12 hr for 10 days III Primary (up to120 days):
All‐cause hospital mortality
Secondary (up to120 days):
Length of hospital stay, Need of mechanical ventilation, ventilator free days, Grade 3–4 adverse reaction NCT04315896/Not yet recruiting, Mar23‐Mar22 2020–2012
Tocilizumab in COVID‐19 pneumonia (TOCIVID‐19) Drug: tocilizumab Injection Italy/COVID‐19 pneumonia 330, child, adult, older adult, child, adult, older adult Treatment Experimental: Tocilizumab Injection
Tocilizumab 8 mg/kg (up to a maximum of 800 mg per dose), with an interval of 12 hr II Primary (up to 1 month):
One‐month mortality rate
Secondary (up to 1 month):
interleukin‐6 level, lymphocyte count, C‐reactive protein level (cycle 1 and 2 every 12 hr), PaO2 (partial pressure of oxygen)/FiO2 (fraction of inspired oxygen, FiO2) ratio (or P/F ratio) (baseline, during treatment (cycle 1 and 2 every 12 hr), change of the SOFA (sequential organ failure assessment) (baseline, during treatment (cycle 1 and 2 every 12 hr), number of participants with treatment‐related side effects as assessed by Common Terminology Criteria for Adverse Event version 5.0, Radiological response, Time Frame: at baseline (optional), after 7 days and if clinically indicated, duration of hospitalization. Time Frame: from baseline up to patient's discharge, Remission of respiratory symptoms NCT04317092/Recruiting, Mar19‐Dec19 2020–2022
Mesenchymal stem cell NestCell® to treat patients with severe COVID‐19 pneumonia Biological: NestCell® COVID‐19 pneumonia 6, all, 18 years and older Treatment Experimental: NestCell®:
All patients will receive conventional treatment plus 3 times of 1 × 106 cells/kg body weight intravenously on Day1, Day3, and Day7 I Primary (28 days):
Disappear time of ground‐glass shadow in the lungs
Secondary:
Rate of mortality within 28‐days, Improvement of clinical symptoms including duration of fever and respiratory (At Baseline, Day 3, 7, 10, 14, 21, 28), Time of nucleic acid turning negative (28 days), CD4+ and CD8+ T cell count (At Baseline, Day 3, 6, 10, 14, 21, and 28), changes of blood oxygen (At Baseline, Day 3, 6, 10, 14, 21, and Day 28), side effects in the treatment group (28 days) NCT04315987/Not yet recruiting, Apr‐Jun 2020
CD24Fc as a non‐antiviral immunomodulator in COVID‐19 treatment Drug: CD24Fc, drug: placebo United States/severe coronavirus disease (COVID‐19) 230, all, 18 years and older Treatment Experimental: CD24Fc treatment
Single dose at Day 1, CD24Fc, 480 mg, diluted to 100 ml with normal saline, IV infusion in 60 min
Placebo comparator: placebo
Single dose at Day 1, normal saline solution 100 ml, IV infusion in 60 min III Primary (14 days):
Improvement of COVID‐19 disease status secondary (14 days):
Conversion rate of clinical status at Day 8 (7 days), conversion rate of clinical status at Day 15, hospital discharge time, all cause of death, duration of mechanical ventilation, duration of pressors, duration of ECMO, duration of oxygen therapy, length of hospital stay, absolute lymphocyte count NCT04317040/Not yet recruiting,May‐May 2020–2022
Acute kidney injury in patients hospitalized with COVID‐19 – China/COVID‐19 acute kidney injury‐kidney function 287, all, 18 years and older Observational Acute kidney injury:
COVID‐19 patients with acute kidney injury
nonacute kidney injury:
COVID‐19 patients without acute kidney injury –
Rate of death, the length of hospital stay Primary (up to 60 days):
Rate of acute kidney injury
Secondary (up to 60 days): NCT04316299/Completed, Feb 26‐Mar8 2020
Phase I clinical trial in healthy adult Logical: recombinant novel coronavirus vaccine (adenovirus type 5 vector) COVID‐19 108, all, 18–60 Treatment (Adenovirus Type 5 Vector)
Experimental: low‐dose group
Subjects received one dose of 5E10 vp Ad5‐nCoV at 18–60 years old
Experimental: middle‐dose group
Subjects received one dose of 1E11 vp Ad5‐nCoV at 18–60 years old
Experimental: high‐dose group subjects received one dose of 1.5E11vp Ad5‐nCoV at 18–60 years old I Primary (0–7 days postvaccination):
Safety indexes of adverse reactions
Secondary (0–28 days postvaccination, within 6 mouths postvaccination):
Safety indexes of adverse events, Safety indexes of SAE, Safety indexes of lab measures, Immunogencity indexes of GMT (ELISA), Immunogencity indexes of GMT (pseudoviral neutralization test method) (Day 14, 28, Month 6 postvaccination), Immunogencity indexes of seropositivity rates (ELISA) (Day 14, 28, Month 3, 6 postvaccination), Immunogencity indexes of seropositivity rates(pseudoviral neutralization test method) (Day 14, 28, Month 6 postvaccination), Immunogencity indexes of GMI (ELISA) (Day 14, 28, Month 3, 6 postvaccination), Immunogencity indexes of GMI (pseudoviral neutralization test method) (Day 14, 28, Month 6 postvaccination), Immunogencity indexes of GMC (Ad5 vector) (Day 14, 28, Month 3, 6 postvaccination), Immunogencity indexes of GMI(Ad5 vector) (Day 14, 28, Month 3, 6 postvaccination), Immunogencity indexes of cellular immune (Day 14, 28, Month 6 postvaccination)
Other (Day 14,28, Month 6 postvaccination):
Consistency analysis (ELISA and pseudoviral neutralization test method), dose‐response relationship (humoral immunity) (Day 14, 28, Month 3, 6 postvaccination), Persistence analysis of anti‐S protein antibodies (Day 14, 28, Month 3, 6 postvaccination), Time‐dose‐response relationship (Humoral immunity) (Day 14, 28, Month 3, 6 postvaccination), Dose‐response relationship (cellular immunity) (Day 14, 28, Month 6 postvaccination), Persistence analysis of cellular immuse (Day 14, 28, Month 6 postvaccination), Time‐dose‐response relationship (cellular immunity) (Day 14, 28, Month 6 postvaccination) NCT04313127/Not yet recruiting, Mar19‐Dec20 2020–2021
Favipiravir combined with tocilizumab in the treatment of corona virus disease 2019 Drug: favipiravir combined with tocilizumab, drug: favipiravir, drug: tocilizumab China, COVID‐19 150, all, 18–65 Treatment Experimental: favipiravir combined with tocilizumab group
Favipiravir: On the 1st day, 1,600 mg each time, twice a day; from the 2nd to the 7th day, 600 mg each time, twice a day. Oral administration, the maximum number of days taken is not more than 7 days.
Tocilizumab: the first dose is 4–8 mg/kg and the recommended dose is 400 mg. For fever patients, an additional application (the same dose as before) is given if there is still fever within 24 hr after the first dose and the interval between two medications ≥12 hr. Intravenous infusion. The maximum of cumulative number is two, and the maximum single dose does not exceed 800 mg
Active comparator: favipiravir group
On the 1st day, 1,600 mg each time, twice a day; from the 2nd to the 7th day, 600 mg each time, twice a day. Oral administration, the maximum number of days taken is not more than 7 days
Active comparator: tocilizumab group
The first dose is 4–8 mg/kg and the recommended dose is 400 mg. For fever patients, an additional application (the same dose as before) is given if there is still fever within 24 hr after the first dose and the interval between two medications ≥12 hr. Intravenous infusion, The maximum of cumulative number is two, and the maximum single dose does not exceed 800 mg Not applicable Primary (3 months):
Clinical cure rate
Secondary (14 days after taking medicine):
Viral nucleic acid test negative conversion rate and days from positive to negative, duration of fever, lung imaging improvement time, mortality rate because of corona virus disease 2019 (3 months), rate of noninvasive or invasive mechanical ventilation when respiratory failure occurs (3 months), mean in‐hospital time (3 months) NCT04310228/Recruiting, Mar8‐May 2020
Novel coronavirus induced severe pneumonia treated by dental pulp mesenchymal stem cells Biological: dental pulp mesenchymal stem cells ‐COVID‐19 24, all, 18–75 Treatment Experimental: pulp mesenchymal stem cells 1. 3, 7 days to increase the injection of mesenchymal stem cells Early Phase I Primary (14 days):
Disppear time of ground‐glass shadow in the lungs
Secondary:
Absorption of lung shadow absorption by CT Scan‐Chest (7, 14, 28, and 360 days), Changes of blood oxygen (3, 7, and 14 days) NCT04302519/Not yet Recruiting, Mar5‐Jul30 2020–2021
Multicenter clinical study on the efficacy and safety of Xiyanping injection in the treatment of new coronavirus infection pneumonia (general and severe) Drug: lopinavir/ritonavir tablets combined with Xiyanping injection drug: lopinavir/ritonavir treatment COVID‐19 80, all, 18–100 Treatment Experimental: experimental group of ordinary COVID‐19:
Xiyanping injection, 10–20 ml daily, Qd, the maximum daily does not exceed 500 mg (20 ml) + lopinavir tablet or ritonavir tablet + alpha‐interferon nebulization, for 7–14 days,
Active comparator: control group of ordinary COVID‐19:
Lopinavir/ritonavir tablets, two times a day, two tablets at a time; alpha‐interferon nebulization
Experimental: experimental group of severe COVID‐19:
Xiyanping injection, 10–20 ml daily, Qd, the maximum daily does not exceed 500 mg (20 ml) + lopinavir tablet or ritonavir tablet + alpha‐interferon nebulization, for 7–14 days Not applicable Primary:
Clinical recovery time (up to Day 28) NCT04295551/Not yet Recruiting, Mar14‐Apr14 2020–2021
Prognostic factors of patients with COVID‐19 – China/SARS‐CoV‐2 outcome, fatal 201, all, 18 years and older Prognostic SARS‐CoV‐2Outcome, fatal – Primary (30 days):
all‐cause mortality
Secondary (15 days):
all‐cause mortality,
Severe state NCT04292964/Completed Mar1‐Mar13 2020
Chloroquine prevention of coronavirus disease (COVID‐19) in the healthcare setting Drug: chloroquine, drug: placebo COVID19 coronavirus acute respiratory illnesses 10,000, all, 16 years and older Prevention Experimental: chloroquine:
a loading dose of 10 mg base/kg followed by 150 mg daily (250 mg chloroquine phosphate salt) will be taken for 3 months
Placebo comparator: placebo Not applicable Primary (approximately 100 days):
Number of symptomatic COVID‐19 infections
Secondary (approximately 100 days):
Symptoms severity of COVID‐19, duration of COVID‐19, number of asymptomatic cases of COVID‐19, number of symptomatic acute respiratory illnesses, genetic loci and levels of biochemical components will be correlated with frequency of COVID‐19, ARI, and disease severity
Other (approximately 100 days):
Drug exposure‐protection relationship NCT04303507/Not yet recruiting, May‐May 2020–2022
Yinhu Qingwen decoction for the treatment of mild/common CoVID‐19 Drug: YinHu QingWen decoction, drug: YinHu QingWen decoction(low dose), other: Chinese medicine treatment, other: standard western medicine treatment China/CoVID‐19 Chinese medicine 300, all, 18 years and older Treatment Experimental: Yin Hu Qing Wen decoction group
Based on the standard western medicine treatment, the patients will be given Yinhu Qingwen decoction (granula) for 10 days.
Drug: YinHu QingWen decoction YinHu QingWen decoction (granula) consits of 11 Chinese herbal medicine as honeysuckle, Polygonum cuspidatum, Schizonepeta, Longspur epimedium, and so forth. The decoction granula will be dissolved into 600 ml decoction and divided to three times (once with 200 ml). It will be given a 200 ml per time, three times a day, for 10 days
Other: standard western medicine treatment treatment is according to the protocol of treatment of CoVID‐19 infection according to guideline appoved by National Health Commission of China
Placebo comparator: Yinhu Qingwen decoction low‐dose group
Based on the standard western medicine treatment, the patients will be given 10% dose of Yinhu Qingwen decoction (granula) for 10 days
Drug: YinHu QingWen decoction (low dose) this intervention is given as 10% dose of YinHu QingWen decoction (granula). The granula will be dissolved into 600 ml decoction and divided to three times (once with 200 ml). It will be given a 200 ml per time, three times a day, for 10 days
Other: standard western medicine treatment standard western medicine treatment is according to the protocol of treatment of CoVID‐19 infection according to guideline appoved by National Health Commission of China
Active comparator: integrated Chinese and western medicine group
Based on the standard western medicine treatment, the patients will be given Chinese medicine decotion granula according to their symptoms. The daily dose of Chinese medicine decoction granula will also be dissolved to 600 ml decoction and divided into three times (once with 200 ml). The Chinese medicine decoction will be given 200 ml per time, three times a day for 10 days
Other: Chinese medicine treatment
This intervention will be given with Chinese medicine decoction granula based on the symptoms differentiation of the patients for 10 days
Other: standard western medicine treatment
Standard western medicine treatment is according to the protocol of treatment of CoVID‐19 infection according to guideline appoved by National Health Commission of China II
III Primary (up to 28 days):
Mean clinical recovery time
Secondary (up to 28 days):
Time to CoVID‐19 RT‐PCR negative in upper respiratory tract specimen, change (reduction) in CoVID‐19 viral load in upper respiratory tract specimen as assessed by area under viral load curve, time to defervescence (in those with fever at enrollment), time to cough reported as mild or absent (in those with cough at enrollment rated severe or moderate), time to dyspnea reported as mild or absent (on a scale of severe, moderate, mild absent, in those with dyspnea at enrollment rated as severe or moderate)
Frequency of requirement for supplemental oxygen or noninvasive ventilation, frequency of respiratory progression, severe case incidence, proportion of rehospitalization or admission to ICU, all‐cause mortality, frequency of serious adverse events NCT04278963/Active, Not Recruiting, Feb27‐Jan 2020
Prognositc factors in COVID‐19 patients complicated with hypertension – China, COVID‐19 0, all, 18–100 Prognostic ACEI treatment
hypertension patients with ACEI treatment when suffered with novel coronavirus infection in China
Control
hypertension patients without ACEI treatment when suffered with novel coronavirus infection in China – Primary (up to 28 days):
Occupancy rate in the intensive care unit, mechanical ventilation, death
Secondary (up to 28 days):
All cause mortality, time from onset of symptoms to main outcome and its components, time to clinical recovery NCT04272710/Withdrawn, Jan25‐Apr30 2020
Evaluating the efficacy and safety of bromhexine hydrochloride tablets combined with standard treatment/standard treatment in patients with suspected and mild novel coronavirus pneumonia (COVID‐19) Drug: bromhexine hydrochloride tablets, drug: arbidol hydrochloride granules, drug: recombinant human interferon α2b spray, drug: favipiravir tablets China, novel coronavirus pneumonia 2019‐nCoV 60, all, 18–80 Treatment Experimental: group A treatment group:
Bromhexine hydrochloride tablets, arbidol hydrochloride granules:
Standard treatment refers to the latest edition of pneumonia diagnosis and treatment scheme for novel coronavirus infection. Arbidol hydrochloride granules is recommended but not enforced to use
Recombinant human interferon α2b spray:
Standard treatment refers to the latest edition of pneumonia diagnosis and treatment scheme for novel coronavirus infection
Favipiravir tablets
Active comparator; group B control group:
Drug: arbidol hydrochloride granules
Standard treatment refers to the latest edition of pneumonia diagnosis and treatment scheme for novel coronavirus infection. arbidol hydrochloride granules is recommended but not enforced to use
Drug: recombinant human interferon α2b spray
Standard treatment refers to the latest edition of pneumonia diagnosis and treatment scheme for novel coronavirus infection Not applicable Primary (within 14 days from the start of medication):
Time to clinical recovery after treatment
Secondary (within 14 days from the start of medication):
Rate of aggravation, clinical remission rate, dynamic changes of oxygenation index, time to cure, rate to cure, time to defervescence, time to cough remission,days of supplemental oxygenation, rate of patients with requring supplemental oxygen, rate of patients with mechanical ventilation, time of negative COVID‐19 nucleic acid results, rate of negative COVID‐19 nucleic acid results, rate of ICU admission, 28‐day mortality (From the first day of screening to the day of follow‐up (28 days)) NCT04273763/Enrolling by invitation, Feb16‐Apr30 2020
Various combination of protease inhibitors, oseltamivir, favipiravir, and chloroquin for treatment of covid19: a randomized control trial Drug: oral Thailand, coronavirus infections COVID19 80, all, 16–100 Treatment Experimental: oseltamivir plus chloroquin in mild COVID19
Oseltamivir 300 mg per day plus chloroquin 1,000 mg per Day In mild COVID19
Experimental: lopinavir and ritonavir plus favipiravir
Lopinavir 10 mg/kg and ritonavir 2.5 mg/kg plus favipiravir 2,400 mg, 2,400 mg, and 1,200 mg every 8 hr on Day 1, and a maintenance dose of 1,200 mg twice a day in Mild COVID19
Experimental: lopinavir and ritonavir plus oseltamivir in mild COVID19
Lopipinavir 10 mg/kg and ritonavir 2.5 mg/kg plus oseltamivir 4–6 mg/kg In mild COVID19
Experimental: lopinavir and ritonavir oseltamivir moderate to severe COVID19
Lopipinavir 10 mg/kg and ritonavir 2.5 mg/kg plus oseltamivir 4–6 mg/kg in moderate to critically ill COVID19
Experimental: favipiravir lopinavir/ritonavir for mod. To severe
favipiravir 2,400 mg, 2,400 mg, and 1,200 mg every 8 hr on Day 1, and a maintenance dose of 1,200 mg twice a day plus lopipinavir 10 mg/kg and ritonavir 2.5 mg/kg in moderate to critically ill COVID19
Experimental: darunavir/ritonavir oseltamivir chloroquine mod‐severe
Combination of Darunavir 400 mg every 8 hr ritonavir Ritonavir 2.5 mg/kg plus Oseltamivir 4–6 mg/kg plus Chloroquine 500 mg per Day In moderate to critically ill COVID19
Experimental: darunavir/ritonavir favipiravir chloroquine mod‐severe
Favipiravir 2,400 mg, 2,400 mg, and 1,200 mg every 8 hr on Day 1, and a maintenance dose of 1,200 mg twice a day plus darunavir 400 mg every 8 hr ritonavir ritonavir 2.5 mg/kg plus chloroquine 500 mg per Day In moderate to critically ill COVID19
No intervention: conventional qurantine
Patient who unwilling to treatment and willing to quarantine in mild COVID19 III Primary (Up to 24 weeks):
SARS‐CoV‐2 eradication time
Secondary (up to 24 weeks):
Number of patient with death, number of patient with recovery adjusted by initial severity in each arm, number of day with ventilator dependent adjusted by initial severity in each arm,number of patient developed acute respiratory distress syndrome after treatment
Other (up to 24 weeks):
Number of patient with acute respiratory distress syndrome recovery NCT04303299/Not yet recruiting, Mar15‐Nov30 2020
Yinhu Qingwen Granula for the treatment of severe CoVID‐19 Drug: Yinhu Qingwen granula, drug: Yin Hu Qing Wen granula (low does), other: standard medical treatment China, COVID‐19 severe pneumonia Chinese medicine 116, all, 18 years and older Treatment Experimental:
Yinhu Qingwen granula group:
Drug: Yinhu Qingwen Granula
Yinhu Qingwen granula is a kind of herbal granula made from “Yinhu Qingwen Decoction,” which consits of 11 Chinese herbal medicine as honeysuckle, Polygonum cuspidatum, schizonepeta, Longspur epimedium, etc. The granula will be dissolved into 600 ml decoction and divided to three times (once with 200 ml). It will be given a 200 ml per time, three times a day, for 10 days.
Other: standard medical treatment Standard medical treatment is adhered to the protocol of the treatment for the severe CoVID‐19 according to the guideline approved by National Health Commission of China.
Placebo comparator: Yinhu Qingwen granula low‐dose group:
Drug: Yin Hu Qing Wen granula (low does). This intervention is given as 10% dose of YinHu QingWen Granula.The granula will be dissolved into 600 ml decoction and divided to three times (once with 200 ml).
Other: standard medical treatment Standard medical treatment is adhered to the protocol of the treatment for the severe CoVID‐19 according to the guideline approved by National Health Commission of China. II Primary (Day 10):
changes in the ratio of PaO2 to FiO2 from baseline
Secondary (up to 30 days):
PaO2, blood oxygen saturation (SpO2), clinical status rating on the 7‐point ordinal scale, time to clinical improvement, duration (hours) of noninvasive mechanical ventilation or high‐flow nasal catheter oxygen inhalation use, duration (hours) of invasive mechanical ventilation use, duration (hours) of extracorporeal membrane oxygenation (ECMO) use, duration (days) of oxygen use, The proportion of the patients reporting 2019‐nCoV RT‐PCR negativity at Day 10 after treatment, the counts/percentage of lymphocyte, time to hospital discharge with clinical recovery from the randomization, the incidence of critical status conversion in 30 days, all‐cause mortality within 30 days, frequency of severe adverse drug events NCT04310865/Not yet recruiting, Mar20‐Jun30 2020–2021
Clinical characteristics and long‐term prognosis of 2019‐nCoV infection in children – China, 2019‐nCoV 500, all, up to 18 years Prognosis 2019‐nCoV infection group
Children hospitalized with direct laboratory confirmed of novel coronavirus with or without pneumonia are classified as the 2019‐nCoV infection group
Control group Children hospitalized with pneumonia other than the novel coronavirus pneumonia during the same hospitalization period as 2019‐nCoV infection group are classified as the control group – Primary (6 months):
The cure rate of 2019‐nCoV, the improvement rate of 2019‐nCoV, the incidence of long‐term adverse outcomes
Secondary (2 weeks):
Duration of fever, duration of respiratory symptoms, duration of hospitalization, number of participant(s) need intensive care, number of participant(s) with acute respiratory distress syndrome, number of participant(s) with extra‐pulmonary complications, including shock, renal failure, multiple organ failure, hemophagocytosis syndrome, et al., number of participant(s) who died during the trial (10 months) NCT04270383/Not yet recruiting, Feb15‐Dec30 2020
The effect of T89 on improving oxygen saturation and clinical symptoms in patients with COVID‐19 Drug: T89 Coronavirus disease 2019 novel coronavirus pneumonia 120, all, 18–85 Treatment Experimental: The T89 treatment group Besides a standard background treatment (antiviral drug + antibacterial + oxygen therapy + Traditional Chinese Medicine decoction), all subjects in the T89 treatment group will receive 30 pills of T89 each time, orally, BID (every morning and evening), for 10 days (depending on clinical need and practicability, the use can be extended for up to 14 days)
No intervention: the blank control group
All subjects in the blank control group will only receive a standard background treatment (antiviral drug + antibacterial + oxygen therapy + Traditional Chinese Medicine decoction), for 10 days. Not applicable Primary (Day −1 to 10): the time to oxygen saturation recovery to normal level (≥97%), the proportion of patients with normal level of oxygen saturation(≥97%)
Secondary (Day −1 to 10):
The degree of remission of symptoms of patients, including: fatigue, nausea, vomiting, chest tightness, shortness of breath, and so forth, the time to the myocardial enzyme spectrum recovery to normal after treatment, the proportion of the patients with normal myocardial enzyme spectrum after treatment, the time to the electrocardiogram recovery to normal level after treatment, the proportion of the patients with normal electrocardiogram after treatment, the time to the hemodynamics recovery to normal after treatment, the proportion of the patients with normal hemodynamics after treatment, the time to exacerbation or remission of the disease after treatment, the proportion of the patients with exacerbation or remission of disease after treatment, the proportion of patients who need other treatment (e.g., heparin, anticoagulants) due to microcirculation disorders, the all‐cause mortality rate, the proportion of patients with acidosis, the total duration of the patients in‐hospital, the total duration of oxygen inhalation during treatment, the oxygen flow rate during treatment, the oxygen concentration during treatment NCT04285190/Not yet recruiting, Feb26‐Sep15 2020
Immunoregulatory therapy for 2019‐nCoV Drug: PD‐1 blocking antibody + standard treatment, drug: Thymosin + standard treatment, other: standard treatment ‐2019 nCoV, PD‐1 120, all, 18 years and older Treatment Experimental: PD‐1 group
Anti‐PD‐1 antibody, 200 mg, IV, one time
Experimental: thymosin group
Thymosin, 1.6 mg sc qd, last for 5 days
Placebo comparator: control group stand treatment II Primary (7 days):
lung injury score
Secondary:
Absolute lymphocyte counts (7, 14 and 28 days), serum level of CRP, PCT and IL‐6 (3, 7 and 14 days), SOFA score (7 days), all cause mortality rate (28 days), ventilation free days (28 days), ICU free days (up to 28 days) NCT04268537/Not yet recruiting, Feb10‐Oct31 2020
Tocilizumab vs CRRT in management of cytokine release syndrome (CRS) in COVID‐19 Drug: tocilizumab, other: standard of care, procedure: continuous renal replacement therapy China, Covid‐19 SARS cytokine storm (and 2 more…) 120, all, 18–80 Observational Tocilizumab
Subjects received 8 mg/kg (body weight) Tocilizumab once in 100 ml 0.9% saline solution and administered intravenously within no <60 min. Tocilizumab was administered according—continuous renal replacement therapy
Femoral vein catheterization was performed to complete continuous renal replacement therapy for consecutive three times or more. to the local label
Standard care
Standard of care therapy per local written policies or guidelines – Primary (up to 14 days):
Proportion of participants with normalization of fever and oxygen saturation
Secondary:
Duration of hospitalization (Up to 28 days), proportion of participants with normalization of fever (up to 14 days), change from baseline in white blood cell and differential count (up to 28 days), time to first negative in 2019 novel corona virus RT‐PCR test (Up to 28 days), all‐cause mortality (up to 12 weeks), change from baseline in hsCRP (Up to 28 days), change from baseline in cytokines IL‐1β, IL‐10, sIL‐2R, IL‐6, IL‐8 and TNF‐α (Up to 28 days), change from baseline in proportion of CD4 + CD3/CD8 + CD3 T cells (Up to 28 days) NCT04306705/Recruiting, Feb20‐Jun20 2020
Sars‐CoV2 seroconversion among front line medical and paramedical staff in emergency, intensive care units and infectious disease departments during the 2020 Epidemic Other: blood sample France, Sars‐CoV2 1,000, all, child, adult, older adult Other Caregiver
caregivers from emergency, ICU, virology and infectious disease services:
Two blood samples at T0 and 3 months Not applicable Primary (3 months):
Quantify the proportion of patients with documented Sars‐CoV2 infection among medical and paramedical staff
Secondary (3 months):
Identification of risk factors for seroconversion, quantify the proportion of asymptomatic infections among staff who have seroconverted, describe symptomatic infections for personnel developing acute clinical (respiratory or digestive) viral syndrome NCT04304690/Recruiting, Mar16‐Oct16 2020
John Wiley & Sons, Ltd. This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.
5.3.1 Reverse transcriptase polymerase chain reaction
Despite being the diagnostic gold standard, pathogenic lab testing is a rather time‐consuming procedure, with unavoidable false‐positive results (Wang, Kang, et al., 2020). It is recommended that lab testing should be performed, as soon as the patient is identified as a “person under investigation” (PUI). Viral nucleic acid required for an RT‐PCR test is usually extracted from secretions of the lower respiratory tract, for example, bronchoalveolar lavage; however, tracheal aspirate or sputum can also be used (Chu et al., 2020; Corman et al., 2020). Since the onset of the epidemic, several factors have been found to affect the final efficiency of nucleic acid testing, that is, availability, quality, stability, and reproducibility of detection kits. In most of the cases, the tests need to be repeated for several times (Wang, Kang, et al., 2020), as the estimated detection rate of the test falls in an underwhelming range of 30–50% (Chu et al., 2020; Corman et al., 2020; Zhang et al., 2020). In spite of being a valuable asset, the undesirable false‐negative results of RT‐PCR have prompted careful clinical and etiological evaluation of COVID‐19 in suspected cases as the first‐line diagnostic method (Zu et al., 2020).
5.3.2 Computed tomography (CT)
CT has proved to be of great value in diagnosis of the COVID‐19‐associated pneumonia, as it provides major evidence, that cannot readily be obtained with alternative methods. It is true that CT is a reliable imaging modality in subtle detection of viral pneumonia and screening of suspected cases; however, it should be noted that many pulmonary diseases of inflammatory nature share similar radiographic findings (Wang, Kang, et al., 2020). The majority of patients with COVID‐19 present with GGO in their chest CT, which later progress into multilobar consolidations. There have been several reports of rounded opacities, which are sometimes peripherally distributed in the lung (Chung et al., 2020; Huang et al., 2020). In contrast to CT, plain chest radiography (CXR) has not been recommended as a first‐line imaging method, because this modality does not provide the clarity viewed on CT scans, especially in the early stages of pulmonary infection (Ng et al., 2020). Nevertheless, CXR is capable of recording pathologic changes in patients with severely progressed COVID‐19, as the bilateral multifocal consolidations present in these patients are too dense to be missed. The notorious “white lung” appearance can be optimally viewed on CXRs of critically ill patients (Zu et al., 2020). CT resulted in diagnosis of 14,840 new cases as of February 13, 2020 (Zu et al., 2020). Therefore, slice chest CT is an adequately sensitive and reliable method in early detection of pneumonia in patients with COVID‐19 (Chan et al., 2020; Ng et al., 2020).
5.3.3 Novel approaches: Artificial intelligence‐based technologies
Depp learning, as a novel AI‐based modality might be able to analyze radiographic features of COVID‐19, and help clinicians provide an accurate clinical diagnosis based on a precedented pattern (Wang, Kang, et al., 2020). As part of recent advancements, Convolutional Neural Network (CNN), a class of deep neural networks, has been shown to be capable of medical image analysis. To this date, CNN has been successfully employed in investigations on the nature of pulmonary nodules reported in CT images, diagnosis of pneumonia in children based on CXR, and image recognition in cystoscopy videos (Choe et al., 2019; Kermany et al., 2018; Negassi, Suarez‐Ibarrola, Hein, Miernik, & Reiterer, 2020; Wang et al., 2018).
The 21st century has seen many AI‐based models to be incorporated in several scientific fields, particularly imaging studies. Diagnostic AI‐based models might actually be a forward leap in tasks that simply cannot be handled by manpower, especially risk prioritization, that can greatly help improve patient turnaround time. Given the shortage of human resources and inadequate number of hospital beds in a country like China, AI‐based models for analysis of CXR and CT scans can be useful in ruling out irrelevant cases, and resource‐wise admission of patients to the hospitals (Kim, 2020).
|
|
label
|
5
|
|
title
|
DIAGNOSIS
|
|
p
|
A proper diagnosis of COVID‐19 is made based on the following criteria, which have been recently suggested based on the initial investigations: (a) clinical signs and symptoms, (b) history of traveling or close contact with people suspected to be infected, (c) positive test result for the pathogen, and (d) pathologic findings on CT images. The key clinical features of COVID‐19, though nonspecific, include fever, dry cough, dyspnea, and pneumonia (Chen, Zhou, et al., 2020; Huang et al., 2020; Li, Guan, et al., 2020; Wang, Hu, et al., 2020). Rapid screening of patients with acute respiratory symptoms, initiation of an appropriate quarantine program, and development of therapeutic measures have been suggested as a top‐priority strategy to control the spread of COVID‐19 (Tian et al., 2020; Wang, Kang, et al., 2020). According to the data gathered by individual‐level surveillance, it is strongly recommended that the elderly and male patients should be diagnosed in a timely manner, as progression of the respiratory pathology to pneumonia might result in catastrophic outcomes (Jian‐ya, 2020).
|
|
sec
|
5.1 Clinical symptom spectrum
Understanding the otherwise nonspecific clinical signs and symptoms of COVID‐19 is a crucial step toward appropriate management of the disease. Patients mostly complain of fever, non‐productive cough, and body ache or extreme tiredness. In some cases, diarrhea and nausea precede fever by a few days, suggesting that fever might not be the initial manifestation of infection. A small number of patients reportedly had headache, or even developed hemoptysis (Guan et al., 2020; Wang, Hu, et al., 2020). Some patients remained asymptomatic, despite being tested positive for the disease (Chan et al., 2020). According to several studies, infection with SARS‐CoV‐2 in the elderly, especially the male community, is more likely to result in severe alveolar damage and respiratory failure (Chen, Zhou, et al., 2020). Occasionally, the disease may be demonstrated with a fulminant natural history, rapidly progressing to organ dysfunction, and even death in critical cases. Organ dysfunction includes conditions such as shock, ARDS, acute cardiac injury, and acute kidney injury (Huang et al., 2020; Wang, Hu, et al., 2020). From a laboratory point of view, lymphopenia, thrombocytopenia, impaired prothrombin time (PT), and elevated serum levels of CRP stand among the findings that can be reported for patients with COVID‐19 (Chen, Zhou, et al., 2020; Guan et al., 2020; Huang et al., 2020; Wang, Hu, et al., 2020). Overall, any patient with fever and acute respiratory symptoms, who is reported to have lymphopenia or leukopenia on lab examination, should be suspected. A history of travel to Wuhan or having close contact with local residents is a strong indicator for careful management of the patient (Zu et al., 2020). Table 2 represents the criteria for diagnosis of COVID‐19 infected patients (Committee, 2020b; Zu et al., 2020; WWW.ClinicalTrials.gov).
Table 2 Criteria for clinical severity of confirmed COVID‐19 pneumonia
Patient Clinical findings CT (imaging findings of pneumonia) Organ damage
Mild Negative None None
No dyspnea, with or without cough, fever <38°C (quelled without treatment)
No history of chronic respiratory disease
Moderate dyspnea, with or without cough Multifocal patchy GGOs with subpleural distribution None
SpO2 >93% without oxygen inhalation
Severe Fever Diffuse heterogeneous consolidation with GGO, None
Muscle ache Rapid progression (>50%) on CT imaging within 24–48 hr
Headache
Confusion
Respiratory distress:
RR ≥ 30 times/min
SpO2 < 93% at rest
PaO2/FiO2 ≤ 300 mmHg
Critical Shock “Extra pulmonary” organ failure or MODS
Respiratory failure
need mechanical assistance
Intensive care unit is needed
Abbreviations: FiO2, fraction of inspired oxygen; GGO, ground‐glass opacity; MODS, multiple organ dysfunction syndrome; PaO2, partial pressure of oxygen; RR, respiratory rate, SpO2, oxygen saturation.
John Wiley & Sons, Ltd. This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.
|
|
label
|
5.1
|
|
title
|
Clinical symptom spectrum
|
|
p
|
Understanding the otherwise nonspecific clinical signs and symptoms of COVID‐19 is a crucial step toward appropriate management of the disease. Patients mostly complain of fever, non‐productive cough, and body ache or extreme tiredness. In some cases, diarrhea and nausea precede fever by a few days, suggesting that fever might not be the initial manifestation of infection. A small number of patients reportedly had headache, or even developed hemoptysis (Guan et al., 2020; Wang, Hu, et al., 2020). Some patients remained asymptomatic, despite being tested positive for the disease (Chan et al., 2020). According to several studies, infection with SARS‐CoV‐2 in the elderly, especially the male community, is more likely to result in severe alveolar damage and respiratory failure (Chen, Zhou, et al., 2020). Occasionally, the disease may be demonstrated with a fulminant natural history, rapidly progressing to organ dysfunction, and even death in critical cases. Organ dysfunction includes conditions such as shock, ARDS, acute cardiac injury, and acute kidney injury (Huang et al., 2020; Wang, Hu, et al., 2020). From a laboratory point of view, lymphopenia, thrombocytopenia, impaired prothrombin time (PT), and elevated serum levels of CRP stand among the findings that can be reported for patients with COVID‐19 (Chen, Zhou, et al., 2020; Guan et al., 2020; Huang et al., 2020; Wang, Hu, et al., 2020). Overall, any patient with fever and acute respiratory symptoms, who is reported to have lymphopenia or leukopenia on lab examination, should be suspected. A history of travel to Wuhan or having close contact with local residents is a strong indicator for careful management of the patient (Zu et al., 2020). Table 2 represents the criteria for diagnosis of COVID‐19 infected patients (Committee, 2020b; Zu et al., 2020; WWW.ClinicalTrials.gov).
|
|
table-wrap
|
Table 2 Criteria for clinical severity of confirmed COVID‐19 pneumonia
Patient Clinical findings CT (imaging findings of pneumonia) Organ damage
Mild Negative None None
No dyspnea, with or without cough, fever <38°C (quelled without treatment)
No history of chronic respiratory disease
Moderate dyspnea, with or without cough Multifocal patchy GGOs with subpleural distribution None
SpO2 >93% without oxygen inhalation
Severe Fever Diffuse heterogeneous consolidation with GGO, None
Muscle ache Rapid progression (>50%) on CT imaging within 24–48 hr
Headache
Confusion
Respiratory distress:
RR ≥ 30 times/min
SpO2 < 93% at rest
PaO2/FiO2 ≤ 300 mmHg
Critical Shock “Extra pulmonary” organ failure or MODS
Respiratory failure
need mechanical assistance
Intensive care unit is needed
Abbreviations: FiO2, fraction of inspired oxygen; GGO, ground‐glass opacity; MODS, multiple organ dysfunction syndrome; PaO2, partial pressure of oxygen; RR, respiratory rate, SpO2, oxygen saturation.
John Wiley & Sons, Ltd. This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.
|
|
label
|
Table 2
|
|
caption
|
Criteria for clinical severity of confirmed COVID‐19 pneumonia
|
|
p
|
Criteria for clinical severity of confirmed COVID‐19 pneumonia
|
|
table
|
Patient Clinical findings CT (imaging findings of pneumonia) Organ damage
Mild Negative None None
No dyspnea, with or without cough, fever <38°C (quelled without treatment)
No history of chronic respiratory disease
Moderate dyspnea, with or without cough Multifocal patchy GGOs with subpleural distribution None
SpO2 >93% without oxygen inhalation
Severe Fever Diffuse heterogeneous consolidation with GGO, None
Muscle ache Rapid progression (>50%) on CT imaging within 24–48 hr
Headache
Confusion
Respiratory distress:
RR ≥ 30 times/min
SpO2 < 93% at rest
PaO2/FiO2 ≤ 300 mmHg
Critical Shock “Extra pulmonary” organ failure or MODS
Respiratory failure
need mechanical assistance
Intensive care unit is needed
|
|
tr
|
Patient Clinical findings CT (imaging findings of pneumonia) Organ damage
|
|
th
|
Patient
|
|
th
|
Clinical findings
|
|
th
|
CT (imaging findings of pneumonia)
|
|
th
|
Organ damage
|
|
tr
|
Mild Negative None None
|
|
td
|
Mild
|
|
td
|
Negative
|
|
td
|
None
|
|
td
|
None
|
|
tr
|
No dyspnea, with or without cough, fever <38°C (quelled without treatment)
|
|
td
|
No dyspnea, with or without cough, fever <38°C (quelled without treatment)
|
|
tr
|
No history of chronic respiratory disease
|
|
td
|
No history of chronic respiratory disease
|
|
tr
|
Moderate dyspnea, with or without cough Multifocal patchy GGOs with subpleural distribution None
|
|
td
|
Moderate
|
|
td
|
dyspnea, with or without cough
|
|
td
|
Multifocal patchy GGOs with subpleural distribution
|
|
td
|
None
|
|
tr
|
SpO2 >93% without oxygen inhalation
|
|
td
|
SpO2 >93% without oxygen inhalation
|
|
tr
|
Severe Fever Diffuse heterogeneous consolidation with GGO, None
|
|
td
|
Severe
|
|
td
|
Fever
|
|
td
|
Diffuse heterogeneous consolidation with GGO,
|
|
td
|
None
|
|
tr
|
Muscle ache Rapid progression (>50%) on CT imaging within 24–48 hr
|
|
td
|
Muscle ache
|
|
td
|
Rapid progression (>50%) on CT imaging within 24–48 hr
|
|
tr
|
Headache
|
|
td
|
Headache
|
|
tr
|
Confusion
|
|
td
|
Confusion
|
|
tr
|
Respiratory distress:
|
|
td
|
Respiratory distress:
|
|
tr
|
RR ≥ 30 times/min
|
|
td
|
RR ≥ 30 times/min
|
|
tr
|
SpO2 < 93% at rest
|
|
td
|
SpO2 < 93% at rest
|
|
tr
|
PaO2/FiO2 ≤ 300 mmHg
|
|
td
|
PaO2/FiO2 ≤ 300 mmHg
|
|
tr
|
Critical Shock “Extra pulmonary” organ failure or MODS
|
|
td
|
Critical
|
|
td
|
Shock
|
|
td
|
“Extra pulmonary” organ failure or MODS
|
|
tr
|
Respiratory failure
|
|
td
|
Respiratory failure
|
|
tr
|
need mechanical assistance
|
|
td
|
need mechanical assistance
|
|
tr
|
Intensive care unit is needed
|
|
td
|
Intensive care unit is needed
|
|
table-wrap-foot
|
Abbreviations: FiO2, fraction of inspired oxygen; GGO, ground‐glass opacity; MODS, multiple organ dysfunction syndrome; PaO2, partial pressure of oxygen; RR, respiratory rate, SpO2, oxygen saturation.
|
|
footnote
|
Abbreviations: FiO2, fraction of inspired oxygen; GGO, ground‐glass opacity; MODS, multiple organ dysfunction syndrome; PaO2, partial pressure of oxygen; RR, respiratory rate, SpO2, oxygen saturation.
|
|
p
|
Abbreviations: FiO2, fraction of inspired oxygen; GGO, ground‐glass opacity; MODS, multiple organ dysfunction syndrome; PaO2, partial pressure of oxygen; RR, respiratory rate, SpO2, oxygen saturation.
|
|
sec
|
5.2 Epidemiological history
Shortly after the onset of the epidemic, The National Health Commission of China (Committee, 2020a; Organization, 2020a) initiated the Diagnosis and Treatment Program of COVID‐19‐associated pneumonia, following the guidelines provided by WHO on SARS and MERS (Azhar & EI‐Kafrawy, 2014; Organization, 2017, 2020b).
According to the newly formulated criteria, a “suspected case” is defined as a patient with epidemiological history, that is traveling and contact, and two clinical findings pertinent to the disease. If, however, an epidemiological history is not confirmed, then the patient must present at least three clinical findings to be considered as a suspected case. Based on the Trial, Fifth Edition (Committee, 2020b), pathologic findings indicative of viral pneumonia on chest CT scans provide enough evidence for clinical diagnosis of COVID‐19. Nonetheless, as of February 17, 2020, WHO does not approve of any diagnosis based solely on radiologic findings, without obtaining an RT‐PCR test from the patient (Organization, 2020c). In the more recent revision of the Chinese Diagnosis and Treatment Program, 6th Edition, the term “clinical diagnosis” was removed and replaced with “etiological diagnosis” (Organization, 2020a). According to the recent revision, it is imperative that an etiological diagnosis of COVID‐19 is made at first, which can then be complemented by a positive real‐time RT‐PCR assay for SARS‐CoV‐2, which is duly performed on the sputum or blood sample of the patient. After the final diagnosis is made, confirmed patients are categorized into mild, moderate, severe, and critical types, based on the severity of disease (Zu et al., 2020).
|
|
label
|
5.2
|
|
title
|
Epidemiological history
|
|
p
|
Shortly after the onset of the epidemic, The National Health Commission of China (Committee, 2020a; Organization, 2020a) initiated the Diagnosis and Treatment Program of COVID‐19‐associated pneumonia, following the guidelines provided by WHO on SARS and MERS (Azhar & EI‐Kafrawy, 2014; Organization, 2017, 2020b).
|
|
p
|
According to the newly formulated criteria, a “suspected case” is defined as a patient with epidemiological history, that is traveling and contact, and two clinical findings pertinent to the disease. If, however, an epidemiological history is not confirmed, then the patient must present at least three clinical findings to be considered as a suspected case. Based on the Trial, Fifth Edition (Committee, 2020b), pathologic findings indicative of viral pneumonia on chest CT scans provide enough evidence for clinical diagnosis of COVID‐19. Nonetheless, as of February 17, 2020, WHO does not approve of any diagnosis based solely on radiologic findings, without obtaining an RT‐PCR test from the patient (Organization, 2020c). In the more recent revision of the Chinese Diagnosis and Treatment Program, 6th Edition, the term “clinical diagnosis” was removed and replaced with “etiological diagnosis” (Organization, 2020a). According to the recent revision, it is imperative that an etiological diagnosis of COVID‐19 is made at first, which can then be complemented by a positive real‐time RT‐PCR assay for SARS‐CoV‐2, which is duly performed on the sputum or blood sample of the patient. After the final diagnosis is made, confirmed patients are categorized into mild, moderate, severe, and critical types, based on the severity of disease (Zu et al., 2020).
|
|
sec
|
5.3 COVID‐19 detection tests: Pathogenic laboratory testing, real‐time RT‐PCR, and sequencing of nucleic acid
Table 3 (Ai et al., 2020; Bai et al., 2020; Chen, Zhao, et al., 2020; Shi et al., 2020; Tian et al., 2020; Wang, Kang, et al., 2020; Wu & McGoogan, 2020; Yan et al., 2020; Yang et al., 2020) and Table 4 represent 2020 studies on diagnosis of COVID‐19 infected patients and related clinical trials, respectively.
Table 3 Studies for diagnosis, prognosis and therapy of COVID‐19 patients
Study/region Study type/medical team Patient/median age/sex Diagnostic test Sample Inclusion criteria/residency Test results Most common symptoms/chronic disease Incubation period (day) Case fatality rate Diagnosis/prognosis/therapy
Wu et al. (2020), China Retrospective study/Chinese Center for Disease Control and Prevention 72,314; subjects: confirmed cases 44,672 (62%), suspected cases 16,186 (22%), diagnosed cases 10,567 (15%), asymptomatic cases 889 (1%)/age N = 44,672: 80: 3% (1,408), 30–79: 87% (38,680), 20–29: 8% (3,619), 10–19: 1% (549), <10: 1% (416) PCR Throat swab samples Confirmed cases based on positive PCR, suspected cases based on symptoms and exposures only, clinically cases based on symptoms, exposures, and CT, asymptomatic cases diagnosis by positive PCR Spectrum of disease: (N = 44,415); mild: 81% (36,160), severe: 14% (6,168), critical: 5% (2,087) Cardiovascular disease: 10.5%, diabetes: 7.3%, chronic respiratory disease: 6.3%, hypertension: 6.0%, cancer: 5.6% About a week 2.3% (1,023 of 44,672 confirmed cases), 14.8% aged >80 years (208 of 1,408), 8.0% aged 70–79 years (312 of 3,918) 49.0% in critical cases (1,023 of 2,087) Next step: to help “buy time” for more diagnostic and therapeutic research before COVID‐19 becomes too widespread
Tian et al. (2020), China Retrospective study/Beijing Emergency Medical Service 262/47.5/48.5% male Real‐time RT‐PCR Respiratory specimens COVID‐19 infected patients/residents of Beijing: 92 (73.3%), patients had been to Wuhan: 50 (26.0%), close contact with confirmed cases: 116 (60.4%), no contact history: 21 (10.9%) Spectrum of disease: sever: 46 (17.6%); common: 216; (82.4%); mild: 192 (73.3%); nonpneumonia: 11 (4.2%); asymptomatic:13 (5.0%) Fever (82.1%), cough (45.8%), fatigue (26.3%), dyspnea (6.9%), headache (6.5%)/pulmonary infection, chronic cardiovascular disease and heart failure: 1, pulmonary infection and multiple chronic diseases: 1 Incubation: 6.7 days, illness onset to visit hospital: 4.5 days 3 (0.9%) Results: As of February 10, 45 (17.2%) patients have discharged
For COVID‐19 control: first step is prevent transmission at early stage, next steps is early isolation and quarantine of suspected subjects
Wang et al. (2020), China Retrospective cohort/Xi'an Jiaotong University First Affiliated Hospital, Nanchang University First Hospital and Xi'an No.8 Hospital of Xi'an Medical College 99 CT, artificial intelligence, inception migration‐learning model – Pathogen‐confirmed COVID‐19 patients Spectrum of disease: typical viral pneumonia or negative group: 55, confirmed nucleic acid testing or positive group: 44. CT (453 CT images): negative: 258, positive: 195 Viral pneumonia symptoms – – Screening:
The internal validation; accuracy: 82·9%, specificity: 80·5%, sensitivity: 84%
The external testing; accuracy: 73·1%, specificity: 67%, sensitivity: 74%
Algorithm prediction: a rate of 2 s per case on the graphic processing unit
Interpretation: the early diagnosis through fast, accurate, safe and noninvasive methods is crucial for control of virus
Yan et al. (2020), China Retrospective study/Tongji Hospital 375, 58.83, 58.7% males CT, machine learning model (a supervised XGBoost classifier) – Validated or suspected COVID‐19 patient/Wuhan residents (37.9%), familial cluster (6.4%), health workers (1.9%) Spectrum of disease: critical patients: 46.1%, severe cases: RR ≥ 30bpm or SPO2 ≤93% on rest Fever: 49.9%, cough: 13.9%, fatigue 3.7%, dyspnea 2.1%, shock: 2 174
16 + 1 Interpretation: the three indices‐based prognostic prediction model might predict themortality risk, recognition of critical cases, help to early identification, on time intervention, reducing mortality rate
Shi et al. (2020), China Retrospective/hospitals in Wuhan 81, 49–5, 42 (52%) men and 39 (48%) women Next‐generation sequencing or RT‐PCR, serial chest CT Throat swab specimens Confirmed COVID‐19 pneumonia patients/direct exposure to Huanan seafood market: 31 (38%), health‐care workers: 15 (19%), familial clusters: 7 (9%), any obvious history of exposure: 28 (35%) Spectrum of disease: mean number of involved lung segments: 10.5 (SD 6.4): group 1: subclinical patients (CT before symptom onset): 2.8 (3.3), group 2: ≤1 week after symptom onset/11.1 (5.4), group 3: >1–2 weeks/13.0 (5.7), group 4: >2–3 weeks/12.1 (5.9).
CT:
ALL:
bilateral abnormality: 64 [79%], peripheral 44 [54%], Ill‐defined 66 [81%], GGO: 53 [65%], mainly involving the right lower lobes: 225 [27%] of 849.
Group 1 (n=15): unilateral: 9 [60%]/multifocal 8 [53%]/GGO: 14 [93%]; Group 2 (n = 21): bilateral 19 [90%]/diffuse 11 [52%]/GGO predominance 17 [81%]; Group 3 (n = 30): GGO 17 [57%], consolidation/mixed patterns: 12 [40%]; Group 4 (n=15): consolidation/mixed patterns: 8 [53%].
Blood:
Group1: Lower CRP and AST Fever: 59 [73%], dry cough: 48 [59%] nonspecific symptoms:
dizziness:
2 [2%], diarrhea:
3 [4%], vomiting:
4 [5%], headache:
5 [6%], generalised weakness:
7 [9%]/chronic pulmonary disease (tuberculosis): 1, T2D: 1, hypertension/cardiovascular/erebrovascular disease: 1 Symptom onset and discharge of 23–2 days 3 (4%) By February 8, 2020, 62 (77%) patients discharged
Interpretation: COVID‐19 pneumonia include CT abnormalities that rapidly progress from focal unilateral to diffuse bilateral GGO coexisted with consolidations within 1–3 weeks (even in asymptomatic patients).
Early diagnosis through combined CT with clinical and laboratory findings
Bai et al. (2020), China Case study/The Fifth People's Hospital of Anyang 6, Patient 1: 20‐year‐old woman, patients 2–6: four women 42–57 years old CT, RT‐PCR Nasopharyngeal swabs Patient 1: met with Patients 2 and 3, and accompanied five relatives (Patients 2–6), Patients 2–6: no visited Wuhan or been in contact with any other people traveled to Wuhan Spectrum of disease: severe pneumonia: 2, moderate: others. A familial cluster of five patients with respiratory symptoms, 1 asymptomatic family member.
Blood:
all symptomatic patients: increased CRP, reduced lymphocyte.
CT: multifocal GGO: in all symptomatic patients, subsegmental consolidation/fibrosis: 1.
Patient 1: normal CT, CRP and lymphocyte count, RT‐PCR: negative, positive, negative.
Patients 2–6:
COVID‐19 confirmed.
PCR: positive for patients 2–6 within 1 day Fever: patients 2–6 19 days for patient 1 – Transmission: COVID‐19 transmission could transmit by an asymptomatic carrier S
Ai et al. (2020), China Cohort/Tangji hospital of Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei 1,014/51 ± 15/46% man Laboratory test, chest CT (7 day interval), RT‐PCR (Taq man one step): multiple assays (3 day interval) Throat swab Suspected of nCoV/China Positive CT: 88% (888/1,014), positive RT‐PCR: 59% (601/1,014).
Sensitivity of CT based on positive RT‐PCR: 97% (95%CI, 95–98%, 580/601).
Negative RT‐PCR/positive CT: 75% (308/413).
Initial positive CT consistent with COVID‐19 before the initial positive RT‐PCR: 60–93%.
Improvement in follow‐up CT before the RT‐PCR turning negative: 42% (24/57), CT: GGO: 46% [409/888], consolidations: 50% [447/888], bilateral findings: 90% [801/888] Fever, dry cough Initial + to − PCR: 5.1 ± 1.5 days,
Initial − to + PCR: 6.9 ± 2.3 days – Diagnosis: chest CT, as a highly sensitive method, could be considered as a primary tool for infection diagnosis in epidemic areas
Chen et al. (2020), China General Hospital of Central Theater Command, PLA 48/age; critically ill: 79.6 ± 12, sever: 63.9 ± 15, mild: 45.8 ± 14/31 males (77.1%) and 17 females (22.9%) Real‐time RT‐PCR, CT, GLMs analysis Serum, throat‐swab specimens Laboratory confirmed cases Spectrum of disease: mild: 21 (43.7%), severe 10 (20.8%), critically ill 17 (35.4%).
Blood: low/lower lymphocytes: severe and critically ill, higher neutrophils: critically ill, higher PCT: critically ill.
Parameters stand for the organ dysfunction; TnT, AST, ALT, CRE, and BUN: higher in critically ill patients.
PCR:
positive RNAaemia: (a) serum: 5 (10.4%) of critically ill, (b) throat‐swab: 48 positive.
IL‐6: value ≥100: 35.3% in critically ill, 10‐folds higher IL‐6 (cytokine storm): critically ill, RNAaemia positive: IL‐6 ≥100 (R = 0.902) Mild: fever, respiratory symptoms
Severe: shortness of breath, RR ≥ 30 times/min, oxygen saturation (resting state) ≤93%, PaO2/FiO2 ≤300 mmHg
Critically ill: respiratory failure, shock, multiple organ failure/diabetes: 12 [25%], hypertension: 23 [49.7%], heart disease: 8 [16.7%], mixed fungal infection: 27.1%, bacterial infection: (2.1%) – 3 Diagnosis; RNAaemia positive test confirmed critically ill patients
Prognosis: strong association between RNAaemia with cytokine storm can be applied to predict the poor prognosis
Therapeutic approach: in critically patients, IL‐6 should be considered as a therapeutic target
Fan et al. (2020), China Retrospective cohort study/three tertiary hospitals of Wenzhou 149/45.11 ± 13.35/81 (54.4%) males Laboratory test, PCR, CT Blood RT‐PCR confirmed patients: Hubei travel/residence history: N=85,
contact with people of Hubei: N=49, no traceable exposure history: N=15 Blood:
decreased oxygen saturation: 14(9.4%), leukopenia: 33 (24.2%), lymphopenia: 53 (35.6%), low platelets: 20 (13.4%), elevated CRP: 82 (55.0%), ALT/AST/CK and D‐dimer: less common.
CT: most involved lung segments: 6 and, GGO: 287 segments, mixed opacity: 637 segments, consolidation: 170 segments, lesions: more in the peripheral lung with a patchy form, normal CT on admission: N=17, negative CT: N=12, no significant difference between patients with or without exposure history Fever:
114/149, 76.5%,
Cough: 87/149, 58.4%,
Expectoration:
4 8/149, 32.2%, mild infection/cerebrovascular or digestive diseases:
52 (34.9%) Negative CT: 10 days, 6.8 (5.0) days 0 (0.0%) Diagnosis: a normal CT cannot exclude the diagnosis of COVID‐19
Fan et al. (2020), China Retrospective, case series/Chongqing University Three Gorges Hospital 51/45/32 (62.7%) men Laboratory test, CT Blood Confirmed COVID‐19: patients had been to Wuhan:
43 (84.3%), contact history of COVID‐19 patients: 4 (7.7%), no clear contact history:4 (7.7%) Spectrum of disease:
nonsevere patients: n = 44, severe patients: 7 (13.7%)
Blood: lymphopenia: 26 (51.0%), elevated CRP: 32 (62.7%).
CT:
GGO: 41 [80.4%], local consolidation of pneumonia:
17 [33.3%], pleural thickening: 20 (39.2%), small amount of pleural effusion:
7 (13.7%), streak shadow of lung: 8 (15.7%), multiple solid nodular shadow: 4 (7.8%), air bronchogram: 2 (3.9%), single lobe lesions: 2 (3.9%), multiple lobe lesions: 49 (96.1%) Fever:
43 [84.3%], cough:
38 [74.5%], dry cough with expectoration:
16 (31.4%), fatigue: 22 [43.1%], asthenia: 22 (43.1%), dyspnea: 11/DM: 4 [57.1%] 2–5 days 1 Therapy:
TCM decoction: 28 [54.9%], aerosol inhalation of recombinant human
Interferon a‐1b: 51 (100%), Lopinavir/Ritonavir: 51 [100%], Bacillus licheniformis capsules: 44 [86.3%], glucocorticoid treatment: 10 (19.6%)
Older patients with server COVID‐19 (N = 7)
Antibiotic treatment: 7 [100%], nutritional diet: 6 [85.7%), human albumin infusion: 4 (57.1%), immunoglobulin treatment: 4 (57.1%), mechanical ventilation: 6 [85.7%]
Results and interpretation: discharged 50 patients after 12 days, without the common clinical symptoms, with the significant increased lymphocyte (p = .008) and significant decreased CRP significantly (p < .001)
Fan et al. (2020), China Retrospective/Shanghai Public Health Clinical Center 148/50.5/49.3% females and 50.7% males Laboratory test, RT‐PCR and CT scanning Sera Confirmed SARS‐CoV‐2‐infected patients/a history of related epidemiology Blood:
elevated LDH, AST, ALT, GGT, TB, ALP:
35.1%, 21.6%, 18.2%, 17.6%, 6.1%, 4.1% in all patients; lower CD4+ and CD8+ T cells: (62.67%)/(56.1%) patients with abnormal liver function received more treatment compared with normal liver function (25%) (p = .009) Fever: (70.1%), cough: (45.3%), expectoration at admission:
(26.7%),
Abnormal liver functions at admission: 75 patients (50.7%) with moderate‐high degree fever (44%) in males,/chronic hepatitis B or C: N = 8 5 days (3–7) 1 Therapy:
Antibiotics (Levofloxacin, Meropenem, Moxifloxacin, Cephalosporin), interferon, antiviral drugs (Arbidol, Lopinavir/ritonavir, Dnrunavir)
Results and interpretation:
all patients discharged from the hospital.
Lopinavir/Ritonavir treatment can significantly alleviate the SARS‐CoV‐2‐induced liver function damage
Chen et al. (2020) China Retrospective/Zhongnan Hospital of Wuhan University, Wuhan 9/26–34/female Clinical records, laboratory results, CT scans Amniotic fluid, cord blood, and neonatal throat swab, breastmilk samples Pregnant women with laboratory‐confirmed COVID‐19 pneumonia and caesarean section in their third trimester/a history of epidemiological exposure to COVID‐19 Blood:
lymphopenia: N = 5, elevated CRP: N = 6, increased ALT and AST: N = 3, normal WBC count: N = 7, lower WBC: N = 1.
Nine mothers: none developed severe COVID‐19 pneumonia or dying as of Feb4.
Six mothers:
amniotic fluid, cord blood, neonatal throat swab, and breastmilk: negative for COVID‐19.
Nine livebirths:
with 1‐min Apgar score of 8–9 and a 5‐min Apgar score of 9–10, No neonatal asphyxia.
CT:
multiple patchy ground‐glass shadows: N=8 Fever: N = 7, cough N = 4, myalgia N = 3, sore throat: N = 2, malaise: N = 2, fetal distress:
N = 2/gestational hypertension:
N = 1, pre‐eclampsia: N = 1, influenza virus infection: N = 1 Short None Therapy: oxygen support (nasal cannula) and empirical antibiotic treatment: N = 9, antiviral therapy: N = 6
Interpretation: no evidence for intrauterine infection caused by vertical transmission in late pregnancy
Lim et al. (2020), Korea Public health center, Myongji Hospital 1/54/male PCR, CT Throat swab, sputum A Korean man living in Wuhan China/Virus transmission;
from index patient Patient A to Patients B, C, D@@ Spectrum of disease: mild respiratory symptoms.
CT:
small consolidation in right upper lobe, GGO in both lower lobes Chills, muscle pain 5–7 days – Therapy:
Lopinavir/Ritonavir
Results and interpretation:
significant decrease in β‐coronavirus viral loads due to the natural course of the healing process rather than administration of Lopinavir/Ritonavir, or both
Wu et al. (2020), China Retrospective/three Grade IIIA hospitals of Jiangsu 80/46.1/41 female (51.25%) Laboratory testing, real time RT‐PCR, CT Throat swab and/or nose swab, blood Confirmed COVID‐19 patients/with a history of epidemic in Wuhan and without contact with the seafood market Spectrum of disease:
mild: 28 (35.00%), moderate: 49 (61.25%), severe: 3 (3.75%), critically ill: none
Laboratory:
lower WBC: 36 (45.00%), lymphocytopenia: 26 (32.50%), lower platelets: 11 (13.75%), high CRP: 62 (77.50%), high ESR: 59 (73.75%), elevated PCT: 1 (1.25%).
Liver function:
increased ALT/AST: 3 (3.75%), lower albumin: 2 (2.50%).
Abnormal myocardial enzyme spectrum and increase of CK: 18 (22.50%).
Increased LDH: 17 (21.25%).
Renal function damage: 2 (2.50%).
Serious renal function damage: 1.
Hyperglycemia: 19 (23.17%).
Increased D‐dimer: 3 (3.75%).
9 kinds of respiratory pathogens and influenza A/B nucleic acids: all patients.
CT: abnormal: 55 (68.75%), bilateral pneumonia: 36 (45.00%), unilateral pneumonia: 19 (23.75%), normal: 25 (31.25%).
Organ damage: acute respiratory injury: 10 (12.50%), renal injury: 2 (2.50%) Fever:
63 (78.75%), cough: 51 (63.75%), shortness of breath: 30 (37.50%), muscle ache: 18 (22.50%), headache: 13 (16.25%) liver dysfunction: 3 (3.75%)/cardiovascular/cerebrovascular, endocrine, digestive, respiratory, malignancies and nervous system diseases: 38 (47.50%) 8.0 Not now Therapy:
all patients:
single antibiotic mainly Moxifloxacin and Ribavirin antiviral therapy, 12 (14.63%) patients:
methylprednisolone sodium succinate or methylprednisolone, 35 (43.75%) patients:
noninvasive ventilator, 1 patient: hemodialysis, 3 patients: TCM
Interpretation: 21 cases discharged from the hospital: With no obvious gender susceptivity, lower proportion of liver dysfunction, abnormal CT and higher frequency nucleic acid detection
Li et al. (2020), China Retrospective study/hospital in Wenzhou 175/46/92 women, 83/men Real‐time PCR, CT Respiratory tract samples or blood samples Confirmed COVID‐19/a history of exposure to the epidemic area: 57 (33%) patients Spectrum of disease:
COVID‐19:
mild: mild clinical manifestations, no pneumonia; moderate: respiratory symptoms, mild pneumonia, severe (37): pneumonia, ARDS with RR >30 times/min, oxygen saturation <93%; critical (3): pneumonia, shock, respiratory failure, and failures in other organs, nearly all patients: GGO
K+:
severe hypokalemia: 39 (higher body temperature, higher heart rate and RR, higher prevalence of dyspnea or tachypnea (p < .05)), hypokalemia 69, normokalemia patients 67.
Correlations: severity of hypokalemia with body temperature, CK, CK‐MB, LDH, and CRP (p < .01), 93% of severe/critically ill patients showed hypokalemia Cough, fever, pneumonia/hypertension: 28, diabetes: 12, other conditions:31 6 – Therapy:
1 severe hypokalemia patients;
3 g/day K+, 34 (SD = 4) g potassium during hospital stay
Good response of patients to K+ supplements when they inclined to recovery
Interpretation: hypokalemia is prevailing in COVID‐19 patients
Lan et al. (2020), China Case study/Zhongnan Hospital of Wuhan University, Wuhan 4, 30–36 years, 2 male RT‐PCR, thin‐section CT Throat swabs Medical personnel quarantined at home with COVID‐19 Spectrum of disease: mild to moderate
Results: (at admission); PCR positive: for all CT positive: for all GGO, or mixed GGO/consolidation
(after therapy); 2 consecutive negative RT‐PCR: all (after discharge); repeated RT‐PCR 5–13 days later: all positive Fever:3, cough: 3, both: 3 Symptom onset to recovery: 12–32 days – Therapy: antiviral treatment (75 mg of oseltamivir every 12 hr)
Resolved clinical symptoms and CT abnormalities: 3
Delicate patches of GGO: 1
Interpretation: possibility of at least a proportion of recovered patients act as virus carriers
Li et al. (2020), China Retrospective study/Sino‐French New Town area Tongji Hospital 47, 62, 28 (59.6%) men Real‐time RT‐PCR Throat‐swab specimens, sputum or endotracheal aspirates Patients with severe COVID‐19 Spectrum of disease: severe: 41 critical: 5(17.9%) men and 1 (5.3%) women
Common: oxygen saturation <93% after routine
Nasal oxygen supply: 3 men/1 woman
Blood: PCT: higher in men, N‐terminal‐pro brain natriuretic peptide: Higher in 16(57.1%) men/5 (26.3%) women,
Positive influenza A antibody: 5 men (17.9%) Fever: 34 [72.3%], cough: 36 [76.6%], myalgia: 5 [10.6%], fatigue: 7 [14.9%]/comorbidities: 30 (63.8%):
COPD, hypertension/CVD lower in men – 3.6% in men and 0 in women Therapy:
antibiotics applied more in the men than the women
Results and interpretation: 4 (21.1%) women/1 man (3.6%) discharged.
Possibility of sex differences in severe COVID‐19 patients, Men with more complicated clinical condition and worse outcomes
Han et al. (2020) Case study/People's Hospital in Wuwei A 47‐year‐old man/smoking for 20 years/no alcohol abuse RT‐PCR, CT Nasopharyngeal swab specimens Confirmed SARS‐CoV‐2/returned to Wuwei city on January 18 from Wuhan city by car Blood:
decreased lymphocytes, increased CRP, slightly elevated fibrinogen, neutrophil, LDH, and fibrinogen
PCR: positive for expression of RdRPN, N and E genes
CT: multiple patchy high‐density shadows scattered mainly in the border regions of lungs, solid changes, GGO changes, slightly thickened pleura Fever, cough productive of white phlegm, bosom frowsty, stuffy/runny noses, vertigo, fatigue, chest tightness, nausea, expiratory dyspnea, poor diet, lethargy/hypertension grade 2 and T2D – – Therapy:
combination therapy including:
Lopinavir/Ritonavir (800/200 mg daily), methylprednisolone (40 mg daily), recombinant human interferon α‐2b (10 million IU daily), ambroxol hydrochloride (60 mg daily) moxifloxacin hydrochloride (0.4 g daily), high flow humidification oxygen inhalation therapy, treatment of blood glucose, blood pressure, and rehydration therapy
Results interpretation: the persistent negative results of SARS‐CoV‐2 on days 6 and 7, normal TLC, lung lesions partially absorbed, The patient discharged. Laboratory tests like TLC are necessary, CT combined with RT‐PCR is helpful, Lopinavir/Ritonavir are effective after failure of methylprednisolone/interferon alfa‐2b
Liu et al. (2020), China Retrospective cohort and case study/Zhongnan Hospital of Wuhan University Dawu County People's Hospital 124 patients, 22 patients:
12 therapy (mean age 53), 10 control (mean age 58) CT, PCR Serum 124 confirmed COVID‐19 cases, 12 HCOV infected patients Blood: (Study 1) decreased platelet: 25 (20.2%), prolonged PT: 77 (62.1%), increased FIB: 27 (21.8%), and increased D‐dimer: 26 (21.0%)
Spectrum of disease: (study 2) severe cases: 6 mild cases: 4 critically ill: 2
CT: (study 2) Bilateral pneumonia: all Study 1: hypercoagulability
Study 2: cough: all shortness of breath: most of them, nausea and vomiting: 60.0%/DM, cardiovascular and cerebrovascular diseases: 4 patients from the DIP, 5 patients control group – 1 Therapy: Dipyridamole (150 mg in three separate doses for 7 consecutive days), antiviral (ribavirin, 0.5 g, Q12hr), corticoid (methylprednisolone sodium succinate, 40 mg, qd), oxygen therapy, nutritional support
Results and interpretation: significant increase in platelet/lymphocyte, significant decrease in D‐dimer levels
Discharged patients: 50% of severe cases and all 4 mild cases.
Dipyridamole adjunctive therapy could significantly reduce viral replication, inhibits hypercoagulability and improves immune recovery
Abbreviations: ALP, alkaline phosphatase; ALT, alanine aminotransferase; ARDS, acute respiratory distress syndrome; AST, aspartate aminotransferase; BUN, blood urea nitrogen; CK, creatine kinase; CK‐MB, creatine kinase myocardial band; COPD, chronic obstructive pulmonary disease; CRE, serum creatinine; CRP, C‐reactive protein; CT, computed tomography; CVD, cardiovascular disease; DM, diabetes mellitus; DM, diabetes mellitus; ESR, erythrocyte sedimentation rate; FIB, fibrinogen; FiO2, fraction of inspired oxygen; GGO, ground‐glass opacity; GGT, γ‐glutamyltransferase; GLM, Generalized Linear Model; LDH, lactate dehydrogenase; nCoV, novel coronavirus; PaO2, partial pressure of oxygen; PCT, procalcitonin; PT, prothrombin time; RNAaemia, SARS‐CoV‐2 nucleic acid; RR, respiratory rate; RT‐PCR, reverse transcriptase polymerase chain reaction; SpO2, oxygen saturation; T2D, type 2 diabetes; TB, total bilirubin; TCM, traditional Chinese medicine; TCM, traditional Chinese medicine; TLC, total lymphocyte count; TnT, troponin T; WBC, white blood cell.
John Wiley & Sons, Ltd. This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.
Table 4 Clinical trials for COVID‐19 or SARS‐nCoV2
Study title Interventions Location/condition Subjects, sex, age Primary purpose Arms Phase Measure outcome/time frame Code/status/date
The efficacy and safety of huaier in the adjuvant treatment of COVID‐19 Drug: Huaier Granule COVID‐19 550, all, 18–75 Treatment Experimental group: standard therapy + Huaier granule 20 g, po, tid for 2 weeks (or until discharge)
Control group: standard therapy II, III Primary (up to 28 days): all cause mortality
Secondary (up to 28 days): clinical status, differences in oxygen intake methods, supplemental oxygenation, mechanical ventilation, mean PaO2/FiO2, length of hospital stay, Length of ICU stay (days), pulmonary function (up to 3 months after discharge) NCT04291053/Not yet recruiting, Apr1‐Sep1 2020
Clinical trial on regularity of TCM syndrome and differentiation treatment of COVID‐19 Drug: TCM prescriptions China/COVID‐19 340, all, 18–75 Treatment Exposure group: integrated TCM and western medicine cohort (routine treatment + one or two of the following antiviral drugs + the following TCM regimens: take decocted or granule, one dose a day)
Control group: western medicine cohort (routine treatment + one or both of the following antiviral drugs) Not applicable Primary (9 days): The relief/disappearance rate of main symptoms, chest CT absorption
Secondary (9 days): virus antigen negative conversion rate, Clinical effective time: the average effective time. The number of severe and critical conversion cases, Incidence of complications, Traditional Chinese Medicine Syndrome Score
Other outcome measures (9 days): CRP changes, ESR changes, PCTchanges, The index of T cell subsets changed NCT04306497/Recruiting, Mar2‐May 2020
Recombinant human angiotensin‐converting enzyme 2 (rhACE2) as a treatment for patients with COVID‐19 Drug: Recombinant human angiotensin‐converting enzyme 2 (rhACE2) China/COVID‐19 24, all, 18–80 Treatment Experimental group: 0.4 mg/kg rhACE2 IV BID for 7 days and standard of care
Control group: standard of care Not applicable Primary (14 days): time course of body temperature, viral load over time
Secondary (14 days): P/F ratio over time, sequential organ failure assessment score over time, Pulmonary Severity Index, image examination of chest over time, proportion of subjects who progressed to critical illness or death, Time from first dose to conversion to normal or mild pneumonia, T‐lymphocyte counts over time, C‐reactive protein levels over time, angiotensin II (Ang II) changes over time, angiotensin 1–7 (Ang 1–7) changes over time, angiotensin 1–5 (Ang 1–5) changes over time, renin changes over time, aldosterone changes over time, angiotensin‐converting enzyme changes over time, angiotensin‐converting enzyme 2 (ACE2) changes over time, IL‐6 changes over time, IL‐8 changes over time, soluble tumor necrosis factor receptor type II (sTNFrII) changes over time, Plasminogen activator inhibitor type‐1 changes over time, Von willebrand factor changes over time, tumor necrosis factor‐α changes over time, soluble receptor for advanced glycation end products (sRAGE) changes over time, surfactant protein‐D changes over time, angiopoietin‐2 changes over time, frequency of adverse events and severe adverse events NCT04287686/Withdraw, Feb‐Apr 2020
The COVID‐19 mobile health study (CMHS) nCapp, a cell phone‐based autodiagnosis system China/COVID‐19 450, all, 18–90 Diagnosis Training: nCapp, a cell phone‐based autodiagnosis system, combined with 15 questions online, and a predicated formula to autodiagnosis of the risk of COVID‐19
Validation: nCapp, a cell phone‐based autodiagnosis system, combined with 15 questions online, and a predicated formula to auto‐diagnosis of the risk of COVID‐19 – Primary (1 day): accuracy of nCapp COVID‐19 risk diagnostic model NCT04275947/Recruiting, Feb 14‐May 31 2020
A Pilot Study of Sildenafil in COVID‐19 Drug: Sildenafil citrate tablets (G1) China/COVID‐19 10, all, 18 years and older Treatment Experimental group: sildenafil citrate tablet 0.1 g/day for 14 days Not applicable Primary (14 days): rate of disease remission, rate of entering the critical stage, time of entering the critical stage
Secondary (14 days): rate of no fever, rate of respiratory symptom remission, rate of lung imaging recovery, rate of C‐reactive protein (CRP) recovery, rate of Biochemical criterion (CK, ALT, Mb) recovery, rate of undetectable viral RNA (continuous twice), time for hospitalization, rate of adverse event NCT04304313/Recruiting, Feb 9‐Nov 9 2020
Critically Ill patients with COVID‐19 in Hong Kong: a multicentre observational cohort study – Hong Kong/COVID‐19 8 descriptive A case series of 41 hospitalized patients with confirmed infection
30% required critical care admission: developed severe respiratory failure, 10% required mechanical ventilation, 5% needed extracorporeal membrane oxygenation support mortality rate: 15% − Primary (28 days): 28 day mortality
Secondary (28 days): vasopressor days, days on mechanical ventilation, sequential organ function assessment score, ECMO use, percentage nitric oxide use, percentage free from oxygen supplement NCT04285801/Completed, Feb 14‐Feb 25 2020
Treatment of mild cases and chemoprophylaxis of contacts as prevention of the COVID‐19 epidemic Drug: antiviral treatment and prophylaxis, Standard Public Health measures COVID‐19 3,040, All, 18 Years and older Treatment Experimental: antiviral treatment and prophylaxis: darunavir 800 mg/cobicistat 150 mg tablets (oral, 1 tablet q24h, taking for 7 days) and hydroxychloroquine (200 mg tablets) 800 mg on Day 1, and 400 mg on days 2, 3, 4. Contacts: a prophylactic regimen of hydroxychloroquine (200 mg tablets) 800 mg on Day 1, and 400 mg on days 2,3,4. Other: standard public health measures
Active comparator: standard public health measures III Primary (up to 14 days after start of treatment): effectiveness of chemoprophylaxis assessed by incidence of secondary COVID‐19 cases
Secondary: the virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at days 3, the mortality rate of subjects at weeks 2, proportion of participants that drop out of study (up to 14 days after start of treatment), proportion of participants that show noncompliance with study drug (up to 14 days after start of treatment) NCT04304053/Not yet recruiting, Mar15‐Jul15 2020
Comparison of lopinavir/ritonavir or hydroxychloroquine in patients with mild coronavirus disease (COVID‐19) Drug: lopinavir/ritonavir, Drug: hydroxychloroquine sulfate Korea/COVID‐19 150, all, 16 years to 99 years Treatment Experimental: lopinavir/ritonavir 200 mg/100 mg 2 tablets by mouth, every 12 hr for 7–10 days
Active comparator: hydroxychloroquine 200 mg 2 tablets by mouth, every 12 hr for 7–10 days
No intervention: control, no lopinavir/ritonavir and hydroxychloroquine II Primary: viral load (hospital Day 3, 5, 7, 10, 14, 18)
Secondary viral load change (hospital Day 3, 5, 7, 10, 14, 18), time to clinical improvement (time frame: up to 28 days), percentage of progression to supplemental oxygen requirement by Day 7, Time to NEWS2 (National Early Warning Score 2) of 3 or more maintained for 24 hr by Day 7, time to clinical failure, defined as the time to death, mechanical ventilation, or ICU admission (up to 28 days), rate of switch to lopinavir/ritonavir or hydroxychloroquine by Day 7, adverse effects (up to 28 days), concentration of lopinavir/ritonavir and hydroxychloroquine (1, 2, 4, 5, 12 hr after taking intervention medicine) NCT04307693/Recruiting, Mar11‐May 2020
Study to evaluate the safety and antiviral activity of remdesivir (GS‐5734™) in participants with severe coronavirus disease (COVID‐19) Drug: remdesivir, standard of care United States, Hong Kong/COVID‐19 400, all, 18 years and older Treatment Experimental: demdesivir (RDV), 5 days participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, and 5
Experimental: remdesivir, 10 days participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, 5, 6, 7, 8, 9, and 10 III Primary: proportion of participants with normalization of fever and oxygen saturation through day 14
Secondary: proportion of participants with treatment emergent adverse events leading to study drug discontinuation (first dose date up to 10 days) NCT04292899/Recruiting, Mar6‐May 2020
Study to evaluate the safety and antiviral activity of remdesivir (GS‐5734™) in participants with moderate coronavirus disease (COVID‐19) compared to standard of care treatment Drug: remdesivir, standard of care United States, Hong Kong, 600, all, 18 years and older Treatment Experimental: remdesivir, 5 days participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, and 5.
Experimental: remdesivir, 10 days participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, 5, 6, 7, 8, 9, and 10.
Active comparator: continued standard of care therapy III Primary (up to 14 days): proportion of participants discharged by day 14‐secondary (up to 10 days): proportion of participants with treatment emergent adverse events leading to study drug discontinuation NCT04292730/Recruiting, Mar‐May 2020
Bevacizumab in severe or critical patients with COVID‐19 pneumonia‐RCT Drug: bevacizumab China/COVID‐19 Pneumonia 118, all, 18–80 Treatment Experimental; bevacizumab, group:
bevacizumab 500 mg + 0.9% NaCl 100 ml, intravenous drip
No intervention: control group Not applicable Primary: proportion of patients whose oxygenation index increased by 100 mmHg on the 7th day after admission NCT04305106/Not yet recruiting, Mar12‐May31 2020
The efficacy and safety of thalidomide in the adjuvant treatment of moderate new coronavirus (COVID‐19) pneumonia Drug: thalidomide, placebo COVID‐19 thalidomide 100, all, 18 years and older Treatment Placebo comparator: control group: placebo 100 mg, po, qn, for 14 days
Experimental: thalidomide group 100 mg, po, qn, for 14 days. Other name: fanyingting II Primary (up to 28 days): time to clinical recovery time to clinical recovery (up to 28 days)
Secondary (up to 28 days): all cause mortality (up to 28 days), frequency of respiratory progression, Time to defervescence
Others(up to 28 days): time to cough reported as mild or absent, respiratory improvement time, frequency of requirement for supplemental oxygen or noninvasive ventilation, Time to 2019‐nCoV RT‐PCR negative in upper respiratory tract specimen, change (reduction) in 2019‐nCoV viral load in upper respiratory tract specimen as assessed by area under viral load curve, frequency of requirement for mechanical ventilation, frequency of serious adverse events, Serum TNF‐α, IL‐1β, IL‐2, IL‐6, IL‐7, IL‐10, GSCF, IP10, MCP1, MIP1α and other cytokine expression levels before and after treatment NCT04273529/Not yet recruiting, Feb20‐Jun30 2020
The efficacy and safety of thalidomide combined with low‐dose hormones in the treatment of Severe COVID‐19 Placebo, drug: thalidomide COVID‐19 thalidomide 40, all, 18 years and older Treatment Placebo comparator: control group α‐interferon: nebulized inhalation, 5 million U or equivalent dose added 2 ml of sterile water for injection, 2 times a day, for 7 days; abidol, 200 mg/time, 3 times a day, for 7 days; methylprednisolone: 40 mg, q12h, for 5 days. placebo: 100 mg/d, qn, for 14 days
Experimental: thalidomide group α‐interferon: nebulized inhalation, 5 million U or equivalent dose added 2 ml of sterile water for injection, 2 times a day, for 7 days; abidol, 200 mg/time, 3 times a day, for 7 days; methylprednisolone: 40 mg, q12h, for 5 days. thalidomide: 100 mg/d qn for 14 days II Primary (up to 28 days): time to clinical improvement
Secondary (up to 28 days): clinical status (days 7, 14, 21, and 28), time to hospital discharge or NEWS2 (National Early Warning Score 2) of ≤2 maintained for 24 hr, all cause mortality, duration (days) of mechanical ventilation, duration (days) of extracorporeal membrane oxygenation, duration (days) of supplemental oxygenation, length of hospital stay (days), time to 2019‐nCoV RT‐PCR, change (reduction) in 2019‐nCoV viral load in upper and lower respiratory tract specimens as assessed by area under viral load curve, frequency of serious adverse drug events, Serum TNF‐α, IL‐1β, IL‐2, IL‐6, IL‐7, IL‐10, GSCF, IP10#MCP1, MIP1α, and other cytokine expression levels before and after treatment NCT04273581/Not yet recruiting, Feb18‐May30 2020
Tetrandrine tablets used in the treatment of COVID‐19 Drug: tetrandrine China/COVID‐19 60, all, 18–75 Treatment Experimental: tetrandrine cohort after the subjects were enrolled, they were given “Tetrandrine 60 mg QD” for a course of 1 week (take 6 days, stop using for 1 day)
No intervention: control cohort treatment according to standard protocols without intervention IV Primary (12 weeks): survival rate secondary (2 weeks): body temperature NCT04308317/Enrolling by invitation, Mar5‐May1 2020
Fingolimod in COVID‐19 Biological: UC‐MSCs, other: placebo China/COVID‐19 30, all, 18–80 Treatment Experimental: treatment group: each patient in the fingolimod treatment group was given 0.5 mg of fingolimod orally once daily, for three consecutive days
No Intervention: control group II Primary (5 day after treatment): the change of pneumonia severity on X‐ray images NCT04280588/Recruiting, Feb22‐Jul1 2020
Therapy for pneumonia patients infected by 2019 novel coronavirus Biological: UC‐MSCs, other: placebo China/COVID‐19 48, all, 18–75 Treatment Experimental: UC‐MSCs treatment group, participants will receive conventional treatment plus four times of 0.5*10E6 UC‐MSCs/kg body weight intravenously at Day1, Day3, Day5, Day7)
Placebo comparator: control group, participants will receive conventional treatment plus 4 times of placebo intravenously at Day1, Day3, Day5, Day7 Not applicable Primary (at baseline, Day 1, Weeks 1, 2, 4, 8): size of lesion area by chest imaging, blood oxygen saturation
Secondary (at baseline, Day 1, Weeks 1, 2, 4, 8): rate of mortality within 28‐days, sequential organ failure assessment, side effects in the UC‐MSCs treatment group, Electrocardiogram, the changes of ST‐T interval mostly, Concentration of C‐reactive protein C‐reactive protein, immunoglobulin, CD4 + and CD8 + T cells count, Concentration of the blood cytokine (IL‐1β, IL‐6, IL‐8,IL‐10,TNF‐α), Concentration of the myocardial enzymes NCT04293692/Recruiting, Feb24‐Feb1 2020–2021
The Use PUL‐042 inhalation solution to prevent COVID‐19 in adults exposed to SARS‐CoV‐2 Drug: PUL‐042 inhalation solution, drug: placebo COVID‐19 200, all, 18 years and older Treatment Experimental: PUL‐042 inhalation solution, PUL‐042 inhalation solution (20.3 µg Pam2: 29.8 µg ODN/mL) given by nebulization on study days 1,3, 6, and 10
Placebo comparator: sterile normal saline for inhalation, sterile normal saline for inhalation given by nebulization on study days 1, 3, 6, and 10 II Primary (14 days): Prevention of COVID‐19 NCT04313023/Not yet recruiting, Apr‐Oct 2020
Treatment of COVID‐19 patients using Wharton's jelly‐mesenchymal stem cells Biological: WJ‐MSCs Arabia Amman, Jordan/use of stem cells for COVID‐19 treatment 5, all, 18 years and older Treatment Experimental: WJ‐MSCs WJ‐MSCs will be derived from cord tissue of newborns, screened for HIV1/2, HBV, HCV, CMV, mycoplasma, and cultured to enrich for MSCs.
WJ‐MSCs will be counted and suspended in 25 ml of saline solution containing 0.5% human serum albumin, and will be given to patient intravenously I Primary (3 weeks): Clinical outcome, CT Scan, RT‐PCR results
Secondary (8 weeks): RT‐PCR results NCT04313322/Recruiting, Mar16‐Sep30 2020
Myocardial damage in COVID‐19 Non China/COVID‐19 cardiovascular diseases 500, all, 18 years and older Prognostic Discharged group (no intervention) the individual which is defined as patient discharged from hospital
Dead group (no intervention) The individual which is defined as patient with all‐cause death – Primary (75 days): the myocardial injury incidence, the risk factors analysis for the death
Secondary (75 days): clinical characteristics, clinical course, cardiovascular comorbidity, Analysis of causes of death NCT04312464/Enrolling by invitation, Jun1‐Mar18 2020
Treatment with mesenchymal stem cells for severe corona virus disease 2019(COVID‐19) Biological: MSCs, biological: saline containing 1%, human serum albumin (solution of MSC China/COVID‐19 60, all, 18–70 Treatment Experimental: mesenchymal stem cells (MSCs), conventional treatment plus MSCs participants will receive conventional treatment plus 3 times of MSCs ((4.0*10E7 cells per time) intravenously at Day 0, Day 3, Day 6)
Placebo comparator: placebo conventional treatment plus placebo participants will receive conventional treatment plus 3 times of placebo (saline containing 1% human serum albumin (solution of MSC) 3 times of placebo (intravenously at Day 0, Day 3, Day 6) I, II Primary (28 days): improvement time of clinical critical treatment index, side effects in the MSCs treatment group
Secondary: proportion of patients in each classification of clinical critical treatment index (baseline, Days 7, 14, 28), all cause mortality on Day 28, invasive mechanical ventilation rate (Day 28), duration of oxygen therapy (Day 28), duration of hospitalization (Day 28), incidence of nosocomial infection (Day 28), CD4+ T cell count by flow cytometry in two groups (baseline, Day, 3, 6, 10, 14, 21, 28) NCT04288102/Recruiting, May5‐Dec31 2020–2021
The clinical study of carrimycin on treatment patients with COVID‐19 Drug: carrimycin, drug: lopinavir/ritonavir tablets or arbidol or chloroquine phosphate, Drug: basic treatment – 520, all, 18–75 Treatment Experimental: carrimycin basic treatment + carrimycin
Active comparator: lopinavir/ritonavir or arbidol or chloroquine phosphate any of basic treatment + lopinavir/ritonavir tablets or arbidol or chloroquine phosphate IV Primary (30 days): fever to normal time (day), pulmonary inflammation resolution time (HRCT) (day), negative conversion (%) of 2019‐nCOVRNA in gargle (throat swabs) at the end of treatment NCT04286503/Not yet recruiting, Feb23‐Feb28 2020–2021
Efficacy and safety of corticosteroids in COVID‐19 Drug: methylprednisolone China/COVID‐19 400, all, 18 years and older Treatment Experimental; Pred group: methylprednisolone 1 mg/kg/day ivgtt for 7 days
No intervention: con group Not applicable Primary (14 days): the incidence of treatment failure in 14 days
Secondary: clinical cure incidence (14 days), the duration of virus change to negative (14 days), mortality at Day 30, ICU admission rate in 30 days NCT04273321/Recruiting, Feb14‐May30 2020
Evaluation of the efficacy and safety of sarilumab in hospitalized patients with COVID‐19 Drug: sarilumab, drug: placebo United States/COVID‐19 400, all, 18 years and older Treatment Experimental: sarilumab high dose: single intravenous (IV) dose of sarilumab, other names: Kevzara®, REGN88, SAR153191
Experimental: sarilumab low dose: single intravenous (IV) dose of sarilumab Other Names: Kevzara®, REGN88, SAR153191
Placebo comparator: single intravenous (IV) dose of placebo to match sarilumab administration II, III Primary: time to resolution of fever for at least 48 hr without antipyretics for 48 hr (Up to Day 29), percentage of patients reporting each severity rating on a 6‐point ordinal scale (Day 15)
Secondary (up to Day 29): time to improvement in oxygenation for at least 48 hr, mean change in the 6‐point ordinal scale, clinical status using the 6‐point ordinal scale, time to improvement in one category from admission using the 6‐point ordinal scale, time to resolution of fever for at least 48 hr without antipyretics by clinical severity, time to resolution of fever for at least 48 hr without antipyretics by baseline IL‐6 levels, time to improvement in oxygenation for at least 48 hr by clinical severity, time to improvement in oxygenation for at least 48 hr by baseline IL‐6 levels, time to resolution of fever and improvement in oxygenation for at least 48 hr, time to change in National Early Warning Score 2 (NEWS2) scoring system, time to score of <2 maintained for 24 hr in NEWS2 scoring system, mean change in NEWS2 scoring system, number of days with fever, number of patients alive off oxygen, number of days of resting respiratory rate >24 breaths/min, number of days with hypoxemia, number of days of supplemental oxygen use, time to saturation ≥94% on room air, number of ventilator free days in the first 28 days, number of patients requiring initiation of mechanical ventilation, number of patients requiring noninvasive ventilation, number of patients requiring the use of high flow nasal cannula, number of patients admitted into an intensive care unit, number of days of hospitalization among survivors, number of deaths due to any cause (up to Day 60), incidence of serious adverse events (Up to Day 60), incidence of severe or life‐threatening bacterial, invasive fungal, or opportunistic infection, Incidence of severe or life‐threatening bacterial, invasive fungal, or opportunistic infection in patients with grade 4 neutropenia, Incidence of hypersensitivity reactions, incidence of infusion reactions, incidence of gastrointestinal perforation, white blood cell count, hemoglobin levels, platelet count, creatinine levels, total bilirubin level, alanine aminotransferase level, aspartate aminotransferase level NCT04315298/Recruiting, Mar16‐Mar16 2020–2021
Washed microbiota transplantation for patients with 2019‐nCoV infection Other: washed microbiota transplantation, other: placebo China/COVID‐19 complicated with refractory intestinal infections 0, all, 14–70 complicated with refractory intestinal infections Treatment Experimental: observational group 5 u washed microbiota suspension administered via nasogastric tube, nasojejunal tube or oral, combining with standard therapy
Placebo comparator: control group 5 u placebo (edible suspension of the same color as the washed microbiota suspension) administered via nasogastric tube, nasojejunal tube or oral, combining with standard therapy Not applicable Primary (2 weeks): number of participants with improvement from severe type to common type NCT04251767/Withdrawn, Feb5‐Apr30 2020
Safety and immunity of Covid‐19 aAPC vaccine Biological: pathogen‐specific aAPC China/Covid‐19 infection 100, all, 6 months to 80 years Treat and Prevent Covid‐19 Infection Experimental: the subjects will receive three injections of 5×10^6 each Covid‐19/aAPC vaccine via subcutaneous injections I Primary (0–28 day): frequency of vaccine events, frequency of serious vaccine events, proportion of subjects with positive T cell response
Secondary (0–28 day): mortality, duration of mechanical ventilation if applicable, proportion of patients in each category of the 7‐point scale (7, 14, and 28 days after randomization), proportion of patients with normalized inflammation factors (7 and 14 days after randomization), clinical improvement based on the 7‐point scale if applicable, lower Murray lung injury score if applicable (7 days after randomization) NCT04299724/Recruiting, Feb15‐Dec31 2020–2024
Safety related factors of endotracheal intubation in patients with severe Covid‐19 pneumonia Severe covid‐19 pneumonia with ET COVID‐19 endotracheal intubation 120, all, 18–90 Observational Intervention details: other: severe covid‐19 pneumonia with ET, severe covid‐19 pneumonia undergoing endotracheal intubation – Primary:
Success rate of intubation (the time span between 1 hr before intubation and 24 hr after intubation), infection rate of anesthesiologist (the time span between 1 hr before intubation and 14 days after intubation)
Secondary:
Extubation time (the time span between 1 hr before intubation and 30 days after intubation) NCT04298814/Not yet recruiting, Mar7‐Jul30 2020
Immunity and safety of Covid‐19 synthetic minigene vaccine Biological: injection and infusion of LV‐SMENP‐DC vaccine and antigen‐specific CTLs China/COVID‐19 100, all, 6 months to 80 years Treatment Experimental: pathogen‐specific DC and CTLs patients will receive approximately 5 × 106 LV‐DC vaccine and 1 × 108 CTLs via subcutaneous injections and iv infusions, respectively I
II Primary:
Clinical improvement based on the 7‐point scale (28 days after randomization), lower Murray lung injury score (7 days after randomization)
Secondary (0–28 day): 28‐day mortality, duration of mechanical ventilation, duration of hospitalization, proportion of patients with negative RT‐PCR results (7 and 14 days after randomization), proportion of patients in each category of the 7‐point scale (7, 14, and 28 days after randomization), proportion of patients with normalized inflammation factors (7 and 14 days after randomization), frequency of vaccine/CTL events, frequency of serious vaccine/CTL events NCT04276896/Recruiting, Mar24‐Dec31 2020–2024
Phase I clinical trial in healthy adult Biological: recombinant novel coronavirus vaccine (adenovirus type 5 vector) – 108, all, 18–60 Prevention Experimental: low‐dose group subjects received one dose of 5E10 vp Ad5‐nCoV at 18–60 years old
Experimental: middle‐dose group
Subjects received one dose of 1E11 vp Ad5‐nCoV at 18–60 years old
Experimental: high‐dose group
Subjects received one dose of 1.5E11vp Ad5‐nCoV at 18–60 years old I Primary (0–7 days postvaccination): safety indexes of adverse reactions
Secondary (Day 14, 28, Month 3, 6 postvaccination):
Safety indexes of adverse events (0–28 days postvaccination), safety indexes of SAE (0–28 days, within 6 mouths postvaccination), safety indexes of lab measures (pre‐vaccination, Day 7 postvaccination), immunogencity indexes of GMT(ELISA) (Day 14, 28, Month 3, 6 postvaccination), immunogencity indexes of GMT (pseudoviral neutralization test method), immunogencity indexes of seropositivity rates, immunogencity indexes of seropositivity rates (pseudoviral neutralization test method, immunogencity indexes of GMI (ELISA), immunogencity indexes of GMI (pseudoviral neutralization test method), immunogencity indexes of GMC (Ad5 vector), immunogencity indexes of GMI (Ad5 vector), immunogencity indexes of cellular immune
Other (day、14,28, Month3,6 postvaccination):
Consistency analysis(ELISA and pseudoviral neutralization test method), Dose‐response relationship (Humoral immunity), Persistence analysis of anti‐S protein antibodies, Time‐dose‐response relationship (Humoral immunity), Dose‐response relationship (cellular immunity), Persistence analysis of cellular immuse, Time‐dose‐response relationship (cellular immunity) NCT04313127/Not yet recruiting, Mar1Dec20 2020–2022
Development and verification of a new coronavirus multiplex nucleic acid detection system Diagnostic test: new QIAstat‐Dx fully automatic multiple PCR detection platform China/COVID‐19 100, all, 16 years to 100 years Diagnostic Diagnostic test: new QIAstat‐Dx fully automatic multiple PCR detection platform
We use the new QIAstat‐Dx fully automatic multiple PCR detection platform to test the enrolled patients – Primary:
Sensitivity, spectivity turnaround time of the New QIAstat‐Dx fully automatic multiple PCR detection platform (3 months) NCT04311398/Not yet recruiting, Mar14‐Dec1, 2020
Hydroxychloroquine treatment for severe COVID‐19 pulmonary infection (HYDRA Trial) Drug: hydroxychloroquine, drug: placebo oral tablet COVID‐19 severe acute respiratory syndrome 500, all, 18–0 Treatment Active comparator: treatment
Hydroxychloroquine tablet 200 mg every 12 hr for 10 days
Placebo comparator: placebo
identical placebo, one tablet every 12 hr for 10 days III Primary (up to120 days):
All‐cause hospital mortality
Secondary (up to120 days):
Length of hospital stay, Need of mechanical ventilation, ventilator free days, Grade 3–4 adverse reaction NCT04315896/Not yet recruiting, Mar23‐Mar22 2020–2012
Tocilizumab in COVID‐19 pneumonia (TOCIVID‐19) Drug: tocilizumab Injection Italy/COVID‐19 pneumonia 330, child, adult, older adult, child, adult, older adult Treatment Experimental: Tocilizumab Injection
Tocilizumab 8 mg/kg (up to a maximum of 800 mg per dose), with an interval of 12 hr II Primary (up to 1 month):
One‐month mortality rate
Secondary (up to 1 month):
interleukin‐6 level, lymphocyte count, C‐reactive protein level (cycle 1 and 2 every 12 hr), PaO2 (partial pressure of oxygen)/FiO2 (fraction of inspired oxygen, FiO2) ratio (or P/F ratio) (baseline, during treatment (cycle 1 and 2 every 12 hr), change of the SOFA (sequential organ failure assessment) (baseline, during treatment (cycle 1 and 2 every 12 hr), number of participants with treatment‐related side effects as assessed by Common Terminology Criteria for Adverse Event version 5.0, Radiological response, Time Frame: at baseline (optional), after 7 days and if clinically indicated, duration of hospitalization. Time Frame: from baseline up to patient's discharge, Remission of respiratory symptoms NCT04317092/Recruiting, Mar19‐Dec19 2020–2022
Mesenchymal stem cell NestCell® to treat patients with severe COVID‐19 pneumonia Biological: NestCell® COVID‐19 pneumonia 6, all, 18 years and older Treatment Experimental: NestCell®:
All patients will receive conventional treatment plus 3 times of 1 × 106 cells/kg body weight intravenously on Day1, Day3, and Day7 I Primary (28 days):
Disappear time of ground‐glass shadow in the lungs
Secondary:
Rate of mortality within 28‐days, Improvement of clinical symptoms including duration of fever and respiratory (At Baseline, Day 3, 7, 10, 14, 21, 28), Time of nucleic acid turning negative (28 days), CD4+ and CD8+ T cell count (At Baseline, Day 3, 6, 10, 14, 21, and 28), changes of blood oxygen (At Baseline, Day 3, 6, 10, 14, 21, and Day 28), side effects in the treatment group (28 days) NCT04315987/Not yet recruiting, Apr‐Jun 2020
CD24Fc as a non‐antiviral immunomodulator in COVID‐19 treatment Drug: CD24Fc, drug: placebo United States/severe coronavirus disease (COVID‐19) 230, all, 18 years and older Treatment Experimental: CD24Fc treatment
Single dose at Day 1, CD24Fc, 480 mg, diluted to 100 ml with normal saline, IV infusion in 60 min
Placebo comparator: placebo
Single dose at Day 1, normal saline solution 100 ml, IV infusion in 60 min III Primary (14 days):
Improvement of COVID‐19 disease status secondary (14 days):
Conversion rate of clinical status at Day 8 (7 days), conversion rate of clinical status at Day 15, hospital discharge time, all cause of death, duration of mechanical ventilation, duration of pressors, duration of ECMO, duration of oxygen therapy, length of hospital stay, absolute lymphocyte count NCT04317040/Not yet recruiting,May‐May 2020–2022
Acute kidney injury in patients hospitalized with COVID‐19 – China/COVID‐19 acute kidney injury‐kidney function 287, all, 18 years and older Observational Acute kidney injury:
COVID‐19 patients with acute kidney injury
nonacute kidney injury:
COVID‐19 patients without acute kidney injury –
Rate of death, the length of hospital stay Primary (up to 60 days):
Rate of acute kidney injury
Secondary (up to 60 days): NCT04316299/Completed, Feb 26‐Mar8 2020
Phase I clinical trial in healthy adult Logical: recombinant novel coronavirus vaccine (adenovirus type 5 vector) COVID‐19 108, all, 18–60 Treatment (Adenovirus Type 5 Vector)
Experimental: low‐dose group
Subjects received one dose of 5E10 vp Ad5‐nCoV at 18–60 years old
Experimental: middle‐dose group
Subjects received one dose of 1E11 vp Ad5‐nCoV at 18–60 years old
Experimental: high‐dose group subjects received one dose of 1.5E11vp Ad5‐nCoV at 18–60 years old I Primary (0–7 days postvaccination):
Safety indexes of adverse reactions
Secondary (0–28 days postvaccination, within 6 mouths postvaccination):
Safety indexes of adverse events, Safety indexes of SAE, Safety indexes of lab measures, Immunogencity indexes of GMT (ELISA), Immunogencity indexes of GMT (pseudoviral neutralization test method) (Day 14, 28, Month 6 postvaccination), Immunogencity indexes of seropositivity rates (ELISA) (Day 14, 28, Month 3, 6 postvaccination), Immunogencity indexes of seropositivity rates(pseudoviral neutralization test method) (Day 14, 28, Month 6 postvaccination), Immunogencity indexes of GMI (ELISA) (Day 14, 28, Month 3, 6 postvaccination), Immunogencity indexes of GMI (pseudoviral neutralization test method) (Day 14, 28, Month 6 postvaccination), Immunogencity indexes of GMC (Ad5 vector) (Day 14, 28, Month 3, 6 postvaccination), Immunogencity indexes of GMI(Ad5 vector) (Day 14, 28, Month 3, 6 postvaccination), Immunogencity indexes of cellular immune (Day 14, 28, Month 6 postvaccination)
Other (Day 14,28, Month 6 postvaccination):
Consistency analysis (ELISA and pseudoviral neutralization test method), dose‐response relationship (humoral immunity) (Day 14, 28, Month 3, 6 postvaccination), Persistence analysis of anti‐S protein antibodies (Day 14, 28, Month 3, 6 postvaccination), Time‐dose‐response relationship (Humoral immunity) (Day 14, 28, Month 3, 6 postvaccination), Dose‐response relationship (cellular immunity) (Day 14, 28, Month 6 postvaccination), Persistence analysis of cellular immuse (Day 14, 28, Month 6 postvaccination), Time‐dose‐response relationship (cellular immunity) (Day 14, 28, Month 6 postvaccination) NCT04313127/Not yet recruiting, Mar19‐Dec20 2020–2021
Favipiravir combined with tocilizumab in the treatment of corona virus disease 2019 Drug: favipiravir combined with tocilizumab, drug: favipiravir, drug: tocilizumab China, COVID‐19 150, all, 18–65 Treatment Experimental: favipiravir combined with tocilizumab group
Favipiravir: On the 1st day, 1,600 mg each time, twice a day; from the 2nd to the 7th day, 600 mg each time, twice a day. Oral administration, the maximum number of days taken is not more than 7 days.
Tocilizumab: the first dose is 4–8 mg/kg and the recommended dose is 400 mg. For fever patients, an additional application (the same dose as before) is given if there is still fever within 24 hr after the first dose and the interval between two medications ≥12 hr. Intravenous infusion. The maximum of cumulative number is two, and the maximum single dose does not exceed 800 mg
Active comparator: favipiravir group
On the 1st day, 1,600 mg each time, twice a day; from the 2nd to the 7th day, 600 mg each time, twice a day. Oral administration, the maximum number of days taken is not more than 7 days
Active comparator: tocilizumab group
The first dose is 4–8 mg/kg and the recommended dose is 400 mg. For fever patients, an additional application (the same dose as before) is given if there is still fever within 24 hr after the first dose and the interval between two medications ≥12 hr. Intravenous infusion, The maximum of cumulative number is two, and the maximum single dose does not exceed 800 mg Not applicable Primary (3 months):
Clinical cure rate
Secondary (14 days after taking medicine):
Viral nucleic acid test negative conversion rate and days from positive to negative, duration of fever, lung imaging improvement time, mortality rate because of corona virus disease 2019 (3 months), rate of noninvasive or invasive mechanical ventilation when respiratory failure occurs (3 months), mean in‐hospital time (3 months) NCT04310228/Recruiting, Mar8‐May 2020
Novel coronavirus induced severe pneumonia treated by dental pulp mesenchymal stem cells Biological: dental pulp mesenchymal stem cells ‐COVID‐19 24, all, 18–75 Treatment Experimental: pulp mesenchymal stem cells 1. 3, 7 days to increase the injection of mesenchymal stem cells Early Phase I Primary (14 days):
Disppear time of ground‐glass shadow in the lungs
Secondary:
Absorption of lung shadow absorption by CT Scan‐Chest (7, 14, 28, and 360 days), Changes of blood oxygen (3, 7, and 14 days) NCT04302519/Not yet Recruiting, Mar5‐Jul30 2020–2021
Multicenter clinical study on the efficacy and safety of Xiyanping injection in the treatment of new coronavirus infection pneumonia (general and severe) Drug: lopinavir/ritonavir tablets combined with Xiyanping injection drug: lopinavir/ritonavir treatment COVID‐19 80, all, 18–100 Treatment Experimental: experimental group of ordinary COVID‐19:
Xiyanping injection, 10–20 ml daily, Qd, the maximum daily does not exceed 500 mg (20 ml) + lopinavir tablet or ritonavir tablet + alpha‐interferon nebulization, for 7–14 days,
Active comparator: control group of ordinary COVID‐19:
Lopinavir/ritonavir tablets, two times a day, two tablets at a time; alpha‐interferon nebulization
Experimental: experimental group of severe COVID‐19:
Xiyanping injection, 10–20 ml daily, Qd, the maximum daily does not exceed 500 mg (20 ml) + lopinavir tablet or ritonavir tablet + alpha‐interferon nebulization, for 7–14 days Not applicable Primary:
Clinical recovery time (up to Day 28) NCT04295551/Not yet Recruiting, Mar14‐Apr14 2020–2021
Prognostic factors of patients with COVID‐19 – China/SARS‐CoV‐2 outcome, fatal 201, all, 18 years and older Prognostic SARS‐CoV‐2Outcome, fatal – Primary (30 days):
all‐cause mortality
Secondary (15 days):
all‐cause mortality,
Severe state NCT04292964/Completed Mar1‐Mar13 2020
Chloroquine prevention of coronavirus disease (COVID‐19) in the healthcare setting Drug: chloroquine, drug: placebo COVID19 coronavirus acute respiratory illnesses 10,000, all, 16 years and older Prevention Experimental: chloroquine:
a loading dose of 10 mg base/kg followed by 150 mg daily (250 mg chloroquine phosphate salt) will be taken for 3 months
Placebo comparator: placebo Not applicable Primary (approximately 100 days):
Number of symptomatic COVID‐19 infections
Secondary (approximately 100 days):
Symptoms severity of COVID‐19, duration of COVID‐19, number of asymptomatic cases of COVID‐19, number of symptomatic acute respiratory illnesses, genetic loci and levels of biochemical components will be correlated with frequency of COVID‐19, ARI, and disease severity
Other (approximately 100 days):
Drug exposure‐protection relationship NCT04303507/Not yet recruiting, May‐May 2020–2022
Yinhu Qingwen decoction for the treatment of mild/common CoVID‐19 Drug: YinHu QingWen decoction, drug: YinHu QingWen decoction(low dose), other: Chinese medicine treatment, other: standard western medicine treatment China/CoVID‐19 Chinese medicine 300, all, 18 years and older Treatment Experimental: Yin Hu Qing Wen decoction group
Based on the standard western medicine treatment, the patients will be given Yinhu Qingwen decoction (granula) for 10 days.
Drug: YinHu QingWen decoction YinHu QingWen decoction (granula) consits of 11 Chinese herbal medicine as honeysuckle, Polygonum cuspidatum, Schizonepeta, Longspur epimedium, and so forth. The decoction granula will be dissolved into 600 ml decoction and divided to three times (once with 200 ml). It will be given a 200 ml per time, three times a day, for 10 days
Other: standard western medicine treatment treatment is according to the protocol of treatment of CoVID‐19 infection according to guideline appoved by National Health Commission of China
Placebo comparator: Yinhu Qingwen decoction low‐dose group
Based on the standard western medicine treatment, the patients will be given 10% dose of Yinhu Qingwen decoction (granula) for 10 days
Drug: YinHu QingWen decoction (low dose) this intervention is given as 10% dose of YinHu QingWen decoction (granula). The granula will be dissolved into 600 ml decoction and divided to three times (once with 200 ml). It will be given a 200 ml per time, three times a day, for 10 days
Other: standard western medicine treatment standard western medicine treatment is according to the protocol of treatment of CoVID‐19 infection according to guideline appoved by National Health Commission of China
Active comparator: integrated Chinese and western medicine group
Based on the standard western medicine treatment, the patients will be given Chinese medicine decotion granula according to their symptoms. The daily dose of Chinese medicine decoction granula will also be dissolved to 600 ml decoction and divided into three times (once with 200 ml). The Chinese medicine decoction will be given 200 ml per time, three times a day for 10 days
Other: Chinese medicine treatment
This intervention will be given with Chinese medicine decoction granula based on the symptoms differentiation of the patients for 10 days
Other: standard western medicine treatment
Standard western medicine treatment is according to the protocol of treatment of CoVID‐19 infection according to guideline appoved by National Health Commission of China II
III Primary (up to 28 days):
Mean clinical recovery time
Secondary (up to 28 days):
Time to CoVID‐19 RT‐PCR negative in upper respiratory tract specimen, change (reduction) in CoVID‐19 viral load in upper respiratory tract specimen as assessed by area under viral load curve, time to defervescence (in those with fever at enrollment), time to cough reported as mild or absent (in those with cough at enrollment rated severe or moderate), time to dyspnea reported as mild or absent (on a scale of severe, moderate, mild absent, in those with dyspnea at enrollment rated as severe or moderate)
Frequency of requirement for supplemental oxygen or noninvasive ventilation, frequency of respiratory progression, severe case incidence, proportion of rehospitalization or admission to ICU, all‐cause mortality, frequency of serious adverse events NCT04278963/Active, Not Recruiting, Feb27‐Jan 2020
Prognositc factors in COVID‐19 patients complicated with hypertension – China, COVID‐19 0, all, 18–100 Prognostic ACEI treatment
hypertension patients with ACEI treatment when suffered with novel coronavirus infection in China
Control
hypertension patients without ACEI treatment when suffered with novel coronavirus infection in China – Primary (up to 28 days):
Occupancy rate in the intensive care unit, mechanical ventilation, death
Secondary (up to 28 days):
All cause mortality, time from onset of symptoms to main outcome and its components, time to clinical recovery NCT04272710/Withdrawn, Jan25‐Apr30 2020
Evaluating the efficacy and safety of bromhexine hydrochloride tablets combined with standard treatment/standard treatment in patients with suspected and mild novel coronavirus pneumonia (COVID‐19) Drug: bromhexine hydrochloride tablets, drug: arbidol hydrochloride granules, drug: recombinant human interferon α2b spray, drug: favipiravir tablets China, novel coronavirus pneumonia 2019‐nCoV 60, all, 18–80 Treatment Experimental: group A treatment group:
Bromhexine hydrochloride tablets, arbidol hydrochloride granules:
Standard treatment refers to the latest edition of pneumonia diagnosis and treatment scheme for novel coronavirus infection. Arbidol hydrochloride granules is recommended but not enforced to use
Recombinant human interferon α2b spray:
Standard treatment refers to the latest edition of pneumonia diagnosis and treatment scheme for novel coronavirus infection
Favipiravir tablets
Active comparator; group B control group:
Drug: arbidol hydrochloride granules
Standard treatment refers to the latest edition of pneumonia diagnosis and treatment scheme for novel coronavirus infection. arbidol hydrochloride granules is recommended but not enforced to use
Drug: recombinant human interferon α2b spray
Standard treatment refers to the latest edition of pneumonia diagnosis and treatment scheme for novel coronavirus infection Not applicable Primary (within 14 days from the start of medication):
Time to clinical recovery after treatment
Secondary (within 14 days from the start of medication):
Rate of aggravation, clinical remission rate, dynamic changes of oxygenation index, time to cure, rate to cure, time to defervescence, time to cough remission,days of supplemental oxygenation, rate of patients with requring supplemental oxygen, rate of patients with mechanical ventilation, time of negative COVID‐19 nucleic acid results, rate of negative COVID‐19 nucleic acid results, rate of ICU admission, 28‐day mortality (From the first day of screening to the day of follow‐up (28 days)) NCT04273763/Enrolling by invitation, Feb16‐Apr30 2020
Various combination of protease inhibitors, oseltamivir, favipiravir, and chloroquin for treatment of covid19: a randomized control trial Drug: oral Thailand, coronavirus infections COVID19 80, all, 16–100 Treatment Experimental: oseltamivir plus chloroquin in mild COVID19
Oseltamivir 300 mg per day plus chloroquin 1,000 mg per Day In mild COVID19
Experimental: lopinavir and ritonavir plus favipiravir
Lopinavir 10 mg/kg and ritonavir 2.5 mg/kg plus favipiravir 2,400 mg, 2,400 mg, and 1,200 mg every 8 hr on Day 1, and a maintenance dose of 1,200 mg twice a day in Mild COVID19
Experimental: lopinavir and ritonavir plus oseltamivir in mild COVID19
Lopipinavir 10 mg/kg and ritonavir 2.5 mg/kg plus oseltamivir 4–6 mg/kg In mild COVID19
Experimental: lopinavir and ritonavir oseltamivir moderate to severe COVID19
Lopipinavir 10 mg/kg and ritonavir 2.5 mg/kg plus oseltamivir 4–6 mg/kg in moderate to critically ill COVID19
Experimental: favipiravir lopinavir/ritonavir for mod. To severe
favipiravir 2,400 mg, 2,400 mg, and 1,200 mg every 8 hr on Day 1, and a maintenance dose of 1,200 mg twice a day plus lopipinavir 10 mg/kg and ritonavir 2.5 mg/kg in moderate to critically ill COVID19
Experimental: darunavir/ritonavir oseltamivir chloroquine mod‐severe
Combination of Darunavir 400 mg every 8 hr ritonavir Ritonavir 2.5 mg/kg plus Oseltamivir 4–6 mg/kg plus Chloroquine 500 mg per Day In moderate to critically ill COVID19
Experimental: darunavir/ritonavir favipiravir chloroquine mod‐severe
Favipiravir 2,400 mg, 2,400 mg, and 1,200 mg every 8 hr on Day 1, and a maintenance dose of 1,200 mg twice a day plus darunavir 400 mg every 8 hr ritonavir ritonavir 2.5 mg/kg plus chloroquine 500 mg per Day In moderate to critically ill COVID19
No intervention: conventional qurantine
Patient who unwilling to treatment and willing to quarantine in mild COVID19 III Primary (Up to 24 weeks):
SARS‐CoV‐2 eradication time
Secondary (up to 24 weeks):
Number of patient with death, number of patient with recovery adjusted by initial severity in each arm, number of day with ventilator dependent adjusted by initial severity in each arm,number of patient developed acute respiratory distress syndrome after treatment
Other (up to 24 weeks):
Number of patient with acute respiratory distress syndrome recovery NCT04303299/Not yet recruiting, Mar15‐Nov30 2020
Yinhu Qingwen Granula for the treatment of severe CoVID‐19 Drug: Yinhu Qingwen granula, drug: Yin Hu Qing Wen granula (low does), other: standard medical treatment China, COVID‐19 severe pneumonia Chinese medicine 116, all, 18 years and older Treatment Experimental:
Yinhu Qingwen granula group:
Drug: Yinhu Qingwen Granula
Yinhu Qingwen granula is a kind of herbal granula made from “Yinhu Qingwen Decoction,” which consits of 11 Chinese herbal medicine as honeysuckle, Polygonum cuspidatum, schizonepeta, Longspur epimedium, etc. The granula will be dissolved into 600 ml decoction and divided to three times (once with 200 ml). It will be given a 200 ml per time, three times a day, for 10 days.
Other: standard medical treatment Standard medical treatment is adhered to the protocol of the treatment for the severe CoVID‐19 according to the guideline approved by National Health Commission of China.
Placebo comparator: Yinhu Qingwen granula low‐dose group:
Drug: Yin Hu Qing Wen granula (low does). This intervention is given as 10% dose of YinHu QingWen Granula.The granula will be dissolved into 600 ml decoction and divided to three times (once with 200 ml).
Other: standard medical treatment Standard medical treatment is adhered to the protocol of the treatment for the severe CoVID‐19 according to the guideline approved by National Health Commission of China. II Primary (Day 10):
changes in the ratio of PaO2 to FiO2 from baseline
Secondary (up to 30 days):
PaO2, blood oxygen saturation (SpO2), clinical status rating on the 7‐point ordinal scale, time to clinical improvement, duration (hours) of noninvasive mechanical ventilation or high‐flow nasal catheter oxygen inhalation use, duration (hours) of invasive mechanical ventilation use, duration (hours) of extracorporeal membrane oxygenation (ECMO) use, duration (days) of oxygen use, The proportion of the patients reporting 2019‐nCoV RT‐PCR negativity at Day 10 after treatment, the counts/percentage of lymphocyte, time to hospital discharge with clinical recovery from the randomization, the incidence of critical status conversion in 30 days, all‐cause mortality within 30 days, frequency of severe adverse drug events NCT04310865/Not yet recruiting, Mar20‐Jun30 2020–2021
Clinical characteristics and long‐term prognosis of 2019‐nCoV infection in children – China, 2019‐nCoV 500, all, up to 18 years Prognosis 2019‐nCoV infection group
Children hospitalized with direct laboratory confirmed of novel coronavirus with or without pneumonia are classified as the 2019‐nCoV infection group
Control group Children hospitalized with pneumonia other than the novel coronavirus pneumonia during the same hospitalization period as 2019‐nCoV infection group are classified as the control group – Primary (6 months):
The cure rate of 2019‐nCoV, the improvement rate of 2019‐nCoV, the incidence of long‐term adverse outcomes
Secondary (2 weeks):
Duration of fever, duration of respiratory symptoms, duration of hospitalization, number of participant(s) need intensive care, number of participant(s) with acute respiratory distress syndrome, number of participant(s) with extra‐pulmonary complications, including shock, renal failure, multiple organ failure, hemophagocytosis syndrome, et al., number of participant(s) who died during the trial (10 months) NCT04270383/Not yet recruiting, Feb15‐Dec30 2020
The effect of T89 on improving oxygen saturation and clinical symptoms in patients with COVID‐19 Drug: T89 Coronavirus disease 2019 novel coronavirus pneumonia 120, all, 18–85 Treatment Experimental: The T89 treatment group Besides a standard background treatment (antiviral drug + antibacterial + oxygen therapy + Traditional Chinese Medicine decoction), all subjects in the T89 treatment group will receive 30 pills of T89 each time, orally, BID (every morning and evening), for 10 days (depending on clinical need and practicability, the use can be extended for up to 14 days)
No intervention: the blank control group
All subjects in the blank control group will only receive a standard background treatment (antiviral drug + antibacterial + oxygen therapy + Traditional Chinese Medicine decoction), for 10 days. Not applicable Primary (Day −1 to 10): the time to oxygen saturation recovery to normal level (≥97%), the proportion of patients with normal level of oxygen saturation(≥97%)
Secondary (Day −1 to 10):
The degree of remission of symptoms of patients, including: fatigue, nausea, vomiting, chest tightness, shortness of breath, and so forth, the time to the myocardial enzyme spectrum recovery to normal after treatment, the proportion of the patients with normal myocardial enzyme spectrum after treatment, the time to the electrocardiogram recovery to normal level after treatment, the proportion of the patients with normal electrocardiogram after treatment, the time to the hemodynamics recovery to normal after treatment, the proportion of the patients with normal hemodynamics after treatment, the time to exacerbation or remission of the disease after treatment, the proportion of the patients with exacerbation or remission of disease after treatment, the proportion of patients who need other treatment (e.g., heparin, anticoagulants) due to microcirculation disorders, the all‐cause mortality rate, the proportion of patients with acidosis, the total duration of the patients in‐hospital, the total duration of oxygen inhalation during treatment, the oxygen flow rate during treatment, the oxygen concentration during treatment NCT04285190/Not yet recruiting, Feb26‐Sep15 2020
Immunoregulatory therapy for 2019‐nCoV Drug: PD‐1 blocking antibody + standard treatment, drug: Thymosin + standard treatment, other: standard treatment ‐2019 nCoV, PD‐1 120, all, 18 years and older Treatment Experimental: PD‐1 group
Anti‐PD‐1 antibody, 200 mg, IV, one time
Experimental: thymosin group
Thymosin, 1.6 mg sc qd, last for 5 days
Placebo comparator: control group stand treatment II Primary (7 days):
lung injury score
Secondary:
Absolute lymphocyte counts (7, 14 and 28 days), serum level of CRP, PCT and IL‐6 (3, 7 and 14 days), SOFA score (7 days), all cause mortality rate (28 days), ventilation free days (28 days), ICU free days (up to 28 days) NCT04268537/Not yet recruiting, Feb10‐Oct31 2020
Tocilizumab vs CRRT in management of cytokine release syndrome (CRS) in COVID‐19 Drug: tocilizumab, other: standard of care, procedure: continuous renal replacement therapy China, Covid‐19 SARS cytokine storm (and 2 more…) 120, all, 18–80 Observational Tocilizumab
Subjects received 8 mg/kg (body weight) Tocilizumab once in 100 ml 0.9% saline solution and administered intravenously within no <60 min. Tocilizumab was administered according—continuous renal replacement therapy
Femoral vein catheterization was performed to complete continuous renal replacement therapy for consecutive three times or more. to the local label
Standard care
Standard of care therapy per local written policies or guidelines – Primary (up to 14 days):
Proportion of participants with normalization of fever and oxygen saturation
Secondary:
Duration of hospitalization (Up to 28 days), proportion of participants with normalization of fever (up to 14 days), change from baseline in white blood cell and differential count (up to 28 days), time to first negative in 2019 novel corona virus RT‐PCR test (Up to 28 days), all‐cause mortality (up to 12 weeks), change from baseline in hsCRP (Up to 28 days), change from baseline in cytokines IL‐1β, IL‐10, sIL‐2R, IL‐6, IL‐8 and TNF‐α (Up to 28 days), change from baseline in proportion of CD4 + CD3/CD8 + CD3 T cells (Up to 28 days) NCT04306705/Recruiting, Feb20‐Jun20 2020
Sars‐CoV2 seroconversion among front line medical and paramedical staff in emergency, intensive care units and infectious disease departments during the 2020 Epidemic Other: blood sample France, Sars‐CoV2 1,000, all, child, adult, older adult Other Caregiver
caregivers from emergency, ICU, virology and infectious disease services:
Two blood samples at T0 and 3 months Not applicable Primary (3 months):
Quantify the proportion of patients with documented Sars‐CoV2 infection among medical and paramedical staff
Secondary (3 months):
Identification of risk factors for seroconversion, quantify the proportion of asymptomatic infections among staff who have seroconverted, describe symptomatic infections for personnel developing acute clinical (respiratory or digestive) viral syndrome NCT04304690/Recruiting, Mar16‐Oct16 2020
John Wiley & Sons, Ltd. This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.
5.3.1 Reverse transcriptase polymerase chain reaction
Despite being the diagnostic gold standard, pathogenic lab testing is a rather time‐consuming procedure, with unavoidable false‐positive results (Wang, Kang, et al., 2020). It is recommended that lab testing should be performed, as soon as the patient is identified as a “person under investigation” (PUI). Viral nucleic acid required for an RT‐PCR test is usually extracted from secretions of the lower respiratory tract, for example, bronchoalveolar lavage; however, tracheal aspirate or sputum can also be used (Chu et al., 2020; Corman et al., 2020). Since the onset of the epidemic, several factors have been found to affect the final efficiency of nucleic acid testing, that is, availability, quality, stability, and reproducibility of detection kits. In most of the cases, the tests need to be repeated for several times (Wang, Kang, et al., 2020), as the estimated detection rate of the test falls in an underwhelming range of 30–50% (Chu et al., 2020; Corman et al., 2020; Zhang et al., 2020). In spite of being a valuable asset, the undesirable false‐negative results of RT‐PCR have prompted careful clinical and etiological evaluation of COVID‐19 in suspected cases as the first‐line diagnostic method (Zu et al., 2020).
5.3.2 Computed tomography (CT)
CT has proved to be of great value in diagnosis of the COVID‐19‐associated pneumonia, as it provides major evidence, that cannot readily be obtained with alternative methods. It is true that CT is a reliable imaging modality in subtle detection of viral pneumonia and screening of suspected cases; however, it should be noted that many pulmonary diseases of inflammatory nature share similar radiographic findings (Wang, Kang, et al., 2020). The majority of patients with COVID‐19 present with GGO in their chest CT, which later progress into multilobar consolidations. There have been several reports of rounded opacities, which are sometimes peripherally distributed in the lung (Chung et al., 2020; Huang et al., 2020). In contrast to CT, plain chest radiography (CXR) has not been recommended as a first‐line imaging method, because this modality does not provide the clarity viewed on CT scans, especially in the early stages of pulmonary infection (Ng et al., 2020). Nevertheless, CXR is capable of recording pathologic changes in patients with severely progressed COVID‐19, as the bilateral multifocal consolidations present in these patients are too dense to be missed. The notorious “white lung” appearance can be optimally viewed on CXRs of critically ill patients (Zu et al., 2020). CT resulted in diagnosis of 14,840 new cases as of February 13, 2020 (Zu et al., 2020). Therefore, slice chest CT is an adequately sensitive and reliable method in early detection of pneumonia in patients with COVID‐19 (Chan et al., 2020; Ng et al., 2020).
5.3.3 Novel approaches: Artificial intelligence‐based technologies
Depp learning, as a novel AI‐based modality might be able to analyze radiographic features of COVID‐19, and help clinicians provide an accurate clinical diagnosis based on a precedented pattern (Wang, Kang, et al., 2020). As part of recent advancements, Convolutional Neural Network (CNN), a class of deep neural networks, has been shown to be capable of medical image analysis. To this date, CNN has been successfully employed in investigations on the nature of pulmonary nodules reported in CT images, diagnosis of pneumonia in children based on CXR, and image recognition in cystoscopy videos (Choe et al., 2019; Kermany et al., 2018; Negassi, Suarez‐Ibarrola, Hein, Miernik, & Reiterer, 2020; Wang et al., 2018).
The 21st century has seen many AI‐based models to be incorporated in several scientific fields, particularly imaging studies. Diagnostic AI‐based models might actually be a forward leap in tasks that simply cannot be handled by manpower, especially risk prioritization, that can greatly help improve patient turnaround time. Given the shortage of human resources and inadequate number of hospital beds in a country like China, AI‐based models for analysis of CXR and CT scans can be useful in ruling out irrelevant cases, and resource‐wise admission of patients to the hospitals (Kim, 2020).
|
|
label
|
5.3
|
|
title
|
COVID‐19 detection tests: Pathogenic laboratory testing, real‐time RT‐PCR, and sequencing of nucleic acid
|
|
p
|
Table 3 (Ai et al., 2020; Bai et al., 2020; Chen, Zhao, et al., 2020; Shi et al., 2020; Tian et al., 2020; Wang, Kang, et al., 2020; Wu & McGoogan, 2020; Yan et al., 2020; Yang et al., 2020) and Table 4 represent 2020 studies on diagnosis of COVID‐19 infected patients and related clinical trials, respectively.
|
|
table-wrap
|
Table 3 Studies for diagnosis, prognosis and therapy of COVID‐19 patients
Study/region Study type/medical team Patient/median age/sex Diagnostic test Sample Inclusion criteria/residency Test results Most common symptoms/chronic disease Incubation period (day) Case fatality rate Diagnosis/prognosis/therapy
Wu et al. (2020), China Retrospective study/Chinese Center for Disease Control and Prevention 72,314; subjects: confirmed cases 44,672 (62%), suspected cases 16,186 (22%), diagnosed cases 10,567 (15%), asymptomatic cases 889 (1%)/age N = 44,672: 80: 3% (1,408), 30–79: 87% (38,680), 20–29: 8% (3,619), 10–19: 1% (549), <10: 1% (416) PCR Throat swab samples Confirmed cases based on positive PCR, suspected cases based on symptoms and exposures only, clinically cases based on symptoms, exposures, and CT, asymptomatic cases diagnosis by positive PCR Spectrum of disease: (N = 44,415); mild: 81% (36,160), severe: 14% (6,168), critical: 5% (2,087) Cardiovascular disease: 10.5%, diabetes: 7.3%, chronic respiratory disease: 6.3%, hypertension: 6.0%, cancer: 5.6% About a week 2.3% (1,023 of 44,672 confirmed cases), 14.8% aged >80 years (208 of 1,408), 8.0% aged 70–79 years (312 of 3,918) 49.0% in critical cases (1,023 of 2,087) Next step: to help “buy time” for more diagnostic and therapeutic research before COVID‐19 becomes too widespread
Tian et al. (2020), China Retrospective study/Beijing Emergency Medical Service 262/47.5/48.5% male Real‐time RT‐PCR Respiratory specimens COVID‐19 infected patients/residents of Beijing: 92 (73.3%), patients had been to Wuhan: 50 (26.0%), close contact with confirmed cases: 116 (60.4%), no contact history: 21 (10.9%) Spectrum of disease: sever: 46 (17.6%); common: 216; (82.4%); mild: 192 (73.3%); nonpneumonia: 11 (4.2%); asymptomatic:13 (5.0%) Fever (82.1%), cough (45.8%), fatigue (26.3%), dyspnea (6.9%), headache (6.5%)/pulmonary infection, chronic cardiovascular disease and heart failure: 1, pulmonary infection and multiple chronic diseases: 1 Incubation: 6.7 days, illness onset to visit hospital: 4.5 days 3 (0.9%) Results: As of February 10, 45 (17.2%) patients have discharged
For COVID‐19 control: first step is prevent transmission at early stage, next steps is early isolation and quarantine of suspected subjects
Wang et al. (2020), China Retrospective cohort/Xi'an Jiaotong University First Affiliated Hospital, Nanchang University First Hospital and Xi'an No.8 Hospital of Xi'an Medical College 99 CT, artificial intelligence, inception migration‐learning model – Pathogen‐confirmed COVID‐19 patients Spectrum of disease: typical viral pneumonia or negative group: 55, confirmed nucleic acid testing or positive group: 44. CT (453 CT images): negative: 258, positive: 195 Viral pneumonia symptoms – – Screening:
The internal validation; accuracy: 82·9%, specificity: 80·5%, sensitivity: 84%
The external testing; accuracy: 73·1%, specificity: 67%, sensitivity: 74%
Algorithm prediction: a rate of 2 s per case on the graphic processing unit
Interpretation: the early diagnosis through fast, accurate, safe and noninvasive methods is crucial for control of virus
Yan et al. (2020), China Retrospective study/Tongji Hospital 375, 58.83, 58.7% males CT, machine learning model (a supervised XGBoost classifier) – Validated or suspected COVID‐19 patient/Wuhan residents (37.9%), familial cluster (6.4%), health workers (1.9%) Spectrum of disease: critical patients: 46.1%, severe cases: RR ≥ 30bpm or SPO2 ≤93% on rest Fever: 49.9%, cough: 13.9%, fatigue 3.7%, dyspnea 2.1%, shock: 2 174
16 + 1 Interpretation: the three indices‐based prognostic prediction model might predict themortality risk, recognition of critical cases, help to early identification, on time intervention, reducing mortality rate
Shi et al. (2020), China Retrospective/hospitals in Wuhan 81, 49–5, 42 (52%) men and 39 (48%) women Next‐generation sequencing or RT‐PCR, serial chest CT Throat swab specimens Confirmed COVID‐19 pneumonia patients/direct exposure to Huanan seafood market: 31 (38%), health‐care workers: 15 (19%), familial clusters: 7 (9%), any obvious history of exposure: 28 (35%) Spectrum of disease: mean number of involved lung segments: 10.5 (SD 6.4): group 1: subclinical patients (CT before symptom onset): 2.8 (3.3), group 2: ≤1 week after symptom onset/11.1 (5.4), group 3: >1–2 weeks/13.0 (5.7), group 4: >2–3 weeks/12.1 (5.9).
CT:
ALL:
bilateral abnormality: 64 [79%], peripheral 44 [54%], Ill‐defined 66 [81%], GGO: 53 [65%], mainly involving the right lower lobes: 225 [27%] of 849.
Group 1 (n=15): unilateral: 9 [60%]/multifocal 8 [53%]/GGO: 14 [93%]; Group 2 (n = 21): bilateral 19 [90%]/diffuse 11 [52%]/GGO predominance 17 [81%]; Group 3 (n = 30): GGO 17 [57%], consolidation/mixed patterns: 12 [40%]; Group 4 (n=15): consolidation/mixed patterns: 8 [53%].
Blood:
Group1: Lower CRP and AST Fever: 59 [73%], dry cough: 48 [59%] nonspecific symptoms:
dizziness:
2 [2%], diarrhea:
3 [4%], vomiting:
4 [5%], headache:
5 [6%], generalised weakness:
7 [9%]/chronic pulmonary disease (tuberculosis): 1, T2D: 1, hypertension/cardiovascular/erebrovascular disease: 1 Symptom onset and discharge of 23–2 days 3 (4%) By February 8, 2020, 62 (77%) patients discharged
Interpretation: COVID‐19 pneumonia include CT abnormalities that rapidly progress from focal unilateral to diffuse bilateral GGO coexisted with consolidations within 1–3 weeks (even in asymptomatic patients).
Early diagnosis through combined CT with clinical and laboratory findings
Bai et al. (2020), China Case study/The Fifth People's Hospital of Anyang 6, Patient 1: 20‐year‐old woman, patients 2–6: four women 42–57 years old CT, RT‐PCR Nasopharyngeal swabs Patient 1: met with Patients 2 and 3, and accompanied five relatives (Patients 2–6), Patients 2–6: no visited Wuhan or been in contact with any other people traveled to Wuhan Spectrum of disease: severe pneumonia: 2, moderate: others. A familial cluster of five patients with respiratory symptoms, 1 asymptomatic family member.
Blood:
all symptomatic patients: increased CRP, reduced lymphocyte.
CT: multifocal GGO: in all symptomatic patients, subsegmental consolidation/fibrosis: 1.
Patient 1: normal CT, CRP and lymphocyte count, RT‐PCR: negative, positive, negative.
Patients 2–6:
COVID‐19 confirmed.
PCR: positive for patients 2–6 within 1 day Fever: patients 2–6 19 days for patient 1 – Transmission: COVID‐19 transmission could transmit by an asymptomatic carrier S
Ai et al. (2020), China Cohort/Tangji hospital of Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei 1,014/51 ± 15/46% man Laboratory test, chest CT (7 day interval), RT‐PCR (Taq man one step): multiple assays (3 day interval) Throat swab Suspected of nCoV/China Positive CT: 88% (888/1,014), positive RT‐PCR: 59% (601/1,014).
Sensitivity of CT based on positive RT‐PCR: 97% (95%CI, 95–98%, 580/601).
Negative RT‐PCR/positive CT: 75% (308/413).
Initial positive CT consistent with COVID‐19 before the initial positive RT‐PCR: 60–93%.
Improvement in follow‐up CT before the RT‐PCR turning negative: 42% (24/57), CT: GGO: 46% [409/888], consolidations: 50% [447/888], bilateral findings: 90% [801/888] Fever, dry cough Initial + to − PCR: 5.1 ± 1.5 days,
Initial − to + PCR: 6.9 ± 2.3 days – Diagnosis: chest CT, as a highly sensitive method, could be considered as a primary tool for infection diagnosis in epidemic areas
Chen et al. (2020), China General Hospital of Central Theater Command, PLA 48/age; critically ill: 79.6 ± 12, sever: 63.9 ± 15, mild: 45.8 ± 14/31 males (77.1%) and 17 females (22.9%) Real‐time RT‐PCR, CT, GLMs analysis Serum, throat‐swab specimens Laboratory confirmed cases Spectrum of disease: mild: 21 (43.7%), severe 10 (20.8%), critically ill 17 (35.4%).
Blood: low/lower lymphocytes: severe and critically ill, higher neutrophils: critically ill, higher PCT: critically ill.
Parameters stand for the organ dysfunction; TnT, AST, ALT, CRE, and BUN: higher in critically ill patients.
PCR:
positive RNAaemia: (a) serum: 5 (10.4%) of critically ill, (b) throat‐swab: 48 positive.
IL‐6: value ≥100: 35.3% in critically ill, 10‐folds higher IL‐6 (cytokine storm): critically ill, RNAaemia positive: IL‐6 ≥100 (R = 0.902) Mild: fever, respiratory symptoms
Severe: shortness of breath, RR ≥ 30 times/min, oxygen saturation (resting state) ≤93%, PaO2/FiO2 ≤300 mmHg
Critically ill: respiratory failure, shock, multiple organ failure/diabetes: 12 [25%], hypertension: 23 [49.7%], heart disease: 8 [16.7%], mixed fungal infection: 27.1%, bacterial infection: (2.1%) – 3 Diagnosis; RNAaemia positive test confirmed critically ill patients
Prognosis: strong association between RNAaemia with cytokine storm can be applied to predict the poor prognosis
Therapeutic approach: in critically patients, IL‐6 should be considered as a therapeutic target
Fan et al. (2020), China Retrospective cohort study/three tertiary hospitals of Wenzhou 149/45.11 ± 13.35/81 (54.4%) males Laboratory test, PCR, CT Blood RT‐PCR confirmed patients: Hubei travel/residence history: N=85,
contact with people of Hubei: N=49, no traceable exposure history: N=15 Blood:
decreased oxygen saturation: 14(9.4%), leukopenia: 33 (24.2%), lymphopenia: 53 (35.6%), low platelets: 20 (13.4%), elevated CRP: 82 (55.0%), ALT/AST/CK and D‐dimer: less common.
CT: most involved lung segments: 6 and, GGO: 287 segments, mixed opacity: 637 segments, consolidation: 170 segments, lesions: more in the peripheral lung with a patchy form, normal CT on admission: N=17, negative CT: N=12, no significant difference between patients with or without exposure history Fever:
114/149, 76.5%,
Cough: 87/149, 58.4%,
Expectoration:
4 8/149, 32.2%, mild infection/cerebrovascular or digestive diseases:
52 (34.9%) Negative CT: 10 days, 6.8 (5.0) days 0 (0.0%) Diagnosis: a normal CT cannot exclude the diagnosis of COVID‐19
Fan et al. (2020), China Retrospective, case series/Chongqing University Three Gorges Hospital 51/45/32 (62.7%) men Laboratory test, CT Blood Confirmed COVID‐19: patients had been to Wuhan:
43 (84.3%), contact history of COVID‐19 patients: 4 (7.7%), no clear contact history:4 (7.7%) Spectrum of disease:
nonsevere patients: n = 44, severe patients: 7 (13.7%)
Blood: lymphopenia: 26 (51.0%), elevated CRP: 32 (62.7%).
CT:
GGO: 41 [80.4%], local consolidation of pneumonia:
17 [33.3%], pleural thickening: 20 (39.2%), small amount of pleural effusion:
7 (13.7%), streak shadow of lung: 8 (15.7%), multiple solid nodular shadow: 4 (7.8%), air bronchogram: 2 (3.9%), single lobe lesions: 2 (3.9%), multiple lobe lesions: 49 (96.1%) Fever:
43 [84.3%], cough:
38 [74.5%], dry cough with expectoration:
16 (31.4%), fatigue: 22 [43.1%], asthenia: 22 (43.1%), dyspnea: 11/DM: 4 [57.1%] 2–5 days 1 Therapy:
TCM decoction: 28 [54.9%], aerosol inhalation of recombinant human
Interferon a‐1b: 51 (100%), Lopinavir/Ritonavir: 51 [100%], Bacillus licheniformis capsules: 44 [86.3%], glucocorticoid treatment: 10 (19.6%)
Older patients with server COVID‐19 (N = 7)
Antibiotic treatment: 7 [100%], nutritional diet: 6 [85.7%), human albumin infusion: 4 (57.1%), immunoglobulin treatment: 4 (57.1%), mechanical ventilation: 6 [85.7%]
Results and interpretation: discharged 50 patients after 12 days, without the common clinical symptoms, with the significant increased lymphocyte (p = .008) and significant decreased CRP significantly (p < .001)
Fan et al. (2020), China Retrospective/Shanghai Public Health Clinical Center 148/50.5/49.3% females and 50.7% males Laboratory test, RT‐PCR and CT scanning Sera Confirmed SARS‐CoV‐2‐infected patients/a history of related epidemiology Blood:
elevated LDH, AST, ALT, GGT, TB, ALP:
35.1%, 21.6%, 18.2%, 17.6%, 6.1%, 4.1% in all patients; lower CD4+ and CD8+ T cells: (62.67%)/(56.1%) patients with abnormal liver function received more treatment compared with normal liver function (25%) (p = .009) Fever: (70.1%), cough: (45.3%), expectoration at admission:
(26.7%),
Abnormal liver functions at admission: 75 patients (50.7%) with moderate‐high degree fever (44%) in males,/chronic hepatitis B or C: N = 8 5 days (3–7) 1 Therapy:
Antibiotics (Levofloxacin, Meropenem, Moxifloxacin, Cephalosporin), interferon, antiviral drugs (Arbidol, Lopinavir/ritonavir, Dnrunavir)
Results and interpretation:
all patients discharged from the hospital.
Lopinavir/Ritonavir treatment can significantly alleviate the SARS‐CoV‐2‐induced liver function damage
Chen et al. (2020) China Retrospective/Zhongnan Hospital of Wuhan University, Wuhan 9/26–34/female Clinical records, laboratory results, CT scans Amniotic fluid, cord blood, and neonatal throat swab, breastmilk samples Pregnant women with laboratory‐confirmed COVID‐19 pneumonia and caesarean section in their third trimester/a history of epidemiological exposure to COVID‐19 Blood:
lymphopenia: N = 5, elevated CRP: N = 6, increased ALT and AST: N = 3, normal WBC count: N = 7, lower WBC: N = 1.
Nine mothers: none developed severe COVID‐19 pneumonia or dying as of Feb4.
Six mothers:
amniotic fluid, cord blood, neonatal throat swab, and breastmilk: negative for COVID‐19.
Nine livebirths:
with 1‐min Apgar score of 8–9 and a 5‐min Apgar score of 9–10, No neonatal asphyxia.
CT:
multiple patchy ground‐glass shadows: N=8 Fever: N = 7, cough N = 4, myalgia N = 3, sore throat: N = 2, malaise: N = 2, fetal distress:
N = 2/gestational hypertension:
N = 1, pre‐eclampsia: N = 1, influenza virus infection: N = 1 Short None Therapy: oxygen support (nasal cannula) and empirical antibiotic treatment: N = 9, antiviral therapy: N = 6
Interpretation: no evidence for intrauterine infection caused by vertical transmission in late pregnancy
Lim et al. (2020), Korea Public health center, Myongji Hospital 1/54/male PCR, CT Throat swab, sputum A Korean man living in Wuhan China/Virus transmission;
from index patient Patient A to Patients B, C, D@@ Spectrum of disease: mild respiratory symptoms.
CT:
small consolidation in right upper lobe, GGO in both lower lobes Chills, muscle pain 5–7 days – Therapy:
Lopinavir/Ritonavir
Results and interpretation:
significant decrease in β‐coronavirus viral loads due to the natural course of the healing process rather than administration of Lopinavir/Ritonavir, or both
Wu et al. (2020), China Retrospective/three Grade IIIA hospitals of Jiangsu 80/46.1/41 female (51.25%) Laboratory testing, real time RT‐PCR, CT Throat swab and/or nose swab, blood Confirmed COVID‐19 patients/with a history of epidemic in Wuhan and without contact with the seafood market Spectrum of disease:
mild: 28 (35.00%), moderate: 49 (61.25%), severe: 3 (3.75%), critically ill: none
Laboratory:
lower WBC: 36 (45.00%), lymphocytopenia: 26 (32.50%), lower platelets: 11 (13.75%), high CRP: 62 (77.50%), high ESR: 59 (73.75%), elevated PCT: 1 (1.25%).
Liver function:
increased ALT/AST: 3 (3.75%), lower albumin: 2 (2.50%).
Abnormal myocardial enzyme spectrum and increase of CK: 18 (22.50%).
Increased LDH: 17 (21.25%).
Renal function damage: 2 (2.50%).
Serious renal function damage: 1.
Hyperglycemia: 19 (23.17%).
Increased D‐dimer: 3 (3.75%).
9 kinds of respiratory pathogens and influenza A/B nucleic acids: all patients.
CT: abnormal: 55 (68.75%), bilateral pneumonia: 36 (45.00%), unilateral pneumonia: 19 (23.75%), normal: 25 (31.25%).
Organ damage: acute respiratory injury: 10 (12.50%), renal injury: 2 (2.50%) Fever:
63 (78.75%), cough: 51 (63.75%), shortness of breath: 30 (37.50%), muscle ache: 18 (22.50%), headache: 13 (16.25%) liver dysfunction: 3 (3.75%)/cardiovascular/cerebrovascular, endocrine, digestive, respiratory, malignancies and nervous system diseases: 38 (47.50%) 8.0 Not now Therapy:
all patients:
single antibiotic mainly Moxifloxacin and Ribavirin antiviral therapy, 12 (14.63%) patients:
methylprednisolone sodium succinate or methylprednisolone, 35 (43.75%) patients:
noninvasive ventilator, 1 patient: hemodialysis, 3 patients: TCM
Interpretation: 21 cases discharged from the hospital: With no obvious gender susceptivity, lower proportion of liver dysfunction, abnormal CT and higher frequency nucleic acid detection
Li et al. (2020), China Retrospective study/hospital in Wenzhou 175/46/92 women, 83/men Real‐time PCR, CT Respiratory tract samples or blood samples Confirmed COVID‐19/a history of exposure to the epidemic area: 57 (33%) patients Spectrum of disease:
COVID‐19:
mild: mild clinical manifestations, no pneumonia; moderate: respiratory symptoms, mild pneumonia, severe (37): pneumonia, ARDS with RR >30 times/min, oxygen saturation <93%; critical (3): pneumonia, shock, respiratory failure, and failures in other organs, nearly all patients: GGO
K+:
severe hypokalemia: 39 (higher body temperature, higher heart rate and RR, higher prevalence of dyspnea or tachypnea (p < .05)), hypokalemia 69, normokalemia patients 67.
Correlations: severity of hypokalemia with body temperature, CK, CK‐MB, LDH, and CRP (p < .01), 93% of severe/critically ill patients showed hypokalemia Cough, fever, pneumonia/hypertension: 28, diabetes: 12, other conditions:31 6 – Therapy:
1 severe hypokalemia patients;
3 g/day K+, 34 (SD = 4) g potassium during hospital stay
Good response of patients to K+ supplements when they inclined to recovery
Interpretation: hypokalemia is prevailing in COVID‐19 patients
Lan et al. (2020), China Case study/Zhongnan Hospital of Wuhan University, Wuhan 4, 30–36 years, 2 male RT‐PCR, thin‐section CT Throat swabs Medical personnel quarantined at home with COVID‐19 Spectrum of disease: mild to moderate
Results: (at admission); PCR positive: for all CT positive: for all GGO, or mixed GGO/consolidation
(after therapy); 2 consecutive negative RT‐PCR: all (after discharge); repeated RT‐PCR 5–13 days later: all positive Fever:3, cough: 3, both: 3 Symptom onset to recovery: 12–32 days – Therapy: antiviral treatment (75 mg of oseltamivir every 12 hr)
Resolved clinical symptoms and CT abnormalities: 3
Delicate patches of GGO: 1
Interpretation: possibility of at least a proportion of recovered patients act as virus carriers
Li et al. (2020), China Retrospective study/Sino‐French New Town area Tongji Hospital 47, 62, 28 (59.6%) men Real‐time RT‐PCR Throat‐swab specimens, sputum or endotracheal aspirates Patients with severe COVID‐19 Spectrum of disease: severe: 41 critical: 5(17.9%) men and 1 (5.3%) women
Common: oxygen saturation <93% after routine
Nasal oxygen supply: 3 men/1 woman
Blood: PCT: higher in men, N‐terminal‐pro brain natriuretic peptide: Higher in 16(57.1%) men/5 (26.3%) women,
Positive influenza A antibody: 5 men (17.9%) Fever: 34 [72.3%], cough: 36 [76.6%], myalgia: 5 [10.6%], fatigue: 7 [14.9%]/comorbidities: 30 (63.8%):
COPD, hypertension/CVD lower in men – 3.6% in men and 0 in women Therapy:
antibiotics applied more in the men than the women
Results and interpretation: 4 (21.1%) women/1 man (3.6%) discharged.
Possibility of sex differences in severe COVID‐19 patients, Men with more complicated clinical condition and worse outcomes
Han et al. (2020) Case study/People's Hospital in Wuwei A 47‐year‐old man/smoking for 20 years/no alcohol abuse RT‐PCR, CT Nasopharyngeal swab specimens Confirmed SARS‐CoV‐2/returned to Wuwei city on January 18 from Wuhan city by car Blood:
decreased lymphocytes, increased CRP, slightly elevated fibrinogen, neutrophil, LDH, and fibrinogen
PCR: positive for expression of RdRPN, N and E genes
CT: multiple patchy high‐density shadows scattered mainly in the border regions of lungs, solid changes, GGO changes, slightly thickened pleura Fever, cough productive of white phlegm, bosom frowsty, stuffy/runny noses, vertigo, fatigue, chest tightness, nausea, expiratory dyspnea, poor diet, lethargy/hypertension grade 2 and T2D – – Therapy:
combination therapy including:
Lopinavir/Ritonavir (800/200 mg daily), methylprednisolone (40 mg daily), recombinant human interferon α‐2b (10 million IU daily), ambroxol hydrochloride (60 mg daily) moxifloxacin hydrochloride (0.4 g daily), high flow humidification oxygen inhalation therapy, treatment of blood glucose, blood pressure, and rehydration therapy
Results interpretation: the persistent negative results of SARS‐CoV‐2 on days 6 and 7, normal TLC, lung lesions partially absorbed, The patient discharged. Laboratory tests like TLC are necessary, CT combined with RT‐PCR is helpful, Lopinavir/Ritonavir are effective after failure of methylprednisolone/interferon alfa‐2b
Liu et al. (2020), China Retrospective cohort and case study/Zhongnan Hospital of Wuhan University Dawu County People's Hospital 124 patients, 22 patients:
12 therapy (mean age 53), 10 control (mean age 58) CT, PCR Serum 124 confirmed COVID‐19 cases, 12 HCOV infected patients Blood: (Study 1) decreased platelet: 25 (20.2%), prolonged PT: 77 (62.1%), increased FIB: 27 (21.8%), and increased D‐dimer: 26 (21.0%)
Spectrum of disease: (study 2) severe cases: 6 mild cases: 4 critically ill: 2
CT: (study 2) Bilateral pneumonia: all Study 1: hypercoagulability
Study 2: cough: all shortness of breath: most of them, nausea and vomiting: 60.0%/DM, cardiovascular and cerebrovascular diseases: 4 patients from the DIP, 5 patients control group – 1 Therapy: Dipyridamole (150 mg in three separate doses for 7 consecutive days), antiviral (ribavirin, 0.5 g, Q12hr), corticoid (methylprednisolone sodium succinate, 40 mg, qd), oxygen therapy, nutritional support
Results and interpretation: significant increase in platelet/lymphocyte, significant decrease in D‐dimer levels
Discharged patients: 50% of severe cases and all 4 mild cases.
Dipyridamole adjunctive therapy could significantly reduce viral replication, inhibits hypercoagulability and improves immune recovery
Abbreviations: ALP, alkaline phosphatase; ALT, alanine aminotransferase; ARDS, acute respiratory distress syndrome; AST, aspartate aminotransferase; BUN, blood urea nitrogen; CK, creatine kinase; CK‐MB, creatine kinase myocardial band; COPD, chronic obstructive pulmonary disease; CRE, serum creatinine; CRP, C‐reactive protein; CT, computed tomography; CVD, cardiovascular disease; DM, diabetes mellitus; DM, diabetes mellitus; ESR, erythrocyte sedimentation rate; FIB, fibrinogen; FiO2, fraction of inspired oxygen; GGO, ground‐glass opacity; GGT, γ‐glutamyltransferase; GLM, Generalized Linear Model; LDH, lactate dehydrogenase; nCoV, novel coronavirus; PaO2, partial pressure of oxygen; PCT, procalcitonin; PT, prothrombin time; RNAaemia, SARS‐CoV‐2 nucleic acid; RR, respiratory rate; RT‐PCR, reverse transcriptase polymerase chain reaction; SpO2, oxygen saturation; T2D, type 2 diabetes; TB, total bilirubin; TCM, traditional Chinese medicine; TCM, traditional Chinese medicine; TLC, total lymphocyte count; TnT, troponin T; WBC, white blood cell.
John Wiley & Sons, Ltd. This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.
|
|
label
|
Table 3
|
|
caption
|
Studies for diagnosis, prognosis and therapy of COVID‐19 patients
|
|
p
|
Studies for diagnosis, prognosis and therapy of COVID‐19 patients
|
|
table
|
Study/region Study type/medical team Patient/median age/sex Diagnostic test Sample Inclusion criteria/residency Test results Most common symptoms/chronic disease Incubation period (day) Case fatality rate Diagnosis/prognosis/therapy
Wu et al. (2020), China Retrospective study/Chinese Center for Disease Control and Prevention 72,314; subjects: confirmed cases 44,672 (62%), suspected cases 16,186 (22%), diagnosed cases 10,567 (15%), asymptomatic cases 889 (1%)/age N = 44,672: 80: 3% (1,408), 30–79: 87% (38,680), 20–29: 8% (3,619), 10–19: 1% (549), <10: 1% (416) PCR Throat swab samples Confirmed cases based on positive PCR, suspected cases based on symptoms and exposures only, clinically cases based on symptoms, exposures, and CT, asymptomatic cases diagnosis by positive PCR Spectrum of disease: (N = 44,415); mild: 81% (36,160), severe: 14% (6,168), critical: 5% (2,087) Cardiovascular disease: 10.5%, diabetes: 7.3%, chronic respiratory disease: 6.3%, hypertension: 6.0%, cancer: 5.6% About a week 2.3% (1,023 of 44,672 confirmed cases), 14.8% aged >80 years (208 of 1,408), 8.0% aged 70–79 years (312 of 3,918) 49.0% in critical cases (1,023 of 2,087) Next step: to help “buy time” for more diagnostic and therapeutic research before COVID‐19 becomes too widespread
Tian et al. (2020), China Retrospective study/Beijing Emergency Medical Service 262/47.5/48.5% male Real‐time RT‐PCR Respiratory specimens COVID‐19 infected patients/residents of Beijing: 92 (73.3%), patients had been to Wuhan: 50 (26.0%), close contact with confirmed cases: 116 (60.4%), no contact history: 21 (10.9%) Spectrum of disease: sever: 46 (17.6%); common: 216; (82.4%); mild: 192 (73.3%); nonpneumonia: 11 (4.2%); asymptomatic:13 (5.0%) Fever (82.1%), cough (45.8%), fatigue (26.3%), dyspnea (6.9%), headache (6.5%)/pulmonary infection, chronic cardiovascular disease and heart failure: 1, pulmonary infection and multiple chronic diseases: 1 Incubation: 6.7 days, illness onset to visit hospital: 4.5 days 3 (0.9%) Results: As of February 10, 45 (17.2%) patients have discharged
For COVID‐19 control: first step is prevent transmission at early stage, next steps is early isolation and quarantine of suspected subjects
Wang et al. (2020), China Retrospective cohort/Xi'an Jiaotong University First Affiliated Hospital, Nanchang University First Hospital and Xi'an No.8 Hospital of Xi'an Medical College 99 CT, artificial intelligence, inception migration‐learning model – Pathogen‐confirmed COVID‐19 patients Spectrum of disease: typical viral pneumonia or negative group: 55, confirmed nucleic acid testing or positive group: 44. CT (453 CT images): negative: 258, positive: 195 Viral pneumonia symptoms – – Screening:
The internal validation; accuracy: 82·9%, specificity: 80·5%, sensitivity: 84%
The external testing; accuracy: 73·1%, specificity: 67%, sensitivity: 74%
Algorithm prediction: a rate of 2 s per case on the graphic processing unit
Interpretation: the early diagnosis through fast, accurate, safe and noninvasive methods is crucial for control of virus
Yan et al. (2020), China Retrospective study/Tongji Hospital 375, 58.83, 58.7% males CT, machine learning model (a supervised XGBoost classifier) – Validated or suspected COVID‐19 patient/Wuhan residents (37.9%), familial cluster (6.4%), health workers (1.9%) Spectrum of disease: critical patients: 46.1%, severe cases: RR ≥ 30bpm or SPO2 ≤93% on rest Fever: 49.9%, cough: 13.9%, fatigue 3.7%, dyspnea 2.1%, shock: 2 174
16 + 1 Interpretation: the three indices‐based prognostic prediction model might predict themortality risk, recognition of critical cases, help to early identification, on time intervention, reducing mortality rate
Shi et al. (2020), China Retrospective/hospitals in Wuhan 81, 49–5, 42 (52%) men and 39 (48%) women Next‐generation sequencing or RT‐PCR, serial chest CT Throat swab specimens Confirmed COVID‐19 pneumonia patients/direct exposure to Huanan seafood market: 31 (38%), health‐care workers: 15 (19%), familial clusters: 7 (9%), any obvious history of exposure: 28 (35%) Spectrum of disease: mean number of involved lung segments: 10.5 (SD 6.4): group 1: subclinical patients (CT before symptom onset): 2.8 (3.3), group 2: ≤1 week after symptom onset/11.1 (5.4), group 3: >1–2 weeks/13.0 (5.7), group 4: >2–3 weeks/12.1 (5.9).
CT:
ALL:
bilateral abnormality: 64 [79%], peripheral 44 [54%], Ill‐defined 66 [81%], GGO: 53 [65%], mainly involving the right lower lobes: 225 [27%] of 849.
Group 1 (n=15): unilateral: 9 [60%]/multifocal 8 [53%]/GGO: 14 [93%]; Group 2 (n = 21): bilateral 19 [90%]/diffuse 11 [52%]/GGO predominance 17 [81%]; Group 3 (n = 30): GGO 17 [57%], consolidation/mixed patterns: 12 [40%]; Group 4 (n=15): consolidation/mixed patterns: 8 [53%].
Blood:
Group1: Lower CRP and AST Fever: 59 [73%], dry cough: 48 [59%] nonspecific symptoms:
dizziness:
2 [2%], diarrhea:
3 [4%], vomiting:
4 [5%], headache:
5 [6%], generalised weakness:
7 [9%]/chronic pulmonary disease (tuberculosis): 1, T2D: 1, hypertension/cardiovascular/erebrovascular disease: 1 Symptom onset and discharge of 23–2 days 3 (4%) By February 8, 2020, 62 (77%) patients discharged
Interpretation: COVID‐19 pneumonia include CT abnormalities that rapidly progress from focal unilateral to diffuse bilateral GGO coexisted with consolidations within 1–3 weeks (even in asymptomatic patients).
Early diagnosis through combined CT with clinical and laboratory findings
Bai et al. (2020), China Case study/The Fifth People's Hospital of Anyang 6, Patient 1: 20‐year‐old woman, patients 2–6: four women 42–57 years old CT, RT‐PCR Nasopharyngeal swabs Patient 1: met with Patients 2 and 3, and accompanied five relatives (Patients 2–6), Patients 2–6: no visited Wuhan or been in contact with any other people traveled to Wuhan Spectrum of disease: severe pneumonia: 2, moderate: others. A familial cluster of five patients with respiratory symptoms, 1 asymptomatic family member.
Blood:
all symptomatic patients: increased CRP, reduced lymphocyte.
CT: multifocal GGO: in all symptomatic patients, subsegmental consolidation/fibrosis: 1.
Patient 1: normal CT, CRP and lymphocyte count, RT‐PCR: negative, positive, negative.
Patients 2–6:
COVID‐19 confirmed.
PCR: positive for patients 2–6 within 1 day Fever: patients 2–6 19 days for patient 1 – Transmission: COVID‐19 transmission could transmit by an asymptomatic carrier S
Ai et al. (2020), China Cohort/Tangji hospital of Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei 1,014/51 ± 15/46% man Laboratory test, chest CT (7 day interval), RT‐PCR (Taq man one step): multiple assays (3 day interval) Throat swab Suspected of nCoV/China Positive CT: 88% (888/1,014), positive RT‐PCR: 59% (601/1,014).
Sensitivity of CT based on positive RT‐PCR: 97% (95%CI, 95–98%, 580/601).
Negative RT‐PCR/positive CT: 75% (308/413).
Initial positive CT consistent with COVID‐19 before the initial positive RT‐PCR: 60–93%.
Improvement in follow‐up CT before the RT‐PCR turning negative: 42% (24/57), CT: GGO: 46% [409/888], consolidations: 50% [447/888], bilateral findings: 90% [801/888] Fever, dry cough Initial + to − PCR: 5.1 ± 1.5 days,
Initial − to + PCR: 6.9 ± 2.3 days – Diagnosis: chest CT, as a highly sensitive method, could be considered as a primary tool for infection diagnosis in epidemic areas
Chen et al. (2020), China General Hospital of Central Theater Command, PLA 48/age; critically ill: 79.6 ± 12, sever: 63.9 ± 15, mild: 45.8 ± 14/31 males (77.1%) and 17 females (22.9%) Real‐time RT‐PCR, CT, GLMs analysis Serum, throat‐swab specimens Laboratory confirmed cases Spectrum of disease: mild: 21 (43.7%), severe 10 (20.8%), critically ill 17 (35.4%).
Blood: low/lower lymphocytes: severe and critically ill, higher neutrophils: critically ill, higher PCT: critically ill.
Parameters stand for the organ dysfunction; TnT, AST, ALT, CRE, and BUN: higher in critically ill patients.
PCR:
positive RNAaemia: (a) serum: 5 (10.4%) of critically ill, (b) throat‐swab: 48 positive.
IL‐6: value ≥100: 35.3% in critically ill, 10‐folds higher IL‐6 (cytokine storm): critically ill, RNAaemia positive: IL‐6 ≥100 (R = 0.902) Mild: fever, respiratory symptoms
Severe: shortness of breath, RR ≥ 30 times/min, oxygen saturation (resting state) ≤93%, PaO2/FiO2 ≤300 mmHg
Critically ill: respiratory failure, shock, multiple organ failure/diabetes: 12 [25%], hypertension: 23 [49.7%], heart disease: 8 [16.7%], mixed fungal infection: 27.1%, bacterial infection: (2.1%) – 3 Diagnosis; RNAaemia positive test confirmed critically ill patients
Prognosis: strong association between RNAaemia with cytokine storm can be applied to predict the poor prognosis
Therapeutic approach: in critically patients, IL‐6 should be considered as a therapeutic target
Fan et al. (2020), China Retrospective cohort study/three tertiary hospitals of Wenzhou 149/45.11 ± 13.35/81 (54.4%) males Laboratory test, PCR, CT Blood RT‐PCR confirmed patients: Hubei travel/residence history: N=85,
contact with people of Hubei: N=49, no traceable exposure history: N=15 Blood:
decreased oxygen saturation: 14(9.4%), leukopenia: 33 (24.2%), lymphopenia: 53 (35.6%), low platelets: 20 (13.4%), elevated CRP: 82 (55.0%), ALT/AST/CK and D‐dimer: less common.
CT: most involved lung segments: 6 and, GGO: 287 segments, mixed opacity: 637 segments, consolidation: 170 segments, lesions: more in the peripheral lung with a patchy form, normal CT on admission: N=17, negative CT: N=12, no significant difference between patients with or without exposure history Fever:
114/149, 76.5%,
Cough: 87/149, 58.4%,
Expectoration:
4 8/149, 32.2%, mild infection/cerebrovascular or digestive diseases:
52 (34.9%) Negative CT: 10 days, 6.8 (5.0) days 0 (0.0%) Diagnosis: a normal CT cannot exclude the diagnosis of COVID‐19
Fan et al. (2020), China Retrospective, case series/Chongqing University Three Gorges Hospital 51/45/32 (62.7%) men Laboratory test, CT Blood Confirmed COVID‐19: patients had been to Wuhan:
43 (84.3%), contact history of COVID‐19 patients: 4 (7.7%), no clear contact history:4 (7.7%) Spectrum of disease:
nonsevere patients: n = 44, severe patients: 7 (13.7%)
Blood: lymphopenia: 26 (51.0%), elevated CRP: 32 (62.7%).
CT:
GGO: 41 [80.4%], local consolidation of pneumonia:
17 [33.3%], pleural thickening: 20 (39.2%), small amount of pleural effusion:
7 (13.7%), streak shadow of lung: 8 (15.7%), multiple solid nodular shadow: 4 (7.8%), air bronchogram: 2 (3.9%), single lobe lesions: 2 (3.9%), multiple lobe lesions: 49 (96.1%) Fever:
43 [84.3%], cough:
38 [74.5%], dry cough with expectoration:
16 (31.4%), fatigue: 22 [43.1%], asthenia: 22 (43.1%), dyspnea: 11/DM: 4 [57.1%] 2–5 days 1 Therapy:
TCM decoction: 28 [54.9%], aerosol inhalation of recombinant human
Interferon a‐1b: 51 (100%), Lopinavir/Ritonavir: 51 [100%], Bacillus licheniformis capsules: 44 [86.3%], glucocorticoid treatment: 10 (19.6%)
Older patients with server COVID‐19 (N = 7)
Antibiotic treatment: 7 [100%], nutritional diet: 6 [85.7%), human albumin infusion: 4 (57.1%), immunoglobulin treatment: 4 (57.1%), mechanical ventilation: 6 [85.7%]
Results and interpretation: discharged 50 patients after 12 days, without the common clinical symptoms, with the significant increased lymphocyte (p = .008) and significant decreased CRP significantly (p < .001)
Fan et al. (2020), China Retrospective/Shanghai Public Health Clinical Center 148/50.5/49.3% females and 50.7% males Laboratory test, RT‐PCR and CT scanning Sera Confirmed SARS‐CoV‐2‐infected patients/a history of related epidemiology Blood:
elevated LDH, AST, ALT, GGT, TB, ALP:
35.1%, 21.6%, 18.2%, 17.6%, 6.1%, 4.1% in all patients; lower CD4+ and CD8+ T cells: (62.67%)/(56.1%) patients with abnormal liver function received more treatment compared with normal liver function (25%) (p = .009) Fever: (70.1%), cough: (45.3%), expectoration at admission:
(26.7%),
Abnormal liver functions at admission: 75 patients (50.7%) with moderate‐high degree fever (44%) in males,/chronic hepatitis B or C: N = 8 5 days (3–7) 1 Therapy:
Antibiotics (Levofloxacin, Meropenem, Moxifloxacin, Cephalosporin), interferon, antiviral drugs (Arbidol, Lopinavir/ritonavir, Dnrunavir)
Results and interpretation:
all patients discharged from the hospital.
Lopinavir/Ritonavir treatment can significantly alleviate the SARS‐CoV‐2‐induced liver function damage
Chen et al. (2020) China Retrospective/Zhongnan Hospital of Wuhan University, Wuhan 9/26–34/female Clinical records, laboratory results, CT scans Amniotic fluid, cord blood, and neonatal throat swab, breastmilk samples Pregnant women with laboratory‐confirmed COVID‐19 pneumonia and caesarean section in their third trimester/a history of epidemiological exposure to COVID‐19 Blood:
lymphopenia: N = 5, elevated CRP: N = 6, increased ALT and AST: N = 3, normal WBC count: N = 7, lower WBC: N = 1.
Nine mothers: none developed severe COVID‐19 pneumonia or dying as of Feb4.
Six mothers:
amniotic fluid, cord blood, neonatal throat swab, and breastmilk: negative for COVID‐19.
Nine livebirths:
with 1‐min Apgar score of 8–9 and a 5‐min Apgar score of 9–10, No neonatal asphyxia.
CT:
multiple patchy ground‐glass shadows: N=8 Fever: N = 7, cough N = 4, myalgia N = 3, sore throat: N = 2, malaise: N = 2, fetal distress:
N = 2/gestational hypertension:
N = 1, pre‐eclampsia: N = 1, influenza virus infection: N = 1 Short None Therapy: oxygen support (nasal cannula) and empirical antibiotic treatment: N = 9, antiviral therapy: N = 6
Interpretation: no evidence for intrauterine infection caused by vertical transmission in late pregnancy
Lim et al. (2020), Korea Public health center, Myongji Hospital 1/54/male PCR, CT Throat swab, sputum A Korean man living in Wuhan China/Virus transmission;
from index patient Patient A to Patients B, C, D@@ Spectrum of disease: mild respiratory symptoms.
CT:
small consolidation in right upper lobe, GGO in both lower lobes Chills, muscle pain 5–7 days – Therapy:
Lopinavir/Ritonavir
Results and interpretation:
significant decrease in β‐coronavirus viral loads due to the natural course of the healing process rather than administration of Lopinavir/Ritonavir, or both
Wu et al. (2020), China Retrospective/three Grade IIIA hospitals of Jiangsu 80/46.1/41 female (51.25%) Laboratory testing, real time RT‐PCR, CT Throat swab and/or nose swab, blood Confirmed COVID‐19 patients/with a history of epidemic in Wuhan and without contact with the seafood market Spectrum of disease:
mild: 28 (35.00%), moderate: 49 (61.25%), severe: 3 (3.75%), critically ill: none
Laboratory:
lower WBC: 36 (45.00%), lymphocytopenia: 26 (32.50%), lower platelets: 11 (13.75%), high CRP: 62 (77.50%), high ESR: 59 (73.75%), elevated PCT: 1 (1.25%).
Liver function:
increased ALT/AST: 3 (3.75%), lower albumin: 2 (2.50%).
Abnormal myocardial enzyme spectrum and increase of CK: 18 (22.50%).
Increased LDH: 17 (21.25%).
Renal function damage: 2 (2.50%).
Serious renal function damage: 1.
Hyperglycemia: 19 (23.17%).
Increased D‐dimer: 3 (3.75%).
9 kinds of respiratory pathogens and influenza A/B nucleic acids: all patients.
CT: abnormal: 55 (68.75%), bilateral pneumonia: 36 (45.00%), unilateral pneumonia: 19 (23.75%), normal: 25 (31.25%).
Organ damage: acute respiratory injury: 10 (12.50%), renal injury: 2 (2.50%) Fever:
63 (78.75%), cough: 51 (63.75%), shortness of breath: 30 (37.50%), muscle ache: 18 (22.50%), headache: 13 (16.25%) liver dysfunction: 3 (3.75%)/cardiovascular/cerebrovascular, endocrine, digestive, respiratory, malignancies and nervous system diseases: 38 (47.50%) 8.0 Not now Therapy:
all patients:
single antibiotic mainly Moxifloxacin and Ribavirin antiviral therapy, 12 (14.63%) patients:
methylprednisolone sodium succinate or methylprednisolone, 35 (43.75%) patients:
noninvasive ventilator, 1 patient: hemodialysis, 3 patients: TCM
Interpretation: 21 cases discharged from the hospital: With no obvious gender susceptivity, lower proportion of liver dysfunction, abnormal CT and higher frequency nucleic acid detection
Li et al. (2020), China Retrospective study/hospital in Wenzhou 175/46/92 women, 83/men Real‐time PCR, CT Respiratory tract samples or blood samples Confirmed COVID‐19/a history of exposure to the epidemic area: 57 (33%) patients Spectrum of disease:
COVID‐19:
mild: mild clinical manifestations, no pneumonia; moderate: respiratory symptoms, mild pneumonia, severe (37): pneumonia, ARDS with RR >30 times/min, oxygen saturation <93%; critical (3): pneumonia, shock, respiratory failure, and failures in other organs, nearly all patients: GGO
K+:
severe hypokalemia: 39 (higher body temperature, higher heart rate and RR, higher prevalence of dyspnea or tachypnea (p < .05)), hypokalemia 69, normokalemia patients 67.
Correlations: severity of hypokalemia with body temperature, CK, CK‐MB, LDH, and CRP (p < .01), 93% of severe/critically ill patients showed hypokalemia Cough, fever, pneumonia/hypertension: 28, diabetes: 12, other conditions:31 6 – Therapy:
1 severe hypokalemia patients;
3 g/day K+, 34 (SD = 4) g potassium during hospital stay
Good response of patients to K+ supplements when they inclined to recovery
Interpretation: hypokalemia is prevailing in COVID‐19 patients
Lan et al. (2020), China Case study/Zhongnan Hospital of Wuhan University, Wuhan 4, 30–36 years, 2 male RT‐PCR, thin‐section CT Throat swabs Medical personnel quarantined at home with COVID‐19 Spectrum of disease: mild to moderate
Results: (at admission); PCR positive: for all CT positive: for all GGO, or mixed GGO/consolidation
(after therapy); 2 consecutive negative RT‐PCR: all (after discharge); repeated RT‐PCR 5–13 days later: all positive Fever:3, cough: 3, both: 3 Symptom onset to recovery: 12–32 days – Therapy: antiviral treatment (75 mg of oseltamivir every 12 hr)
Resolved clinical symptoms and CT abnormalities: 3
Delicate patches of GGO: 1
Interpretation: possibility of at least a proportion of recovered patients act as virus carriers
Li et al. (2020), China Retrospective study/Sino‐French New Town area Tongji Hospital 47, 62, 28 (59.6%) men Real‐time RT‐PCR Throat‐swab specimens, sputum or endotracheal aspirates Patients with severe COVID‐19 Spectrum of disease: severe: 41 critical: 5(17.9%) men and 1 (5.3%) women
Common: oxygen saturation <93% after routine
Nasal oxygen supply: 3 men/1 woman
Blood: PCT: higher in men, N‐terminal‐pro brain natriuretic peptide: Higher in 16(57.1%) men/5 (26.3%) women,
Positive influenza A antibody: 5 men (17.9%) Fever: 34 [72.3%], cough: 36 [76.6%], myalgia: 5 [10.6%], fatigue: 7 [14.9%]/comorbidities: 30 (63.8%):
COPD, hypertension/CVD lower in men – 3.6% in men and 0 in women Therapy:
antibiotics applied more in the men than the women
Results and interpretation: 4 (21.1%) women/1 man (3.6%) discharged.
Possibility of sex differences in severe COVID‐19 patients, Men with more complicated clinical condition and worse outcomes
Han et al. (2020) Case study/People's Hospital in Wuwei A 47‐year‐old man/smoking for 20 years/no alcohol abuse RT‐PCR, CT Nasopharyngeal swab specimens Confirmed SARS‐CoV‐2/returned to Wuwei city on January 18 from Wuhan city by car Blood:
decreased lymphocytes, increased CRP, slightly elevated fibrinogen, neutrophil, LDH, and fibrinogen
PCR: positive for expression of RdRPN, N and E genes
CT: multiple patchy high‐density shadows scattered mainly in the border regions of lungs, solid changes, GGO changes, slightly thickened pleura Fever, cough productive of white phlegm, bosom frowsty, stuffy/runny noses, vertigo, fatigue, chest tightness, nausea, expiratory dyspnea, poor diet, lethargy/hypertension grade 2 and T2D – – Therapy:
combination therapy including:
Lopinavir/Ritonavir (800/200 mg daily), methylprednisolone (40 mg daily), recombinant human interferon α‐2b (10 million IU daily), ambroxol hydrochloride (60 mg daily) moxifloxacin hydrochloride (0.4 g daily), high flow humidification oxygen inhalation therapy, treatment of blood glucose, blood pressure, and rehydration therapy
Results interpretation: the persistent negative results of SARS‐CoV‐2 on days 6 and 7, normal TLC, lung lesions partially absorbed, The patient discharged. Laboratory tests like TLC are necessary, CT combined with RT‐PCR is helpful, Lopinavir/Ritonavir are effective after failure of methylprednisolone/interferon alfa‐2b
Liu et al. (2020), China Retrospective cohort and case study/Zhongnan Hospital of Wuhan University Dawu County People's Hospital 124 patients, 22 patients:
12 therapy (mean age 53), 10 control (mean age 58) CT, PCR Serum 124 confirmed COVID‐19 cases, 12 HCOV infected patients Blood: (Study 1) decreased platelet: 25 (20.2%), prolonged PT: 77 (62.1%), increased FIB: 27 (21.8%), and increased D‐dimer: 26 (21.0%)
Spectrum of disease: (study 2) severe cases: 6 mild cases: 4 critically ill: 2
CT: (study 2) Bilateral pneumonia: all Study 1: hypercoagulability
Study 2: cough: all shortness of breath: most of them, nausea and vomiting: 60.0%/DM, cardiovascular and cerebrovascular diseases: 4 patients from the DIP, 5 patients control group – 1 Therapy: Dipyridamole (150 mg in three separate doses for 7 consecutive days), antiviral (ribavirin, 0.5 g, Q12hr), corticoid (methylprednisolone sodium succinate, 40 mg, qd), oxygen therapy, nutritional support
Results and interpretation: significant increase in platelet/lymphocyte, significant decrease in D‐dimer levels
Discharged patients: 50% of severe cases and all 4 mild cases.
Dipyridamole adjunctive therapy could significantly reduce viral replication, inhibits hypercoagulability and improves immune recovery
|
|
tr
|
Study/region Study type/medical team Patient/median age/sex Diagnostic test Sample Inclusion criteria/residency Test results Most common symptoms/chronic disease Incubation period (day) Case fatality rate Diagnosis/prognosis/therapy
|
|
th
|
Study/region
|
|
th
|
Study type/medical team
|
|
th
|
Patient/median age/sex
|
|
th
|
Diagnostic test
|
|
th
|
Sample
|
|
th
|
Inclusion criteria/residency
|
|
th
|
Test results
|
|
th
|
Most common symptoms/chronic disease
|
|
th
|
Incubation period (day)
|
|
th
|
Case fatality rate
|
|
th
|
Diagnosis/prognosis/therapy
|
|
tr
|
Wu et al. (2020), China Retrospective study/Chinese Center for Disease Control and Prevention 72,314; subjects: confirmed cases 44,672 (62%), suspected cases 16,186 (22%), diagnosed cases 10,567 (15%), asymptomatic cases 889 (1%)/age N = 44,672: 80: 3% (1,408), 30–79: 87% (38,680), 20–29: 8% (3,619), 10–19: 1% (549), <10: 1% (416) PCR Throat swab samples Confirmed cases based on positive PCR, suspected cases based on symptoms and exposures only, clinically cases based on symptoms, exposures, and CT, asymptomatic cases diagnosis by positive PCR Spectrum of disease: (N = 44,415); mild: 81% (36,160), severe: 14% (6,168), critical: 5% (2,087) Cardiovascular disease: 10.5%, diabetes: 7.3%, chronic respiratory disease: 6.3%, hypertension: 6.0%, cancer: 5.6% About a week 2.3% (1,023 of 44,672 confirmed cases), 14.8% aged >80 years (208 of 1,408), 8.0% aged 70–79 years (312 of 3,918) 49.0% in critical cases (1,023 of 2,087) Next step: to help “buy time” for more diagnostic and therapeutic research before COVID‐19 becomes too widespread
|
|
td
|
Wu et al. (2020), China
|
|
td
|
Retrospective study/Chinese Center for Disease Control and Prevention
|
|
td
|
72,314; subjects: confirmed cases 44,672 (62%), suspected cases 16,186 (22%), diagnosed cases 10,567 (15%), asymptomatic cases 889 (1%)/age N = 44,672: 80: 3% (1,408), 30–79: 87% (38,680), 20–29: 8% (3,619), 10–19: 1% (549), <10: 1% (416)
|
|
td
|
PCR
|
|
td
|
Throat swab samples
|
|
td
|
Confirmed cases based on positive PCR, suspected cases based on symptoms and exposures only, clinically cases based on symptoms, exposures, and CT, asymptomatic cases diagnosis by positive PCR
|
|
td
|
Spectrum of disease: (N = 44,415); mild: 81% (36,160), severe: 14% (6,168), critical: 5% (2,087)
|
|
td
|
Cardiovascular disease: 10.5%, diabetes: 7.3%, chronic respiratory disease: 6.3%, hypertension: 6.0%, cancer: 5.6%
|
|
td
|
About a week
|
|
td
|
2.3% (1,023 of 44,672 confirmed cases), 14.8% aged >80 years (208 of 1,408), 8.0% aged 70–79 years (312 of 3,918) 49.0% in critical cases (1,023 of 2,087)
|
|
td
|
Next step: to help “buy time” for more diagnostic and therapeutic research before COVID‐19 becomes too widespread
|
|
tr
|
Tian et al. (2020), China Retrospective study/Beijing Emergency Medical Service 262/47.5/48.5% male Real‐time RT‐PCR Respiratory specimens COVID‐19 infected patients/residents of Beijing: 92 (73.3%), patients had been to Wuhan: 50 (26.0%), close contact with confirmed cases: 116 (60.4%), no contact history: 21 (10.9%) Spectrum of disease: sever: 46 (17.6%); common: 216; (82.4%); mild: 192 (73.3%); nonpneumonia: 11 (4.2%); asymptomatic:13 (5.0%) Fever (82.1%), cough (45.8%), fatigue (26.3%), dyspnea (6.9%), headache (6.5%)/pulmonary infection, chronic cardiovascular disease and heart failure: 1, pulmonary infection and multiple chronic diseases: 1 Incubation: 6.7 days, illness onset to visit hospital: 4.5 days 3 (0.9%) Results: As of February 10, 45 (17.2%) patients have discharged
For COVID‐19 control: first step is prevent transmission at early stage, next steps is early isolation and quarantine of suspected subjects
|
|
td
|
Tian et al. (2020), China
|
|
td
|
Retrospective study/Beijing Emergency Medical Service
|
|
td
|
262/47.5/48.5% male
|
|
td
|
Real‐time RT‐PCR
|
|
td
|
Respiratory specimens
|
|
td
|
COVID‐19 infected patients/residents of Beijing: 92 (73.3%), patients had been to Wuhan: 50 (26.0%), close contact with confirmed cases: 116 (60.4%), no contact history: 21 (10.9%)
|
|
td
|
Spectrum of disease: sever: 46 (17.6%); common: 216; (82.4%); mild: 192 (73.3%); nonpneumonia: 11 (4.2%); asymptomatic:13 (5.0%)
|
|
td
|
Fever (82.1%), cough (45.8%), fatigue (26.3%), dyspnea (6.9%), headache (6.5%)/pulmonary infection, chronic cardiovascular disease and heart failure: 1, pulmonary infection and multiple chronic diseases: 1
|
|
td
|
Incubation: 6.7 days, illness onset to visit hospital: 4.5 days
|
|
td
|
3 (0.9%)
|
|
td
|
Results: As of February 10, 45 (17.2%) patients have discharged
For COVID‐19 control: first step is prevent transmission at early stage, next steps is early isolation and quarantine of suspected subjects
|
|
p
|
Results: As of February 10, 45 (17.2%) patients have discharged
|
|
p
|
For COVID‐19 control: first step is prevent transmission at early stage, next steps is early isolation and quarantine of suspected subjects
|
|
tr
|
Wang et al. (2020), China Retrospective cohort/Xi'an Jiaotong University First Affiliated Hospital, Nanchang University First Hospital and Xi'an No.8 Hospital of Xi'an Medical College 99 CT, artificial intelligence, inception migration‐learning model – Pathogen‐confirmed COVID‐19 patients Spectrum of disease: typical viral pneumonia or negative group: 55, confirmed nucleic acid testing or positive group: 44. CT (453 CT images): negative: 258, positive: 195 Viral pneumonia symptoms – – Screening:
The internal validation; accuracy: 82·9%, specificity: 80·5%, sensitivity: 84%
The external testing; accuracy: 73·1%, specificity: 67%, sensitivity: 74%
Algorithm prediction: a rate of 2 s per case on the graphic processing unit
Interpretation: the early diagnosis through fast, accurate, safe and noninvasive methods is crucial for control of virus
|
|
td
|
Wang et al. (2020), China
|
|
td
|
Retrospective cohort/Xi'an Jiaotong University First Affiliated Hospital, Nanchang University First Hospital and Xi'an No.8 Hospital of Xi'an Medical College
|
|
td
|
99
|
|
td
|
CT, artificial intelligence, inception migration‐learning model
|
|
td
|
–
|
|
td
|
Pathogen‐confirmed COVID‐19 patients
|
|
td
|
Spectrum of disease: typical viral pneumonia or negative group: 55, confirmed nucleic acid testing or positive group: 44. CT (453 CT images): negative: 258, positive: 195
|
|
td
|
Viral pneumonia symptoms
|
|
td
|
–
|
|
td
|
–
|
|
td
|
Screening:
The internal validation; accuracy: 82·9%, specificity: 80·5%, sensitivity: 84%
The external testing; accuracy: 73·1%, specificity: 67%, sensitivity: 74%
Algorithm prediction: a rate of 2 s per case on the graphic processing unit
Interpretation: the early diagnosis through fast, accurate, safe and noninvasive methods is crucial for control of virus
|
|
p
|
Screening:
|
|
p
|
The internal validation; accuracy: 82·9%, specificity: 80·5%, sensitivity: 84%
|
|
p
|
The external testing; accuracy: 73·1%, specificity: 67%, sensitivity: 74%
|
|
p
|
Algorithm prediction: a rate of 2 s per case on the graphic processing unit
|
|
p
|
Interpretation: the early diagnosis through fast, accurate, safe and noninvasive methods is crucial for control of virus
|
|
tr
|
Yan et al. (2020), China Retrospective study/Tongji Hospital 375, 58.83, 58.7% males CT, machine learning model (a supervised XGBoost classifier) – Validated or suspected COVID‐19 patient/Wuhan residents (37.9%), familial cluster (6.4%), health workers (1.9%) Spectrum of disease: critical patients: 46.1%, severe cases: RR ≥ 30bpm or SPO2 ≤93% on rest Fever: 49.9%, cough: 13.9%, fatigue 3.7%, dyspnea 2.1%, shock: 2 174
16 + 1 Interpretation: the three indices‐based prognostic prediction model might predict themortality risk, recognition of critical cases, help to early identification, on time intervention, reducing mortality rate
|
|
td
|
Yan et al. (2020), China
|
|
td
|
Retrospective study/Tongji Hospital
|
|
td
|
375, 58.83, 58.7% males
|
|
td
|
CT, machine learning model (a supervised XGBoost classifier)
|
|
td
|
–
|
|
td
|
Validated or suspected COVID‐19 patient/Wuhan residents (37.9%), familial cluster (6.4%), health workers (1.9%)
|
|
td
|
Spectrum of disease: critical patients: 46.1%, severe cases: RR ≥ 30bpm or SPO2 ≤93% on rest
|
|
td
|
Fever: 49.9%, cough: 13.9%, fatigue 3.7%, dyspnea 2.1%, shock: 2
|
|
td
|
174
16 + 1
|
|
p
|
174
|
|
p
|
16 + 1
|
|
td
|
Interpretation: the three indices‐based prognostic prediction model might predict themortality risk, recognition of critical cases, help to early identification, on time intervention, reducing mortality rate
|
|
tr
|
Shi et al. (2020), China Retrospective/hospitals in Wuhan 81, 49–5, 42 (52%) men and 39 (48%) women Next‐generation sequencing or RT‐PCR, serial chest CT Throat swab specimens Confirmed COVID‐19 pneumonia patients/direct exposure to Huanan seafood market: 31 (38%), health‐care workers: 15 (19%), familial clusters: 7 (9%), any obvious history of exposure: 28 (35%) Spectrum of disease: mean number of involved lung segments: 10.5 (SD 6.4): group 1: subclinical patients (CT before symptom onset): 2.8 (3.3), group 2: ≤1 week after symptom onset/11.1 (5.4), group 3: >1–2 weeks/13.0 (5.7), group 4: >2–3 weeks/12.1 (5.9).
CT:
ALL:
bilateral abnormality: 64 [79%], peripheral 44 [54%], Ill‐defined 66 [81%], GGO: 53 [65%], mainly involving the right lower lobes: 225 [27%] of 849.
Group 1 (n=15): unilateral: 9 [60%]/multifocal 8 [53%]/GGO: 14 [93%]; Group 2 (n = 21): bilateral 19 [90%]/diffuse 11 [52%]/GGO predominance 17 [81%]; Group 3 (n = 30): GGO 17 [57%], consolidation/mixed patterns: 12 [40%]; Group 4 (n=15): consolidation/mixed patterns: 8 [53%].
Blood:
Group1: Lower CRP and AST Fever: 59 [73%], dry cough: 48 [59%] nonspecific symptoms:
dizziness:
2 [2%], diarrhea:
3 [4%], vomiting:
4 [5%], headache:
5 [6%], generalised weakness:
7 [9%]/chronic pulmonary disease (tuberculosis): 1, T2D: 1, hypertension/cardiovascular/erebrovascular disease: 1 Symptom onset and discharge of 23–2 days 3 (4%) By February 8, 2020, 62 (77%) patients discharged
Interpretation: COVID‐19 pneumonia include CT abnormalities that rapidly progress from focal unilateral to diffuse bilateral GGO coexisted with consolidations within 1–3 weeks (even in asymptomatic patients).
Early diagnosis through combined CT with clinical and laboratory findings
|
|
td
|
Shi et al. (2020), China
|
|
td
|
Retrospective/hospitals in Wuhan
|
|
td
|
81, 49–5, 42 (52%) men and 39 (48%) women
|
|
td
|
Next‐generation sequencing or RT‐PCR, serial chest CT
|
|
td
|
Throat swab specimens
|
|
td
|
Confirmed COVID‐19 pneumonia patients/direct exposure to Huanan seafood market: 31 (38%), health‐care workers: 15 (19%), familial clusters: 7 (9%), any obvious history of exposure: 28 (35%)
|
|
td
|
Spectrum of disease: mean number of involved lung segments: 10.5 (SD 6.4): group 1: subclinical patients (CT before symptom onset): 2.8 (3.3), group 2: ≤1 week after symptom onset/11.1 (5.4), group 3: >1–2 weeks/13.0 (5.7), group 4: >2–3 weeks/12.1 (5.9).
CT:
ALL:
bilateral abnormality: 64 [79%], peripheral 44 [54%], Ill‐defined 66 [81%], GGO: 53 [65%], mainly involving the right lower lobes: 225 [27%] of 849.
Group 1 (n=15): unilateral: 9 [60%]/multifocal 8 [53%]/GGO: 14 [93%]; Group 2 (n = 21): bilateral 19 [90%]/diffuse 11 [52%]/GGO predominance 17 [81%]; Group 3 (n = 30): GGO 17 [57%], consolidation/mixed patterns: 12 [40%]; Group 4 (n=15): consolidation/mixed patterns: 8 [53%].
Blood:
Group1: Lower CRP and AST
|
|
p
|
Spectrum of disease: mean number of involved lung segments: 10.5 (SD 6.4): group 1: subclinical patients (CT before symptom onset): 2.8 (3.3), group 2: ≤1 week after symptom onset/11.1 (5.4), group 3: >1–2 weeks/13.0 (5.7), group 4: >2–3 weeks/12.1 (5.9).
|
|
p
|
CT:
|
|
p
|
ALL:
|
|
p
|
bilateral abnormality: 64 [79%], peripheral 44 [54%], Ill‐defined 66 [81%], GGO: 53 [65%], mainly involving the right lower lobes: 225 [27%] of 849.
|
|
p
|
Group 1 (n=15): unilateral: 9 [60%]/multifocal 8 [53%]/GGO: 14 [93%]; Group 2 (n = 21): bilateral 19 [90%]/diffuse 11 [52%]/GGO predominance 17 [81%]; Group 3 (n = 30): GGO 17 [57%], consolidation/mixed patterns: 12 [40%]; Group 4 (n=15): consolidation/mixed patterns: 8 [53%].
|
|
p
|
Blood:
|
|
p
|
Group1: Lower CRP and AST
|
|
td
|
Fever: 59 [73%], dry cough: 48 [59%] nonspecific symptoms:
dizziness:
2 [2%], diarrhea:
3 [4%], vomiting:
4 [5%], headache:
5 [6%], generalised weakness:
7 [9%]/chronic pulmonary disease (tuberculosis): 1, T2D: 1, hypertension/cardiovascular/erebrovascular disease: 1
|
|
p
|
Fever: 59 [73%], dry cough: 48 [59%] nonspecific symptoms:
|
|
p
|
dizziness:
|
|
p
|
2 [2%], diarrhea:
|
|
p
|
3 [4%], vomiting:
|
|
p
|
4 [5%], headache:
|
|
p
|
5 [6%], generalised weakness:
|
|
p
|
7 [9%]/chronic pulmonary disease (tuberculosis): 1, T2D: 1, hypertension/cardiovascular/erebrovascular disease: 1
|
|
td
|
Symptom onset and discharge of 23–2 days
|
|
td
|
3 (4%)
|
|
td
|
By February 8, 2020, 62 (77%) patients discharged
Interpretation: COVID‐19 pneumonia include CT abnormalities that rapidly progress from focal unilateral to diffuse bilateral GGO coexisted with consolidations within 1–3 weeks (even in asymptomatic patients).
Early diagnosis through combined CT with clinical and laboratory findings
|
|
p
|
By February 8, 2020, 62 (77%) patients discharged
|
|
p
|
Interpretation: COVID‐19 pneumonia include CT abnormalities that rapidly progress from focal unilateral to diffuse bilateral GGO coexisted with consolidations within 1–3 weeks (even in asymptomatic patients).
|
|
p
|
Early diagnosis through combined CT with clinical and laboratory findings
|
|
tr
|
Bai et al. (2020), China Case study/The Fifth People's Hospital of Anyang 6, Patient 1: 20‐year‐old woman, patients 2–6: four women 42–57 years old CT, RT‐PCR Nasopharyngeal swabs Patient 1: met with Patients 2 and 3, and accompanied five relatives (Patients 2–6), Patients 2–6: no visited Wuhan or been in contact with any other people traveled to Wuhan Spectrum of disease: severe pneumonia: 2, moderate: others. A familial cluster of five patients with respiratory symptoms, 1 asymptomatic family member.
Blood:
all symptomatic patients: increased CRP, reduced lymphocyte.
CT: multifocal GGO: in all symptomatic patients, subsegmental consolidation/fibrosis: 1.
Patient 1: normal CT, CRP and lymphocyte count, RT‐PCR: negative, positive, negative.
Patients 2–6:
COVID‐19 confirmed.
PCR: positive for patients 2–6 within 1 day Fever: patients 2–6 19 days for patient 1 – Transmission: COVID‐19 transmission could transmit by an asymptomatic carrier S
|
|
td
|
Bai et al. (2020), China
|
|
td
|
Case study/The Fifth People's Hospital of Anyang
|
|
td
|
6, Patient 1: 20‐year‐old woman, patients 2–6: four women 42–57 years old
|
|
td
|
CT, RT‐PCR
|
|
td
|
Nasopharyngeal swabs
|
|
td
|
Patient 1: met with Patients 2 and 3, and accompanied five relatives (Patients 2–6), Patients 2–6: no visited Wuhan or been in contact with any other people traveled to Wuhan
|
|
td
|
Spectrum of disease: severe pneumonia: 2, moderate: others. A familial cluster of five patients with respiratory symptoms, 1 asymptomatic family member.
Blood:
all symptomatic patients: increased CRP, reduced lymphocyte.
CT: multifocal GGO: in all symptomatic patients, subsegmental consolidation/fibrosis: 1.
Patient 1: normal CT, CRP and lymphocyte count, RT‐PCR: negative, positive, negative.
Patients 2–6:
COVID‐19 confirmed.
PCR: positive for patients 2–6 within 1 day
|
|
p
|
Spectrum of disease: severe pneumonia: 2, moderate: others. A familial cluster of five patients with respiratory symptoms, 1 asymptomatic family member.
|
|
p
|
Blood:
|
|
p
|
all symptomatic patients: increased CRP, reduced lymphocyte.
|
|
p
|
CT: multifocal GGO: in all symptomatic patients, subsegmental consolidation/fibrosis: 1.
|
|
p
|
Patient 1: normal CT, CRP and lymphocyte count, RT‐PCR: negative, positive, negative.
|
|
p
|
Patients 2–6:
|
|
p
|
COVID‐19 confirmed.
|
|
p
|
PCR: positive for patients 2–6 within 1 day
|
|
td
|
Fever: patients 2–6
|
|
td
|
19 days for patient 1
|
|
td
|
–
|
|
td
|
Transmission: COVID‐19 transmission could transmit by an asymptomatic carrier S
|
|
tr
|
Ai et al. (2020), China Cohort/Tangji hospital of Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei 1,014/51 ± 15/46% man Laboratory test, chest CT (7 day interval), RT‐PCR (Taq man one step): multiple assays (3 day interval) Throat swab Suspected of nCoV/China Positive CT: 88% (888/1,014), positive RT‐PCR: 59% (601/1,014).
Sensitivity of CT based on positive RT‐PCR: 97% (95%CI, 95–98%, 580/601).
Negative RT‐PCR/positive CT: 75% (308/413).
Initial positive CT consistent with COVID‐19 before the initial positive RT‐PCR: 60–93%.
Improvement in follow‐up CT before the RT‐PCR turning negative: 42% (24/57), CT: GGO: 46% [409/888], consolidations: 50% [447/888], bilateral findings: 90% [801/888] Fever, dry cough Initial + to − PCR: 5.1 ± 1.5 days,
Initial − to + PCR: 6.9 ± 2.3 days – Diagnosis: chest CT, as a highly sensitive method, could be considered as a primary tool for infection diagnosis in epidemic areas
|
|
td
|
Ai et al. (2020), China
|
|
td
|
Cohort/Tangji hospital of Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei
|
|
td
|
1,014/51 ± 15/46% man
|
|
td
|
Laboratory test, chest CT (7 day interval), RT‐PCR (Taq man one step): multiple assays (3 day interval)
|
|
td
|
Throat swab
|
|
td
|
Suspected of nCoV/China
|
|
td
|
Positive CT: 88% (888/1,014), positive RT‐PCR: 59% (601/1,014).
Sensitivity of CT based on positive RT‐PCR: 97% (95%CI, 95–98%, 580/601).
Negative RT‐PCR/positive CT: 75% (308/413).
Initial positive CT consistent with COVID‐19 before the initial positive RT‐PCR: 60–93%.
Improvement in follow‐up CT before the RT‐PCR turning negative: 42% (24/57), CT: GGO: 46% [409/888], consolidations: 50% [447/888], bilateral findings: 90% [801/888]
|
|
p
|
Positive CT: 88% (888/1,014), positive RT‐PCR: 59% (601/1,014).
|
|
p
|
Sensitivity of CT based on positive RT‐PCR: 97% (95%CI, 95–98%, 580/601).
|
|
p
|
Negative RT‐PCR/positive CT: 75% (308/413).
|
|
p
|
Initial positive CT consistent with COVID‐19 before the initial positive RT‐PCR: 60–93%.
|
|
p
|
Improvement in follow‐up CT before the RT‐PCR turning negative: 42% (24/57), CT: GGO: 46% [409/888], consolidations: 50% [447/888], bilateral findings: 90% [801/888]
|
|
td
|
Fever, dry cough
|
|
td
|
Initial + to − PCR: 5.1 ± 1.5 days,
Initial − to + PCR: 6.9 ± 2.3 days
|
|
p
|
Initial + to − PCR: 5.1 ± 1.5 days,
|
|
p
|
Initial − to + PCR: 6.9 ± 2.3 days
|
|
td
|
–
|
|
td
|
Diagnosis: chest CT, as a highly sensitive method, could be considered as a primary tool for infection diagnosis in epidemic areas
|
|
tr
|
Chen et al. (2020), China General Hospital of Central Theater Command, PLA 48/age; critically ill: 79.6 ± 12, sever: 63.9 ± 15, mild: 45.8 ± 14/31 males (77.1%) and 17 females (22.9%) Real‐time RT‐PCR, CT, GLMs analysis Serum, throat‐swab specimens Laboratory confirmed cases Spectrum of disease: mild: 21 (43.7%), severe 10 (20.8%), critically ill 17 (35.4%).
Blood: low/lower lymphocytes: severe and critically ill, higher neutrophils: critically ill, higher PCT: critically ill.
Parameters stand for the organ dysfunction; TnT, AST, ALT, CRE, and BUN: higher in critically ill patients.
PCR:
positive RNAaemia: (a) serum: 5 (10.4%) of critically ill, (b) throat‐swab: 48 positive.
IL‐6: value ≥100: 35.3% in critically ill, 10‐folds higher IL‐6 (cytokine storm): critically ill, RNAaemia positive: IL‐6 ≥100 (R = 0.902) Mild: fever, respiratory symptoms
Severe: shortness of breath, RR ≥ 30 times/min, oxygen saturation (resting state) ≤93%, PaO2/FiO2 ≤300 mmHg
Critically ill: respiratory failure, shock, multiple organ failure/diabetes: 12 [25%], hypertension: 23 [49.7%], heart disease: 8 [16.7%], mixed fungal infection: 27.1%, bacterial infection: (2.1%) – 3 Diagnosis; RNAaemia positive test confirmed critically ill patients
Prognosis: strong association between RNAaemia with cytokine storm can be applied to predict the poor prognosis
Therapeutic approach: in critically patients, IL‐6 should be considered as a therapeutic target
|
|
td
|
Chen et al. (2020), China
|
|
td
|
General Hospital of Central Theater Command, PLA
|
|
td
|
48/age; critically ill: 79.6 ± 12, sever: 63.9 ± 15, mild: 45.8 ± 14/31 males (77.1%) and 17 females (22.9%)
|
|
td
|
Real‐time RT‐PCR, CT, GLMs analysis
|
|
td
|
Serum, throat‐swab specimens
|
|
td
|
Laboratory confirmed cases
|
|
td
|
Spectrum of disease: mild: 21 (43.7%), severe 10 (20.8%), critically ill 17 (35.4%).
Blood: low/lower lymphocytes: severe and critically ill, higher neutrophils: critically ill, higher PCT: critically ill.
Parameters stand for the organ dysfunction; TnT, AST, ALT, CRE, and BUN: higher in critically ill patients.
PCR:
positive RNAaemia: (a) serum: 5 (10.4%) of critically ill, (b) throat‐swab: 48 positive.
IL‐6: value ≥100: 35.3% in critically ill, 10‐folds higher IL‐6 (cytokine storm): critically ill, RNAaemia positive: IL‐6 ≥100 (R = 0.902)
|
|
p
|
Spectrum of disease: mild: 21 (43.7%), severe 10 (20.8%), critically ill 17 (35.4%).
|
|
p
|
Blood: low/lower lymphocytes: severe and critically ill, higher neutrophils: critically ill, higher PCT: critically ill.
|
|
p
|
Parameters stand for the organ dysfunction; TnT, AST, ALT, CRE, and BUN: higher in critically ill patients.
|
|
p
|
PCR:
|
|
p
|
positive RNAaemia: (a) serum: 5 (10.4%) of critically ill, (b) throat‐swab: 48 positive.
|
|
p
|
IL‐6: value ≥100: 35.3% in critically ill, 10‐folds higher IL‐6 (cytokine storm): critically ill, RNAaemia positive: IL‐6 ≥100 (R = 0.902)
|
|
td
|
Mild: fever, respiratory symptoms
Severe: shortness of breath, RR ≥ 30 times/min, oxygen saturation (resting state) ≤93%, PaO2/FiO2 ≤300 mmHg
Critically ill: respiratory failure, shock, multiple organ failure/diabetes: 12 [25%], hypertension: 23 [49.7%], heart disease: 8 [16.7%], mixed fungal infection: 27.1%, bacterial infection: (2.1%)
|
|
p
|
Mild: fever, respiratory symptoms
|
|
p
|
Severe: shortness of breath, RR ≥ 30 times/min, oxygen saturation (resting state) ≤93%, PaO2/FiO2 ≤300 mmHg
|
|
p
|
Critically ill: respiratory failure, shock, multiple organ failure/diabetes: 12 [25%], hypertension: 23 [49.7%], heart disease: 8 [16.7%], mixed fungal infection: 27.1%, bacterial infection: (2.1%)
|
|
td
|
–
|
|
td
|
3
|
|
td
|
Diagnosis; RNAaemia positive test confirmed critically ill patients
Prognosis: strong association between RNAaemia with cytokine storm can be applied to predict the poor prognosis
Therapeutic approach: in critically patients, IL‐6 should be considered as a therapeutic target
|
|
p
|
Diagnosis; RNAaemia positive test confirmed critically ill patients
|
|
p
|
Prognosis: strong association between RNAaemia with cytokine storm can be applied to predict the poor prognosis
|
|
p
|
Therapeutic approach: in critically patients, IL‐6 should be considered as a therapeutic target
|
|
tr
|
Fan et al. (2020), China Retrospective cohort study/three tertiary hospitals of Wenzhou 149/45.11 ± 13.35/81 (54.4%) males Laboratory test, PCR, CT Blood RT‐PCR confirmed patients: Hubei travel/residence history: N=85,
contact with people of Hubei: N=49, no traceable exposure history: N=15 Blood:
decreased oxygen saturation: 14(9.4%), leukopenia: 33 (24.2%), lymphopenia: 53 (35.6%), low platelets: 20 (13.4%), elevated CRP: 82 (55.0%), ALT/AST/CK and D‐dimer: less common.
CT: most involved lung segments: 6 and, GGO: 287 segments, mixed opacity: 637 segments, consolidation: 170 segments, lesions: more in the peripheral lung with a patchy form, normal CT on admission: N=17, negative CT: N=12, no significant difference between patients with or without exposure history Fever:
114/149, 76.5%,
Cough: 87/149, 58.4%,
Expectoration:
4 8/149, 32.2%, mild infection/cerebrovascular or digestive diseases:
52 (34.9%) Negative CT: 10 days, 6.8 (5.0) days 0 (0.0%) Diagnosis: a normal CT cannot exclude the diagnosis of COVID‐19
|
|
td
|
Fan et al. (2020), China
|
|
td
|
Retrospective cohort study/three tertiary hospitals of Wenzhou
|
|
td
|
149/45.11 ± 13.35/81 (54.4%) males
|
|
td
|
Laboratory test, PCR, CT
|
|
td
|
Blood
|
|
td
|
RT‐PCR confirmed patients: Hubei travel/residence history: N=85,
contact with people of Hubei: N=49, no traceable exposure history: N=15
|
|
p
|
RT‐PCR confirmed patients: Hubei travel/residence history: N=85,
|
|
p
|
contact with people of Hubei: N=49, no traceable exposure history: N=15
|
|
td
|
Blood:
decreased oxygen saturation: 14(9.4%), leukopenia: 33 (24.2%), lymphopenia: 53 (35.6%), low platelets: 20 (13.4%), elevated CRP: 82 (55.0%), ALT/AST/CK and D‐dimer: less common.
CT: most involved lung segments: 6 and, GGO: 287 segments, mixed opacity: 637 segments, consolidation: 170 segments, lesions: more in the peripheral lung with a patchy form, normal CT on admission: N=17, negative CT: N=12, no significant difference between patients with or without exposure history
|
|
p
|
Blood:
|
|
p
|
decreased oxygen saturation: 14(9.4%), leukopenia: 33 (24.2%), lymphopenia: 53 (35.6%), low platelets: 20 (13.4%), elevated CRP: 82 (55.0%), ALT/AST/CK and D‐dimer: less common.
|
|
p
|
CT: most involved lung segments: 6 and, GGO: 287 segments, mixed opacity: 637 segments, consolidation: 170 segments, lesions: more in the peripheral lung with a patchy form, normal CT on admission: N=17, negative CT: N=12, no significant difference between patients with or without exposure history
|
|
td
|
Fever:
114/149, 76.5%,
Cough: 87/149, 58.4%,
Expectoration:
4 8/149, 32.2%, mild infection/cerebrovascular or digestive diseases:
52 (34.9%)
|
|
p
|
Fever:
|
|
p
|
114/149, 76.5%,
|
|
p
|
Cough: 87/149, 58.4%,
|
|
p
|
Expectoration:
|
|
p
|
4 8/149, 32.2%, mild infection/cerebrovascular or digestive diseases:
|
|
p
|
52 (34.9%)
|
|
td
|
Negative CT: 10 days, 6.8 (5.0) days
|
|
td
|
0 (0.0%)
|
|
td
|
Diagnosis: a normal CT cannot exclude the diagnosis of COVID‐19
|
|
tr
|
Fan et al. (2020), China Retrospective, case series/Chongqing University Three Gorges Hospital 51/45/32 (62.7%) men Laboratory test, CT Blood Confirmed COVID‐19: patients had been to Wuhan:
43 (84.3%), contact history of COVID‐19 patients: 4 (7.7%), no clear contact history:4 (7.7%) Spectrum of disease:
nonsevere patients: n = 44, severe patients: 7 (13.7%)
Blood: lymphopenia: 26 (51.0%), elevated CRP: 32 (62.7%).
CT:
GGO: 41 [80.4%], local consolidation of pneumonia:
17 [33.3%], pleural thickening: 20 (39.2%), small amount of pleural effusion:
7 (13.7%), streak shadow of lung: 8 (15.7%), multiple solid nodular shadow: 4 (7.8%), air bronchogram: 2 (3.9%), single lobe lesions: 2 (3.9%), multiple lobe lesions: 49 (96.1%) Fever:
43 [84.3%], cough:
38 [74.5%], dry cough with expectoration:
16 (31.4%), fatigue: 22 [43.1%], asthenia: 22 (43.1%), dyspnea: 11/DM: 4 [57.1%] 2–5 days 1 Therapy:
TCM decoction: 28 [54.9%], aerosol inhalation of recombinant human
Interferon a‐1b: 51 (100%), Lopinavir/Ritonavir: 51 [100%], Bacillus licheniformis capsules: 44 [86.3%], glucocorticoid treatment: 10 (19.6%)
Older patients with server COVID‐19 (N = 7)
Antibiotic treatment: 7 [100%], nutritional diet: 6 [85.7%), human albumin infusion: 4 (57.1%), immunoglobulin treatment: 4 (57.1%), mechanical ventilation: 6 [85.7%]
Results and interpretation: discharged 50 patients after 12 days, without the common clinical symptoms, with the significant increased lymphocyte (p = .008) and significant decreased CRP significantly (p < .001)
|
|
td
|
Fan et al. (2020), China
|
|
td
|
Retrospective, case series/Chongqing University Three Gorges Hospital
|
|
td
|
51/45/32 (62.7%) men
|
|
td
|
Laboratory test, CT
|
|
td
|
Blood
|
|
td
|
Confirmed COVID‐19: patients had been to Wuhan:
43 (84.3%), contact history of COVID‐19 patients: 4 (7.7%), no clear contact history:4 (7.7%)
|
|
p
|
Confirmed COVID‐19: patients had been to Wuhan:
|
|
p
|
43 (84.3%), contact history of COVID‐19 patients: 4 (7.7%), no clear contact history:4 (7.7%)
|
|
td
|
Spectrum of disease:
nonsevere patients: n = 44, severe patients: 7 (13.7%)
Blood: lymphopenia: 26 (51.0%), elevated CRP: 32 (62.7%).
CT:
GGO: 41 [80.4%], local consolidation of pneumonia:
17 [33.3%], pleural thickening: 20 (39.2%), small amount of pleural effusion:
7 (13.7%), streak shadow of lung: 8 (15.7%), multiple solid nodular shadow: 4 (7.8%), air bronchogram: 2 (3.9%), single lobe lesions: 2 (3.9%), multiple lobe lesions: 49 (96.1%)
|
|
p
|
Spectrum of disease:
|
|
p
|
nonsevere patients: n = 44, severe patients: 7 (13.7%)
|
|
p
|
Blood: lymphopenia: 26 (51.0%), elevated CRP: 32 (62.7%).
|
|
p
|
CT:
|
|
p
|
GGO: 41 [80.4%], local consolidation of pneumonia:
|
|
p
|
17 [33.3%], pleural thickening: 20 (39.2%), small amount of pleural effusion:
|
|
p
|
7 (13.7%), streak shadow of lung: 8 (15.7%), multiple solid nodular shadow: 4 (7.8%), air bronchogram: 2 (3.9%), single lobe lesions: 2 (3.9%), multiple lobe lesions: 49 (96.1%)
|
|
td
|
Fever:
43 [84.3%], cough:
38 [74.5%], dry cough with expectoration:
16 (31.4%), fatigue: 22 [43.1%], asthenia: 22 (43.1%), dyspnea: 11/DM: 4 [57.1%]
|
|
p
|
Fever:
|
|
p
|
43 [84.3%], cough:
|
|
p
|
38 [74.5%], dry cough with expectoration:
|
|
p
|
16 (31.4%), fatigue: 22 [43.1%], asthenia: 22 (43.1%), dyspnea: 11/DM: 4 [57.1%]
|
|
td
|
2–5 days
|
|
td
|
1
|
|
td
|
Therapy:
TCM decoction: 28 [54.9%], aerosol inhalation of recombinant human
Interferon a‐1b: 51 (100%), Lopinavir/Ritonavir: 51 [100%], Bacillus licheniformis capsules: 44 [86.3%], glucocorticoid treatment: 10 (19.6%)
Older patients with server COVID‐19 (N = 7)
Antibiotic treatment: 7 [100%], nutritional diet: 6 [85.7%), human albumin infusion: 4 (57.1%), immunoglobulin treatment: 4 (57.1%), mechanical ventilation: 6 [85.7%]
Results and interpretation: discharged 50 patients after 12 days, without the common clinical symptoms, with the significant increased lymphocyte (p = .008) and significant decreased CRP significantly (p < .001)
|
|
p
|
Therapy:
|
|
p
|
TCM decoction: 28 [54.9%], aerosol inhalation of recombinant human
|
|
p
|
Interferon a‐1b: 51 (100%), Lopinavir/Ritonavir: 51 [100%], Bacillus licheniformis capsules: 44 [86.3%], glucocorticoid treatment: 10 (19.6%)
|
|
p
|
Older patients with server COVID‐19 (N = 7)
|
|
p
|
Antibiotic treatment: 7 [100%], nutritional diet: 6 [85.7%), human albumin infusion: 4 (57.1%), immunoglobulin treatment: 4 (57.1%), mechanical ventilation: 6 [85.7%]
|
|
p
|
Results and interpretation: discharged 50 patients after 12 days, without the common clinical symptoms, with the significant increased lymphocyte (p = .008) and significant decreased CRP significantly (p < .001)
|
|
tr
|
Fan et al. (2020), China Retrospective/Shanghai Public Health Clinical Center 148/50.5/49.3% females and 50.7% males Laboratory test, RT‐PCR and CT scanning Sera Confirmed SARS‐CoV‐2‐infected patients/a history of related epidemiology Blood:
elevated LDH, AST, ALT, GGT, TB, ALP:
35.1%, 21.6%, 18.2%, 17.6%, 6.1%, 4.1% in all patients; lower CD4+ and CD8+ T cells: (62.67%)/(56.1%) patients with abnormal liver function received more treatment compared with normal liver function (25%) (p = .009) Fever: (70.1%), cough: (45.3%), expectoration at admission:
(26.7%),
Abnormal liver functions at admission: 75 patients (50.7%) with moderate‐high degree fever (44%) in males,/chronic hepatitis B or C: N = 8 5 days (3–7) 1 Therapy:
Antibiotics (Levofloxacin, Meropenem, Moxifloxacin, Cephalosporin), interferon, antiviral drugs (Arbidol, Lopinavir/ritonavir, Dnrunavir)
Results and interpretation:
all patients discharged from the hospital.
Lopinavir/Ritonavir treatment can significantly alleviate the SARS‐CoV‐2‐induced liver function damage
|
|
td
|
Fan et al. (2020), China
|
|
td
|
Retrospective/Shanghai Public Health Clinical Center
|
|
td
|
148/50.5/49.3% females and 50.7% males
|
|
td
|
Laboratory test, RT‐PCR and CT scanning
|
|
td
|
Sera
|
|
td
|
Confirmed SARS‐CoV‐2‐infected patients/a history of related epidemiology
|
|
td
|
Blood:
elevated LDH, AST, ALT, GGT, TB, ALP:
35.1%, 21.6%, 18.2%, 17.6%, 6.1%, 4.1% in all patients; lower CD4+ and CD8+ T cells: (62.67%)/(56.1%) patients with abnormal liver function received more treatment compared with normal liver function (25%) (p = .009)
|
|
p
|
Blood:
|
|
p
|
elevated LDH, AST, ALT, GGT, TB, ALP:
|
|
p
|
35.1%, 21.6%, 18.2%, 17.6%, 6.1%, 4.1% in all patients; lower CD4+ and CD8+ T cells: (62.67%)/(56.1%) patients with abnormal liver function received more treatment compared with normal liver function (25%) (p = .009)
|
|
td
|
Fever: (70.1%), cough: (45.3%), expectoration at admission:
(26.7%),
Abnormal liver functions at admission: 75 patients (50.7%) with moderate‐high degree fever (44%) in males,/chronic hepatitis B or C: N = 8
|
|
p
|
Fever: (70.1%), cough: (45.3%), expectoration at admission:
|
|
p
|
(26.7%),
|
|
p
|
Abnormal liver functions at admission: 75 patients (50.7%) with moderate‐high degree fever (44%) in males,/chronic hepatitis B or C: N = 8
|
|
td
|
5 days (3–7)
|
|
td
|
1
|
|
td
|
Therapy:
Antibiotics (Levofloxacin, Meropenem, Moxifloxacin, Cephalosporin), interferon, antiviral drugs (Arbidol, Lopinavir/ritonavir, Dnrunavir)
Results and interpretation:
all patients discharged from the hospital.
Lopinavir/Ritonavir treatment can significantly alleviate the SARS‐CoV‐2‐induced liver function damage
|
|
p
|
Therapy:
|
|
p
|
Antibiotics (Levofloxacin, Meropenem, Moxifloxacin, Cephalosporin), interferon, antiviral drugs (Arbidol, Lopinavir/ritonavir, Dnrunavir)
|
|
p
|
Results and interpretation:
|
|
p
|
all patients discharged from the hospital.
|
|
p
|
Lopinavir/Ritonavir treatment can significantly alleviate the SARS‐CoV‐2‐induced liver function damage
|
|
tr
|
Chen et al. (2020) China Retrospective/Zhongnan Hospital of Wuhan University, Wuhan 9/26–34/female Clinical records, laboratory results, CT scans Amniotic fluid, cord blood, and neonatal throat swab, breastmilk samples Pregnant women with laboratory‐confirmed COVID‐19 pneumonia and caesarean section in their third trimester/a history of epidemiological exposure to COVID‐19 Blood:
lymphopenia: N = 5, elevated CRP: N = 6, increased ALT and AST: N = 3, normal WBC count: N = 7, lower WBC: N = 1.
Nine mothers: none developed severe COVID‐19 pneumonia or dying as of Feb4.
Six mothers:
amniotic fluid, cord blood, neonatal throat swab, and breastmilk: negative for COVID‐19.
Nine livebirths:
with 1‐min Apgar score of 8–9 and a 5‐min Apgar score of 9–10, No neonatal asphyxia.
CT:
multiple patchy ground‐glass shadows: N=8 Fever: N = 7, cough N = 4, myalgia N = 3, sore throat: N = 2, malaise: N = 2, fetal distress:
N = 2/gestational hypertension:
N = 1, pre‐eclampsia: N = 1, influenza virus infection: N = 1 Short None Therapy: oxygen support (nasal cannula) and empirical antibiotic treatment: N = 9, antiviral therapy: N = 6
Interpretation: no evidence for intrauterine infection caused by vertical transmission in late pregnancy
|
|
td
|
Chen et al. (2020) China
|
|
td
|
Retrospective/Zhongnan Hospital of Wuhan University, Wuhan
|
|
td
|
9/26–34/female
|
|
td
|
Clinical records, laboratory results, CT scans
|
|
td
|
Amniotic fluid, cord blood, and neonatal throat swab, breastmilk samples
|
|
td
|
Pregnant women with laboratory‐confirmed COVID‐19 pneumonia and caesarean section in their third trimester/a history of epidemiological exposure to COVID‐19
|
|
td
|
Blood:
lymphopenia: N = 5, elevated CRP: N = 6, increased ALT and AST: N = 3, normal WBC count: N = 7, lower WBC: N = 1.
Nine mothers: none developed severe COVID‐19 pneumonia or dying as of Feb4.
Six mothers:
amniotic fluid, cord blood, neonatal throat swab, and breastmilk: negative for COVID‐19.
Nine livebirths:
with 1‐min Apgar score of 8–9 and a 5‐min Apgar score of 9–10, No neonatal asphyxia.
CT:
multiple patchy ground‐glass shadows: N=8
|
|
p
|
Blood:
|
|
p
|
lymphopenia: N = 5, elevated CRP: N = 6, increased ALT and AST: N = 3, normal WBC count: N = 7, lower WBC: N = 1.
|
|
p
|
Nine mothers: none developed severe COVID‐19 pneumonia or dying as of Feb4.
|
|
p
|
Six mothers:
|
|
p
|
amniotic fluid, cord blood, neonatal throat swab, and breastmilk: negative for COVID‐19.
|
|
p
|
Nine livebirths:
|
|
p
|
with 1‐min Apgar score of 8–9 and a 5‐min Apgar score of 9–10, No neonatal asphyxia.
|
|
p
|
CT:
|
|
p
|
multiple patchy ground‐glass shadows: N=8
|
|
td
|
Fever: N = 7, cough N = 4, myalgia N = 3, sore throat: N = 2, malaise: N = 2, fetal distress:
N = 2/gestational hypertension:
N = 1, pre‐eclampsia: N = 1, influenza virus infection: N = 1
|
|
p
|
Fever: N = 7, cough N = 4, myalgia N = 3, sore throat: N = 2, malaise: N = 2, fetal distress:
|
|
p
|
N = 2/gestational hypertension:
|
|
p
|
N = 1, pre‐eclampsia: N = 1, influenza virus infection: N = 1
|
|
td
|
Short
|
|
td
|
None
|
|
td
|
Therapy: oxygen support (nasal cannula) and empirical antibiotic treatment: N = 9, antiviral therapy: N = 6
Interpretation: no evidence for intrauterine infection caused by vertical transmission in late pregnancy
|
|
p
|
Therapy: oxygen support (nasal cannula) and empirical antibiotic treatment: N = 9, antiviral therapy: N = 6
|
|
p
|
Interpretation: no evidence for intrauterine infection caused by vertical transmission in late pregnancy
|
|
tr
|
Lim et al. (2020), Korea Public health center, Myongji Hospital 1/54/male PCR, CT Throat swab, sputum A Korean man living in Wuhan China/Virus transmission;
from index patient Patient A to Patients B, C, D@@ Spectrum of disease: mild respiratory symptoms.
CT:
small consolidation in right upper lobe, GGO in both lower lobes Chills, muscle pain 5–7 days – Therapy:
Lopinavir/Ritonavir
Results and interpretation:
significant decrease in β‐coronavirus viral loads due to the natural course of the healing process rather than administration of Lopinavir/Ritonavir, or both
|
|
td
|
Lim et al. (2020), Korea
|
|
td
|
Public health center, Myongji Hospital
|
|
td
|
1/54/male
|
|
td
|
PCR, CT
|
|
td
|
Throat swab, sputum
|
|
td
|
A Korean man living in Wuhan China/Virus transmission;
from index patient Patient A to Patients B, C, D@@
|
|
p
|
A Korean man living in Wuhan China/Virus transmission;
|
|
p
|
from index patient Patient A to Patients B, C, D@@
|
|
td
|
Spectrum of disease: mild respiratory symptoms.
CT:
small consolidation in right upper lobe, GGO in both lower lobes
|
|
p
|
Spectrum of disease: mild respiratory symptoms.
|
|
p
|
CT:
|
|
p
|
small consolidation in right upper lobe, GGO in both lower lobes
|
|
td
|
Chills, muscle pain
|
|
td
|
5–7 days
|
|
td
|
–
|
|
td
|
Therapy:
Lopinavir/Ritonavir
Results and interpretation:
significant decrease in β‐coronavirus viral loads due to the natural course of the healing process rather than administration of Lopinavir/Ritonavir, or both
|
|
p
|
Therapy:
|
|
p
|
Lopinavir/Ritonavir
|
|
p
|
Results and interpretation:
|
|
p
|
significant decrease in β‐coronavirus viral loads due to the natural course of the healing process rather than administration of Lopinavir/Ritonavir, or both
|
|
tr
|
Wu et al. (2020), China Retrospective/three Grade IIIA hospitals of Jiangsu 80/46.1/41 female (51.25%) Laboratory testing, real time RT‐PCR, CT Throat swab and/or nose swab, blood Confirmed COVID‐19 patients/with a history of epidemic in Wuhan and without contact with the seafood market Spectrum of disease:
mild: 28 (35.00%), moderate: 49 (61.25%), severe: 3 (3.75%), critically ill: none
Laboratory:
lower WBC: 36 (45.00%), lymphocytopenia: 26 (32.50%), lower platelets: 11 (13.75%), high CRP: 62 (77.50%), high ESR: 59 (73.75%), elevated PCT: 1 (1.25%).
Liver function:
increased ALT/AST: 3 (3.75%), lower albumin: 2 (2.50%).
Abnormal myocardial enzyme spectrum and increase of CK: 18 (22.50%).
Increased LDH: 17 (21.25%).
Renal function damage: 2 (2.50%).
Serious renal function damage: 1.
Hyperglycemia: 19 (23.17%).
Increased D‐dimer: 3 (3.75%).
9 kinds of respiratory pathogens and influenza A/B nucleic acids: all patients.
CT: abnormal: 55 (68.75%), bilateral pneumonia: 36 (45.00%), unilateral pneumonia: 19 (23.75%), normal: 25 (31.25%).
Organ damage: acute respiratory injury: 10 (12.50%), renal injury: 2 (2.50%) Fever:
63 (78.75%), cough: 51 (63.75%), shortness of breath: 30 (37.50%), muscle ache: 18 (22.50%), headache: 13 (16.25%) liver dysfunction: 3 (3.75%)/cardiovascular/cerebrovascular, endocrine, digestive, respiratory, malignancies and nervous system diseases: 38 (47.50%) 8.0 Not now Therapy:
all patients:
single antibiotic mainly Moxifloxacin and Ribavirin antiviral therapy, 12 (14.63%) patients:
methylprednisolone sodium succinate or methylprednisolone, 35 (43.75%) patients:
noninvasive ventilator, 1 patient: hemodialysis, 3 patients: TCM
Interpretation: 21 cases discharged from the hospital: With no obvious gender susceptivity, lower proportion of liver dysfunction, abnormal CT and higher frequency nucleic acid detection
|
|
td
|
Wu et al. (2020), China
|
|
td
|
Retrospective/three Grade IIIA hospitals of Jiangsu
|
|
td
|
80/46.1/41 female (51.25%)
|
|
td
|
Laboratory testing, real time RT‐PCR, CT
|
|
td
|
Throat swab and/or nose swab, blood
|
|
td
|
Confirmed COVID‐19 patients/with a history of epidemic in Wuhan and without contact with the seafood market
|
|
td
|
Spectrum of disease:
mild: 28 (35.00%), moderate: 49 (61.25%), severe: 3 (3.75%), critically ill: none
Laboratory:
lower WBC: 36 (45.00%), lymphocytopenia: 26 (32.50%), lower platelets: 11 (13.75%), high CRP: 62 (77.50%), high ESR: 59 (73.75%), elevated PCT: 1 (1.25%).
Liver function:
increased ALT/AST: 3 (3.75%), lower albumin: 2 (2.50%).
Abnormal myocardial enzyme spectrum and increase of CK: 18 (22.50%).
Increased LDH: 17 (21.25%).
Renal function damage: 2 (2.50%).
Serious renal function damage: 1.
Hyperglycemia: 19 (23.17%).
Increased D‐dimer: 3 (3.75%).
9 kinds of respiratory pathogens and influenza A/B nucleic acids: all patients.
CT: abnormal: 55 (68.75%), bilateral pneumonia: 36 (45.00%), unilateral pneumonia: 19 (23.75%), normal: 25 (31.25%).
Organ damage: acute respiratory injury: 10 (12.50%), renal injury: 2 (2.50%)
|
|
p
|
Spectrum of disease:
|
|
p
|
mild: 28 (35.00%), moderate: 49 (61.25%), severe: 3 (3.75%), critically ill: none
|
|
p
|
Laboratory:
|
|
p
|
lower WBC: 36 (45.00%), lymphocytopenia: 26 (32.50%), lower platelets: 11 (13.75%), high CRP: 62 (77.50%), high ESR: 59 (73.75%), elevated PCT: 1 (1.25%).
|
|
p
|
Liver function:
|
|
p
|
increased ALT/AST: 3 (3.75%), lower albumin: 2 (2.50%).
|
|
p
|
Abnormal myocardial enzyme spectrum and increase of CK: 18 (22.50%).
|
|
p
|
Increased LDH: 17 (21.25%).
|
|
p
|
Renal function damage: 2 (2.50%).
|
|
p
|
Serious renal function damage: 1.
|
|
p
|
Hyperglycemia: 19 (23.17%).
|
|
p
|
Increased D‐dimer: 3 (3.75%).
|
|
p
|
9 kinds of respiratory pathogens and influenza A/B nucleic acids: all patients.
|
|
p
|
CT: abnormal: 55 (68.75%), bilateral pneumonia: 36 (45.00%), unilateral pneumonia: 19 (23.75%), normal: 25 (31.25%).
|
|
p
|
Organ damage: acute respiratory injury: 10 (12.50%), renal injury: 2 (2.50%)
|
|
td
|
Fever:
63 (78.75%), cough: 51 (63.75%), shortness of breath: 30 (37.50%), muscle ache: 18 (22.50%), headache: 13 (16.25%) liver dysfunction: 3 (3.75%)/cardiovascular/cerebrovascular, endocrine, digestive, respiratory, malignancies and nervous system diseases: 38 (47.50%)
|
|
p
|
Fever:
|
|
p
|
63 (78.75%), cough: 51 (63.75%), shortness of breath: 30 (37.50%), muscle ache: 18 (22.50%), headache: 13 (16.25%) liver dysfunction: 3 (3.75%)/cardiovascular/cerebrovascular, endocrine, digestive, respiratory, malignancies and nervous system diseases: 38 (47.50%)
|
|
td
|
8.0
|
|
td
|
Not now
|
|
td
|
Therapy:
all patients:
single antibiotic mainly Moxifloxacin and Ribavirin antiviral therapy, 12 (14.63%) patients:
methylprednisolone sodium succinate or methylprednisolone, 35 (43.75%) patients:
noninvasive ventilator, 1 patient: hemodialysis, 3 patients: TCM
Interpretation: 21 cases discharged from the hospital: With no obvious gender susceptivity, lower proportion of liver dysfunction, abnormal CT and higher frequency nucleic acid detection
|
|
p
|
Therapy:
|
|
p
|
all patients:
|
|
p
|
single antibiotic mainly Moxifloxacin and Ribavirin antiviral therapy, 12 (14.63%) patients:
|
|
p
|
methylprednisolone sodium succinate or methylprednisolone, 35 (43.75%) patients:
|
|
p
|
noninvasive ventilator, 1 patient: hemodialysis, 3 patients: TCM
|
|
p
|
Interpretation: 21 cases discharged from the hospital: With no obvious gender susceptivity, lower proportion of liver dysfunction, abnormal CT and higher frequency nucleic acid detection
|
|
tr
|
Li et al. (2020), China Retrospective study/hospital in Wenzhou 175/46/92 women, 83/men Real‐time PCR, CT Respiratory tract samples or blood samples Confirmed COVID‐19/a history of exposure to the epidemic area: 57 (33%) patients Spectrum of disease:
COVID‐19:
mild: mild clinical manifestations, no pneumonia; moderate: respiratory symptoms, mild pneumonia, severe (37): pneumonia, ARDS with RR >30 times/min, oxygen saturation <93%; critical (3): pneumonia, shock, respiratory failure, and failures in other organs, nearly all patients: GGO
K+:
severe hypokalemia: 39 (higher body temperature, higher heart rate and RR, higher prevalence of dyspnea or tachypnea (p < .05)), hypokalemia 69, normokalemia patients 67.
Correlations: severity of hypokalemia with body temperature, CK, CK‐MB, LDH, and CRP (p < .01), 93% of severe/critically ill patients showed hypokalemia Cough, fever, pneumonia/hypertension: 28, diabetes: 12, other conditions:31 6 – Therapy:
1 severe hypokalemia patients;
3 g/day K+, 34 (SD = 4) g potassium during hospital stay
Good response of patients to K+ supplements when they inclined to recovery
Interpretation: hypokalemia is prevailing in COVID‐19 patients
|
|
td
|
Li et al. (2020), China
|
|
td
|
Retrospective study/hospital in Wenzhou
|
|
td
|
175/46/92 women, 83/men
|
|
td
|
Real‐time PCR, CT
|
|
td
|
Respiratory tract samples or blood samples
|
|
td
|
Confirmed COVID‐19/a history of exposure to the epidemic area: 57 (33%) patients
|
|
td
|
Spectrum of disease:
COVID‐19:
mild: mild clinical manifestations, no pneumonia; moderate: respiratory symptoms, mild pneumonia, severe (37): pneumonia, ARDS with RR >30 times/min, oxygen saturation <93%; critical (3): pneumonia, shock, respiratory failure, and failures in other organs, nearly all patients: GGO
K+:
severe hypokalemia: 39 (higher body temperature, higher heart rate and RR, higher prevalence of dyspnea or tachypnea (p < .05)), hypokalemia 69, normokalemia patients 67.
Correlations: severity of hypokalemia with body temperature, CK, CK‐MB, LDH, and CRP (p < .01), 93% of severe/critically ill patients showed hypokalemia
|
|
p
|
Spectrum of disease:
|
|
p
|
COVID‐19:
|
|
p
|
mild: mild clinical manifestations, no pneumonia; moderate: respiratory symptoms, mild pneumonia, severe (37): pneumonia, ARDS with RR >30 times/min, oxygen saturation <93%; critical (3): pneumonia, shock, respiratory failure, and failures in other organs, nearly all patients: GGO
|
|
p
|
K+:
|
|
p
|
severe hypokalemia: 39 (higher body temperature, higher heart rate and RR, higher prevalence of dyspnea or tachypnea (p < .05)), hypokalemia 69, normokalemia patients 67.
|
|
p
|
Correlations: severity of hypokalemia with body temperature, CK, CK‐MB, LDH, and CRP (p < .01), 93% of severe/critically ill patients showed hypokalemia
|
|
td
|
Cough, fever, pneumonia/hypertension: 28, diabetes: 12, other conditions:31
|
|
td
|
6
|
|
td
|
–
|
|
td
|
Therapy:
1 severe hypokalemia patients;
3 g/day K+, 34 (SD = 4) g potassium during hospital stay
Good response of patients to K+ supplements when they inclined to recovery
Interpretation: hypokalemia is prevailing in COVID‐19 patients
|
|
p
|
Therapy:
|
|
p
|
1 severe hypokalemia patients;
|
|
p
|
3 g/day K+, 34 (SD = 4) g potassium during hospital stay
|
|
p
|
Good response of patients to K+ supplements when they inclined to recovery
|
|
p
|
Interpretation: hypokalemia is prevailing in COVID‐19 patients
|
|
tr
|
Lan et al. (2020), China Case study/Zhongnan Hospital of Wuhan University, Wuhan 4, 30–36 years, 2 male RT‐PCR, thin‐section CT Throat swabs Medical personnel quarantined at home with COVID‐19 Spectrum of disease: mild to moderate
Results: (at admission); PCR positive: for all CT positive: for all GGO, or mixed GGO/consolidation
(after therapy); 2 consecutive negative RT‐PCR: all (after discharge); repeated RT‐PCR 5–13 days later: all positive Fever:3, cough: 3, both: 3 Symptom onset to recovery: 12–32 days – Therapy: antiviral treatment (75 mg of oseltamivir every 12 hr)
Resolved clinical symptoms and CT abnormalities: 3
Delicate patches of GGO: 1
Interpretation: possibility of at least a proportion of recovered patients act as virus carriers
|
|
td
|
Lan et al. (2020), China
|
|
td
|
Case study/Zhongnan Hospital of Wuhan University, Wuhan
|
|
td
|
4, 30–36 years, 2 male
|
|
td
|
RT‐PCR, thin‐section CT
|
|
td
|
Throat swabs
|
|
td
|
Medical personnel quarantined at home with COVID‐19
|
|
td
|
Spectrum of disease: mild to moderate
Results: (at admission); PCR positive: for all CT positive: for all GGO, or mixed GGO/consolidation
(after therapy); 2 consecutive negative RT‐PCR: all (after discharge); repeated RT‐PCR 5–13 days later: all positive
|
|
p
|
Spectrum of disease: mild to moderate
|
|
p
|
Results: (at admission); PCR positive: for all CT positive: for all GGO, or mixed GGO/consolidation
|
|
p
|
(after therapy); 2 consecutive negative RT‐PCR: all (after discharge); repeated RT‐PCR 5–13 days later: all positive
|
|
td
|
Fever:3, cough: 3, both: 3
|
|
td
|
Symptom onset to recovery: 12–32 days
|
|
td
|
–
|
|
td
|
Therapy: antiviral treatment (75 mg of oseltamivir every 12 hr)
Resolved clinical symptoms and CT abnormalities: 3
Delicate patches of GGO: 1
Interpretation: possibility of at least a proportion of recovered patients act as virus carriers
|
|
p
|
Therapy: antiviral treatment (75 mg of oseltamivir every 12 hr)
|
|
p
|
Resolved clinical symptoms and CT abnormalities: 3
|
|
p
|
Delicate patches of GGO: 1
|
|
p
|
Interpretation: possibility of at least a proportion of recovered patients act as virus carriers
|
|
tr
|
Li et al. (2020), China Retrospective study/Sino‐French New Town area Tongji Hospital 47, 62, 28 (59.6%) men Real‐time RT‐PCR Throat‐swab specimens, sputum or endotracheal aspirates Patients with severe COVID‐19 Spectrum of disease: severe: 41 critical: 5(17.9%) men and 1 (5.3%) women
Common: oxygen saturation <93% after routine
Nasal oxygen supply: 3 men/1 woman
Blood: PCT: higher in men, N‐terminal‐pro brain natriuretic peptide: Higher in 16(57.1%) men/5 (26.3%) women,
Positive influenza A antibody: 5 men (17.9%) Fever: 34 [72.3%], cough: 36 [76.6%], myalgia: 5 [10.6%], fatigue: 7 [14.9%]/comorbidities: 30 (63.8%):
COPD, hypertension/CVD lower in men – 3.6% in men and 0 in women Therapy:
antibiotics applied more in the men than the women
Results and interpretation: 4 (21.1%) women/1 man (3.6%) discharged.
Possibility of sex differences in severe COVID‐19 patients, Men with more complicated clinical condition and worse outcomes
|
|
td
|
Li et al. (2020), China
|
|
td
|
Retrospective study/Sino‐French New Town area Tongji Hospital
|
|
td
|
47, 62, 28 (59.6%) men
|
|
td
|
Real‐time RT‐PCR
|
|
td
|
Throat‐swab specimens, sputum or endotracheal aspirates
|
|
td
|
Patients with severe COVID‐19
|
|
td
|
Spectrum of disease: severe: 41 critical: 5(17.9%) men and 1 (5.3%) women
Common: oxygen saturation <93% after routine
Nasal oxygen supply: 3 men/1 woman
Blood: PCT: higher in men, N‐terminal‐pro brain natriuretic peptide: Higher in 16(57.1%) men/5 (26.3%) women,
Positive influenza A antibody: 5 men (17.9%)
|
|
p
|
Spectrum of disease: severe: 41 critical: 5(17.9%) men and 1 (5.3%) women
|
|
p
|
Common: oxygen saturation <93% after routine
|
|
p
|
Nasal oxygen supply: 3 men/1 woman
|
|
p
|
Blood: PCT: higher in men, N‐terminal‐pro brain natriuretic peptide: Higher in 16(57.1%) men/5 (26.3%) women,
|
|
p
|
Positive influenza A antibody: 5 men (17.9%)
|
|
td
|
Fever: 34 [72.3%], cough: 36 [76.6%], myalgia: 5 [10.6%], fatigue: 7 [14.9%]/comorbidities: 30 (63.8%):
COPD, hypertension/CVD lower in men
|
|
p
|
Fever: 34 [72.3%], cough: 36 [76.6%], myalgia: 5 [10.6%], fatigue: 7 [14.9%]/comorbidities: 30 (63.8%):
|
|
p
|
COPD, hypertension/CVD lower in men
|
|
td
|
–
|
|
td
|
3.6% in men and 0 in women
|
|
td
|
Therapy:
antibiotics applied more in the men than the women
Results and interpretation: 4 (21.1%) women/1 man (3.6%) discharged.
Possibility of sex differences in severe COVID‐19 patients, Men with more complicated clinical condition and worse outcomes
|
|
p
|
Therapy:
|
|
p
|
antibiotics applied more in the men than the women
|
|
p
|
Results and interpretation: 4 (21.1%) women/1 man (3.6%) discharged.
|
|
p
|
Possibility of sex differences in severe COVID‐19 patients, Men with more complicated clinical condition and worse outcomes
|
|
tr
|
Han et al. (2020) Case study/People's Hospital in Wuwei A 47‐year‐old man/smoking for 20 years/no alcohol abuse RT‐PCR, CT Nasopharyngeal swab specimens Confirmed SARS‐CoV‐2/returned to Wuwei city on January 18 from Wuhan city by car Blood:
decreased lymphocytes, increased CRP, slightly elevated fibrinogen, neutrophil, LDH, and fibrinogen
PCR: positive for expression of RdRPN, N and E genes
CT: multiple patchy high‐density shadows scattered mainly in the border regions of lungs, solid changes, GGO changes, slightly thickened pleura Fever, cough productive of white phlegm, bosom frowsty, stuffy/runny noses, vertigo, fatigue, chest tightness, nausea, expiratory dyspnea, poor diet, lethargy/hypertension grade 2 and T2D – – Therapy:
combination therapy including:
Lopinavir/Ritonavir (800/200 mg daily), methylprednisolone (40 mg daily), recombinant human interferon α‐2b (10 million IU daily), ambroxol hydrochloride (60 mg daily) moxifloxacin hydrochloride (0.4 g daily), high flow humidification oxygen inhalation therapy, treatment of blood glucose, blood pressure, and rehydration therapy
Results interpretation: the persistent negative results of SARS‐CoV‐2 on days 6 and 7, normal TLC, lung lesions partially absorbed, The patient discharged. Laboratory tests like TLC are necessary, CT combined with RT‐PCR is helpful, Lopinavir/Ritonavir are effective after failure of methylprednisolone/interferon alfa‐2b
|
|
td
|
Han et al. (2020)
|
|
td
|
Case study/People's Hospital in Wuwei
|
|
td
|
A 47‐year‐old man/smoking for 20 years/no alcohol abuse
|
|
td
|
RT‐PCR, CT
|
|
td
|
Nasopharyngeal swab specimens
|
|
td
|
Confirmed SARS‐CoV‐2/returned to Wuwei city on January 18 from Wuhan city by car
|
|
td
|
Blood:
decreased lymphocytes, increased CRP, slightly elevated fibrinogen, neutrophil, LDH, and fibrinogen
PCR: positive for expression of RdRPN, N and E genes
CT: multiple patchy high‐density shadows scattered mainly in the border regions of lungs, solid changes, GGO changes, slightly thickened pleura
|
|
p
|
Blood:
|
|
p
|
decreased lymphocytes, increased CRP, slightly elevated fibrinogen, neutrophil, LDH, and fibrinogen
|
|
p
|
PCR: positive for expression of RdRPN, N and E genes
|
|
p
|
CT: multiple patchy high‐density shadows scattered mainly in the border regions of lungs, solid changes, GGO changes, slightly thickened pleura
|
|
td
|
Fever, cough productive of white phlegm, bosom frowsty, stuffy/runny noses, vertigo, fatigue, chest tightness, nausea, expiratory dyspnea, poor diet, lethargy/hypertension grade 2 and T2D
|
|
td
|
–
|
|
td
|
–
|
|
td
|
Therapy:
combination therapy including:
Lopinavir/Ritonavir (800/200 mg daily), methylprednisolone (40 mg daily), recombinant human interferon α‐2b (10 million IU daily), ambroxol hydrochloride (60 mg daily) moxifloxacin hydrochloride (0.4 g daily), high flow humidification oxygen inhalation therapy, treatment of blood glucose, blood pressure, and rehydration therapy
Results interpretation: the persistent negative results of SARS‐CoV‐2 on days 6 and 7, normal TLC, lung lesions partially absorbed, The patient discharged. Laboratory tests like TLC are necessary, CT combined with RT‐PCR is helpful, Lopinavir/Ritonavir are effective after failure of methylprednisolone/interferon alfa‐2b
|
|
p
|
Therapy:
|
|
p
|
combination therapy including:
|
|
p
|
Lopinavir/Ritonavir (800/200 mg daily), methylprednisolone (40 mg daily), recombinant human interferon α‐2b (10 million IU daily), ambroxol hydrochloride (60 mg daily) moxifloxacin hydrochloride (0.4 g daily), high flow humidification oxygen inhalation therapy, treatment of blood glucose, blood pressure, and rehydration therapy
|
|
p
|
Results interpretation: the persistent negative results of SARS‐CoV‐2 on days 6 and 7, normal TLC, lung lesions partially absorbed, The patient discharged. Laboratory tests like TLC are necessary, CT combined with RT‐PCR is helpful, Lopinavir/Ritonavir are effective after failure of methylprednisolone/interferon alfa‐2b
|
|
tr
|
Liu et al. (2020), China Retrospective cohort and case study/Zhongnan Hospital of Wuhan University Dawu County People's Hospital 124 patients, 22 patients:
12 therapy (mean age 53), 10 control (mean age 58) CT, PCR Serum 124 confirmed COVID‐19 cases, 12 HCOV infected patients Blood: (Study 1) decreased platelet: 25 (20.2%), prolonged PT: 77 (62.1%), increased FIB: 27 (21.8%), and increased D‐dimer: 26 (21.0%)
Spectrum of disease: (study 2) severe cases: 6 mild cases: 4 critically ill: 2
CT: (study 2) Bilateral pneumonia: all Study 1: hypercoagulability
Study 2: cough: all shortness of breath: most of them, nausea and vomiting: 60.0%/DM, cardiovascular and cerebrovascular diseases: 4 patients from the DIP, 5 patients control group – 1 Therapy: Dipyridamole (150 mg in three separate doses for 7 consecutive days), antiviral (ribavirin, 0.5 g, Q12hr), corticoid (methylprednisolone sodium succinate, 40 mg, qd), oxygen therapy, nutritional support
Results and interpretation: significant increase in platelet/lymphocyte, significant decrease in D‐dimer levels
Discharged patients: 50% of severe cases and all 4 mild cases.
Dipyridamole adjunctive therapy could significantly reduce viral replication, inhibits hypercoagulability and improves immune recovery
|
|
td
|
Liu et al. (2020), China
|
|
td
|
Retrospective cohort and case study/Zhongnan Hospital of Wuhan University Dawu County People's Hospital
|
|
td
|
124 patients, 22 patients:
12 therapy (mean age 53), 10 control (mean age 58)
|
|
p
|
124 patients, 22 patients:
|
|
p
|
12 therapy (mean age 53), 10 control (mean age 58)
|
|
td
|
CT, PCR
|
|
td
|
Serum
|
|
td
|
124 confirmed COVID‐19 cases, 12 HCOV infected patients
|
|
td
|
Blood: (Study 1) decreased platelet: 25 (20.2%), prolonged PT: 77 (62.1%), increased FIB: 27 (21.8%), and increased D‐dimer: 26 (21.0%)
Spectrum of disease: (study 2) severe cases: 6 mild cases: 4 critically ill: 2
CT: (study 2) Bilateral pneumonia: all
|
|
p
|
Blood: (Study 1) decreased platelet: 25 (20.2%), prolonged PT: 77 (62.1%), increased FIB: 27 (21.8%), and increased D‐dimer: 26 (21.0%)
|
|
p
|
Spectrum of disease: (study 2) severe cases: 6 mild cases: 4 critically ill: 2
|
|
p
|
CT: (study 2) Bilateral pneumonia: all
|
|
td
|
Study 1: hypercoagulability
Study 2: cough: all shortness of breath: most of them, nausea and vomiting: 60.0%/DM, cardiovascular and cerebrovascular diseases: 4 patients from the DIP, 5 patients control group
|
|
p
|
Study 1: hypercoagulability
|
|
p
|
Study 2: cough: all shortness of breath: most of them, nausea and vomiting: 60.0%/DM, cardiovascular and cerebrovascular diseases: 4 patients from the DIP, 5 patients control group
|
|
td
|
–
|
|
td
|
1
|
|
td
|
Therapy: Dipyridamole (150 mg in three separate doses for 7 consecutive days), antiviral (ribavirin, 0.5 g, Q12hr), corticoid (methylprednisolone sodium succinate, 40 mg, qd), oxygen therapy, nutritional support
Results and interpretation: significant increase in platelet/lymphocyte, significant decrease in D‐dimer levels
Discharged patients: 50% of severe cases and all 4 mild cases.
Dipyridamole adjunctive therapy could significantly reduce viral replication, inhibits hypercoagulability and improves immune recovery
|
|
p
|
Therapy: Dipyridamole (150 mg in three separate doses for 7 consecutive days), antiviral (ribavirin, 0.5 g, Q12hr), corticoid (methylprednisolone sodium succinate, 40 mg, qd), oxygen therapy, nutritional support
|
|
p
|
Results and interpretation: significant increase in platelet/lymphocyte, significant decrease in D‐dimer levels
|
|
p
|
Discharged patients: 50% of severe cases and all 4 mild cases.
|
|
p
|
Dipyridamole adjunctive therapy could significantly reduce viral replication, inhibits hypercoagulability and improves immune recovery
|
|
table-wrap-foot
|
Abbreviations: ALP, alkaline phosphatase; ALT, alanine aminotransferase; ARDS, acute respiratory distress syndrome; AST, aspartate aminotransferase; BUN, blood urea nitrogen; CK, creatine kinase; CK‐MB, creatine kinase myocardial band; COPD, chronic obstructive pulmonary disease; CRE, serum creatinine; CRP, C‐reactive protein; CT, computed tomography; CVD, cardiovascular disease; DM, diabetes mellitus; DM, diabetes mellitus; ESR, erythrocyte sedimentation rate; FIB, fibrinogen; FiO2, fraction of inspired oxygen; GGO, ground‐glass opacity; GGT, γ‐glutamyltransferase; GLM, Generalized Linear Model; LDH, lactate dehydrogenase; nCoV, novel coronavirus; PaO2, partial pressure of oxygen; PCT, procalcitonin; PT, prothrombin time; RNAaemia, SARS‐CoV‐2 nucleic acid; RR, respiratory rate; RT‐PCR, reverse transcriptase polymerase chain reaction; SpO2, oxygen saturation; T2D, type 2 diabetes; TB, total bilirubin; TCM, traditional Chinese medicine; TCM, traditional Chinese medicine; TLC, total lymphocyte count; TnT, troponin T; WBC, white blood cell.
|
|
footnote
|
Abbreviations: ALP, alkaline phosphatase; ALT, alanine aminotransferase; ARDS, acute respiratory distress syndrome; AST, aspartate aminotransferase; BUN, blood urea nitrogen; CK, creatine kinase; CK‐MB, creatine kinase myocardial band; COPD, chronic obstructive pulmonary disease; CRE, serum creatinine; CRP, C‐reactive protein; CT, computed tomography; CVD, cardiovascular disease; DM, diabetes mellitus; DM, diabetes mellitus; ESR, erythrocyte sedimentation rate; FIB, fibrinogen; FiO2, fraction of inspired oxygen; GGO, ground‐glass opacity; GGT, γ‐glutamyltransferase; GLM, Generalized Linear Model; LDH, lactate dehydrogenase; nCoV, novel coronavirus; PaO2, partial pressure of oxygen; PCT, procalcitonin; PT, prothrombin time; RNAaemia, SARS‐CoV‐2 nucleic acid; RR, respiratory rate; RT‐PCR, reverse transcriptase polymerase chain reaction; SpO2, oxygen saturation; T2D, type 2 diabetes; TB, total bilirubin; TCM, traditional Chinese medicine; TCM, traditional Chinese medicine; TLC, total lymphocyte count; TnT, troponin T; WBC, white blood cell.
|
|
p
|
Abbreviations: ALP, alkaline phosphatase; ALT, alanine aminotransferase; ARDS, acute respiratory distress syndrome; AST, aspartate aminotransferase; BUN, blood urea nitrogen; CK, creatine kinase; CK‐MB, creatine kinase myocardial band; COPD, chronic obstructive pulmonary disease; CRE, serum creatinine; CRP, C‐reactive protein; CT, computed tomography; CVD, cardiovascular disease; DM, diabetes mellitus; DM, diabetes mellitus; ESR, erythrocyte sedimentation rate; FIB, fibrinogen; FiO2, fraction of inspired oxygen; GGO, ground‐glass opacity; GGT, γ‐glutamyltransferase; GLM, Generalized Linear Model; LDH, lactate dehydrogenase; nCoV, novel coronavirus; PaO2, partial pressure of oxygen; PCT, procalcitonin; PT, prothrombin time; RNAaemia, SARS‐CoV‐2 nucleic acid; RR, respiratory rate; RT‐PCR, reverse transcriptase polymerase chain reaction; SpO2, oxygen saturation; T2D, type 2 diabetes; TB, total bilirubin; TCM, traditional Chinese medicine; TCM, traditional Chinese medicine; TLC, total lymphocyte count; TnT, troponin T; WBC, white blood cell.
|
|
table-wrap
|
Table 4 Clinical trials for COVID‐19 or SARS‐nCoV2
Study title Interventions Location/condition Subjects, sex, age Primary purpose Arms Phase Measure outcome/time frame Code/status/date
The efficacy and safety of huaier in the adjuvant treatment of COVID‐19 Drug: Huaier Granule COVID‐19 550, all, 18–75 Treatment Experimental group: standard therapy + Huaier granule 20 g, po, tid for 2 weeks (or until discharge)
Control group: standard therapy II, III Primary (up to 28 days): all cause mortality
Secondary (up to 28 days): clinical status, differences in oxygen intake methods, supplemental oxygenation, mechanical ventilation, mean PaO2/FiO2, length of hospital stay, Length of ICU stay (days), pulmonary function (up to 3 months after discharge) NCT04291053/Not yet recruiting, Apr1‐Sep1 2020
Clinical trial on regularity of TCM syndrome and differentiation treatment of COVID‐19 Drug: TCM prescriptions China/COVID‐19 340, all, 18–75 Treatment Exposure group: integrated TCM and western medicine cohort (routine treatment + one or two of the following antiviral drugs + the following TCM regimens: take decocted or granule, one dose a day)
Control group: western medicine cohort (routine treatment + one or both of the following antiviral drugs) Not applicable Primary (9 days): The relief/disappearance rate of main symptoms, chest CT absorption
Secondary (9 days): virus antigen negative conversion rate, Clinical effective time: the average effective time. The number of severe and critical conversion cases, Incidence of complications, Traditional Chinese Medicine Syndrome Score
Other outcome measures (9 days): CRP changes, ESR changes, PCTchanges, The index of T cell subsets changed NCT04306497/Recruiting, Mar2‐May 2020
Recombinant human angiotensin‐converting enzyme 2 (rhACE2) as a treatment for patients with COVID‐19 Drug: Recombinant human angiotensin‐converting enzyme 2 (rhACE2) China/COVID‐19 24, all, 18–80 Treatment Experimental group: 0.4 mg/kg rhACE2 IV BID for 7 days and standard of care
Control group: standard of care Not applicable Primary (14 days): time course of body temperature, viral load over time
Secondary (14 days): P/F ratio over time, sequential organ failure assessment score over time, Pulmonary Severity Index, image examination of chest over time, proportion of subjects who progressed to critical illness or death, Time from first dose to conversion to normal or mild pneumonia, T‐lymphocyte counts over time, C‐reactive protein levels over time, angiotensin II (Ang II) changes over time, angiotensin 1–7 (Ang 1–7) changes over time, angiotensin 1–5 (Ang 1–5) changes over time, renin changes over time, aldosterone changes over time, angiotensin‐converting enzyme changes over time, angiotensin‐converting enzyme 2 (ACE2) changes over time, IL‐6 changes over time, IL‐8 changes over time, soluble tumor necrosis factor receptor type II (sTNFrII) changes over time, Plasminogen activator inhibitor type‐1 changes over time, Von willebrand factor changes over time, tumor necrosis factor‐α changes over time, soluble receptor for advanced glycation end products (sRAGE) changes over time, surfactant protein‐D changes over time, angiopoietin‐2 changes over time, frequency of adverse events and severe adverse events NCT04287686/Withdraw, Feb‐Apr 2020
The COVID‐19 mobile health study (CMHS) nCapp, a cell phone‐based autodiagnosis system China/COVID‐19 450, all, 18–90 Diagnosis Training: nCapp, a cell phone‐based autodiagnosis system, combined with 15 questions online, and a predicated formula to autodiagnosis of the risk of COVID‐19
Validation: nCapp, a cell phone‐based autodiagnosis system, combined with 15 questions online, and a predicated formula to auto‐diagnosis of the risk of COVID‐19 – Primary (1 day): accuracy of nCapp COVID‐19 risk diagnostic model NCT04275947/Recruiting, Feb 14‐May 31 2020
A Pilot Study of Sildenafil in COVID‐19 Drug: Sildenafil citrate tablets (G1) China/COVID‐19 10, all, 18 years and older Treatment Experimental group: sildenafil citrate tablet 0.1 g/day for 14 days Not applicable Primary (14 days): rate of disease remission, rate of entering the critical stage, time of entering the critical stage
Secondary (14 days): rate of no fever, rate of respiratory symptom remission, rate of lung imaging recovery, rate of C‐reactive protein (CRP) recovery, rate of Biochemical criterion (CK, ALT, Mb) recovery, rate of undetectable viral RNA (continuous twice), time for hospitalization, rate of adverse event NCT04304313/Recruiting, Feb 9‐Nov 9 2020
Critically Ill patients with COVID‐19 in Hong Kong: a multicentre observational cohort study – Hong Kong/COVID‐19 8 descriptive A case series of 41 hospitalized patients with confirmed infection
30% required critical care admission: developed severe respiratory failure, 10% required mechanical ventilation, 5% needed extracorporeal membrane oxygenation support mortality rate: 15% − Primary (28 days): 28 day mortality
Secondary (28 days): vasopressor days, days on mechanical ventilation, sequential organ function assessment score, ECMO use, percentage nitric oxide use, percentage free from oxygen supplement NCT04285801/Completed, Feb 14‐Feb 25 2020
Treatment of mild cases and chemoprophylaxis of contacts as prevention of the COVID‐19 epidemic Drug: antiviral treatment and prophylaxis, Standard Public Health measures COVID‐19 3,040, All, 18 Years and older Treatment Experimental: antiviral treatment and prophylaxis: darunavir 800 mg/cobicistat 150 mg tablets (oral, 1 tablet q24h, taking for 7 days) and hydroxychloroquine (200 mg tablets) 800 mg on Day 1, and 400 mg on days 2, 3, 4. Contacts: a prophylactic regimen of hydroxychloroquine (200 mg tablets) 800 mg on Day 1, and 400 mg on days 2,3,4. Other: standard public health measures
Active comparator: standard public health measures III Primary (up to 14 days after start of treatment): effectiveness of chemoprophylaxis assessed by incidence of secondary COVID‐19 cases
Secondary: the virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at days 3, the mortality rate of subjects at weeks 2, proportion of participants that drop out of study (up to 14 days after start of treatment), proportion of participants that show noncompliance with study drug (up to 14 days after start of treatment) NCT04304053/Not yet recruiting, Mar15‐Jul15 2020
Comparison of lopinavir/ritonavir or hydroxychloroquine in patients with mild coronavirus disease (COVID‐19) Drug: lopinavir/ritonavir, Drug: hydroxychloroquine sulfate Korea/COVID‐19 150, all, 16 years to 99 years Treatment Experimental: lopinavir/ritonavir 200 mg/100 mg 2 tablets by mouth, every 12 hr for 7–10 days
Active comparator: hydroxychloroquine 200 mg 2 tablets by mouth, every 12 hr for 7–10 days
No intervention: control, no lopinavir/ritonavir and hydroxychloroquine II Primary: viral load (hospital Day 3, 5, 7, 10, 14, 18)
Secondary viral load change (hospital Day 3, 5, 7, 10, 14, 18), time to clinical improvement (time frame: up to 28 days), percentage of progression to supplemental oxygen requirement by Day 7, Time to NEWS2 (National Early Warning Score 2) of 3 or more maintained for 24 hr by Day 7, time to clinical failure, defined as the time to death, mechanical ventilation, or ICU admission (up to 28 days), rate of switch to lopinavir/ritonavir or hydroxychloroquine by Day 7, adverse effects (up to 28 days), concentration of lopinavir/ritonavir and hydroxychloroquine (1, 2, 4, 5, 12 hr after taking intervention medicine) NCT04307693/Recruiting, Mar11‐May 2020
Study to evaluate the safety and antiviral activity of remdesivir (GS‐5734™) in participants with severe coronavirus disease (COVID‐19) Drug: remdesivir, standard of care United States, Hong Kong/COVID‐19 400, all, 18 years and older Treatment Experimental: demdesivir (RDV), 5 days participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, and 5
Experimental: remdesivir, 10 days participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, 5, 6, 7, 8, 9, and 10 III Primary: proportion of participants with normalization of fever and oxygen saturation through day 14
Secondary: proportion of participants with treatment emergent adverse events leading to study drug discontinuation (first dose date up to 10 days) NCT04292899/Recruiting, Mar6‐May 2020
Study to evaluate the safety and antiviral activity of remdesivir (GS‐5734™) in participants with moderate coronavirus disease (COVID‐19) compared to standard of care treatment Drug: remdesivir, standard of care United States, Hong Kong, 600, all, 18 years and older Treatment Experimental: remdesivir, 5 days participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, and 5.
Experimental: remdesivir, 10 days participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, 5, 6, 7, 8, 9, and 10.
Active comparator: continued standard of care therapy III Primary (up to 14 days): proportion of participants discharged by day 14‐secondary (up to 10 days): proportion of participants with treatment emergent adverse events leading to study drug discontinuation NCT04292730/Recruiting, Mar‐May 2020
Bevacizumab in severe or critical patients with COVID‐19 pneumonia‐RCT Drug: bevacizumab China/COVID‐19 Pneumonia 118, all, 18–80 Treatment Experimental; bevacizumab, group:
bevacizumab 500 mg + 0.9% NaCl 100 ml, intravenous drip
No intervention: control group Not applicable Primary: proportion of patients whose oxygenation index increased by 100 mmHg on the 7th day after admission NCT04305106/Not yet recruiting, Mar12‐May31 2020
The efficacy and safety of thalidomide in the adjuvant treatment of moderate new coronavirus (COVID‐19) pneumonia Drug: thalidomide, placebo COVID‐19 thalidomide 100, all, 18 years and older Treatment Placebo comparator: control group: placebo 100 mg, po, qn, for 14 days
Experimental: thalidomide group 100 mg, po, qn, for 14 days. Other name: fanyingting II Primary (up to 28 days): time to clinical recovery time to clinical recovery (up to 28 days)
Secondary (up to 28 days): all cause mortality (up to 28 days), frequency of respiratory progression, Time to defervescence
Others(up to 28 days): time to cough reported as mild or absent, respiratory improvement time, frequency of requirement for supplemental oxygen or noninvasive ventilation, Time to 2019‐nCoV RT‐PCR negative in upper respiratory tract specimen, change (reduction) in 2019‐nCoV viral load in upper respiratory tract specimen as assessed by area under viral load curve, frequency of requirement for mechanical ventilation, frequency of serious adverse events, Serum TNF‐α, IL‐1β, IL‐2, IL‐6, IL‐7, IL‐10, GSCF, IP10, MCP1, MIP1α and other cytokine expression levels before and after treatment NCT04273529/Not yet recruiting, Feb20‐Jun30 2020
The efficacy and safety of thalidomide combined with low‐dose hormones in the treatment of Severe COVID‐19 Placebo, drug: thalidomide COVID‐19 thalidomide 40, all, 18 years and older Treatment Placebo comparator: control group α‐interferon: nebulized inhalation, 5 million U or equivalent dose added 2 ml of sterile water for injection, 2 times a day, for 7 days; abidol, 200 mg/time, 3 times a day, for 7 days; methylprednisolone: 40 mg, q12h, for 5 days. placebo: 100 mg/d, qn, for 14 days
Experimental: thalidomide group α‐interferon: nebulized inhalation, 5 million U or equivalent dose added 2 ml of sterile water for injection, 2 times a day, for 7 days; abidol, 200 mg/time, 3 times a day, for 7 days; methylprednisolone: 40 mg, q12h, for 5 days. thalidomide: 100 mg/d qn for 14 days II Primary (up to 28 days): time to clinical improvement
Secondary (up to 28 days): clinical status (days 7, 14, 21, and 28), time to hospital discharge or NEWS2 (National Early Warning Score 2) of ≤2 maintained for 24 hr, all cause mortality, duration (days) of mechanical ventilation, duration (days) of extracorporeal membrane oxygenation, duration (days) of supplemental oxygenation, length of hospital stay (days), time to 2019‐nCoV RT‐PCR, change (reduction) in 2019‐nCoV viral load in upper and lower respiratory tract specimens as assessed by area under viral load curve, frequency of serious adverse drug events, Serum TNF‐α, IL‐1β, IL‐2, IL‐6, IL‐7, IL‐10, GSCF, IP10#MCP1, MIP1α, and other cytokine expression levels before and after treatment NCT04273581/Not yet recruiting, Feb18‐May30 2020
Tetrandrine tablets used in the treatment of COVID‐19 Drug: tetrandrine China/COVID‐19 60, all, 18–75 Treatment Experimental: tetrandrine cohort after the subjects were enrolled, they were given “Tetrandrine 60 mg QD” for a course of 1 week (take 6 days, stop using for 1 day)
No intervention: control cohort treatment according to standard protocols without intervention IV Primary (12 weeks): survival rate secondary (2 weeks): body temperature NCT04308317/Enrolling by invitation, Mar5‐May1 2020
Fingolimod in COVID‐19 Biological: UC‐MSCs, other: placebo China/COVID‐19 30, all, 18–80 Treatment Experimental: treatment group: each patient in the fingolimod treatment group was given 0.5 mg of fingolimod orally once daily, for three consecutive days
No Intervention: control group II Primary (5 day after treatment): the change of pneumonia severity on X‐ray images NCT04280588/Recruiting, Feb22‐Jul1 2020
Therapy for pneumonia patients infected by 2019 novel coronavirus Biological: UC‐MSCs, other: placebo China/COVID‐19 48, all, 18–75 Treatment Experimental: UC‐MSCs treatment group, participants will receive conventional treatment plus four times of 0.5*10E6 UC‐MSCs/kg body weight intravenously at Day1, Day3, Day5, Day7)
Placebo comparator: control group, participants will receive conventional treatment plus 4 times of placebo intravenously at Day1, Day3, Day5, Day7 Not applicable Primary (at baseline, Day 1, Weeks 1, 2, 4, 8): size of lesion area by chest imaging, blood oxygen saturation
Secondary (at baseline, Day 1, Weeks 1, 2, 4, 8): rate of mortality within 28‐days, sequential organ failure assessment, side effects in the UC‐MSCs treatment group, Electrocardiogram, the changes of ST‐T interval mostly, Concentration of C‐reactive protein C‐reactive protein, immunoglobulin, CD4 + and CD8 + T cells count, Concentration of the blood cytokine (IL‐1β, IL‐6, IL‐8,IL‐10,TNF‐α), Concentration of the myocardial enzymes NCT04293692/Recruiting, Feb24‐Feb1 2020–2021
The Use PUL‐042 inhalation solution to prevent COVID‐19 in adults exposed to SARS‐CoV‐2 Drug: PUL‐042 inhalation solution, drug: placebo COVID‐19 200, all, 18 years and older Treatment Experimental: PUL‐042 inhalation solution, PUL‐042 inhalation solution (20.3 µg Pam2: 29.8 µg ODN/mL) given by nebulization on study days 1,3, 6, and 10
Placebo comparator: sterile normal saline for inhalation, sterile normal saline for inhalation given by nebulization on study days 1, 3, 6, and 10 II Primary (14 days): Prevention of COVID‐19 NCT04313023/Not yet recruiting, Apr‐Oct 2020
Treatment of COVID‐19 patients using Wharton's jelly‐mesenchymal stem cells Biological: WJ‐MSCs Arabia Amman, Jordan/use of stem cells for COVID‐19 treatment 5, all, 18 years and older Treatment Experimental: WJ‐MSCs WJ‐MSCs will be derived from cord tissue of newborns, screened for HIV1/2, HBV, HCV, CMV, mycoplasma, and cultured to enrich for MSCs.
WJ‐MSCs will be counted and suspended in 25 ml of saline solution containing 0.5% human serum albumin, and will be given to patient intravenously I Primary (3 weeks): Clinical outcome, CT Scan, RT‐PCR results
Secondary (8 weeks): RT‐PCR results NCT04313322/Recruiting, Mar16‐Sep30 2020
Myocardial damage in COVID‐19 Non China/COVID‐19 cardiovascular diseases 500, all, 18 years and older Prognostic Discharged group (no intervention) the individual which is defined as patient discharged from hospital
Dead group (no intervention) The individual which is defined as patient with all‐cause death – Primary (75 days): the myocardial injury incidence, the risk factors analysis for the death
Secondary (75 days): clinical characteristics, clinical course, cardiovascular comorbidity, Analysis of causes of death NCT04312464/Enrolling by invitation, Jun1‐Mar18 2020
Treatment with mesenchymal stem cells for severe corona virus disease 2019(COVID‐19) Biological: MSCs, biological: saline containing 1%, human serum albumin (solution of MSC China/COVID‐19 60, all, 18–70 Treatment Experimental: mesenchymal stem cells (MSCs), conventional treatment plus MSCs participants will receive conventional treatment plus 3 times of MSCs ((4.0*10E7 cells per time) intravenously at Day 0, Day 3, Day 6)
Placebo comparator: placebo conventional treatment plus placebo participants will receive conventional treatment plus 3 times of placebo (saline containing 1% human serum albumin (solution of MSC) 3 times of placebo (intravenously at Day 0, Day 3, Day 6) I, II Primary (28 days): improvement time of clinical critical treatment index, side effects in the MSCs treatment group
Secondary: proportion of patients in each classification of clinical critical treatment index (baseline, Days 7, 14, 28), all cause mortality on Day 28, invasive mechanical ventilation rate (Day 28), duration of oxygen therapy (Day 28), duration of hospitalization (Day 28), incidence of nosocomial infection (Day 28), CD4+ T cell count by flow cytometry in two groups (baseline, Day, 3, 6, 10, 14, 21, 28) NCT04288102/Recruiting, May5‐Dec31 2020–2021
The clinical study of carrimycin on treatment patients with COVID‐19 Drug: carrimycin, drug: lopinavir/ritonavir tablets or arbidol or chloroquine phosphate, Drug: basic treatment – 520, all, 18–75 Treatment Experimental: carrimycin basic treatment + carrimycin
Active comparator: lopinavir/ritonavir or arbidol or chloroquine phosphate any of basic treatment + lopinavir/ritonavir tablets or arbidol or chloroquine phosphate IV Primary (30 days): fever to normal time (day), pulmonary inflammation resolution time (HRCT) (day), negative conversion (%) of 2019‐nCOVRNA in gargle (throat swabs) at the end of treatment NCT04286503/Not yet recruiting, Feb23‐Feb28 2020–2021
Efficacy and safety of corticosteroids in COVID‐19 Drug: methylprednisolone China/COVID‐19 400, all, 18 years and older Treatment Experimental; Pred group: methylprednisolone 1 mg/kg/day ivgtt for 7 days
No intervention: con group Not applicable Primary (14 days): the incidence of treatment failure in 14 days
Secondary: clinical cure incidence (14 days), the duration of virus change to negative (14 days), mortality at Day 30, ICU admission rate in 30 days NCT04273321/Recruiting, Feb14‐May30 2020
Evaluation of the efficacy and safety of sarilumab in hospitalized patients with COVID‐19 Drug: sarilumab, drug: placebo United States/COVID‐19 400, all, 18 years and older Treatment Experimental: sarilumab high dose: single intravenous (IV) dose of sarilumab, other names: Kevzara®, REGN88, SAR153191
Experimental: sarilumab low dose: single intravenous (IV) dose of sarilumab Other Names: Kevzara®, REGN88, SAR153191
Placebo comparator: single intravenous (IV) dose of placebo to match sarilumab administration II, III Primary: time to resolution of fever for at least 48 hr without antipyretics for 48 hr (Up to Day 29), percentage of patients reporting each severity rating on a 6‐point ordinal scale (Day 15)
Secondary (up to Day 29): time to improvement in oxygenation for at least 48 hr, mean change in the 6‐point ordinal scale, clinical status using the 6‐point ordinal scale, time to improvement in one category from admission using the 6‐point ordinal scale, time to resolution of fever for at least 48 hr without antipyretics by clinical severity, time to resolution of fever for at least 48 hr without antipyretics by baseline IL‐6 levels, time to improvement in oxygenation for at least 48 hr by clinical severity, time to improvement in oxygenation for at least 48 hr by baseline IL‐6 levels, time to resolution of fever and improvement in oxygenation for at least 48 hr, time to change in National Early Warning Score 2 (NEWS2) scoring system, time to score of <2 maintained for 24 hr in NEWS2 scoring system, mean change in NEWS2 scoring system, number of days with fever, number of patients alive off oxygen, number of days of resting respiratory rate >24 breaths/min, number of days with hypoxemia, number of days of supplemental oxygen use, time to saturation ≥94% on room air, number of ventilator free days in the first 28 days, number of patients requiring initiation of mechanical ventilation, number of patients requiring noninvasive ventilation, number of patients requiring the use of high flow nasal cannula, number of patients admitted into an intensive care unit, number of days of hospitalization among survivors, number of deaths due to any cause (up to Day 60), incidence of serious adverse events (Up to Day 60), incidence of severe or life‐threatening bacterial, invasive fungal, or opportunistic infection, Incidence of severe or life‐threatening bacterial, invasive fungal, or opportunistic infection in patients with grade 4 neutropenia, Incidence of hypersensitivity reactions, incidence of infusion reactions, incidence of gastrointestinal perforation, white blood cell count, hemoglobin levels, platelet count, creatinine levels, total bilirubin level, alanine aminotransferase level, aspartate aminotransferase level NCT04315298/Recruiting, Mar16‐Mar16 2020–2021
Washed microbiota transplantation for patients with 2019‐nCoV infection Other: washed microbiota transplantation, other: placebo China/COVID‐19 complicated with refractory intestinal infections 0, all, 14–70 complicated with refractory intestinal infections Treatment Experimental: observational group 5 u washed microbiota suspension administered via nasogastric tube, nasojejunal tube or oral, combining with standard therapy
Placebo comparator: control group 5 u placebo (edible suspension of the same color as the washed microbiota suspension) administered via nasogastric tube, nasojejunal tube or oral, combining with standard therapy Not applicable Primary (2 weeks): number of participants with improvement from severe type to common type NCT04251767/Withdrawn, Feb5‐Apr30 2020
Safety and immunity of Covid‐19 aAPC vaccine Biological: pathogen‐specific aAPC China/Covid‐19 infection 100, all, 6 months to 80 years Treat and Prevent Covid‐19 Infection Experimental: the subjects will receive three injections of 5×10^6 each Covid‐19/aAPC vaccine via subcutaneous injections I Primary (0–28 day): frequency of vaccine events, frequency of serious vaccine events, proportion of subjects with positive T cell response
Secondary (0–28 day): mortality, duration of mechanical ventilation if applicable, proportion of patients in each category of the 7‐point scale (7, 14, and 28 days after randomization), proportion of patients with normalized inflammation factors (7 and 14 days after randomization), clinical improvement based on the 7‐point scale if applicable, lower Murray lung injury score if applicable (7 days after randomization) NCT04299724/Recruiting, Feb15‐Dec31 2020–2024
Safety related factors of endotracheal intubation in patients with severe Covid‐19 pneumonia Severe covid‐19 pneumonia with ET COVID‐19 endotracheal intubation 120, all, 18–90 Observational Intervention details: other: severe covid‐19 pneumonia with ET, severe covid‐19 pneumonia undergoing endotracheal intubation – Primary:
Success rate of intubation (the time span between 1 hr before intubation and 24 hr after intubation), infection rate of anesthesiologist (the time span between 1 hr before intubation and 14 days after intubation)
Secondary:
Extubation time (the time span between 1 hr before intubation and 30 days after intubation) NCT04298814/Not yet recruiting, Mar7‐Jul30 2020
Immunity and safety of Covid‐19 synthetic minigene vaccine Biological: injection and infusion of LV‐SMENP‐DC vaccine and antigen‐specific CTLs China/COVID‐19 100, all, 6 months to 80 years Treatment Experimental: pathogen‐specific DC and CTLs patients will receive approximately 5 × 106 LV‐DC vaccine and 1 × 108 CTLs via subcutaneous injections and iv infusions, respectively I
II Primary:
Clinical improvement based on the 7‐point scale (28 days after randomization), lower Murray lung injury score (7 days after randomization)
Secondary (0–28 day): 28‐day mortality, duration of mechanical ventilation, duration of hospitalization, proportion of patients with negative RT‐PCR results (7 and 14 days after randomization), proportion of patients in each category of the 7‐point scale (7, 14, and 28 days after randomization), proportion of patients with normalized inflammation factors (7 and 14 days after randomization), frequency of vaccine/CTL events, frequency of serious vaccine/CTL events NCT04276896/Recruiting, Mar24‐Dec31 2020–2024
Phase I clinical trial in healthy adult Biological: recombinant novel coronavirus vaccine (adenovirus type 5 vector) – 108, all, 18–60 Prevention Experimental: low‐dose group subjects received one dose of 5E10 vp Ad5‐nCoV at 18–60 years old
Experimental: middle‐dose group
Subjects received one dose of 1E11 vp Ad5‐nCoV at 18–60 years old
Experimental: high‐dose group
Subjects received one dose of 1.5E11vp Ad5‐nCoV at 18–60 years old I Primary (0–7 days postvaccination): safety indexes of adverse reactions
Secondary (Day 14, 28, Month 3, 6 postvaccination):
Safety indexes of adverse events (0–28 days postvaccination), safety indexes of SAE (0–28 days, within 6 mouths postvaccination), safety indexes of lab measures (pre‐vaccination, Day 7 postvaccination), immunogencity indexes of GMT(ELISA) (Day 14, 28, Month 3, 6 postvaccination), immunogencity indexes of GMT (pseudoviral neutralization test method), immunogencity indexes of seropositivity rates, immunogencity indexes of seropositivity rates (pseudoviral neutralization test method, immunogencity indexes of GMI (ELISA), immunogencity indexes of GMI (pseudoviral neutralization test method), immunogencity indexes of GMC (Ad5 vector), immunogencity indexes of GMI (Ad5 vector), immunogencity indexes of cellular immune
Other (day、14,28, Month3,6 postvaccination):
Consistency analysis(ELISA and pseudoviral neutralization test method), Dose‐response relationship (Humoral immunity), Persistence analysis of anti‐S protein antibodies, Time‐dose‐response relationship (Humoral immunity), Dose‐response relationship (cellular immunity), Persistence analysis of cellular immuse, Time‐dose‐response relationship (cellular immunity) NCT04313127/Not yet recruiting, Mar1Dec20 2020–2022
Development and verification of a new coronavirus multiplex nucleic acid detection system Diagnostic test: new QIAstat‐Dx fully automatic multiple PCR detection platform China/COVID‐19 100, all, 16 years to 100 years Diagnostic Diagnostic test: new QIAstat‐Dx fully automatic multiple PCR detection platform
We use the new QIAstat‐Dx fully automatic multiple PCR detection platform to test the enrolled patients – Primary:
Sensitivity, spectivity turnaround time of the New QIAstat‐Dx fully automatic multiple PCR detection platform (3 months) NCT04311398/Not yet recruiting, Mar14‐Dec1, 2020
Hydroxychloroquine treatment for severe COVID‐19 pulmonary infection (HYDRA Trial) Drug: hydroxychloroquine, drug: placebo oral tablet COVID‐19 severe acute respiratory syndrome 500, all, 18–0 Treatment Active comparator: treatment
Hydroxychloroquine tablet 200 mg every 12 hr for 10 days
Placebo comparator: placebo
identical placebo, one tablet every 12 hr for 10 days III Primary (up to120 days):
All‐cause hospital mortality
Secondary (up to120 days):
Length of hospital stay, Need of mechanical ventilation, ventilator free days, Grade 3–4 adverse reaction NCT04315896/Not yet recruiting, Mar23‐Mar22 2020–2012
Tocilizumab in COVID‐19 pneumonia (TOCIVID‐19) Drug: tocilizumab Injection Italy/COVID‐19 pneumonia 330, child, adult, older adult, child, adult, older adult Treatment Experimental: Tocilizumab Injection
Tocilizumab 8 mg/kg (up to a maximum of 800 mg per dose), with an interval of 12 hr II Primary (up to 1 month):
One‐month mortality rate
Secondary (up to 1 month):
interleukin‐6 level, lymphocyte count, C‐reactive protein level (cycle 1 and 2 every 12 hr), PaO2 (partial pressure of oxygen)/FiO2 (fraction of inspired oxygen, FiO2) ratio (or P/F ratio) (baseline, during treatment (cycle 1 and 2 every 12 hr), change of the SOFA (sequential organ failure assessment) (baseline, during treatment (cycle 1 and 2 every 12 hr), number of participants with treatment‐related side effects as assessed by Common Terminology Criteria for Adverse Event version 5.0, Radiological response, Time Frame: at baseline (optional), after 7 days and if clinically indicated, duration of hospitalization. Time Frame: from baseline up to patient's discharge, Remission of respiratory symptoms NCT04317092/Recruiting, Mar19‐Dec19 2020–2022
Mesenchymal stem cell NestCell® to treat patients with severe COVID‐19 pneumonia Biological: NestCell® COVID‐19 pneumonia 6, all, 18 years and older Treatment Experimental: NestCell®:
All patients will receive conventional treatment plus 3 times of 1 × 106 cells/kg body weight intravenously on Day1, Day3, and Day7 I Primary (28 days):
Disappear time of ground‐glass shadow in the lungs
Secondary:
Rate of mortality within 28‐days, Improvement of clinical symptoms including duration of fever and respiratory (At Baseline, Day 3, 7, 10, 14, 21, 28), Time of nucleic acid turning negative (28 days), CD4+ and CD8+ T cell count (At Baseline, Day 3, 6, 10, 14, 21, and 28), changes of blood oxygen (At Baseline, Day 3, 6, 10, 14, 21, and Day 28), side effects in the treatment group (28 days) NCT04315987/Not yet recruiting, Apr‐Jun 2020
CD24Fc as a non‐antiviral immunomodulator in COVID‐19 treatment Drug: CD24Fc, drug: placebo United States/severe coronavirus disease (COVID‐19) 230, all, 18 years and older Treatment Experimental: CD24Fc treatment
Single dose at Day 1, CD24Fc, 480 mg, diluted to 100 ml with normal saline, IV infusion in 60 min
Placebo comparator: placebo
Single dose at Day 1, normal saline solution 100 ml, IV infusion in 60 min III Primary (14 days):
Improvement of COVID‐19 disease status secondary (14 days):
Conversion rate of clinical status at Day 8 (7 days), conversion rate of clinical status at Day 15, hospital discharge time, all cause of death, duration of mechanical ventilation, duration of pressors, duration of ECMO, duration of oxygen therapy, length of hospital stay, absolute lymphocyte count NCT04317040/Not yet recruiting,May‐May 2020–2022
Acute kidney injury in patients hospitalized with COVID‐19 – China/COVID‐19 acute kidney injury‐kidney function 287, all, 18 years and older Observational Acute kidney injury:
COVID‐19 patients with acute kidney injury
nonacute kidney injury:
COVID‐19 patients without acute kidney injury –
Rate of death, the length of hospital stay Primary (up to 60 days):
Rate of acute kidney injury
Secondary (up to 60 days): NCT04316299/Completed, Feb 26‐Mar8 2020
Phase I clinical trial in healthy adult Logical: recombinant novel coronavirus vaccine (adenovirus type 5 vector) COVID‐19 108, all, 18–60 Treatment (Adenovirus Type 5 Vector)
Experimental: low‐dose group
Subjects received one dose of 5E10 vp Ad5‐nCoV at 18–60 years old
Experimental: middle‐dose group
Subjects received one dose of 1E11 vp Ad5‐nCoV at 18–60 years old
Experimental: high‐dose group subjects received one dose of 1.5E11vp Ad5‐nCoV at 18–60 years old I Primary (0–7 days postvaccination):
Safety indexes of adverse reactions
Secondary (0–28 days postvaccination, within 6 mouths postvaccination):
Safety indexes of adverse events, Safety indexes of SAE, Safety indexes of lab measures, Immunogencity indexes of GMT (ELISA), Immunogencity indexes of GMT (pseudoviral neutralization test method) (Day 14, 28, Month 6 postvaccination), Immunogencity indexes of seropositivity rates (ELISA) (Day 14, 28, Month 3, 6 postvaccination), Immunogencity indexes of seropositivity rates(pseudoviral neutralization test method) (Day 14, 28, Month 6 postvaccination), Immunogencity indexes of GMI (ELISA) (Day 14, 28, Month 3, 6 postvaccination), Immunogencity indexes of GMI (pseudoviral neutralization test method) (Day 14, 28, Month 6 postvaccination), Immunogencity indexes of GMC (Ad5 vector) (Day 14, 28, Month 3, 6 postvaccination), Immunogencity indexes of GMI(Ad5 vector) (Day 14, 28, Month 3, 6 postvaccination), Immunogencity indexes of cellular immune (Day 14, 28, Month 6 postvaccination)
Other (Day 14,28, Month 6 postvaccination):
Consistency analysis (ELISA and pseudoviral neutralization test method), dose‐response relationship (humoral immunity) (Day 14, 28, Month 3, 6 postvaccination), Persistence analysis of anti‐S protein antibodies (Day 14, 28, Month 3, 6 postvaccination), Time‐dose‐response relationship (Humoral immunity) (Day 14, 28, Month 3, 6 postvaccination), Dose‐response relationship (cellular immunity) (Day 14, 28, Month 6 postvaccination), Persistence analysis of cellular immuse (Day 14, 28, Month 6 postvaccination), Time‐dose‐response relationship (cellular immunity) (Day 14, 28, Month 6 postvaccination) NCT04313127/Not yet recruiting, Mar19‐Dec20 2020–2021
Favipiravir combined with tocilizumab in the treatment of corona virus disease 2019 Drug: favipiravir combined with tocilizumab, drug: favipiravir, drug: tocilizumab China, COVID‐19 150, all, 18–65 Treatment Experimental: favipiravir combined with tocilizumab group
Favipiravir: On the 1st day, 1,600 mg each time, twice a day; from the 2nd to the 7th day, 600 mg each time, twice a day. Oral administration, the maximum number of days taken is not more than 7 days.
Tocilizumab: the first dose is 4–8 mg/kg and the recommended dose is 400 mg. For fever patients, an additional application (the same dose as before) is given if there is still fever within 24 hr after the first dose and the interval between two medications ≥12 hr. Intravenous infusion. The maximum of cumulative number is two, and the maximum single dose does not exceed 800 mg
Active comparator: favipiravir group
On the 1st day, 1,600 mg each time, twice a day; from the 2nd to the 7th day, 600 mg each time, twice a day. Oral administration, the maximum number of days taken is not more than 7 days
Active comparator: tocilizumab group
The first dose is 4–8 mg/kg and the recommended dose is 400 mg. For fever patients, an additional application (the same dose as before) is given if there is still fever within 24 hr after the first dose and the interval between two medications ≥12 hr. Intravenous infusion, The maximum of cumulative number is two, and the maximum single dose does not exceed 800 mg Not applicable Primary (3 months):
Clinical cure rate
Secondary (14 days after taking medicine):
Viral nucleic acid test negative conversion rate and days from positive to negative, duration of fever, lung imaging improvement time, mortality rate because of corona virus disease 2019 (3 months), rate of noninvasive or invasive mechanical ventilation when respiratory failure occurs (3 months), mean in‐hospital time (3 months) NCT04310228/Recruiting, Mar8‐May 2020
Novel coronavirus induced severe pneumonia treated by dental pulp mesenchymal stem cells Biological: dental pulp mesenchymal stem cells ‐COVID‐19 24, all, 18–75 Treatment Experimental: pulp mesenchymal stem cells 1. 3, 7 days to increase the injection of mesenchymal stem cells Early Phase I Primary (14 days):
Disppear time of ground‐glass shadow in the lungs
Secondary:
Absorption of lung shadow absorption by CT Scan‐Chest (7, 14, 28, and 360 days), Changes of blood oxygen (3, 7, and 14 days) NCT04302519/Not yet Recruiting, Mar5‐Jul30 2020–2021
Multicenter clinical study on the efficacy and safety of Xiyanping injection in the treatment of new coronavirus infection pneumonia (general and severe) Drug: lopinavir/ritonavir tablets combined with Xiyanping injection drug: lopinavir/ritonavir treatment COVID‐19 80, all, 18–100 Treatment Experimental: experimental group of ordinary COVID‐19:
Xiyanping injection, 10–20 ml daily, Qd, the maximum daily does not exceed 500 mg (20 ml) + lopinavir tablet or ritonavir tablet + alpha‐interferon nebulization, for 7–14 days,
Active comparator: control group of ordinary COVID‐19:
Lopinavir/ritonavir tablets, two times a day, two tablets at a time; alpha‐interferon nebulization
Experimental: experimental group of severe COVID‐19:
Xiyanping injection, 10–20 ml daily, Qd, the maximum daily does not exceed 500 mg (20 ml) + lopinavir tablet or ritonavir tablet + alpha‐interferon nebulization, for 7–14 days Not applicable Primary:
Clinical recovery time (up to Day 28) NCT04295551/Not yet Recruiting, Mar14‐Apr14 2020–2021
Prognostic factors of patients with COVID‐19 – China/SARS‐CoV‐2 outcome, fatal 201, all, 18 years and older Prognostic SARS‐CoV‐2Outcome, fatal – Primary (30 days):
all‐cause mortality
Secondary (15 days):
all‐cause mortality,
Severe state NCT04292964/Completed Mar1‐Mar13 2020
Chloroquine prevention of coronavirus disease (COVID‐19) in the healthcare setting Drug: chloroquine, drug: placebo COVID19 coronavirus acute respiratory illnesses 10,000, all, 16 years and older Prevention Experimental: chloroquine:
a loading dose of 10 mg base/kg followed by 150 mg daily (250 mg chloroquine phosphate salt) will be taken for 3 months
Placebo comparator: placebo Not applicable Primary (approximately 100 days):
Number of symptomatic COVID‐19 infections
Secondary (approximately 100 days):
Symptoms severity of COVID‐19, duration of COVID‐19, number of asymptomatic cases of COVID‐19, number of symptomatic acute respiratory illnesses, genetic loci and levels of biochemical components will be correlated with frequency of COVID‐19, ARI, and disease severity
Other (approximately 100 days):
Drug exposure‐protection relationship NCT04303507/Not yet recruiting, May‐May 2020–2022
Yinhu Qingwen decoction for the treatment of mild/common CoVID‐19 Drug: YinHu QingWen decoction, drug: YinHu QingWen decoction(low dose), other: Chinese medicine treatment, other: standard western medicine treatment China/CoVID‐19 Chinese medicine 300, all, 18 years and older Treatment Experimental: Yin Hu Qing Wen decoction group
Based on the standard western medicine treatment, the patients will be given Yinhu Qingwen decoction (granula) for 10 days.
Drug: YinHu QingWen decoction YinHu QingWen decoction (granula) consits of 11 Chinese herbal medicine as honeysuckle, Polygonum cuspidatum, Schizonepeta, Longspur epimedium, and so forth. The decoction granula will be dissolved into 600 ml decoction and divided to three times (once with 200 ml). It will be given a 200 ml per time, three times a day, for 10 days
Other: standard western medicine treatment treatment is according to the protocol of treatment of CoVID‐19 infection according to guideline appoved by National Health Commission of China
Placebo comparator: Yinhu Qingwen decoction low‐dose group
Based on the standard western medicine treatment, the patients will be given 10% dose of Yinhu Qingwen decoction (granula) for 10 days
Drug: YinHu QingWen decoction (low dose) this intervention is given as 10% dose of YinHu QingWen decoction (granula). The granula will be dissolved into 600 ml decoction and divided to three times (once with 200 ml). It will be given a 200 ml per time, three times a day, for 10 days
Other: standard western medicine treatment standard western medicine treatment is according to the protocol of treatment of CoVID‐19 infection according to guideline appoved by National Health Commission of China
Active comparator: integrated Chinese and western medicine group
Based on the standard western medicine treatment, the patients will be given Chinese medicine decotion granula according to their symptoms. The daily dose of Chinese medicine decoction granula will also be dissolved to 600 ml decoction and divided into three times (once with 200 ml). The Chinese medicine decoction will be given 200 ml per time, three times a day for 10 days
Other: Chinese medicine treatment
This intervention will be given with Chinese medicine decoction granula based on the symptoms differentiation of the patients for 10 days
Other: standard western medicine treatment
Standard western medicine treatment is according to the protocol of treatment of CoVID‐19 infection according to guideline appoved by National Health Commission of China II
III Primary (up to 28 days):
Mean clinical recovery time
Secondary (up to 28 days):
Time to CoVID‐19 RT‐PCR negative in upper respiratory tract specimen, change (reduction) in CoVID‐19 viral load in upper respiratory tract specimen as assessed by area under viral load curve, time to defervescence (in those with fever at enrollment), time to cough reported as mild or absent (in those with cough at enrollment rated severe or moderate), time to dyspnea reported as mild or absent (on a scale of severe, moderate, mild absent, in those with dyspnea at enrollment rated as severe or moderate)
Frequency of requirement for supplemental oxygen or noninvasive ventilation, frequency of respiratory progression, severe case incidence, proportion of rehospitalization or admission to ICU, all‐cause mortality, frequency of serious adverse events NCT04278963/Active, Not Recruiting, Feb27‐Jan 2020
Prognositc factors in COVID‐19 patients complicated with hypertension – China, COVID‐19 0, all, 18–100 Prognostic ACEI treatment
hypertension patients with ACEI treatment when suffered with novel coronavirus infection in China
Control
hypertension patients without ACEI treatment when suffered with novel coronavirus infection in China – Primary (up to 28 days):
Occupancy rate in the intensive care unit, mechanical ventilation, death
Secondary (up to 28 days):
All cause mortality, time from onset of symptoms to main outcome and its components, time to clinical recovery NCT04272710/Withdrawn, Jan25‐Apr30 2020
Evaluating the efficacy and safety of bromhexine hydrochloride tablets combined with standard treatment/standard treatment in patients with suspected and mild novel coronavirus pneumonia (COVID‐19) Drug: bromhexine hydrochloride tablets, drug: arbidol hydrochloride granules, drug: recombinant human interferon α2b spray, drug: favipiravir tablets China, novel coronavirus pneumonia 2019‐nCoV 60, all, 18–80 Treatment Experimental: group A treatment group:
Bromhexine hydrochloride tablets, arbidol hydrochloride granules:
Standard treatment refers to the latest edition of pneumonia diagnosis and treatment scheme for novel coronavirus infection. Arbidol hydrochloride granules is recommended but not enforced to use
Recombinant human interferon α2b spray:
Standard treatment refers to the latest edition of pneumonia diagnosis and treatment scheme for novel coronavirus infection
Favipiravir tablets
Active comparator; group B control group:
Drug: arbidol hydrochloride granules
Standard treatment refers to the latest edition of pneumonia diagnosis and treatment scheme for novel coronavirus infection. arbidol hydrochloride granules is recommended but not enforced to use
Drug: recombinant human interferon α2b spray
Standard treatment refers to the latest edition of pneumonia diagnosis and treatment scheme for novel coronavirus infection Not applicable Primary (within 14 days from the start of medication):
Time to clinical recovery after treatment
Secondary (within 14 days from the start of medication):
Rate of aggravation, clinical remission rate, dynamic changes of oxygenation index, time to cure, rate to cure, time to defervescence, time to cough remission,days of supplemental oxygenation, rate of patients with requring supplemental oxygen, rate of patients with mechanical ventilation, time of negative COVID‐19 nucleic acid results, rate of negative COVID‐19 nucleic acid results, rate of ICU admission, 28‐day mortality (From the first day of screening to the day of follow‐up (28 days)) NCT04273763/Enrolling by invitation, Feb16‐Apr30 2020
Various combination of protease inhibitors, oseltamivir, favipiravir, and chloroquin for treatment of covid19: a randomized control trial Drug: oral Thailand, coronavirus infections COVID19 80, all, 16–100 Treatment Experimental: oseltamivir plus chloroquin in mild COVID19
Oseltamivir 300 mg per day plus chloroquin 1,000 mg per Day In mild COVID19
Experimental: lopinavir and ritonavir plus favipiravir
Lopinavir 10 mg/kg and ritonavir 2.5 mg/kg plus favipiravir 2,400 mg, 2,400 mg, and 1,200 mg every 8 hr on Day 1, and a maintenance dose of 1,200 mg twice a day in Mild COVID19
Experimental: lopinavir and ritonavir plus oseltamivir in mild COVID19
Lopipinavir 10 mg/kg and ritonavir 2.5 mg/kg plus oseltamivir 4–6 mg/kg In mild COVID19
Experimental: lopinavir and ritonavir oseltamivir moderate to severe COVID19
Lopipinavir 10 mg/kg and ritonavir 2.5 mg/kg plus oseltamivir 4–6 mg/kg in moderate to critically ill COVID19
Experimental: favipiravir lopinavir/ritonavir for mod. To severe
favipiravir 2,400 mg, 2,400 mg, and 1,200 mg every 8 hr on Day 1, and a maintenance dose of 1,200 mg twice a day plus lopipinavir 10 mg/kg and ritonavir 2.5 mg/kg in moderate to critically ill COVID19
Experimental: darunavir/ritonavir oseltamivir chloroquine mod‐severe
Combination of Darunavir 400 mg every 8 hr ritonavir Ritonavir 2.5 mg/kg plus Oseltamivir 4–6 mg/kg plus Chloroquine 500 mg per Day In moderate to critically ill COVID19
Experimental: darunavir/ritonavir favipiravir chloroquine mod‐severe
Favipiravir 2,400 mg, 2,400 mg, and 1,200 mg every 8 hr on Day 1, and a maintenance dose of 1,200 mg twice a day plus darunavir 400 mg every 8 hr ritonavir ritonavir 2.5 mg/kg plus chloroquine 500 mg per Day In moderate to critically ill COVID19
No intervention: conventional qurantine
Patient who unwilling to treatment and willing to quarantine in mild COVID19 III Primary (Up to 24 weeks):
SARS‐CoV‐2 eradication time
Secondary (up to 24 weeks):
Number of patient with death, number of patient with recovery adjusted by initial severity in each arm, number of day with ventilator dependent adjusted by initial severity in each arm,number of patient developed acute respiratory distress syndrome after treatment
Other (up to 24 weeks):
Number of patient with acute respiratory distress syndrome recovery NCT04303299/Not yet recruiting, Mar15‐Nov30 2020
Yinhu Qingwen Granula for the treatment of severe CoVID‐19 Drug: Yinhu Qingwen granula, drug: Yin Hu Qing Wen granula (low does), other: standard medical treatment China, COVID‐19 severe pneumonia Chinese medicine 116, all, 18 years and older Treatment Experimental:
Yinhu Qingwen granula group:
Drug: Yinhu Qingwen Granula
Yinhu Qingwen granula is a kind of herbal granula made from “Yinhu Qingwen Decoction,” which consits of 11 Chinese herbal medicine as honeysuckle, Polygonum cuspidatum, schizonepeta, Longspur epimedium, etc. The granula will be dissolved into 600 ml decoction and divided to three times (once with 200 ml). It will be given a 200 ml per time, three times a day, for 10 days.
Other: standard medical treatment Standard medical treatment is adhered to the protocol of the treatment for the severe CoVID‐19 according to the guideline approved by National Health Commission of China.
Placebo comparator: Yinhu Qingwen granula low‐dose group:
Drug: Yin Hu Qing Wen granula (low does). This intervention is given as 10% dose of YinHu QingWen Granula.The granula will be dissolved into 600 ml decoction and divided to three times (once with 200 ml).
Other: standard medical treatment Standard medical treatment is adhered to the protocol of the treatment for the severe CoVID‐19 according to the guideline approved by National Health Commission of China. II Primary (Day 10):
changes in the ratio of PaO2 to FiO2 from baseline
Secondary (up to 30 days):
PaO2, blood oxygen saturation (SpO2), clinical status rating on the 7‐point ordinal scale, time to clinical improvement, duration (hours) of noninvasive mechanical ventilation or high‐flow nasal catheter oxygen inhalation use, duration (hours) of invasive mechanical ventilation use, duration (hours) of extracorporeal membrane oxygenation (ECMO) use, duration (days) of oxygen use, The proportion of the patients reporting 2019‐nCoV RT‐PCR negativity at Day 10 after treatment, the counts/percentage of lymphocyte, time to hospital discharge with clinical recovery from the randomization, the incidence of critical status conversion in 30 days, all‐cause mortality within 30 days, frequency of severe adverse drug events NCT04310865/Not yet recruiting, Mar20‐Jun30 2020–2021
Clinical characteristics and long‐term prognosis of 2019‐nCoV infection in children – China, 2019‐nCoV 500, all, up to 18 years Prognosis 2019‐nCoV infection group
Children hospitalized with direct laboratory confirmed of novel coronavirus with or without pneumonia are classified as the 2019‐nCoV infection group
Control group Children hospitalized with pneumonia other than the novel coronavirus pneumonia during the same hospitalization period as 2019‐nCoV infection group are classified as the control group – Primary (6 months):
The cure rate of 2019‐nCoV, the improvement rate of 2019‐nCoV, the incidence of long‐term adverse outcomes
Secondary (2 weeks):
Duration of fever, duration of respiratory symptoms, duration of hospitalization, number of participant(s) need intensive care, number of participant(s) with acute respiratory distress syndrome, number of participant(s) with extra‐pulmonary complications, including shock, renal failure, multiple organ failure, hemophagocytosis syndrome, et al., number of participant(s) who died during the trial (10 months) NCT04270383/Not yet recruiting, Feb15‐Dec30 2020
The effect of T89 on improving oxygen saturation and clinical symptoms in patients with COVID‐19 Drug: T89 Coronavirus disease 2019 novel coronavirus pneumonia 120, all, 18–85 Treatment Experimental: The T89 treatment group Besides a standard background treatment (antiviral drug + antibacterial + oxygen therapy + Traditional Chinese Medicine decoction), all subjects in the T89 treatment group will receive 30 pills of T89 each time, orally, BID (every morning and evening), for 10 days (depending on clinical need and practicability, the use can be extended for up to 14 days)
No intervention: the blank control group
All subjects in the blank control group will only receive a standard background treatment (antiviral drug + antibacterial + oxygen therapy + Traditional Chinese Medicine decoction), for 10 days. Not applicable Primary (Day −1 to 10): the time to oxygen saturation recovery to normal level (≥97%), the proportion of patients with normal level of oxygen saturation(≥97%)
Secondary (Day −1 to 10):
The degree of remission of symptoms of patients, including: fatigue, nausea, vomiting, chest tightness, shortness of breath, and so forth, the time to the myocardial enzyme spectrum recovery to normal after treatment, the proportion of the patients with normal myocardial enzyme spectrum after treatment, the time to the electrocardiogram recovery to normal level after treatment, the proportion of the patients with normal electrocardiogram after treatment, the time to the hemodynamics recovery to normal after treatment, the proportion of the patients with normal hemodynamics after treatment, the time to exacerbation or remission of the disease after treatment, the proportion of the patients with exacerbation or remission of disease after treatment, the proportion of patients who need other treatment (e.g., heparin, anticoagulants) due to microcirculation disorders, the all‐cause mortality rate, the proportion of patients with acidosis, the total duration of the patients in‐hospital, the total duration of oxygen inhalation during treatment, the oxygen flow rate during treatment, the oxygen concentration during treatment NCT04285190/Not yet recruiting, Feb26‐Sep15 2020
Immunoregulatory therapy for 2019‐nCoV Drug: PD‐1 blocking antibody + standard treatment, drug: Thymosin + standard treatment, other: standard treatment ‐2019 nCoV, PD‐1 120, all, 18 years and older Treatment Experimental: PD‐1 group
Anti‐PD‐1 antibody, 200 mg, IV, one time
Experimental: thymosin group
Thymosin, 1.6 mg sc qd, last for 5 days
Placebo comparator: control group stand treatment II Primary (7 days):
lung injury score
Secondary:
Absolute lymphocyte counts (7, 14 and 28 days), serum level of CRP, PCT and IL‐6 (3, 7 and 14 days), SOFA score (7 days), all cause mortality rate (28 days), ventilation free days (28 days), ICU free days (up to 28 days) NCT04268537/Not yet recruiting, Feb10‐Oct31 2020
Tocilizumab vs CRRT in management of cytokine release syndrome (CRS) in COVID‐19 Drug: tocilizumab, other: standard of care, procedure: continuous renal replacement therapy China, Covid‐19 SARS cytokine storm (and 2 more…) 120, all, 18–80 Observational Tocilizumab
Subjects received 8 mg/kg (body weight) Tocilizumab once in 100 ml 0.9% saline solution and administered intravenously within no <60 min. Tocilizumab was administered according—continuous renal replacement therapy
Femoral vein catheterization was performed to complete continuous renal replacement therapy for consecutive three times or more. to the local label
Standard care
Standard of care therapy per local written policies or guidelines – Primary (up to 14 days):
Proportion of participants with normalization of fever and oxygen saturation
Secondary:
Duration of hospitalization (Up to 28 days), proportion of participants with normalization of fever (up to 14 days), change from baseline in white blood cell and differential count (up to 28 days), time to first negative in 2019 novel corona virus RT‐PCR test (Up to 28 days), all‐cause mortality (up to 12 weeks), change from baseline in hsCRP (Up to 28 days), change from baseline in cytokines IL‐1β, IL‐10, sIL‐2R, IL‐6, IL‐8 and TNF‐α (Up to 28 days), change from baseline in proportion of CD4 + CD3/CD8 + CD3 T cells (Up to 28 days) NCT04306705/Recruiting, Feb20‐Jun20 2020
Sars‐CoV2 seroconversion among front line medical and paramedical staff in emergency, intensive care units and infectious disease departments during the 2020 Epidemic Other: blood sample France, Sars‐CoV2 1,000, all, child, adult, older adult Other Caregiver
caregivers from emergency, ICU, virology and infectious disease services:
Two blood samples at T0 and 3 months Not applicable Primary (3 months):
Quantify the proportion of patients with documented Sars‐CoV2 infection among medical and paramedical staff
Secondary (3 months):
Identification of risk factors for seroconversion, quantify the proportion of asymptomatic infections among staff who have seroconverted, describe symptomatic infections for personnel developing acute clinical (respiratory or digestive) viral syndrome NCT04304690/Recruiting, Mar16‐Oct16 2020
John Wiley & Sons, Ltd. This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.
|
|
label
|
Table 4
|
|
caption
|
Clinical trials for COVID‐19 or SARS‐nCoV2
|
|
p
|
Clinical trials for COVID‐19 or SARS‐nCoV2
|
|
table
|
Study title Interventions Location/condition Subjects, sex, age Primary purpose Arms Phase Measure outcome/time frame Code/status/date
The efficacy and safety of huaier in the adjuvant treatment of COVID‐19 Drug: Huaier Granule COVID‐19 550, all, 18–75 Treatment Experimental group: standard therapy + Huaier granule 20 g, po, tid for 2 weeks (or until discharge)
Control group: standard therapy II, III Primary (up to 28 days): all cause mortality
Secondary (up to 28 days): clinical status, differences in oxygen intake methods, supplemental oxygenation, mechanical ventilation, mean PaO2/FiO2, length of hospital stay, Length of ICU stay (days), pulmonary function (up to 3 months after discharge) NCT04291053/Not yet recruiting, Apr1‐Sep1 2020
Clinical trial on regularity of TCM syndrome and differentiation treatment of COVID‐19 Drug: TCM prescriptions China/COVID‐19 340, all, 18–75 Treatment Exposure group: integrated TCM and western medicine cohort (routine treatment + one or two of the following antiviral drugs + the following TCM regimens: take decocted or granule, one dose a day)
Control group: western medicine cohort (routine treatment + one or both of the following antiviral drugs) Not applicable Primary (9 days): The relief/disappearance rate of main symptoms, chest CT absorption
Secondary (9 days): virus antigen negative conversion rate, Clinical effective time: the average effective time. The number of severe and critical conversion cases, Incidence of complications, Traditional Chinese Medicine Syndrome Score
Other outcome measures (9 days): CRP changes, ESR changes, PCTchanges, The index of T cell subsets changed NCT04306497/Recruiting, Mar2‐May 2020
Recombinant human angiotensin‐converting enzyme 2 (rhACE2) as a treatment for patients with COVID‐19 Drug: Recombinant human angiotensin‐converting enzyme 2 (rhACE2) China/COVID‐19 24, all, 18–80 Treatment Experimental group: 0.4 mg/kg rhACE2 IV BID for 7 days and standard of care
Control group: standard of care Not applicable Primary (14 days): time course of body temperature, viral load over time
Secondary (14 days): P/F ratio over time, sequential organ failure assessment score over time, Pulmonary Severity Index, image examination of chest over time, proportion of subjects who progressed to critical illness or death, Time from first dose to conversion to normal or mild pneumonia, T‐lymphocyte counts over time, C‐reactive protein levels over time, angiotensin II (Ang II) changes over time, angiotensin 1–7 (Ang 1–7) changes over time, angiotensin 1–5 (Ang 1–5) changes over time, renin changes over time, aldosterone changes over time, angiotensin‐converting enzyme changes over time, angiotensin‐converting enzyme 2 (ACE2) changes over time, IL‐6 changes over time, IL‐8 changes over time, soluble tumor necrosis factor receptor type II (sTNFrII) changes over time, Plasminogen activator inhibitor type‐1 changes over time, Von willebrand factor changes over time, tumor necrosis factor‐α changes over time, soluble receptor for advanced glycation end products (sRAGE) changes over time, surfactant protein‐D changes over time, angiopoietin‐2 changes over time, frequency of adverse events and severe adverse events NCT04287686/Withdraw, Feb‐Apr 2020
The COVID‐19 mobile health study (CMHS) nCapp, a cell phone‐based autodiagnosis system China/COVID‐19 450, all, 18–90 Diagnosis Training: nCapp, a cell phone‐based autodiagnosis system, combined with 15 questions online, and a predicated formula to autodiagnosis of the risk of COVID‐19
Validation: nCapp, a cell phone‐based autodiagnosis system, combined with 15 questions online, and a predicated formula to auto‐diagnosis of the risk of COVID‐19 – Primary (1 day): accuracy of nCapp COVID‐19 risk diagnostic model NCT04275947/Recruiting, Feb 14‐May 31 2020
A Pilot Study of Sildenafil in COVID‐19 Drug: Sildenafil citrate tablets (G1) China/COVID‐19 10, all, 18 years and older Treatment Experimental group: sildenafil citrate tablet 0.1 g/day for 14 days Not applicable Primary (14 days): rate of disease remission, rate of entering the critical stage, time of entering the critical stage
Secondary (14 days): rate of no fever, rate of respiratory symptom remission, rate of lung imaging recovery, rate of C‐reactive protein (CRP) recovery, rate of Biochemical criterion (CK, ALT, Mb) recovery, rate of undetectable viral RNA (continuous twice), time for hospitalization, rate of adverse event NCT04304313/Recruiting, Feb 9‐Nov 9 2020
Critically Ill patients with COVID‐19 in Hong Kong: a multicentre observational cohort study – Hong Kong/COVID‐19 8 descriptive A case series of 41 hospitalized patients with confirmed infection
30% required critical care admission: developed severe respiratory failure, 10% required mechanical ventilation, 5% needed extracorporeal membrane oxygenation support mortality rate: 15% − Primary (28 days): 28 day mortality
Secondary (28 days): vasopressor days, days on mechanical ventilation, sequential organ function assessment score, ECMO use, percentage nitric oxide use, percentage free from oxygen supplement NCT04285801/Completed, Feb 14‐Feb 25 2020
Treatment of mild cases and chemoprophylaxis of contacts as prevention of the COVID‐19 epidemic Drug: antiviral treatment and prophylaxis, Standard Public Health measures COVID‐19 3,040, All, 18 Years and older Treatment Experimental: antiviral treatment and prophylaxis: darunavir 800 mg/cobicistat 150 mg tablets (oral, 1 tablet q24h, taking for 7 days) and hydroxychloroquine (200 mg tablets) 800 mg on Day 1, and 400 mg on days 2, 3, 4. Contacts: a prophylactic regimen of hydroxychloroquine (200 mg tablets) 800 mg on Day 1, and 400 mg on days 2,3,4. Other: standard public health measures
Active comparator: standard public health measures III Primary (up to 14 days after start of treatment): effectiveness of chemoprophylaxis assessed by incidence of secondary COVID‐19 cases
Secondary: the virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at days 3, the mortality rate of subjects at weeks 2, proportion of participants that drop out of study (up to 14 days after start of treatment), proportion of participants that show noncompliance with study drug (up to 14 days after start of treatment) NCT04304053/Not yet recruiting, Mar15‐Jul15 2020
Comparison of lopinavir/ritonavir or hydroxychloroquine in patients with mild coronavirus disease (COVID‐19) Drug: lopinavir/ritonavir, Drug: hydroxychloroquine sulfate Korea/COVID‐19 150, all, 16 years to 99 years Treatment Experimental: lopinavir/ritonavir 200 mg/100 mg 2 tablets by mouth, every 12 hr for 7–10 days
Active comparator: hydroxychloroquine 200 mg 2 tablets by mouth, every 12 hr for 7–10 days
No intervention: control, no lopinavir/ritonavir and hydroxychloroquine II Primary: viral load (hospital Day 3, 5, 7, 10, 14, 18)
Secondary viral load change (hospital Day 3, 5, 7, 10, 14, 18), time to clinical improvement (time frame: up to 28 days), percentage of progression to supplemental oxygen requirement by Day 7, Time to NEWS2 (National Early Warning Score 2) of 3 or more maintained for 24 hr by Day 7, time to clinical failure, defined as the time to death, mechanical ventilation, or ICU admission (up to 28 days), rate of switch to lopinavir/ritonavir or hydroxychloroquine by Day 7, adverse effects (up to 28 days), concentration of lopinavir/ritonavir and hydroxychloroquine (1, 2, 4, 5, 12 hr after taking intervention medicine) NCT04307693/Recruiting, Mar11‐May 2020
Study to evaluate the safety and antiviral activity of remdesivir (GS‐5734™) in participants with severe coronavirus disease (COVID‐19) Drug: remdesivir, standard of care United States, Hong Kong/COVID‐19 400, all, 18 years and older Treatment Experimental: demdesivir (RDV), 5 days participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, and 5
Experimental: remdesivir, 10 days participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, 5, 6, 7, 8, 9, and 10 III Primary: proportion of participants with normalization of fever and oxygen saturation through day 14
Secondary: proportion of participants with treatment emergent adverse events leading to study drug discontinuation (first dose date up to 10 days) NCT04292899/Recruiting, Mar6‐May 2020
Study to evaluate the safety and antiviral activity of remdesivir (GS‐5734™) in participants with moderate coronavirus disease (COVID‐19) compared to standard of care treatment Drug: remdesivir, standard of care United States, Hong Kong, 600, all, 18 years and older Treatment Experimental: remdesivir, 5 days participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, and 5.
Experimental: remdesivir, 10 days participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, 5, 6, 7, 8, 9, and 10.
Active comparator: continued standard of care therapy III Primary (up to 14 days): proportion of participants discharged by day 14‐secondary (up to 10 days): proportion of participants with treatment emergent adverse events leading to study drug discontinuation NCT04292730/Recruiting, Mar‐May 2020
Bevacizumab in severe or critical patients with COVID‐19 pneumonia‐RCT Drug: bevacizumab China/COVID‐19 Pneumonia 118, all, 18–80 Treatment Experimental; bevacizumab, group:
bevacizumab 500 mg + 0.9% NaCl 100 ml, intravenous drip
No intervention: control group Not applicable Primary: proportion of patients whose oxygenation index increased by 100 mmHg on the 7th day after admission NCT04305106/Not yet recruiting, Mar12‐May31 2020
The efficacy and safety of thalidomide in the adjuvant treatment of moderate new coronavirus (COVID‐19) pneumonia Drug: thalidomide, placebo COVID‐19 thalidomide 100, all, 18 years and older Treatment Placebo comparator: control group: placebo 100 mg, po, qn, for 14 days
Experimental: thalidomide group 100 mg, po, qn, for 14 days. Other name: fanyingting II Primary (up to 28 days): time to clinical recovery time to clinical recovery (up to 28 days)
Secondary (up to 28 days): all cause mortality (up to 28 days), frequency of respiratory progression, Time to defervescence
Others(up to 28 days): time to cough reported as mild or absent, respiratory improvement time, frequency of requirement for supplemental oxygen or noninvasive ventilation, Time to 2019‐nCoV RT‐PCR negative in upper respiratory tract specimen, change (reduction) in 2019‐nCoV viral load in upper respiratory tract specimen as assessed by area under viral load curve, frequency of requirement for mechanical ventilation, frequency of serious adverse events, Serum TNF‐α, IL‐1β, IL‐2, IL‐6, IL‐7, IL‐10, GSCF, IP10, MCP1, MIP1α and other cytokine expression levels before and after treatment NCT04273529/Not yet recruiting, Feb20‐Jun30 2020
The efficacy and safety of thalidomide combined with low‐dose hormones in the treatment of Severe COVID‐19 Placebo, drug: thalidomide COVID‐19 thalidomide 40, all, 18 years and older Treatment Placebo comparator: control group α‐interferon: nebulized inhalation, 5 million U or equivalent dose added 2 ml of sterile water for injection, 2 times a day, for 7 days; abidol, 200 mg/time, 3 times a day, for 7 days; methylprednisolone: 40 mg, q12h, for 5 days. placebo: 100 mg/d, qn, for 14 days
Experimental: thalidomide group α‐interferon: nebulized inhalation, 5 million U or equivalent dose added 2 ml of sterile water for injection, 2 times a day, for 7 days; abidol, 200 mg/time, 3 times a day, for 7 days; methylprednisolone: 40 mg, q12h, for 5 days. thalidomide: 100 mg/d qn for 14 days II Primary (up to 28 days): time to clinical improvement
Secondary (up to 28 days): clinical status (days 7, 14, 21, and 28), time to hospital discharge or NEWS2 (National Early Warning Score 2) of ≤2 maintained for 24 hr, all cause mortality, duration (days) of mechanical ventilation, duration (days) of extracorporeal membrane oxygenation, duration (days) of supplemental oxygenation, length of hospital stay (days), time to 2019‐nCoV RT‐PCR, change (reduction) in 2019‐nCoV viral load in upper and lower respiratory tract specimens as assessed by area under viral load curve, frequency of serious adverse drug events, Serum TNF‐α, IL‐1β, IL‐2, IL‐6, IL‐7, IL‐10, GSCF, IP10#MCP1, MIP1α, and other cytokine expression levels before and after treatment NCT04273581/Not yet recruiting, Feb18‐May30 2020
Tetrandrine tablets used in the treatment of COVID‐19 Drug: tetrandrine China/COVID‐19 60, all, 18–75 Treatment Experimental: tetrandrine cohort after the subjects were enrolled, they were given “Tetrandrine 60 mg QD” for a course of 1 week (take 6 days, stop using for 1 day)
No intervention: control cohort treatment according to standard protocols without intervention IV Primary (12 weeks): survival rate secondary (2 weeks): body temperature NCT04308317/Enrolling by invitation, Mar5‐May1 2020
Fingolimod in COVID‐19 Biological: UC‐MSCs, other: placebo China/COVID‐19 30, all, 18–80 Treatment Experimental: treatment group: each patient in the fingolimod treatment group was given 0.5 mg of fingolimod orally once daily, for three consecutive days
No Intervention: control group II Primary (5 day after treatment): the change of pneumonia severity on X‐ray images NCT04280588/Recruiting, Feb22‐Jul1 2020
Therapy for pneumonia patients infected by 2019 novel coronavirus Biological: UC‐MSCs, other: placebo China/COVID‐19 48, all, 18–75 Treatment Experimental: UC‐MSCs treatment group, participants will receive conventional treatment plus four times of 0.5*10E6 UC‐MSCs/kg body weight intravenously at Day1, Day3, Day5, Day7)
Placebo comparator: control group, participants will receive conventional treatment plus 4 times of placebo intravenously at Day1, Day3, Day5, Day7 Not applicable Primary (at baseline, Day 1, Weeks 1, 2, 4, 8): size of lesion area by chest imaging, blood oxygen saturation
Secondary (at baseline, Day 1, Weeks 1, 2, 4, 8): rate of mortality within 28‐days, sequential organ failure assessment, side effects in the UC‐MSCs treatment group, Electrocardiogram, the changes of ST‐T interval mostly, Concentration of C‐reactive protein C‐reactive protein, immunoglobulin, CD4 + and CD8 + T cells count, Concentration of the blood cytokine (IL‐1β, IL‐6, IL‐8,IL‐10,TNF‐α), Concentration of the myocardial enzymes NCT04293692/Recruiting, Feb24‐Feb1 2020–2021
The Use PUL‐042 inhalation solution to prevent COVID‐19 in adults exposed to SARS‐CoV‐2 Drug: PUL‐042 inhalation solution, drug: placebo COVID‐19 200, all, 18 years and older Treatment Experimental: PUL‐042 inhalation solution, PUL‐042 inhalation solution (20.3 µg Pam2: 29.8 µg ODN/mL) given by nebulization on study days 1,3, 6, and 10
Placebo comparator: sterile normal saline for inhalation, sterile normal saline for inhalation given by nebulization on study days 1, 3, 6, and 10 II Primary (14 days): Prevention of COVID‐19 NCT04313023/Not yet recruiting, Apr‐Oct 2020
Treatment of COVID‐19 patients using Wharton's jelly‐mesenchymal stem cells Biological: WJ‐MSCs Arabia Amman, Jordan/use of stem cells for COVID‐19 treatment 5, all, 18 years and older Treatment Experimental: WJ‐MSCs WJ‐MSCs will be derived from cord tissue of newborns, screened for HIV1/2, HBV, HCV, CMV, mycoplasma, and cultured to enrich for MSCs.
WJ‐MSCs will be counted and suspended in 25 ml of saline solution containing 0.5% human serum albumin, and will be given to patient intravenously I Primary (3 weeks): Clinical outcome, CT Scan, RT‐PCR results
Secondary (8 weeks): RT‐PCR results NCT04313322/Recruiting, Mar16‐Sep30 2020
Myocardial damage in COVID‐19 Non China/COVID‐19 cardiovascular diseases 500, all, 18 years and older Prognostic Discharged group (no intervention) the individual which is defined as patient discharged from hospital
Dead group (no intervention) The individual which is defined as patient with all‐cause death – Primary (75 days): the myocardial injury incidence, the risk factors analysis for the death
Secondary (75 days): clinical characteristics, clinical course, cardiovascular comorbidity, Analysis of causes of death NCT04312464/Enrolling by invitation, Jun1‐Mar18 2020
Treatment with mesenchymal stem cells for severe corona virus disease 2019(COVID‐19) Biological: MSCs, biological: saline containing 1%, human serum albumin (solution of MSC China/COVID‐19 60, all, 18–70 Treatment Experimental: mesenchymal stem cells (MSCs), conventional treatment plus MSCs participants will receive conventional treatment plus 3 times of MSCs ((4.0*10E7 cells per time) intravenously at Day 0, Day 3, Day 6)
Placebo comparator: placebo conventional treatment plus placebo participants will receive conventional treatment plus 3 times of placebo (saline containing 1% human serum albumin (solution of MSC) 3 times of placebo (intravenously at Day 0, Day 3, Day 6) I, II Primary (28 days): improvement time of clinical critical treatment index, side effects in the MSCs treatment group
Secondary: proportion of patients in each classification of clinical critical treatment index (baseline, Days 7, 14, 28), all cause mortality on Day 28, invasive mechanical ventilation rate (Day 28), duration of oxygen therapy (Day 28), duration of hospitalization (Day 28), incidence of nosocomial infection (Day 28), CD4+ T cell count by flow cytometry in two groups (baseline, Day, 3, 6, 10, 14, 21, 28) NCT04288102/Recruiting, May5‐Dec31 2020–2021
The clinical study of carrimycin on treatment patients with COVID‐19 Drug: carrimycin, drug: lopinavir/ritonavir tablets or arbidol or chloroquine phosphate, Drug: basic treatment – 520, all, 18–75 Treatment Experimental: carrimycin basic treatment + carrimycin
Active comparator: lopinavir/ritonavir or arbidol or chloroquine phosphate any of basic treatment + lopinavir/ritonavir tablets or arbidol or chloroquine phosphate IV Primary (30 days): fever to normal time (day), pulmonary inflammation resolution time (HRCT) (day), negative conversion (%) of 2019‐nCOVRNA in gargle (throat swabs) at the end of treatment NCT04286503/Not yet recruiting, Feb23‐Feb28 2020–2021
Efficacy and safety of corticosteroids in COVID‐19 Drug: methylprednisolone China/COVID‐19 400, all, 18 years and older Treatment Experimental; Pred group: methylprednisolone 1 mg/kg/day ivgtt for 7 days
No intervention: con group Not applicable Primary (14 days): the incidence of treatment failure in 14 days
Secondary: clinical cure incidence (14 days), the duration of virus change to negative (14 days), mortality at Day 30, ICU admission rate in 30 days NCT04273321/Recruiting, Feb14‐May30 2020
Evaluation of the efficacy and safety of sarilumab in hospitalized patients with COVID‐19 Drug: sarilumab, drug: placebo United States/COVID‐19 400, all, 18 years and older Treatment Experimental: sarilumab high dose: single intravenous (IV) dose of sarilumab, other names: Kevzara®, REGN88, SAR153191
Experimental: sarilumab low dose: single intravenous (IV) dose of sarilumab Other Names: Kevzara®, REGN88, SAR153191
Placebo comparator: single intravenous (IV) dose of placebo to match sarilumab administration II, III Primary: time to resolution of fever for at least 48 hr without antipyretics for 48 hr (Up to Day 29), percentage of patients reporting each severity rating on a 6‐point ordinal scale (Day 15)
Secondary (up to Day 29): time to improvement in oxygenation for at least 48 hr, mean change in the 6‐point ordinal scale, clinical status using the 6‐point ordinal scale, time to improvement in one category from admission using the 6‐point ordinal scale, time to resolution of fever for at least 48 hr without antipyretics by clinical severity, time to resolution of fever for at least 48 hr without antipyretics by baseline IL‐6 levels, time to improvement in oxygenation for at least 48 hr by clinical severity, time to improvement in oxygenation for at least 48 hr by baseline IL‐6 levels, time to resolution of fever and improvement in oxygenation for at least 48 hr, time to change in National Early Warning Score 2 (NEWS2) scoring system, time to score of <2 maintained for 24 hr in NEWS2 scoring system, mean change in NEWS2 scoring system, number of days with fever, number of patients alive off oxygen, number of days of resting respiratory rate >24 breaths/min, number of days with hypoxemia, number of days of supplemental oxygen use, time to saturation ≥94% on room air, number of ventilator free days in the first 28 days, number of patients requiring initiation of mechanical ventilation, number of patients requiring noninvasive ventilation, number of patients requiring the use of high flow nasal cannula, number of patients admitted into an intensive care unit, number of days of hospitalization among survivors, number of deaths due to any cause (up to Day 60), incidence of serious adverse events (Up to Day 60), incidence of severe or life‐threatening bacterial, invasive fungal, or opportunistic infection, Incidence of severe or life‐threatening bacterial, invasive fungal, or opportunistic infection in patients with grade 4 neutropenia, Incidence of hypersensitivity reactions, incidence of infusion reactions, incidence of gastrointestinal perforation, white blood cell count, hemoglobin levels, platelet count, creatinine levels, total bilirubin level, alanine aminotransferase level, aspartate aminotransferase level NCT04315298/Recruiting, Mar16‐Mar16 2020–2021
Washed microbiota transplantation for patients with 2019‐nCoV infection Other: washed microbiota transplantation, other: placebo China/COVID‐19 complicated with refractory intestinal infections 0, all, 14–70 complicated with refractory intestinal infections Treatment Experimental: observational group 5 u washed microbiota suspension administered via nasogastric tube, nasojejunal tube or oral, combining with standard therapy
Placebo comparator: control group 5 u placebo (edible suspension of the same color as the washed microbiota suspension) administered via nasogastric tube, nasojejunal tube or oral, combining with standard therapy Not applicable Primary (2 weeks): number of participants with improvement from severe type to common type NCT04251767/Withdrawn, Feb5‐Apr30 2020
Safety and immunity of Covid‐19 aAPC vaccine Biological: pathogen‐specific aAPC China/Covid‐19 infection 100, all, 6 months to 80 years Treat and Prevent Covid‐19 Infection Experimental: the subjects will receive three injections of 5×10^6 each Covid‐19/aAPC vaccine via subcutaneous injections I Primary (0–28 day): frequency of vaccine events, frequency of serious vaccine events, proportion of subjects with positive T cell response
Secondary (0–28 day): mortality, duration of mechanical ventilation if applicable, proportion of patients in each category of the 7‐point scale (7, 14, and 28 days after randomization), proportion of patients with normalized inflammation factors (7 and 14 days after randomization), clinical improvement based on the 7‐point scale if applicable, lower Murray lung injury score if applicable (7 days after randomization) NCT04299724/Recruiting, Feb15‐Dec31 2020–2024
Safety related factors of endotracheal intubation in patients with severe Covid‐19 pneumonia Severe covid‐19 pneumonia with ET COVID‐19 endotracheal intubation 120, all, 18–90 Observational Intervention details: other: severe covid‐19 pneumonia with ET, severe covid‐19 pneumonia undergoing endotracheal intubation – Primary:
Success rate of intubation (the time span between 1 hr before intubation and 24 hr after intubation), infection rate of anesthesiologist (the time span between 1 hr before intubation and 14 days after intubation)
Secondary:
Extubation time (the time span between 1 hr before intubation and 30 days after intubation) NCT04298814/Not yet recruiting, Mar7‐Jul30 2020
Immunity and safety of Covid‐19 synthetic minigene vaccine Biological: injection and infusion of LV‐SMENP‐DC vaccine and antigen‐specific CTLs China/COVID‐19 100, all, 6 months to 80 years Treatment Experimental: pathogen‐specific DC and CTLs patients will receive approximately 5 × 106 LV‐DC vaccine and 1 × 108 CTLs via subcutaneous injections and iv infusions, respectively I
II Primary:
Clinical improvement based on the 7‐point scale (28 days after randomization), lower Murray lung injury score (7 days after randomization)
Secondary (0–28 day): 28‐day mortality, duration of mechanical ventilation, duration of hospitalization, proportion of patients with negative RT‐PCR results (7 and 14 days after randomization), proportion of patients in each category of the 7‐point scale (7, 14, and 28 days after randomization), proportion of patients with normalized inflammation factors (7 and 14 days after randomization), frequency of vaccine/CTL events, frequency of serious vaccine/CTL events NCT04276896/Recruiting, Mar24‐Dec31 2020–2024
Phase I clinical trial in healthy adult Biological: recombinant novel coronavirus vaccine (adenovirus type 5 vector) – 108, all, 18–60 Prevention Experimental: low‐dose group subjects received one dose of 5E10 vp Ad5‐nCoV at 18–60 years old
Experimental: middle‐dose group
Subjects received one dose of 1E11 vp Ad5‐nCoV at 18–60 years old
Experimental: high‐dose group
Subjects received one dose of 1.5E11vp Ad5‐nCoV at 18–60 years old I Primary (0–7 days postvaccination): safety indexes of adverse reactions
Secondary (Day 14, 28, Month 3, 6 postvaccination):
Safety indexes of adverse events (0–28 days postvaccination), safety indexes of SAE (0–28 days, within 6 mouths postvaccination), safety indexes of lab measures (pre‐vaccination, Day 7 postvaccination), immunogencity indexes of GMT(ELISA) (Day 14, 28, Month 3, 6 postvaccination), immunogencity indexes of GMT (pseudoviral neutralization test method), immunogencity indexes of seropositivity rates, immunogencity indexes of seropositivity rates (pseudoviral neutralization test method, immunogencity indexes of GMI (ELISA), immunogencity indexes of GMI (pseudoviral neutralization test method), immunogencity indexes of GMC (Ad5 vector), immunogencity indexes of GMI (Ad5 vector), immunogencity indexes of cellular immune
Other (day、14,28, Month3,6 postvaccination):
Consistency analysis(ELISA and pseudoviral neutralization test method), Dose‐response relationship (Humoral immunity), Persistence analysis of anti‐S protein antibodies, Time‐dose‐response relationship (Humoral immunity), Dose‐response relationship (cellular immunity), Persistence analysis of cellular immuse, Time‐dose‐response relationship (cellular immunity) NCT04313127/Not yet recruiting, Mar1Dec20 2020–2022
Development and verification of a new coronavirus multiplex nucleic acid detection system Diagnostic test: new QIAstat‐Dx fully automatic multiple PCR detection platform China/COVID‐19 100, all, 16 years to 100 years Diagnostic Diagnostic test: new QIAstat‐Dx fully automatic multiple PCR detection platform
We use the new QIAstat‐Dx fully automatic multiple PCR detection platform to test the enrolled patients – Primary:
Sensitivity, spectivity turnaround time of the New QIAstat‐Dx fully automatic multiple PCR detection platform (3 months) NCT04311398/Not yet recruiting, Mar14‐Dec1, 2020
Hydroxychloroquine treatment for severe COVID‐19 pulmonary infection (HYDRA Trial) Drug: hydroxychloroquine, drug: placebo oral tablet COVID‐19 severe acute respiratory syndrome 500, all, 18–0 Treatment Active comparator: treatment
Hydroxychloroquine tablet 200 mg every 12 hr for 10 days
Placebo comparator: placebo
identical placebo, one tablet every 12 hr for 10 days III Primary (up to120 days):
All‐cause hospital mortality
Secondary (up to120 days):
Length of hospital stay, Need of mechanical ventilation, ventilator free days, Grade 3–4 adverse reaction NCT04315896/Not yet recruiting, Mar23‐Mar22 2020–2012
Tocilizumab in COVID‐19 pneumonia (TOCIVID‐19) Drug: tocilizumab Injection Italy/COVID‐19 pneumonia 330, child, adult, older adult, child, adult, older adult Treatment Experimental: Tocilizumab Injection
Tocilizumab 8 mg/kg (up to a maximum of 800 mg per dose), with an interval of 12 hr II Primary (up to 1 month):
One‐month mortality rate
Secondary (up to 1 month):
interleukin‐6 level, lymphocyte count, C‐reactive protein level (cycle 1 and 2 every 12 hr), PaO2 (partial pressure of oxygen)/FiO2 (fraction of inspired oxygen, FiO2) ratio (or P/F ratio) (baseline, during treatment (cycle 1 and 2 every 12 hr), change of the SOFA (sequential organ failure assessment) (baseline, during treatment (cycle 1 and 2 every 12 hr), number of participants with treatment‐related side effects as assessed by Common Terminology Criteria for Adverse Event version 5.0, Radiological response, Time Frame: at baseline (optional), after 7 days and if clinically indicated, duration of hospitalization. Time Frame: from baseline up to patient's discharge, Remission of respiratory symptoms NCT04317092/Recruiting, Mar19‐Dec19 2020–2022
Mesenchymal stem cell NestCell® to treat patients with severe COVID‐19 pneumonia Biological: NestCell® COVID‐19 pneumonia 6, all, 18 years and older Treatment Experimental: NestCell®:
All patients will receive conventional treatment plus 3 times of 1 × 106 cells/kg body weight intravenously on Day1, Day3, and Day7 I Primary (28 days):
Disappear time of ground‐glass shadow in the lungs
Secondary:
Rate of mortality within 28‐days, Improvement of clinical symptoms including duration of fever and respiratory (At Baseline, Day 3, 7, 10, 14, 21, 28), Time of nucleic acid turning negative (28 days), CD4+ and CD8+ T cell count (At Baseline, Day 3, 6, 10, 14, 21, and 28), changes of blood oxygen (At Baseline, Day 3, 6, 10, 14, 21, and Day 28), side effects in the treatment group (28 days) NCT04315987/Not yet recruiting, Apr‐Jun 2020
CD24Fc as a non‐antiviral immunomodulator in COVID‐19 treatment Drug: CD24Fc, drug: placebo United States/severe coronavirus disease (COVID‐19) 230, all, 18 years and older Treatment Experimental: CD24Fc treatment
Single dose at Day 1, CD24Fc, 480 mg, diluted to 100 ml with normal saline, IV infusion in 60 min
Placebo comparator: placebo
Single dose at Day 1, normal saline solution 100 ml, IV infusion in 60 min III Primary (14 days):
Improvement of COVID‐19 disease status secondary (14 days):
Conversion rate of clinical status at Day 8 (7 days), conversion rate of clinical status at Day 15, hospital discharge time, all cause of death, duration of mechanical ventilation, duration of pressors, duration of ECMO, duration of oxygen therapy, length of hospital stay, absolute lymphocyte count NCT04317040/Not yet recruiting,May‐May 2020–2022
Acute kidney injury in patients hospitalized with COVID‐19 – China/COVID‐19 acute kidney injury‐kidney function 287, all, 18 years and older Observational Acute kidney injury:
COVID‐19 patients with acute kidney injury
nonacute kidney injury:
COVID‐19 patients without acute kidney injury –
Rate of death, the length of hospital stay Primary (up to 60 days):
Rate of acute kidney injury
Secondary (up to 60 days): NCT04316299/Completed, Feb 26‐Mar8 2020
Phase I clinical trial in healthy adult Logical: recombinant novel coronavirus vaccine (adenovirus type 5 vector) COVID‐19 108, all, 18–60 Treatment (Adenovirus Type 5 Vector)
Experimental: low‐dose group
Subjects received one dose of 5E10 vp Ad5‐nCoV at 18–60 years old
Experimental: middle‐dose group
Subjects received one dose of 1E11 vp Ad5‐nCoV at 18–60 years old
Experimental: high‐dose group subjects received one dose of 1.5E11vp Ad5‐nCoV at 18–60 years old I Primary (0–7 days postvaccination):
Safety indexes of adverse reactions
Secondary (0–28 days postvaccination, within 6 mouths postvaccination):
Safety indexes of adverse events, Safety indexes of SAE, Safety indexes of lab measures, Immunogencity indexes of GMT (ELISA), Immunogencity indexes of GMT (pseudoviral neutralization test method) (Day 14, 28, Month 6 postvaccination), Immunogencity indexes of seropositivity rates (ELISA) (Day 14, 28, Month 3, 6 postvaccination), Immunogencity indexes of seropositivity rates(pseudoviral neutralization test method) (Day 14, 28, Month 6 postvaccination), Immunogencity indexes of GMI (ELISA) (Day 14, 28, Month 3, 6 postvaccination), Immunogencity indexes of GMI (pseudoviral neutralization test method) (Day 14, 28, Month 6 postvaccination), Immunogencity indexes of GMC (Ad5 vector) (Day 14, 28, Month 3, 6 postvaccination), Immunogencity indexes of GMI(Ad5 vector) (Day 14, 28, Month 3, 6 postvaccination), Immunogencity indexes of cellular immune (Day 14, 28, Month 6 postvaccination)
Other (Day 14,28, Month 6 postvaccination):
Consistency analysis (ELISA and pseudoviral neutralization test method), dose‐response relationship (humoral immunity) (Day 14, 28, Month 3, 6 postvaccination), Persistence analysis of anti‐S protein antibodies (Day 14, 28, Month 3, 6 postvaccination), Time‐dose‐response relationship (Humoral immunity) (Day 14, 28, Month 3, 6 postvaccination), Dose‐response relationship (cellular immunity) (Day 14, 28, Month 6 postvaccination), Persistence analysis of cellular immuse (Day 14, 28, Month 6 postvaccination), Time‐dose‐response relationship (cellular immunity) (Day 14, 28, Month 6 postvaccination) NCT04313127/Not yet recruiting, Mar19‐Dec20 2020–2021
Favipiravir combined with tocilizumab in the treatment of corona virus disease 2019 Drug: favipiravir combined with tocilizumab, drug: favipiravir, drug: tocilizumab China, COVID‐19 150, all, 18–65 Treatment Experimental: favipiravir combined with tocilizumab group
Favipiravir: On the 1st day, 1,600 mg each time, twice a day; from the 2nd to the 7th day, 600 mg each time, twice a day. Oral administration, the maximum number of days taken is not more than 7 days.
Tocilizumab: the first dose is 4–8 mg/kg and the recommended dose is 400 mg. For fever patients, an additional application (the same dose as before) is given if there is still fever within 24 hr after the first dose and the interval between two medications ≥12 hr. Intravenous infusion. The maximum of cumulative number is two, and the maximum single dose does not exceed 800 mg
Active comparator: favipiravir group
On the 1st day, 1,600 mg each time, twice a day; from the 2nd to the 7th day, 600 mg each time, twice a day. Oral administration, the maximum number of days taken is not more than 7 days
Active comparator: tocilizumab group
The first dose is 4–8 mg/kg and the recommended dose is 400 mg. For fever patients, an additional application (the same dose as before) is given if there is still fever within 24 hr after the first dose and the interval between two medications ≥12 hr. Intravenous infusion, The maximum of cumulative number is two, and the maximum single dose does not exceed 800 mg Not applicable Primary (3 months):
Clinical cure rate
Secondary (14 days after taking medicine):
Viral nucleic acid test negative conversion rate and days from positive to negative, duration of fever, lung imaging improvement time, mortality rate because of corona virus disease 2019 (3 months), rate of noninvasive or invasive mechanical ventilation when respiratory failure occurs (3 months), mean in‐hospital time (3 months) NCT04310228/Recruiting, Mar8‐May 2020
Novel coronavirus induced severe pneumonia treated by dental pulp mesenchymal stem cells Biological: dental pulp mesenchymal stem cells ‐COVID‐19 24, all, 18–75 Treatment Experimental: pulp mesenchymal stem cells 1. 3, 7 days to increase the injection of mesenchymal stem cells Early Phase I Primary (14 days):
Disppear time of ground‐glass shadow in the lungs
Secondary:
Absorption of lung shadow absorption by CT Scan‐Chest (7, 14, 28, and 360 days), Changes of blood oxygen (3, 7, and 14 days) NCT04302519/Not yet Recruiting, Mar5‐Jul30 2020–2021
Multicenter clinical study on the efficacy and safety of Xiyanping injection in the treatment of new coronavirus infection pneumonia (general and severe) Drug: lopinavir/ritonavir tablets combined with Xiyanping injection drug: lopinavir/ritonavir treatment COVID‐19 80, all, 18–100 Treatment Experimental: experimental group of ordinary COVID‐19:
Xiyanping injection, 10–20 ml daily, Qd, the maximum daily does not exceed 500 mg (20 ml) + lopinavir tablet or ritonavir tablet + alpha‐interferon nebulization, for 7–14 days,
Active comparator: control group of ordinary COVID‐19:
Lopinavir/ritonavir tablets, two times a day, two tablets at a time; alpha‐interferon nebulization
Experimental: experimental group of severe COVID‐19:
Xiyanping injection, 10–20 ml daily, Qd, the maximum daily does not exceed 500 mg (20 ml) + lopinavir tablet or ritonavir tablet + alpha‐interferon nebulization, for 7–14 days Not applicable Primary:
Clinical recovery time (up to Day 28) NCT04295551/Not yet Recruiting, Mar14‐Apr14 2020–2021
Prognostic factors of patients with COVID‐19 – China/SARS‐CoV‐2 outcome, fatal 201, all, 18 years and older Prognostic SARS‐CoV‐2Outcome, fatal – Primary (30 days):
all‐cause mortality
Secondary (15 days):
all‐cause mortality,
Severe state NCT04292964/Completed Mar1‐Mar13 2020
Chloroquine prevention of coronavirus disease (COVID‐19) in the healthcare setting Drug: chloroquine, drug: placebo COVID19 coronavirus acute respiratory illnesses 10,000, all, 16 years and older Prevention Experimental: chloroquine:
a loading dose of 10 mg base/kg followed by 150 mg daily (250 mg chloroquine phosphate salt) will be taken for 3 months
Placebo comparator: placebo Not applicable Primary (approximately 100 days):
Number of symptomatic COVID‐19 infections
Secondary (approximately 100 days):
Symptoms severity of COVID‐19, duration of COVID‐19, number of asymptomatic cases of COVID‐19, number of symptomatic acute respiratory illnesses, genetic loci and levels of biochemical components will be correlated with frequency of COVID‐19, ARI, and disease severity
Other (approximately 100 days):
Drug exposure‐protection relationship NCT04303507/Not yet recruiting, May‐May 2020–2022
Yinhu Qingwen decoction for the treatment of mild/common CoVID‐19 Drug: YinHu QingWen decoction, drug: YinHu QingWen decoction(low dose), other: Chinese medicine treatment, other: standard western medicine treatment China/CoVID‐19 Chinese medicine 300, all, 18 years and older Treatment Experimental: Yin Hu Qing Wen decoction group
Based on the standard western medicine treatment, the patients will be given Yinhu Qingwen decoction (granula) for 10 days.
Drug: YinHu QingWen decoction YinHu QingWen decoction (granula) consits of 11 Chinese herbal medicine as honeysuckle, Polygonum cuspidatum, Schizonepeta, Longspur epimedium, and so forth. The decoction granula will be dissolved into 600 ml decoction and divided to three times (once with 200 ml). It will be given a 200 ml per time, three times a day, for 10 days
Other: standard western medicine treatment treatment is according to the protocol of treatment of CoVID‐19 infection according to guideline appoved by National Health Commission of China
Placebo comparator: Yinhu Qingwen decoction low‐dose group
Based on the standard western medicine treatment, the patients will be given 10% dose of Yinhu Qingwen decoction (granula) for 10 days
Drug: YinHu QingWen decoction (low dose) this intervention is given as 10% dose of YinHu QingWen decoction (granula). The granula will be dissolved into 600 ml decoction and divided to three times (once with 200 ml). It will be given a 200 ml per time, three times a day, for 10 days
Other: standard western medicine treatment standard western medicine treatment is according to the protocol of treatment of CoVID‐19 infection according to guideline appoved by National Health Commission of China
Active comparator: integrated Chinese and western medicine group
Based on the standard western medicine treatment, the patients will be given Chinese medicine decotion granula according to their symptoms. The daily dose of Chinese medicine decoction granula will also be dissolved to 600 ml decoction and divided into three times (once with 200 ml). The Chinese medicine decoction will be given 200 ml per time, three times a day for 10 days
Other: Chinese medicine treatment
This intervention will be given with Chinese medicine decoction granula based on the symptoms differentiation of the patients for 10 days
Other: standard western medicine treatment
Standard western medicine treatment is according to the protocol of treatment of CoVID‐19 infection according to guideline appoved by National Health Commission of China II
III Primary (up to 28 days):
Mean clinical recovery time
Secondary (up to 28 days):
Time to CoVID‐19 RT‐PCR negative in upper respiratory tract specimen, change (reduction) in CoVID‐19 viral load in upper respiratory tract specimen as assessed by area under viral load curve, time to defervescence (in those with fever at enrollment), time to cough reported as mild or absent (in those with cough at enrollment rated severe or moderate), time to dyspnea reported as mild or absent (on a scale of severe, moderate, mild absent, in those with dyspnea at enrollment rated as severe or moderate)
Frequency of requirement for supplemental oxygen or noninvasive ventilation, frequency of respiratory progression, severe case incidence, proportion of rehospitalization or admission to ICU, all‐cause mortality, frequency of serious adverse events NCT04278963/Active, Not Recruiting, Feb27‐Jan 2020
Prognositc factors in COVID‐19 patients complicated with hypertension – China, COVID‐19 0, all, 18–100 Prognostic ACEI treatment
hypertension patients with ACEI treatment when suffered with novel coronavirus infection in China
Control
hypertension patients without ACEI treatment when suffered with novel coronavirus infection in China – Primary (up to 28 days):
Occupancy rate in the intensive care unit, mechanical ventilation, death
Secondary (up to 28 days):
All cause mortality, time from onset of symptoms to main outcome and its components, time to clinical recovery NCT04272710/Withdrawn, Jan25‐Apr30 2020
Evaluating the efficacy and safety of bromhexine hydrochloride tablets combined with standard treatment/standard treatment in patients with suspected and mild novel coronavirus pneumonia (COVID‐19) Drug: bromhexine hydrochloride tablets, drug: arbidol hydrochloride granules, drug: recombinant human interferon α2b spray, drug: favipiravir tablets China, novel coronavirus pneumonia 2019‐nCoV 60, all, 18–80 Treatment Experimental: group A treatment group:
Bromhexine hydrochloride tablets, arbidol hydrochloride granules:
Standard treatment refers to the latest edition of pneumonia diagnosis and treatment scheme for novel coronavirus infection. Arbidol hydrochloride granules is recommended but not enforced to use
Recombinant human interferon α2b spray:
Standard treatment refers to the latest edition of pneumonia diagnosis and treatment scheme for novel coronavirus infection
Favipiravir tablets
Active comparator; group B control group:
Drug: arbidol hydrochloride granules
Standard treatment refers to the latest edition of pneumonia diagnosis and treatment scheme for novel coronavirus infection. arbidol hydrochloride granules is recommended but not enforced to use
Drug: recombinant human interferon α2b spray
Standard treatment refers to the latest edition of pneumonia diagnosis and treatment scheme for novel coronavirus infection Not applicable Primary (within 14 days from the start of medication):
Time to clinical recovery after treatment
Secondary (within 14 days from the start of medication):
Rate of aggravation, clinical remission rate, dynamic changes of oxygenation index, time to cure, rate to cure, time to defervescence, time to cough remission,days of supplemental oxygenation, rate of patients with requring supplemental oxygen, rate of patients with mechanical ventilation, time of negative COVID‐19 nucleic acid results, rate of negative COVID‐19 nucleic acid results, rate of ICU admission, 28‐day mortality (From the first day of screening to the day of follow‐up (28 days)) NCT04273763/Enrolling by invitation, Feb16‐Apr30 2020
Various combination of protease inhibitors, oseltamivir, favipiravir, and chloroquin for treatment of covid19: a randomized control trial Drug: oral Thailand, coronavirus infections COVID19 80, all, 16–100 Treatment Experimental: oseltamivir plus chloroquin in mild COVID19
Oseltamivir 300 mg per day plus chloroquin 1,000 mg per Day In mild COVID19
Experimental: lopinavir and ritonavir plus favipiravir
Lopinavir 10 mg/kg and ritonavir 2.5 mg/kg plus favipiravir 2,400 mg, 2,400 mg, and 1,200 mg every 8 hr on Day 1, and a maintenance dose of 1,200 mg twice a day in Mild COVID19
Experimental: lopinavir and ritonavir plus oseltamivir in mild COVID19
Lopipinavir 10 mg/kg and ritonavir 2.5 mg/kg plus oseltamivir 4–6 mg/kg In mild COVID19
Experimental: lopinavir and ritonavir oseltamivir moderate to severe COVID19
Lopipinavir 10 mg/kg and ritonavir 2.5 mg/kg plus oseltamivir 4–6 mg/kg in moderate to critically ill COVID19
Experimental: favipiravir lopinavir/ritonavir for mod. To severe
favipiravir 2,400 mg, 2,400 mg, and 1,200 mg every 8 hr on Day 1, and a maintenance dose of 1,200 mg twice a day plus lopipinavir 10 mg/kg and ritonavir 2.5 mg/kg in moderate to critically ill COVID19
Experimental: darunavir/ritonavir oseltamivir chloroquine mod‐severe
Combination of Darunavir 400 mg every 8 hr ritonavir Ritonavir 2.5 mg/kg plus Oseltamivir 4–6 mg/kg plus Chloroquine 500 mg per Day In moderate to critically ill COVID19
Experimental: darunavir/ritonavir favipiravir chloroquine mod‐severe
Favipiravir 2,400 mg, 2,400 mg, and 1,200 mg every 8 hr on Day 1, and a maintenance dose of 1,200 mg twice a day plus darunavir 400 mg every 8 hr ritonavir ritonavir 2.5 mg/kg plus chloroquine 500 mg per Day In moderate to critically ill COVID19
No intervention: conventional qurantine
Patient who unwilling to treatment and willing to quarantine in mild COVID19 III Primary (Up to 24 weeks):
SARS‐CoV‐2 eradication time
Secondary (up to 24 weeks):
Number of patient with death, number of patient with recovery adjusted by initial severity in each arm, number of day with ventilator dependent adjusted by initial severity in each arm,number of patient developed acute respiratory distress syndrome after treatment
Other (up to 24 weeks):
Number of patient with acute respiratory distress syndrome recovery NCT04303299/Not yet recruiting, Mar15‐Nov30 2020
Yinhu Qingwen Granula for the treatment of severe CoVID‐19 Drug: Yinhu Qingwen granula, drug: Yin Hu Qing Wen granula (low does), other: standard medical treatment China, COVID‐19 severe pneumonia Chinese medicine 116, all, 18 years and older Treatment Experimental:
Yinhu Qingwen granula group:
Drug: Yinhu Qingwen Granula
Yinhu Qingwen granula is a kind of herbal granula made from “Yinhu Qingwen Decoction,” which consits of 11 Chinese herbal medicine as honeysuckle, Polygonum cuspidatum, schizonepeta, Longspur epimedium, etc. The granula will be dissolved into 600 ml decoction and divided to three times (once with 200 ml). It will be given a 200 ml per time, three times a day, for 10 days.
Other: standard medical treatment Standard medical treatment is adhered to the protocol of the treatment for the severe CoVID‐19 according to the guideline approved by National Health Commission of China.
Placebo comparator: Yinhu Qingwen granula low‐dose group:
Drug: Yin Hu Qing Wen granula (low does). This intervention is given as 10% dose of YinHu QingWen Granula.The granula will be dissolved into 600 ml decoction and divided to three times (once with 200 ml).
Other: standard medical treatment Standard medical treatment is adhered to the protocol of the treatment for the severe CoVID‐19 according to the guideline approved by National Health Commission of China. II Primary (Day 10):
changes in the ratio of PaO2 to FiO2 from baseline
Secondary (up to 30 days):
PaO2, blood oxygen saturation (SpO2), clinical status rating on the 7‐point ordinal scale, time to clinical improvement, duration (hours) of noninvasive mechanical ventilation or high‐flow nasal catheter oxygen inhalation use, duration (hours) of invasive mechanical ventilation use, duration (hours) of extracorporeal membrane oxygenation (ECMO) use, duration (days) of oxygen use, The proportion of the patients reporting 2019‐nCoV RT‐PCR negativity at Day 10 after treatment, the counts/percentage of lymphocyte, time to hospital discharge with clinical recovery from the randomization, the incidence of critical status conversion in 30 days, all‐cause mortality within 30 days, frequency of severe adverse drug events NCT04310865/Not yet recruiting, Mar20‐Jun30 2020–2021
Clinical characteristics and long‐term prognosis of 2019‐nCoV infection in children – China, 2019‐nCoV 500, all, up to 18 years Prognosis 2019‐nCoV infection group
Children hospitalized with direct laboratory confirmed of novel coronavirus with or without pneumonia are classified as the 2019‐nCoV infection group
Control group Children hospitalized with pneumonia other than the novel coronavirus pneumonia during the same hospitalization period as 2019‐nCoV infection group are classified as the control group – Primary (6 months):
The cure rate of 2019‐nCoV, the improvement rate of 2019‐nCoV, the incidence of long‐term adverse outcomes
Secondary (2 weeks):
Duration of fever, duration of respiratory symptoms, duration of hospitalization, number of participant(s) need intensive care, number of participant(s) with acute respiratory distress syndrome, number of participant(s) with extra‐pulmonary complications, including shock, renal failure, multiple organ failure, hemophagocytosis syndrome, et al., number of participant(s) who died during the trial (10 months) NCT04270383/Not yet recruiting, Feb15‐Dec30 2020
The effect of T89 on improving oxygen saturation and clinical symptoms in patients with COVID‐19 Drug: T89 Coronavirus disease 2019 novel coronavirus pneumonia 120, all, 18–85 Treatment Experimental: The T89 treatment group Besides a standard background treatment (antiviral drug + antibacterial + oxygen therapy + Traditional Chinese Medicine decoction), all subjects in the T89 treatment group will receive 30 pills of T89 each time, orally, BID (every morning and evening), for 10 days (depending on clinical need and practicability, the use can be extended for up to 14 days)
No intervention: the blank control group
All subjects in the blank control group will only receive a standard background treatment (antiviral drug + antibacterial + oxygen therapy + Traditional Chinese Medicine decoction), for 10 days. Not applicable Primary (Day −1 to 10): the time to oxygen saturation recovery to normal level (≥97%), the proportion of patients with normal level of oxygen saturation(≥97%)
Secondary (Day −1 to 10):
The degree of remission of symptoms of patients, including: fatigue, nausea, vomiting, chest tightness, shortness of breath, and so forth, the time to the myocardial enzyme spectrum recovery to normal after treatment, the proportion of the patients with normal myocardial enzyme spectrum after treatment, the time to the electrocardiogram recovery to normal level after treatment, the proportion of the patients with normal electrocardiogram after treatment, the time to the hemodynamics recovery to normal after treatment, the proportion of the patients with normal hemodynamics after treatment, the time to exacerbation or remission of the disease after treatment, the proportion of the patients with exacerbation or remission of disease after treatment, the proportion of patients who need other treatment (e.g., heparin, anticoagulants) due to microcirculation disorders, the all‐cause mortality rate, the proportion of patients with acidosis, the total duration of the patients in‐hospital, the total duration of oxygen inhalation during treatment, the oxygen flow rate during treatment, the oxygen concentration during treatment NCT04285190/Not yet recruiting, Feb26‐Sep15 2020
Immunoregulatory therapy for 2019‐nCoV Drug: PD‐1 blocking antibody + standard treatment, drug: Thymosin + standard treatment, other: standard treatment ‐2019 nCoV, PD‐1 120, all, 18 years and older Treatment Experimental: PD‐1 group
Anti‐PD‐1 antibody, 200 mg, IV, one time
Experimental: thymosin group
Thymosin, 1.6 mg sc qd, last for 5 days
Placebo comparator: control group stand treatment II Primary (7 days):
lung injury score
Secondary:
Absolute lymphocyte counts (7, 14 and 28 days), serum level of CRP, PCT and IL‐6 (3, 7 and 14 days), SOFA score (7 days), all cause mortality rate (28 days), ventilation free days (28 days), ICU free days (up to 28 days) NCT04268537/Not yet recruiting, Feb10‐Oct31 2020
Tocilizumab vs CRRT in management of cytokine release syndrome (CRS) in COVID‐19 Drug: tocilizumab, other: standard of care, procedure: continuous renal replacement therapy China, Covid‐19 SARS cytokine storm (and 2 more…) 120, all, 18–80 Observational Tocilizumab
Subjects received 8 mg/kg (body weight) Tocilizumab once in 100 ml 0.9% saline solution and administered intravenously within no <60 min. Tocilizumab was administered according—continuous renal replacement therapy
Femoral vein catheterization was performed to complete continuous renal replacement therapy for consecutive three times or more. to the local label
Standard care
Standard of care therapy per local written policies or guidelines – Primary (up to 14 days):
Proportion of participants with normalization of fever and oxygen saturation
Secondary:
Duration of hospitalization (Up to 28 days), proportion of participants with normalization of fever (up to 14 days), change from baseline in white blood cell and differential count (up to 28 days), time to first negative in 2019 novel corona virus RT‐PCR test (Up to 28 days), all‐cause mortality (up to 12 weeks), change from baseline in hsCRP (Up to 28 days), change from baseline in cytokines IL‐1β, IL‐10, sIL‐2R, IL‐6, IL‐8 and TNF‐α (Up to 28 days), change from baseline in proportion of CD4 + CD3/CD8 + CD3 T cells (Up to 28 days) NCT04306705/Recruiting, Feb20‐Jun20 2020
Sars‐CoV2 seroconversion among front line medical and paramedical staff in emergency, intensive care units and infectious disease departments during the 2020 Epidemic Other: blood sample France, Sars‐CoV2 1,000, all, child, adult, older adult Other Caregiver
caregivers from emergency, ICU, virology and infectious disease services:
Two blood samples at T0 and 3 months Not applicable Primary (3 months):
Quantify the proportion of patients with documented Sars‐CoV2 infection among medical and paramedical staff
Secondary (3 months):
Identification of risk factors for seroconversion, quantify the proportion of asymptomatic infections among staff who have seroconverted, describe symptomatic infections for personnel developing acute clinical (respiratory or digestive) viral syndrome NCT04304690/Recruiting, Mar16‐Oct16 2020
|
|
tr
|
Study title Interventions Location/condition Subjects, sex, age Primary purpose Arms Phase Measure outcome/time frame Code/status/date
|
|
th
|
Study title
|
|
th
|
Interventions
|
|
th
|
Location/condition
|
|
th
|
Subjects, sex, age
|
|
th
|
Primary purpose
|
|
th
|
Arms
|
|
th
|
Phase
|
|
th
|
Measure outcome/time frame
|
|
th
|
Code/status/date
|
|
tr
|
The efficacy and safety of huaier in the adjuvant treatment of COVID‐19 Drug: Huaier Granule COVID‐19 550, all, 18–75 Treatment Experimental group: standard therapy + Huaier granule 20 g, po, tid for 2 weeks (or until discharge)
Control group: standard therapy II, III Primary (up to 28 days): all cause mortality
Secondary (up to 28 days): clinical status, differences in oxygen intake methods, supplemental oxygenation, mechanical ventilation, mean PaO2/FiO2, length of hospital stay, Length of ICU stay (days), pulmonary function (up to 3 months after discharge) NCT04291053/Not yet recruiting, Apr1‐Sep1 2020
|
|
td
|
The efficacy and safety of huaier in the adjuvant treatment of COVID‐19
|
|
td
|
Drug: Huaier Granule
|
|
td
|
COVID‐19
|
|
td
|
550, all, 18–75
|
|
td
|
Treatment
|
|
td
|
Experimental group: standard therapy + Huaier granule 20 g, po, tid for 2 weeks (or until discharge)
Control group: standard therapy
|
|
p
|
Experimental group: standard therapy + Huaier granule 20 g, po, tid for 2 weeks (or until discharge)
|
|
p
|
Control group: standard therapy
|
|
td
|
II, III
|
|
td
|
Primary (up to 28 days): all cause mortality
Secondary (up to 28 days): clinical status, differences in oxygen intake methods, supplemental oxygenation, mechanical ventilation, mean PaO2/FiO2, length of hospital stay, Length of ICU stay (days), pulmonary function (up to 3 months after discharge)
|
|
p
|
Primary (up to 28 days): all cause mortality
|
|
p
|
Secondary (up to 28 days): clinical status, differences in oxygen intake methods, supplemental oxygenation, mechanical ventilation, mean PaO2/FiO2, length of hospital stay, Length of ICU stay (days), pulmonary function (up to 3 months after discharge)
|
|
td
|
NCT04291053/Not yet recruiting, Apr1‐Sep1 2020
|
|
tr
|
Clinical trial on regularity of TCM syndrome and differentiation treatment of COVID‐19 Drug: TCM prescriptions China/COVID‐19 340, all, 18–75 Treatment Exposure group: integrated TCM and western medicine cohort (routine treatment + one or two of the following antiviral drugs + the following TCM regimens: take decocted or granule, one dose a day)
Control group: western medicine cohort (routine treatment + one or both of the following antiviral drugs) Not applicable Primary (9 days): The relief/disappearance rate of main symptoms, chest CT absorption
Secondary (9 days): virus antigen negative conversion rate, Clinical effective time: the average effective time. The number of severe and critical conversion cases, Incidence of complications, Traditional Chinese Medicine Syndrome Score
Other outcome measures (9 days): CRP changes, ESR changes, PCTchanges, The index of T cell subsets changed NCT04306497/Recruiting, Mar2‐May 2020
|
|
td
|
Clinical trial on regularity of TCM syndrome and differentiation treatment of COVID‐19
|
|
td
|
Drug: TCM prescriptions
|
|
td
|
China/COVID‐19
|
|
td
|
340, all, 18–75
|
|
td
|
Treatment
|
|
td
|
Exposure group: integrated TCM and western medicine cohort (routine treatment + one or two of the following antiviral drugs + the following TCM regimens: take decocted or granule, one dose a day)
Control group: western medicine cohort (routine treatment + one or both of the following antiviral drugs)
|
|
p
|
Exposure group: integrated TCM and western medicine cohort (routine treatment + one or two of the following antiviral drugs + the following TCM regimens: take decocted or granule, one dose a day)
|
|
p
|
Control group: western medicine cohort (routine treatment + one or both of the following antiviral drugs)
|
|
td
|
Not applicable
|
|
td
|
Primary (9 days): The relief/disappearance rate of main symptoms, chest CT absorption
Secondary (9 days): virus antigen negative conversion rate, Clinical effective time: the average effective time. The number of severe and critical conversion cases, Incidence of complications, Traditional Chinese Medicine Syndrome Score
Other outcome measures (9 days): CRP changes, ESR changes, PCTchanges, The index of T cell subsets changed
|
|
p
|
Primary (9 days): The relief/disappearance rate of main symptoms, chest CT absorption
|
|
p
|
Secondary (9 days): virus antigen negative conversion rate, Clinical effective time: the average effective time. The number of severe and critical conversion cases, Incidence of complications, Traditional Chinese Medicine Syndrome Score
|
|
p
|
Other outcome measures (9 days): CRP changes, ESR changes, PCTchanges, The index of T cell subsets changed
|
|
td
|
NCT04306497/Recruiting, Mar2‐May 2020
|
|
tr
|
Recombinant human angiotensin‐converting enzyme 2 (rhACE2) as a treatment for patients with COVID‐19 Drug: Recombinant human angiotensin‐converting enzyme 2 (rhACE2) China/COVID‐19 24, all, 18–80 Treatment Experimental group: 0.4 mg/kg rhACE2 IV BID for 7 days and standard of care
Control group: standard of care Not applicable Primary (14 days): time course of body temperature, viral load over time
Secondary (14 days): P/F ratio over time, sequential organ failure assessment score over time, Pulmonary Severity Index, image examination of chest over time, proportion of subjects who progressed to critical illness or death, Time from first dose to conversion to normal or mild pneumonia, T‐lymphocyte counts over time, C‐reactive protein levels over time, angiotensin II (Ang II) changes over time, angiotensin 1–7 (Ang 1–7) changes over time, angiotensin 1–5 (Ang 1–5) changes over time, renin changes over time, aldosterone changes over time, angiotensin‐converting enzyme changes over time, angiotensin‐converting enzyme 2 (ACE2) changes over time, IL‐6 changes over time, IL‐8 changes over time, soluble tumor necrosis factor receptor type II (sTNFrII) changes over time, Plasminogen activator inhibitor type‐1 changes over time, Von willebrand factor changes over time, tumor necrosis factor‐α changes over time, soluble receptor for advanced glycation end products (sRAGE) changes over time, surfactant protein‐D changes over time, angiopoietin‐2 changes over time, frequency of adverse events and severe adverse events NCT04287686/Withdraw, Feb‐Apr 2020
|
|
td
|
Recombinant human angiotensin‐converting enzyme 2 (rhACE2) as a treatment for patients with COVID‐19
|
|
td
|
Drug: Recombinant human angiotensin‐converting enzyme 2 (rhACE2)
|
|
td
|
China/COVID‐19
|
|
td
|
24, all, 18–80
|
|
td
|
Treatment
|
|
td
|
Experimental group: 0.4 mg/kg rhACE2 IV BID for 7 days and standard of care
Control group: standard of care
|
|
p
|
Experimental group: 0.4 mg/kg rhACE2 IV BID for 7 days and standard of care
|
|
p
|
Control group: standard of care
|
|
td
|
Not applicable
|
|
td
|
Primary (14 days): time course of body temperature, viral load over time
Secondary (14 days): P/F ratio over time, sequential organ failure assessment score over time, Pulmonary Severity Index, image examination of chest over time, proportion of subjects who progressed to critical illness or death, Time from first dose to conversion to normal or mild pneumonia, T‐lymphocyte counts over time, C‐reactive protein levels over time, angiotensin II (Ang II) changes over time, angiotensin 1–7 (Ang 1–7) changes over time, angiotensin 1–5 (Ang 1–5) changes over time, renin changes over time, aldosterone changes over time, angiotensin‐converting enzyme changes over time, angiotensin‐converting enzyme 2 (ACE2) changes over time, IL‐6 changes over time, IL‐8 changes over time, soluble tumor necrosis factor receptor type II (sTNFrII) changes over time, Plasminogen activator inhibitor type‐1 changes over time, Von willebrand factor changes over time, tumor necrosis factor‐α changes over time, soluble receptor for advanced glycation end products (sRAGE) changes over time, surfactant protein‐D changes over time, angiopoietin‐2 changes over time, frequency of adverse events and severe adverse events
|
|
p
|
Primary (14 days): time course of body temperature, viral load over time
|
|
p
|
Secondary (14 days): P/F ratio over time, sequential organ failure assessment score over time, Pulmonary Severity Index, image examination of chest over time, proportion of subjects who progressed to critical illness or death, Time from first dose to conversion to normal or mild pneumonia, T‐lymphocyte counts over time, C‐reactive protein levels over time, angiotensin II (Ang II) changes over time, angiotensin 1–7 (Ang 1–7) changes over time, angiotensin 1–5 (Ang 1–5) changes over time, renin changes over time, aldosterone changes over time, angiotensin‐converting enzyme changes over time, angiotensin‐converting enzyme 2 (ACE2) changes over time, IL‐6 changes over time, IL‐8 changes over time, soluble tumor necrosis factor receptor type II (sTNFrII) changes over time, Plasminogen activator inhibitor type‐1 changes over time, Von willebrand factor changes over time, tumor necrosis factor‐α changes over time, soluble receptor for advanced glycation end products (sRAGE) changes over time, surfactant protein‐D changes over time, angiopoietin‐2 changes over time, frequency of adverse events and severe adverse events
|
|
td
|
NCT04287686/Withdraw, Feb‐Apr 2020
|
|
tr
|
The COVID‐19 mobile health study (CMHS) nCapp, a cell phone‐based autodiagnosis system China/COVID‐19 450, all, 18–90 Diagnosis Training: nCapp, a cell phone‐based autodiagnosis system, combined with 15 questions online, and a predicated formula to autodiagnosis of the risk of COVID‐19
Validation: nCapp, a cell phone‐based autodiagnosis system, combined with 15 questions online, and a predicated formula to auto‐diagnosis of the risk of COVID‐19 – Primary (1 day): accuracy of nCapp COVID‐19 risk diagnostic model NCT04275947/Recruiting, Feb 14‐May 31 2020
|
|
td
|
The COVID‐19 mobile health study (CMHS)
|
|
td
|
nCapp, a cell phone‐based autodiagnosis system
|
|
td
|
China/COVID‐19
|
|
td
|
450, all, 18–90
|
|
td
|
Diagnosis
|
|
td
|
Training: nCapp, a cell phone‐based autodiagnosis system, combined with 15 questions online, and a predicated formula to autodiagnosis of the risk of COVID‐19
Validation: nCapp, a cell phone‐based autodiagnosis system, combined with 15 questions online, and a predicated formula to auto‐diagnosis of the risk of COVID‐19
|
|
p
|
Training: nCapp, a cell phone‐based autodiagnosis system, combined with 15 questions online, and a predicated formula to autodiagnosis of the risk of COVID‐19
|
|
p
|
Validation: nCapp, a cell phone‐based autodiagnosis system, combined with 15 questions online, and a predicated formula to auto‐diagnosis of the risk of COVID‐19
|
|
td
|
–
|
|
td
|
Primary (1 day): accuracy of nCapp COVID‐19 risk diagnostic model
|
|
td
|
NCT04275947/Recruiting, Feb 14‐May 31 2020
|
|
tr
|
A Pilot Study of Sildenafil in COVID‐19 Drug: Sildenafil citrate tablets (G1) China/COVID‐19 10, all, 18 years and older Treatment Experimental group: sildenafil citrate tablet 0.1 g/day for 14 days Not applicable Primary (14 days): rate of disease remission, rate of entering the critical stage, time of entering the critical stage
Secondary (14 days): rate of no fever, rate of respiratory symptom remission, rate of lung imaging recovery, rate of C‐reactive protein (CRP) recovery, rate of Biochemical criterion (CK, ALT, Mb) recovery, rate of undetectable viral RNA (continuous twice), time for hospitalization, rate of adverse event NCT04304313/Recruiting, Feb 9‐Nov 9 2020
|
|
td
|
A Pilot Study of Sildenafil in COVID‐19
|
|
td
|
Drug: Sildenafil citrate tablets (G1)
|
|
td
|
China/COVID‐19
|
|
td
|
10, all, 18 years and older
|
|
td
|
Treatment
|
|
td
|
Experimental group: sildenafil citrate tablet 0.1 g/day for 14 days
|
|
td
|
Not applicable
|
|
td
|
Primary (14 days): rate of disease remission, rate of entering the critical stage, time of entering the critical stage
Secondary (14 days): rate of no fever, rate of respiratory symptom remission, rate of lung imaging recovery, rate of C‐reactive protein (CRP) recovery, rate of Biochemical criterion (CK, ALT, Mb) recovery, rate of undetectable viral RNA (continuous twice), time for hospitalization, rate of adverse event
|
|
p
|
Primary (14 days): rate of disease remission, rate of entering the critical stage, time of entering the critical stage
|
|
p
|
Secondary (14 days): rate of no fever, rate of respiratory symptom remission, rate of lung imaging recovery, rate of C‐reactive protein (CRP) recovery, rate of Biochemical criterion (CK, ALT, Mb) recovery, rate of undetectable viral RNA (continuous twice), time for hospitalization, rate of adverse event
|
|
td
|
NCT04304313/Recruiting, Feb 9‐Nov 9 2020
|
|
tr
|
Critically Ill patients with COVID‐19 in Hong Kong: a multicentre observational cohort study – Hong Kong/COVID‐19 8 descriptive A case series of 41 hospitalized patients with confirmed infection
30% required critical care admission: developed severe respiratory failure, 10% required mechanical ventilation, 5% needed extracorporeal membrane oxygenation support mortality rate: 15% − Primary (28 days): 28 day mortality
Secondary (28 days): vasopressor days, days on mechanical ventilation, sequential organ function assessment score, ECMO use, percentage nitric oxide use, percentage free from oxygen supplement NCT04285801/Completed, Feb 14‐Feb 25 2020
|
|
td
|
Critically Ill patients with COVID‐19 in Hong Kong: a multicentre observational cohort study
|
|
td
|
–
|
|
td
|
Hong Kong/COVID‐19
|
|
td
|
8
|
|
td
|
descriptive
|
|
td
|
A case series of 41 hospitalized patients with confirmed infection
30% required critical care admission: developed severe respiratory failure, 10% required mechanical ventilation, 5% needed extracorporeal membrane oxygenation support mortality rate: 15%
|
|
p
|
A case series of 41 hospitalized patients with confirmed infection
|
|
p
|
30% required critical care admission: developed severe respiratory failure, 10% required mechanical ventilation, 5% needed extracorporeal membrane oxygenation support mortality rate: 15%
|
|
td
|
−
|
|
td
|
Primary (28 days): 28 day mortality
Secondary (28 days): vasopressor days, days on mechanical ventilation, sequential organ function assessment score, ECMO use, percentage nitric oxide use, percentage free from oxygen supplement
|
|
p
|
Primary (28 days): 28 day mortality
|
|
p
|
Secondary (28 days): vasopressor days, days on mechanical ventilation, sequential organ function assessment score, ECMO use, percentage nitric oxide use, percentage free from oxygen supplement
|
|
td
|
NCT04285801/Completed, Feb 14‐Feb 25 2020
|
|
tr
|
Treatment of mild cases and chemoprophylaxis of contacts as prevention of the COVID‐19 epidemic Drug: antiviral treatment and prophylaxis, Standard Public Health measures COVID‐19 3,040, All, 18 Years and older Treatment Experimental: antiviral treatment and prophylaxis: darunavir 800 mg/cobicistat 150 mg tablets (oral, 1 tablet q24h, taking for 7 days) and hydroxychloroquine (200 mg tablets) 800 mg on Day 1, and 400 mg on days 2, 3, 4. Contacts: a prophylactic regimen of hydroxychloroquine (200 mg tablets) 800 mg on Day 1, and 400 mg on days 2,3,4. Other: standard public health measures
Active comparator: standard public health measures III Primary (up to 14 days after start of treatment): effectiveness of chemoprophylaxis assessed by incidence of secondary COVID‐19 cases
Secondary: the virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at days 3, the mortality rate of subjects at weeks 2, proportion of participants that drop out of study (up to 14 days after start of treatment), proportion of participants that show noncompliance with study drug (up to 14 days after start of treatment) NCT04304053/Not yet recruiting, Mar15‐Jul15 2020
|
|
td
|
Treatment of mild cases and chemoprophylaxis of contacts as prevention of the COVID‐19 epidemic
|
|
td
|
Drug: antiviral treatment and prophylaxis, Standard Public Health measures
|
|
td
|
COVID‐19
|
|
td
|
3,040, All, 18 Years and older
|
|
td
|
Treatment
|
|
td
|
Experimental: antiviral treatment and prophylaxis: darunavir 800 mg/cobicistat 150 mg tablets (oral, 1 tablet q24h, taking for 7 days) and hydroxychloroquine (200 mg tablets) 800 mg on Day 1, and 400 mg on days 2, 3, 4. Contacts: a prophylactic regimen of hydroxychloroquine (200 mg tablets) 800 mg on Day 1, and 400 mg on days 2,3,4. Other: standard public health measures
Active comparator: standard public health measures
|
|
p
|
Experimental: antiviral treatment and prophylaxis: darunavir 800 mg/cobicistat 150 mg tablets (oral, 1 tablet q24h, taking for 7 days) and hydroxychloroquine (200 mg tablets) 800 mg on Day 1, and 400 mg on days 2, 3, 4. Contacts: a prophylactic regimen of hydroxychloroquine (200 mg tablets) 800 mg on Day 1, and 400 mg on days 2,3,4. Other: standard public health measures
|
|
p
|
Active comparator: standard public health measures
|
|
td
|
III
|
|
td
|
Primary (up to 14 days after start of treatment): effectiveness of chemoprophylaxis assessed by incidence of secondary COVID‐19 cases
Secondary: the virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at days 3, the mortality rate of subjects at weeks 2, proportion of participants that drop out of study (up to 14 days after start of treatment), proportion of participants that show noncompliance with study drug (up to 14 days after start of treatment)
|
|
p
|
Primary (up to 14 days after start of treatment): effectiveness of chemoprophylaxis assessed by incidence of secondary COVID‐19 cases
|
|
p
|
Secondary: the virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at days 3, the mortality rate of subjects at weeks 2, proportion of participants that drop out of study (up to 14 days after start of treatment), proportion of participants that show noncompliance with study drug (up to 14 days after start of treatment)
|
|
td
|
NCT04304053/Not yet recruiting, Mar15‐Jul15 2020
|
|
tr
|
Comparison of lopinavir/ritonavir or hydroxychloroquine in patients with mild coronavirus disease (COVID‐19) Drug: lopinavir/ritonavir, Drug: hydroxychloroquine sulfate Korea/COVID‐19 150, all, 16 years to 99 years Treatment Experimental: lopinavir/ritonavir 200 mg/100 mg 2 tablets by mouth, every 12 hr for 7–10 days
Active comparator: hydroxychloroquine 200 mg 2 tablets by mouth, every 12 hr for 7–10 days
No intervention: control, no lopinavir/ritonavir and hydroxychloroquine II Primary: viral load (hospital Day 3, 5, 7, 10, 14, 18)
Secondary viral load change (hospital Day 3, 5, 7, 10, 14, 18), time to clinical improvement (time frame: up to 28 days), percentage of progression to supplemental oxygen requirement by Day 7, Time to NEWS2 (National Early Warning Score 2) of 3 or more maintained for 24 hr by Day 7, time to clinical failure, defined as the time to death, mechanical ventilation, or ICU admission (up to 28 days), rate of switch to lopinavir/ritonavir or hydroxychloroquine by Day 7, adverse effects (up to 28 days), concentration of lopinavir/ritonavir and hydroxychloroquine (1, 2, 4, 5, 12 hr after taking intervention medicine) NCT04307693/Recruiting, Mar11‐May 2020
|
|
td
|
Comparison of lopinavir/ritonavir or hydroxychloroquine in patients with mild coronavirus disease (COVID‐19)
|
|
td
|
Drug: lopinavir/ritonavir, Drug: hydroxychloroquine sulfate
|
|
td
|
Korea/COVID‐19
|
|
td
|
150, all, 16 years to 99 years
|
|
td
|
Treatment
|
|
td
|
Experimental: lopinavir/ritonavir 200 mg/100 mg 2 tablets by mouth, every 12 hr for 7–10 days
Active comparator: hydroxychloroquine 200 mg 2 tablets by mouth, every 12 hr for 7–10 days
No intervention: control, no lopinavir/ritonavir and hydroxychloroquine
|
|
p
|
Experimental: lopinavir/ritonavir 200 mg/100 mg 2 tablets by mouth, every 12 hr for 7–10 days
|
|
p
|
Active comparator: hydroxychloroquine 200 mg 2 tablets by mouth, every 12 hr for 7–10 days
|
|
p
|
No intervention: control, no lopinavir/ritonavir and hydroxychloroquine
|
|
td
|
II
|
|
td
|
Primary: viral load (hospital Day 3, 5, 7, 10, 14, 18)
Secondary viral load change (hospital Day 3, 5, 7, 10, 14, 18), time to clinical improvement (time frame: up to 28 days), percentage of progression to supplemental oxygen requirement by Day 7, Time to NEWS2 (National Early Warning Score 2) of 3 or more maintained for 24 hr by Day 7, time to clinical failure, defined as the time to death, mechanical ventilation, or ICU admission (up to 28 days), rate of switch to lopinavir/ritonavir or hydroxychloroquine by Day 7, adverse effects (up to 28 days), concentration of lopinavir/ritonavir and hydroxychloroquine (1, 2, 4, 5, 12 hr after taking intervention medicine)
|
|
p
|
Primary: viral load (hospital Day 3, 5, 7, 10, 14, 18)
|
|
p
|
Secondary viral load change (hospital Day 3, 5, 7, 10, 14, 18), time to clinical improvement (time frame: up to 28 days), percentage of progression to supplemental oxygen requirement by Day 7, Time to NEWS2 (National Early Warning Score 2) of 3 or more maintained for 24 hr by Day 7, time to clinical failure, defined as the time to death, mechanical ventilation, or ICU admission (up to 28 days), rate of switch to lopinavir/ritonavir or hydroxychloroquine by Day 7, adverse effects (up to 28 days), concentration of lopinavir/ritonavir and hydroxychloroquine (1, 2, 4, 5, 12 hr after taking intervention medicine)
|
|
td
|
NCT04307693/Recruiting, Mar11‐May 2020
|
|
tr
|
Study to evaluate the safety and antiviral activity of remdesivir (GS‐5734™) in participants with severe coronavirus disease (COVID‐19) Drug: remdesivir, standard of care United States, Hong Kong/COVID‐19 400, all, 18 years and older Treatment Experimental: demdesivir (RDV), 5 days participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, and 5
Experimental: remdesivir, 10 days participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, 5, 6, 7, 8, 9, and 10 III Primary: proportion of participants with normalization of fever and oxygen saturation through day 14
Secondary: proportion of participants with treatment emergent adverse events leading to study drug discontinuation (first dose date up to 10 days) NCT04292899/Recruiting, Mar6‐May 2020
|
|
td
|
Study to evaluate the safety and antiviral activity of remdesivir (GS‐5734™) in participants with severe coronavirus disease (COVID‐19)
|
|
td
|
Drug: remdesivir, standard of care
|
|
td
|
United States, Hong Kong/COVID‐19
|
|
td
|
400, all, 18 years and older
|
|
td
|
Treatment
|
|
td
|
Experimental: demdesivir (RDV), 5 days participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, and 5
Experimental: remdesivir, 10 days participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, 5, 6, 7, 8, 9, and 10
|
|
p
|
Experimental: demdesivir (RDV), 5 days participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, and 5
|
|
p
|
Experimental: remdesivir, 10 days participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, 5, 6, 7, 8, 9, and 10
|
|
td
|
III
|
|
td
|
Primary: proportion of participants with normalization of fever and oxygen saturation through day 14
Secondary: proportion of participants with treatment emergent adverse events leading to study drug discontinuation (first dose date up to 10 days)
|
|
p
|
Primary: proportion of participants with normalization of fever and oxygen saturation through day 14
|
|
p
|
Secondary: proportion of participants with treatment emergent adverse events leading to study drug discontinuation (first dose date up to 10 days)
|
|
td
|
NCT04292899/Recruiting, Mar6‐May 2020
|
|
tr
|
Study to evaluate the safety and antiviral activity of remdesivir (GS‐5734™) in participants with moderate coronavirus disease (COVID‐19) compared to standard of care treatment Drug: remdesivir, standard of care United States, Hong Kong, 600, all, 18 years and older Treatment Experimental: remdesivir, 5 days participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, and 5.
Experimental: remdesivir, 10 days participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, 5, 6, 7, 8, 9, and 10.
Active comparator: continued standard of care therapy III Primary (up to 14 days): proportion of participants discharged by day 14‐secondary (up to 10 days): proportion of participants with treatment emergent adverse events leading to study drug discontinuation NCT04292730/Recruiting, Mar‐May 2020
|
|
td
|
Study to evaluate the safety and antiviral activity of remdesivir (GS‐5734™) in participants with moderate coronavirus disease (COVID‐19) compared to standard of care treatment
|
|
td
|
Drug: remdesivir, standard of care
|
|
td
|
United States, Hong Kong,
|
|
td
|
600, all, 18 years and older
|
|
td
|
Treatment
|
|
td
|
Experimental: remdesivir, 5 days participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, and 5.
Experimental: remdesivir, 10 days participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, 5, 6, 7, 8, 9, and 10.
Active comparator: continued standard of care therapy
|
|
p
|
Experimental: remdesivir, 5 days participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, and 5.
|
|
p
|
Experimental: remdesivir, 10 days participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, 5, 6, 7, 8, 9, and 10.
|
|
p
|
Active comparator: continued standard of care therapy
|
|
td
|
III
|
|
td
|
Primary (up to 14 days): proportion of participants discharged by day 14‐secondary (up to 10 days): proportion of participants with treatment emergent adverse events leading to study drug discontinuation
|
|
td
|
NCT04292730/Recruiting, Mar‐May 2020
|
|
tr
|
Bevacizumab in severe or critical patients with COVID‐19 pneumonia‐RCT Drug: bevacizumab China/COVID‐19 Pneumonia 118, all, 18–80 Treatment Experimental; bevacizumab, group:
bevacizumab 500 mg + 0.9% NaCl 100 ml, intravenous drip
No intervention: control group Not applicable Primary: proportion of patients whose oxygenation index increased by 100 mmHg on the 7th day after admission NCT04305106/Not yet recruiting, Mar12‐May31 2020
|
|
td
|
Bevacizumab in severe or critical patients with COVID‐19 pneumonia‐RCT
|
|
td
|
Drug: bevacizumab
|
|
td
|
China/COVID‐19 Pneumonia
|
|
td
|
118, all, 18–80
|
|
td
|
Treatment
|
|
td
|
Experimental; bevacizumab, group:
bevacizumab 500 mg + 0.9% NaCl 100 ml, intravenous drip
No intervention: control group
|
|
p
|
Experimental; bevacizumab, group:
|
|
p
|
bevacizumab 500 mg + 0.9% NaCl 100 ml, intravenous drip
|
|
p
|
No intervention: control group
|
|
td
|
Not applicable
|
|
td
|
Primary: proportion of patients whose oxygenation index increased by 100 mmHg on the 7th day after admission
|
|
td
|
NCT04305106/Not yet recruiting, Mar12‐May31 2020
|
|
tr
|
The efficacy and safety of thalidomide in the adjuvant treatment of moderate new coronavirus (COVID‐19) pneumonia Drug: thalidomide, placebo COVID‐19 thalidomide 100, all, 18 years and older Treatment Placebo comparator: control group: placebo 100 mg, po, qn, for 14 days
Experimental: thalidomide group 100 mg, po, qn, for 14 days. Other name: fanyingting II Primary (up to 28 days): time to clinical recovery time to clinical recovery (up to 28 days)
Secondary (up to 28 days): all cause mortality (up to 28 days), frequency of respiratory progression, Time to defervescence
Others(up to 28 days): time to cough reported as mild or absent, respiratory improvement time, frequency of requirement for supplemental oxygen or noninvasive ventilation, Time to 2019‐nCoV RT‐PCR negative in upper respiratory tract specimen, change (reduction) in 2019‐nCoV viral load in upper respiratory tract specimen as assessed by area under viral load curve, frequency of requirement for mechanical ventilation, frequency of serious adverse events, Serum TNF‐α, IL‐1β, IL‐2, IL‐6, IL‐7, IL‐10, GSCF, IP10, MCP1, MIP1α and other cytokine expression levels before and after treatment NCT04273529/Not yet recruiting, Feb20‐Jun30 2020
|
|
td
|
The efficacy and safety of thalidomide in the adjuvant treatment of moderate new coronavirus (COVID‐19) pneumonia
|
|
td
|
Drug: thalidomide, placebo
|
|
td
|
COVID‐19 thalidomide
|
|
td
|
100, all, 18 years and older
|
|
td
|
Treatment
|
|
td
|
Placebo comparator: control group: placebo 100 mg, po, qn, for 14 days
Experimental: thalidomide group 100 mg, po, qn, for 14 days. Other name: fanyingting
|
|
p
|
Placebo comparator: control group: placebo 100 mg, po, qn, for 14 days
|
|
p
|
Experimental: thalidomide group 100 mg, po, qn, for 14 days. Other name: fanyingting
|
|
td
|
II
|
|
td
|
Primary (up to 28 days): time to clinical recovery time to clinical recovery (up to 28 days)
Secondary (up to 28 days): all cause mortality (up to 28 days), frequency of respiratory progression, Time to defervescence
Others(up to 28 days): time to cough reported as mild or absent, respiratory improvement time, frequency of requirement for supplemental oxygen or noninvasive ventilation, Time to 2019‐nCoV RT‐PCR negative in upper respiratory tract specimen, change (reduction) in 2019‐nCoV viral load in upper respiratory tract specimen as assessed by area under viral load curve, frequency of requirement for mechanical ventilation, frequency of serious adverse events, Serum TNF‐α, IL‐1β, IL‐2, IL‐6, IL‐7, IL‐10, GSCF, IP10, MCP1, MIP1α and other cytokine expression levels before and after treatment
|
|
p
|
Primary (up to 28 days): time to clinical recovery time to clinical recovery (up to 28 days)
|
|
p
|
Secondary (up to 28 days): all cause mortality (up to 28 days), frequency of respiratory progression, Time to defervescence
|
|
p
|
Others(up to 28 days): time to cough reported as mild or absent, respiratory improvement time, frequency of requirement for supplemental oxygen or noninvasive ventilation, Time to 2019‐nCoV RT‐PCR negative in upper respiratory tract specimen, change (reduction) in 2019‐nCoV viral load in upper respiratory tract specimen as assessed by area under viral load curve, frequency of requirement for mechanical ventilation, frequency of serious adverse events, Serum TNF‐α, IL‐1β, IL‐2, IL‐6, IL‐7, IL‐10, GSCF, IP10, MCP1, MIP1α and other cytokine expression levels before and after treatment
|
|
td
|
NCT04273529/Not yet recruiting, Feb20‐Jun30 2020
|
|
tr
|
The efficacy and safety of thalidomide combined with low‐dose hormones in the treatment of Severe COVID‐19 Placebo, drug: thalidomide COVID‐19 thalidomide 40, all, 18 years and older Treatment Placebo comparator: control group α‐interferon: nebulized inhalation, 5 million U or equivalent dose added 2 ml of sterile water for injection, 2 times a day, for 7 days; abidol, 200 mg/time, 3 times a day, for 7 days; methylprednisolone: 40 mg, q12h, for 5 days. placebo: 100 mg/d, qn, for 14 days
Experimental: thalidomide group α‐interferon: nebulized inhalation, 5 million U or equivalent dose added 2 ml of sterile water for injection, 2 times a day, for 7 days; abidol, 200 mg/time, 3 times a day, for 7 days; methylprednisolone: 40 mg, q12h, for 5 days. thalidomide: 100 mg/d qn for 14 days II Primary (up to 28 days): time to clinical improvement
Secondary (up to 28 days): clinical status (days 7, 14, 21, and 28), time to hospital discharge or NEWS2 (National Early Warning Score 2) of ≤2 maintained for 24 hr, all cause mortality, duration (days) of mechanical ventilation, duration (days) of extracorporeal membrane oxygenation, duration (days) of supplemental oxygenation, length of hospital stay (days), time to 2019‐nCoV RT‐PCR, change (reduction) in 2019‐nCoV viral load in upper and lower respiratory tract specimens as assessed by area under viral load curve, frequency of serious adverse drug events, Serum TNF‐α, IL‐1β, IL‐2, IL‐6, IL‐7, IL‐10, GSCF, IP10#MCP1, MIP1α, and other cytokine expression levels before and after treatment NCT04273581/Not yet recruiting, Feb18‐May30 2020
|
|
td
|
The efficacy and safety of thalidomide combined with low‐dose hormones in the treatment of Severe COVID‐19
|
|
td
|
Placebo, drug: thalidomide
|
|
td
|
COVID‐19 thalidomide
|
|
td
|
40, all, 18 years and older
|
|
td
|
Treatment
|
|
td
|
Placebo comparator: control group α‐interferon: nebulized inhalation, 5 million U or equivalent dose added 2 ml of sterile water for injection, 2 times a day, for 7 days; abidol, 200 mg/time, 3 times a day, for 7 days; methylprednisolone: 40 mg, q12h, for 5 days. placebo: 100 mg/d, qn, for 14 days
Experimental: thalidomide group α‐interferon: nebulized inhalation, 5 million U or equivalent dose added 2 ml of sterile water for injection, 2 times a day, for 7 days; abidol, 200 mg/time, 3 times a day, for 7 days; methylprednisolone: 40 mg, q12h, for 5 days. thalidomide: 100 mg/d qn for 14 days
|
|
p
|
Placebo comparator: control group α‐interferon: nebulized inhalation, 5 million U or equivalent dose added 2 ml of sterile water for injection, 2 times a day, for 7 days; abidol, 200 mg/time, 3 times a day, for 7 days; methylprednisolone: 40 mg, q12h, for 5 days. placebo: 100 mg/d, qn, for 14 days
|
|
p
|
Experimental: thalidomide group α‐interferon: nebulized inhalation, 5 million U or equivalent dose added 2 ml of sterile water for injection, 2 times a day, for 7 days; abidol, 200 mg/time, 3 times a day, for 7 days; methylprednisolone: 40 mg, q12h, for 5 days. thalidomide: 100 mg/d qn for 14 days
|
|
td
|
II
|
|
td
|
Primary (up to 28 days): time to clinical improvement
Secondary (up to 28 days): clinical status (days 7, 14, 21, and 28), time to hospital discharge or NEWS2 (National Early Warning Score 2) of ≤2 maintained for 24 hr, all cause mortality, duration (days) of mechanical ventilation, duration (days) of extracorporeal membrane oxygenation, duration (days) of supplemental oxygenation, length of hospital stay (days), time to 2019‐nCoV RT‐PCR, change (reduction) in 2019‐nCoV viral load in upper and lower respiratory tract specimens as assessed by area under viral load curve, frequency of serious adverse drug events, Serum TNF‐α, IL‐1β, IL‐2, IL‐6, IL‐7, IL‐10, GSCF, IP10#MCP1, MIP1α, and other cytokine expression levels before and after treatment
|
|
p
|
Primary (up to 28 days): time to clinical improvement
|
|
p
|
Secondary (up to 28 days): clinical status (days 7, 14, 21, and 28), time to hospital discharge or NEWS2 (National Early Warning Score 2) of ≤2 maintained for 24 hr, all cause mortality, duration (days) of mechanical ventilation, duration (days) of extracorporeal membrane oxygenation, duration (days) of supplemental oxygenation, length of hospital stay (days), time to 2019‐nCoV RT‐PCR, change (reduction) in 2019‐nCoV viral load in upper and lower respiratory tract specimens as assessed by area under viral load curve, frequency of serious adverse drug events, Serum TNF‐α, IL‐1β, IL‐2, IL‐6, IL‐7, IL‐10, GSCF, IP10#MCP1, MIP1α, and other cytokine expression levels before and after treatment
|
|
td
|
NCT04273581/Not yet recruiting, Feb18‐May30 2020
|
|
tr
|
Tetrandrine tablets used in the treatment of COVID‐19 Drug: tetrandrine China/COVID‐19 60, all, 18–75 Treatment Experimental: tetrandrine cohort after the subjects were enrolled, they were given “Tetrandrine 60 mg QD” for a course of 1 week (take 6 days, stop using for 1 day)
No intervention: control cohort treatment according to standard protocols without intervention IV Primary (12 weeks): survival rate secondary (2 weeks): body temperature NCT04308317/Enrolling by invitation, Mar5‐May1 2020
|
|
td
|
Tetrandrine tablets used in the treatment of COVID‐19
|
|
td
|
Drug: tetrandrine
|
|
td
|
China/COVID‐19
|
|
td
|
60, all, 18–75
|
|
td
|
Treatment
|
|
td
|
Experimental: tetrandrine cohort after the subjects were enrolled, they were given “Tetrandrine 60 mg QD” for a course of 1 week (take 6 days, stop using for 1 day)
No intervention: control cohort treatment according to standard protocols without intervention
|
|
p
|
Experimental: tetrandrine cohort after the subjects were enrolled, they were given “Tetrandrine 60 mg QD” for a course of 1 week (take 6 days, stop using for 1 day)
|
|
p
|
No intervention: control cohort treatment according to standard protocols without intervention
|
|
td
|
IV
|
|
td
|
Primary (12 weeks): survival rate secondary (2 weeks): body temperature
|
|
td
|
NCT04308317/Enrolling by invitation, Mar5‐May1 2020
|
|
tr
|
Fingolimod in COVID‐19 Biological: UC‐MSCs, other: placebo China/COVID‐19 30, all, 18–80 Treatment Experimental: treatment group: each patient in the fingolimod treatment group was given 0.5 mg of fingolimod orally once daily, for three consecutive days
No Intervention: control group II Primary (5 day after treatment): the change of pneumonia severity on X‐ray images NCT04280588/Recruiting, Feb22‐Jul1 2020
|
|
td
|
Fingolimod in COVID‐19
|
|
td
|
Biological: UC‐MSCs, other: placebo
|
|
td
|
China/COVID‐19
|
|
td
|
30, all, 18–80
|
|
td
|
Treatment
|
|
td
|
Experimental: treatment group: each patient in the fingolimod treatment group was given 0.5 mg of fingolimod orally once daily, for three consecutive days
No Intervention: control group
|
|
p
|
Experimental: treatment group: each patient in the fingolimod treatment group was given 0.5 mg of fingolimod orally once daily, for three consecutive days
|
|
p
|
No Intervention: control group
|
|
td
|
II
|
|
td
|
Primary (5 day after treatment): the change of pneumonia severity on X‐ray images
|
|
td
|
NCT04280588/Recruiting, Feb22‐Jul1 2020
|
|
tr
|
Therapy for pneumonia patients infected by 2019 novel coronavirus Biological: UC‐MSCs, other: placebo China/COVID‐19 48, all, 18–75 Treatment Experimental: UC‐MSCs treatment group, participants will receive conventional treatment plus four times of 0.5*10E6 UC‐MSCs/kg body weight intravenously at Day1, Day3, Day5, Day7)
Placebo comparator: control group, participants will receive conventional treatment plus 4 times of placebo intravenously at Day1, Day3, Day5, Day7 Not applicable Primary (at baseline, Day 1, Weeks 1, 2, 4, 8): size of lesion area by chest imaging, blood oxygen saturation
Secondary (at baseline, Day 1, Weeks 1, 2, 4, 8): rate of mortality within 28‐days, sequential organ failure assessment, side effects in the UC‐MSCs treatment group, Electrocardiogram, the changes of ST‐T interval mostly, Concentration of C‐reactive protein C‐reactive protein, immunoglobulin, CD4 + and CD8 + T cells count, Concentration of the blood cytokine (IL‐1β, IL‐6, IL‐8,IL‐10,TNF‐α), Concentration of the myocardial enzymes NCT04293692/Recruiting, Feb24‐Feb1 2020–2021
|
|
td
|
Therapy for pneumonia patients infected by 2019 novel coronavirus
|
|
td
|
Biological: UC‐MSCs, other: placebo
|
|
td
|
China/COVID‐19
|
|
td
|
48, all, 18–75
|
|
td
|
Treatment
|
|
td
|
Experimental: UC‐MSCs treatment group, participants will receive conventional treatment plus four times of 0.5*10E6 UC‐MSCs/kg body weight intravenously at Day1, Day3, Day5, Day7)
Placebo comparator: control group, participants will receive conventional treatment plus 4 times of placebo intravenously at Day1, Day3, Day5, Day7
|
|
p
|
Experimental: UC‐MSCs treatment group, participants will receive conventional treatment plus four times of 0.5*10E6 UC‐MSCs/kg body weight intravenously at Day1, Day3, Day5, Day7)
|
|
p
|
Placebo comparator: control group, participants will receive conventional treatment plus 4 times of placebo intravenously at Day1, Day3, Day5, Day7
|
|
td
|
Not applicable
|
|
td
|
Primary (at baseline, Day 1, Weeks 1, 2, 4, 8): size of lesion area by chest imaging, blood oxygen saturation
Secondary (at baseline, Day 1, Weeks 1, 2, 4, 8): rate of mortality within 28‐days, sequential organ failure assessment, side effects in the UC‐MSCs treatment group, Electrocardiogram, the changes of ST‐T interval mostly, Concentration of C‐reactive protein C‐reactive protein, immunoglobulin, CD4 + and CD8 + T cells count, Concentration of the blood cytokine (IL‐1β, IL‐6, IL‐8,IL‐10,TNF‐α), Concentration of the myocardial enzymes
|
|
p
|
Primary (at baseline, Day 1, Weeks 1, 2, 4, 8): size of lesion area by chest imaging, blood oxygen saturation
|
|
p
|
Secondary (at baseline, Day 1, Weeks 1, 2, 4, 8): rate of mortality within 28‐days, sequential organ failure assessment, side effects in the UC‐MSCs treatment group, Electrocardiogram, the changes of ST‐T interval mostly, Concentration of C‐reactive protein C‐reactive protein, immunoglobulin, CD4 + and CD8 + T cells count, Concentration of the blood cytokine (IL‐1β, IL‐6, IL‐8,IL‐10,TNF‐α), Concentration of the myocardial enzymes
|
|
td
|
NCT04293692/Recruiting, Feb24‐Feb1 2020–2021
|
|
tr
|
The Use PUL‐042 inhalation solution to prevent COVID‐19 in adults exposed to SARS‐CoV‐2 Drug: PUL‐042 inhalation solution, drug: placebo COVID‐19 200, all, 18 years and older Treatment Experimental: PUL‐042 inhalation solution, PUL‐042 inhalation solution (20.3 µg Pam2: 29.8 µg ODN/mL) given by nebulization on study days 1,3, 6, and 10
Placebo comparator: sterile normal saline for inhalation, sterile normal saline for inhalation given by nebulization on study days 1, 3, 6, and 10 II Primary (14 days): Prevention of COVID‐19 NCT04313023/Not yet recruiting, Apr‐Oct 2020
|
|
td
|
The Use PUL‐042 inhalation solution to prevent COVID‐19 in adults exposed to SARS‐CoV‐2
|
|
td
|
Drug: PUL‐042 inhalation solution, drug: placebo
|
|
td
|
COVID‐19
|
|
td
|
200, all, 18 years and older
|
|
td
|
Treatment
|
|
td
|
Experimental: PUL‐042 inhalation solution, PUL‐042 inhalation solution (20.3 µg Pam2: 29.8 µg ODN/mL) given by nebulization on study days 1,3, 6, and 10
Placebo comparator: sterile normal saline for inhalation, sterile normal saline for inhalation given by nebulization on study days 1, 3, 6, and 10
|
|
p
|
Experimental: PUL‐042 inhalation solution, PUL‐042 inhalation solution (20.3 µg Pam2: 29.8 µg ODN/mL) given by nebulization on study days 1,3, 6, and 10
|
|
p
|
Placebo comparator: sterile normal saline for inhalation, sterile normal saline for inhalation given by nebulization on study days 1, 3, 6, and 10
|
|
td
|
II
|
|
td
|
Primary (14 days): Prevention of COVID‐19
|
|
td
|
NCT04313023/Not yet recruiting, Apr‐Oct 2020
|
|
tr
|
Treatment of COVID‐19 patients using Wharton's jelly‐mesenchymal stem cells Biological: WJ‐MSCs Arabia Amman, Jordan/use of stem cells for COVID‐19 treatment 5, all, 18 years and older Treatment Experimental: WJ‐MSCs WJ‐MSCs will be derived from cord tissue of newborns, screened for HIV1/2, HBV, HCV, CMV, mycoplasma, and cultured to enrich for MSCs.
WJ‐MSCs will be counted and suspended in 25 ml of saline solution containing 0.5% human serum albumin, and will be given to patient intravenously I Primary (3 weeks): Clinical outcome, CT Scan, RT‐PCR results
Secondary (8 weeks): RT‐PCR results NCT04313322/Recruiting, Mar16‐Sep30 2020
|
|
td
|
Treatment of COVID‐19 patients using Wharton's jelly‐mesenchymal stem cells
|
|
td
|
Biological: WJ‐MSCs
|
|
td
|
Arabia Amman, Jordan/use of stem cells for COVID‐19 treatment
|
|
td
|
5, all, 18 years and older
|
|
td
|
Treatment
|
|
td
|
Experimental: WJ‐MSCs WJ‐MSCs will be derived from cord tissue of newborns, screened for HIV1/2, HBV, HCV, CMV, mycoplasma, and cultured to enrich for MSCs.
WJ‐MSCs will be counted and suspended in 25 ml of saline solution containing 0.5% human serum albumin, and will be given to patient intravenously
|
|
p
|
Experimental: WJ‐MSCs WJ‐MSCs will be derived from cord tissue of newborns, screened for HIV1/2, HBV, HCV, CMV, mycoplasma, and cultured to enrich for MSCs.
|
|
p
|
WJ‐MSCs will be counted and suspended in 25 ml of saline solution containing 0.5% human serum albumin, and will be given to patient intravenously
|
|
td
|
I
|
|
td
|
Primary (3 weeks): Clinical outcome, CT Scan, RT‐PCR results
Secondary (8 weeks): RT‐PCR results
|
|
p
|
Primary (3 weeks): Clinical outcome, CT Scan, RT‐PCR results
|
|
p
|
Secondary (8 weeks): RT‐PCR results
|
|
td
|
NCT04313322/Recruiting, Mar16‐Sep30 2020
|
|
tr
|
Myocardial damage in COVID‐19 Non China/COVID‐19 cardiovascular diseases 500, all, 18 years and older Prognostic Discharged group (no intervention) the individual which is defined as patient discharged from hospital
Dead group (no intervention) The individual which is defined as patient with all‐cause death – Primary (75 days): the myocardial injury incidence, the risk factors analysis for the death
Secondary (75 days): clinical characteristics, clinical course, cardiovascular comorbidity, Analysis of causes of death NCT04312464/Enrolling by invitation, Jun1‐Mar18 2020
|
|
td
|
Myocardial damage in COVID‐19
|
|
td
|
Non
|
|
td
|
China/COVID‐19 cardiovascular diseases
|
|
td
|
500, all, 18 years and older
|
|
td
|
Prognostic
|
|
td
|
Discharged group (no intervention) the individual which is defined as patient discharged from hospital
Dead group (no intervention) The individual which is defined as patient with all‐cause death
|
|
p
|
Discharged group (no intervention) the individual which is defined as patient discharged from hospital
|
|
p
|
Dead group (no intervention) The individual which is defined as patient with all‐cause death
|
|
td
|
–
|
|
td
|
Primary (75 days): the myocardial injury incidence, the risk factors analysis for the death
Secondary (75 days): clinical characteristics, clinical course, cardiovascular comorbidity, Analysis of causes of death
|
|
p
|
Primary (75 days): the myocardial injury incidence, the risk factors analysis for the death
|
|
p
|
Secondary (75 days): clinical characteristics, clinical course, cardiovascular comorbidity, Analysis of causes of death
|
|
td
|
NCT04312464/Enrolling by invitation, Jun1‐Mar18 2020
|
|
tr
|
Treatment with mesenchymal stem cells for severe corona virus disease 2019(COVID‐19) Biological: MSCs, biological: saline containing 1%, human serum albumin (solution of MSC China/COVID‐19 60, all, 18–70 Treatment Experimental: mesenchymal stem cells (MSCs), conventional treatment plus MSCs participants will receive conventional treatment plus 3 times of MSCs ((4.0*10E7 cells per time) intravenously at Day 0, Day 3, Day 6)
Placebo comparator: placebo conventional treatment plus placebo participants will receive conventional treatment plus 3 times of placebo (saline containing 1% human serum albumin (solution of MSC) 3 times of placebo (intravenously at Day 0, Day 3, Day 6) I, II Primary (28 days): improvement time of clinical critical treatment index, side effects in the MSCs treatment group
Secondary: proportion of patients in each classification of clinical critical treatment index (baseline, Days 7, 14, 28), all cause mortality on Day 28, invasive mechanical ventilation rate (Day 28), duration of oxygen therapy (Day 28), duration of hospitalization (Day 28), incidence of nosocomial infection (Day 28), CD4+ T cell count by flow cytometry in two groups (baseline, Day, 3, 6, 10, 14, 21, 28) NCT04288102/Recruiting, May5‐Dec31 2020–2021
|
|
td
|
Treatment with mesenchymal stem cells for severe corona virus disease 2019(COVID‐19)
|
|
td
|
Biological: MSCs, biological: saline containing 1%, human serum albumin (solution of MSC
|
|
td
|
China/COVID‐19
|
|
td
|
60, all, 18–70
|
|
td
|
Treatment
|
|
td
|
Experimental: mesenchymal stem cells (MSCs), conventional treatment plus MSCs participants will receive conventional treatment plus 3 times of MSCs ((4.0*10E7 cells per time) intravenously at Day 0, Day 3, Day 6)
Placebo comparator: placebo conventional treatment plus placebo participants will receive conventional treatment plus 3 times of placebo (saline containing 1% human serum albumin (solution of MSC) 3 times of placebo (intravenously at Day 0, Day 3, Day 6)
|
|
p
|
Experimental: mesenchymal stem cells (MSCs), conventional treatment plus MSCs participants will receive conventional treatment plus 3 times of MSCs ((4.0*10E7 cells per time) intravenously at Day 0, Day 3, Day 6)
|
|
p
|
Placebo comparator: placebo conventional treatment plus placebo participants will receive conventional treatment plus 3 times of placebo (saline containing 1% human serum albumin (solution of MSC) 3 times of placebo (intravenously at Day 0, Day 3, Day 6)
|
|
td
|
I, II
|
|
td
|
Primary (28 days): improvement time of clinical critical treatment index, side effects in the MSCs treatment group
Secondary: proportion of patients in each classification of clinical critical treatment index (baseline, Days 7, 14, 28), all cause mortality on Day 28, invasive mechanical ventilation rate (Day 28), duration of oxygen therapy (Day 28), duration of hospitalization (Day 28), incidence of nosocomial infection (Day 28), CD4+ T cell count by flow cytometry in two groups (baseline, Day, 3, 6, 10, 14, 21, 28)
|
|
p
|
Primary (28 days): improvement time of clinical critical treatment index, side effects in the MSCs treatment group
|
|
p
|
Secondary: proportion of patients in each classification of clinical critical treatment index (baseline, Days 7, 14, 28), all cause mortality on Day 28, invasive mechanical ventilation rate (Day 28), duration of oxygen therapy (Day 28), duration of hospitalization (Day 28), incidence of nosocomial infection (Day 28), CD4+ T cell count by flow cytometry in two groups (baseline, Day, 3, 6, 10, 14, 21, 28)
|
|
td
|
NCT04288102/Recruiting, May5‐Dec31 2020–2021
|
|
tr
|
The clinical study of carrimycin on treatment patients with COVID‐19 Drug: carrimycin, drug: lopinavir/ritonavir tablets or arbidol or chloroquine phosphate, Drug: basic treatment – 520, all, 18–75 Treatment Experimental: carrimycin basic treatment + carrimycin
Active comparator: lopinavir/ritonavir or arbidol or chloroquine phosphate any of basic treatment + lopinavir/ritonavir tablets or arbidol or chloroquine phosphate IV Primary (30 days): fever to normal time (day), pulmonary inflammation resolution time (HRCT) (day), negative conversion (%) of 2019‐nCOVRNA in gargle (throat swabs) at the end of treatment NCT04286503/Not yet recruiting, Feb23‐Feb28 2020–2021
|
|
td
|
The clinical study of carrimycin on treatment patients with COVID‐19
|
|
td
|
Drug: carrimycin, drug: lopinavir/ritonavir tablets or arbidol or chloroquine phosphate, Drug: basic treatment
|
|
td
|
–
|
|
td
|
520, all, 18–75
|
|
td
|
Treatment
|
|
td
|
Experimental: carrimycin basic treatment + carrimycin
Active comparator: lopinavir/ritonavir or arbidol or chloroquine phosphate any of basic treatment + lopinavir/ritonavir tablets or arbidol or chloroquine phosphate
|
|
p
|
Experimental: carrimycin basic treatment + carrimycin
|
|
p
|
Active comparator: lopinavir/ritonavir or arbidol or chloroquine phosphate any of basic treatment + lopinavir/ritonavir tablets or arbidol or chloroquine phosphate
|
|
td
|
IV
|
|
td
|
Primary (30 days): fever to normal time (day), pulmonary inflammation resolution time (HRCT) (day), negative conversion (%) of 2019‐nCOVRNA in gargle (throat swabs) at the end of treatment
|
|
td
|
NCT04286503/Not yet recruiting, Feb23‐Feb28 2020–2021
|
|
tr
|
Efficacy and safety of corticosteroids in COVID‐19 Drug: methylprednisolone China/COVID‐19 400, all, 18 years and older Treatment Experimental; Pred group: methylprednisolone 1 mg/kg/day ivgtt for 7 days
No intervention: con group Not applicable Primary (14 days): the incidence of treatment failure in 14 days
Secondary: clinical cure incidence (14 days), the duration of virus change to negative (14 days), mortality at Day 30, ICU admission rate in 30 days NCT04273321/Recruiting, Feb14‐May30 2020
|
|
td
|
Efficacy and safety of corticosteroids in COVID‐19
|
|
td
|
Drug: methylprednisolone
|
|
td
|
China/COVID‐19
|
|
td
|
400, all, 18 years and older
|
|
td
|
Treatment
|
|
td
|
Experimental; Pred group: methylprednisolone 1 mg/kg/day ivgtt for 7 days
No intervention: con group
|
|
p
|
Experimental; Pred group: methylprednisolone 1 mg/kg/day ivgtt for 7 days
|
|
p
|
No intervention: con group
|
|
td
|
Not applicable
|
|
td
|
Primary (14 days): the incidence of treatment failure in 14 days
Secondary: clinical cure incidence (14 days), the duration of virus change to negative (14 days), mortality at Day 30, ICU admission rate in 30 days
|
|
p
|
Primary (14 days): the incidence of treatment failure in 14 days
|
|
p
|
Secondary: clinical cure incidence (14 days), the duration of virus change to negative (14 days), mortality at Day 30, ICU admission rate in 30 days
|
|
td
|
NCT04273321/Recruiting, Feb14‐May30 2020
|
|
tr
|
Evaluation of the efficacy and safety of sarilumab in hospitalized patients with COVID‐19 Drug: sarilumab, drug: placebo United States/COVID‐19 400, all, 18 years and older Treatment Experimental: sarilumab high dose: single intravenous (IV) dose of sarilumab, other names: Kevzara®, REGN88, SAR153191
Experimental: sarilumab low dose: single intravenous (IV) dose of sarilumab Other Names: Kevzara®, REGN88, SAR153191
Placebo comparator: single intravenous (IV) dose of placebo to match sarilumab administration II, III Primary: time to resolution of fever for at least 48 hr without antipyretics for 48 hr (Up to Day 29), percentage of patients reporting each severity rating on a 6‐point ordinal scale (Day 15)
Secondary (up to Day 29): time to improvement in oxygenation for at least 48 hr, mean change in the 6‐point ordinal scale, clinical status using the 6‐point ordinal scale, time to improvement in one category from admission using the 6‐point ordinal scale, time to resolution of fever for at least 48 hr without antipyretics by clinical severity, time to resolution of fever for at least 48 hr without antipyretics by baseline IL‐6 levels, time to improvement in oxygenation for at least 48 hr by clinical severity, time to improvement in oxygenation for at least 48 hr by baseline IL‐6 levels, time to resolution of fever and improvement in oxygenation for at least 48 hr, time to change in National Early Warning Score 2 (NEWS2) scoring system, time to score of <2 maintained for 24 hr in NEWS2 scoring system, mean change in NEWS2 scoring system, number of days with fever, number of patients alive off oxygen, number of days of resting respiratory rate >24 breaths/min, number of days with hypoxemia, number of days of supplemental oxygen use, time to saturation ≥94% on room air, number of ventilator free days in the first 28 days, number of patients requiring initiation of mechanical ventilation, number of patients requiring noninvasive ventilation, number of patients requiring the use of high flow nasal cannula, number of patients admitted into an intensive care unit, number of days of hospitalization among survivors, number of deaths due to any cause (up to Day 60), incidence of serious adverse events (Up to Day 60), incidence of severe or life‐threatening bacterial, invasive fungal, or opportunistic infection, Incidence of severe or life‐threatening bacterial, invasive fungal, or opportunistic infection in patients with grade 4 neutropenia, Incidence of hypersensitivity reactions, incidence of infusion reactions, incidence of gastrointestinal perforation, white blood cell count, hemoglobin levels, platelet count, creatinine levels, total bilirubin level, alanine aminotransferase level, aspartate aminotransferase level NCT04315298/Recruiting, Mar16‐Mar16 2020–2021
|
|
td
|
Evaluation of the efficacy and safety of sarilumab in hospitalized patients with COVID‐19
|
|
td
|
Drug: sarilumab, drug: placebo
|
|
td
|
United States/COVID‐19
|
|
td
|
400, all, 18 years and older
|
|
td
|
Treatment
|
|
td
|
Experimental: sarilumab high dose: single intravenous (IV) dose of sarilumab, other names: Kevzara®, REGN88, SAR153191
Experimental: sarilumab low dose: single intravenous (IV) dose of sarilumab Other Names: Kevzara®, REGN88, SAR153191
Placebo comparator: single intravenous (IV) dose of placebo to match sarilumab administration
|
|
p
|
Experimental: sarilumab high dose: single intravenous (IV) dose of sarilumab, other names: Kevzara®, REGN88, SAR153191
|
|
p
|
Experimental: sarilumab low dose: single intravenous (IV) dose of sarilumab Other Names: Kevzara®, REGN88, SAR153191
|
|
p
|
Placebo comparator: single intravenous (IV) dose of placebo to match sarilumab administration
|
|
td
|
II, III
|
|
td
|
Primary: time to resolution of fever for at least 48 hr without antipyretics for 48 hr (Up to Day 29), percentage of patients reporting each severity rating on a 6‐point ordinal scale (Day 15)
Secondary (up to Day 29): time to improvement in oxygenation for at least 48 hr, mean change in the 6‐point ordinal scale, clinical status using the 6‐point ordinal scale, time to improvement in one category from admission using the 6‐point ordinal scale, time to resolution of fever for at least 48 hr without antipyretics by clinical severity, time to resolution of fever for at least 48 hr without antipyretics by baseline IL‐6 levels, time to improvement in oxygenation for at least 48 hr by clinical severity, time to improvement in oxygenation for at least 48 hr by baseline IL‐6 levels, time to resolution of fever and improvement in oxygenation for at least 48 hr, time to change in National Early Warning Score 2 (NEWS2) scoring system, time to score of <2 maintained for 24 hr in NEWS2 scoring system, mean change in NEWS2 scoring system, number of days with fever, number of patients alive off oxygen, number of days of resting respiratory rate >24 breaths/min, number of days with hypoxemia, number of days of supplemental oxygen use, time to saturation ≥94% on room air, number of ventilator free days in the first 28 days, number of patients requiring initiation of mechanical ventilation, number of patients requiring noninvasive ventilation, number of patients requiring the use of high flow nasal cannula, number of patients admitted into an intensive care unit, number of days of hospitalization among survivors, number of deaths due to any cause (up to Day 60), incidence of serious adverse events (Up to Day 60), incidence of severe or life‐threatening bacterial, invasive fungal, or opportunistic infection, Incidence of severe or life‐threatening bacterial, invasive fungal, or opportunistic infection in patients with grade 4 neutropenia, Incidence of hypersensitivity reactions, incidence of infusion reactions, incidence of gastrointestinal perforation, white blood cell count, hemoglobin levels, platelet count, creatinine levels, total bilirubin level, alanine aminotransferase level, aspartate aminotransferase level
|
|
p
|
Primary: time to resolution of fever for at least 48 hr without antipyretics for 48 hr (Up to Day 29), percentage of patients reporting each severity rating on a 6‐point ordinal scale (Day 15)
|
|
p
|
Secondary (up to Day 29): time to improvement in oxygenation for at least 48 hr, mean change in the 6‐point ordinal scale, clinical status using the 6‐point ordinal scale, time to improvement in one category from admission using the 6‐point ordinal scale, time to resolution of fever for at least 48 hr without antipyretics by clinical severity, time to resolution of fever for at least 48 hr without antipyretics by baseline IL‐6 levels, time to improvement in oxygenation for at least 48 hr by clinical severity, time to improvement in oxygenation for at least 48 hr by baseline IL‐6 levels, time to resolution of fever and improvement in oxygenation for at least 48 hr, time to change in National Early Warning Score 2 (NEWS2) scoring system, time to score of <2 maintained for 24 hr in NEWS2 scoring system, mean change in NEWS2 scoring system, number of days with fever, number of patients alive off oxygen, number of days of resting respiratory rate >24 breaths/min, number of days with hypoxemia, number of days of supplemental oxygen use, time to saturation ≥94% on room air, number of ventilator free days in the first 28 days, number of patients requiring initiation of mechanical ventilation, number of patients requiring noninvasive ventilation, number of patients requiring the use of high flow nasal cannula, number of patients admitted into an intensive care unit, number of days of hospitalization among survivors, number of deaths due to any cause (up to Day 60), incidence of serious adverse events (Up to Day 60), incidence of severe or life‐threatening bacterial, invasive fungal, or opportunistic infection, Incidence of severe or life‐threatening bacterial, invasive fungal, or opportunistic infection in patients with grade 4 neutropenia, Incidence of hypersensitivity reactions, incidence of infusion reactions, incidence of gastrointestinal perforation, white blood cell count, hemoglobin levels, platelet count, creatinine levels, total bilirubin level, alanine aminotransferase level, aspartate aminotransferase level
|
|
td
|
NCT04315298/Recruiting, Mar16‐Mar16 2020–2021
|
|
tr
|
Washed microbiota transplantation for patients with 2019‐nCoV infection Other: washed microbiota transplantation, other: placebo China/COVID‐19 complicated with refractory intestinal infections 0, all, 14–70 complicated with refractory intestinal infections Treatment Experimental: observational group 5 u washed microbiota suspension administered via nasogastric tube, nasojejunal tube or oral, combining with standard therapy
Placebo comparator: control group 5 u placebo (edible suspension of the same color as the washed microbiota suspension) administered via nasogastric tube, nasojejunal tube or oral, combining with standard therapy Not applicable Primary (2 weeks): number of participants with improvement from severe type to common type NCT04251767/Withdrawn, Feb5‐Apr30 2020
|
|
td
|
Washed microbiota transplantation for patients with 2019‐nCoV infection
|
|
td
|
Other: washed microbiota transplantation, other: placebo
|
|
td
|
China/COVID‐19 complicated with refractory intestinal infections
|
|
td
|
0, all, 14–70 complicated with refractory intestinal infections
|
|
td
|
Treatment
|
|
td
|
Experimental: observational group 5 u washed microbiota suspension administered via nasogastric tube, nasojejunal tube or oral, combining with standard therapy
Placebo comparator: control group 5 u placebo (edible suspension of the same color as the washed microbiota suspension) administered via nasogastric tube, nasojejunal tube or oral, combining with standard therapy
|
|
p
|
Experimental: observational group 5 u washed microbiota suspension administered via nasogastric tube, nasojejunal tube or oral, combining with standard therapy
|
|
p
|
Placebo comparator: control group 5 u placebo (edible suspension of the same color as the washed microbiota suspension) administered via nasogastric tube, nasojejunal tube or oral, combining with standard therapy
|
|
td
|
Not applicable
|
|
td
|
Primary (2 weeks): number of participants with improvement from severe type to common type
|
|
td
|
NCT04251767/Withdrawn, Feb5‐Apr30 2020
|
|
tr
|
Safety and immunity of Covid‐19 aAPC vaccine Biological: pathogen‐specific aAPC China/Covid‐19 infection 100, all, 6 months to 80 years Treat and Prevent Covid‐19 Infection Experimental: the subjects will receive three injections of 5×10^6 each Covid‐19/aAPC vaccine via subcutaneous injections I Primary (0–28 day): frequency of vaccine events, frequency of serious vaccine events, proportion of subjects with positive T cell response
Secondary (0–28 day): mortality, duration of mechanical ventilation if applicable, proportion of patients in each category of the 7‐point scale (7, 14, and 28 days after randomization), proportion of patients with normalized inflammation factors (7 and 14 days after randomization), clinical improvement based on the 7‐point scale if applicable, lower Murray lung injury score if applicable (7 days after randomization) NCT04299724/Recruiting, Feb15‐Dec31 2020–2024
|
|
td
|
Safety and immunity of Covid‐19 aAPC vaccine
|
|
td
|
Biological: pathogen‐specific aAPC
|
|
td
|
China/Covid‐19 infection
|
|
td
|
100, all, 6 months to 80 years
|
|
td
|
Treat and Prevent Covid‐19 Infection
|
|
td
|
Experimental: the subjects will receive three injections of 5×10^6 each Covid‐19/aAPC vaccine via subcutaneous injections
|
|
td
|
I
|
|
td
|
Primary (0–28 day): frequency of vaccine events, frequency of serious vaccine events, proportion of subjects with positive T cell response
Secondary (0–28 day): mortality, duration of mechanical ventilation if applicable, proportion of patients in each category of the 7‐point scale (7, 14, and 28 days after randomization), proportion of patients with normalized inflammation factors (7 and 14 days after randomization), clinical improvement based on the 7‐point scale if applicable, lower Murray lung injury score if applicable (7 days after randomization)
|
|
p
|
Primary (0–28 day): frequency of vaccine events, frequency of serious vaccine events, proportion of subjects with positive T cell response
|
|
p
|
Secondary (0–28 day): mortality, duration of mechanical ventilation if applicable, proportion of patients in each category of the 7‐point scale (7, 14, and 28 days after randomization), proportion of patients with normalized inflammation factors (7 and 14 days after randomization), clinical improvement based on the 7‐point scale if applicable, lower Murray lung injury score if applicable (7 days after randomization)
|
|
td
|
NCT04299724/Recruiting, Feb15‐Dec31 2020–2024
|
|
tr
|
Safety related factors of endotracheal intubation in patients with severe Covid‐19 pneumonia Severe covid‐19 pneumonia with ET COVID‐19 endotracheal intubation 120, all, 18–90 Observational Intervention details: other: severe covid‐19 pneumonia with ET, severe covid‐19 pneumonia undergoing endotracheal intubation – Primary:
Success rate of intubation (the time span between 1 hr before intubation and 24 hr after intubation), infection rate of anesthesiologist (the time span between 1 hr before intubation and 14 days after intubation)
Secondary:
Extubation time (the time span between 1 hr before intubation and 30 days after intubation) NCT04298814/Not yet recruiting, Mar7‐Jul30 2020
|
|
td
|
Safety related factors of endotracheal intubation in patients with severe Covid‐19 pneumonia
|
|
td
|
Severe covid‐19 pneumonia with ET
|
|
td
|
COVID‐19 endotracheal intubation
|
|
td
|
120, all, 18–90
|
|
td
|
Observational
|
|
td
|
Intervention details: other: severe covid‐19 pneumonia with ET, severe covid‐19 pneumonia undergoing endotracheal intubation
|
|
td
|
–
|
|
td
|
Primary:
Success rate of intubation (the time span between 1 hr before intubation and 24 hr after intubation), infection rate of anesthesiologist (the time span between 1 hr before intubation and 14 days after intubation)
Secondary:
Extubation time (the time span between 1 hr before intubation and 30 days after intubation)
|
|
p
|
Primary:
|
|
p
|
Success rate of intubation (the time span between 1 hr before intubation and 24 hr after intubation), infection rate of anesthesiologist (the time span between 1 hr before intubation and 14 days after intubation)
|
|
p
|
Secondary:
|
|
p
|
Extubation time (the time span between 1 hr before intubation and 30 days after intubation)
|
|
td
|
NCT04298814/Not yet recruiting, Mar7‐Jul30 2020
|
|
tr
|
Immunity and safety of Covid‐19 synthetic minigene vaccine Biological: injection and infusion of LV‐SMENP‐DC vaccine and antigen‐specific CTLs China/COVID‐19 100, all, 6 months to 80 years Treatment Experimental: pathogen‐specific DC and CTLs patients will receive approximately 5 × 106 LV‐DC vaccine and 1 × 108 CTLs via subcutaneous injections and iv infusions, respectively I
II Primary:
Clinical improvement based on the 7‐point scale (28 days after randomization), lower Murray lung injury score (7 days after randomization)
Secondary (0–28 day): 28‐day mortality, duration of mechanical ventilation, duration of hospitalization, proportion of patients with negative RT‐PCR results (7 and 14 days after randomization), proportion of patients in each category of the 7‐point scale (7, 14, and 28 days after randomization), proportion of patients with normalized inflammation factors (7 and 14 days after randomization), frequency of vaccine/CTL events, frequency of serious vaccine/CTL events NCT04276896/Recruiting, Mar24‐Dec31 2020–2024
|
|
td
|
Immunity and safety of Covid‐19 synthetic minigene vaccine
|
|
td
|
Biological: injection and infusion of LV‐SMENP‐DC vaccine and antigen‐specific CTLs
|
|
td
|
China/COVID‐19
|
|
td
|
100, all, 6 months to 80 years
|
|
td
|
Treatment
|
|
td
|
Experimental: pathogen‐specific DC and CTLs patients will receive approximately 5 × 106 LV‐DC vaccine and 1 × 108 CTLs via subcutaneous injections and iv infusions, respectively
|
|
td
|
I
II
|
|
p
|
I
|
|
p
|
II
|
|
td
|
Primary:
Clinical improvement based on the 7‐point scale (28 days after randomization), lower Murray lung injury score (7 days after randomization)
Secondary (0–28 day): 28‐day mortality, duration of mechanical ventilation, duration of hospitalization, proportion of patients with negative RT‐PCR results (7 and 14 days after randomization), proportion of patients in each category of the 7‐point scale (7, 14, and 28 days after randomization), proportion of patients with normalized inflammation factors (7 and 14 days after randomization), frequency of vaccine/CTL events, frequency of serious vaccine/CTL events
|
|
p
|
Primary:
|
|
p
|
Clinical improvement based on the 7‐point scale (28 days after randomization), lower Murray lung injury score (7 days after randomization)
|
|
p
|
Secondary (0–28 day): 28‐day mortality, duration of mechanical ventilation, duration of hospitalization, proportion of patients with negative RT‐PCR results (7 and 14 days after randomization), proportion of patients in each category of the 7‐point scale (7, 14, and 28 days after randomization), proportion of patients with normalized inflammation factors (7 and 14 days after randomization), frequency of vaccine/CTL events, frequency of serious vaccine/CTL events
|
|
td
|
NCT04276896/Recruiting, Mar24‐Dec31 2020–2024
|
|
tr
|
Phase I clinical trial in healthy adult Biological: recombinant novel coronavirus vaccine (adenovirus type 5 vector) – 108, all, 18–60 Prevention Experimental: low‐dose group subjects received one dose of 5E10 vp Ad5‐nCoV at 18–60 years old
Experimental: middle‐dose group
Subjects received one dose of 1E11 vp Ad5‐nCoV at 18–60 years old
Experimental: high‐dose group
Subjects received one dose of 1.5E11vp Ad5‐nCoV at 18–60 years old I Primary (0–7 days postvaccination): safety indexes of adverse reactions
Secondary (Day 14, 28, Month 3, 6 postvaccination):
Safety indexes of adverse events (0–28 days postvaccination), safety indexes of SAE (0–28 days, within 6 mouths postvaccination), safety indexes of lab measures (pre‐vaccination, Day 7 postvaccination), immunogencity indexes of GMT(ELISA) (Day 14, 28, Month 3, 6 postvaccination), immunogencity indexes of GMT (pseudoviral neutralization test method), immunogencity indexes of seropositivity rates, immunogencity indexes of seropositivity rates (pseudoviral neutralization test method, immunogencity indexes of GMI (ELISA), immunogencity indexes of GMI (pseudoviral neutralization test method), immunogencity indexes of GMC (Ad5 vector), immunogencity indexes of GMI (Ad5 vector), immunogencity indexes of cellular immune
Other (day、14,28, Month3,6 postvaccination):
Consistency analysis(ELISA and pseudoviral neutralization test method), Dose‐response relationship (Humoral immunity), Persistence analysis of anti‐S protein antibodies, Time‐dose‐response relationship (Humoral immunity), Dose‐response relationship (cellular immunity), Persistence analysis of cellular immuse, Time‐dose‐response relationship (cellular immunity) NCT04313127/Not yet recruiting, Mar1Dec20 2020–2022
|
|
td
|
Phase I clinical trial in healthy adult
|
|
td
|
Biological: recombinant novel coronavirus vaccine (adenovirus type 5 vector)
|
|
td
|
–
|
|
td
|
108, all, 18–60
|
|
td
|
Prevention
|
|
td
|
Experimental: low‐dose group subjects received one dose of 5E10 vp Ad5‐nCoV at 18–60 years old
Experimental: middle‐dose group
Subjects received one dose of 1E11 vp Ad5‐nCoV at 18–60 years old
Experimental: high‐dose group
Subjects received one dose of 1.5E11vp Ad5‐nCoV at 18–60 years old
|
|
p
|
Experimental: low‐dose group subjects received one dose of 5E10 vp Ad5‐nCoV at 18–60 years old
|
|
p
|
Experimental: middle‐dose group
|
|
p
|
Subjects received one dose of 1E11 vp Ad5‐nCoV at 18–60 years old
|
|
p
|
Experimental: high‐dose group
|
|
p
|
Subjects received one dose of 1.5E11vp Ad5‐nCoV at 18–60 years old
|
|
td
|
I
|
|
td
|
Primary (0–7 days postvaccination): safety indexes of adverse reactions
Secondary (Day 14, 28, Month 3, 6 postvaccination):
Safety indexes of adverse events (0–28 days postvaccination), safety indexes of SAE (0–28 days, within 6 mouths postvaccination), safety indexes of lab measures (pre‐vaccination, Day 7 postvaccination), immunogencity indexes of GMT(ELISA) (Day 14, 28, Month 3, 6 postvaccination), immunogencity indexes of GMT (pseudoviral neutralization test method), immunogencity indexes of seropositivity rates, immunogencity indexes of seropositivity rates (pseudoviral neutralization test method, immunogencity indexes of GMI (ELISA), immunogencity indexes of GMI (pseudoviral neutralization test method), immunogencity indexes of GMC (Ad5 vector), immunogencity indexes of GMI (Ad5 vector), immunogencity indexes of cellular immune
Other (day、14,28, Month3,6 postvaccination):
Consistency analysis(ELISA and pseudoviral neutralization test method), Dose‐response relationship (Humoral immunity), Persistence analysis of anti‐S protein antibodies, Time‐dose‐response relationship (Humoral immunity), Dose‐response relationship (cellular immunity), Persistence analysis of cellular immuse, Time‐dose‐response relationship (cellular immunity)
|
|
p
|
Primary (0–7 days postvaccination): safety indexes of adverse reactions
|
|
p
|
Secondary (Day 14, 28, Month 3, 6 postvaccination):
|
|
p
|
Safety indexes of adverse events (0–28 days postvaccination), safety indexes of SAE (0–28 days, within 6 mouths postvaccination), safety indexes of lab measures (pre‐vaccination, Day 7 postvaccination), immunogencity indexes of GMT(ELISA) (Day 14, 28, Month 3, 6 postvaccination), immunogencity indexes of GMT (pseudoviral neutralization test method), immunogencity indexes of seropositivity rates, immunogencity indexes of seropositivity rates (pseudoviral neutralization test method, immunogencity indexes of GMI (ELISA), immunogencity indexes of GMI (pseudoviral neutralization test method), immunogencity indexes of GMC (Ad5 vector), immunogencity indexes of GMI (Ad5 vector), immunogencity indexes of cellular immune
|
|
p
|
Other (day、14,28, Month3,6 postvaccination):
|
|
p
|
Consistency analysis(ELISA and pseudoviral neutralization test method), Dose‐response relationship (Humoral immunity), Persistence analysis of anti‐S protein antibodies, Time‐dose‐response relationship (Humoral immunity), Dose‐response relationship (cellular immunity), Persistence analysis of cellular immuse, Time‐dose‐response relationship (cellular immunity)
|
|
td
|
NCT04313127/Not yet recruiting, Mar1Dec20 2020–2022
|
|
tr
|
Development and verification of a new coronavirus multiplex nucleic acid detection system Diagnostic test: new QIAstat‐Dx fully automatic multiple PCR detection platform China/COVID‐19 100, all, 16 years to 100 years Diagnostic Diagnostic test: new QIAstat‐Dx fully automatic multiple PCR detection platform
We use the new QIAstat‐Dx fully automatic multiple PCR detection platform to test the enrolled patients – Primary:
Sensitivity, spectivity turnaround time of the New QIAstat‐Dx fully automatic multiple PCR detection platform (3 months) NCT04311398/Not yet recruiting, Mar14‐Dec1, 2020
|
|
td
|
Development and verification of a new coronavirus multiplex nucleic acid detection system
|
|
td
|
Diagnostic test: new QIAstat‐Dx fully automatic multiple PCR detection platform
|
|
td
|
China/COVID‐19
|
|
td
|
100, all, 16 years to 100 years
|
|
td
|
Diagnostic
|
|
td
|
Diagnostic test: new QIAstat‐Dx fully automatic multiple PCR detection platform
We use the new QIAstat‐Dx fully automatic multiple PCR detection platform to test the enrolled patients
|
|
p
|
Diagnostic test: new QIAstat‐Dx fully automatic multiple PCR detection platform
|
|
p
|
We use the new QIAstat‐Dx fully automatic multiple PCR detection platform to test the enrolled patients
|
|
td
|
–
|
|
td
|
Primary:
Sensitivity, spectivity turnaround time of the New QIAstat‐Dx fully automatic multiple PCR detection platform (3 months)
|
|
p
|
Primary:
|
|
p
|
Sensitivity, spectivity turnaround time of the New QIAstat‐Dx fully automatic multiple PCR detection platform (3 months)
|
|
td
|
NCT04311398/Not yet recruiting, Mar14‐Dec1, 2020
|
|
tr
|
Hydroxychloroquine treatment for severe COVID‐19 pulmonary infection (HYDRA Trial) Drug: hydroxychloroquine, drug: placebo oral tablet COVID‐19 severe acute respiratory syndrome 500, all, 18–0 Treatment Active comparator: treatment
Hydroxychloroquine tablet 200 mg every 12 hr for 10 days
Placebo comparator: placebo
identical placebo, one tablet every 12 hr for 10 days III Primary (up to120 days):
All‐cause hospital mortality
Secondary (up to120 days):
Length of hospital stay, Need of mechanical ventilation, ventilator free days, Grade 3–4 adverse reaction NCT04315896/Not yet recruiting, Mar23‐Mar22 2020–2012
|
|
td
|
Hydroxychloroquine treatment for severe COVID‐19 pulmonary infection (HYDRA Trial)
|
|
td
|
Drug: hydroxychloroquine, drug: placebo oral tablet
|
|
td
|
COVID‐19 severe acute respiratory syndrome
|
|
td
|
500, all, 18–0
|
|
td
|
Treatment
|
|
td
|
Active comparator: treatment
Hydroxychloroquine tablet 200 mg every 12 hr for 10 days
Placebo comparator: placebo
identical placebo, one tablet every 12 hr for 10 days
|
|
p
|
Active comparator: treatment
|
|
p
|
Hydroxychloroquine tablet 200 mg every 12 hr for 10 days
|
|
p
|
Placebo comparator: placebo
|
|
p
|
identical placebo, one tablet every 12 hr for 10 days
|
|
td
|
III
|
|
td
|
Primary (up to120 days):
All‐cause hospital mortality
Secondary (up to120 days):
Length of hospital stay, Need of mechanical ventilation, ventilator free days, Grade 3–4 adverse reaction
|
|
p
|
Primary (up to120 days):
|
|
p
|
All‐cause hospital mortality
|
|
p
|
Secondary (up to120 days):
|
|
p
|
Length of hospital stay, Need of mechanical ventilation, ventilator free days, Grade 3–4 adverse reaction
|
|
td
|
NCT04315896/Not yet recruiting, Mar23‐Mar22 2020–2012
|
|
tr
|
Tocilizumab in COVID‐19 pneumonia (TOCIVID‐19) Drug: tocilizumab Injection Italy/COVID‐19 pneumonia 330, child, adult, older adult, child, adult, older adult Treatment Experimental: Tocilizumab Injection
Tocilizumab 8 mg/kg (up to a maximum of 800 mg per dose), with an interval of 12 hr II Primary (up to 1 month):
One‐month mortality rate
Secondary (up to 1 month):
interleukin‐6 level, lymphocyte count, C‐reactive protein level (cycle 1 and 2 every 12 hr), PaO2 (partial pressure of oxygen)/FiO2 (fraction of inspired oxygen, FiO2) ratio (or P/F ratio) (baseline, during treatment (cycle 1 and 2 every 12 hr), change of the SOFA (sequential organ failure assessment) (baseline, during treatment (cycle 1 and 2 every 12 hr), number of participants with treatment‐related side effects as assessed by Common Terminology Criteria for Adverse Event version 5.0, Radiological response, Time Frame: at baseline (optional), after 7 days and if clinically indicated, duration of hospitalization. Time Frame: from baseline up to patient's discharge, Remission of respiratory symptoms NCT04317092/Recruiting, Mar19‐Dec19 2020–2022
|
|
td
|
Tocilizumab in COVID‐19 pneumonia (TOCIVID‐19)
|
|
td
|
Drug: tocilizumab Injection
|
|
td
|
Italy/COVID‐19 pneumonia
|
|
td
|
330, child, adult, older adult, child, adult, older adult
|
|
td
|
Treatment
|
|
td
|
Experimental: Tocilizumab Injection
Tocilizumab 8 mg/kg (up to a maximum of 800 mg per dose), with an interval of 12 hr
|
|
p
|
Experimental: Tocilizumab Injection
|
|
p
|
Tocilizumab 8 mg/kg (up to a maximum of 800 mg per dose), with an interval of 12 hr
|
|
td
|
II
|
|
td
|
Primary (up to 1 month):
One‐month mortality rate
Secondary (up to 1 month):
interleukin‐6 level, lymphocyte count, C‐reactive protein level (cycle 1 and 2 every 12 hr), PaO2 (partial pressure of oxygen)/FiO2 (fraction of inspired oxygen, FiO2) ratio (or P/F ratio) (baseline, during treatment (cycle 1 and 2 every 12 hr), change of the SOFA (sequential organ failure assessment) (baseline, during treatment (cycle 1 and 2 every 12 hr), number of participants with treatment‐related side effects as assessed by Common Terminology Criteria for Adverse Event version 5.0, Radiological response, Time Frame: at baseline (optional), after 7 days and if clinically indicated, duration of hospitalization. Time Frame: from baseline up to patient's discharge, Remission of respiratory symptoms
|
|
p
|
Primary (up to 1 month):
|
|
p
|
One‐month mortality rate
|
|
p
|
Secondary (up to 1 month):
|
|
p
|
interleukin‐6 level, lymphocyte count, C‐reactive protein level (cycle 1 and 2 every 12 hr), PaO2 (partial pressure of oxygen)/FiO2 (fraction of inspired oxygen, FiO2) ratio (or P/F ratio) (baseline, during treatment (cycle 1 and 2 every 12 hr), change of the SOFA (sequential organ failure assessment) (baseline, during treatment (cycle 1 and 2 every 12 hr), number of participants with treatment‐related side effects as assessed by Common Terminology Criteria for Adverse Event version 5.0, Radiological response, Time Frame: at baseline (optional), after 7 days and if clinically indicated, duration of hospitalization. Time Frame: from baseline up to patient's discharge, Remission of respiratory symptoms
|
|
td
|
NCT04317092/Recruiting, Mar19‐Dec19 2020–2022
|
|
tr
|
Mesenchymal stem cell NestCell® to treat patients with severe COVID‐19 pneumonia Biological: NestCell® COVID‐19 pneumonia 6, all, 18 years and older Treatment Experimental: NestCell®:
All patients will receive conventional treatment plus 3 times of 1 × 106 cells/kg body weight intravenously on Day1, Day3, and Day7 I Primary (28 days):
Disappear time of ground‐glass shadow in the lungs
Secondary:
Rate of mortality within 28‐days, Improvement of clinical symptoms including duration of fever and respiratory (At Baseline, Day 3, 7, 10, 14, 21, 28), Time of nucleic acid turning negative (28 days), CD4+ and CD8+ T cell count (At Baseline, Day 3, 6, 10, 14, 21, and 28), changes of blood oxygen (At Baseline, Day 3, 6, 10, 14, 21, and Day 28), side effects in the treatment group (28 days) NCT04315987/Not yet recruiting, Apr‐Jun 2020
|
|
td
|
Mesenchymal stem cell NestCell® to treat patients with severe COVID‐19 pneumonia
|
|
td
|
Biological: NestCell®
|
|
td
|
COVID‐19 pneumonia
|
|
td
|
6, all, 18 years and older
|
|
td
|
Treatment
|
|
td
|
Experimental: NestCell®:
All patients will receive conventional treatment plus 3 times of 1 × 106 cells/kg body weight intravenously on Day1, Day3, and Day7
|
|
p
|
Experimental: NestCell®:
|
|
p
|
All patients will receive conventional treatment plus 3 times of 1 × 106 cells/kg body weight intravenously on Day1, Day3, and Day7
|
|
td
|
I
|
|
td
|
Primary (28 days):
Disappear time of ground‐glass shadow in the lungs
Secondary:
Rate of mortality within 28‐days, Improvement of clinical symptoms including duration of fever and respiratory (At Baseline, Day 3, 7, 10, 14, 21, 28), Time of nucleic acid turning negative (28 days), CD4+ and CD8+ T cell count (At Baseline, Day 3, 6, 10, 14, 21, and 28), changes of blood oxygen (At Baseline, Day 3, 6, 10, 14, 21, and Day 28), side effects in the treatment group (28 days)
|
|
p
|
Primary (28 days):
|
|
p
|
Disappear time of ground‐glass shadow in the lungs
|
|
p
|
Secondary:
|
|
p
|
Rate of mortality within 28‐days, Improvement of clinical symptoms including duration of fever and respiratory (At Baseline, Day 3, 7, 10, 14, 21, 28), Time of nucleic acid turning negative (28 days), CD4+ and CD8+ T cell count (At Baseline, Day 3, 6, 10, 14, 21, and 28), changes of blood oxygen (At Baseline, Day 3, 6, 10, 14, 21, and Day 28), side effects in the treatment group (28 days)
|
|
td
|
NCT04315987/Not yet recruiting, Apr‐Jun 2020
|
|
tr
|
CD24Fc as a non‐antiviral immunomodulator in COVID‐19 treatment Drug: CD24Fc, drug: placebo United States/severe coronavirus disease (COVID‐19) 230, all, 18 years and older Treatment Experimental: CD24Fc treatment
Single dose at Day 1, CD24Fc, 480 mg, diluted to 100 ml with normal saline, IV infusion in 60 min
Placebo comparator: placebo
Single dose at Day 1, normal saline solution 100 ml, IV infusion in 60 min III Primary (14 days):
Improvement of COVID‐19 disease status secondary (14 days):
Conversion rate of clinical status at Day 8 (7 days), conversion rate of clinical status at Day 15, hospital discharge time, all cause of death, duration of mechanical ventilation, duration of pressors, duration of ECMO, duration of oxygen therapy, length of hospital stay, absolute lymphocyte count NCT04317040/Not yet recruiting,May‐May 2020–2022
|
|
td
|
CD24Fc as a non‐antiviral immunomodulator in COVID‐19 treatment
|
|
td
|
Drug: CD24Fc, drug: placebo
|
|
td
|
United States/severe coronavirus disease (COVID‐19)
|
|
td
|
230, all, 18 years and older
|
|
td
|
Treatment
|
|
td
|
Experimental: CD24Fc treatment
Single dose at Day 1, CD24Fc, 480 mg, diluted to 100 ml with normal saline, IV infusion in 60 min
Placebo comparator: placebo
Single dose at Day 1, normal saline solution 100 ml, IV infusion in 60 min
|
|
p
|
Experimental: CD24Fc treatment
|
|
p
|
Single dose at Day 1, CD24Fc, 480 mg, diluted to 100 ml with normal saline, IV infusion in 60 min
|
|
p
|
Placebo comparator: placebo
|
|
p
|
Single dose at Day 1, normal saline solution 100 ml, IV infusion in 60 min
|
|
td
|
III
|
|
td
|
Primary (14 days):
Improvement of COVID‐19 disease status secondary (14 days):
Conversion rate of clinical status at Day 8 (7 days), conversion rate of clinical status at Day 15, hospital discharge time, all cause of death, duration of mechanical ventilation, duration of pressors, duration of ECMO, duration of oxygen therapy, length of hospital stay, absolute lymphocyte count
|
|
p
|
Primary (14 days):
|
|
p
|
Improvement of COVID‐19 disease status secondary (14 days):
|
|
p
|
Conversion rate of clinical status at Day 8 (7 days), conversion rate of clinical status at Day 15, hospital discharge time, all cause of death, duration of mechanical ventilation, duration of pressors, duration of ECMO, duration of oxygen therapy, length of hospital stay, absolute lymphocyte count
|
|
td
|
NCT04317040/Not yet recruiting,May‐May 2020–2022
|
|
tr
|
Acute kidney injury in patients hospitalized with COVID‐19 – China/COVID‐19 acute kidney injury‐kidney function 287, all, 18 years and older Observational Acute kidney injury:
COVID‐19 patients with acute kidney injury
nonacute kidney injury:
COVID‐19 patients without acute kidney injury –
Rate of death, the length of hospital stay Primary (up to 60 days):
Rate of acute kidney injury
Secondary (up to 60 days): NCT04316299/Completed, Feb 26‐Mar8 2020
|
|
td
|
Acute kidney injury in patients hospitalized with COVID‐19
|
|
td
|
–
|
|
td
|
China/COVID‐19 acute kidney injury‐kidney function
|
|
td
|
287, all, 18 years and older
|
|
td
|
Observational
|
|
td
|
Acute kidney injury:
COVID‐19 patients with acute kidney injury
nonacute kidney injury:
COVID‐19 patients without acute kidney injury
|
|
p
|
Acute kidney injury:
|
|
p
|
COVID‐19 patients with acute kidney injury
|
|
p
|
nonacute kidney injury:
|
|
p
|
COVID‐19 patients without acute kidney injury
|
|
td
|
–
Rate of death, the length of hospital stay
|
|
p
|
–
|
|
p
|
Rate of death, the length of hospital stay
|
|
td
|
Primary (up to 60 days):
Rate of acute kidney injury
Secondary (up to 60 days):
|
|
p
|
Primary (up to 60 days):
|
|
p
|
Rate of acute kidney injury
|
|
p
|
Secondary (up to 60 days):
|
|
td
|
NCT04316299/Completed, Feb 26‐Mar8 2020
|
|
tr
|
Phase I clinical trial in healthy adult Logical: recombinant novel coronavirus vaccine (adenovirus type 5 vector) COVID‐19 108, all, 18–60 Treatment (Adenovirus Type 5 Vector)
Experimental: low‐dose group
Subjects received one dose of 5E10 vp Ad5‐nCoV at 18–60 years old
Experimental: middle‐dose group
Subjects received one dose of 1E11 vp Ad5‐nCoV at 18–60 years old
Experimental: high‐dose group subjects received one dose of 1.5E11vp Ad5‐nCoV at 18–60 years old I Primary (0–7 days postvaccination):
Safety indexes of adverse reactions
Secondary (0–28 days postvaccination, within 6 mouths postvaccination):
Safety indexes of adverse events, Safety indexes of SAE, Safety indexes of lab measures, Immunogencity indexes of GMT (ELISA), Immunogencity indexes of GMT (pseudoviral neutralization test method) (Day 14, 28, Month 6 postvaccination), Immunogencity indexes of seropositivity rates (ELISA) (Day 14, 28, Month 3, 6 postvaccination), Immunogencity indexes of seropositivity rates(pseudoviral neutralization test method) (Day 14, 28, Month 6 postvaccination), Immunogencity indexes of GMI (ELISA) (Day 14, 28, Month 3, 6 postvaccination), Immunogencity indexes of GMI (pseudoviral neutralization test method) (Day 14, 28, Month 6 postvaccination), Immunogencity indexes of GMC (Ad5 vector) (Day 14, 28, Month 3, 6 postvaccination), Immunogencity indexes of GMI(Ad5 vector) (Day 14, 28, Month 3, 6 postvaccination), Immunogencity indexes of cellular immune (Day 14, 28, Month 6 postvaccination)
Other (Day 14,28, Month 6 postvaccination):
Consistency analysis (ELISA and pseudoviral neutralization test method), dose‐response relationship (humoral immunity) (Day 14, 28, Month 3, 6 postvaccination), Persistence analysis of anti‐S protein antibodies (Day 14, 28, Month 3, 6 postvaccination), Time‐dose‐response relationship (Humoral immunity) (Day 14, 28, Month 3, 6 postvaccination), Dose‐response relationship (cellular immunity) (Day 14, 28, Month 6 postvaccination), Persistence analysis of cellular immuse (Day 14, 28, Month 6 postvaccination), Time‐dose‐response relationship (cellular immunity) (Day 14, 28, Month 6 postvaccination) NCT04313127/Not yet recruiting, Mar19‐Dec20 2020–2021
|
|
td
|
Phase I clinical trial in healthy adult
|
|
td
|
Logical: recombinant novel coronavirus vaccine (adenovirus type 5 vector)
|
|
td
|
COVID‐19
|
|
td
|
108, all, 18–60
|
|
td
|
Treatment
|
|
td
|
(Adenovirus Type 5 Vector)
Experimental: low‐dose group
Subjects received one dose of 5E10 vp Ad5‐nCoV at 18–60 years old
Experimental: middle‐dose group
Subjects received one dose of 1E11 vp Ad5‐nCoV at 18–60 years old
Experimental: high‐dose group subjects received one dose of 1.5E11vp Ad5‐nCoV at 18–60 years old
|
|
p
|
(Adenovirus Type 5 Vector)
|
|
p
|
Experimental: low‐dose group
|
|
p
|
Subjects received one dose of 5E10 vp Ad5‐nCoV at 18–60 years old
|
|
p
|
Experimental: middle‐dose group
|
|
p
|
Subjects received one dose of 1E11 vp Ad5‐nCoV at 18–60 years old
|
|
p
|
Experimental: high‐dose group subjects received one dose of 1.5E11vp Ad5‐nCoV at 18–60 years old
|
|
td
|
I
|
|
td
|
Primary (0–7 days postvaccination):
Safety indexes of adverse reactions
Secondary (0–28 days postvaccination, within 6 mouths postvaccination):
Safety indexes of adverse events, Safety indexes of SAE, Safety indexes of lab measures, Immunogencity indexes of GMT (ELISA), Immunogencity indexes of GMT (pseudoviral neutralization test method) (Day 14, 28, Month 6 postvaccination), Immunogencity indexes of seropositivity rates (ELISA) (Day 14, 28, Month 3, 6 postvaccination), Immunogencity indexes of seropositivity rates(pseudoviral neutralization test method) (Day 14, 28, Month 6 postvaccination), Immunogencity indexes of GMI (ELISA) (Day 14, 28, Month 3, 6 postvaccination), Immunogencity indexes of GMI (pseudoviral neutralization test method) (Day 14, 28, Month 6 postvaccination), Immunogencity indexes of GMC (Ad5 vector) (Day 14, 28, Month 3, 6 postvaccination), Immunogencity indexes of GMI(Ad5 vector) (Day 14, 28, Month 3, 6 postvaccination), Immunogencity indexes of cellular immune (Day 14, 28, Month 6 postvaccination)
Other (Day 14,28, Month 6 postvaccination):
Consistency analysis (ELISA and pseudoviral neutralization test method), dose‐response relationship (humoral immunity) (Day 14, 28, Month 3, 6 postvaccination), Persistence analysis of anti‐S protein antibodies (Day 14, 28, Month 3, 6 postvaccination), Time‐dose‐response relationship (Humoral immunity) (Day 14, 28, Month 3, 6 postvaccination), Dose‐response relationship (cellular immunity) (Day 14, 28, Month 6 postvaccination), Persistence analysis of cellular immuse (Day 14, 28, Month 6 postvaccination), Time‐dose‐response relationship (cellular immunity) (Day 14, 28, Month 6 postvaccination)
|
|
p
|
Primary (0–7 days postvaccination):
|
|
p
|
Safety indexes of adverse reactions
|
|
p
|
Secondary (0–28 days postvaccination, within 6 mouths postvaccination):
|
|
p
|
Safety indexes of adverse events, Safety indexes of SAE, Safety indexes of lab measures, Immunogencity indexes of GMT (ELISA), Immunogencity indexes of GMT (pseudoviral neutralization test method) (Day 14, 28, Month 6 postvaccination), Immunogencity indexes of seropositivity rates (ELISA) (Day 14, 28, Month 3, 6 postvaccination), Immunogencity indexes of seropositivity rates(pseudoviral neutralization test method) (Day 14, 28, Month 6 postvaccination), Immunogencity indexes of GMI (ELISA) (Day 14, 28, Month 3, 6 postvaccination), Immunogencity indexes of GMI (pseudoviral neutralization test method) (Day 14, 28, Month 6 postvaccination), Immunogencity indexes of GMC (Ad5 vector) (Day 14, 28, Month 3, 6 postvaccination), Immunogencity indexes of GMI(Ad5 vector) (Day 14, 28, Month 3, 6 postvaccination), Immunogencity indexes of cellular immune (Day 14, 28, Month 6 postvaccination)
|
|
p
|
Other (Day 14,28, Month 6 postvaccination):
|
|
p
|
Consistency analysis (ELISA and pseudoviral neutralization test method), dose‐response relationship (humoral immunity) (Day 14, 28, Month 3, 6 postvaccination), Persistence analysis of anti‐S protein antibodies (Day 14, 28, Month 3, 6 postvaccination), Time‐dose‐response relationship (Humoral immunity) (Day 14, 28, Month 3, 6 postvaccination), Dose‐response relationship (cellular immunity) (Day 14, 28, Month 6 postvaccination), Persistence analysis of cellular immuse (Day 14, 28, Month 6 postvaccination), Time‐dose‐response relationship (cellular immunity) (Day 14, 28, Month 6 postvaccination)
|
|
td
|
NCT04313127/Not yet recruiting, Mar19‐Dec20 2020–2021
|
|
tr
|
Favipiravir combined with tocilizumab in the treatment of corona virus disease 2019 Drug: favipiravir combined with tocilizumab, drug: favipiravir, drug: tocilizumab China, COVID‐19 150, all, 18–65 Treatment Experimental: favipiravir combined with tocilizumab group
Favipiravir: On the 1st day, 1,600 mg each time, twice a day; from the 2nd to the 7th day, 600 mg each time, twice a day. Oral administration, the maximum number of days taken is not more than 7 days.
Tocilizumab: the first dose is 4–8 mg/kg and the recommended dose is 400 mg. For fever patients, an additional application (the same dose as before) is given if there is still fever within 24 hr after the first dose and the interval between two medications ≥12 hr. Intravenous infusion. The maximum of cumulative number is two, and the maximum single dose does not exceed 800 mg
Active comparator: favipiravir group
On the 1st day, 1,600 mg each time, twice a day; from the 2nd to the 7th day, 600 mg each time, twice a day. Oral administration, the maximum number of days taken is not more than 7 days
Active comparator: tocilizumab group
The first dose is 4–8 mg/kg and the recommended dose is 400 mg. For fever patients, an additional application (the same dose as before) is given if there is still fever within 24 hr after the first dose and the interval between two medications ≥12 hr. Intravenous infusion, The maximum of cumulative number is two, and the maximum single dose does not exceed 800 mg Not applicable Primary (3 months):
Clinical cure rate
Secondary (14 days after taking medicine):
Viral nucleic acid test negative conversion rate and days from positive to negative, duration of fever, lung imaging improvement time, mortality rate because of corona virus disease 2019 (3 months), rate of noninvasive or invasive mechanical ventilation when respiratory failure occurs (3 months), mean in‐hospital time (3 months) NCT04310228/Recruiting, Mar8‐May 2020
|
|
td
|
Favipiravir combined with tocilizumab in the treatment of corona virus disease 2019
|
|
td
|
Drug: favipiravir combined with tocilizumab, drug: favipiravir, drug: tocilizumab
|
|
td
|
China, COVID‐19
|
|
td
|
150, all, 18–65
|
|
td
|
Treatment
|
|
td
|
Experimental: favipiravir combined with tocilizumab group
Favipiravir: On the 1st day, 1,600 mg each time, twice a day; from the 2nd to the 7th day, 600 mg each time, twice a day. Oral administration, the maximum number of days taken is not more than 7 days.
Tocilizumab: the first dose is 4–8 mg/kg and the recommended dose is 400 mg. For fever patients, an additional application (the same dose as before) is given if there is still fever within 24 hr after the first dose and the interval between two medications ≥12 hr. Intravenous infusion. The maximum of cumulative number is two, and the maximum single dose does not exceed 800 mg
Active comparator: favipiravir group
On the 1st day, 1,600 mg each time, twice a day; from the 2nd to the 7th day, 600 mg each time, twice a day. Oral administration, the maximum number of days taken is not more than 7 days
Active comparator: tocilizumab group
The first dose is 4–8 mg/kg and the recommended dose is 400 mg. For fever patients, an additional application (the same dose as before) is given if there is still fever within 24 hr after the first dose and the interval between two medications ≥12 hr. Intravenous infusion, The maximum of cumulative number is two, and the maximum single dose does not exceed 800 mg
|
|
p
|
Experimental: favipiravir combined with tocilizumab group
|
|
p
|
Favipiravir: On the 1st day, 1,600 mg each time, twice a day; from the 2nd to the 7th day, 600 mg each time, twice a day. Oral administration, the maximum number of days taken is not more than 7 days.
|
|
p
|
Tocilizumab: the first dose is 4–8 mg/kg and the recommended dose is 400 mg. For fever patients, an additional application (the same dose as before) is given if there is still fever within 24 hr after the first dose and the interval between two medications ≥12 hr. Intravenous infusion. The maximum of cumulative number is two, and the maximum single dose does not exceed 800 mg
|
|
p
|
Active comparator: favipiravir group
|
|
p
|
On the 1st day, 1,600 mg each time, twice a day; from the 2nd to the 7th day, 600 mg each time, twice a day. Oral administration, the maximum number of days taken is not more than 7 days
|
|
p
|
Active comparator: tocilizumab group
|
|
p
|
The first dose is 4–8 mg/kg and the recommended dose is 400 mg. For fever patients, an additional application (the same dose as before) is given if there is still fever within 24 hr after the first dose and the interval between two medications ≥12 hr. Intravenous infusion, The maximum of cumulative number is two, and the maximum single dose does not exceed 800 mg
|
|
td
|
Not applicable
|
|
td
|
Primary (3 months):
Clinical cure rate
Secondary (14 days after taking medicine):
Viral nucleic acid test negative conversion rate and days from positive to negative, duration of fever, lung imaging improvement time, mortality rate because of corona virus disease 2019 (3 months), rate of noninvasive or invasive mechanical ventilation when respiratory failure occurs (3 months), mean in‐hospital time (3 months)
|
|
p
|
Primary (3 months):
|
|
p
|
Clinical cure rate
|
|
p
|
Secondary (14 days after taking medicine):
|
|
p
|
Viral nucleic acid test negative conversion rate and days from positive to negative, duration of fever, lung imaging improvement time, mortality rate because of corona virus disease 2019 (3 months), rate of noninvasive or invasive mechanical ventilation when respiratory failure occurs (3 months), mean in‐hospital time (3 months)
|
|
td
|
NCT04310228/Recruiting, Mar8‐May 2020
|
|
tr
|
Novel coronavirus induced severe pneumonia treated by dental pulp mesenchymal stem cells Biological: dental pulp mesenchymal stem cells ‐COVID‐19 24, all, 18–75 Treatment Experimental: pulp mesenchymal stem cells 1. 3, 7 days to increase the injection of mesenchymal stem cells Early Phase I Primary (14 days):
Disppear time of ground‐glass shadow in the lungs
Secondary:
Absorption of lung shadow absorption by CT Scan‐Chest (7, 14, 28, and 360 days), Changes of blood oxygen (3, 7, and 14 days) NCT04302519/Not yet Recruiting, Mar5‐Jul30 2020–2021
|
|
td
|
Novel coronavirus induced severe pneumonia treated by dental pulp mesenchymal stem cells
|
|
td
|
Biological: dental pulp mesenchymal stem cells
|
|
td
|
‐COVID‐19
|
|
td
|
24, all, 18–75
|
|
td
|
Treatment
|
|
td
|
Experimental: pulp mesenchymal stem cells 1. 3, 7 days to increase the injection of mesenchymal stem cells
|
|
td
|
Early Phase I
|
|
td
|
Primary (14 days):
Disppear time of ground‐glass shadow in the lungs
Secondary:
Absorption of lung shadow absorption by CT Scan‐Chest (7, 14, 28, and 360 days), Changes of blood oxygen (3, 7, and 14 days)
|
|
p
|
Primary (14 days):
|
|
p
|
Disppear time of ground‐glass shadow in the lungs
|
|
p
|
Secondary:
|
|
p
|
Absorption of lung shadow absorption by CT Scan‐Chest (7, 14, 28, and 360 days), Changes of blood oxygen (3, 7, and 14 days)
|
|
td
|
NCT04302519/Not yet Recruiting, Mar5‐Jul30 2020–2021
|
|
tr
|
Multicenter clinical study on the efficacy and safety of Xiyanping injection in the treatment of new coronavirus infection pneumonia (general and severe) Drug: lopinavir/ritonavir tablets combined with Xiyanping injection drug: lopinavir/ritonavir treatment COVID‐19 80, all, 18–100 Treatment Experimental: experimental group of ordinary COVID‐19:
Xiyanping injection, 10–20 ml daily, Qd, the maximum daily does not exceed 500 mg (20 ml) + lopinavir tablet or ritonavir tablet + alpha‐interferon nebulization, for 7–14 days,
Active comparator: control group of ordinary COVID‐19:
Lopinavir/ritonavir tablets, two times a day, two tablets at a time; alpha‐interferon nebulization
Experimental: experimental group of severe COVID‐19:
Xiyanping injection, 10–20 ml daily, Qd, the maximum daily does not exceed 500 mg (20 ml) + lopinavir tablet or ritonavir tablet + alpha‐interferon nebulization, for 7–14 days Not applicable Primary:
Clinical recovery time (up to Day 28) NCT04295551/Not yet Recruiting, Mar14‐Apr14 2020–2021
|
|
td
|
Multicenter clinical study on the efficacy and safety of Xiyanping injection in the treatment of new coronavirus infection pneumonia (general and severe)
|
|
td
|
Drug: lopinavir/ritonavir tablets combined with Xiyanping injection drug: lopinavir/ritonavir treatment
|
|
td
|
COVID‐19
|
|
td
|
80, all, 18–100
|
|
td
|
Treatment
|
|
td
|
Experimental: experimental group of ordinary COVID‐19:
Xiyanping injection, 10–20 ml daily, Qd, the maximum daily does not exceed 500 mg (20 ml) + lopinavir tablet or ritonavir tablet + alpha‐interferon nebulization, for 7–14 days,
Active comparator: control group of ordinary COVID‐19:
Lopinavir/ritonavir tablets, two times a day, two tablets at a time; alpha‐interferon nebulization
Experimental: experimental group of severe COVID‐19:
Xiyanping injection, 10–20 ml daily, Qd, the maximum daily does not exceed 500 mg (20 ml) + lopinavir tablet or ritonavir tablet + alpha‐interferon nebulization, for 7–14 days
|
|
p
|
Experimental: experimental group of ordinary COVID‐19:
|
|
p
|
Xiyanping injection, 10–20 ml daily, Qd, the maximum daily does not exceed 500 mg (20 ml) + lopinavir tablet or ritonavir tablet + alpha‐interferon nebulization, for 7–14 days,
|
|
p
|
Active comparator: control group of ordinary COVID‐19:
|
|
p
|
Lopinavir/ritonavir tablets, two times a day, two tablets at a time; alpha‐interferon nebulization
|
|
p
|
Experimental: experimental group of severe COVID‐19:
|
|
p
|
Xiyanping injection, 10–20 ml daily, Qd, the maximum daily does not exceed 500 mg (20 ml) + lopinavir tablet or ritonavir tablet + alpha‐interferon nebulization, for 7–14 days
|
|
td
|
Not applicable
|
|
td
|
Primary:
Clinical recovery time (up to Day 28)
|
|
p
|
Primary:
|
|
p
|
Clinical recovery time (up to Day 28)
|
|
td
|
NCT04295551/Not yet Recruiting, Mar14‐Apr14 2020–2021
|
|
tr
|
Prognostic factors of patients with COVID‐19 – China/SARS‐CoV‐2 outcome, fatal 201, all, 18 years and older Prognostic SARS‐CoV‐2Outcome, fatal – Primary (30 days):
all‐cause mortality
Secondary (15 days):
all‐cause mortality,
Severe state NCT04292964/Completed Mar1‐Mar13 2020
|
|
td
|
Prognostic factors of patients with COVID‐19
|
|
td
|
–
|
|
td
|
China/SARS‐CoV‐2 outcome, fatal
|
|
td
|
201, all, 18 years and older
|
|
td
|
Prognostic
|
|
td
|
SARS‐CoV‐2Outcome, fatal
|
|
td
|
–
|
|
td
|
Primary (30 days):
all‐cause mortality
Secondary (15 days):
all‐cause mortality,
Severe state
|
|
p
|
Primary (30 days):
|
|
p
|
all‐cause mortality
|
|
p
|
Secondary (15 days):
|
|
p
|
all‐cause mortality,
|
|
p
|
Severe state
|
|
td
|
NCT04292964/Completed Mar1‐Mar13 2020
|
|
tr
|
Chloroquine prevention of coronavirus disease (COVID‐19) in the healthcare setting Drug: chloroquine, drug: placebo COVID19 coronavirus acute respiratory illnesses 10,000, all, 16 years and older Prevention Experimental: chloroquine:
a loading dose of 10 mg base/kg followed by 150 mg daily (250 mg chloroquine phosphate salt) will be taken for 3 months
Placebo comparator: placebo Not applicable Primary (approximately 100 days):
Number of symptomatic COVID‐19 infections
Secondary (approximately 100 days):
Symptoms severity of COVID‐19, duration of COVID‐19, number of asymptomatic cases of COVID‐19, number of symptomatic acute respiratory illnesses, genetic loci and levels of biochemical components will be correlated with frequency of COVID‐19, ARI, and disease severity
Other (approximately 100 days):
Drug exposure‐protection relationship NCT04303507/Not yet recruiting, May‐May 2020–2022
|
|
td
|
Chloroquine prevention of coronavirus disease (COVID‐19) in the healthcare setting
|
|
td
|
Drug: chloroquine, drug: placebo
|
|
td
|
COVID19 coronavirus acute respiratory illnesses
|
|
td
|
10,000, all, 16 years and older
|
|
td
|
Prevention
|
|
td
|
Experimental: chloroquine:
a loading dose of 10 mg base/kg followed by 150 mg daily (250 mg chloroquine phosphate salt) will be taken for 3 months
Placebo comparator: placebo
|
|
p
|
Experimental: chloroquine:
|
|
p
|
a loading dose of 10 mg base/kg followed by 150 mg daily (250 mg chloroquine phosphate salt) will be taken for 3 months
|
|
p
|
Placebo comparator: placebo
|
|
td
|
Not applicable
|
|
td
|
Primary (approximately 100 days):
Number of symptomatic COVID‐19 infections
Secondary (approximately 100 days):
Symptoms severity of COVID‐19, duration of COVID‐19, number of asymptomatic cases of COVID‐19, number of symptomatic acute respiratory illnesses, genetic loci and levels of biochemical components will be correlated with frequency of COVID‐19, ARI, and disease severity
Other (approximately 100 days):
Drug exposure‐protection relationship
|
|
p
|
Primary (approximately 100 days):
|
|
p
|
Number of symptomatic COVID‐19 infections
|
|
p
|
Secondary (approximately 100 days):
|
|
p
|
Symptoms severity of COVID‐19, duration of COVID‐19, number of asymptomatic cases of COVID‐19, number of symptomatic acute respiratory illnesses, genetic loci and levels of biochemical components will be correlated with frequency of COVID‐19, ARI, and disease severity
|
|
p
|
Other (approximately 100 days):
|
|
p
|
Drug exposure‐protection relationship
|
|
td
|
NCT04303507/Not yet recruiting, May‐May 2020–2022
|
|
tr
|
Yinhu Qingwen decoction for the treatment of mild/common CoVID‐19 Drug: YinHu QingWen decoction, drug: YinHu QingWen decoction(low dose), other: Chinese medicine treatment, other: standard western medicine treatment China/CoVID‐19 Chinese medicine 300, all, 18 years and older Treatment Experimental: Yin Hu Qing Wen decoction group
Based on the standard western medicine treatment, the patients will be given Yinhu Qingwen decoction (granula) for 10 days.
Drug: YinHu QingWen decoction YinHu QingWen decoction (granula) consits of 11 Chinese herbal medicine as honeysuckle, Polygonum cuspidatum, Schizonepeta, Longspur epimedium, and so forth. The decoction granula will be dissolved into 600 ml decoction and divided to three times (once with 200 ml). It will be given a 200 ml per time, three times a day, for 10 days
Other: standard western medicine treatment treatment is according to the protocol of treatment of CoVID‐19 infection according to guideline appoved by National Health Commission of China
Placebo comparator: Yinhu Qingwen decoction low‐dose group
Based on the standard western medicine treatment, the patients will be given 10% dose of Yinhu Qingwen decoction (granula) for 10 days
Drug: YinHu QingWen decoction (low dose) this intervention is given as 10% dose of YinHu QingWen decoction (granula). The granula will be dissolved into 600 ml decoction and divided to three times (once with 200 ml). It will be given a 200 ml per time, three times a day, for 10 days
Other: standard western medicine treatment standard western medicine treatment is according to the protocol of treatment of CoVID‐19 infection according to guideline appoved by National Health Commission of China
Active comparator: integrated Chinese and western medicine group
Based on the standard western medicine treatment, the patients will be given Chinese medicine decotion granula according to their symptoms. The daily dose of Chinese medicine decoction granula will also be dissolved to 600 ml decoction and divided into three times (once with 200 ml). The Chinese medicine decoction will be given 200 ml per time, three times a day for 10 days
Other: Chinese medicine treatment
This intervention will be given with Chinese medicine decoction granula based on the symptoms differentiation of the patients for 10 days
Other: standard western medicine treatment
Standard western medicine treatment is according to the protocol of treatment of CoVID‐19 infection according to guideline appoved by National Health Commission of China II
III Primary (up to 28 days):
Mean clinical recovery time
Secondary (up to 28 days):
Time to CoVID‐19 RT‐PCR negative in upper respiratory tract specimen, change (reduction) in CoVID‐19 viral load in upper respiratory tract specimen as assessed by area under viral load curve, time to defervescence (in those with fever at enrollment), time to cough reported as mild or absent (in those with cough at enrollment rated severe or moderate), time to dyspnea reported as mild or absent (on a scale of severe, moderate, mild absent, in those with dyspnea at enrollment rated as severe or moderate)
Frequency of requirement for supplemental oxygen or noninvasive ventilation, frequency of respiratory progression, severe case incidence, proportion of rehospitalization or admission to ICU, all‐cause mortality, frequency of serious adverse events NCT04278963/Active, Not Recruiting, Feb27‐Jan 2020
|
|
td
|
Yinhu Qingwen decoction for the treatment of mild/common CoVID‐19
|
|
td
|
Drug: YinHu QingWen decoction, drug: YinHu QingWen decoction(low dose), other: Chinese medicine treatment, other: standard western medicine treatment
|
|
td
|
China/CoVID‐19 Chinese medicine
|
|
td
|
300, all, 18 years and older
|
|
td
|
Treatment
|
|
td
|
Experimental: Yin Hu Qing Wen decoction group
Based on the standard western medicine treatment, the patients will be given Yinhu Qingwen decoction (granula) for 10 days.
Drug: YinHu QingWen decoction YinHu QingWen decoction (granula) consits of 11 Chinese herbal medicine as honeysuckle, Polygonum cuspidatum, Schizonepeta, Longspur epimedium, and so forth. The decoction granula will be dissolved into 600 ml decoction and divided to three times (once with 200 ml). It will be given a 200 ml per time, three times a day, for 10 days
Other: standard western medicine treatment treatment is according to the protocol of treatment of CoVID‐19 infection according to guideline appoved by National Health Commission of China
Placebo comparator: Yinhu Qingwen decoction low‐dose group
Based on the standard western medicine treatment, the patients will be given 10% dose of Yinhu Qingwen decoction (granula) for 10 days
Drug: YinHu QingWen decoction (low dose) this intervention is given as 10% dose of YinHu QingWen decoction (granula). The granula will be dissolved into 600 ml decoction and divided to three times (once with 200 ml). It will be given a 200 ml per time, three times a day, for 10 days
Other: standard western medicine treatment standard western medicine treatment is according to the protocol of treatment of CoVID‐19 infection according to guideline appoved by National Health Commission of China
Active comparator: integrated Chinese and western medicine group
Based on the standard western medicine treatment, the patients will be given Chinese medicine decotion granula according to their symptoms. The daily dose of Chinese medicine decoction granula will also be dissolved to 600 ml decoction and divided into three times (once with 200 ml). The Chinese medicine decoction will be given 200 ml per time, three times a day for 10 days
Other: Chinese medicine treatment
This intervention will be given with Chinese medicine decoction granula based on the symptoms differentiation of the patients for 10 days
Other: standard western medicine treatment
Standard western medicine treatment is according to the protocol of treatment of CoVID‐19 infection according to guideline appoved by National Health Commission of China
|
|
p
|
Experimental: Yin Hu Qing Wen decoction group
|
|
p
|
Based on the standard western medicine treatment, the patients will be given Yinhu Qingwen decoction (granula) for 10 days.
|
|
p
|
Drug: YinHu QingWen decoction YinHu QingWen decoction (granula) consits of 11 Chinese herbal medicine as honeysuckle, Polygonum cuspidatum, Schizonepeta, Longspur epimedium, and so forth. The decoction granula will be dissolved into 600 ml decoction and divided to three times (once with 200 ml). It will be given a 200 ml per time, three times a day, for 10 days
|
|
p
|
Other: standard western medicine treatment treatment is according to the protocol of treatment of CoVID‐19 infection according to guideline appoved by National Health Commission of China
|
|
p
|
Placebo comparator: Yinhu Qingwen decoction low‐dose group
|
|
p
|
Based on the standard western medicine treatment, the patients will be given 10% dose of Yinhu Qingwen decoction (granula) for 10 days
|
|
p
|
Drug: YinHu QingWen decoction (low dose) this intervention is given as 10% dose of YinHu QingWen decoction (granula). The granula will be dissolved into 600 ml decoction and divided to three times (once with 200 ml). It will be given a 200 ml per time, three times a day, for 10 days
|
|
p
|
Other: standard western medicine treatment standard western medicine treatment is according to the protocol of treatment of CoVID‐19 infection according to guideline appoved by National Health Commission of China
|
|
p
|
Active comparator: integrated Chinese and western medicine group
|
|
p
|
Based on the standard western medicine treatment, the patients will be given Chinese medicine decotion granula according to their symptoms. The daily dose of Chinese medicine decoction granula will also be dissolved to 600 ml decoction and divided into three times (once with 200 ml). The Chinese medicine decoction will be given 200 ml per time, three times a day for 10 days
|
|
p
|
Other: Chinese medicine treatment
|
|
p
|
This intervention will be given with Chinese medicine decoction granula based on the symptoms differentiation of the patients for 10 days
|
|
p
|
Other: standard western medicine treatment
|
|
p
|
Standard western medicine treatment is according to the protocol of treatment of CoVID‐19 infection according to guideline appoved by National Health Commission of China
|
|
td
|
II
III
|
|
p
|
II
|
|
p
|
III
|
|
td
|
Primary (up to 28 days):
Mean clinical recovery time
Secondary (up to 28 days):
Time to CoVID‐19 RT‐PCR negative in upper respiratory tract specimen, change (reduction) in CoVID‐19 viral load in upper respiratory tract specimen as assessed by area under viral load curve, time to defervescence (in those with fever at enrollment), time to cough reported as mild or absent (in those with cough at enrollment rated severe or moderate), time to dyspnea reported as mild or absent (on a scale of severe, moderate, mild absent, in those with dyspnea at enrollment rated as severe or moderate)
Frequency of requirement for supplemental oxygen or noninvasive ventilation, frequency of respiratory progression, severe case incidence, proportion of rehospitalization or admission to ICU, all‐cause mortality, frequency of serious adverse events
|
|
p
|
Primary (up to 28 days):
|
|
p
|
Mean clinical recovery time
|
|
p
|
Secondary (up to 28 days):
|
|
p
|
Time to CoVID‐19 RT‐PCR negative in upper respiratory tract specimen, change (reduction) in CoVID‐19 viral load in upper respiratory tract specimen as assessed by area under viral load curve, time to defervescence (in those with fever at enrollment), time to cough reported as mild or absent (in those with cough at enrollment rated severe or moderate), time to dyspnea reported as mild or absent (on a scale of severe, moderate, mild absent, in those with dyspnea at enrollment rated as severe or moderate)
|
|
p
|
Frequency of requirement for supplemental oxygen or noninvasive ventilation, frequency of respiratory progression, severe case incidence, proportion of rehospitalization or admission to ICU, all‐cause mortality, frequency of serious adverse events
|
|
td
|
NCT04278963/Active, Not Recruiting, Feb27‐Jan 2020
|
|
tr
|
Prognositc factors in COVID‐19 patients complicated with hypertension – China, COVID‐19 0, all, 18–100 Prognostic ACEI treatment
hypertension patients with ACEI treatment when suffered with novel coronavirus infection in China
Control
hypertension patients without ACEI treatment when suffered with novel coronavirus infection in China – Primary (up to 28 days):
Occupancy rate in the intensive care unit, mechanical ventilation, death
Secondary (up to 28 days):
All cause mortality, time from onset of symptoms to main outcome and its components, time to clinical recovery NCT04272710/Withdrawn, Jan25‐Apr30 2020
|
|
td
|
Prognositc factors in COVID‐19 patients complicated with hypertension
|
|
td
|
–
|
|
td
|
China, COVID‐19
|
|
td
|
0, all, 18–100
|
|
td
|
Prognostic
|
|
td
|
ACEI treatment
hypertension patients with ACEI treatment when suffered with novel coronavirus infection in China
Control
hypertension patients without ACEI treatment when suffered with novel coronavirus infection in China
|
|
p
|
ACEI treatment
|
|
p
|
hypertension patients with ACEI treatment when suffered with novel coronavirus infection in China
|
|
p
|
Control
|
|
p
|
hypertension patients without ACEI treatment when suffered with novel coronavirus infection in China
|
|
td
|
–
|
|
td
|
Primary (up to 28 days):
Occupancy rate in the intensive care unit, mechanical ventilation, death
Secondary (up to 28 days):
All cause mortality, time from onset of symptoms to main outcome and its components, time to clinical recovery
|
|
p
|
Primary (up to 28 days):
|
|
p
|
Occupancy rate in the intensive care unit, mechanical ventilation, death
|
|
p
|
Secondary (up to 28 days):
|
|
p
|
All cause mortality, time from onset of symptoms to main outcome and its components, time to clinical recovery
|
|
td
|
NCT04272710/Withdrawn, Jan25‐Apr30 2020
|
|
tr
|
Evaluating the efficacy and safety of bromhexine hydrochloride tablets combined with standard treatment/standard treatment in patients with suspected and mild novel coronavirus pneumonia (COVID‐19) Drug: bromhexine hydrochloride tablets, drug: arbidol hydrochloride granules, drug: recombinant human interferon α2b spray, drug: favipiravir tablets China, novel coronavirus pneumonia 2019‐nCoV 60, all, 18–80 Treatment Experimental: group A treatment group:
Bromhexine hydrochloride tablets, arbidol hydrochloride granules:
Standard treatment refers to the latest edition of pneumonia diagnosis and treatment scheme for novel coronavirus infection. Arbidol hydrochloride granules is recommended but not enforced to use
Recombinant human interferon α2b spray:
Standard treatment refers to the latest edition of pneumonia diagnosis and treatment scheme for novel coronavirus infection
Favipiravir tablets
Active comparator; group B control group:
Drug: arbidol hydrochloride granules
Standard treatment refers to the latest edition of pneumonia diagnosis and treatment scheme for novel coronavirus infection. arbidol hydrochloride granules is recommended but not enforced to use
Drug: recombinant human interferon α2b spray
Standard treatment refers to the latest edition of pneumonia diagnosis and treatment scheme for novel coronavirus infection Not applicable Primary (within 14 days from the start of medication):
Time to clinical recovery after treatment
Secondary (within 14 days from the start of medication):
Rate of aggravation, clinical remission rate, dynamic changes of oxygenation index, time to cure, rate to cure, time to defervescence, time to cough remission,days of supplemental oxygenation, rate of patients with requring supplemental oxygen, rate of patients with mechanical ventilation, time of negative COVID‐19 nucleic acid results, rate of negative COVID‐19 nucleic acid results, rate of ICU admission, 28‐day mortality (From the first day of screening to the day of follow‐up (28 days)) NCT04273763/Enrolling by invitation, Feb16‐Apr30 2020
|
|
td
|
Evaluating the efficacy and safety of bromhexine hydrochloride tablets combined with standard treatment/standard treatment in patients with suspected and mild novel coronavirus pneumonia (COVID‐19)
|
|
td
|
Drug: bromhexine hydrochloride tablets, drug: arbidol hydrochloride granules, drug: recombinant human interferon α2b spray, drug: favipiravir tablets
|
|
td
|
China, novel coronavirus pneumonia 2019‐nCoV
|
|
td
|
60, all, 18–80
|
|
td
|
Treatment
|
|
td
|
Experimental: group A treatment group:
Bromhexine hydrochloride tablets, arbidol hydrochloride granules:
Standard treatment refers to the latest edition of pneumonia diagnosis and treatment scheme for novel coronavirus infection. Arbidol hydrochloride granules is recommended but not enforced to use
Recombinant human interferon α2b spray:
Standard treatment refers to the latest edition of pneumonia diagnosis and treatment scheme for novel coronavirus infection
Favipiravir tablets
Active comparator; group B control group:
Drug: arbidol hydrochloride granules
Standard treatment refers to the latest edition of pneumonia diagnosis and treatment scheme for novel coronavirus infection. arbidol hydrochloride granules is recommended but not enforced to use
Drug: recombinant human interferon α2b spray
Standard treatment refers to the latest edition of pneumonia diagnosis and treatment scheme for novel coronavirus infection
|
|
p
|
Experimental: group A treatment group:
|
|
p
|
Bromhexine hydrochloride tablets, arbidol hydrochloride granules:
|
|
p
|
Standard treatment refers to the latest edition of pneumonia diagnosis and treatment scheme for novel coronavirus infection. Arbidol hydrochloride granules is recommended but not enforced to use
|
|
p
|
Recombinant human interferon α2b spray:
|
|
p
|
Standard treatment refers to the latest edition of pneumonia diagnosis and treatment scheme for novel coronavirus infection
|
|
p
|
Favipiravir tablets
|
|
p
|
Active comparator; group B control group:
|
|
p
|
Drug: arbidol hydrochloride granules
|
|
p
|
Standard treatment refers to the latest edition of pneumonia diagnosis and treatment scheme for novel coronavirus infection. arbidol hydrochloride granules is recommended but not enforced to use
|
|
p
|
Drug: recombinant human interferon α2b spray
|
|
p
|
Standard treatment refers to the latest edition of pneumonia diagnosis and treatment scheme for novel coronavirus infection
|
|
td
|
Not applicable
|
|
td
|
Primary (within 14 days from the start of medication):
Time to clinical recovery after treatment
Secondary (within 14 days from the start of medication):
Rate of aggravation, clinical remission rate, dynamic changes of oxygenation index, time to cure, rate to cure, time to defervescence, time to cough remission,days of supplemental oxygenation, rate of patients with requring supplemental oxygen, rate of patients with mechanical ventilation, time of negative COVID‐19 nucleic acid results, rate of negative COVID‐19 nucleic acid results, rate of ICU admission, 28‐day mortality (From the first day of screening to the day of follow‐up (28 days))
|
|
p
|
Primary (within 14 days from the start of medication):
|
|
p
|
Time to clinical recovery after treatment
|
|
p
|
Secondary (within 14 days from the start of medication):
|
|
p
|
Rate of aggravation, clinical remission rate, dynamic changes of oxygenation index, time to cure, rate to cure, time to defervescence, time to cough remission,days of supplemental oxygenation, rate of patients with requring supplemental oxygen, rate of patients with mechanical ventilation, time of negative COVID‐19 nucleic acid results, rate of negative COVID‐19 nucleic acid results, rate of ICU admission, 28‐day mortality (From the first day of screening to the day of follow‐up (28 days))
|
|
td
|
NCT04273763/Enrolling by invitation, Feb16‐Apr30 2020
|
|
tr
|
Various combination of protease inhibitors, oseltamivir, favipiravir, and chloroquin for treatment of covid19: a randomized control trial Drug: oral Thailand, coronavirus infections COVID19 80, all, 16–100 Treatment Experimental: oseltamivir plus chloroquin in mild COVID19
Oseltamivir 300 mg per day plus chloroquin 1,000 mg per Day In mild COVID19
Experimental: lopinavir and ritonavir plus favipiravir
Lopinavir 10 mg/kg and ritonavir 2.5 mg/kg plus favipiravir 2,400 mg, 2,400 mg, and 1,200 mg every 8 hr on Day 1, and a maintenance dose of 1,200 mg twice a day in Mild COVID19
Experimental: lopinavir and ritonavir plus oseltamivir in mild COVID19
Lopipinavir 10 mg/kg and ritonavir 2.5 mg/kg plus oseltamivir 4–6 mg/kg In mild COVID19
Experimental: lopinavir and ritonavir oseltamivir moderate to severe COVID19
Lopipinavir 10 mg/kg and ritonavir 2.5 mg/kg plus oseltamivir 4–6 mg/kg in moderate to critically ill COVID19
Experimental: favipiravir lopinavir/ritonavir for mod. To severe
favipiravir 2,400 mg, 2,400 mg, and 1,200 mg every 8 hr on Day 1, and a maintenance dose of 1,200 mg twice a day plus lopipinavir 10 mg/kg and ritonavir 2.5 mg/kg in moderate to critically ill COVID19
Experimental: darunavir/ritonavir oseltamivir chloroquine mod‐severe
Combination of Darunavir 400 mg every 8 hr ritonavir Ritonavir 2.5 mg/kg plus Oseltamivir 4–6 mg/kg plus Chloroquine 500 mg per Day In moderate to critically ill COVID19
Experimental: darunavir/ritonavir favipiravir chloroquine mod‐severe
Favipiravir 2,400 mg, 2,400 mg, and 1,200 mg every 8 hr on Day 1, and a maintenance dose of 1,200 mg twice a day plus darunavir 400 mg every 8 hr ritonavir ritonavir 2.5 mg/kg plus chloroquine 500 mg per Day In moderate to critically ill COVID19
No intervention: conventional qurantine
Patient who unwilling to treatment and willing to quarantine in mild COVID19 III Primary (Up to 24 weeks):
SARS‐CoV‐2 eradication time
Secondary (up to 24 weeks):
Number of patient with death, number of patient with recovery adjusted by initial severity in each arm, number of day with ventilator dependent adjusted by initial severity in each arm,number of patient developed acute respiratory distress syndrome after treatment
Other (up to 24 weeks):
Number of patient with acute respiratory distress syndrome recovery NCT04303299/Not yet recruiting, Mar15‐Nov30 2020
|
|
td
|
Various combination of protease inhibitors, oseltamivir, favipiravir, and chloroquin for treatment of covid19: a randomized control trial
|
|
td
|
Drug: oral
|
|
td
|
Thailand, coronavirus infections COVID19
|
|
td
|
80, all, 16–100
|
|
td
|
Treatment
|
|
td
|
Experimental: oseltamivir plus chloroquin in mild COVID19
Oseltamivir 300 mg per day plus chloroquin 1,000 mg per Day In mild COVID19
Experimental: lopinavir and ritonavir plus favipiravir
Lopinavir 10 mg/kg and ritonavir 2.5 mg/kg plus favipiravir 2,400 mg, 2,400 mg, and 1,200 mg every 8 hr on Day 1, and a maintenance dose of 1,200 mg twice a day in Mild COVID19
Experimental: lopinavir and ritonavir plus oseltamivir in mild COVID19
Lopipinavir 10 mg/kg and ritonavir 2.5 mg/kg plus oseltamivir 4–6 mg/kg In mild COVID19
Experimental: lopinavir and ritonavir oseltamivir moderate to severe COVID19
Lopipinavir 10 mg/kg and ritonavir 2.5 mg/kg plus oseltamivir 4–6 mg/kg in moderate to critically ill COVID19
Experimental: favipiravir lopinavir/ritonavir for mod. To severe
favipiravir 2,400 mg, 2,400 mg, and 1,200 mg every 8 hr on Day 1, and a maintenance dose of 1,200 mg twice a day plus lopipinavir 10 mg/kg and ritonavir 2.5 mg/kg in moderate to critically ill COVID19
Experimental: darunavir/ritonavir oseltamivir chloroquine mod‐severe
Combination of Darunavir 400 mg every 8 hr ritonavir Ritonavir 2.5 mg/kg plus Oseltamivir 4–6 mg/kg plus Chloroquine 500 mg per Day In moderate to critically ill COVID19
Experimental: darunavir/ritonavir favipiravir chloroquine mod‐severe
Favipiravir 2,400 mg, 2,400 mg, and 1,200 mg every 8 hr on Day 1, and a maintenance dose of 1,200 mg twice a day plus darunavir 400 mg every 8 hr ritonavir ritonavir 2.5 mg/kg plus chloroquine 500 mg per Day In moderate to critically ill COVID19
No intervention: conventional qurantine
Patient who unwilling to treatment and willing to quarantine in mild COVID19
|
|
p
|
Experimental: oseltamivir plus chloroquin in mild COVID19
|
|
p
|
Oseltamivir 300 mg per day plus chloroquin 1,000 mg per Day In mild COVID19
|
|
p
|
Experimental: lopinavir and ritonavir plus favipiravir
|
|
p
|
Lopinavir 10 mg/kg and ritonavir 2.5 mg/kg plus favipiravir 2,400 mg, 2,400 mg, and 1,200 mg every 8 hr on Day 1, and a maintenance dose of 1,200 mg twice a day in Mild COVID19
|
|
p
|
Experimental: lopinavir and ritonavir plus oseltamivir in mild COVID19
|
|
p
|
Lopipinavir 10 mg/kg and ritonavir 2.5 mg/kg plus oseltamivir 4–6 mg/kg In mild COVID19
|
|
p
|
Experimental: lopinavir and ritonavir oseltamivir moderate to severe COVID19
|
|
p
|
Lopipinavir 10 mg/kg and ritonavir 2.5 mg/kg plus oseltamivir 4–6 mg/kg in moderate to critically ill COVID19
|
|
p
|
Experimental: favipiravir lopinavir/ritonavir for mod. To severe
|
|
p
|
favipiravir 2,400 mg, 2,400 mg, and 1,200 mg every 8 hr on Day 1, and a maintenance dose of 1,200 mg twice a day plus lopipinavir 10 mg/kg and ritonavir 2.5 mg/kg in moderate to critically ill COVID19
|
|
p
|
Experimental: darunavir/ritonavir oseltamivir chloroquine mod‐severe
|
|
p
|
Combination of Darunavir 400 mg every 8 hr ritonavir Ritonavir 2.5 mg/kg plus Oseltamivir 4–6 mg/kg plus Chloroquine 500 mg per Day In moderate to critically ill COVID19
|
|
p
|
Experimental: darunavir/ritonavir favipiravir chloroquine mod‐severe
|
|
p
|
Favipiravir 2,400 mg, 2,400 mg, and 1,200 mg every 8 hr on Day 1, and a maintenance dose of 1,200 mg twice a day plus darunavir 400 mg every 8 hr ritonavir ritonavir 2.5 mg/kg plus chloroquine 500 mg per Day In moderate to critically ill COVID19
|
|
p
|
No intervention: conventional qurantine
|
|
p
|
Patient who unwilling to treatment and willing to quarantine in mild COVID19
|
|
td
|
III
|
|
td
|
Primary (Up to 24 weeks):
SARS‐CoV‐2 eradication time
Secondary (up to 24 weeks):
Number of patient with death, number of patient with recovery adjusted by initial severity in each arm, number of day with ventilator dependent adjusted by initial severity in each arm,number of patient developed acute respiratory distress syndrome after treatment
Other (up to 24 weeks):
Number of patient with acute respiratory distress syndrome recovery
|
|
p
|
Primary (Up to 24 weeks):
|
|
p
|
SARS‐CoV‐2 eradication time
|
|
p
|
Secondary (up to 24 weeks):
|
|
p
|
Number of patient with death, number of patient with recovery adjusted by initial severity in each arm, number of day with ventilator dependent adjusted by initial severity in each arm,number of patient developed acute respiratory distress syndrome after treatment
|
|
p
|
Other (up to 24 weeks):
|
|
p
|
Number of patient with acute respiratory distress syndrome recovery
|
|
td
|
NCT04303299/Not yet recruiting, Mar15‐Nov30 2020
|
|
tr
|
Yinhu Qingwen Granula for the treatment of severe CoVID‐19 Drug: Yinhu Qingwen granula, drug: Yin Hu Qing Wen granula (low does), other: standard medical treatment China, COVID‐19 severe pneumonia Chinese medicine 116, all, 18 years and older Treatment Experimental:
Yinhu Qingwen granula group:
Drug: Yinhu Qingwen Granula
Yinhu Qingwen granula is a kind of herbal granula made from “Yinhu Qingwen Decoction,” which consits of 11 Chinese herbal medicine as honeysuckle, Polygonum cuspidatum, schizonepeta, Longspur epimedium, etc. The granula will be dissolved into 600 ml decoction and divided to three times (once with 200 ml). It will be given a 200 ml per time, three times a day, for 10 days.
Other: standard medical treatment Standard medical treatment is adhered to the protocol of the treatment for the severe CoVID‐19 according to the guideline approved by National Health Commission of China.
Placebo comparator: Yinhu Qingwen granula low‐dose group:
Drug: Yin Hu Qing Wen granula (low does). This intervention is given as 10% dose of YinHu QingWen Granula.The granula will be dissolved into 600 ml decoction and divided to three times (once with 200 ml).
Other: standard medical treatment Standard medical treatment is adhered to the protocol of the treatment for the severe CoVID‐19 according to the guideline approved by National Health Commission of China. II Primary (Day 10):
changes in the ratio of PaO2 to FiO2 from baseline
Secondary (up to 30 days):
PaO2, blood oxygen saturation (SpO2), clinical status rating on the 7‐point ordinal scale, time to clinical improvement, duration (hours) of noninvasive mechanical ventilation or high‐flow nasal catheter oxygen inhalation use, duration (hours) of invasive mechanical ventilation use, duration (hours) of extracorporeal membrane oxygenation (ECMO) use, duration (days) of oxygen use, The proportion of the patients reporting 2019‐nCoV RT‐PCR negativity at Day 10 after treatment, the counts/percentage of lymphocyte, time to hospital discharge with clinical recovery from the randomization, the incidence of critical status conversion in 30 days, all‐cause mortality within 30 days, frequency of severe adverse drug events NCT04310865/Not yet recruiting, Mar20‐Jun30 2020–2021
|
|
td
|
Yinhu Qingwen Granula for the treatment of severe CoVID‐19
|
|
td
|
Drug: Yinhu Qingwen granula, drug: Yin Hu Qing Wen granula (low does), other: standard medical treatment
|
|
td
|
China, COVID‐19 severe pneumonia Chinese medicine
|
|
td
|
116, all, 18 years and older
|
|
td
|
Treatment
|
|
td
|
Experimental:
Yinhu Qingwen granula group:
Drug: Yinhu Qingwen Granula
Yinhu Qingwen granula is a kind of herbal granula made from “Yinhu Qingwen Decoction,” which consits of 11 Chinese herbal medicine as honeysuckle, Polygonum cuspidatum, schizonepeta, Longspur epimedium, etc. The granula will be dissolved into 600 ml decoction and divided to three times (once with 200 ml). It will be given a 200 ml per time, three times a day, for 10 days.
Other: standard medical treatment Standard medical treatment is adhered to the protocol of the treatment for the severe CoVID‐19 according to the guideline approved by National Health Commission of China.
Placebo comparator: Yinhu Qingwen granula low‐dose group:
Drug: Yin Hu Qing Wen granula (low does). This intervention is given as 10% dose of YinHu QingWen Granula.The granula will be dissolved into 600 ml decoction and divided to three times (once with 200 ml).
Other: standard medical treatment Standard medical treatment is adhered to the protocol of the treatment for the severe CoVID‐19 according to the guideline approved by National Health Commission of China.
|
|
p
|
Experimental:
|
|
p
|
Yinhu Qingwen granula group:
|
|
p
|
Drug: Yinhu Qingwen Granula
|
|
p
|
Yinhu Qingwen granula is a kind of herbal granula made from “Yinhu Qingwen Decoction,” which consits of 11 Chinese herbal medicine as honeysuckle, Polygonum cuspidatum, schizonepeta, Longspur epimedium, etc. The granula will be dissolved into 600 ml decoction and divided to three times (once with 200 ml). It will be given a 200 ml per time, three times a day, for 10 days.
|
|
p
|
Other: standard medical treatment Standard medical treatment is adhered to the protocol of the treatment for the severe CoVID‐19 according to the guideline approved by National Health Commission of China.
|
|
p
|
Placebo comparator: Yinhu Qingwen granula low‐dose group:
|
|
p
|
Drug: Yin Hu Qing Wen granula (low does). This intervention is given as 10% dose of YinHu QingWen Granula.The granula will be dissolved into 600 ml decoction and divided to three times (once with 200 ml).
|
|
p
|
Other: standard medical treatment Standard medical treatment is adhered to the protocol of the treatment for the severe CoVID‐19 according to the guideline approved by National Health Commission of China.
|
|
td
|
II
|
|
td
|
Primary (Day 10):
changes in the ratio of PaO2 to FiO2 from baseline
Secondary (up to 30 days):
PaO2, blood oxygen saturation (SpO2), clinical status rating on the 7‐point ordinal scale, time to clinical improvement, duration (hours) of noninvasive mechanical ventilation or high‐flow nasal catheter oxygen inhalation use, duration (hours) of invasive mechanical ventilation use, duration (hours) of extracorporeal membrane oxygenation (ECMO) use, duration (days) of oxygen use, The proportion of the patients reporting 2019‐nCoV RT‐PCR negativity at Day 10 after treatment, the counts/percentage of lymphocyte, time to hospital discharge with clinical recovery from the randomization, the incidence of critical status conversion in 30 days, all‐cause mortality within 30 days, frequency of severe adverse drug events
|
|
p
|
Primary (Day 10):
|
|
p
|
changes in the ratio of PaO2 to FiO2 from baseline
|
|
p
|
Secondary (up to 30 days):
|
|
p
|
PaO2, blood oxygen saturation (SpO2), clinical status rating on the 7‐point ordinal scale, time to clinical improvement, duration (hours) of noninvasive mechanical ventilation or high‐flow nasal catheter oxygen inhalation use, duration (hours) of invasive mechanical ventilation use, duration (hours) of extracorporeal membrane oxygenation (ECMO) use, duration (days) of oxygen use, The proportion of the patients reporting 2019‐nCoV RT‐PCR negativity at Day 10 after treatment, the counts/percentage of lymphocyte, time to hospital discharge with clinical recovery from the randomization, the incidence of critical status conversion in 30 days, all‐cause mortality within 30 days, frequency of severe adverse drug events
|
|
td
|
NCT04310865/Not yet recruiting, Mar20‐Jun30 2020–2021
|
|
tr
|
Clinical characteristics and long‐term prognosis of 2019‐nCoV infection in children – China, 2019‐nCoV 500, all, up to 18 years Prognosis 2019‐nCoV infection group
Children hospitalized with direct laboratory confirmed of novel coronavirus with or without pneumonia are classified as the 2019‐nCoV infection group
Control group Children hospitalized with pneumonia other than the novel coronavirus pneumonia during the same hospitalization period as 2019‐nCoV infection group are classified as the control group – Primary (6 months):
The cure rate of 2019‐nCoV, the improvement rate of 2019‐nCoV, the incidence of long‐term adverse outcomes
Secondary (2 weeks):
Duration of fever, duration of respiratory symptoms, duration of hospitalization, number of participant(s) need intensive care, number of participant(s) with acute respiratory distress syndrome, number of participant(s) with extra‐pulmonary complications, including shock, renal failure, multiple organ failure, hemophagocytosis syndrome, et al., number of participant(s) who died during the trial (10 months) NCT04270383/Not yet recruiting, Feb15‐Dec30 2020
|
|
td
|
Clinical characteristics and long‐term prognosis of 2019‐nCoV infection in children
|
|
td
|
–
|
|
td
|
China, 2019‐nCoV
|
|
td
|
500, all, up to 18 years
|
|
td
|
Prognosis
|
|
td
|
2019‐nCoV infection group
Children hospitalized with direct laboratory confirmed of novel coronavirus with or without pneumonia are classified as the 2019‐nCoV infection group
Control group Children hospitalized with pneumonia other than the novel coronavirus pneumonia during the same hospitalization period as 2019‐nCoV infection group are classified as the control group
|
|
p
|
2019‐nCoV infection group
|
|
p
|
Children hospitalized with direct laboratory confirmed of novel coronavirus with or without pneumonia are classified as the 2019‐nCoV infection group
|
|
p
|
Control group Children hospitalized with pneumonia other than the novel coronavirus pneumonia during the same hospitalization period as 2019‐nCoV infection group are classified as the control group
|
|
td
|
–
|
|
td
|
Primary (6 months):
The cure rate of 2019‐nCoV, the improvement rate of 2019‐nCoV, the incidence of long‐term adverse outcomes
Secondary (2 weeks):
Duration of fever, duration of respiratory symptoms, duration of hospitalization, number of participant(s) need intensive care, number of participant(s) with acute respiratory distress syndrome, number of participant(s) with extra‐pulmonary complications, including shock, renal failure, multiple organ failure, hemophagocytosis syndrome, et al., number of participant(s) who died during the trial (10 months)
|
|
p
|
Primary (6 months):
|
|
p
|
The cure rate of 2019‐nCoV, the improvement rate of 2019‐nCoV, the incidence of long‐term adverse outcomes
|
|
p
|
Secondary (2 weeks):
|
|
p
|
Duration of fever, duration of respiratory symptoms, duration of hospitalization, number of participant(s) need intensive care, number of participant(s) with acute respiratory distress syndrome, number of participant(s) with extra‐pulmonary complications, including shock, renal failure, multiple organ failure, hemophagocytosis syndrome, et al., number of participant(s) who died during the trial (10 months)
|
|
td
|
NCT04270383/Not yet recruiting, Feb15‐Dec30 2020
|
|
tr
|
The effect of T89 on improving oxygen saturation and clinical symptoms in patients with COVID‐19 Drug: T89 Coronavirus disease 2019 novel coronavirus pneumonia 120, all, 18–85 Treatment Experimental: The T89 treatment group Besides a standard background treatment (antiviral drug + antibacterial + oxygen therapy + Traditional Chinese Medicine decoction), all subjects in the T89 treatment group will receive 30 pills of T89 each time, orally, BID (every morning and evening), for 10 days (depending on clinical need and practicability, the use can be extended for up to 14 days)
No intervention: the blank control group
All subjects in the blank control group will only receive a standard background treatment (antiviral drug + antibacterial + oxygen therapy + Traditional Chinese Medicine decoction), for 10 days. Not applicable Primary (Day −1 to 10): the time to oxygen saturation recovery to normal level (≥97%), the proportion of patients with normal level of oxygen saturation(≥97%)
Secondary (Day −1 to 10):
The degree of remission of symptoms of patients, including: fatigue, nausea, vomiting, chest tightness, shortness of breath, and so forth, the time to the myocardial enzyme spectrum recovery to normal after treatment, the proportion of the patients with normal myocardial enzyme spectrum after treatment, the time to the electrocardiogram recovery to normal level after treatment, the proportion of the patients with normal electrocardiogram after treatment, the time to the hemodynamics recovery to normal after treatment, the proportion of the patients with normal hemodynamics after treatment, the time to exacerbation or remission of the disease after treatment, the proportion of the patients with exacerbation or remission of disease after treatment, the proportion of patients who need other treatment (e.g., heparin, anticoagulants) due to microcirculation disorders, the all‐cause mortality rate, the proportion of patients with acidosis, the total duration of the patients in‐hospital, the total duration of oxygen inhalation during treatment, the oxygen flow rate during treatment, the oxygen concentration during treatment NCT04285190/Not yet recruiting, Feb26‐Sep15 2020
|
|
td
|
The effect of T89 on improving oxygen saturation and clinical symptoms in patients with COVID‐19
|
|
td
|
Drug: T89
|
|
td
|
Coronavirus disease 2019 novel coronavirus pneumonia
|
|
td
|
120, all, 18–85
|
|
td
|
Treatment
|
|
td
|
Experimental: The T89 treatment group Besides a standard background treatment (antiviral drug + antibacterial + oxygen therapy + Traditional Chinese Medicine decoction), all subjects in the T89 treatment group will receive 30 pills of T89 each time, orally, BID (every morning and evening), for 10 days (depending on clinical need and practicability, the use can be extended for up to 14 days)
No intervention: the blank control group
All subjects in the blank control group will only receive a standard background treatment (antiviral drug + antibacterial + oxygen therapy + Traditional Chinese Medicine decoction), for 10 days.
|
|
p
|
Experimental: The T89 treatment group Besides a standard background treatment (antiviral drug + antibacterial + oxygen therapy + Traditional Chinese Medicine decoction), all subjects in the T89 treatment group will receive 30 pills of T89 each time, orally, BID (every morning and evening), for 10 days (depending on clinical need and practicability, the use can be extended for up to 14 days)
|
|
p
|
No intervention: the blank control group
|
|
p
|
All subjects in the blank control group will only receive a standard background treatment (antiviral drug + antibacterial + oxygen therapy + Traditional Chinese Medicine decoction), for 10 days.
|
|
td
|
Not applicable
|
|
td
|
Primary (Day −1 to 10): the time to oxygen saturation recovery to normal level (≥97%), the proportion of patients with normal level of oxygen saturation(≥97%)
Secondary (Day −1 to 10):
The degree of remission of symptoms of patients, including: fatigue, nausea, vomiting, chest tightness, shortness of breath, and so forth, the time to the myocardial enzyme spectrum recovery to normal after treatment, the proportion of the patients with normal myocardial enzyme spectrum after treatment, the time to the electrocardiogram recovery to normal level after treatment, the proportion of the patients with normal electrocardiogram after treatment, the time to the hemodynamics recovery to normal after treatment, the proportion of the patients with normal hemodynamics after treatment, the time to exacerbation or remission of the disease after treatment, the proportion of the patients with exacerbation or remission of disease after treatment, the proportion of patients who need other treatment (e.g., heparin, anticoagulants) due to microcirculation disorders, the all‐cause mortality rate, the proportion of patients with acidosis, the total duration of the patients in‐hospital, the total duration of oxygen inhalation during treatment, the oxygen flow rate during treatment, the oxygen concentration during treatment
|
|
p
|
Primary (Day −1 to 10): the time to oxygen saturation recovery to normal level (≥97%), the proportion of patients with normal level of oxygen saturation(≥97%)
|
|
p
|
Secondary (Day −1 to 10):
|
|
p
|
The degree of remission of symptoms of patients, including: fatigue, nausea, vomiting, chest tightness, shortness of breath, and so forth, the time to the myocardial enzyme spectrum recovery to normal after treatment, the proportion of the patients with normal myocardial enzyme spectrum after treatment, the time to the electrocardiogram recovery to normal level after treatment, the proportion of the patients with normal electrocardiogram after treatment, the time to the hemodynamics recovery to normal after treatment, the proportion of the patients with normal hemodynamics after treatment, the time to exacerbation or remission of the disease after treatment, the proportion of the patients with exacerbation or remission of disease after treatment, the proportion of patients who need other treatment (e.g., heparin, anticoagulants) due to microcirculation disorders, the all‐cause mortality rate, the proportion of patients with acidosis, the total duration of the patients in‐hospital, the total duration of oxygen inhalation during treatment, the oxygen flow rate during treatment, the oxygen concentration during treatment
|
|
td
|
NCT04285190/Not yet recruiting, Feb26‐Sep15 2020
|
|
tr
|
Immunoregulatory therapy for 2019‐nCoV Drug: PD‐1 blocking antibody + standard treatment, drug: Thymosin + standard treatment, other: standard treatment ‐2019 nCoV, PD‐1 120, all, 18 years and older Treatment Experimental: PD‐1 group
Anti‐PD‐1 antibody, 200 mg, IV, one time
Experimental: thymosin group
Thymosin, 1.6 mg sc qd, last for 5 days
Placebo comparator: control group stand treatment II Primary (7 days):
lung injury score
Secondary:
Absolute lymphocyte counts (7, 14 and 28 days), serum level of CRP, PCT and IL‐6 (3, 7 and 14 days), SOFA score (7 days), all cause mortality rate (28 days), ventilation free days (28 days), ICU free days (up to 28 days) NCT04268537/Not yet recruiting, Feb10‐Oct31 2020
|
|
td
|
Immunoregulatory therapy for 2019‐nCoV
|
|
td
|
Drug: PD‐1 blocking antibody + standard treatment, drug: Thymosin + standard treatment, other: standard treatment
|
|
td
|
‐2019 nCoV, PD‐1
|
|
td
|
120, all, 18 years and older
|
|
td
|
Treatment
|
|
td
|
Experimental: PD‐1 group
Anti‐PD‐1 antibody, 200 mg, IV, one time
Experimental: thymosin group
Thymosin, 1.6 mg sc qd, last for 5 days
Placebo comparator: control group stand treatment
|
|
p
|
Experimental: PD‐1 group
|
|
p
|
Anti‐PD‐1 antibody, 200 mg, IV, one time
|
|
p
|
Experimental: thymosin group
|
|
p
|
Thymosin, 1.6 mg sc qd, last for 5 days
|
|
p
|
Placebo comparator: control group stand treatment
|
|
td
|
II
|
|
td
|
Primary (7 days):
lung injury score
Secondary:
Absolute lymphocyte counts (7, 14 and 28 days), serum level of CRP, PCT and IL‐6 (3, 7 and 14 days), SOFA score (7 days), all cause mortality rate (28 days), ventilation free days (28 days), ICU free days (up to 28 days)
|
|
p
|
Primary (7 days):
|
|
p
|
lung injury score
|
|
p
|
Secondary:
|
|
p
|
Absolute lymphocyte counts (7, 14 and 28 days), serum level of CRP, PCT and IL‐6 (3, 7 and 14 days), SOFA score (7 days), all cause mortality rate (28 days), ventilation free days (28 days), ICU free days (up to 28 days)
|
|
td
|
NCT04268537/Not yet recruiting, Feb10‐Oct31 2020
|
|
tr
|
Tocilizumab vs CRRT in management of cytokine release syndrome (CRS) in COVID‐19 Drug: tocilizumab, other: standard of care, procedure: continuous renal replacement therapy China, Covid‐19 SARS cytokine storm (and 2 more…) 120, all, 18–80 Observational Tocilizumab
Subjects received 8 mg/kg (body weight) Tocilizumab once in 100 ml 0.9% saline solution and administered intravenously within no <60 min. Tocilizumab was administered according—continuous renal replacement therapy
Femoral vein catheterization was performed to complete continuous renal replacement therapy for consecutive three times or more. to the local label
Standard care
Standard of care therapy per local written policies or guidelines – Primary (up to 14 days):
Proportion of participants with normalization of fever and oxygen saturation
Secondary:
Duration of hospitalization (Up to 28 days), proportion of participants with normalization of fever (up to 14 days), change from baseline in white blood cell and differential count (up to 28 days), time to first negative in 2019 novel corona virus RT‐PCR test (Up to 28 days), all‐cause mortality (up to 12 weeks), change from baseline in hsCRP (Up to 28 days), change from baseline in cytokines IL‐1β, IL‐10, sIL‐2R, IL‐6, IL‐8 and TNF‐α (Up to 28 days), change from baseline in proportion of CD4 + CD3/CD8 + CD3 T cells (Up to 28 days) NCT04306705/Recruiting, Feb20‐Jun20 2020
|
|
td
|
Tocilizumab vs CRRT in management of cytokine release syndrome (CRS) in COVID‐19
|
|
td
|
Drug: tocilizumab, other: standard of care, procedure: continuous renal replacement therapy
|
|
td
|
China, Covid‐19 SARS cytokine storm (and 2 more…)
|
|
td
|
120, all, 18–80
|
|
td
|
Observational
|
|
td
|
Tocilizumab
Subjects received 8 mg/kg (body weight) Tocilizumab once in 100 ml 0.9% saline solution and administered intravenously within no <60 min. Tocilizumab was administered according—continuous renal replacement therapy
Femoral vein catheterization was performed to complete continuous renal replacement therapy for consecutive three times or more. to the local label
Standard care
Standard of care therapy per local written policies or guidelines
|
|
p
|
Tocilizumab
|
|
p
|
Subjects received 8 mg/kg (body weight) Tocilizumab once in 100 ml 0.9% saline solution and administered intravenously within no <60 min. Tocilizumab was administered according—continuous renal replacement therapy
|
|
p
|
Femoral vein catheterization was performed to complete continuous renal replacement therapy for consecutive three times or more. to the local label
|
|
p
|
Standard care
|
|
p
|
Standard of care therapy per local written policies or guidelines
|
|
td
|
–
|
|
td
|
Primary (up to 14 days):
Proportion of participants with normalization of fever and oxygen saturation
Secondary:
Duration of hospitalization (Up to 28 days), proportion of participants with normalization of fever (up to 14 days), change from baseline in white blood cell and differential count (up to 28 days), time to first negative in 2019 novel corona virus RT‐PCR test (Up to 28 days), all‐cause mortality (up to 12 weeks), change from baseline in hsCRP (Up to 28 days), change from baseline in cytokines IL‐1β, IL‐10, sIL‐2R, IL‐6, IL‐8 and TNF‐α (Up to 28 days), change from baseline in proportion of CD4 + CD3/CD8 + CD3 T cells (Up to 28 days)
|
|
p
|
Primary (up to 14 days):
|
|
p
|
Proportion of participants with normalization of fever and oxygen saturation
|
|
p
|
Secondary:
|
|
p
|
Duration of hospitalization (Up to 28 days), proportion of participants with normalization of fever (up to 14 days), change from baseline in white blood cell and differential count (up to 28 days), time to first negative in 2019 novel corona virus RT‐PCR test (Up to 28 days), all‐cause mortality (up to 12 weeks), change from baseline in hsCRP (Up to 28 days), change from baseline in cytokines IL‐1β, IL‐10, sIL‐2R, IL‐6, IL‐8 and TNF‐α (Up to 28 days), change from baseline in proportion of CD4 + CD3/CD8 + CD3 T cells (Up to 28 days)
|
|
td
|
NCT04306705/Recruiting, Feb20‐Jun20 2020
|
|
tr
|
Sars‐CoV2 seroconversion among front line medical and paramedical staff in emergency, intensive care units and infectious disease departments during the 2020 Epidemic Other: blood sample France, Sars‐CoV2 1,000, all, child, adult, older adult Other Caregiver
caregivers from emergency, ICU, virology and infectious disease services:
Two blood samples at T0 and 3 months Not applicable Primary (3 months):
Quantify the proportion of patients with documented Sars‐CoV2 infection among medical and paramedical staff
Secondary (3 months):
Identification of risk factors for seroconversion, quantify the proportion of asymptomatic infections among staff who have seroconverted, describe symptomatic infections for personnel developing acute clinical (respiratory or digestive) viral syndrome NCT04304690/Recruiting, Mar16‐Oct16 2020
|
|
td
|
Sars‐CoV2 seroconversion among front line medical and paramedical staff in emergency, intensive care units and infectious disease departments during the 2020 Epidemic
|
|
td
|
Other: blood sample
|
|
td
|
France, Sars‐CoV2
|
|
td
|
1,000, all, child, adult, older adult
|
|
td
|
Other
|
|
td
|
Caregiver
caregivers from emergency, ICU, virology and infectious disease services:
Two blood samples at T0 and 3 months
|
|
p
|
Caregiver
|
|
p
|
caregivers from emergency, ICU, virology and infectious disease services:
|
|
p
|
Two blood samples at T0 and 3 months
|
|
td
|
Not applicable
|
|
td
|
Primary (3 months):
Quantify the proportion of patients with documented Sars‐CoV2 infection among medical and paramedical staff
Secondary (3 months):
Identification of risk factors for seroconversion, quantify the proportion of asymptomatic infections among staff who have seroconverted, describe symptomatic infections for personnel developing acute clinical (respiratory or digestive) viral syndrome
|
|
p
|
Primary (3 months):
|
|
p
|
Quantify the proportion of patients with documented Sars‐CoV2 infection among medical and paramedical staff
|
|
p
|
Secondary (3 months):
|
|
p
|
Identification of risk factors for seroconversion, quantify the proportion of asymptomatic infections among staff who have seroconverted, describe symptomatic infections for personnel developing acute clinical (respiratory or digestive) viral syndrome
|
|
td
|
NCT04304690/Recruiting, Mar16‐Oct16 2020
|
|
sec
|
5.3.1 Reverse transcriptase polymerase chain reaction
Despite being the diagnostic gold standard, pathogenic lab testing is a rather time‐consuming procedure, with unavoidable false‐positive results (Wang, Kang, et al., 2020). It is recommended that lab testing should be performed, as soon as the patient is identified as a “person under investigation” (PUI). Viral nucleic acid required for an RT‐PCR test is usually extracted from secretions of the lower respiratory tract, for example, bronchoalveolar lavage; however, tracheal aspirate or sputum can also be used (Chu et al., 2020; Corman et al., 2020). Since the onset of the epidemic, several factors have been found to affect the final efficiency of nucleic acid testing, that is, availability, quality, stability, and reproducibility of detection kits. In most of the cases, the tests need to be repeated for several times (Wang, Kang, et al., 2020), as the estimated detection rate of the test falls in an underwhelming range of 30–50% (Chu et al., 2020; Corman et al., 2020; Zhang et al., 2020). In spite of being a valuable asset, the undesirable false‐negative results of RT‐PCR have prompted careful clinical and etiological evaluation of COVID‐19 in suspected cases as the first‐line diagnostic method (Zu et al., 2020).
|
|
label
|
5.3.1
|
|
title
|
Reverse transcriptase polymerase chain reaction
|
|
p
|
Despite being the diagnostic gold standard, pathogenic lab testing is a rather time‐consuming procedure, with unavoidable false‐positive results (Wang, Kang, et al., 2020). It is recommended that lab testing should be performed, as soon as the patient is identified as a “person under investigation” (PUI). Viral nucleic acid required for an RT‐PCR test is usually extracted from secretions of the lower respiratory tract, for example, bronchoalveolar lavage; however, tracheal aspirate or sputum can also be used (Chu et al., 2020; Corman et al., 2020). Since the onset of the epidemic, several factors have been found to affect the final efficiency of nucleic acid testing, that is, availability, quality, stability, and reproducibility of detection kits. In most of the cases, the tests need to be repeated for several times (Wang, Kang, et al., 2020), as the estimated detection rate of the test falls in an underwhelming range of 30–50% (Chu et al., 2020; Corman et al., 2020; Zhang et al., 2020). In spite of being a valuable asset, the undesirable false‐negative results of RT‐PCR have prompted careful clinical and etiological evaluation of COVID‐19 in suspected cases as the first‐line diagnostic method (Zu et al., 2020).
|
|
sec
|
5.3.2 Computed tomography (CT)
CT has proved to be of great value in diagnosis of the COVID‐19‐associated pneumonia, as it provides major evidence, that cannot readily be obtained with alternative methods. It is true that CT is a reliable imaging modality in subtle detection of viral pneumonia and screening of suspected cases; however, it should be noted that many pulmonary diseases of inflammatory nature share similar radiographic findings (Wang, Kang, et al., 2020). The majority of patients with COVID‐19 present with GGO in their chest CT, which later progress into multilobar consolidations. There have been several reports of rounded opacities, which are sometimes peripherally distributed in the lung (Chung et al., 2020; Huang et al., 2020). In contrast to CT, plain chest radiography (CXR) has not been recommended as a first‐line imaging method, because this modality does not provide the clarity viewed on CT scans, especially in the early stages of pulmonary infection (Ng et al., 2020). Nevertheless, CXR is capable of recording pathologic changes in patients with severely progressed COVID‐19, as the bilateral multifocal consolidations present in these patients are too dense to be missed. The notorious “white lung” appearance can be optimally viewed on CXRs of critically ill patients (Zu et al., 2020). CT resulted in diagnosis of 14,840 new cases as of February 13, 2020 (Zu et al., 2020). Therefore, slice chest CT is an adequately sensitive and reliable method in early detection of pneumonia in patients with COVID‐19 (Chan et al., 2020; Ng et al., 2020).
|
|
label
|
5.3.2
|
|
title
|
Computed tomography (CT)
|
|
p
|
CT has proved to be of great value in diagnosis of the COVID‐19‐associated pneumonia, as it provides major evidence, that cannot readily be obtained with alternative methods. It is true that CT is a reliable imaging modality in subtle detection of viral pneumonia and screening of suspected cases; however, it should be noted that many pulmonary diseases of inflammatory nature share similar radiographic findings (Wang, Kang, et al., 2020). The majority of patients with COVID‐19 present with GGO in their chest CT, which later progress into multilobar consolidations. There have been several reports of rounded opacities, which are sometimes peripherally distributed in the lung (Chung et al., 2020; Huang et al., 2020). In contrast to CT, plain chest radiography (CXR) has not been recommended as a first‐line imaging method, because this modality does not provide the clarity viewed on CT scans, especially in the early stages of pulmonary infection (Ng et al., 2020). Nevertheless, CXR is capable of recording pathologic changes in patients with severely progressed COVID‐19, as the bilateral multifocal consolidations present in these patients are too dense to be missed. The notorious “white lung” appearance can be optimally viewed on CXRs of critically ill patients (Zu et al., 2020). CT resulted in diagnosis of 14,840 new cases as of February 13, 2020 (Zu et al., 2020). Therefore, slice chest CT is an adequately sensitive and reliable method in early detection of pneumonia in patients with COVID‐19 (Chan et al., 2020; Ng et al., 2020).
|
|
sec
|
5.3.3 Novel approaches: Artificial intelligence‐based technologies
Depp learning, as a novel AI‐based modality might be able to analyze radiographic features of COVID‐19, and help clinicians provide an accurate clinical diagnosis based on a precedented pattern (Wang, Kang, et al., 2020). As part of recent advancements, Convolutional Neural Network (CNN), a class of deep neural networks, has been shown to be capable of medical image analysis. To this date, CNN has been successfully employed in investigations on the nature of pulmonary nodules reported in CT images, diagnosis of pneumonia in children based on CXR, and image recognition in cystoscopy videos (Choe et al., 2019; Kermany et al., 2018; Negassi, Suarez‐Ibarrola, Hein, Miernik, & Reiterer, 2020; Wang et al., 2018).
The 21st century has seen many AI‐based models to be incorporated in several scientific fields, particularly imaging studies. Diagnostic AI‐based models might actually be a forward leap in tasks that simply cannot be handled by manpower, especially risk prioritization, that can greatly help improve patient turnaround time. Given the shortage of human resources and inadequate number of hospital beds in a country like China, AI‐based models for analysis of CXR and CT scans can be useful in ruling out irrelevant cases, and resource‐wise admission of patients to the hospitals (Kim, 2020).
|
|
label
|
5.3.3
|
|
title
|
Novel approaches: Artificial intelligence‐based technologies
|
|
p
|
Depp learning, as a novel AI‐based modality might be able to analyze radiographic features of COVID‐19, and help clinicians provide an accurate clinical diagnosis based on a precedented pattern (Wang, Kang, et al., 2020). As part of recent advancements, Convolutional Neural Network (CNN), a class of deep neural networks, has been shown to be capable of medical image analysis. To this date, CNN has been successfully employed in investigations on the nature of pulmonary nodules reported in CT images, diagnosis of pneumonia in children based on CXR, and image recognition in cystoscopy videos (Choe et al., 2019; Kermany et al., 2018; Negassi, Suarez‐Ibarrola, Hein, Miernik, & Reiterer, 2020; Wang et al., 2018).
|
|
p
|
The 21st century has seen many AI‐based models to be incorporated in several scientific fields, particularly imaging studies. Diagnostic AI‐based models might actually be a forward leap in tasks that simply cannot be handled by manpower, especially risk prioritization, that can greatly help improve patient turnaround time. Given the shortage of human resources and inadequate number of hospital beds in a country like China, AI‐based models for analysis of CXR and CT scans can be useful in ruling out irrelevant cases, and resource‐wise admission of patients to the hospitals (Kim, 2020).
|
|
sec
|
6 PREDICTION
Recent studies focused on prognosis of COVID‐19 concluded that the load of SARS‐CoV‐2 RNA in blood (RNAemia) is correlated with Cytokine Release Storm (CRS) and poor prognosis of the disease. In one particular study, scientists used Generalized Linear Models to generate a prediction model for natural history of disease based on the C t value of real‐time RT‐PCR results. They reported that traceable amounts of SARS‐CoV‐2 RNA was detected in blood plasma of 15% of COVID‐19 positive patients enrolled at the study. Their findings drew a direct link between serum markers and disease severity, as RNAemia and high levels of IL‐6 (nearly 10‐fold) were exclusively reported in critically ill patients. Interestingly, there was also an association between the extremely high levels of IL‐6 with the incidence of RNAemia (R = 0.902) in patients. Findings also suggested that vital signs of patients were also affected by high levels of both serum markers (R = 0.682). According to this study, IL‐6 might be of clinical value in identification and treatment of patients with an excessive inflammatory response (Chen, Zhao, et al., 2020). Table 3 (Chen, Zhao, et al., 2020; Yan et al., 2020) and Table 4 represent 2020 studies on prognosis of COVID‐19 infected patients and related clinical trials, respectively.
|
|
label
|
6
|
|
title
|
PREDICTION
|
|
p
|
Recent studies focused on prognosis of COVID‐19 concluded that the load of SARS‐CoV‐2 RNA in blood (RNAemia) is correlated with Cytokine Release Storm (CRS) and poor prognosis of the disease. In one particular study, scientists used Generalized Linear Models to generate a prediction model for natural history of disease based on the C t value of real‐time RT‐PCR results. They reported that traceable amounts of SARS‐CoV‐2 RNA was detected in blood plasma of 15% of COVID‐19 positive patients enrolled at the study. Their findings drew a direct link between serum markers and disease severity, as RNAemia and high levels of IL‐6 (nearly 10‐fold) were exclusively reported in critically ill patients. Interestingly, there was also an association between the extremely high levels of IL‐6 with the incidence of RNAemia (R = 0.902) in patients. Findings also suggested that vital signs of patients were also affected by high levels of both serum markers (R = 0.682). According to this study, IL‐6 might be of clinical value in identification and treatment of patients with an excessive inflammatory response (Chen, Zhao, et al., 2020). Table 3 (Chen, Zhao, et al., 2020; Yan et al., 2020) and Table 4 represent 2020 studies on prognosis of COVID‐19 infected patients and related clinical trials, respectively.
|
|
sec
|
7 THERAPY
Scientists have made strenuous efforts to come up with an effective regimen for successful treatment of COVID‐19 (Gao, Tian, & Yang, 2020). Table 3 (Chen, Guo, et al., 2020; Fan et al., 2020; Han et al., 2020; Lan et al., 2020; Li, Zhang, et al., 2020; Li, Hu, et al., 2020; Lim et al., 2020; Liu et al., 2020; Liu et al., 2020; Wu et al., 2020; Wu & McGoogan, 2020), Tables 4 and 5 (Zhang & Liu, 2020) represent 2020 studies on treatment of COVID‐19 infected patients, related clinical trials and available therapeutic options, respectively.
Table 5 Therapeutic options that are available for the treatment of novel coronaviruses (cell line, animal, and human studies)
General treatment Nutritional interventions, targets or function Vit A Measles virus, measles‐related pneumonia, HIV, avian CoV, IBV Upregulating the elements of the innate immune, Making the cells refractory to infection
B vit MERS‐CoV Enhancing immune system, Inhibiting the of neutrophil infiltration into the lungs, Anti‐inflammatory effects during ventilator‐induced lung injury
Vit C Avian CoV Supporting immune functions, protecting against CoV infection, preventing of the lower respiratory tract infections
Vit D Bovine CoV Triggering the maturation of immune cells
Vit E Coxsackievirus, bovine CoV Antioxidant function
Omega‐3 PUFA Influenza virus, HIV Attenuating the replication of influenza virus
Selenium Influenza virus, avian CoV Antioxidant function, inducing immune response
Zinc Influenza virus, avian CoV, SARS‐CoV Maintenance/development of innate and adaptive immune systems simultaneously
Iron Viral mutations Enhancing the immune system
Immunoenhancers IFNs SARS‐CoV, MERS‐CoV Acting as apart of the innate immune response, Inhibiting the replication of CoVs in animal and human
IVIg SARS‐CoV Increasing the viscosity in hypercoagulable states
Ta1 SARS‐CoV Restoring the homeostasis of the immune system, Increasint the resistance glucocorticoid‐induced death of thymocyte
TP5, munox Restore antibody production Restoring antibody production, Enhancing the antibody response, As adjuvant treatment
Levamisole Immunostimulant/immunosuppressive agent Increasing the functions of cellular immunity, Act as immunostimulant agent or immunosuppressive agent through dose‐ and time‐dependent manner, reversing the depressed helper/inducer lymphocytes
Cyclosporine A SARS‐CoV, avian infectious bronchitis virus Both facilitating or inhibiting virus replication, blocking the all genera replication of CoV
CTM Glycyrrhizin, Baicalin, Ginseng SARS‐CoV, avian infectious bronchitis virus Enhancing host immunity, Inhibiting the replication of SARS‐associated virus and SARS‐CoV, Enhancing the specific‐antibody responses
Specific treatments Protease inhibitors 3C‐like inhibitors Cinanserin, SARS‐CoV Act as serotonin receptor antagonist, Inhibiting the replication
Flavonoids MERS‐CoV Act as antioxidant and antiviral compound, blocking the enzymatic activity of MERS‐CoV/3CLpro
PLP inhibitors SARS‐CoV Inhibit PLP of SARS‐CoV
S protein‐ACE2 blockers Human mAb SARS‐CoV Neutralizing SARS‐CoV, inhibiting syncytia formation between cells expressing the S protein and the SARS‐CoV receptor ACE2
Chloroquine SARS‐CoV Possess antiviral effect, inhibiting of SARS‐CoV infection via interfering with ACE2
Emodin SARS‐CoV Blocking the interaction between the S protein of virus and ACE2
Promazine SARS‐CoV Inhibiting the replication of virus, inhibiting the binding of S protein to ACE2
Nicotianamine Inhibiting the ACE2
Antiviral treatments Ribavirin SARS‐CoV Inhibiting the the replication of SARS‐associated CoV
LPV/RTV (Kaletra) HIV, SARS‐CoV, MERS‐CoV protease inhibitor
RDV SARS‐CoV, MERS‐CoV Improving the pulmonary function, reducing the lung viral loads and severe lung pathology
Nelfinavir HIV, SARS‐CoV Act as selective inhibitor of HIV protease, Inhibiting the replication virus
ARB influenza A/B, hepatitis C virus Blocking viral fusion, entry and replication
Nitric oxide SARS Antiviral effects
Other compounds ALA human CoV‐229E, HIV Act as antioxidant, inhibiting the replication of HIV‐1
Estradiol and phytoestrogen SARS‐CoV, MERS, influenza A Reducing virus replication in primary human nasal epithelial cells
Mucroporin‐M1 influenza H5N1 viruses, and SARS‐CoV Virucidal activity against viruses
Abbreviations: 3 CLpro, 3C‐like protease; Ab, antibody; ACE2, angiotensin converting enzyme 2; ALA, α‐lipoic acid; ARB, arbidol; CoV, coronavirus; CTM, Chinese traditional medicine; HIV, human immunodeficiency virus; IBV, bronchitis virus; IFN, interferons; IVIg, intravenous gammaglobulin; LPV/RTV, lopinavir/ritonavir; mAb, monoclonal antibody; PLpro, papain‐like protease; PUFA, polyunsaturated fatty acids; RDV, remdesivir; S, spike; Ta1, thymosin α‐1; TP5, thymopentin; Vit, vitamin.
John Wiley & Sons, Ltd. This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.
7.1 Chloroquine phosphate
Chloroquine phosphate is an old medicine, that has been widely used for treatment of malaria in endemic regions. It is also a salutary treatment of choice for certain progressive anti‐inflammatory diseases, for example, rheumatoid arthritis, and systemic lupus erythematosus. Recently, an investigation in China reported that remdesivir and chloroquine phosphate were effective experimental agents for controlling SARS‐CoV‐2 infection in the lab (Chen et al., 2013). Initial findings reported by a recent study on effectiveness of therapeutic agents in management of SARS‐CoV‐2 infection, and suggested successful application of chloroquine phosphate in treatment of patients with COVID‐19‐associated pneumonia. Following the promising results, scientists recommended chloroquine phosphate to be included in treatment regimen of COVID‐19 patients with severe involvement of the lungs (Yu et al., 2013). On February 15, 2020, participants from different organizations, including medical experts and authorities, made an agreement on potency of Chloroquine phosphate against SARS‐CoV‐2 infection (https://www.clinicaltrialsarena.com/analysis/coronavirus-mers-cov-drugs/).
So far, close monitoring of over 100 patients, who were under treatment of chloroquine phosphate, has provided further evidence regarding the effectiveness of this long‐known medicine. Investigations indicated that chloroquine phosphate prevented exacerbation of pneumonia in these patients, improved their chest CT findings, and shortened the otherwise long natural course of the disease. Importantly, there have been no records of severe reaction or hypersensitivity to this therapeutic agent. It has been suggested that the broad‐spectrum antiviral activity of chloroquine phosphate lies within the complicated pharmacodynamics of the drug that results in a basic shift in the endosomal pH required for successful fusion of virus onto the host cell. chloroquine phosphate also seems to have disruptive effects on glycosylation of cellular receptors of SARS‐CoV (Yin & Wunderink, 2018; Zumla et al., 2020), rendering them nonfunctional. It also interferes with activation of p38 mitogen‐activated protein kinase, a signaling event involved in replication of HCoV‐229E (Kono et al., 2008).
7.2 Lopinavir/ritonavir, leronlimab, galidesivir
Lopinavir/Ritonavir, commonly used for treatment of HIV infection, has been indicated for treatment of COVID‐19 in a number of reports (Kim et al., 2020). Previous studies suggested that when combined together, Lopinavir and Ritonavir act in concert to hinder further replication of SARS‐CoV, and improve the clinical status of patients with SARS (Chu et al., 2004). This might also mean that the well‐known antiretroviral duo can also prove beneficial in treatment of COVID‐19.
Other candidates for possible management of SARS‐CoV‐2 include Leronlimab and Galidesivir, both of which have been of clinical value in treatment of several fatal viral infections, and were shown to improve the survival of patients. Leronlimab is a humanized monoclonal antibody (CCR5 antagonist). Galidesivir, on the other hand, belongs to the family of nucleoside RNA polymerase inhibitors (https://www.clinicaltrialsarena.com/analysis/coronavirus-mers-cov-drugs/). In the absence of any specific therapeutic agents to quell SARs‐CoV‐2, it might be a salutary strategy to repurpose the already available medicine, and include them in treatment of COVID‐19 (Tian et al., 2020).
Several clinical trials can be viewed at ClinicalTrials.gov, that are currently in progress. These trials have specially focused on potency of Remdesivir, immunoglobulins, and combinational therapies, for example, Arbidol hydrochloride with interferon atomization, ASC09F and oseltamivir, ritonavir and oseltamivir, and lopinavir combined with ritonavir (https://clinicaltrials.gov/ct2/results?cond=&2019nCoV&term=&cntry=&state=&city=&dist=).
7.3 RAAS inhibitors
ACE2 is a prominent regulatory arm in the RAAS axis, thus, a disruption in ACE‐Angiotensin II‐Angiotensin Type 1 Receptor (AT1R), and ACE2/Angiotensin‐(1‐7)/Mas Receptor axes can result in multisystem inflammation. Increased levels of ACE and Angiotensin II in plasma are considered poor prognostic factors in severe pneumonia. Several studies on animal models have reported effectiveness of RAAS inhibitors in alleviation of severe pneumonia and acute respiratory failure. In the aftermath of SARS‐CoV‐2 and ACE2 binding, the enzyme is eventually degraded, hence, the inhibition of ACE2/Angiotensin‐(1‐7)/Mas Receptor pathway. Accordingly, it is assumed that ACE and AT1R inhibitors might be game‐changing agents that can especially be administered for COVID‐19 patients who have serious impairments in their homeostasis. Maintenance of homeostasis may ultimately result in suppression of the inflammatory response, mostly in the pulmonary tissue (Sun, Yang, Sun, & Su, 2020).
7.4 Combination therapy
Combination therapy is a more extensive and rigorous approach mainly aimed at correction of life‐threatening events such as shock, hypoxemia, secondary or super infection, and maintenance of homeostasis, that is, electrolyte, acid and base balance. As a palliative practice, antiviral treatment in the early stages of COVID‐19 might lessen the severity and prevent further progression of the disease. Trials on combination therapy with lopinavir/ritonavir and arbidol (umifenovir) have reported satisfactory results in treatment of COVID‐19. Alongside a proper antiviral treatment, patients may also benefit from an artificial liver blood purification system, which is capable of rapidly removing the inflammatory factors from blood, thus, halting the disastrous cytokine release syndrome. This system can also facilitate the sustenance of critically ill patients by preserving the balance of bodily fluid. Administration of glucocorticoids in moderate doses is another intervention that has recently been indicated for patients with severe COVID‐19‐associated pneumonia. However, secondary fungal infection should be considered. Patients with an oxygenation index of less than 200 mmHg might benefit more from oxygen therapy than noninvasive ventilation. A rational prescription of antimicrobial medicines has been cautioned only for patients with remittent fever and elevated antimicrobial prophylaxis should be prescribed rationally and was not recommended except for patients with long course of disease, repeated fever, and elevated PCT levels. Ultimately, to maintain the balance of intestinal microbiota, oral intake of prebiotics or probiotics has been suggested. This can reduce the risk of secondary infections as a result of microbial translocation; however, effectiveness of such interventions on postinfection clearance pattern of SARS‐CoV‐2 has not been studied (Xu et al., 2020).
7.5 Other future possible options
7.5.1 Convalescent blood therapy
A conspicuously conventional method, transfusion of human convalescent plasma, might be viewed as a beneficial strategy for prevention and even treatment of COVID‐19. The method is as facile as its age since it only requires an adequate number of recovered patients who are willing to donate their immunoglobulin‐containing serum. Although one still might argue the possibility of SARS‐CoV‐2 infection via convalescent blood transfusion, no such incident with SARS‐CoV was reported by WHO amidst the outbreak of the disease in 2003. The heft of past experience should come to mind once it is noted that the majority of approaches and therapeutic strategies that are currently being tested for COVID‐19 are derived from clinical experience in treatment of SARS, MERS, and other correspondents viral epidemics (Casadevall & Pirofski, 2020; Cunningham, Goh, & Koh, 2020).
7.5.2 Mesenchymal stem cell (MSC) therapy
A new therapeutic for treating immune‐mediated diseases, MSC therapy might have the capability to terminate the inappropriate release of cytokines in COVID‐19. Through its anti‐inflammatory effects, MSC therapy has been reported to improve respiratory function in murine models with acute lung injury. Evidence suggests that MSCs might be doing so by repressing the aberrant release of inflammatory factors (Hu & Li, 2018; Wang, Yao, Lv, Ling, & Li, 2017; Xiang et al., 2017). In particular, a study by Chinese scientists concluded that transplantation of MSCs could be considered as a novel approach in treatment of viral pneumonia, noting promissory implications of this method in management of H7N9‐induced ARDS. Since H7N9 and SARS‐CoV‐2 can result in similar complications, for example, ARDS and respiratory failure, MSC‐based therapy might lead to a new path in treatment of COVID‐19‐associated pneumonia (Chen, Hu, et al., 2020).
7.5.3 Nano drug delivery systems
It has long been known that the traditional circulation‐based delivery of therapeutic agents is not as effect, prompting pharmaceutical industries to develop novel platforms for delivery of molecules to hard‐to‐reach tissues in human body. Conjugation of antiviral agents, particularly nucleoside analogs, with specific nanoparticles has proved to be effectual in treatment of resistant HIV infection (Agarwal, Chhikara, Doncel, & Parang, 2017; Agarwal, Chhikara, Quiterio, Doncel, & Parang, 2012). Today, an appreciable number of drug delivery platforms based on nanotechnology are available that can be experimentally used with custom therapeutic formulations for treatment of COVID‐19 (Chhikara & Varma, 2019) in hopes of shortening the course of the disease (Chhikara et al., 2020).
7.5.4 Psychological interventions
Progression of COVID‐19, similar to any other disease, can result in suffering of the patients, prompting psychological symptoms, which will require special interventions. It has been well‐established today that individuals who fall victim to public health emergencies, for example, disease outbreaks, develop variable degrees of stress disorders. The problem persists even after the individual has recovered and discharged from the hospital (Cheng, Wong, Tsang, & Wong, 2004; Fan, Long, Zhou, Zheng, & Liu, 2015). With that in mind, one should consider several factors for classification of patients who will most probably benefit from psychological interventions; that is overall course of the disease, severity, and quality of hospitalization (e.g., home, ordinary wards, ICU, etc.) (Duan & Zhu, 2020).
In large‐scale outbreaks such as COVID‐19 epidemic, healthcare workers become the frontline at providing psychological cares for patients who battle against the disease. Primary medical and mental care should be provided for those individuals who are recognized as “suspected case” and duly quarantined at home. (Duan & Zhu, 2020).
Interventions should be discreetly formulated following a thorough evaluation of risk factors involved in emerging of these psychological issues, including a history of impaired mental health, bereavement after a deceased family member, panic, separation from loved ones, and a low income (Kun, Han, Chen, Yao, & Anxiety, 2009).
|
|
label
|
7
|
|
title
|
THERAPY
|
|
p
|
Scientists have made strenuous efforts to come up with an effective regimen for successful treatment of COVID‐19 (Gao, Tian, & Yang, 2020). Table 3 (Chen, Guo, et al., 2020; Fan et al., 2020; Han et al., 2020; Lan et al., 2020; Li, Zhang, et al., 2020; Li, Hu, et al., 2020; Lim et al., 2020; Liu et al., 2020; Liu et al., 2020; Wu et al., 2020; Wu & McGoogan, 2020), Tables 4 and 5 (Zhang & Liu, 2020) represent 2020 studies on treatment of COVID‐19 infected patients, related clinical trials and available therapeutic options, respectively.
|
|
table-wrap
|
Table 5 Therapeutic options that are available for the treatment of novel coronaviruses (cell line, animal, and human studies)
General treatment Nutritional interventions, targets or function Vit A Measles virus, measles‐related pneumonia, HIV, avian CoV, IBV Upregulating the elements of the innate immune, Making the cells refractory to infection
B vit MERS‐CoV Enhancing immune system, Inhibiting the of neutrophil infiltration into the lungs, Anti‐inflammatory effects during ventilator‐induced lung injury
Vit C Avian CoV Supporting immune functions, protecting against CoV infection, preventing of the lower respiratory tract infections
Vit D Bovine CoV Triggering the maturation of immune cells
Vit E Coxsackievirus, bovine CoV Antioxidant function
Omega‐3 PUFA Influenza virus, HIV Attenuating the replication of influenza virus
Selenium Influenza virus, avian CoV Antioxidant function, inducing immune response
Zinc Influenza virus, avian CoV, SARS‐CoV Maintenance/development of innate and adaptive immune systems simultaneously
Iron Viral mutations Enhancing the immune system
Immunoenhancers IFNs SARS‐CoV, MERS‐CoV Acting as apart of the innate immune response, Inhibiting the replication of CoVs in animal and human
IVIg SARS‐CoV Increasing the viscosity in hypercoagulable states
Ta1 SARS‐CoV Restoring the homeostasis of the immune system, Increasint the resistance glucocorticoid‐induced death of thymocyte
TP5, munox Restore antibody production Restoring antibody production, Enhancing the antibody response, As adjuvant treatment
Levamisole Immunostimulant/immunosuppressive agent Increasing the functions of cellular immunity, Act as immunostimulant agent or immunosuppressive agent through dose‐ and time‐dependent manner, reversing the depressed helper/inducer lymphocytes
Cyclosporine A SARS‐CoV, avian infectious bronchitis virus Both facilitating or inhibiting virus replication, blocking the all genera replication of CoV
CTM Glycyrrhizin, Baicalin, Ginseng SARS‐CoV, avian infectious bronchitis virus Enhancing host immunity, Inhibiting the replication of SARS‐associated virus and SARS‐CoV, Enhancing the specific‐antibody responses
Specific treatments Protease inhibitors 3C‐like inhibitors Cinanserin, SARS‐CoV Act as serotonin receptor antagonist, Inhibiting the replication
Flavonoids MERS‐CoV Act as antioxidant and antiviral compound, blocking the enzymatic activity of MERS‐CoV/3CLpro
PLP inhibitors SARS‐CoV Inhibit PLP of SARS‐CoV
S protein‐ACE2 blockers Human mAb SARS‐CoV Neutralizing SARS‐CoV, inhibiting syncytia formation between cells expressing the S protein and the SARS‐CoV receptor ACE2
Chloroquine SARS‐CoV Possess antiviral effect, inhibiting of SARS‐CoV infection via interfering with ACE2
Emodin SARS‐CoV Blocking the interaction between the S protein of virus and ACE2
Promazine SARS‐CoV Inhibiting the replication of virus, inhibiting the binding of S protein to ACE2
Nicotianamine Inhibiting the ACE2
Antiviral treatments Ribavirin SARS‐CoV Inhibiting the the replication of SARS‐associated CoV
LPV/RTV (Kaletra) HIV, SARS‐CoV, MERS‐CoV protease inhibitor
RDV SARS‐CoV, MERS‐CoV Improving the pulmonary function, reducing the lung viral loads and severe lung pathology
Nelfinavir HIV, SARS‐CoV Act as selective inhibitor of HIV protease, Inhibiting the replication virus
ARB influenza A/B, hepatitis C virus Blocking viral fusion, entry and replication
Nitric oxide SARS Antiviral effects
Other compounds ALA human CoV‐229E, HIV Act as antioxidant, inhibiting the replication of HIV‐1
Estradiol and phytoestrogen SARS‐CoV, MERS, influenza A Reducing virus replication in primary human nasal epithelial cells
Mucroporin‐M1 influenza H5N1 viruses, and SARS‐CoV Virucidal activity against viruses
Abbreviations: 3 CLpro, 3C‐like protease; Ab, antibody; ACE2, angiotensin converting enzyme 2; ALA, α‐lipoic acid; ARB, arbidol; CoV, coronavirus; CTM, Chinese traditional medicine; HIV, human immunodeficiency virus; IBV, bronchitis virus; IFN, interferons; IVIg, intravenous gammaglobulin; LPV/RTV, lopinavir/ritonavir; mAb, monoclonal antibody; PLpro, papain‐like protease; PUFA, polyunsaturated fatty acids; RDV, remdesivir; S, spike; Ta1, thymosin α‐1; TP5, thymopentin; Vit, vitamin.
John Wiley & Sons, Ltd. This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.
|
|
label
|
Table 5
|
|
caption
|
Therapeutic options that are available for the treatment of novel coronaviruses (cell line, animal, and human studies)
|
|
p
|
Therapeutic options that are available for the treatment of novel coronaviruses (cell line, animal, and human studies)
|
|
table
|
General treatment Nutritional interventions, targets or function Vit A Measles virus, measles‐related pneumonia, HIV, avian CoV, IBV Upregulating the elements of the innate immune, Making the cells refractory to infection
B vit MERS‐CoV Enhancing immune system, Inhibiting the of neutrophil infiltration into the lungs, Anti‐inflammatory effects during ventilator‐induced lung injury
Vit C Avian CoV Supporting immune functions, protecting against CoV infection, preventing of the lower respiratory tract infections
Vit D Bovine CoV Triggering the maturation of immune cells
Vit E Coxsackievirus, bovine CoV Antioxidant function
Omega‐3 PUFA Influenza virus, HIV Attenuating the replication of influenza virus
Selenium Influenza virus, avian CoV Antioxidant function, inducing immune response
Zinc Influenza virus, avian CoV, SARS‐CoV Maintenance/development of innate and adaptive immune systems simultaneously
Iron Viral mutations Enhancing the immune system
Immunoenhancers IFNs SARS‐CoV, MERS‐CoV Acting as apart of the innate immune response, Inhibiting the replication of CoVs in animal and human
IVIg SARS‐CoV Increasing the viscosity in hypercoagulable states
Ta1 SARS‐CoV Restoring the homeostasis of the immune system, Increasint the resistance glucocorticoid‐induced death of thymocyte
TP5, munox Restore antibody production Restoring antibody production, Enhancing the antibody response, As adjuvant treatment
Levamisole Immunostimulant/immunosuppressive agent Increasing the functions of cellular immunity, Act as immunostimulant agent or immunosuppressive agent through dose‐ and time‐dependent manner, reversing the depressed helper/inducer lymphocytes
Cyclosporine A SARS‐CoV, avian infectious bronchitis virus Both facilitating or inhibiting virus replication, blocking the all genera replication of CoV
CTM Glycyrrhizin, Baicalin, Ginseng SARS‐CoV, avian infectious bronchitis virus Enhancing host immunity, Inhibiting the replication of SARS‐associated virus and SARS‐CoV, Enhancing the specific‐antibody responses
Specific treatments Protease inhibitors 3C‐like inhibitors Cinanserin, SARS‐CoV Act as serotonin receptor antagonist, Inhibiting the replication
Flavonoids MERS‐CoV Act as antioxidant and antiviral compound, blocking the enzymatic activity of MERS‐CoV/3CLpro
PLP inhibitors SARS‐CoV Inhibit PLP of SARS‐CoV
S protein‐ACE2 blockers Human mAb SARS‐CoV Neutralizing SARS‐CoV, inhibiting syncytia formation between cells expressing the S protein and the SARS‐CoV receptor ACE2
Chloroquine SARS‐CoV Possess antiviral effect, inhibiting of SARS‐CoV infection via interfering with ACE2
Emodin SARS‐CoV Blocking the interaction between the S protein of virus and ACE2
Promazine SARS‐CoV Inhibiting the replication of virus, inhibiting the binding of S protein to ACE2
Nicotianamine Inhibiting the ACE2
Antiviral treatments Ribavirin SARS‐CoV Inhibiting the the replication of SARS‐associated CoV
LPV/RTV (Kaletra) HIV, SARS‐CoV, MERS‐CoV protease inhibitor
RDV SARS‐CoV, MERS‐CoV Improving the pulmonary function, reducing the lung viral loads and severe lung pathology
Nelfinavir HIV, SARS‐CoV Act as selective inhibitor of HIV protease, Inhibiting the replication virus
ARB influenza A/B, hepatitis C virus Blocking viral fusion, entry and replication
Nitric oxide SARS Antiviral effects
Other compounds ALA human CoV‐229E, HIV Act as antioxidant, inhibiting the replication of HIV‐1
Estradiol and phytoestrogen SARS‐CoV, MERS, influenza A Reducing virus replication in primary human nasal epithelial cells
Mucroporin‐M1 influenza H5N1 viruses, and SARS‐CoV Virucidal activity against viruses
|
|
tr
|
General treatment Nutritional interventions, targets or function Vit A Measles virus, measles‐related pneumonia, HIV, avian CoV, IBV Upregulating the elements of the innate immune, Making the cells refractory to infection
|
|
td
|
General treatment
|
|
td
|
Nutritional interventions, targets or function
|
|
td
|
Vit A
|
|
td
|
Measles virus, measles‐related pneumonia, HIV, avian CoV, IBV
|
|
td
|
Upregulating the elements of the innate immune, Making the cells refractory to infection
|
|
tr
|
B vit MERS‐CoV Enhancing immune system, Inhibiting the of neutrophil infiltration into the lungs, Anti‐inflammatory effects during ventilator‐induced lung injury
|
|
td
|
B vit
|
|
td
|
MERS‐CoV
|
|
td
|
Enhancing immune system, Inhibiting the of neutrophil infiltration into the lungs, Anti‐inflammatory effects during ventilator‐induced lung injury
|
|
tr
|
Vit C Avian CoV Supporting immune functions, protecting against CoV infection, preventing of the lower respiratory tract infections
|
|
td
|
Vit C
|
|
td
|
Avian CoV
|
|
td
|
Supporting immune functions, protecting against CoV infection, preventing of the lower respiratory tract infections
|
|
tr
|
Vit D Bovine CoV Triggering the maturation of immune cells
|
|
td
|
Vit D
|
|
td
|
Bovine CoV
|
|
td
|
Triggering the maturation of immune cells
|
|
tr
|
Vit E Coxsackievirus, bovine CoV Antioxidant function
|
|
td
|
Vit E
|
|
td
|
Coxsackievirus, bovine CoV
|
|
td
|
Antioxidant function
|
|
tr
|
Omega‐3 PUFA Influenza virus, HIV Attenuating the replication of influenza virus
|
|
td
|
Omega‐3 PUFA
|
|
td
|
Influenza virus, HIV
|
|
td
|
Attenuating the replication of influenza virus
|
|
tr
|
Selenium Influenza virus, avian CoV Antioxidant function, inducing immune response
|
|
td
|
Selenium
|
|
td
|
Influenza virus, avian CoV
|
|
td
|
Antioxidant function, inducing immune response
|
|
tr
|
Zinc Influenza virus, avian CoV, SARS‐CoV Maintenance/development of innate and adaptive immune systems simultaneously
|
|
td
|
Zinc
|
|
td
|
Influenza virus, avian CoV, SARS‐CoV
|
|
td
|
Maintenance/development of innate and adaptive immune systems simultaneously
|
|
tr
|
Iron Viral mutations Enhancing the immune system
|
|
td
|
Iron
|
|
td
|
Viral mutations
|
|
td
|
Enhancing the immune system
|
|
tr
|
Immunoenhancers IFNs SARS‐CoV, MERS‐CoV Acting as apart of the innate immune response, Inhibiting the replication of CoVs in animal and human
|
|
td
|
Immunoenhancers
|
|
td
|
IFNs
|
|
td
|
SARS‐CoV, MERS‐CoV
|
|
td
|
Acting as apart of the innate immune response, Inhibiting the replication of CoVs in animal and human
|
|
tr
|
IVIg SARS‐CoV Increasing the viscosity in hypercoagulable states
|
|
td
|
IVIg
|
|
td
|
SARS‐CoV
|
|
td
|
Increasing the viscosity in hypercoagulable states
|
|
tr
|
Ta1 SARS‐CoV Restoring the homeostasis of the immune system, Increasint the resistance glucocorticoid‐induced death of thymocyte
|
|
td
|
Ta1
|
|
td
|
SARS‐CoV
|
|
td
|
Restoring the homeostasis of the immune system, Increasint the resistance glucocorticoid‐induced death of thymocyte
|
|
tr
|
TP5, munox Restore antibody production Restoring antibody production, Enhancing the antibody response, As adjuvant treatment
|
|
td
|
TP5, munox
|
|
td
|
Restore antibody production
|
|
td
|
Restoring antibody production, Enhancing the antibody response, As adjuvant treatment
|
|
tr
|
Levamisole Immunostimulant/immunosuppressive agent Increasing the functions of cellular immunity, Act as immunostimulant agent or immunosuppressive agent through dose‐ and time‐dependent manner, reversing the depressed helper/inducer lymphocytes
|
|
td
|
Levamisole
|
|
td
|
Immunostimulant/immunosuppressive agent
|
|
td
|
Increasing the functions of cellular immunity, Act as immunostimulant agent or immunosuppressive agent through dose‐ and time‐dependent manner, reversing the depressed helper/inducer lymphocytes
|
|
tr
|
Cyclosporine A SARS‐CoV, avian infectious bronchitis virus Both facilitating or inhibiting virus replication, blocking the all genera replication of CoV
|
|
td
|
Cyclosporine A
|
|
td
|
SARS‐CoV, avian infectious bronchitis virus
|
|
td
|
Both facilitating or inhibiting virus replication, blocking the all genera replication of CoV
|
|
tr
|
CTM Glycyrrhizin, Baicalin, Ginseng SARS‐CoV, avian infectious bronchitis virus Enhancing host immunity, Inhibiting the replication of SARS‐associated virus and SARS‐CoV, Enhancing the specific‐antibody responses
|
|
td
|
CTM
|
|
td
|
Glycyrrhizin, Baicalin, Ginseng
|
|
td
|
SARS‐CoV, avian infectious bronchitis virus
|
|
td
|
Enhancing host immunity, Inhibiting the replication of SARS‐associated virus and SARS‐CoV, Enhancing the specific‐antibody responses
|
|
tr
|
Specific treatments Protease inhibitors 3C‐like inhibitors Cinanserin, SARS‐CoV Act as serotonin receptor antagonist, Inhibiting the replication
|
|
td
|
Specific treatments
|
|
td
|
Protease inhibitors
|
|
td
|
3C‐like inhibitors
|
|
td
|
Cinanserin,
|
|
td
|
SARS‐CoV
|
|
td
|
Act as serotonin receptor antagonist, Inhibiting the replication
|
|
tr
|
Flavonoids MERS‐CoV Act as antioxidant and antiviral compound, blocking the enzymatic activity of MERS‐CoV/3CLpro
|
|
td
|
Flavonoids
|
|
td
|
MERS‐CoV
|
|
td
|
Act as antioxidant and antiviral compound, blocking the enzymatic activity of MERS‐CoV/3CLpro
|
|
tr
|
PLP inhibitors SARS‐CoV Inhibit PLP of SARS‐CoV
|
|
td
|
PLP inhibitors
|
|
td
|
SARS‐CoV
|
|
td
|
Inhibit PLP of SARS‐CoV
|
|
tr
|
S protein‐ACE2 blockers Human mAb SARS‐CoV Neutralizing SARS‐CoV, inhibiting syncytia formation between cells expressing the S protein and the SARS‐CoV receptor ACE2
|
|
td
|
S protein‐ACE2 blockers
|
|
td
|
Human mAb
|
|
td
|
SARS‐CoV
|
|
td
|
Neutralizing SARS‐CoV, inhibiting syncytia formation between cells expressing the S protein and the SARS‐CoV receptor ACE2
|
|
tr
|
Chloroquine SARS‐CoV Possess antiviral effect, inhibiting of SARS‐CoV infection via interfering with ACE2
|
|
td
|
Chloroquine
|
|
td
|
SARS‐CoV
|
|
td
|
Possess antiviral effect, inhibiting of SARS‐CoV infection via interfering with ACE2
|
|
tr
|
Emodin SARS‐CoV Blocking the interaction between the S protein of virus and ACE2
|
|
td
|
Emodin
|
|
td
|
SARS‐CoV
|
|
td
|
Blocking the interaction between the S protein of virus and ACE2
|
|
tr
|
Promazine SARS‐CoV Inhibiting the replication of virus, inhibiting the binding of S protein to ACE2
|
|
td
|
Promazine
|
|
td
|
SARS‐CoV
|
|
td
|
Inhibiting the replication of virus, inhibiting the binding of S protein to ACE2
|
|
tr
|
Nicotianamine Inhibiting the ACE2
|
|
td
|
Nicotianamine
|
|
td
|
Inhibiting the ACE2
|
|
tr
|
Antiviral treatments Ribavirin SARS‐CoV Inhibiting the the replication of SARS‐associated CoV
|
|
td
|
Antiviral treatments
|
|
td
|
Ribavirin
|
|
td
|
SARS‐CoV
|
|
td
|
Inhibiting the the replication of SARS‐associated CoV
|
|
tr
|
LPV/RTV (Kaletra) HIV, SARS‐CoV, MERS‐CoV protease inhibitor
|
|
td
|
LPV/RTV (Kaletra)
|
|
td
|
HIV, SARS‐CoV, MERS‐CoV
|
|
td
|
protease inhibitor
|
|
tr
|
RDV SARS‐CoV, MERS‐CoV Improving the pulmonary function, reducing the lung viral loads and severe lung pathology
|
|
td
|
RDV
|
|
td
|
SARS‐CoV, MERS‐CoV
|
|
td
|
Improving the pulmonary function, reducing the lung viral loads and severe lung pathology
|
|
tr
|
Nelfinavir HIV, SARS‐CoV Act as selective inhibitor of HIV protease, Inhibiting the replication virus
|
|
td
|
Nelfinavir
|
|
td
|
HIV, SARS‐CoV
|
|
td
|
Act as selective inhibitor of HIV protease, Inhibiting the replication virus
|
|
tr
|
ARB influenza A/B, hepatitis C virus Blocking viral fusion, entry and replication
|
|
td
|
ARB
|
|
td
|
influenza A/B, hepatitis C virus
|
|
td
|
Blocking viral fusion, entry and replication
|
|
tr
|
Nitric oxide SARS Antiviral effects
|
|
td
|
Nitric oxide
|
|
td
|
SARS
|
|
td
|
Antiviral effects
|
|
tr
|
Other compounds ALA human CoV‐229E, HIV Act as antioxidant, inhibiting the replication of HIV‐1
|
|
td
|
Other compounds
|
|
td
|
ALA
|
|
td
|
human CoV‐229E, HIV
|
|
td
|
Act as antioxidant, inhibiting the replication of HIV‐1
|
|
tr
|
Estradiol and phytoestrogen SARS‐CoV, MERS, influenza A Reducing virus replication in primary human nasal epithelial cells
|
|
td
|
Estradiol and phytoestrogen
|
|
td
|
SARS‐CoV, MERS, influenza A
|
|
td
|
Reducing virus replication in primary human nasal epithelial cells
|
|
tr
|
Mucroporin‐M1 influenza H5N1 viruses, and SARS‐CoV Virucidal activity against viruses
|
|
td
|
Mucroporin‐M1
|
|
td
|
influenza H5N1 viruses, and SARS‐CoV
|
|
td
|
Virucidal activity against viruses
|
|
table-wrap-foot
|
Abbreviations: 3 CLpro, 3C‐like protease; Ab, antibody; ACE2, angiotensin converting enzyme 2; ALA, α‐lipoic acid; ARB, arbidol; CoV, coronavirus; CTM, Chinese traditional medicine; HIV, human immunodeficiency virus; IBV, bronchitis virus; IFN, interferons; IVIg, intravenous gammaglobulin; LPV/RTV, lopinavir/ritonavir; mAb, monoclonal antibody; PLpro, papain‐like protease; PUFA, polyunsaturated fatty acids; RDV, remdesivir; S, spike; Ta1, thymosin α‐1; TP5, thymopentin; Vit, vitamin.
|
|
footnote
|
Abbreviations: 3 CLpro, 3C‐like protease; Ab, antibody; ACE2, angiotensin converting enzyme 2; ALA, α‐lipoic acid; ARB, arbidol; CoV, coronavirus; CTM, Chinese traditional medicine; HIV, human immunodeficiency virus; IBV, bronchitis virus; IFN, interferons; IVIg, intravenous gammaglobulin; LPV/RTV, lopinavir/ritonavir; mAb, monoclonal antibody; PLpro, papain‐like protease; PUFA, polyunsaturated fatty acids; RDV, remdesivir; S, spike; Ta1, thymosin α‐1; TP5, thymopentin; Vit, vitamin.
|
|
p
|
Abbreviations: 3 CLpro, 3C‐like protease; Ab, antibody; ACE2, angiotensin converting enzyme 2; ALA, α‐lipoic acid; ARB, arbidol; CoV, coronavirus; CTM, Chinese traditional medicine; HIV, human immunodeficiency virus; IBV, bronchitis virus; IFN, interferons; IVIg, intravenous gammaglobulin; LPV/RTV, lopinavir/ritonavir; mAb, monoclonal antibody; PLpro, papain‐like protease; PUFA, polyunsaturated fatty acids; RDV, remdesivir; S, spike; Ta1, thymosin α‐1; TP5, thymopentin; Vit, vitamin.
|
|
sec
|
7.1 Chloroquine phosphate
Chloroquine phosphate is an old medicine, that has been widely used for treatment of malaria in endemic regions. It is also a salutary treatment of choice for certain progressive anti‐inflammatory diseases, for example, rheumatoid arthritis, and systemic lupus erythematosus. Recently, an investigation in China reported that remdesivir and chloroquine phosphate were effective experimental agents for controlling SARS‐CoV‐2 infection in the lab (Chen et al., 2013). Initial findings reported by a recent study on effectiveness of therapeutic agents in management of SARS‐CoV‐2 infection, and suggested successful application of chloroquine phosphate in treatment of patients with COVID‐19‐associated pneumonia. Following the promising results, scientists recommended chloroquine phosphate to be included in treatment regimen of COVID‐19 patients with severe involvement of the lungs (Yu et al., 2013). On February 15, 2020, participants from different organizations, including medical experts and authorities, made an agreement on potency of Chloroquine phosphate against SARS‐CoV‐2 infection (https://www.clinicaltrialsarena.com/analysis/coronavirus-mers-cov-drugs/).
So far, close monitoring of over 100 patients, who were under treatment of chloroquine phosphate, has provided further evidence regarding the effectiveness of this long‐known medicine. Investigations indicated that chloroquine phosphate prevented exacerbation of pneumonia in these patients, improved their chest CT findings, and shortened the otherwise long natural course of the disease. Importantly, there have been no records of severe reaction or hypersensitivity to this therapeutic agent. It has been suggested that the broad‐spectrum antiviral activity of chloroquine phosphate lies within the complicated pharmacodynamics of the drug that results in a basic shift in the endosomal pH required for successful fusion of virus onto the host cell. chloroquine phosphate also seems to have disruptive effects on glycosylation of cellular receptors of SARS‐CoV (Yin & Wunderink, 2018; Zumla et al., 2020), rendering them nonfunctional. It also interferes with activation of p38 mitogen‐activated protein kinase, a signaling event involved in replication of HCoV‐229E (Kono et al., 2008).
|
|
label
|
7.1
|
|
title
|
Chloroquine phosphate
|
|
p
|
Chloroquine phosphate is an old medicine, that has been widely used for treatment of malaria in endemic regions. It is also a salutary treatment of choice for certain progressive anti‐inflammatory diseases, for example, rheumatoid arthritis, and systemic lupus erythematosus. Recently, an investigation in China reported that remdesivir and chloroquine phosphate were effective experimental agents for controlling SARS‐CoV‐2 infection in the lab (Chen et al., 2013). Initial findings reported by a recent study on effectiveness of therapeutic agents in management of SARS‐CoV‐2 infection, and suggested successful application of chloroquine phosphate in treatment of patients with COVID‐19‐associated pneumonia. Following the promising results, scientists recommended chloroquine phosphate to be included in treatment regimen of COVID‐19 patients with severe involvement of the lungs (Yu et al., 2013). On February 15, 2020, participants from different organizations, including medical experts and authorities, made an agreement on potency of Chloroquine phosphate against SARS‐CoV‐2 infection (https://www.clinicaltrialsarena.com/analysis/coronavirus-mers-cov-drugs/).
|
|
p
|
So far, close monitoring of over 100 patients, who were under treatment of chloroquine phosphate, has provided further evidence regarding the effectiveness of this long‐known medicine. Investigations indicated that chloroquine phosphate prevented exacerbation of pneumonia in these patients, improved their chest CT findings, and shortened the otherwise long natural course of the disease. Importantly, there have been no records of severe reaction or hypersensitivity to this therapeutic agent. It has been suggested that the broad‐spectrum antiviral activity of chloroquine phosphate lies within the complicated pharmacodynamics of the drug that results in a basic shift in the endosomal pH required for successful fusion of virus onto the host cell. chloroquine phosphate also seems to have disruptive effects on glycosylation of cellular receptors of SARS‐CoV (Yin & Wunderink, 2018; Zumla et al., 2020), rendering them nonfunctional. It also interferes with activation of p38 mitogen‐activated protein kinase, a signaling event involved in replication of HCoV‐229E (Kono et al., 2008).
|
|
sec
|
7.2 Lopinavir/ritonavir, leronlimab, galidesivir
Lopinavir/Ritonavir, commonly used for treatment of HIV infection, has been indicated for treatment of COVID‐19 in a number of reports (Kim et al., 2020). Previous studies suggested that when combined together, Lopinavir and Ritonavir act in concert to hinder further replication of SARS‐CoV, and improve the clinical status of patients with SARS (Chu et al., 2004). This might also mean that the well‐known antiretroviral duo can also prove beneficial in treatment of COVID‐19.
Other candidates for possible management of SARS‐CoV‐2 include Leronlimab and Galidesivir, both of which have been of clinical value in treatment of several fatal viral infections, and were shown to improve the survival of patients. Leronlimab is a humanized monoclonal antibody (CCR5 antagonist). Galidesivir, on the other hand, belongs to the family of nucleoside RNA polymerase inhibitors (https://www.clinicaltrialsarena.com/analysis/coronavirus-mers-cov-drugs/). In the absence of any specific therapeutic agents to quell SARs‐CoV‐2, it might be a salutary strategy to repurpose the already available medicine, and include them in treatment of COVID‐19 (Tian et al., 2020).
Several clinical trials can be viewed at ClinicalTrials.gov, that are currently in progress. These trials have specially focused on potency of Remdesivir, immunoglobulins, and combinational therapies, for example, Arbidol hydrochloride with interferon atomization, ASC09F and oseltamivir, ritonavir and oseltamivir, and lopinavir combined with ritonavir (https://clinicaltrials.gov/ct2/results?cond=&2019nCoV&term=&cntry=&state=&city=&dist=).
|
|
label
|
7.2
|
|
title
|
Lopinavir/ritonavir, leronlimab, galidesivir
|
|
p
|
Lopinavir/Ritonavir, commonly used for treatment of HIV infection, has been indicated for treatment of COVID‐19 in a number of reports (Kim et al., 2020). Previous studies suggested that when combined together, Lopinavir and Ritonavir act in concert to hinder further replication of SARS‐CoV, and improve the clinical status of patients with SARS (Chu et al., 2004). This might also mean that the well‐known antiretroviral duo can also prove beneficial in treatment of COVID‐19.
|
|
p
|
Other candidates for possible management of SARS‐CoV‐2 include Leronlimab and Galidesivir, both of which have been of clinical value in treatment of several fatal viral infections, and were shown to improve the survival of patients. Leronlimab is a humanized monoclonal antibody (CCR5 antagonist). Galidesivir, on the other hand, belongs to the family of nucleoside RNA polymerase inhibitors (https://www.clinicaltrialsarena.com/analysis/coronavirus-mers-cov-drugs/). In the absence of any specific therapeutic agents to quell SARs‐CoV‐2, it might be a salutary strategy to repurpose the already available medicine, and include them in treatment of COVID‐19 (Tian et al., 2020).
|
|
p
|
Several clinical trials can be viewed at ClinicalTrials.gov, that are currently in progress. These trials have specially focused on potency of Remdesivir, immunoglobulins, and combinational therapies, for example, Arbidol hydrochloride with interferon atomization, ASC09F and oseltamivir, ritonavir and oseltamivir, and lopinavir combined with ritonavir (https://clinicaltrials.gov/ct2/results?cond=&2019nCoV&term=&cntry=&state=&city=&dist=).
|
|
sec
|
7.3 RAAS inhibitors
ACE2 is a prominent regulatory arm in the RAAS axis, thus, a disruption in ACE‐Angiotensin II‐Angiotensin Type 1 Receptor (AT1R), and ACE2/Angiotensin‐(1‐7)/Mas Receptor axes can result in multisystem inflammation. Increased levels of ACE and Angiotensin II in plasma are considered poor prognostic factors in severe pneumonia. Several studies on animal models have reported effectiveness of RAAS inhibitors in alleviation of severe pneumonia and acute respiratory failure. In the aftermath of SARS‐CoV‐2 and ACE2 binding, the enzyme is eventually degraded, hence, the inhibition of ACE2/Angiotensin‐(1‐7)/Mas Receptor pathway. Accordingly, it is assumed that ACE and AT1R inhibitors might be game‐changing agents that can especially be administered for COVID‐19 patients who have serious impairments in their homeostasis. Maintenance of homeostasis may ultimately result in suppression of the inflammatory response, mostly in the pulmonary tissue (Sun, Yang, Sun, & Su, 2020).
|
|
label
|
7.3
|
|
title
|
RAAS inhibitors
|
|
p
|
ACE2 is a prominent regulatory arm in the RAAS axis, thus, a disruption in ACE‐Angiotensin II‐Angiotensin Type 1 Receptor (AT1R), and ACE2/Angiotensin‐(1‐7)/Mas Receptor axes can result in multisystem inflammation. Increased levels of ACE and Angiotensin II in plasma are considered poor prognostic factors in severe pneumonia. Several studies on animal models have reported effectiveness of RAAS inhibitors in alleviation of severe pneumonia and acute respiratory failure. In the aftermath of SARS‐CoV‐2 and ACE2 binding, the enzyme is eventually degraded, hence, the inhibition of ACE2/Angiotensin‐(1‐7)/Mas Receptor pathway. Accordingly, it is assumed that ACE and AT1R inhibitors might be game‐changing agents that can especially be administered for COVID‐19 patients who have serious impairments in their homeostasis. Maintenance of homeostasis may ultimately result in suppression of the inflammatory response, mostly in the pulmonary tissue (Sun, Yang, Sun, & Su, 2020).
|
|
sec
|
7.4 Combination therapy
Combination therapy is a more extensive and rigorous approach mainly aimed at correction of life‐threatening events such as shock, hypoxemia, secondary or super infection, and maintenance of homeostasis, that is, electrolyte, acid and base balance. As a palliative practice, antiviral treatment in the early stages of COVID‐19 might lessen the severity and prevent further progression of the disease. Trials on combination therapy with lopinavir/ritonavir and arbidol (umifenovir) have reported satisfactory results in treatment of COVID‐19. Alongside a proper antiviral treatment, patients may also benefit from an artificial liver blood purification system, which is capable of rapidly removing the inflammatory factors from blood, thus, halting the disastrous cytokine release syndrome. This system can also facilitate the sustenance of critically ill patients by preserving the balance of bodily fluid. Administration of glucocorticoids in moderate doses is another intervention that has recently been indicated for patients with severe COVID‐19‐associated pneumonia. However, secondary fungal infection should be considered. Patients with an oxygenation index of less than 200 mmHg might benefit more from oxygen therapy than noninvasive ventilation. A rational prescription of antimicrobial medicines has been cautioned only for patients with remittent fever and elevated antimicrobial prophylaxis should be prescribed rationally and was not recommended except for patients with long course of disease, repeated fever, and elevated PCT levels. Ultimately, to maintain the balance of intestinal microbiota, oral intake of prebiotics or probiotics has been suggested. This can reduce the risk of secondary infections as a result of microbial translocation; however, effectiveness of such interventions on postinfection clearance pattern of SARS‐CoV‐2 has not been studied (Xu et al., 2020).
|
|
label
|
7.4
|
|
title
|
Combination therapy
|
|
p
|
Combination therapy is a more extensive and rigorous approach mainly aimed at correction of life‐threatening events such as shock, hypoxemia, secondary or super infection, and maintenance of homeostasis, that is, electrolyte, acid and base balance. As a palliative practice, antiviral treatment in the early stages of COVID‐19 might lessen the severity and prevent further progression of the disease. Trials on combination therapy with lopinavir/ritonavir and arbidol (umifenovir) have reported satisfactory results in treatment of COVID‐19. Alongside a proper antiviral treatment, patients may also benefit from an artificial liver blood purification system, which is capable of rapidly removing the inflammatory factors from blood, thus, halting the disastrous cytokine release syndrome. This system can also facilitate the sustenance of critically ill patients by preserving the balance of bodily fluid. Administration of glucocorticoids in moderate doses is another intervention that has recently been indicated for patients with severe COVID‐19‐associated pneumonia. However, secondary fungal infection should be considered. Patients with an oxygenation index of less than 200 mmHg might benefit more from oxygen therapy than noninvasive ventilation. A rational prescription of antimicrobial medicines has been cautioned only for patients with remittent fever and elevated antimicrobial prophylaxis should be prescribed rationally and was not recommended except for patients with long course of disease, repeated fever, and elevated PCT levels. Ultimately, to maintain the balance of intestinal microbiota, oral intake of prebiotics or probiotics has been suggested. This can reduce the risk of secondary infections as a result of microbial translocation; however, effectiveness of such interventions on postinfection clearance pattern of SARS‐CoV‐2 has not been studied (Xu et al., 2020).
|
|
sec
|
7.5 Other future possible options
7.5.1 Convalescent blood therapy
A conspicuously conventional method, transfusion of human convalescent plasma, might be viewed as a beneficial strategy for prevention and even treatment of COVID‐19. The method is as facile as its age since it only requires an adequate number of recovered patients who are willing to donate their immunoglobulin‐containing serum. Although one still might argue the possibility of SARS‐CoV‐2 infection via convalescent blood transfusion, no such incident with SARS‐CoV was reported by WHO amidst the outbreak of the disease in 2003. The heft of past experience should come to mind once it is noted that the majority of approaches and therapeutic strategies that are currently being tested for COVID‐19 are derived from clinical experience in treatment of SARS, MERS, and other correspondents viral epidemics (Casadevall & Pirofski, 2020; Cunningham, Goh, & Koh, 2020).
7.5.2 Mesenchymal stem cell (MSC) therapy
A new therapeutic for treating immune‐mediated diseases, MSC therapy might have the capability to terminate the inappropriate release of cytokines in COVID‐19. Through its anti‐inflammatory effects, MSC therapy has been reported to improve respiratory function in murine models with acute lung injury. Evidence suggests that MSCs might be doing so by repressing the aberrant release of inflammatory factors (Hu & Li, 2018; Wang, Yao, Lv, Ling, & Li, 2017; Xiang et al., 2017). In particular, a study by Chinese scientists concluded that transplantation of MSCs could be considered as a novel approach in treatment of viral pneumonia, noting promissory implications of this method in management of H7N9‐induced ARDS. Since H7N9 and SARS‐CoV‐2 can result in similar complications, for example, ARDS and respiratory failure, MSC‐based therapy might lead to a new path in treatment of COVID‐19‐associated pneumonia (Chen, Hu, et al., 2020).
7.5.3 Nano drug delivery systems
It has long been known that the traditional circulation‐based delivery of therapeutic agents is not as effect, prompting pharmaceutical industries to develop novel platforms for delivery of molecules to hard‐to‐reach tissues in human body. Conjugation of antiviral agents, particularly nucleoside analogs, with specific nanoparticles has proved to be effectual in treatment of resistant HIV infection (Agarwal, Chhikara, Doncel, & Parang, 2017; Agarwal, Chhikara, Quiterio, Doncel, & Parang, 2012). Today, an appreciable number of drug delivery platforms based on nanotechnology are available that can be experimentally used with custom therapeutic formulations for treatment of COVID‐19 (Chhikara & Varma, 2019) in hopes of shortening the course of the disease (Chhikara et al., 2020).
7.5.4 Psychological interventions
Progression of COVID‐19, similar to any other disease, can result in suffering of the patients, prompting psychological symptoms, which will require special interventions. It has been well‐established today that individuals who fall victim to public health emergencies, for example, disease outbreaks, develop variable degrees of stress disorders. The problem persists even after the individual has recovered and discharged from the hospital (Cheng, Wong, Tsang, & Wong, 2004; Fan, Long, Zhou, Zheng, & Liu, 2015). With that in mind, one should consider several factors for classification of patients who will most probably benefit from psychological interventions; that is overall course of the disease, severity, and quality of hospitalization (e.g., home, ordinary wards, ICU, etc.) (Duan & Zhu, 2020).
In large‐scale outbreaks such as COVID‐19 epidemic, healthcare workers become the frontline at providing psychological cares for patients who battle against the disease. Primary medical and mental care should be provided for those individuals who are recognized as “suspected case” and duly quarantined at home. (Duan & Zhu, 2020).
Interventions should be discreetly formulated following a thorough evaluation of risk factors involved in emerging of these psychological issues, including a history of impaired mental health, bereavement after a deceased family member, panic, separation from loved ones, and a low income (Kun, Han, Chen, Yao, & Anxiety, 2009).
|
|
label
|
7.5
|
|
title
|
Other future possible options
|
|
sec
|
7.5.1 Convalescent blood therapy
A conspicuously conventional method, transfusion of human convalescent plasma, might be viewed as a beneficial strategy for prevention and even treatment of COVID‐19. The method is as facile as its age since it only requires an adequate number of recovered patients who are willing to donate their immunoglobulin‐containing serum. Although one still might argue the possibility of SARS‐CoV‐2 infection via convalescent blood transfusion, no such incident with SARS‐CoV was reported by WHO amidst the outbreak of the disease in 2003. The heft of past experience should come to mind once it is noted that the majority of approaches and therapeutic strategies that are currently being tested for COVID‐19 are derived from clinical experience in treatment of SARS, MERS, and other correspondents viral epidemics (Casadevall & Pirofski, 2020; Cunningham, Goh, & Koh, 2020).
|
|
label
|
7.5.1
|
|
title
|
Convalescent blood therapy
|
|
p
|
A conspicuously conventional method, transfusion of human convalescent plasma, might be viewed as a beneficial strategy for prevention and even treatment of COVID‐19. The method is as facile as its age since it only requires an adequate number of recovered patients who are willing to donate their immunoglobulin‐containing serum. Although one still might argue the possibility of SARS‐CoV‐2 infection via convalescent blood transfusion, no such incident with SARS‐CoV was reported by WHO amidst the outbreak of the disease in 2003. The heft of past experience should come to mind once it is noted that the majority of approaches and therapeutic strategies that are currently being tested for COVID‐19 are derived from clinical experience in treatment of SARS, MERS, and other correspondents viral epidemics (Casadevall & Pirofski, 2020; Cunningham, Goh, & Koh, 2020).
|
|
sec
|
7.5.2 Mesenchymal stem cell (MSC) therapy
A new therapeutic for treating immune‐mediated diseases, MSC therapy might have the capability to terminate the inappropriate release of cytokines in COVID‐19. Through its anti‐inflammatory effects, MSC therapy has been reported to improve respiratory function in murine models with acute lung injury. Evidence suggests that MSCs might be doing so by repressing the aberrant release of inflammatory factors (Hu & Li, 2018; Wang, Yao, Lv, Ling, & Li, 2017; Xiang et al., 2017). In particular, a study by Chinese scientists concluded that transplantation of MSCs could be considered as a novel approach in treatment of viral pneumonia, noting promissory implications of this method in management of H7N9‐induced ARDS. Since H7N9 and SARS‐CoV‐2 can result in similar complications, for example, ARDS and respiratory failure, MSC‐based therapy might lead to a new path in treatment of COVID‐19‐associated pneumonia (Chen, Hu, et al., 2020).
|
|
label
|
7.5.2
|
|
title
|
Mesenchymal stem cell (MSC) therapy
|
|
p
|
A new therapeutic for treating immune‐mediated diseases, MSC therapy might have the capability to terminate the inappropriate release of cytokines in COVID‐19. Through its anti‐inflammatory effects, MSC therapy has been reported to improve respiratory function in murine models with acute lung injury. Evidence suggests that MSCs might be doing so by repressing the aberrant release of inflammatory factors (Hu & Li, 2018; Wang, Yao, Lv, Ling, & Li, 2017; Xiang et al., 2017). In particular, a study by Chinese scientists concluded that transplantation of MSCs could be considered as a novel approach in treatment of viral pneumonia, noting promissory implications of this method in management of H7N9‐induced ARDS. Since H7N9 and SARS‐CoV‐2 can result in similar complications, for example, ARDS and respiratory failure, MSC‐based therapy might lead to a new path in treatment of COVID‐19‐associated pneumonia (Chen, Hu, et al., 2020).
|
|
sec
|
7.5.3 Nano drug delivery systems
It has long been known that the traditional circulation‐based delivery of therapeutic agents is not as effect, prompting pharmaceutical industries to develop novel platforms for delivery of molecules to hard‐to‐reach tissues in human body. Conjugation of antiviral agents, particularly nucleoside analogs, with specific nanoparticles has proved to be effectual in treatment of resistant HIV infection (Agarwal, Chhikara, Doncel, & Parang, 2017; Agarwal, Chhikara, Quiterio, Doncel, & Parang, 2012). Today, an appreciable number of drug delivery platforms based on nanotechnology are available that can be experimentally used with custom therapeutic formulations for treatment of COVID‐19 (Chhikara & Varma, 2019) in hopes of shortening the course of the disease (Chhikara et al., 2020).
|
|
label
|
7.5.3
|
|
title
|
Nano drug delivery systems
|
|
p
|
It has long been known that the traditional circulation‐based delivery of therapeutic agents is not as effect, prompting pharmaceutical industries to develop novel platforms for delivery of molecules to hard‐to‐reach tissues in human body. Conjugation of antiviral agents, particularly nucleoside analogs, with specific nanoparticles has proved to be effectual in treatment of resistant HIV infection (Agarwal, Chhikara, Doncel, & Parang, 2017; Agarwal, Chhikara, Quiterio, Doncel, & Parang, 2012). Today, an appreciable number of drug delivery platforms based on nanotechnology are available that can be experimentally used with custom therapeutic formulations for treatment of COVID‐19 (Chhikara & Varma, 2019) in hopes of shortening the course of the disease (Chhikara et al., 2020).
|
|
sec
|
7.5.4 Psychological interventions
Progression of COVID‐19, similar to any other disease, can result in suffering of the patients, prompting psychological symptoms, which will require special interventions. It has been well‐established today that individuals who fall victim to public health emergencies, for example, disease outbreaks, develop variable degrees of stress disorders. The problem persists even after the individual has recovered and discharged from the hospital (Cheng, Wong, Tsang, & Wong, 2004; Fan, Long, Zhou, Zheng, & Liu, 2015). With that in mind, one should consider several factors for classification of patients who will most probably benefit from psychological interventions; that is overall course of the disease, severity, and quality of hospitalization (e.g., home, ordinary wards, ICU, etc.) (Duan & Zhu, 2020).
In large‐scale outbreaks such as COVID‐19 epidemic, healthcare workers become the frontline at providing psychological cares for patients who battle against the disease. Primary medical and mental care should be provided for those individuals who are recognized as “suspected case” and duly quarantined at home. (Duan & Zhu, 2020).
Interventions should be discreetly formulated following a thorough evaluation of risk factors involved in emerging of these psychological issues, including a history of impaired mental health, bereavement after a deceased family member, panic, separation from loved ones, and a low income (Kun, Han, Chen, Yao, & Anxiety, 2009).
|
|
label
|
7.5.4
|
|
title
|
Psychological interventions
|
|
p
|
Progression of COVID‐19, similar to any other disease, can result in suffering of the patients, prompting psychological symptoms, which will require special interventions. It has been well‐established today that individuals who fall victim to public health emergencies, for example, disease outbreaks, develop variable degrees of stress disorders. The problem persists even after the individual has recovered and discharged from the hospital (Cheng, Wong, Tsang, & Wong, 2004; Fan, Long, Zhou, Zheng, & Liu, 2015). With that in mind, one should consider several factors for classification of patients who will most probably benefit from psychological interventions; that is overall course of the disease, severity, and quality of hospitalization (e.g., home, ordinary wards, ICU, etc.) (Duan & Zhu, 2020).
|
|
p
|
In large‐scale outbreaks such as COVID‐19 epidemic, healthcare workers become the frontline at providing psychological cares for patients who battle against the disease. Primary medical and mental care should be provided for those individuals who are recognized as “suspected case” and duly quarantined at home. (Duan & Zhu, 2020).
|
|
p
|
Interventions should be discreetly formulated following a thorough evaluation of risk factors involved in emerging of these psychological issues, including a history of impaired mental health, bereavement after a deceased family member, panic, separation from loved ones, and a low income (Kun, Han, Chen, Yao, & Anxiety, 2009).
|
|
sec
|
8 PATIENTS RECOVERED FROM COVID‐19
The following criteria must be met in order for a patient to be discharged from hospital or released from quarantine: (a) having been afebrile for at least 3 consecutive days, (b) remission of respiratory distress, (c) regression of infiltrations/consolidations on chest CT images, and two consecutive negative reports of RT‐PCR test performed at least 1 day apart (d). Despite these thoroughly formulated criteria, one study reported positive RT‐PCR test results 5–13 days after hospital discharge for four patients with COVID‐19, who met all of the criteria above before they were discharged. These findings are important in that they imply the slight possibility that even a fully recovered patient might still be a silent carrier of the virus. In this scenario, however, no family members were reported to be infected, since all of the four patients with bizarrely late positive tests were medical professional, and followed all of the guidelines while they were at home quarantine. With due attention to this incident, the current criteria for hospital discharge may need to be reconsidered (Lan et al., 2020).
|
|
label
|
8
|
|
title
|
PATIENTS RECOVERED FROM COVID‐19
|
|
p
|
The following criteria must be met in order for a patient to be discharged from hospital or released from quarantine: (a) having been afebrile for at least 3 consecutive days, (b) remission of respiratory distress, (c) regression of infiltrations/consolidations on chest CT images, and two consecutive negative reports of RT‐PCR test performed at least 1 day apart (d). Despite these thoroughly formulated criteria, one study reported positive RT‐PCR test results 5–13 days after hospital discharge for four patients with COVID‐19, who met all of the criteria above before they were discharged. These findings are important in that they imply the slight possibility that even a fully recovered patient might still be a silent carrier of the virus. In this scenario, however, no family members were reported to be infected, since all of the four patients with bizarrely late positive tests were medical professional, and followed all of the guidelines while they were at home quarantine. With due attention to this incident, the current criteria for hospital discharge may need to be reconsidered (Lan et al., 2020).
|
|
sec
|
9 CONCLUSIONS AND FUTURE PERSPECTIVES
Deemed a global health emergency, COVID‐19 outbreak has continued to be the headline of the news. The number of confirmed cases is on the rise, and the seamless spread of the virus has become a plight for general population, and the entire medical community. In spite of the extreme preventive measures while near a patient, clinicians are still at great risk for contracting the disease from the visitors. Else, it is vividly known that quarantine alone is not the optimal choice for containing of the virus. On the other hand, the devastating potential impact of the outbreak is a much feared topic around the world. Science has always been the ultimate arsenal of weaponry when it comes to battling obstinate pathogens; however, time is needed for conduction of proper investigations on human‐to‐human and animal‐to‐human transmission of SARS‐CoV‐2.
With no access to requisite information on the structure and life cycle of the novel Coronavirus, research and development programs on therapeutic agents become a far‐fetched milestone, rendering the tried‐and‐true primary prevention measures the only proper means to confront SARS‐CoV‐2. As of today, few existing drugs have been considered for treatment of COVID‐19, with scant reports on benevolence of the results. As our meager knowledge of SARS‐CoV‐2 is advancing, one may speculate the advent of an effectual vaccine, alongside treatment options that might include antiviral agents, and even monoclonal antibodies. At the time of writing this manuscript, no definitive treatment option has been known for COVID‐19; however, the unabating flow of investigations and clinical trials may soon lead us to the optimal therapy for COVID‐19‐associated pneumonia.
Needless to say, the fascinatingly high transmissibility of COVID‐19 demands meticulous monitoring of the transmission routes and patterns to a reach a firm theory on adaptive mechanisms wielded by SARs‐CoV‐2, thus, making an accurate prediction about the future outcomes regarding pathogenicity, transmissibility, and evolution of the virus. These efforts will hopefully result in better prognosis and fewer mortalities.
|
|
label
|
9
|
|
title
|
CONCLUSIONS AND FUTURE PERSPECTIVES
|
|
p
|
Deemed a global health emergency, COVID‐19 outbreak has continued to be the headline of the news. The number of confirmed cases is on the rise, and the seamless spread of the virus has become a plight for general population, and the entire medical community. In spite of the extreme preventive measures while near a patient, clinicians are still at great risk for contracting the disease from the visitors. Else, it is vividly known that quarantine alone is not the optimal choice for containing of the virus. On the other hand, the devastating potential impact of the outbreak is a much feared topic around the world. Science has always been the ultimate arsenal of weaponry when it comes to battling obstinate pathogens; however, time is needed for conduction of proper investigations on human‐to‐human and animal‐to‐human transmission of SARS‐CoV‐2.
|
|
p
|
With no access to requisite information on the structure and life cycle of the novel Coronavirus, research and development programs on therapeutic agents become a far‐fetched milestone, rendering the tried‐and‐true primary prevention measures the only proper means to confront SARS‐CoV‐2. As of today, few existing drugs have been considered for treatment of COVID‐19, with scant reports on benevolence of the results. As our meager knowledge of SARS‐CoV‐2 is advancing, one may speculate the advent of an effectual vaccine, alongside treatment options that might include antiviral agents, and even monoclonal antibodies. At the time of writing this manuscript, no definitive treatment option has been known for COVID‐19; however, the unabating flow of investigations and clinical trials may soon lead us to the optimal therapy for COVID‐19‐associated pneumonia.
|
|
p
|
Needless to say, the fascinatingly high transmissibility of COVID‐19 demands meticulous monitoring of the transmission routes and patterns to a reach a firm theory on adaptive mechanisms wielded by SARs‐CoV‐2, thus, making an accurate prediction about the future outcomes regarding pathogenicity, transmissibility, and evolution of the virus. These efforts will hopefully result in better prognosis and fewer mortalities.
|
|
sec
|
CONFLICT OF INTERESTS
The authors declare that they have no conflict of interest.
|
|
title
|
CONFLICT OF INTERESTS
|
|
p
|
The authors declare that they have no conflict of interest.
|
|
sec
|
AUTHOR CONTRIBUTIONS
All authors contributed to different parts of the study.
|
|
title
|
AUTHOR CONTRIBUTIONS
|
|
p
|
All authors contributed to different parts of the study.
|
|
back
|
ACKNOWLEDGMENTS
This review was conducted under supervision of Zahedan University of Medical Sciences and Iran University of Medical Sciences.
|
|
ack
|
ACKNOWLEDGMENTS
This review was conducted under supervision of Zahedan University of Medical Sciences and Iran University of Medical Sciences.
|
|
title
|
ACKNOWLEDGMENTS
|
|
p
|
This review was conducted under supervision of Zahedan University of Medical Sciences and Iran University of Medical Sciences.
|
